graph [
  node [
    id 0
    label "DB00951"
    KEGGDrug "D00346"
    PubChemSubstance "46506039"
    Carriers "ALB"
    WaterSolubility "3.49e+01"
    Wikipedia "Isoniazid"
    HBondAcceptorCount "3"
    ChemSpider "3635"
    ATCcode "J04AM04, J04AM02, J04AM06, J04AM05, J04AM03, J04AM01, J04AC51, J04AC01"
    Polarizability "13.21"
    KEGGCompound "C07054"
    logS "-0.59"
    logP "-0.69"
    Refractivity "37.46"
    pKastrongestbasic "3.35"
    Bioavailability "1"
    DrugClass "Pyridines and derivatives"
    PathwayNames ""
    ChEMBL "CHEMBL64"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "13.61"
    NumberofRings "1"
    BindingDB "50336507"
    MolecularWeight "137.1393"
    PhysiologicalCharge "0"
    Enzymes "CYP3A4_inhibitor, CYP2E1_substrate, CYP2E1_inhibitor, CYP2E1_inducer, CYP2C9_inhibitor, CYP1A2_inhibitor, CYP2D6_inhibitor, CYP2C19_inhibitor, NAT2_substrate, nat_inhibitor, CYP2A6_inhibitor, CYP2C8_inhibitor"
    GhoseFilter "0"
    PolarSurfaceAreaPSA "68.01"
    MonoisotopicWeight "137.058911861"
    MDDRLikeRule "0"
    ChEBI "6030"
    PDB "NIZ"
    DrugsProductDatabaseDPD "6618"
    PharmGKB "PA450112"
    Family "small molecule"
    MolecularFormula "C6H7N3O"
    Transporters ""
    PubChemCompound "3767"
    HBondDonorCount "2"
    DrugSubClass "Pyridinecarboxylic acids and derivatives"
    RotatableBondCount "1"
    Name "Isoniazid"
    Targets "katG_other/unknown, inhA_adduct, CYP2C8_Unkown, CYP1A2_Unkown, CYP3A4_Unkown, CYP2C19_Unkown, folA_Unkown"
    TherapeuticTargetsDatabase "DAP000011"
  ]
  node [
    id 1
    label "DB01162"
    KEGGDrug "D08569"
    PubChemSubstance "46509129"
    Carriers ""
    Wikipedia "Terazosin"
    HBondAcceptorCount "8"
    ChemSpider "5208"
    ATCcode "G04CA03"
    Polarizability "41.26"
    KEGGCompound "C07127"
    logS "-2.4"
    logP "1.18"
    Refractivity "105.18"
    pKastrongestbasic "7.24"
    Bioavailability "1"
    DrugClass "Diazinanes"
    PathwayNames ""
    ChEMBL "CHEMBL611"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "19.93"
    NumberofRings "4"
    BindingDB "50033111"
    MolecularWeight "387.4329"
    PhysiologicalCharge "1"
    Enzymes ""
    GhoseFilter "1"
    PolarSurfaceAreaPSA "103.04"
    MonoisotopicWeight "387.190654313"
    MDDRLikeRule "0"
    ChEBI "9445"
    WaterSolubility "1.50e+00"
    DrugsProductDatabaseDPD "1262"
    PharmGKB "PA451612"
    Family "small molecule"
    MolecularFormula "C19H25N5O4"
    Transporters "ABCB1_inhibitor"
    PubChemCompound "5401"
    HBondDonorCount "1"
    DrugSubClass "Piperazines"
    RotatableBondCount "4"
    Name "Terazosin"
    Targets "ADRA1A_antagonist, ADRA1B_antagonist, ADRA1D_antagonist, KCNH2_inhibitor, KCNH6_inhibitor, KCNH7_inhibitor"
    TherapeuticTargetsDatabase "DAP000371"
  ]
  node [
    id 2
    label "DB04571"
    KEGGDrug "D01034"
    Refractivity "64.86"
    Carriers ""
    PubChemSubstance "46508755"
    Wikipedia "Trioxsalen"
    HBondAcceptorCount "1"
    ChemSpider "5383"
    ATCcode "D05AD01, D05BA01"
    MolecularWeight "228.2433"
    KEGGCompound "C09314"
    logS "-3.6"
    logP "2.95"
    pKastrongestbasic "-2.7"
    Bioavailability "1"
    DrugClass "Coumarins and derivatives"
    PathwayNames ""
    ChEMBL "CHEMBL1475"
    RuleofFive "1"
    Approved "True"
    NumberofRings "3"
    Polarizability "24.77"
    Name "Trioxsalen"
    PhysiologicalCharge "0"
    Enzymes ""
    GhoseFilter "1"
    PolarSurfaceAreaPSA "39.44"
    MonoisotopicWeight "228.07864425"
    MDDRLikeRule "0"
    ChEBI "28329"
    DrugsProductDatabaseDPD "9429"
    PharmGKB "PA164747186"
    Family "small molecule"
    MolecularFormula "C14H12O3"
    Transporters ""
    PubChemCompound "5585"
    HBondDonorCount "0"
    DrugSubClass "Furanocoumarins"
    RotatableBondCount "0"
    WaterSolubility "6.27e-02"
    Targets "DNA"
  ]
  node [
    id 3
    label "DB01167"
    KEGGDrug "D00350"
    NumberofRings "7"
    Carriers ""
    PubChemSubstance "46505954"
    Wikipedia "Itraconazole"
    HBondAcceptorCount "9"
    ChemSpider "49927"
    ATCcode "J02AC02"
    Polarizability "74.7"
    logS "-4.9"
    logP "7.31"
    pKastrongestbasic "3.92"
    Bioavailability "0"
    DrugClass "Diazinanes"
    PathwayNames ""
    ChEMBL "CHEMBL22587"
    RuleofFive "0"
    Approved "True"
    MolecularWeight "705.633"
    Refractivity "200.4"
    BindingDB "50127138"
    Name "Itraconazole"
    PhysiologicalCharge "0"
    Enzymes "CYP3A5_inhibitor, CYP3A7_inhibitor, CYP3A4_substrate, CYP3A4_inhibitor, CYP2D6_inhibitor, CYP2B6_inhibitor, CYP1A1_inducer, CYP2E1_inhibitor"
    GhoseFilter "0"
    PolarSurfaceAreaPSA "100.79"
    MonoisotopicWeight "704.239307158"
    MDDRLikeRule "1"
    ChEBI "6076"
    DrugsProductDatabaseDPD "901"
    PharmGKB "PA450132"
    Family "small molecule"
    MolecularFormula "C35H38Cl2N8O4"
    Transporters "ABCB1_inhibitor"
    PubChemCompound "55283"
    HBondDonorCount "0"
    DrugSubClass "Piperazines"
    RotatableBondCount "11"
    WaterSolubility "9.64e-03"
    Targets "CYP51A1_inhibitor, ERG11_inhibitor"
    TherapeuticTargetsDatabase "DAP000631"
  ]
  node [
    id 4
    label "DB01168"
    KEGGDrug "D08423"
    PubChemSubstance "46507706"
    Carriers ""
    Wikipedia "Procarbazine"
    HBondAcceptorCount "3"
    ChemSpider "4746"
    ATCcode "L01XB01"
    Polarizability "25.88"
    KEGGCompound "C07402"
    logS "-3"
    logP "0.99"
    Refractivity "86.98"
    pKastrongestbasic "5.6"
    Bioavailability "1"
    DrugClass "Benzene and substituted derivatives"
    PathwayNames ""
    ChEMBL "CHEMBL1321"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "15.03"
    NumberofRings "1"
    MolecularWeight "221.2988"
    PhysiologicalCharge "0"
    Enzymes "CYP1B1_substrate"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "53.16"
    MonoisotopicWeight "221.152812245"
    MDDRLikeRule "0"
    ChEBI "71417"
    WaterSolubility "2.28e-01"
    DrugsProductDatabaseDPD "11354"
    PharmGKB "PA451112"
    Family "small molecule"
    MolecularFormula "C12H19N3O"
    Transporters ""
    PubChemCompound "4915"
    HBondDonorCount "3"
    DrugSubClass "Benzoic acids and derivatives"
    RotatableBondCount "5"
    Name "Procarbazine"
    Targets "DNA, MAOA_inhibitor, XDH_Unkown"
    TherapeuticTargetsDatabase "DAP000986"
  ]
  node [
    id 5
    label "DB00674"
    KEGGDrug "D04292"
    PubChemSubstance "46505659"
    Carriers ""
    WaterSolubility "1.70e+00"
    Wikipedia "Galantamine"
    HBondAcceptorCount "4"
    ChemSpider "9272"
    ATCcode "N06DA04"
    Polarizability "31.4"
    KEGGCompound "C08526"
    logS "-2.2"
    logP "1.16"
    Refractivity "82.3"
    pKastrongestbasic "8.91"
    Bioavailability "1"
    DrugClass "Amaryllidaceae alkaloids"
    PathwayNames ""
    ChEMBL "CHEMBL659"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "14.81"
    NumberofRings "4"
    BindingDB "10404"
    MolecularWeight "287.3535"
    PhysiologicalCharge "1"
    Enzymes "CYP3A4_substrate, CYP2D6_substrate"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "41.93"
    MonoisotopicWeight "287.152143543"
    MDDRLikeRule "0"
    ChEBI "42944"
    PDB "GNT"
    DrugsProductDatabaseDPD "12329"
    PharmGKB "PA449726"
    Family "small molecule"
    MolecularFormula "C17H21NO3"
    Transporters ""
    PubChemCompound "9651"
    HBondDonorCount "1"
    DrugSubClass "Galanthamine-type amaryllidaceae alkaloids"
    RotatableBondCount "1"
    Name "Galantamine"
    Targets "ACHE_inhibitor, CHRNA1_allosteric modulator, CHRNB1_allosteric modulator, CHRND_allosteric modulator, CHRNG_allosteric modulator, CHRNE_allosteric modulator, CHRNA2_allosteric modulator, CHRNA3_allosteric modulator, CHRNA4_allosteric modulator, CHRNA5_allosteric modulator, CHRNA6_allosteric modulator, CHRNA7_allosteric modulator, CHRNA9_allosteric modulator, CHRNA10_allosteric modulator, CHRNB2_allosteric modulator, CHRNB3_allosteric modulator, CHRNB4_allosteric modulator, BCHE_inhibitor"
    TherapeuticTargetsDatabase "DAP000559"
  ]
  node [
    id 6
    label "DB00675"
    KEGGDrug "D08559"
    PubChemSubstance "46505515"
    Carriers ""
    Wikipedia "Tamoxifen"
    GuidetoPharmacology "1016"
    HBondAcceptorCount "2"
    ChemSpider "2015313"
    ATCcode "L02BA01"
    RuleofFive "0"
    KEGGCompound "C07108"
    PolarSurfaceAreaPSA "12.47"
    logS "-5.6"
    logP "6.35"
    Refractivity "128.43"
    pKastrongestbasic "8.76"
    Bioavailability "1"
    DrugClass "Stilbenes"
    ChEMBL "CHEMBL83"
    Polarizability "44.19"
    Approved "True"
    MolecularWeight "371.5146"
    NumberofRings "3"
    BindingDB "20607"
    Name "Tamoxifen"
    PhysiologicalCharge "1"
    Enzymes "CYP2D6_substrate, CYP2D6_inhibitor, CYP3A4_substrate, CYP3A4_inhibitor, CYP3A4_inducer, CYP3A5_substrate, CYP3A7_substrate, CYP2C9_substrate, CYP2C9_inhibitor, CYP2C19_substrate, CYP2B6_substrate, CYP2B6_inhibitor, CYP1A1_substrate, CYP1A2_substrate, CYP1B1_substrate, CYP1B1_inhibitor, FMO1_substrate, FMO3_substrate, CYP2C8_inhibitor, CES1_inhibitor, CYP19A1_inhibitor, CYP2A6_substrate, CYP2E1_substrate, UGT1A10_substrate, SULT1A1_substrate"
    IUPHAR "1016"
    GhoseFilter "0"
    PubChemCompound "2733526"
    MonoisotopicWeight "371.224914555"
    MDDRLikeRule "1"
    ChEBI "41774"
    PDB "CTX"
    DrugsProductDatabaseDPD "2137"
    PharmGKB "PA451581"
    Family "small molecule"
    MolecularFormula "C26H29NO"
    Transporters "ABCB1_substrate, ABCB1_inhibitor, ABCB1_inducer, ABCG2_substrate, ABCC2_substrate"
    PathwayNames "Tamoxifen Metabolism Pathway_SMP00606, Tamoxifen Action Pathway_SMP00471"
    HBondDonorCount "0"
    DrugSubClass "None"
    RotatableBondCount "8"
    WaterSolubility "1.02e-03"
    Targets "ESR1_antagonist, ESR1_agonist, ESR2_antagonist, ESR2_agonist, EBP_inhibitor, PRKCA_inhibitor, AR_Unkown, KCNH2_inhibitor, NR1I2_Unkown, ESRRG_Unkown, SHBG_Unkown"
    TherapeuticTargetsDatabase "DAP000108"
  ]
  node [
    id 7
    label "DB00063"
    PubChemSubstance "46505459"
    Name "Eptifibatide"
    Carriers ""
    Enzymes ""
    Wikipedia "Eptifibatide"
    ATCcode "B01AC16"
    DrugsProductDatabaseDPD "11891"
    PharmGKB "PA449483"
    Family "biotech"
    Transporters ""
    PathwayNames "Eptifibatide Action Pathway_SMP00266"
    Approved "True"
    DrugSubClass "Amino Acids, Peptides, and Analogues"
    DrugClass "Carboxylic Acids and Derivatives"
    ChEMBL "CHEMBL1174"
    Targets "ITGB3_Unkown"
    TherapeuticTargetsDatabase "DAP000285"
  ]
  node [
    id 8
    label "DB00673"
    PubChemSubstance "46505211"
    Carriers ""
    Wikipedia "Aprepitant"
    HBondAcceptorCount "5"
    ChemSpider "5293568"
    ATCcode "A04AD12"
    Name "Aprepitant"
    PolarSurfaceAreaPSA "75.19"
    logS "-4.4"
    logP "5.22"
    Polarizability "45.56"
    Refractivity "116.93"
    pKastrongestbasic "3.51"
    Bioavailability "0"
    DrugClass "Oxazinanes"
    ChEMBL "CHEMBL1471"
    RuleofFive "0"
    Approved "True"
    pKastrongestacidic "9.65"
    NumberofRings "4"
    BindingDB "50220136"
    MolecularWeight "534.4267"
    PhysiologicalCharge "0"
    Enzymes "CYP3A4_substrate, CYP3A4_inhibitor, CYP3A5_substrate, CYP3A5_inhibitor, CYP3A7_substrate, CYP3A7_inhibitor, CYP1A2_substrate, CYP2C19_substrate, CYP2C19_inhibitor, CYP2C9_inhibitor, CYP2C9_inducer"
    GhoseFilter "0"
    PubChemCompound "6918365"
    MonoisotopicWeight "534.150187993"
    MDDRLikeRule "1"
    ChEBI "499361"
    DrugsProductDatabaseDPD "20156"
    PharmGKB "PA164747039"
    Family "small molecule"
    MolecularFormula "C23H21F7N4O3"
    Transporters ""
    PathwayNames ""
    HBondDonorCount "2"
    DrugSubClass "Morpholines"
    RotatableBondCount "8"
    WaterSolubility "1.94e-02"
    Targets "TACR1_antagonist"
    TherapeuticTargetsDatabase "DNC000952"
  ]
  node [
    id 9
    label "DB00811"
    KEGGDrug "D00423"
    NumberofRings "2"
    Carriers ""
    PubChemSubstance "46505883"
    WaterSolubility "3.32e+01"
    Wikipedia "Ribavirin"
    HBondAcceptorCount "7"
    ChemSpider "34439"
    ATCcode "J05AB04"
    Polarizability "22.18"
    logS "-0.87"
    logP "-2.8"
    pKastrongestbasic "-1.2"
    Bioavailability "1"
    DrugClass "Triazole ribonucleosides and ribonucleotides"
    PathwayNames ""
    ChEMBL "CHEMBL1643"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "11.88"
    Refractivity "64.57"
    BindingDB "50154375"
    MolecularWeight "244.2047"
    PhysiologicalCharge "0"
    Enzymes "ADK_substrate"
    GhoseFilter "0"
    PolarSurfaceAreaPSA "143.72"
    MonoisotopicWeight "244.080769514"
    MDDRLikeRule "0"
    ChEBI "63580"
    PDB "RBV"
    DrugsProductDatabaseDPD "2184"
    PharmGKB "PA451241"
    Family "small molecule"
    MolecularFormula "C8H12N4O5"
    Transporters "SLC29A1_substrate, SLC28A3_substrate"
    PubChemCompound "37542"
    HBondDonorCount "4"
    DrugSubClass "None"
    RotatableBondCount "3"
    Name "Ribavirin"
    Targets "IMPDH1_inhibitor, ADK_activator, IMPDH2_Unkown, L_antagonist, PB1_inhibitor, NT5C2_inducer, ENPP1_inhibitor, ENPP1_Unkown"
    TherapeuticTargetsDatabase "DNC001210"
  ]
  node [
    id 10
    label "DB04468"
    KEGGDrug "D06551"
    PubChemSubstance "175426858"
    Carriers ""
    WaterSolubility "3.03e-03"
    Wikipedia "Afimoxifene"
    HBondAcceptorCount "3"
    ChemSpider "395987"
    ATCcode ""
    Polarizability "45.22"
    KEGGCompound "C05011"
    logS "-5.1"
    logP "5.69"
    Refractivity "130.41"
    pKastrongestbasic "8.66"
    Bioavailability "1"
    DrugClass "Stilbenes"
    PathwayNames ""
    ChEMBL "CHEMBL489"
    RuleofFive "0"
    Approved "False"
    pKastrongestacidic "9.45"
    NumberofRings "3"
    BindingDB "20608"
    MolecularWeight "387.514"
    PhysiologicalCharge "1"
    Enzymes ""
    GhoseFilter "0"
    PolarSurfaceAreaPSA "32.7"
    MonoisotopicWeight "387.219829177"
    MDDRLikeRule "1"
    ChEBI "44616"
    PDB "OHT"
    Family "small molecule"
    MolecularFormula "C26H29NO2"
    Transporters ""
    PubChemCompound "449459"
    HBondDonorCount "1"
    DrugSubClass "None"
    RotatableBondCount "8"
    Name "Afimoxifene"
    Targets "ESR2_Unkown, ESRRG_Unkown, ESR1_Unkown, TFF1_Unkown, ESRRA_inhibitor, NR1I2_Unkown, SHBG_Unkown"
  ]
  node [
    id 11
    label "DB01144"
    KEGGDrug "D00518"
    PubChemSubstance "46505039"
    Carriers ""
    WaterSolubility "3.98e-01"
    Wikipedia "Dichlorphenamide"
    HBondAcceptorCount "4"
    ChemSpider "2930"
    ATCcode "S01EC02, G01AE10"
    Polarizability "25.04"
    KEGGCompound "C07459"
    logS "-2.9"
    logP "0.39"
    Refractivity "59.98"
    Bioavailability "1"
    DrugClass "Benzene and substituted derivatives"
    PathwayNames ""
    ChEMBL "CHEMBL17"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "7.94"
    NumberofRings "1"
    BindingDB "10883"
    MolecularWeight "305.159"
    PhysiologicalCharge "0"
    Enzymes "CYP2C9_inducer"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "120.32"
    MonoisotopicWeight "303.914603484"
    MDDRLikeRule "0"
    ChEBI "101085"
    PDB "I7A"
    PharmGKB "PA164745512"
    Family "small molecule"
    MolecularFormula "C6H6Cl2N2O4S2"
    Transporters ""
    PubChemCompound "3038"
    HBondDonorCount "2"
    DrugSubClass "Benzenesulfonamides"
    RotatableBondCount "2"
    Name "Diclofenamide"
    Targets "CA1_inhibitor, CA2_inhibitor, CA4_inhibitor, CA7_inhibitor, CA3_inhibitor"
    TherapeuticTargetsDatabase "DAP000601"
  ]
  node [
    id 12
    label "DB00384"
    KEGGDrug "D00386"
    PubChemSubstance "46507623"
    Carriers ""
    WaterSolubility "9.63e-01"
    Wikipedia "Triamterene"
    GuidetoPharmacology "4329"
    HBondAcceptorCount "7"
    ChemSpider "5345"
    ATCcode "C03DB02"
    Polarizability "25.9"
    logS "-2.4"
    logP "1.11"
    Refractivity "75.13"
    pKastrongestbasic "3.11"
    Bioavailability "1"
    DrugClass "Pteridines and derivatives"
    PathwayNames "Triamterene Action Pathway_SMP00132"
    ChEMBL "CHEMBL585"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "15.88"
    NumberofRings "3"
    BindingDB "6644"
    MolecularWeight "253.2626"
    PhysiologicalCharge "0"
    Enzymes "CYP1A2_substrate, CYP1A2_inhibitor"
    IUPHAR "4329"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "129.62"
    MonoisotopicWeight "253.107593387"
    MDDRLikeRule "0"
    ChEBI "9671"
    PDB "DX2"
    DrugsProductDatabaseDPD "10190"
    PharmGKB "PA451752"
    Family "small molecule"
    MolecularFormula "C12H11N7"
    Transporters ""
    PubChemCompound "5546"
    HBondDonorCount "3"
    DrugSubClass "None"
    RotatableBondCount "1"
    Name "Triamterene"
    Targets "SCNN1G_inhibitor, SCNN1A_inhibitor, SCNN1B_inhibitor, SCNN1D_inhibitor"
    TherapeuticTargetsDatabase "DAP000575"
  ]
  node [
    id 13
    label "DB00819"
    KEGGDrug "D00218"
    PubChemSubstance "46504493"
    Carriers ""
    WaterSolubility "2.79e+00"
    Wikipedia "Acetazolamide"
    HBondAcceptorCount "5"
    ChemSpider "1909"
    ATCcode "S01EC01"
    Polarizability "19.16"
    KEGGCompound "C06805"
    logS "-1.9"
    logP "-1"
    Refractivity "47.36"
    pKastrongestbasic "-3.3"
    Bioavailability "1"
    DrugClass "Azoles"
    PathwayNames ""
    ChEMBL "CHEMBL20"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "6.93"
    NumberofRings "1"
    BindingDB "10880"
    MolecularWeight "222.245"
    PhysiologicalCharge "-1"
    Enzymes "CYP3A4_inhibitor"
    GhoseFilter "0"
    PolarSurfaceAreaPSA "115.04"
    MonoisotopicWeight "221.988131458"
    MDDRLikeRule "0"
    ChEBI "27690"
    PDB "AZM"
    DrugsProductDatabaseDPD "6299"
    PharmGKB "PA448018"
    Family "small molecule"
    MolecularFormula "C4H6N4O3S2"
    Transporters "SLC22A6_inhibitor"
    PubChemCompound "1986"
    HBondDonorCount "2"
    DrugSubClass "Thiadiazoles"
    RotatableBondCount "2"
    Name "Acetazolamide"
    Targets "CA1_inhibitor, CA2_inhibitor, CA4_inhibitor, CA12_inhibitor, CA14_inhibitor, CA3_inhibitor, CA7_inhibitor, AQP1_inhibitor"
    TherapeuticTargetsDatabase "DAP000600"
  ]
  node [
    id 14
    label "DB00382"
    KEGGDrug "D08555"
    NumberofRings "3"
    Carriers ""
    PubChemSubstance "46505487"
    Wikipedia "Tacrine"
    HBondAcceptorCount "2"
    ChemSpider "1859"
    ATCcode "N06DA01"
    RuleofFive "1"
    KEGGCompound "C01453"
    logS "-3.2"
    logP "2.63"
    pKastrongestbasic "8.95"
    Bioavailability "1"
    DrugClass "Quinolines and derivatives"
    PathwayNames ""
    ChEMBL "CHEMBL95"
    Polarizability "22.79"
    Approved "False"
    MolecularWeight "198.2637"
    Refractivity "61.74"
    BindingDB "8961"
    Name "Tacrine"
    PhysiologicalCharge "1"
    Enzymes "CYP1A2_substrate"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "38.91"
    MonoisotopicWeight "198.115698458"
    MDDRLikeRule "0"
    ChEBI "45980"
    PDB "THA"
    PharmGKB "PA451576"
    Family "small molecule"
    MolecularFormula "C13H14N2"
    Transporters "ABCB1_substrate"
    PubChemCompound "1935"
    HBondDonorCount "1"
    DrugSubClass "Benzoquinolines"
    RotatableBondCount "0"
    WaterSolubility "1.36e-01"
    Targets "ACHE_inhibitor, BCHE_inhibitor, CES1_Unkown"
    TherapeuticTargetsDatabase "DAP000558"
  ]
  node [
    id 15
    label "DB12221"
    PubChemSubstance "347828500"
    Carriers ""
    Wikipedia "Canrenone"
    HBondAcceptorCount "2"
    ChemSpider "13192"
    ATCcode "C03DA03"
    Name "Canrenone"
    PolarSurfaceAreaPSA "43.37"
    logS "-4.9"
    logP "3.6"
    Refractivity "97.48"
    pKastrongestbasic "-4.8"
    Bioavailability "1"
    DrugClass "Steroids and steroid derivatives"
    ChEMBL "CHEMBL1463345"
    RuleofFive "1"
    Approved "False"
    pKastrongestacidic "19.94"
    NumberofRings "5"
    MolecularWeight "340.4559"
    PhysiologicalCharge "0"
    Enzymes ""
    GhoseFilter "1"
    PubChemCompound "13789"
    MonoisotopicWeight "340.203844762"
    MDDRLikeRule "0"
    ChEBI "135445"
    Polarizability "38.77"
    Family "small molecule"
    MolecularFormula "C22H28O3"
    Transporters ""
    PathwayNames ""
    HBondDonorCount "0"
    DrugSubClass "Steroid lactones"
    RotatableBondCount "0"
    WaterSolubility "4.20e-03"
    Targets ""
  ]
  node [
    id 16
    label "DB00467"
    KEGGDrug "D00310"
    PubChemSubstance "46507505"
    Carriers ""
    Wikipedia "Enoxacin"
    HBondAcceptorCount "7"
    ChemSpider "3116"
    ATCcode "J01MA04"
    Polarizability "31.63"
    KEGGCompound "C06979"
    logS "-2.5"
    logP "-0.98"
    Refractivity "83.95"
    pKastrongestbasic "8.59"
    Bioavailability "1"
    DrugClass "Diazanaphthalenes"
    PathwayNames ""
    ChEMBL "CHEMBL826"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "5.5"
    NumberofRings "3"
    BindingDB "50296358"
    MolecularWeight "320.3189"
    PhysiologicalCharge "0"
    Enzymes "CYP1A2_inhibitor"
    GhoseFilter "0"
    PolarSurfaceAreaPSA "85.77"
    MonoisotopicWeight "320.128468635"
    MDDRLikeRule "0"
    ChEBI "157175"
    WaterSolubility "1.09e+00"
    PharmGKB "PA449462"
    Family "small molecule"
    MolecularFormula "C15H17FN4O3"
    Transporters ""
    PubChemCompound "3229"
    HBondDonorCount "2"
    DrugSubClass "Naphthyridines"
    RotatableBondCount "3"
    Name "Enoxacin"
    Targets "gyrA_inhibitor, parC_inhibitor, TOP2A_inhibitor"
    TherapeuticTargetsDatabase "DAP001000"
  ]
  node [
    id 17
    label "DB06817"
    KEGGDrug "D06676"
    NumberofRings "3"
    Carriers ""
    PubChemSubstance "175427095"
    Wikipedia "Raltegravir"
    HBondAcceptorCount "7"
    ChemSpider "16445111"
    ATCcode "J05AX08, J05AR16"
    RuleofFive "1"
    logP "-0.39"
    pKastrongestbasic "-1.5"
    Bioavailability "1"
    DrugClass "Diazines"
    PathwayNames ""
    ChEMBL "CHEMBL254316"
    Polarizability "42.47"
    Approved "True"
    pKastrongestacidic "5.62"
    Refractivity "112.59"
    BindingDB "25351"
    MolecularWeight "444.4163"
    PhysiologicalCharge "-1"
    Enzymes "UGT1A1_substrate"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "150.02"
    MonoisotopicWeight "444.155746017"
    MDDRLikeRule "1"
    PDB "RLT"
    DrugsProductDatabaseDPD "20173"
    Family "small molecule"
    MolecularFormula "C20H21FN6O5"
    Transporters ""
    PubChemCompound "54671008"
    HBondDonorCount "3"
    DrugSubClass "Pyrimidines and pyrimidine derivatives"
    RotatableBondCount "6"
    Name "Raltegravir"
    Targets "pol_inhibitor"
  ]
  node [
    id 18
    label "DB02520"
    PubChemSubstance "46504708"
    Carriers ""
    WaterSolubility "1.86e-01"
    HBondAcceptorCount "0"
    ChemSpider "8639"
    ATCcode ""
    Polarizability "16.14"
    KEGGCompound "C19150"
    logS "-2.9"
    logP "2.01"
    Refractivity "45.02"
    Bioavailability "1"
    DrugClass "None"
    ChEMBL "CHEMBL961"
    RuleofFive "1"
    Approved "False"
    MolecularWeight "149.278"
    NumberofRings "0"
    BindingDB "50428474"
    PolarSurfaceAreaPSA "3.24"
    PhysiologicalCharge "-1"
    Enzymes ""
    GhoseFilter "0"
    PubChemCompound "8987"
    MonoisotopicWeight "149.033290737"
    MDDRLikeRule "0"
    PDB "DCD"
    Family "small molecule"
    MolecularFormula "C5H11NS2"
    Transporters ""
    PathwayNames ""
    HBondDonorCount "1"
    DrugSubClass "None"
    RotatableBondCount "2"
    pKastrongestacidic "2"
    Name "Ditiocarb"
    Targets ""
  ]
  node [
    id 19
    label "DB00573"
    KEGGDrug "D00968"
    PubChemSubstance "46504597"
    Carriers "ALB"
    Wikipedia "Fenoprofen"
    HBondAcceptorCount "2"
    ChemSpider "3225"
    ATCcode "M01AE04"
    Polarizability "25.3"
    KEGGCompound "C06997"
    logS "-3.5"
    logP "3.65"
    Refractivity "68.18"
    pKastrongestbasic "-8.7"
    Bioavailability "1"
    DrugClass "Benzene and substituted derivatives"
    PathwayNames "Fenoprofen Action Pathway_SMP00696"
    ChEMBL "CHEMBL1297"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "3.96"
    NumberofRings "2"
    BindingDB "54705"
    MolecularWeight "242.2699"
    PhysiologicalCharge "-1"
    Enzymes ""
    GhoseFilter "1"
    PolarSurfaceAreaPSA "46.53"
    MonoisotopicWeight "242.094294314"
    MDDRLikeRule "0"
    ChEBI "5004"
    WaterSolubility "8.11e-02"
    DrugsProductDatabaseDPD "11356"
    PharmGKB "PA449597"
    Family "small molecule"
    MolecularFormula "C15H14O3"
    Transporters ""
    PubChemCompound "3342"
    HBondDonorCount "1"
    DrugSubClass "Diphenylethers"
    RotatableBondCount "4"
    Name "Fenoprofen"
    Targets "PTGS2_inhibitor, PTGS1_inhibitor, PPARA_activator, PPARG_Unkown"
    TherapeuticTargetsDatabase "DAP000619"
  ]
  node [
    id 20
    label "DB00468"
    PubChemSubstance "46507493"
    Carriers ""
    WaterSolubility "3.34e-01"
    Wikipedia "Quinine"
    GuidetoPharmacology "2510"
    HBondAcceptorCount "4"
    ChemSpider "84989"
    ATCcode "M09AA72, P01BC01"
    Polarizability "35.96"
    KEGGCompound "C06526"
    logS "-3"
    logP "2.51"
    Refractivity "94.69"
    pKastrongestbasic "9.05"
    Bioavailability "1"
    DrugClass "Cinchona alkaloids"
    PathwayNames ""
    ChEMBL "CHEMBL170"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "13.89"
    NumberofRings "4"
    BindingDB "50367247"
    MolecularWeight "324.4168"
    PhysiologicalCharge "1"
    Enzymes "CYP3A5_substrate, CYP1A2_substrate, CYP1A2_inhibitor, CYP1A2_inducer, CYP2C8_substrate, CYP2C8_inhibitor, CYP2C9_substrate, CYP2C9_inhibitor, CYP2C19_substrate, CYP2C19_inhibitor, CYP2E1_substrate, CYP3A7_substrate, CYP1A1_inhibitor, CYP1A1_inducer, CYP3A4_substrate, CYP3A4_inhibitor, CYP3A4_inducer, CYP2D6_substrate, CYP2D6_inhibitor"
    IUPHAR "2510"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "45.59"
    MonoisotopicWeight "324.183778022"
    MDDRLikeRule "0"
    ChEBI "15854"
    PDB "QI9"
    DrugsProductDatabaseDPD "10037"
    PharmGKB "PA451213"
    Family "small molecule"
    MolecularFormula "C20H24N2O2"
    Transporters "SLC22A2_inhibitor, SLC22A1_substrate, SLC22A1_inhibitor, SLC22A5_inhibitor, ABCB1_substrate, ABCB1_inhibitor, SLCO1A2_inhibitor, SLC22A4_inhibitor"
    PubChemCompound "3034034"
    HBondDonorCount "1"
    DrugSubClass "None"
    RotatableBondCount "4"
    Name "Quinine"
    Targets "Fe(II)-protoporphyrin IX, GP9_other, KCNN4_inhibitor"
    TherapeuticTargetsDatabase "DAP000491"
  ]
  node [
    id 21
    label "DB00946"
    PubChemSubstance "46506423"
    Carriers "ALB, ORM1"
    Wikipedia "Phenprocoumon"
    HBondAcceptorCount "2"
    ChemSpider "10441592"
    ATCcode "B01AA04"
    Name "Phenprocoumon"
    PolarSurfaceAreaPSA "46.53"
    logS "-3.8"
    logP "3.74"
    Refractivity "81.64"
    pKastrongestbasic "-6.5"
    Bioavailability "1"
    DrugClass "Coumarins and derivatives"
    ChEMBL "CHEMBL1465"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "6.44"
    NumberofRings "3"
    BindingDB "768"
    MolecularWeight "280.3178"
    PhysiologicalCharge "-1"
    Enzymes "CYP2C8_substrate, CYP2C9_substrate, CYP3A4_substrate"
    GhoseFilter "1"
    PubChemCompound "54680692"
    MonoisotopicWeight "280.109944378"
    MDDRLikeRule "0"
    ChEBI "50438"
    Polarizability "29.92"
    PharmGKB "PA450921"
    Family "small molecule"
    MolecularFormula "C18H16O3"
    Transporters ""
    PathwayNames "Phenprocoumon Action Pathway_SMP00271"
    HBondDonorCount "1"
    DrugSubClass "Hydroxycoumarins"
    RotatableBondCount "3"
    WaterSolubility "4.86e-02"
    Targets "VKORC1_inhibitor"
    TherapeuticTargetsDatabase "DAP000771"
  ]
  node [
    id 22
    label "DB00235"
    KEGGDrug "D00417"
    PubChemSubstance "46507838"
    Carriers ""
    WaterSolubility "2.09e-01"
    Wikipedia "Milrinone"
    HBondAcceptorCount "3"
    ChemSpider "4052"
    ATCcode "C01CE02"
    Polarizability "21.46"
    KEGGCompound "C07224"
    logS "-3"
    logP "0.33"
    Refractivity "61.14"
    pKastrongestbasic "4.82"
    Bioavailability "1"
    DrugClass "Pyridines and derivatives"
    PathwayNames ""
    ChEMBL "CHEMBL189"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "7.54"
    NumberofRings "2"
    BindingDB "15296"
    MolecularWeight "211.2194"
    PhysiologicalCharge "0"
    Enzymes ""
    GhoseFilter "1"
    PolarSurfaceAreaPSA "65.78"
    MonoisotopicWeight "211.074561925"
    MDDRLikeRule "0"
    ChEBI "50693"
    PDB "MIL"
    DrugsProductDatabaseDPD "1216"
    PharmGKB "PA164749171"
    Family "small molecule"
    MolecularFormula "C12H9N3O"
    Transporters ""
    PubChemCompound "4197"
    HBondDonorCount "1"
    DrugSubClass "Bipyridines and oligopyridines"
    RotatableBondCount "1"
    Name "Milrinone"
    Targets "PDE3A_inhibitor"
    TherapeuticTargetsDatabase "DAP000150"
  ]
  node [
    id 23
    label "DB06762"
    NumberofRings "1"
    Carriers ""
    Wikipedia "Pinacidil"
    HBondAcceptorCount "5"
    ChemSpider "4660"
    PolarSurfaceAreaPSA "73.1"
    logS "-3.3"
    logP "2.25"
    pKastrongestbasic "5.61"
    Bioavailability "1"
    DrugClass "Pyridines and derivatives"
    ChEMBL "CHEMBL1159"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "14.27"
    Refractivity "72.81"
    BindingDB "50240750"
    MolecularWeight "245.33"
    PhysiologicalCharge "0"
    Enzymes "CYP3A4_substrate"
    GhoseFilter "1"
    PathwayNames ""
    MonoisotopicWeight "245.164045632"
    MDDRLikeRule "0"
    ChEBI "91706"
    WaterSolubility "1.26e-01"
    Polarizability "27.12"
    Family "small molecule"
    MolecularFormula "C13H19N5"
    Transporters ""
    ATCcode "C02DG01, C02LX01"
    HBondDonorCount "2"
    DrugSubClass "None"
    RotatableBondCount "3"
    Name "Pinacidil"
    Targets ""
  ]
  node [
    id 24
    label "DB00549"
    KEGGDrug "D00411"
    PubChemSubstance "46506874"
    Carriers ""
    Wikipedia "Zafirlukast"
    GuidetoPharmacology "3322"
    HBondAcceptorCount "6"
    ChemSpider "5515"
    ATCcode "R03DC01"
    Polarizability "62.06"
    KEGGCompound "C07206"
    logS "-5.8"
    logP "6.4"
    Refractivity "158.58"
    pKastrongestbasic "-1.1"
    Bioavailability "0"
    DrugClass "Benzene and substituted derivatives"
    PathwayNames ""
    ChEMBL "CHEMBL603"
    RuleofFive "0"
    Approved "True"
    pKastrongestacidic "4.29"
    NumberofRings "5"
    BindingDB "50009073"
    MolecularWeight "575.675"
    PhysiologicalCharge "-1"
    Enzymes "CYP2C9_substrate, CYP2C9_inhibitor, CYP2C8_substrate, CYP2C8_inhibitor, PTGS1_substrate, CYP3A4_substrate, CYP3A4_inhibitor, CYP1A2_inhibitor, CYP2C19_inhibitor, CYP2E1_inhibitor"
    IUPHAR "3322"
    GhoseFilter "0"
    PolarSurfaceAreaPSA "115.73"
    MonoisotopicWeight "575.209006493"
    MDDRLikeRule "1"
    ChEBI "10100"
    WaterSolubility "9.62e-04"
    DrugsProductDatabaseDPD "11685"
    PharmGKB "PA451949"
    Family "small molecule"
    MolecularFormula "C31H33N3O6S"
    Transporters "ABCG2_antagonist"
    PubChemCompound "5717"
    HBondDonorCount "2"
    DrugSubClass "Benzenesulfonamides"
    RotatableBondCount "8"
    Name "Zafirlukast"
    Targets "CYSLTR1_antagonist"
    TherapeuticTargetsDatabase "DAP000091"
  ]
  node [
    id 25
    label "DB00704"
    KEGGDrug "D05113"
    PubChemSubstance "46505333"
    Carriers ""
    Wikipedia "Naltrexone"
    HBondAcceptorCount "5"
    ChemSpider "4514524"
    ATCcode "A08AA62, N07BB04"
    Polarizability "35.97"
    KEGGCompound "C07253"
    logS "-2"
    logP "1.36"
    Refractivity "91.5"
    pKastrongestbasic "11.54"
    Bioavailability "1"
    DrugClass "Phenanthrenes and derivatives"
    PathwayNames "Naltrexone Action Pathway_SMP00687"
    ChEMBL "CHEMBL19019"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "7.39"
    NumberofRings "6"
    BindingDB "50000787"
    MolecularWeight "341.4009"
    PhysiologicalCharge "1"
    Enzymes "UGT1A1_substrate, CYP3A4_substrate"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "70"
    MonoisotopicWeight "341.162708229"
    MDDRLikeRule "0"
    ChEBI "7465"
    WaterSolubility "3.07e+00"
    DrugsProductDatabaseDPD "20300"
    PharmGKB "PA450588"
    Family "small molecule"
    MolecularFormula "C20H23NO4"
    Transporters ""
    PubChemCompound "5360515"
    HBondDonorCount "2"
    DrugSubClass "None"
    RotatableBondCount "2"
    Name "Naltrexone"
    Targets "OPRD1_antagonist, OPRM1_antagonist, OPRK1_antagonist, SIGMAR1_antagonist"
    TherapeuticTargetsDatabase "DAP000379"
  ]
  node [
    id 26
    label "DB01012"
    PubChemSubstance "46506315"
    Carriers ""
    Wikipedia "Cinacalcet"
    GuidetoPharmacology "3308"
    HBondAcceptorCount "1"
    ChemSpider "137743"
    ATCcode "H05BX01"
    Polarizability "37.9"
    PolarSurfaceAreaPSA "12.03"
    logS "-6.8"
    logP "6.27"
    Refractivity "100.12"
    pKastrongestbasic "10.3"
    Bioavailability "1"
    DrugClass "Naphthalenes"
    ChEMBL "CHEMBL1201284"
    RuleofFive "0"
    Approved "True"
    MolecularWeight "357.412"
    NumberofRings "3"
    BindingDB "50416875"
    Name "Cinacalcet"
    PhysiologicalCharge "1"
    Enzymes "CYP3A4_substrate, CYP2D6_inhibitor, CYP1A2_substrate"
    IUPHAR "3308"
    GhoseFilter "0"
    PubChemCompound "156419"
    MonoisotopicWeight "357.170434324"
    MDDRLikeRule "1"
    ChEBI "48390"
    DrugsProductDatabaseDPD "13352"
    PharmGKB "PA164776671"
    Family "small molecule"
    MolecularFormula "C22H22F3N"
    Transporters ""
    PathwayNames ""
    HBondDonorCount "1"
    DrugSubClass "None"
    RotatableBondCount "7"
    WaterSolubility "5.59e-05"
    Targets "CASR_agonist"
    TherapeuticTargetsDatabase "DAP000256"
  ]
  node [
    id 27
    label "DB00544"
    KEGGDrug "D00584"
    PubChemSubstance "46508557"
    Carriers "ALB"
    WaterSolubility "5.86e+00"
    Wikipedia "Fluorouracil"
    HBondAcceptorCount "2"
    ChemSpider "3268"
    ATCcode "L01BC02, L01BC52"
    Polarizability "9.46"
    KEGGCompound "C07649"
    logS "-1.4"
    logP "-0.66"
    Refractivity "26.17"
    pKastrongestbasic "-8"
    Bioavailability "1"
    DrugClass "Diazines"
    PathwayNames "Capecitabine Metabolism Pathway_SMP00607, Fluorouracil Metabolism Pathway_SMP00608, Capecitabine Action Pathway_SMP00469, Fluorouracil Action Pathway_SMP00470"
    ChEMBL "CHEMBL185"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "7.76"
    NumberofRings "1"
    BindingDB "50340677"
    MolecularWeight "130.0772"
    PhysiologicalCharge "0"
    Enzymes "CYP2C9_inhibitor, CYP1A2_substrate, TYMP_substrate, DPYD_substrate, UPP1_substrate, UPP2_substrate, CYP2A6_substrate, CYP2C8_substrate, MTHFR_substrate, TYMS_substrate, UMPS_substrate, PPAT_substrate"
    GhoseFilter "0"
    PolarSurfaceAreaPSA "58.2"
    MonoisotopicWeight "130.017855555"
    MDDRLikeRule "0"
    ChEBI "46345"
    PDB "URF"
    DrugsProductDatabaseDPD "6311"
    PharmGKB "PA128406956"
    Family "small molecule"
    MolecularFormula "C4H3FN2O2"
    Transporters "SLC22A7_substrate, SLC29A1_substrate, ABCG2_substrate, ABCC3_substrate, ABCC4_substrate, ABCC5_substrate"
    PubChemCompound "3385"
    HBondDonorCount "2"
    DrugSubClass "Pyrimidines and pyrimidine derivatives"
    RotatableBondCount "0"
    Name "Fluorouracil"
    Targets "TYMS_other/unknown, DNA, RNA"
    TherapeuticTargetsDatabase "DAP000829"
  ]
  node [
    id 28
    label "DB00545"
    KEGGDrug "D00487"
    PubChemSubstance "46506129"
    Carriers ""
    Wikipedia "Pyridostigmine"
    HBondAcceptorCount "1"
    ChemSpider "4817"
    ATCcode "N07AA02"
    Polarizability "19.38"
    KEGGCompound "C07410"
    logS "-2.3"
    logP "-3.5"
    Refractivity "49.66"
    Bioavailability "1"
    DrugClass "Pyridines and derivatives"
    PathwayNames ""
    ChEMBL "CHEMBL1115"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "19.53"
    NumberofRings "1"
    BindingDB "50313079"
    MolecularWeight "181.2117"
    PhysiologicalCharge "1"
    Enzymes "CYP3A4_inducer"
    GhoseFilter "0"
    PolarSurfaceAreaPSA "33.42"
    MonoisotopicWeight "181.09770267"
    MDDRLikeRule "0"
    ChEBI "8665"
    WaterSolubility "1.04e+00"
    DrugsProductDatabaseDPD "6296"
    PharmGKB "PA451185"
    Family "small molecule"
    MolecularFormula "C9H13N2O2"
    Transporters ""
    PubChemCompound "4991"
    HBondDonorCount "0"
    DrugSubClass "Methylpyridines"
    RotatableBondCount "2"
    Name "Pyridostigmine"
    Targets "ACHE_antagonist, ACHE_inhibitor, BCHE_antagonist, ALB_Unkown"
    TherapeuticTargetsDatabase "DNC001171"
  ]
  node [
    id 29
    label "DB00828"
    KEGGDrug "D04253"
    PubChemSubstance "46506665"
    Carriers ""
    WaterSolubility "4.69e+01"
    Wikipedia "Fosfomycin"
    HBondAcceptorCount "4"
    ChemSpider "394204"
    ATCcode "J01XX01"
    Polarizability "10.8"
    KEGGCompound "C06454"
    logS "-0.47"
    logP "-0.74"
    Refractivity "25.87"
    pKastrongestbasic "-4.3"
    Bioavailability "1"
    DrugClass "Organic phosphonic acids and derivatives"
    PathwayNames ""
    ChEMBL "CHEMBL1757"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "1.25"
    NumberofRings "1"
    BindingDB "50024894"
    MolecularWeight "138.059"
    PhysiologicalCharge "-1"
    Enzymes ""
    GhoseFilter "0"
    PolarSurfaceAreaPSA "70.06"
    MonoisotopicWeight "138.008195224"
    MDDRLikeRule "0"
    ChEBI "28915"
    PDB "FCN"
    DrugsProductDatabaseDPD "11861"
    PharmGKB "PA164748039"
    Family "small molecule"
    MolecularFormula "C3H7O4P"
    Transporters ""
    PubChemCompound "446987"
    HBondDonorCount "2"
    DrugSubClass "Organic phosphonic acids"
    RotatableBondCount "1"
    Name "Fosfomycin"
    Targets "murA_inhibitor"
    TherapeuticTargetsDatabase "DAP000767"
  ]
  node [
    id 30
    label "DB00543"
    KEGGDrug "D00228"
    NumberofRings "4"
    Carriers "ORM1"
    PubChemSubstance "46509117"
    Wikipedia "Amoxapine"
    GuidetoPharmacology "201"
    HBondAcceptorCount "3"
    ChemSpider "2085"
    ATCcode "N06AA17"
    Polarizability "32.82"
    logS "-3.3"
    logP "3.08"
    pKastrongestbasic "8.83"
    Bioavailability "1"
    DrugClass "Benzoxazepines"
    PathwayNames ""
    ChEMBL "CHEMBL1113"
    RuleofFive "1"
    Approved "True"
    MolecularWeight "313.781"
    Refractivity "89.82"
    BindingDB "22870"
    Name "Amoxapine"
    PhysiologicalCharge "1"
    Enzymes "CYP2D6_substrate"
    IUPHAR "201"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "36.86"
    MonoisotopicWeight "313.098189856"
    MDDRLikeRule "0"
    ChEBI "2675"
    DrugsProductDatabaseDPD "8001"
    PharmGKB "PA448405"
    Family "small molecule"
    MolecularFormula "C17H16ClN3O"
    Transporters ""
    PubChemCompound "2170"
    HBondDonorCount "1"
    DrugSubClass "Dibenzoxazepines"
    RotatableBondCount "0"
    WaterSolubility "1.71e-01"
    Targets "SLC6A2_inhibitor, SLC6A4_inhibitor, DRD2_antagonist, DRD1_antagonist, ADRA2A_antagonist, ADRA1A_antagonist, CHRM1_antagonist, GABRA1_antagonist, HTR2A_antagonist, HTR2C_antagonist, HTR6_antagonist, HTR7_antagonist, DRD3_antagonist, DRD4_antagonist, HRH1_antagonist, ADRA1A_antagonist, CHRM1_antagonist, HTR2B_antagonist, HTR3A_antagonist, HTR1A_antagonist, HTR1B_antagonist, ADRA2A_antagonist, HRH4_binder, GABRA1_binder, SLC6A3_binder"
    TherapeuticTargetsDatabase "DAP001149"
  ]
  node [
    id 31
    label "DB00765"
    KEGGDrug "D00762"
    PubChemSubstance "46506079"
    Carriers ""
    Wikipedia "Metyrosine"
    HBondAcceptorCount "4"
    ChemSpider "390103"
    ATCcode "C02KB01"
    Polarizability "19.9"
    KEGGCompound "C07921"
    logS "-1.9"
    logP "-1.1"
    Refractivity "51.81"
    pKastrongestbasic "9.93"
    Bioavailability "1"
    DrugClass "Phenylpropanoic acids"
    PathwayNames ""
    ChEMBL "CHEMBL1200862"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "2.06"
    NumberofRings "1"
    MolecularWeight "195.2151"
    PhysiologicalCharge "0"
    Enzymes ""
    GhoseFilter "0"
    PolarSurfaceAreaPSA "83.55"
    MonoisotopicWeight "195.089543287"
    MDDRLikeRule "0"
    ChEBI "6912"
    WaterSolubility "2.48e+00"
    PharmGKB "PA450487"
    Family "small molecule"
    MolecularFormula "C10H13NO3"
    Transporters ""
    PubChemCompound "441350"
    HBondDonorCount "3"
    DrugSubClass "None"
    RotatableBondCount "3"
    Name "Metyrosine"
    Targets "TH_binder"
    TherapeuticTargetsDatabase "DAP000471"
  ]
  node [
    id 32
    label "DB00226"
    KEGGDrug "D00607"
    PubChemSubstance "46506457"
    Carriers ""
    Wikipedia "Guanadrel"
    HBondAcceptorCount "5"
    ChemSpider "35305"
    ATCcode ""
    Polarizability "23.23"
    KEGGCompound "C07035"
    logS "-2"
    logP "0.62"
    Refractivity "56.54"
    pKastrongestbasic "12.56"
    Bioavailability "1"
    DrugClass "Organooxygen compounds"
    PathwayNames ""
    ChEMBL "CHEMBL1037"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "19.85"
    NumberofRings "2"
    MolecularWeight "213.2768"
    PhysiologicalCharge "1"
    Enzymes ""
    GhoseFilter "1"
    PolarSurfaceAreaPSA "82.86"
    MonoisotopicWeight "213.147726867"
    MDDRLikeRule "0"
    ChEBI "5555"
    WaterSolubility "1.93e+00"
    PharmGKB "PA164745308"
    Family "small molecule"
    MolecularFormula "C10H19N3O2"
    Transporters ""
    PubChemCompound "38521"
    HBondDonorCount "2"
    DrugSubClass "Ethers"
    RotatableBondCount "2"
    Name "Guanadrel"
    Targets "SLC6A2_partial agonist"
    TherapeuticTargetsDatabase "DAP000059"
  ]
  node [
    id 33
    label "DB00608"
    KEGGDrug "D02366"
    NumberofRings "2"
    Carriers ""
    PubChemSubstance "46506925"
    Wikipedia "Chloroquine"
    HBondAcceptorCount "3"
    ChemSpider "2618"
    ATCcode "P01BA01"
    RuleofFive "1"
    KEGGCompound "C07625"
    logS "-4.3"
    logP "3.93"
    pKastrongestbasic "10.32"
    Bioavailability "1"
    DrugClass "Quinolines and derivatives"
    PathwayNames ""
    ChEMBL "CHEMBL76"
    Polarizability "37.29"
    Approved "True"
    MolecularWeight "319.872"
    Refractivity "96.42"
    BindingDB "22985"
    Name "Chloroquine"
    PhysiologicalCharge "2"
    Enzymes "CYP3A4_substrate, CYP2D6_substrate, CYP2D6_inhibitor, CYP1A1_substrate, CYP2C8_substrate, CYP3A5_substrate"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "28.16"
    MonoisotopicWeight "319.181525554"
    MDDRLikeRule "0"
    ChEBI "3638"
    PDB "CLQ"
    DrugsProductDatabaseDPD "6547"
    PharmGKB "PA448948"
    Family "small molecule"
    MolecularFormula "C18H26ClN3"
    Transporters ""
    PubChemCompound "2719"
    HBondDonorCount "1"
    DrugSubClass "Aminoquinolines and derivatives"
    RotatableBondCount "8"
    WaterSolubility "1.75e-02"
    Targets "GSTA2_Unkown, Fe(II)-protoporphyrin IX, TNF_Unkown, TLR9_Unkown, GST_inhibitor"
    TherapeuticTargetsDatabase "DAP001357"
  ]
  node [
    id 34
    label "DB00181"
    KEGGDrug "D00241"
    PubChemSubstance "46508181"
    Carriers ""
    Wikipedia "Baclofen"
    GuidetoPharmacology "1084"
    HBondAcceptorCount "3"
    ChemSpider "2197"
    ATCcode "M03BX01"
    Polarizability "21.13"
    logS "-2.5"
    logP "-0.78"
    Refractivity "54.83"
    pKastrongestbasic "9.79"
    Bioavailability "1"
    DrugClass "Carboxylic acids and derivatives"
    PathwayNames ""
    ChEMBL "CHEMBL701"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "3.89"
    NumberofRings "1"
    BindingDB "24182"
    MolecularWeight "213.661"
    PhysiologicalCharge "0"
    Enzymes ""
    IUPHAR "1084"
    GhoseFilter "0"
    PolarSurfaceAreaPSA "63.32"
    MonoisotopicWeight "213.05565634"
    MDDRLikeRule "0"
    ChEBI "2972"
    WaterSolubility "7.12e-01"
    DrugsProductDatabaseDPD "2104"
    PharmGKB "PA448533"
    Family "small molecule"
    MolecularFormula "C10H12ClNO2"
    Transporters "SLC22A8_inhibitor"
    PubChemCompound "2284"
    HBondDonorCount "2"
    DrugSubClass "Amino acids, peptides, and analogues"
    RotatableBondCount "4"
    Name "Baclofen"
    Targets "GABBR1_agonist, GABBR2_agonist"
    TherapeuticTargetsDatabase "DAP000257"
  ]
  node [
    id 35
    label "DB00762"
    KEGGDrug "D08086"
    PubChemSubstance "46505871"
    Carriers "ALB"
    WaterSolubility "1.07e-01"
    Wikipedia "Irinotecan"
    HBondAcceptorCount "6"
    ChemSpider "54825"
    ATCcode "L01XX19"
    Polarizability "65.27"
    KEGGCompound "C16641"
    logS "-3.7"
    logP "2.78"
    Refractivity "161.33"
    pKastrongestbasic "9.47"
    Bioavailability "1"
    DrugClass "Camptothecins"
    PathwayNames "Irinotecan Metabolism Pathway_SMP00600, Irinotecan Action Pathway_SMP00433"
    ChEMBL "CHEMBL481"
    RuleofFive "0"
    Approved "True"
    pKastrongestacidic "11.71"
    NumberofRings "7"
    BindingDB "50128267"
    MolecularWeight "586.678"
    PhysiologicalCharge "1"
    Enzymes "CYP3A4_substrate, CYP3A4_inhibitor, CYP3A5_substrate, CYP2B6_substrate, CYP3A7_substrate, UGT1A1_substrate, UGT1A9_substrate, CES1_substrate, CES2_substrate, BCHE_substrate"
    GhoseFilter "0"
    PolarSurfaceAreaPSA "112.51"
    MonoisotopicWeight "586.279134968"
    MDDRLikeRule "0"
    ChEBI "80630"
    PDB "CP0"
    DrugsProductDatabaseDPD "22885"
    PharmGKB "PA450085"
    Family "small molecule"
    MolecularFormula "C33H38N4O6"
    Transporters "SLC22A3_inhibitor, SLCO1B1_inhibitor, ABCC1_substrate, ABCG2_substrate, ABCB1_substrate, ABCC2_substrate"
    PubChemCompound "60838"
    HBondDonorCount "1"
    DrugSubClass "None"
    RotatableBondCount "5"
    Name "Irinotecan"
    Targets "TOP1_inhibitor, TOP1MT_inhibitor"
    TherapeuticTargetsDatabase "DAP001339"
  ]
  node [
    id 36
    label "DB06422"
    NumberofRings "2"
    Carriers ""
    HBondAcceptorCount "6"
    ChemSpider "187437"
    PolarSurfaceAreaPSA "89.1"
    logS "-3"
    logP "-0.63"
    pKastrongestbasic "9.53"
    Bioavailability "1"
    DrugClass "Benzene and substituted derivatives"
    ChEMBL "CHEMBL2107465"
    RuleofFive "1"
    Approved "False"
    pKastrongestacidic "7.77"
    Refractivity "82.53"
    MolecularWeight "313.78"
    PhysiologicalCharge "2"
    Enzymes ""
    GhoseFilter "0"
    PathwayNames ""
    MonoisotopicWeight "313.119319228"
    MDDRLikeRule "0"
    WaterSolubility "3.41e-01"
    Polarizability "32.45"
    Family "small molecule"
    MolecularFormula "C14H20ClN3O3"
    Transporters ""
    ATCcode ""
    HBondDonorCount "3"
    DrugSubClass "Benzoic acids and derivatives"
    RotatableBondCount "4"
    Name "Ticalopride"
    Targets "HTR4_Unkown, HTR3A_Unkown"
  ]
  node [
    id 37
    label "DB00949"
    KEGGDrug "D00536"
    PubChemSubstance "46506375"
    Carriers ""
    Wikipedia "Felbamate"
    HBondAcceptorCount "2"
    ChemSpider "3214"
    ATCcode "N03AX10"
    Polarizability "23.52"
    KEGGCompound "C07501"
    logS "-2.5"
    logP "0.68"
    Refractivity "59.59"
    Bioavailability "1"
    DrugClass "Benzene and substituted derivatives"
    PathwayNames "Felbamate Metabolism Pathway_SMP00633"
    ChEMBL "CHEMBL1094"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "14.98"
    NumberofRings "1"
    BindingDB "50088430"
    MolecularWeight "238.2399"
    PhysiologicalCharge "0"
    Enzymes "CYP3A4_substrate, CYP3A4_inducer, CYP2C19_inhibitor, CYP2E1_substrate, CYP2C9_inhibitor"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "104.64"
    MonoisotopicWeight "238.095356946"
    MDDRLikeRule "0"
    ChEBI "4995"
    WaterSolubility "7.42e-01"
    PharmGKB "PA449590"
    Family "small molecule"
    MolecularFormula "C11H14N2O4"
    Transporters ""
    PubChemCompound "3331"
    HBondDonorCount "2"
    DrugSubClass "None"
    RotatableBondCount "7"
    Name "Felbamate"
    Targets "GRIN2B_antagonist, GRIN3A_antagonist, GRIN2A_antagonist"
    TherapeuticTargetsDatabase "DAP000093"
  ]
  node [
    id 38
    label "DB01024"
    PubChemSubstance "46504559"
    Carriers ""
    Wikipedia "Mycophenolic_acid"
    HBondAcceptorCount "5"
    ChemSpider "393865"
    ATCcode "L04AA06"
    Name "Mycophenolic acid"
    PolarSurfaceAreaPSA "93.06"
    logS "-4"
    logP "3.53"
    Polarizability "32.95"
    Refractivity "85.23"
    pKastrongestbasic "-4.1"
    Bioavailability "1"
    DrugClass "Isocoumarans"
    ChEMBL "CHEMBL866"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "3.57"
    NumberofRings "2"
    BindingDB "19264"
    MolecularWeight "320.3371"
    PhysiologicalCharge "-1"
    Enzymes "UGT1A1_substrate, UGT1A9_substrate, UGT2B7_substrate, UGT1A7_substrate, UGT1A6_substrate"
    GhoseFilter "1"
    PubChemCompound "446541"
    MonoisotopicWeight "320.125988372"
    MDDRLikeRule "0"
    ChEBI "168396"
    PDB "MOA"
    DrugsProductDatabaseDPD "2139"
    PharmGKB "PA164748728"
    Family "small molecule"
    MolecularFormula "C17H20O6"
    Transporters ""
    PathwayNames "Mycophenolic Acid Metabolism Pathway_SMP00652"
    HBondDonorCount "2"
    DrugSubClass "Isobenzofuranones"
    RotatableBondCount "6"
    WaterSolubility "3.55e-02"
    Targets "IMPDH1_inhibitor, IMPDH2_inhibitor"
    TherapeuticTargetsDatabase "DAP000784"
  ]
  node [
    id 39
    label "DB00604"
    KEGGDrug "D00274"
    PubChemSubstance "46504980"
    Carriers ""
    Wikipedia "Cisapride"
    GuidetoPharmacology "240"
    HBondAcceptorCount "6"
    ChemSpider "5292927"
    ATCcode "A03FA02"
    Polarizability "49.11"
    KEGGCompound "C06910"
    logS "-4.6"
    logP "2.49"
    Refractivity "122.93"
    pKastrongestbasic "8.24"
    Bioavailability "1"
    DrugClass "Benzene and substituted derivatives"
    PathwayNames ""
    ChEMBL "CHEMBL560739"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "14.58"
    NumberofRings "3"
    BindingDB "50005836"
    MolecularWeight "465.945"
    PhysiologicalCharge "1"
    Enzymes "CYP3A7_substrate, CYP3A4_substrate, CYP3A4_inhibitor, CYP3A5_substrate, CYP1A2_substrate, CYP2A6_substrate, CYP2B6_substrate, CYP2C19_substrate, CYP2C8_substrate, CYP2C9_substrate, CYP2D6_inhibitor"
    IUPHAR "240"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "86.05"
    MonoisotopicWeight "465.183062343"
    MDDRLikeRule "1"
    ChEBI "3720"
    WaterSolubility "1.20e-02"
    DrugsProductDatabaseDPD "11322"
    PharmGKB "PA449011"
    Family "small molecule"
    MolecularFormula "C23H29ClFN3O4"
    Transporters ""
    PubChemCompound "6917698"
    HBondDonorCount "2"
    DrugSubClass "Benzoic acids and derivatives"
    RotatableBondCount "9"
    Name "Cisapride"
    Targets "HTR4_agonist, HTR3A_agonist, HTR2A_agonist, KCNH2_inhibitor"
    TherapeuticTargetsDatabase "DAP000222"
  ]
  node [
    id 40
    label "DB09324"
    KEGGDrug "D08533"
    PubChemSubstance "310265206"
    Carriers ""
    WaterSolubility "4.85e+01"
    Wikipedia "Sulbactam"
    HBondAcceptorCount "5"
    ChemSpider "115306"
    ATCcode "J01CG01"
    Polarizability "20.63"
    KEGGCompound "C07770"
    logS "-0.68"
    logP "-0.89"
    Refractivity "48.21"
    pKastrongestbasic "-3.8"
    Bioavailability "1"
    DrugClass "Carboxylic acids and derivatives"
    PathwayNames ""
    ChEMBL "CHEMBL403"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "3.09"
    NumberofRings "2"
    BindingDB "50021954"
    MolecularWeight "233.242"
    PhysiologicalCharge "-1"
    Enzymes ""
    GhoseFilter "0"
    PolarSurfaceAreaPSA "91.75"
    MonoisotopicWeight "233.035793157"
    MDDRLikeRule "0"
    ChEBI "9321"
    PDB "0RN"
    DrugsProductDatabaseDPD "8339"
    Family "small molecule"
    MolecularFormula "C8H11NO5S"
    Transporters ""
    PubChemCompound "130313"
    HBondDonorCount "1"
    DrugSubClass "Amino acids, peptides, and analogues"
    RotatableBondCount "1"
    Name "Sulbactam"
    Targets "blaZ_inhibitor"
  ]
  node [
    id 41
    label "DB00215"
    KEGGDrug "D07704"
    Refractivity "94.02"
    Carriers ""
    PubChemSubstance "46508746"
    Wikipedia "Citalopram"
    HBondAcceptorCount "3"
    ChemSpider "2669"
    ATCcode "N06AB04"
    MolecularWeight "324.3919"
    KEGGCompound "C07572"
    logS "-4.7"
    logP "3.76"
    Polarizability "35.4"
    pKastrongestbasic "9.78"
    Bioavailability "1"
    DrugClass "Benzene and substituted derivatives"
    PathwayNames "Citalopram Action Pathway_SMP00424, Citalopram Metabolism Pathway_SMP00627"
    ChEMBL "CHEMBL549"
    RuleofFive "1"
    Approved "True"
    NumberofRings "3"
    BindingDB "25870"
    Name "Citalopram"
    PhysiologicalCharge "1"
    Enzymes "CYP3A4_substrate, CYP2C19_substrate, CYP2C19_inhibitor, CYP2D6_substrate, CYP2D6_inhibitor, CYP2E1_substrate, CYP1A2_inhibitor, CYP2B6_inhibitor"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "36.26"
    MonoisotopicWeight "324.163791509"
    MDDRLikeRule "0"
    ChEBI "77397"
    DrugsProductDatabaseDPD "11847"
    PharmGKB "PA449015"
    Family "small molecule"
    MolecularFormula "C20H21FN2O"
    Transporters "ABCB1_substrate, ABCB1_inhibitor, SLC6A3_substrate, SLC6A3_inhibitor, SLC6A2_substrate, SLC6A2_inhibitor, SLC6A4_substrate, SLC6A4_inhibitor"
    PubChemCompound "2771"
    HBondDonorCount "0"
    DrugSubClass "Phenylbutylamines"
    RotatableBondCount "5"
    WaterSolubility "5.88e-03"
    Targets "SLC6A4_inhibitor, HRH1_binder, ADRA1A_binder, CHRM1_binder, HTR2C_antagonist"
    TherapeuticTargetsDatabase "DAP000118"
  ]
  node [
    id 42
    label "DB00980"
    PubChemSubstance "46505923"
    Carriers ""
    Wikipedia "Ramelteon"
    GuidetoPharmacology "1356"
    HBondAcceptorCount "2"
    ChemSpider "181000"
    ATCcode "N05CH02"
    RuleofFive "1"
    logS "-4.2"
    logP "2.57"
    Refractivity "75.52"
    pKastrongestbasic "-0.4"
    Bioavailability "1"
    DrugClass "Indanes"
    PathwayNames ""
    ChEMBL "CHEMBL1218"
    Polarizability "29.99"
    Approved "True"
    pKastrongestacidic "15.82"
    NumberofRings "3"
    BindingDB "50118470"
    MolecularWeight "259.3434"
    PhysiologicalCharge "0"
    Enzymes "CYP1A2_substrate, CYP2C19_substrate, CYP3A4_substrate"
    IUPHAR "1356"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "38.33"
    MonoisotopicWeight "259.157228921"
    MDDRLikeRule "0"
    ChEBI "109549"
    WaterSolubility "1.64e-02"
    PharmGKB "PA164744896"
    Family "small molecule"
    MolecularFormula "C16H21NO2"
    Transporters ""
    PubChemCompound "208902"
    HBondDonorCount "1"
    DrugSubClass "None"
    RotatableBondCount "4"
    Name "Ramelteon"
    Targets "MTNR1A_multitarget, MTNR1B_multitarget"
    TherapeuticTargetsDatabase "DAP000070"
  ]
  node [
    id 43
    label "DB01041"
    KEGGDrug "D00754"
    PubChemSubstance "46505665"
    Carriers ""
    Wikipedia "Thalidomide"
    HBondAcceptorCount "4"
    ChemSpider "5233"
    ATCcode "L04AX02"
    Polarizability "24.42"
    KEGGCompound "C07910"
    logS "-2"
    logP "0.016"
    Refractivity "64.32"
    pKastrongestbasic "-6.4"
    Bioavailability "1"
    DrugClass "Isoindoles and derivatives"
    PathwayNames ""
    ChEMBL "CHEMBL468"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "11.59"
    NumberofRings "3"
    BindingDB "50070114"
    MolecularWeight "258.2295"
    PhysiologicalCharge "0"
    Enzymes "CYP2C19_substrate, CYP2C19_inhibitor, CYP1A1_substrate, CYP2E1_substrate, CYP2C9_substrate, PTGS1_substrate, PTGS2_substrate, CYP3A5_inducer, CYP1A2_substrate"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "83.55"
    MonoisotopicWeight "258.064056818"
    MDDRLikeRule "0"
    ChEBI "74947"
    WaterSolubility "2.55e+00"
    DrugsProductDatabaseDPD "6036"
    PharmGKB "PA451644"
    Family "small molecule"
    MolecularFormula "C13H10N2O4"
    Transporters ""
    PubChemCompound "5426"
    HBondDonorCount "1"
    DrugSubClass "Isoindolines"
    RotatableBondCount "1"
    Name "Thalidomide"
    Targets "CRBN_inhibitor, TNF_inhibitor, NFKB1_antagonist, DNA, FGFR2_antagonist, PTGS2_antagonist, Nuclear factor kappa-light-chain-enhancer of activated B cells, ORM1_binder"
    TherapeuticTargetsDatabase "DAP000865"
  ]
  node [
    id 44
    label "DB01032"
    KEGGDrug "D00475"
    PubChemSubstance "46506554"
    Carriers "ALB"
    Wikipedia "Probenecid"
    GuidetoPharmacology "4357"
    HBondAcceptorCount "4"
    ChemSpider "4742"
    ATCcode "M04AB01, G01AE10"
    Polarizability "29.96"
    KEGGCompound "C07372"
    logS "-2.8"
    logP "2.44"
    Refractivity "73.81"
    Bioavailability "1"
    DrugClass "Benzene and substituted derivatives"
    PathwayNames ""
    ChEMBL "CHEMBL897"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "3.53"
    NumberofRings "1"
    BindingDB "50206509"
    MolecularWeight "285.359"
    PhysiologicalCharge "-1"
    Enzymes "CYP2C9_inhibitor, CYP2C19_inhibitor, CYP2C8_inducer, CYP3A4_inducer"
    IUPHAR "4357"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "74.68"
    MonoisotopicWeight "285.103478791"
    MDDRLikeRule "0"
    ChEBI "8426"
    WaterSolubility "4.25e-01"
    DrugsProductDatabaseDPD "9108"
    PharmGKB "PA451106"
    Family "small molecule"
    MolecularFormula "C13H19NO4S"
    Transporters "SLC22A2_inhibitor, SLC22A1_inhibitor, ABCC3_inhibitor, ABCC4_inhibitor, ABCC5_inhibitor, SLC16A7_inhibitor, SLC22A5_inhibitor, ABCC6_inhibitor, ABCC1_inhibitor, SLCO1A2_inhibitor, SLC16A1_inhibitor, SLC10A1_inhibitor, SLC22A6_inhibitor, SLC22A10_inhibitor, SLC22A8_inhibitor, ABCC2_substrate, ABCC2_inhibitor, ABCC11_inhibitor, SLC22A11_inhibitor, SLCO1C1_inhibitor, SLC22A7_inhibitor, SLC22A12_inhibitor, SLC2A9_inhibitor"
    PubChemCompound "4911"
    HBondDonorCount "1"
    DrugSubClass "Benzenesulfonamides"
    RotatableBondCount "6"
    Name "Probenecid"
    Targets "SLC22A6_inhibitor, SLC22A11_inhibitor, SLC22A8_inhibitor, PANX1_antagonist, TAS2R16_Unkown"
    TherapeuticTargetsDatabase "DAP001292"
  ]
  node [
    id 45
    label "DB01088"
    PubChemSubstance "46507818"
    Carriers ""
    Wikipedia "Iloprost"
    HBondAcceptorCount "4"
    ChemSpider "4470703"
    ATCcode "B01AC11"
    Name "Iloprost"
    PolarSurfaceAreaPSA "77.76"
    logS "-4.6"
    logP "3.56"
    Refractivity "105.18"
    pKastrongestbasic "-0.87"
    Bioavailability "1"
    DrugClass "Fatty Acyls"
    ChEMBL "CHEMBL494"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "4.66"
    NumberofRings "2"
    BindingDB "23954"
    MolecularWeight "360.494"
    PhysiologicalCharge "-1"
    Enzymes ""
    GhoseFilter "1"
    PubChemCompound "5311181"
    MonoisotopicWeight "360.23005951"
    MDDRLikeRule "0"
    ChEBI "63916"
    Polarizability "42.68"
    PharmGKB "PA164746843"
    Family "small molecule"
    MolecularFormula "C22H32O4"
    Transporters "SLCO2B1_substrate, SLCO2A1_substrate, SLCO3A1_substrate"
    PathwayNames ""
    HBondDonorCount "3"
    DrugSubClass "Eicosanoids"
    RotatableBondCount "9"
    WaterSolubility "8.74e-03"
    Targets "PTGIR_agonist, PTGER1_agonist, PDE4A_inducer, PDE4B_inducer, PDE4C_inducer, PDE4D_inducer, PLAT_other/unknown, PTGDR2_agonist"
    TherapeuticTargetsDatabase "DAP000273"
  ]
  node [
    id 46
    label "DB00864"
    KEGGDrug "D00107"
    PubChemSubstance "46506004"
    Carriers "ALB, ORM1"
    WaterSolubility "4.02e-03"
    Wikipedia "Tacrolimus"
    HBondAcceptorCount "11"
    ChemSpider "393220"
    ATCcode "D11AH01, L04AD02"
    Polarizability "87.41"
    KEGGCompound "C01375"
    logS "-5.3"
    logP "5.59"
    Refractivity "215.62"
    pKastrongestbasic "-2.9"
    Bioavailability "0"
    DrugClass "Macrolide lactams"
    PathwayNames ""
    ChEMBL "CHEMBL269732"
    RuleofFive "0"
    Approved "True"
    pKastrongestacidic "9.96"
    NumberofRings "4"
    BindingDB "50030448"
    MolecularWeight "804.0182"
    PhysiologicalCharge "0"
    Enzymes "CYP3A7_substrate, CYP3A5_substrate, CYP3A4_substrate, CYP3A4_inhibitor"
    GhoseFilter "0"
    PolarSurfaceAreaPSA "178.36"
    MonoisotopicWeight "803.481976677"
    MDDRLikeRule "1"
    ChEBI "61049"
    PDB "FK5"
    DrugsProductDatabaseDPD "167"
    PharmGKB "PA451578"
    Family "small molecule"
    MolecularFormula "C44H69NO12"
    Transporters "ABCB1_substrate, ABCB1_inhibitor, ABCB1_inducer, ABCA5_substrate"
    PubChemCompound "445643"
    HBondDonorCount "3"
    DrugSubClass "None"
    RotatableBondCount "7"
    Name "Tacrolimus"
    Targets "FKBP1A_inhibitor"
    TherapeuticTargetsDatabase "DAP000162"
  ]
  node [
    id 47
    label "DB00860"
    KEGGDrug "D00472"
    PubChemSubstance "46504847"
    Carriers "SERPINA6"
    Wikipedia "Prednisolone"
    GuidetoPharmacology "2866"
    HBondAcceptorCount "5"
    ChemSpider "5552"
    ATCcode "R01AD52, D07AA03, S02BA03, S01CA02, D07XA02, D07CA03, A07EA01, C05AA04, V03AB05, S01CB02, S02CA01, A01AC54, S03BA02, S03CA02, R01AD02, H02AB06, D07BA01, S01BA04, S01BB02"
    Polarizability "38.78"
    KEGGCompound "C07369"
    logS "-3.2"
    logP "1.27"
    Refractivity "98.49"
    pKastrongestbasic "-2.9"
    Bioavailability "1"
    DrugClass "Steroids and steroid derivatives"
    PathwayNames "Prednisone Action Pathway_SMP00440, Prednisolone Action Pathway_SMP00441, Prednisone Metabolism Pathway_SMP00631, Prednisolone Metabolism Pathway_SMP00632"
    ChEMBL "CHEMBL131"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "12.58"
    NumberofRings "4"
    BindingDB "19190"
    MolecularWeight "360.444"
    PhysiologicalCharge "0"
    Enzymes "CYP3A4_substrate, CYP3A4_inhibitor, CYP2A6_inhibitor"
    IUPHAR "2866"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "94.83"
    MonoisotopicWeight "360.193674006"
    MDDRLikeRule "0"
    ChEBI "8378"
    WaterSolubility "2.39e-01"
    DrugsProductDatabaseDPD "7630"
    PharmGKB "PA451096"
    Family "small molecule"
    MolecularFormula "C21H28O5"
    Transporters "SLCO1A2_inhibitor, ABCB1_substrate"
    PubChemCompound "5755"
    HBondDonorCount "3"
    DrugSubClass "Hydroxysteroids"
    RotatableBondCount "2"
    Name "Prednisolone"
    Targets "NR3C1_agonist"
    TherapeuticTargetsDatabase "DAP000419"
  ]
  node [
    id 48
    label "DB00317"
    KEGGDrug "D01977"
    NumberofRings "4"
    Carriers "ALB, ORM1"
    PubChemSubstance "46508649"
    WaterSolubility "2.70e-02"
    Wikipedia "Gefitinib"
    HBondAcceptorCount "7"
    ChemSpider "110217"
    ATCcode "L01XE02"
    Polarizability "46.11"
    logS "-4.2"
    logP "3.75"
    pKastrongestbasic "6.85"
    Bioavailability "1"
    DrugClass "Diazanaphthalenes"
    PathwayNames "Gefitinib Action Pathway_SMP00473"
    ChEMBL "CHEMBL939"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "16.11"
    Refractivity "117.51"
    BindingDB "5447"
    MolecularWeight "446.902"
    PhysiologicalCharge "0"
    Enzymes "CYP3A4_substrate, CYP2D6_substrate, CYP1A1_substrate, CYP1A1_inhibitor, CYP2C9_inhibitor, CYP2C19_inhibitor"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "68.74"
    MonoisotopicWeight "446.152096566"
    MDDRLikeRule "1"
    ChEBI "49668"
    PDB "IRE"
    DrugsProductDatabaseDPD "13090"
    PharmGKB "PA131301952"
    Family "small molecule"
    MolecularFormula "C22H24ClFN4O3"
    Transporters "ABCB1_substrate, ABCB1_inhibitor, ABCG2_substrate, ABCG2_inhibitor"
    PubChemCompound "123631"
    HBondDonorCount "1"
    DrugSubClass "Benzodiazines"
    RotatableBondCount "8"
    Name "Gefitinib"
    Targets "EGFR_antagonist, CYP3A5_Unkown"
    TherapeuticTargetsDatabase "DAP000657"
  ]
  node [
    id 49
    label "DB00176"
    PubChemSubstance "46507588"
    Carriers ""
    Wikipedia "Fluvoxamine"
    HBondAcceptorCount "4"
    ChemSpider "4481878"
    ATCcode "N06AB08"
    RuleofFive "1"
    KEGGCompound "C07571"
    PolarSurfaceAreaPSA "56.84"
    logS "-4.6"
    logP "2.8"
    Refractivity "79.2"
    pKastrongestbasic "9.16"
    Bioavailability "1"
    DrugClass "Benzene and substituted derivatives"
    ChEMBL "CHEMBL814"
    Polarizability "32.44"
    Approved "True"
    MolecularWeight "318.3346"
    NumberofRings "1"
    BindingDB "50028091"
    Name "Fluvoxamine"
    PhysiologicalCharge "1"
    Enzymes "CYP2D6_substrate, CYP2D6_inhibitor, CYP1A2_substrate, CYP1A2_inhibitor, CYP2E1_substrate, CYP1A1_inhibitor, CYP3A4_inhibitor, CYP3A5_inhibitor, CYP3A7_inhibitor, CYP2C9_inhibitor, CYP2C19_inhibitor, CYP2B6_inhibitor, CYP2C8_inhibitor"
    GhoseFilter "1"
    PubChemCompound "3404"
    MonoisotopicWeight "318.155512541"
    MDDRLikeRule "0"
    ChEBI "5138"
    PDB "FVX"
    DrugsProductDatabaseDPD "1212"
    PharmGKB "PA449690"
    Family "small molecule"
    MolecularFormula "C15H21F3N2O2"
    Transporters "ABCB1_inhibitor"
    PathwayNames ""
    HBondDonorCount "1"
    DrugSubClass "Trifluoromethylbenzenes"
    RotatableBondCount "10"
    WaterSolubility "7.34e-03"
    Targets "SLC6A4_inhibitor, KCNH2_Unkown"
    TherapeuticTargetsDatabase "DNC000897"
  ]
  node [
    id 50
    label "DB01248"
    KEGGDrug "D02165"
    PubChemSubstance "46506766"
    Carriers ""
    WaterSolubility "1.27e-02"
    Wikipedia "Docetaxel"
    HBondAcceptorCount "10"
    ChemSpider "130581"
    ATCcode "L01CD02"
    Polarizability "82.06"
    KEGGCompound "C11231"
    logS "-4.8"
    logP "2.92"
    Refractivity "203.9"
    pKastrongestbasic "-3"
    Bioavailability "0"
    DrugClass "Prenol lipids"
    PathwayNames "Docetaxel Action Pathway_SMP00435"
    ChEMBL "CHEMBL92"
    RuleofFive "0"
    Approved "True"
    pKastrongestacidic "10.96"
    NumberofRings "6"
    BindingDB "36351"
    MolecularWeight "807.8792"
    PhysiologicalCharge "0"
    Enzymes "CYP3A4_substrate, CYP3A4_inhibitor, CYP3A5_substrate, CYP3A7_substrate, CYP1B1_substrate, CYP1B1_inhibitor, CYP1B1_inducer"
    GhoseFilter "0"
    PolarSurfaceAreaPSA "224.45"
    MonoisotopicWeight "807.346605409"
    MDDRLikeRule "1"
    ChEBI "4672"
    PDB "TXL"
    DrugsProductDatabaseDPD "157"
    PharmGKB "PA449383"
    Family "small molecule"
    MolecularFormula "C43H53NO14"
    Transporters "ABCB1_substrate, ABCC10_substrate, SLCO1B3_substrate, SLC22A7_substrate, ABCG2_substrate, ABCC2_substrate, ABCC1_substrate"
    PubChemCompound "148124"
    HBondDonorCount "5"
    DrugSubClass "Diterpenoids"
    RotatableBondCount "13"
    Name "Docetaxel"
    Targets "TUBB1_Unkown, BCL2_Unkown, MAP2_Unkown, MAP4_Unkown, MAPT_Unkown, NR1I2_binder"
    TherapeuticTargetsDatabase "DAP000590"
  ]
  node [
    id 51
    label "DB01004"
    KEGGDrug "D00333"
    NumberofRings "2"
    Carriers ""
    PubChemSubstance "46507294"
    WaterSolubility "1.15e+01"
    Wikipedia "Ganciclovir"
    HBondAcceptorCount "7"
    ChemSpider "3336"
    ATCcode "R03DA20, S01AD09, J05AB06"
    Polarizability "24.15"
    logS "-1.4"
    logP "-2.2"
    pKastrongestbasic "1.76"
    Bioavailability "1"
    DrugClass "Imidazopyrimidines"
    PathwayNames ""
    ChEMBL "CHEMBL182"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "10.16"
    Refractivity "61.03"
    BindingDB "85707"
    MolecularWeight "255.2306"
    PhysiologicalCharge "0"
    Enzymes ""
    GhoseFilter "0"
    PolarSurfaceAreaPSA "134.99"
    MonoisotopicWeight "255.096753929"
    MDDRLikeRule "0"
    ChEBI "465284"
    PDB "GA2"
    DrugsProductDatabaseDPD "1238"
    PharmGKB "PA449733"
    Family "small molecule"
    MolecularFormula "C9H13N5O4"
    Transporters "SLC22A1_inhibitor, SLC22A6_inhibitor, SLC22A8_inhibitor, SLC22A7_inhibitor"
    PubChemCompound "3454"
    HBondDonorCount "4"
    DrugSubClass "Purines and purine derivatives"
    RotatableBondCount "5"
    Name "Ganciclovir"
    Targets "S100P_inhibitor, DNA, TK_inducer"
    TherapeuticTargetsDatabase "DAP000645"
  ]
  node [
    id 52
    label "DB01005"
    KEGGDrug "D00341"
    PubChemSubstance "46506927"
    Carriers ""
    WaterSolubility "2.69e+02"
    Wikipedia "Hydroxyurea"
    HBondAcceptorCount "2"
    ChemSpider "3530"
    ATCcode "L01XX05"
    Polarizability "5.94"
    KEGGCompound "C07044"
    logS "0.55"
    logP "-1.4"
    Refractivity "14.91"
    pKastrongestbasic "-4.9"
    Bioavailability "1"
    DrugClass "Carboximidic acids and derivatives"
    PathwayNames ""
    ChEMBL "CHEMBL467"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "10.14"
    NumberofRings "0"
    BindingDB "50017811"
    MolecularWeight "76.0547"
    PhysiologicalCharge "0"
    Enzymes "CYP2D6_inhibitor"
    GhoseFilter "0"
    PolarSurfaceAreaPSA "75.35"
    MonoisotopicWeight "76.027277382"
    MDDRLikeRule "0"
    ChEBI "44423"
    PDB "NHY"
    DrugsProductDatabaseDPD "10140"
    PharmGKB "PA449942"
    Family "small molecule"
    MolecularFormula "CH4N2O2"
    Transporters ""
    PubChemCompound "3657"
    HBondDonorCount "3"
    DrugSubClass "None"
    RotatableBondCount "0"
    Name "Hydroxyurea"
    Targets "RRM1_inhibitor"
    TherapeuticTargetsDatabase "DAP000739"
  ]
  node [
    id 53
    label "DB00570"
    PubChemSubstance "46504550"
    Carriers ""
    Wikipedia "Vinblastine"
    HBondAcceptorCount "9"
    ChemSpider "12773"
    ATCcode "L01CA01"
    Name "Vinblastine"
    PolarSurfaceAreaPSA "154.1"
    logS "-4.7"
    logP "4.18"
    Polarizability "87.81"
    Refractivity "222.42"
    pKastrongestbasic "8.86"
    Bioavailability "1"
    DrugClass "Vinca alkaloids"
    ChEMBL "CHEMBL159"
    RuleofFive "0"
    Approved "True"
    pKastrongestacidic "10.87"
    NumberofRings "9"
    BindingDB "50012278"
    MolecularWeight "810.9741"
    PhysiologicalCharge "2"
    Enzymes "CYP3A4_substrate, CYP3A4_inhibitor, CYP2D6_substrate, CYP2D6_inhibitor"
    GhoseFilter "0"
    PubChemCompound "13342"
    MonoisotopicWeight "810.420379474"
    MDDRLikeRule "1"
    PDB "VLB"
    DrugsProductDatabaseDPD "9407"
    PharmGKB "PA451877"
    Family "small molecule"
    MolecularFormula "C46H58N4O9"
    Transporters "ABCB1_substrate, ABCB1_inhibitor, ABCB1_inducer, ABCC1_substrate, ABCC1_inhibitor, ABCC1_inducer, ABCC2_substrate, ABCC2_inhibitor, ABCC2_inducer, ABCC6_inhibitor, ABCB11_substrate, ABCB11_inhibitor"
    PathwayNames "Vinblastine Action Pathway_SMP00436"
    HBondDonorCount "3"
    DrugSubClass "None"
    RotatableBondCount "10"
    WaterSolubility "1.69e-02"
    Targets "TUBA1A_adduct, TUBB_adduct, TUBD1_adduct, TUBG1_adduct, TUBE1_adduct, JUN_other/unknown"
    TherapeuticTargetsDatabase "DAP000785"
  ]
  node [
    id 54
    label "DB01008"
    KEGGDrug "D00248"
    PubChemSubstance "46506234"
    Carriers ""
    Wikipedia "Busulfan"
    HBondAcceptorCount "4"
    ChemSpider "2384"
    ATCcode "L01AB01"
    Polarizability "23.64"
    KEGGCompound "C06862"
    PolarSurfaceAreaPSA "86.74"
    logS "-1.7"
    logP "-0.76"
    Refractivity "49.57"
    Bioavailability "1"
    DrugClass "Organic sulfonic acids and derivatives"
    ChEMBL "CHEMBL820"
    RuleofFive "1"
    Approved "True"
    MolecularWeight "246.302"
    NumberofRings "0"
    Name "Busulfan"
    PhysiologicalCharge "0"
    Enzymes "CYP3A4_substrate, GSTA2_substrate, GSTA1_substrate, GSTM1_substrate, GSTP1_substrate, MGST2_substrate"
    GhoseFilter "0"
    PubChemCompound "2478"
    MonoisotopicWeight "246.02317956"
    MDDRLikeRule "0"
    ChEBI "28901"
    DrugsProductDatabaseDPD "9556"
    PharmGKB "PA448691"
    Family "small molecule"
    MolecularFormula "C6H14O6S2"
    Transporters ""
    PathwayNames ""
    HBondDonorCount "0"
    DrugSubClass "Organosulfonic acids and derivatives"
    RotatableBondCount "7"
    WaterSolubility "5.16e+00"
    Targets "DNA"
  ]
  node [
    id 55
    label "DB06718"
    KEGGDrug "D00444"
    PubChemSubstance "99443270"
    Carriers ""
    Wikipedia "Stanozolol"
    HBondAcceptorCount "2"
    ChemSpider "23582"
    ATCcode "A14AA02"
    Polarizability "39.22"
    KEGGCompound "C07311"
    logS "-5.3"
    logP "3.81"
    Refractivity "96.8"
    pKastrongestbasic "2.86"
    Bioavailability "1"
    DrugClass "Steroids and steroid derivatives"
    PathwayNames ""
    ChEMBL "CHEMBL2079587"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "16.23"
    NumberofRings "5"
    MolecularWeight "328.4916"
    PhysiologicalCharge "0"
    Enzymes ""
    GhoseFilter "1"
    PolarSurfaceAreaPSA "48.91"
    MonoisotopicWeight "328.251463656"
    MDDRLikeRule "0"
    ChEBI "9249"
    WaterSolubility "1.73e-03"
    DrugsProductDatabaseDPD "7457"
    PharmGKB "PA165958391"
    Family "small molecule"
    MolecularFormula "C21H32N2O"
    Transporters ""
    PubChemCompound "25249"
    HBondDonorCount "2"
    DrugSubClass "Estrane steroids"
    RotatableBondCount "0"
    Name "Stanozolol"
    Targets " Stanozolol Binding Protein (STBP), Low-affinity glucocorticoid-binding protein (LAGS)"
  ]
  node [
    id 56
    label "DB09477"
    KEGGDrug "D03769"
    PubChemSubstance "347827859"
    Carriers ""
    WaterSolubility "8.76e-01"
    Wikipedia "Enalaprilat"
    HBondAcceptorCount "6"
    ChemSpider "4575429"
    ATCcode ""
    Polarizability "35.82"
    KEGGCompound "C11720"
    logS "-2.6"
    logP "-1.1"
    Refractivity "90.06"
    pKastrongestbasic "7.83"
    Bioavailability "1"
    DrugClass "Carboxylic acids and derivatives"
    PathwayNames ""
    ChEMBL "CHEMBL577"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "3.13"
    NumberofRings "2"
    BindingDB "50367254"
    MolecularWeight "348.3936"
    PhysiologicalCharge "-1"
    Enzymes ""
    GhoseFilter "0"
    PolarSurfaceAreaPSA "106.94"
    MonoisotopicWeight "348.168521888"
    MDDRLikeRule "0"
    ChEBI "4786"
    PDB "EAL"
    DrugsProductDatabaseDPD "1776"
    Family "small molecule"
    MolecularFormula "C18H24N2O5"
    Transporters ""
    PubChemCompound "5462501"
    HBondDonorCount "3"
    DrugSubClass "Amino acids, peptides, and analogues"
    RotatableBondCount "8"
    Name "Enalaprilat"
    Targets "ACE_inhibitor, BDKRB1_Unkown"
  ]
  node [
    id 57
    label "DB00260"
    PubChemSubstance "46506865"
    Carriers ""
    WaterSolubility "8.77e+02"
    Wikipedia "Cycloserine"
    HBondAcceptorCount "3"
    ChemSpider "5998"
    ATCcode "J04AB01"
    Polarizability "8.87"
    KEGGCompound "C08057"
    logS "0.93"
    logP "-2.4"
    Refractivity "21.85"
    pKastrongestbasic "8.36"
    Bioavailability "1"
    DrugClass "Azolines"
    PathwayNames ""
    ChEMBL "CHEMBL771"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "4.21"
    NumberofRings "1"
    BindingDB "50038178"
    MolecularWeight "102.0919"
    PhysiologicalCharge "0"
    Enzymes "DDC_inhibitor"
    GhoseFilter "0"
    PolarSurfaceAreaPSA "64.35"
    MonoisotopicWeight "102.042927446"
    MDDRLikeRule "0"
    ChEBI "40009"
    PDB "4AX"
    DrugsProductDatabaseDPD "8528"
    PharmGKB "PA164764600"
    Family "small molecule"
    MolecularFormula "C3H6N2O2"
    Transporters "SLC36A2_Unkown"
    PubChemCompound "6234"
    HBondDonorCount "2"
    DrugSubClass "Isoxazolines"
    RotatableBondCount "0"
    Name "Cycloserine"
    Targets "ddlA_inhibitor, alr_inhibitor"
    TherapeuticTargetsDatabase "DAP001468"
  ]
  node [
    id 58
    label "DB00308"
    KEGGDrug "D00648"
    PubChemSubstance "46507904"
    Carriers ""
    Wikipedia "Ibutilide"
    HBondAcceptorCount "4"
    ChemSpider "54755"
    ATCcode "C01BD05"
    Polarizability "46.45"
    KEGGCompound "C07753"
    logS "-4.9"
    logP "2.54"
    Refractivity "109.18"
    pKastrongestbasic "10.4"
    Bioavailability "1"
    DrugClass "Benzene and substituted derivatives"
    PathwayNames "Ibutilide Action Pathway_SMP00332"
    ChEMBL "CHEMBL533"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "9.72"
    NumberofRings "1"
    BindingDB "50131432"
    MolecularWeight "384.576"
    PhysiologicalCharge "1"
    Enzymes ""
    GhoseFilter "1"
    PolarSurfaceAreaPSA "69.64"
    MonoisotopicWeight "384.244663718"
    MDDRLikeRule "0"
    ChEBI "5856"
    WaterSolubility "4.73e-03"
    DrugsProductDatabaseDPD "12005"
    PharmGKB "PA449958"
    Family "small molecule"
    MolecularFormula "C20H36N2O3S"
    Transporters ""
    PubChemCompound "60753"
    HBondDonorCount "2"
    DrugSubClass "Phenylbutylamines"
    RotatableBondCount "13"
    Name "Ibutilide"
    Targets "CACNA1C_activator, CACNB1_activator, KCNH2_inhibitor, CACNA2D1_activator, CACNG1_activator, KCNK1_inhibitor, KCNK6_inhibitor, KCNH6_inhibitor, KCNH7_inhibitor, KCNJ11_inhibitor"
    TherapeuticTargetsDatabase "DAP000279"
  ]
  node [
    id 59
    label "DB00262"
    KEGGDrug "D00254"
    PubChemSubstance "46506980"
    Carriers ""
    Wikipedia "Carmustine"
    HBondAcceptorCount "2"
    ChemSpider "2480"
    ATCcode "L01AD01"
    Polarizability "18.8"
    KEGGCompound "C06873"
    logS "-2.2"
    logP "1.02"
    Refractivity "46.98"
    pKastrongestbasic "-5.3"
    Bioavailability "1"
    DrugClass "Organic carbonic acids and derivatives"
    PathwayNames ""
    ChEMBL "CHEMBL513"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "11.96"
    NumberofRings "0"
    BindingDB "50015950"
    MolecularWeight "214.05"
    PhysiologicalCharge "0"
    Enzymes "CYP1A2_substrate"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "61.77"
    MonoisotopicWeight "213.007181961"
    MDDRLikeRule "0"
    ChEBI "3423"
    WaterSolubility "1.53e+00"
    DrugsProductDatabaseDPD "2418"
    PharmGKB "PA448810"
    Family "small molecule"
    MolecularFormula "C5H9Cl2N3O2"
    Transporters ""
    PubChemCompound "2578"
    HBondDonorCount "1"
    DrugSubClass "Ureas"
    RotatableBondCount "5"
    Name "Carmustine"
    Targets "DNA, GSR_inhibitor, RNA"
    TherapeuticTargetsDatabase "DAP000041"
  ]
  node [
    id 60
    label "DB01064"
    PubChemSubstance "46507323"
    Carriers ""
    Wikipedia "Isoproterenol"
    GuidetoPharmacology "536"
    HBondAcceptorCount "4"
    ChemSpider "3647"
    ATCcode "R03AK02, R03CB51, R03CB01, R03AB02, C01CA02"
    Polarizability "23.04"
    KEGGCompound "C07056"
    logS "-1.6"
    logP "0.24"
    Refractivity "58.4"
    pKastrongestbasic "8.96"
    Bioavailability "1"
    DrugClass "Phenols"
    PathwayNames "Isoprenaline Action Pathway_SMP00663"
    ChEMBL "CHEMBL434"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "9.81"
    NumberofRings "1"
    BindingDB "25392"
    MolecularWeight "211.2576"
    PhysiologicalCharge "1"
    Enzymes "CYP1A1_inhibitor"
    IUPHAR "536"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "72.72"
    MonoisotopicWeight "211.120843415"
    MDDRLikeRule "0"
    ChEBI "64317"
    WaterSolubility "5.86e+00"
    DrugsProductDatabaseDPD "10114"
    PharmGKB "PA450121"
    Family "small molecule"
    MolecularFormula "C11H17NO3"
    Transporters ""
    PubChemCompound "3779"
    HBondDonorCount "4"
    DrugSubClass "Benzenediols"
    RotatableBondCount "4"
    Name "Isoprenaline"
    Targets "ADRB1_agonist, ADRB2_agonist, ADRB3_agonist, MAPK1_inducer, PIK3R1_agonist, PIK3R2_agonist, PIK3R3_agonist, PDE4_activator, SOD1_Unkown"
    TherapeuticTargetsDatabase "DNC000819"
  ]
  node [
    id 61
    label "DB00619"
    KEGGDrug "D01441"
    NumberofRings "5"
    Carriers "ALB, ORM1"
    PubChemSubstance "46505055"
    WaterSolubility "1.46e-02"
    Wikipedia "Imatinib"
    HBondAcceptorCount "7"
    ChemSpider "5101"
    ATCcode "L01XE01"
    Polarizability "55.54"
    logS "-4.5"
    logP "4.38"
    pKastrongestbasic "8.27"
    Bioavailability "1"
    DrugClass "Benzene and substituted derivatives"
    PathwayNames "Imatinib Inhibition of BCR-ABL_SMP31694"
    ChEMBL "CHEMBL941"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "12.45"
    Refractivity "148.93"
    BindingDB "13530"
    MolecularWeight "493.6027"
    PhysiologicalCharge "1"
    Enzymes "CYP3A4_substrate, CYP3A4_inhibitor, CYP3A5_substrate, CYP3A5_inhibitor, CYP3A7_substrate, CYP3A7_inhibitor, CYP1A2_substrate, CYP2C9_substrate, CYP2C9_inhibitor, CYP2D6_substrate, CYP2D6_inhibitor, CYP2C19_substrate, PTGS1_substrate"
    GhoseFilter "0"
    PolarSurfaceAreaPSA "86.28"
    MonoisotopicWeight "493.259008649"
    MDDRLikeRule "1"
    ChEBI "45783"
    PDB "STI"
    DrugsProductDatabaseDPD "12429"
    PharmGKB "PA10804"
    Family "small molecule"
    MolecularFormula "C29H31N7O"
    Transporters "SLC22A1_substrate, SLC22A1_inhibitor, ABCB1_substrate, ABCB1_inhibitor, SLC22A2_inhibitor, ABCG2_substrate, ABCG2_inhibitor, ABCA3_substrate"
    PubChemCompound "5291"
    HBondDonorCount "2"
    DrugSubClass "Anilides"
    RotatableBondCount "7"
    Name "Imatinib"
    Targets "BCR/ABL fusion_inhibitor, KIT_antagonist, KIT_multitarget, RET_inhibitor, NTRK1_antagonist, CSF1R_antagonist, PDGFRA_antagonist, DDR1_antagonist, ABL1_inhibitor, PDGFRB_antagonist"
    TherapeuticTargetsDatabase "DNC001383"
  ]
  node [
    id 62
    label "DB00752"
    KEGGDrug "D08625"
    NumberofRings "2"
    Carriers ""
    PubChemSubstance "46505832"
    Wikipedia "Tranylcypromine"
    HBondAcceptorCount "1"
    ChemSpider "5329"
    ATCcode "N06AF04"
    RuleofFive "1"
    KEGGCompound "C07155"
    logS "-2"
    logP "1.34"
    pKastrongestbasic "9.62"
    Bioavailability "1"
    DrugClass "Organonitrogen compounds"
    PathwayNames ""
    ChEMBL "CHEMBL313833"
    Polarizability "15.51"
    Approved "True"
    MolecularWeight "133.194"
    Refractivity "41.7"
    BindingDB "50113851"
    Name "Tranylcypromine"
    PhysiologicalCharge "1"
    Enzymes "CYP3A4_inhibitor, CYP2D6_inhibitor, CYP2C9_inhibitor, CYP2C19_inhibitor, CYP1A2_inhibitor, CYP2E1_inhibitor, CYP2A6_inhibitor"
    GhoseFilter "0"
    PolarSurfaceAreaPSA "26.02"
    MonoisotopicWeight "133.089149358"
    MDDRLikeRule "0"
    ChEBI "131512"
    PDB "GJZ"
    DrugsProductDatabaseDPD "5882"
    PharmGKB "PA451741"
    Family "small molecule"
    MolecularFormula "C9H11N"
    Transporters ""
    PubChemCompound "5530"
    HBondDonorCount "1"
    DrugSubClass "Amines"
    RotatableBondCount "1"
    WaterSolubility "1.49e+00"
    Targets "MAOA_inhibitor, MAOB_inhibitor"
    TherapeuticTargetsDatabase "DAP000081"
  ]
  node [
    id 63
    label "DB00207"
    PubChemSubstance "46507743"
    Carriers ""
    WaterSolubility "5.14e-01"
    Wikipedia "Azithromycin"
    HBondAcceptorCount "13"
    ChemSpider "10482163"
    ATCcode "J01FA10, S01AA26, J01RA07"
    Polarizability "83.11"
    KEGGCompound "C06838"
    logS "-3.2"
    logP "2.44"
    Refractivity "194.11"
    pKastrongestbasic "9.57"
    Bioavailability "0"
    DrugClass "Organooxygen compounds"
    PathwayNames "Azithromycin Action Pathway_SMP00247"
    ChEMBL "CHEMBL529"
    RuleofFive "0"
    Approved "True"
    pKastrongestacidic "12.43"
    NumberofRings "3"
    BindingDB "50373918"
    MolecularWeight "748.9845"
    PhysiologicalCharge "2"
    Enzymes "CYP2A6_inhibitor, CYP1A2_inhibitor, CYP3A4_substrate, CYP3A4_inhibitor"
    GhoseFilter "0"
    PolarSurfaceAreaPSA "180.08"
    MonoisotopicWeight "748.508525778"
    MDDRLikeRule "1"
    ChEBI "2955"
    PDB "ZIT"
    DrugsProductDatabaseDPD "424"
    PharmGKB "PA448519"
    Family "small molecule"
    MolecularFormula "C38H72N2O12"
    Transporters "ABCB1_inhibitor"
    PubChemCompound "447043"
    HBondDonorCount "5"
    DrugSubClass "Carbohydrates and carbohydrate conjugates"
    RotatableBondCount "7"
    Name "Azithromycin"
    Targets "23S rRNA, rplD_inhibitor, rplV_inhibitor, PADI4_Unkown"
    TherapeuticTargetsDatabase "DNC001539"
  ]
  node [
    id 64
    label "DB00758"
    KEGGDrug "D00769"
    NumberofRings "3"
    Carriers ""
    PubChemSubstance "46507295"
    Wikipedia "Clopidogrel"
    HBondAcceptorCount "2"
    ChemSpider "54632"
    ATCcode "B01AC04"
    Polarizability "33.19"
    logS "-4.4"
    logP "4.03"
    pKastrongestbasic "5.14"
    Bioavailability "1"
    DrugClass "Carboxylic acids and derivatives"
    PathwayNames "Clopidogrel Action Pathway_SMP00260, Clopidogrel Metabolism Pathway_SMP00610"
    ChEMBL "CHEMBL1771"
    RuleofFive "1"
    Approved "True"
    MolecularWeight "321.822"
    Refractivity "84.93"
    BindingDB "50318910"
    Name "Clopidogrel"
    PhysiologicalCharge "0"
    Enzymes "CYP3A4_substrate, CYP2B6_substrate, CYP2B6_inhibitor, CYP3A5_substrate, CYP2C19_substrate, CYP2C9_substrate, CYP2C9_inhibitor, CYP1A2_substrate, CYP2C8_inhibitor, CES1_substrate"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "29.54"
    MonoisotopicWeight "321.059027158"
    MDDRLikeRule "0"
    ChEBI "37941"
    PDB "CGE"
    DrugsProductDatabaseDPD "11795"
    PharmGKB "PA449053"
    Family "small molecule"
    MolecularFormula "C16H16ClNO2S"
    Transporters "ABCB1_substrate"
    PubChemCompound "60606"
    HBondDonorCount "0"
    DrugSubClass "Amino acids, peptides, and analogues"
    RotatableBondCount "4"
    WaterSolubility "1.18e-02"
    Targets "P2RY12_antagonist"
    TherapeuticTargetsDatabase "DAP000178"
  ]
  node [
    id 65
    label "DB00977"
    KEGGDrug "D00554"
    PubChemSubstance "46508618"
    Carriers ""
    WaterSolubility "6.77e-03"
    Wikipedia "Ethinylestradiol"
    HBondAcceptorCount "2"
    ChemSpider "5770"
    ATCcode "G03AA03, G03AA04, G03AB07, G03AA10, G03AA08, G03AB05, G03AA09, G03AB01, G03AA11, G03AB03, G03CA01, L02AA03, G03AB02, G03AA02, G03AA01, G03AA05, G03AA12, G03AA07, G03AB04, G03AA13, G03AB06, G03AA15, G03AA16, G03AA06"
    Polarizability "34.53"
    KEGGCompound "C07534"
    logS "-4.6"
    logP "3.9"
    Refractivity "87.37"
    pKastrongestbasic "-1.7"
    Bioavailability "1"
    DrugClass "Steroids and steroid derivatives"
    PathwayNames ""
    ChEMBL "CHEMBL691"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "10.33"
    NumberofRings "4"
    BindingDB "50187243"
    MolecularWeight "296.4034"
    PhysiologicalCharge "0"
    Enzymes "CYP3A4_substrate, CYP2C8_inhibitor, UGT1A1_substrate, UGT1A1_inducer"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "40.46"
    MonoisotopicWeight "296.177630012"
    MDDRLikeRule "0"
    ChEBI "4903"
    PDB "3WF"
    DrugsProductDatabaseDPD "7426"
    PharmGKB "PA449527"
    Family "small molecule"
    MolecularFormula "C20H24O2"
    Transporters "ABCB11_inhibitor, ABCB11_inducer, SLC10A1_inducer, ABCC2_inducer, ABCB1_substrate"
    PubChemCompound "5991"
    HBondDonorCount "2"
    DrugSubClass "Estrane steroids"
    RotatableBondCount "0"
    Name "Ethinyl Estradiol"
    Targets "ESR1_agonist, NR1I2_agonist, SHBG_Unkown"
    TherapeuticTargetsDatabase "DAP001018"
  ]
  node [
    id 66
    label "DB00613"
    KEGGDrug "D02922"
    PubChemSubstance "46506940"
    Carriers ""
    WaterSolubility "8.80e-03"
    Wikipedia "Amodiaquine"
    HBondAcceptorCount "4"
    ChemSpider "2080"
    ATCcode "P01BF03, P01BA06"
    Polarizability "38.89"
    KEGGCompound "C07626"
    logS "-4.6"
    logP "3.76"
    Refractivity "103.29"
    pKastrongestbasic "10.23"
    Bioavailability "1"
    DrugClass "Quinolines and derivatives"
    PathwayNames ""
    ChEMBL "CHEMBL682"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "9.12"
    NumberofRings "3"
    BindingDB "50041457"
    MolecularWeight "355.861"
    PhysiologicalCharge "1"
    Enzymes "CYP2C8_substrate, CYP1A1_substrate, CYP1B1_substrate, CYP2D6_inhibitor, CYP2C9_inhibitor"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "48.39"
    MonoisotopicWeight "355.145140048"
    MDDRLikeRule "1"
    ChEBI "2674"
    PDB "CQA"
    PharmGKB "PA448404"
    Family "small molecule"
    MolecularFormula "C20H22ClN3O"
    Transporters ""
    PubChemCompound "2165"
    HBondDonorCount "2"
    DrugSubClass "Aminoquinolines and derivatives"
    RotatableBondCount "6"
    Name "Amodiaquine"
    Targets "Fe(II)-protoporphyrin IX, HNMT_inhibitor"
    TherapeuticTargetsDatabase "DAP000699"
  ]
  node [
    id 67
    label "DB00614"
    KEGGDrug "D00830"
    Refractivity "51.09"
    Carriers ""
    PubChemSubstance "46507291"
    Wikipedia "Furazolidone"
    HBondAcceptorCount "4"
    ChemSpider "4481255"
    ATCcode "G01AX06"
    MolecularWeight "225.1583"
    KEGGCompound "C07999"
    logS "-2.8"
    logP "0.87"
    pKastrongestbasic "-2.4"
    Bioavailability "1"
    DrugClass "Furans"
    PathwayNames ""
    ChEMBL "CHEMBL1103"
    RuleofFive "1"
    Approved "True"
    NumberofRings "2"
    Polarizability "19.74"
    Name "Furazolidone"
    PhysiologicalCharge "0"
    Enzymes "MAOB_inhibitor, MAOA_inhibitor"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "100.86"
    MonoisotopicWeight "225.038570349"
    MDDRLikeRule "0"
    ChEBI "5195"
    DrugsProductDatabaseDPD "10161"
    PharmGKB "PA164746760"
    Family "small molecule"
    MolecularFormula "C8H7N3O5"
    Transporters ""
    PubChemCompound "3435"
    HBondDonorCount "0"
    DrugSubClass "Nitrofurans"
    RotatableBondCount "3"
    WaterSolubility "3.64e-01"
    Targets "DNA"
    TherapeuticTargetsDatabase "DAP000993"
  ]
  node [
    id 68
    label "DB00615"
    KEGGDrug "D00424"
    PubChemSubstance "46506468"
    Carriers ""
    WaterSolubility "1.70e-02"
    Wikipedia "Rifabutin"
    HBondAcceptorCount "13"
    ChemSpider "10482168"
    ATCcode "J04AB04"
    Polarizability "90.72"
    KEGGCompound "C07235"
    logS "-4.7"
    logP "4.19"
    Refractivity "232.64"
    pKastrongestbasic "8.62"
    Bioavailability "0"
    DrugClass "Macrolactams"
    PathwayNames ""
    ChEMBL "CHEMBL444633"
    RuleofFive "0"
    Approved "True"
    pKastrongestacidic "7.93"
    NumberofRings "6"
    MolecularWeight "847.0047"
    PhysiologicalCharge "1"
    Enzymes "CYP3A4_substrate, CYP3A4_inducer, CYP1A2_substrate"
    GhoseFilter "0"
    PolarSurfaceAreaPSA "205.55"
    MonoisotopicWeight "846.441508846"
    MDDRLikeRule "0"
    ChEBI "45367"
    PDB "RBT"
    DrugsProductDatabaseDPD "8316"
    PharmGKB "PA451249"
    Family "small molecule"
    MolecularFormula "C46H62N4O11"
    Transporters ""
    PubChemCompound "6323490"
    HBondDonorCount "5"
    DrugSubClass "None"
    RotatableBondCount "5"
    Name "Rifabutin"
    Targets "rpoA_inhibitor, rpoB_inhibitor, rpoC_inhibitor, HSP90AA1_other/unknown, HSP90B1_other/unknown"
    TherapeuticTargetsDatabase "DAP000656"
  ]
  node [
    id 69
    label "DB00973"
    KEGGDrug "D01966"
    NumberofRings "4"
    Carriers ""
    PubChemSubstance "46507625"
    Wikipedia "Ezetimibe"
    HBondAcceptorCount "3"
    ChemSpider "132493"
    ATCcode "C10BA02, C10BA05, C10AX09, C10BA06"
    Polarizability "41.64"
    logS "-4.7"
    logP "4.56"
    pKastrongestbasic "-3"
    Bioavailability "1"
    DrugClass "Lactams"
    PathwayNames ""
    ChEMBL "CHEMBL1138"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "9.48"
    Refractivity "108.86"
    BindingDB "50371521"
    MolecularWeight "409.4252"
    PhysiologicalCharge "0"
    Enzymes "UGT1A1_substrate, UGT1A3_substrate, UGT2B15_substrate, UGT2B7_substrate, CYP3A4_inhibitor"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "60.77"
    MonoisotopicWeight "409.148949953"
    MDDRLikeRule "1"
    ChEBI "49040"
    WaterSolubility "8.46e-03"
    DrugsProductDatabaseDPD "12754"
    PharmGKB "PA10816"
    Family "small molecule"
    MolecularFormula "C24H21F2NO3"
    Transporters "ABCB1_substrate, ABCC2_substrate, SLCO1B1_substrate, ABCG5_substrate, ABCC3_substrate, ABCG2_substrate, ABCG8_substrate"
    PubChemCompound "150311"
    HBondDonorCount "2"
    DrugSubClass "Beta lactams"
    RotatableBondCount "6"
    Name "Ezetimibe"
    Targets "SOAT1_inhibitor, NPC1L1_inhibitor, ANPEP_other, CYP2C8_Unkown"
    TherapeuticTargetsDatabase "DAP000717"
  ]
  node [
    id 70
    label "DB00594"
    KEGGDrug "D07447"
    PubChemSubstance "46508156"
    Carriers ""
    WaterSolubility "1.22e+00"
    Wikipedia "Amiloride"
    GuidetoPharmacology "2421"
    HBondAcceptorCount "8"
    ChemSpider "15403"
    ATCcode "C03DB01"
    Polarizability "19.99"
    KEGGCompound "C06821"
    logS "-2.3"
    logP "-0.89"
    Refractivity "56.69"
    pKastrongestbasic "3.29"
    Bioavailability "1"
    DrugClass "Diazines"
    PathwayNames "Amiloride Action Pathway_SMP00133"
    ChEMBL "CHEMBL945"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "16.46"
    NumberofRings "1"
    BindingDB "16173"
    MolecularWeight "229.627"
    PhysiologicalCharge "0"
    Enzymes "AOC1_inhibitor, AOC1_inhibitor"
    IUPHAR "2421"
    GhoseFilter "0"
    PolarSurfaceAreaPSA "159.29"
    MonoisotopicWeight "229.04788562"
    MDDRLikeRule "0"
    ChEBI "2639"
    PDB "AMR"
    DrugsProductDatabaseDPD "20230"
    PharmGKB "PA448368"
    Family "small molecule"
    MolecularFormula "C6H8ClN7O"
    Transporters "SLC22A2_inhibitor, SLC22A1_inhibitor, SLC22A4_inhibitor"
    PubChemCompound "16231"
    HBondDonorCount "4"
    DrugSubClass "Pyrazines"
    RotatableBondCount "1"
    Name "Amiloride"
    Targets "SCNN1A_inhibitor, SCNN1B_inhibitor, SCNN1G_inhibitor, SCNN1D_inhibitor, AOC1_inhibitor, ASIC2_inhibitor, ASIC1_inhibitor, SLC9A1_inhibitor, PLAU_inhibitor"
    TherapeuticTargetsDatabase "DAP000187"
  ]
  node [
    id 71
    label "DB00202"
    PubChemSubstance "46506023"
    Carriers ""
    Wikipedia "Succinylcholine"
    GuidetoPharmacology "4004"
    HBondAcceptorCount "2"
    ChemSpider "5123"
    ATCcode "M03AB01"
    RuleofFive "1"
    KEGGCompound "C07546"
    PolarSurfaceAreaPSA "52.6"
    logS "-5.7"
    logP "-8.4"
    Refractivity "100.94"
    pKastrongestbasic "-6.8"
    Bioavailability "1"
    DrugClass "Organonitrogen compounds"
    ChEMBL "CHEMBL703"
    Polarizability "33.15"
    Approved "True"
    MolecularWeight "290.399"
    NumberofRings "0"
    BindingDB "50061568"
    Name "Succinylcholine"
    PhysiologicalCharge "2"
    Enzymes "BCHE_substrate"
    IUPHAR "4004"
    GhoseFilter "0"
    PubChemCompound "5314"
    MonoisotopicWeight "290.220557458"
    MDDRLikeRule "0"
    ChEBI "45652"
    PDB "SCK"
    DrugsProductDatabaseDPD "8833"
    PharmGKB "PA451522"
    Family "small molecule"
    MolecularFormula "C14H30N2O4"
    Transporters ""
    PathwayNames ""
    HBondDonorCount "0"
    DrugSubClass "Quaternary ammonium salts"
    RotatableBondCount "11"
    WaterSolubility "7.57e-04"
    Targets "CHRNA10_agonist, CHRNA7_agonist, CHRM1_agonist, CHRM2_agonist, CHRM3_agonist"
    TherapeuticTargetsDatabase "DAP001132"
  ]
  node [
    id 72
    label "DB04844"
    KEGGDrug "D08575"
    PubChemSubstance "46506426"
    Carriers ""
    Wikipedia "Tetrabenazine"
    HBondAcceptorCount "4"
    ChemSpider "5796"
    ATCcode "N07XX06"
    Polarizability "36.59"
    KEGGCompound "C11168"
    logS "-2.9"
    logP "3.4"
    Refractivity "91.31"
    pKastrongestbasic "7.41"
    Bioavailability "1"
    DrugClass "Tetrahydroisoquinolines"
    PathwayNames ""
    ChEMBL "CHEMBL117785"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "18.24"
    NumberofRings "3"
    BindingDB "50017701"
    MolecularWeight "317.4226"
    PhysiologicalCharge "1"
    Enzymes "CYP2D6_substrate, CBR1_substrate"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "38.77"
    MonoisotopicWeight "317.199093735"
    MDDRLikeRule "0"
    ChEBI "64028"
    WaterSolubility "3.61e-01"
    DrugsProductDatabaseDPD "109"
    PharmGKB "PA140222719"
    Family "small molecule"
    MolecularFormula "C19H27NO3"
    Transporters ""
    PubChemCompound "6018"
    HBondDonorCount "0"
    DrugSubClass "None"
    RotatableBondCount "4"
    Name "Tetrabenazine"
    Targets "SLC18A2_inhibitor, DRD2_inhibitor"
    TherapeuticTargetsDatabase "DAP000756"
  ]
  node [
    id 73
    label "DB00284"
    KEGGDrug "D00216"
    PubChemSubstance "46508248"
    Carriers ""
    WaterSolubility "1.08e+02"
    Wikipedia "Acarbose"
    HBondAcceptorCount "19"
    ChemSpider "23264314"
    ATCcode "A10BF01, A10BD17"
    Polarizability "62.11"
    KEGGCompound "C06802"
    logS "-0.78"
    logP "-8.3"
    Refractivity "139.02"
    pKastrongestbasic "7.03"
    Bioavailability "0"
    DrugClass "Organooxygen compounds"
    PathwayNames ""
    ChEMBL "CHEMBL1566"
    RuleofFive "0"
    Approved "True"
    pKastrongestacidic "11.83"
    NumberofRings "3"
    MolecularWeight "645.608"
    PhysiologicalCharge "1"
    Enzymes ""
    GhoseFilter "0"
    PolarSurfaceAreaPSA "329.01"
    MonoisotopicWeight "645.248013549"
    MDDRLikeRule "1"
    ChEBI "2376"
    PDB "QPS"
    DrugsProductDatabaseDPD "917"
    PharmGKB "PA448010"
    Family "small molecule"
    MolecularFormula "C25H43NO18"
    Transporters ""
    PubChemCompound "9811704"
    HBondDonorCount "14"
    DrugSubClass "Carbohydrates and carbohydrate conjugates"
    RotatableBondCount "13"
    Name "Acarbose"
    Targets "MGAM_inhibitor, AMY2A_inhibitor, GAA_inhibitor, SI_inhibitor"
    TherapeuticTargetsDatabase "DCL000309"
  ]
  node [
    id 74
    label "DB06335"
    KEGGDrug "D08996"
    NumberofRings "5"
    Carriers ""
    PubChemSubstance "99443245"
    Wikipedia "Saxagliptin"
    HBondAcceptorCount "4"
    ChemSpider "9419005"
    ATCcode "A10BH03, A10BD10, A10BD21"
    Polarizability "34.22"
    logS "-2.1"
    logP "-0.08"
    pKastrongestbasic "7.9"
    Bioavailability "1"
    DrugClass "Carboxylic acids and derivatives"
    PathwayNames ""
    ChEMBL "CHEMBL385517"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "14.74"
    Refractivity "83.99"
    BindingDB "11542"
    MolecularWeight "315.41"
    PhysiologicalCharge "1"
    Enzymes "CYP3A4_substrate, CYP3A5_substrate"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "90.35"
    MonoisotopicWeight "315.194677059"
    MDDRLikeRule "0"
    ChEBI "71272"
    WaterSolubility "2.26e+00"
    DrugsProductDatabaseDPD "20524"
    PharmGKB "PA165958362"
    Family "small molecule"
    MolecularFormula "C18H25N3O2"
    Transporters "ABCC1_substrate, SLCO4C1_substrate, SLC22A8_substrate"
    PubChemCompound "11243969"
    HBondDonorCount "2"
    DrugSubClass "Amino acids, peptides, and analogues"
    RotatableBondCount "2"
    Name "Saxagliptin"
    Targets "DPP4_inhibitor"
  ]
  node [
    id 75
    label "DB08880"
    KEGGDrug "D10172"
    NumberofRings "1"
    Carriers ""
    PubChemSubstance "347827807"
    WaterSolubility "1.24e-02"
    Wikipedia "Teriflunomide"
    HBondAcceptorCount "3"
    ChemSpider "16737143"
    ATCcode "L04AA31"
    Polarizability "23.15"
    logS "-4.3"
    logP "2.14"
    pKastrongestbasic "-3.2"
    Bioavailability "1"
    DrugClass "Benzene and substituted derivatives"
    PathwayNames ""
    ChEMBL "CHEMBL973"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "5.48"
    Refractivity "64.39"
    BindingDB "50018011"
    MolecularWeight "270.2073"
    PhysiologicalCharge "-1"
    Enzymes "CYP2C8_inhibitor"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "73.12"
    MonoisotopicWeight "270.061612157"
    MDDRLikeRule "0"
    ChEBI "68540"
    PDB "A26"
    DrugsProductDatabaseDPD "22169"
    Family "small molecule"
    MolecularFormula "C12H9F3N2O2"
    Transporters "ABCG2_substrate"
    PubChemCompound "54684141"
    HBondDonorCount "2"
    DrugSubClass "Trifluoromethylbenzenes"
    RotatableBondCount "3"
    Name "Teriflunomide"
    Targets "DHODH_inhibitor"
  ]
  node [
    id 76
    label "DB00759"
    KEGGDrug "D00201"
    PubChemSubstance "46506693"
    Carriers "ALB"
    WaterSolubility "1.33e+00"
    Wikipedia "Tetracycline"
    HBondAcceptorCount "9"
    ChemSpider "10257122"
    ATCcode "S02AA08, A02BD08, A01AB13, J01RA08, J01AA20, S03AA02, D06AA04, A02BD02, J01AA07, S01AA09"
    Polarizability "43.03"
    KEGGCompound "C06570"
    logS "-2.5"
    logP "-3.5"
    Refractivity "114.19"
    pKastrongestbasic "8.24"
    Bioavailability "1"
    DrugClass "Tetracyclines"
    PathwayNames "Tetracycline Action Pathway_SMP00294"
    ChEMBL "CHEMBL1440"
    RuleofFive "0"
    Approved "True"
    pKastrongestacidic "-2.2"
    NumberofRings "4"
    MolecularWeight "444.4346"
    PhysiologicalCharge "-1"
    Enzymes "CYP3A4_substrate, CYP3A4_inhibitor"
    GhoseFilter "0"
    PolarSurfaceAreaPSA "181.62"
    MonoisotopicWeight "444.153265754"
    MDDRLikeRule "0"
    ChEBI "27902"
    PDB "TAC"
    DrugsProductDatabaseDPD "8683"
    PharmGKB "PA451640"
    Family "small molecule"
    MolecularFormula "C22H24N2O8"
    Transporters "SLC22A6_inhibitor, SLC22A8_substrate, SLC22A8_inhibitor, SLC22A11_inhibitor, SLC22A7_inhibitor"
    PubChemCompound "54675776"
    HBondDonorCount "6"
    DrugSubClass "None"
    RotatableBondCount "2"
    Name "Tetracycline"
    Targets "rpsG_inhibitor, rpsN_inhibitor, rpsC_inhibitor, rpsH_inhibitor, rpsS_inhibitor, 16S rRNA, PRNP_inhibitor, mdfA_Unkown, PADI4_Unkown"
    TherapeuticTargetsDatabase "DAP001527"
  ]
  node [
    id 77
    label "DB06243"
    KEGGDrug "D07883"
    PubChemSubstance "310264864"
    Carriers ""
    Wikipedia "Eflornithine"
    HBondAcceptorCount "4"
    ChemSpider "2902"
    ATCcode "D11AX16, P01CX03"
    Polarizability "15.8"
    KEGGCompound "C07997"
    logS "-0.56"
    logP "-2.9"
    Refractivity "37.73"
    pKastrongestbasic "10.2"
    Bioavailability "1"
    DrugClass "Carboxylic acids and derivatives"
    PathwayNames ""
    ChEMBL "CHEMBL830"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "2.19"
    NumberofRings "0"
    BindingDB "50028197"
    MolecularWeight "182.171"
    PhysiologicalCharge "1"
    Enzymes ""
    GhoseFilter "0"
    PolarSurfaceAreaPSA "89.34"
    MonoisotopicWeight "182.08668396"
    MDDRLikeRule "0"
    ChEBI "41948"
    WaterSolubility "5.00e+01"
    DrugsProductDatabaseDPD "12187"
    Family "small molecule"
    MolecularFormula "C6H12F2N2O2"
    Transporters ""
    PubChemCompound "3009"
    HBondDonorCount "3"
    DrugSubClass "Amino acids, peptides, and analogues"
    RotatableBondCount "5"
    Name "Eflornithine"
    Targets "ODC1_antagonist, ODC1_blocker"
  ]
  node [
    id 78
    label "DB00832"
    KEGGDrug "D00508"
    PubChemSubstance "46505695"
    Carriers ""
    Wikipedia "Phensuximide"
    HBondAcceptorCount "2"
    ChemSpider "6578"
    ATCcode "N03AD02"
    Polarizability "19.66"
    KEGGCompound "C07437"
    logS "-1.9"
    logP "0.91"
    Refractivity "51.85"
    pKastrongestbasic "-7.4"
    Bioavailability "1"
    DrugClass "Pyrrolidines"
    PathwayNames ""
    ChEMBL "CHEMBL797"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "19.4"
    NumberofRings "2"
    MolecularWeight "189.2105"
    PhysiologicalCharge "0"
    Enzymes "CYP2C19_inhibitor"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "37.38"
    MonoisotopicWeight "189.078978601"
    MDDRLikeRule "0"
    ChEBI "8079"
    WaterSolubility "2.21e+00"
    PharmGKB "PA164771230"
    Family "small molecule"
    MolecularFormula "C11H11NO2"
    Transporters ""
    PubChemCompound "6839"
    HBondDonorCount "0"
    DrugSubClass "Phenylpyrrolidines"
    RotatableBondCount "1"
    Name "Phensuximide"
    Targets ""
  ]
  node [
    id 79
    label "DB00565"
    PubChemSubstance "46506666"
    Carriers ""
    Wikipedia "Cisatracurium_besylate"
    HBondAcceptorCount "10"
    ChemSpider "56615"
    ATCcode "M03AC11"
    RuleofFive "0"
    PolarSurfaceAreaPSA "126.44"
    logS "-7.6"
    logP "-0.96"
    Refractivity "280.68"
    pKastrongestbasic "-4.1"
    Bioavailability "0"
    DrugClass "Isoquinolines and derivatives"
    ChEMBL "CHEMBL1201248"
    Polarizability "104.19"
    Approved "True"
    MolecularWeight "929.16"
    NumberofRings "6"
    Name "Cisatracurium"
    PhysiologicalCharge "2"
    Enzymes ""
    GhoseFilter "0"
    PubChemCompound "62886"
    MonoisotopicWeight "928.507428607"
    MDDRLikeRule "1"
    ChEBI "140621"
    DrugsProductDatabaseDPD "11084"
    PharmGKB "PA164744925"
    Family "small molecule"
    MolecularFormula "C53H72N2O12"
    Transporters ""
    PathwayNames ""
    HBondDonorCount "0"
    DrugSubClass "Benzylisoquinolines"
    RotatableBondCount "26"
    pKastrongestacidic "19.02"
    WaterSolubility "2.32e-05"
    Targets "CHRNA2_antagonist"
    TherapeuticTargetsDatabase "DAP000196"
  ]
  node [
    id 80
    label "DB00563"
    KEGGDrug "D00142"
    PubChemSubstance "46507678"
    Carriers "ALB"
    WaterSolubility "1.71e-01"
    Wikipedia "Methotrexate"
    HBondAcceptorCount "12"
    ChemSpider "112728"
    ATCcode "L04AX03, L01BA01"
    Polarizability "44.54"
    KEGGCompound "C01937"
    logS "-3.4"
    logP "-0.5"
    Refractivity "119.21"
    pKastrongestbasic "2.81"
    Bioavailability "0"
    DrugClass "Carboxylic acids and derivatives"
    PathwayNames "Methotrexate Action Pathway_SMP00432"
    ChEMBL "CHEMBL34259"
    RuleofFive "0"
    Approved "True"
    pKastrongestacidic "3.41"
    NumberofRings "3"
    BindingDB "66082"
    MolecularWeight "454.4393"
    PhysiologicalCharge "-2"
    Enzymes "DHFR_substrate, AOX1_substrate, MTHFR_substrate, PGD_inhibitor, FPGS_substrate, TYMS_substrate, ATIC_inhibitor, GGH_substrate"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "210.54"
    MonoisotopicWeight "454.171315854"
    MDDRLikeRule "1"
    ChEBI "44185"
    PDB "MTX"
    DrugsProductDatabaseDPD "6197"
    PharmGKB "PA450428"
    Family "small molecule"
    MolecularFormula "C20H22N8O5"
    Transporters "ABCC3_substrate, ABCC3_inhibitor, ABCC4_substrate, ABCC4_inhibitor, ABCC1_substrate, ABCC1_inhibitor, SLC22A6_substrate, SLC22A6_inhibitor, ABCC10_inhibitor, SLC22A8_substrate, SLC22A8_inhibitor, ABCC2_substrate, ABCC2_inhibitor, ABCB1_substrate, SLCO1A2_substrate, SLC16A1_substrate, ABCC11_substrate, SLCO1B3_substrate, SLC22A11_substrate, SLCO1C1_substrate, SLCO3A1_substrate, ABCG2_substrate, SLC22A7_substrate, SLC46A1_substrate, SLC46A1_inhibitor, SLCO1B1_substrate, SLCO4C1_Unkown, SLC19A1_substrate, FOLR1_substrate"
    PubChemCompound "126941"
    HBondDonorCount "5"
    DrugSubClass "Amino acids, peptides, and analogues"
    RotatableBondCount "9"
    Name "Methotrexate"
    Targets "DHFR_inhibitor"
    TherapeuticTargetsDatabase "DNC000933"
  ]
  node [
    id 81
    label "DB00561"
    KEGGDrug "D01872"
    NumberofRings "4"
    Carriers ""
    PubChemSubstance "46506829"
    Wikipedia "Doxapram"
    HBondAcceptorCount "3"
    ChemSpider "3044"
    ATCcode "R07AB01"
    Polarizability "43.02"
    logS "-4"
    logP "3.23"
    pKastrongestbasic "7.23"
    Bioavailability "1"
    DrugClass "Benzene and substituted derivatives"
    PathwayNames ""
    ChEMBL "CHEMBL1754"
    RuleofFive "1"
    Approved "True"
    MolecularWeight "378.5072"
    Refractivity "112.85"
    Name "Doxapram"
    PhysiologicalCharge "1"
    Enzymes ""
    GhoseFilter "1"
    PolarSurfaceAreaPSA "32.78"
    MonoisotopicWeight "378.230728214"
    MDDRLikeRule "1"
    ChEBI "681848"
    DrugsProductDatabaseDPD "10198"
    PharmGKB "PA164784026"
    Family "small molecule"
    MolecularFormula "C24H30N2O2"
    Transporters ""
    PubChemCompound "3156"
    HBondDonorCount "0"
    DrugSubClass "Diphenylmethanes"
    RotatableBondCount "6"
    WaterSolubility "3.43e-02"
    Targets "KCNK3_inhibitor, KCNK9_inhibitor"
    TherapeuticTargetsDatabase "DAP001295"
  ]
  node [
    id 82
    label "DB06797"
    KEGGDrug "D01807"
    NumberofRings "0"
    Carriers ""
    Wikipedia "Mebutamate"
    HBondAcceptorCount "2"
    ChemSpider "5919"
    PolarSurfaceAreaPSA "104.64"
    logS "-2.3"
    logP "1.21"
    Bioavailability "1"
    DrugClass "Carboxylic acids and derivatives"
    ChEMBL "CHEMBL1200922"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "15.24"
    Refractivity "57.59"
    MolecularWeight "232.2768"
    PhysiologicalCharge "0"
    Enzymes ""
    GhoseFilter "1"
    PathwayNames ""
    MonoisotopicWeight "232.142307138"
    MDDRLikeRule "0"
    ChEBI "31804"
    WaterSolubility "1.22e+00"
    Polarizability "24.36"
    Family "small molecule"
    MolecularFormula "C10H20N2O4"
    Transporters ""
    ATCcode "N05BC04"
    HBondDonorCount "2"
    DrugSubClass "Amino acids, peptides, and analogues"
    RotatableBondCount "8"
    Name "Mebutamate"
    Targets ""
  ]
  node [
    id 83
    label "DB00915"
    PubChemSubstance "46507081"
    Carriers ""
    Wikipedia "Amantadine"
    HBondAcceptorCount "1"
    ChemSpider "2045"
    ATCcode "N04BB01"
    RuleofFive "1"
    KEGGCompound "C06818"
    PolarSurfaceAreaPSA "26.02"
    logS "-3.2"
    logP "1.47"
    Refractivity "45.54"
    pKastrongestbasic "10.71"
    Bioavailability "1"
    DrugClass "Organonitrogen compounds"
    ChEMBL "CHEMBL660"
    Polarizability "17.92"
    Approved "True"
    MolecularWeight "151.2487"
    NumberofRings "3"
    BindingDB "50033369"
    Name "Amantadine"
    PhysiologicalCharge "1"
    Enzymes "DDC_inducer, MAOB_inhibitor"
    GhoseFilter "0"
    PubChemCompound "2130"
    MonoisotopicWeight "151.136099549"
    MDDRLikeRule "0"
    ChEBI "2618"
    DrugsProductDatabaseDPD "9905"
    PharmGKB "PA448360"
    Family "small molecule"
    MolecularFormula "C10H17N"
    Transporters "SLC22A2_inhibitor, SLC22A1_inhibitor"
    PathwayNames ""
    HBondDonorCount "1"
    DrugSubClass "Amines"
    RotatableBondCount "0"
    WaterSolubility "8.46e-02"
    Targets "M_inhibitor, GRIN3A_antagonist, CHRNA7_antagonist, DRD2_agonist, CHRNA4_antagonist, CHRNA3_antagonist"
    TherapeuticTargetsDatabase "DAP000781"
  ]
  node [
    id 84
    label "DB00440"
    KEGGDrug "D00145"
    PubChemSubstance "46507125"
    Carriers ""
    WaterSolubility "6.15e-01"
    Wikipedia "Trimethoprim"
    HBondAcceptorCount "7"
    ChemSpider "5376"
    ATCcode "J01EE01, J01EE07, J01EA01, J01EE05, J01EE04, J01EE02, J01EE03"
    Polarizability "29.71"
    KEGGCompound "C01965"
    logS "-2.7"
    logP "1.28"
    Refractivity "81.51"
    pKastrongestbasic "7.16"
    Bioavailability "1"
    DrugClass "Phenol ethers"
    PathwayNames ""
    ChEMBL "CHEMBL22"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "17.33"
    NumberofRings "2"
    BindingDB "18069"
    MolecularWeight "290.3177"
    PhysiologicalCharge "1"
    Enzymes "CYP2C9_substrate, CYP2C9_inhibitor, CYP3A4_substrate, CYP2C8_substrate, CYP2C8_inhibitor"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "105.51"
    MonoisotopicWeight "290.137890462"
    MDDRLikeRule "0"
    ChEBI "45924"
    PDB "TOP"
    DrugsProductDatabaseDPD "8452"
    PharmGKB "PA451788"
    Family "small molecule"
    MolecularFormula "C14H18N4O3"
    Transporters "ABCB1_inhibitor, ABCB1_inducer"
    PubChemCompound "5578"
    HBondDonorCount "2"
    DrugSubClass "Anisoles"
    RotatableBondCount "5"
    Name "Trimethoprim"
    Targets "TYMS_inhibitor, DHFR_inhibitor"
    TherapeuticTargetsDatabase "DAP000927"
  ]
  node [
    id 85
    label "DB01396"
    KEGGDrug "D00297"
    PubChemSubstance "46506035"
    Carriers "ALB"
    Wikipedia "Digitoxin"
    HBondAcceptorCount "12"
    ChemSpider "389987"
    ATCcode "C01AA04"
    Polarizability "83.58"
    KEGGCompound "C06955"
    logS "-4.4"
    logP "3.6"
    Refractivity "191.72"
    pKastrongestbasic "0.24"
    Bioavailability "0"
    DrugClass "Steroids and steroid derivatives"
    PathwayNames ""
    ChEMBL "CHEMBL254219"
    RuleofFive "0"
    Approved "True"
    pKastrongestacidic "7.18"
    NumberofRings "8"
    BindingDB "46356"
    MolecularWeight "764.9391"
    PhysiologicalCharge "0"
    Enzymes "CYP3A4_substrate"
    GhoseFilter "0"
    PolarSurfaceAreaPSA "182.83"
    MonoisotopicWeight "764.434692134"
    MDDRLikeRule "1"
    ChEBI "28544"
    WaterSolubility "2.89e-02"
    DrugsProductDatabaseDPD "10107"
    PharmGKB "PA449316"
    Family "small molecule"
    MolecularFormula "C41H64O13"
    Transporters "SLCO1A2_inhibitor, SLCO4C1_inhibitor, ABCB1_substrate"
    PubChemCompound "441207"
    HBondDonorCount "5"
    DrugSubClass "Steroid lactones"
    RotatableBondCount "7"
    Name "Digitoxin"
    Targets "ATP1A1_inhibitor, CYP11A1_Unkown"
    TherapeuticTargetsDatabase "DAP000120"
  ]
  node [
    id 86
    label "DB00278"
    PubChemSubstance "46507650"
    Carriers ""
    Wikipedia "Argatroban"
    HBondAcceptorCount "9"
    ChemSpider "83702"
    ATCcode "B01AE03"
    Polarizability "53.77"
    KEGGCompound "C04931"
    logS "-3.5"
    logP "-0.92"
    Refractivity "143.83"
    pKastrongestbasic "11.8"
    Bioavailability "0"
    DrugClass "None"
    PathwayNames "Argatroban Action Pathway_SMP00276"
    ChEMBL "CHEMBL1166"
    RuleofFive "0"
    Approved "True"
    pKastrongestacidic "3.06"
    NumberofRings "3"
    BindingDB "50038001"
    MolecularWeight "508.64"
    PhysiologicalCharge "0"
    Enzymes "CYP3A4_substrate, CYP3A5_substrate"
    GhoseFilter "0"
    PolarSurfaceAreaPSA "177.71"
    MonoisotopicWeight "508.246789457"
    MDDRLikeRule "1"
    ChEBI "94385"
    WaterSolubility "1.68e-01"
    DrugsProductDatabaseDPD "12184"
    PharmGKB "PA164745516"
    Family "small molecule"
    MolecularFormula "C23H36N6O5S"
    Transporters ""
    PubChemCompound "152951"
    HBondDonorCount "6"
    DrugSubClass "None"
    RotatableBondCount "8"
    Name "Argatroban"
    Targets "F2_inhibitor"
    TherapeuticTargetsDatabase "DAP000758"
  ]
  node [
    id 87
    label "DB00631"
    PubChemSubstance "46504968"
    Carriers ""
    WaterSolubility "4.89e+00"
    Wikipedia "Clofarabine"
    HBondAcceptorCount "7"
    ChemSpider "106472"
    ATCcode "L01BB06"
    RuleofFive "1"
    logS "-1.8"
    logP "-0.29"
    Refractivity "67"
    pKastrongestbasic "1.3"
    Bioavailability "1"
    DrugClass "Purine nucleosides"
    ChEMBL "CHEMBL1750"
    Polarizability "26.06"
    Approved "True"
    MolecularWeight "303.677"
    NumberofRings "3"
    PolarSurfaceAreaPSA "119.31"
    PhysiologicalCharge "0"
    Enzymes "DCK_substrate"
    GhoseFilter "1"
    PubChemCompound "119182"
    MonoisotopicWeight "303.053445155"
    MDDRLikeRule "0"
    ChEBI "681569"
    PDB "CFB"
    DrugsProductDatabaseDPD "20504"
    PharmGKB "PA164754863"
    Family "small molecule"
    MolecularFormula "C10H11ClFN5O3"
    Transporters "ABCG2_substrate"
    PathwayNames ""
    HBondDonorCount "3"
    DrugSubClass "Purine 2'-deoxyribonucleosides"
    RotatableBondCount "2"
    pKastrongestacidic "12.71"
    Name "Clofarabine"
    Targets "POLA1_inhibitor, RRM1_inhibitor, DNA"
    TherapeuticTargetsDatabase "DAP000849"
  ]
  node [
    id 88
    label "DB00376"
    PubChemSubstance "46507717"
    Carriers ""
    Wikipedia "Trihexyphenidyl"
    HBondAcceptorCount "2"
    ChemSpider "5371"
    ATCcode "N04AA01"
    Polarizability "36.73"
    KEGGCompound "C07171"
    logS "-5"
    logP "4.23"
    Refractivity "93.21"
    pKastrongestbasic "9.32"
    Bioavailability "1"
    DrugClass "Organonitrogen compounds"
    PathwayNames ""
    ChEMBL "CHEMBL1490"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "13.84"
    NumberofRings "3"
    BindingDB "81462"
    MolecularWeight "301.4662"
    PhysiologicalCharge "1"
    Enzymes ""
    GhoseFilter "1"
    PolarSurfaceAreaPSA "23.47"
    MonoisotopicWeight "301.240564619"
    MDDRLikeRule "0"
    ChEBI "9720"
    WaterSolubility "3.14e-03"
    DrugsProductDatabaseDPD "9845"
    PharmGKB "PA164747026"
    Family "small molecule"
    MolecularFormula "C20H31NO"
    Transporters ""
    PubChemCompound "5572"
    HBondDonorCount "1"
    DrugSubClass "Amines"
    RotatableBondCount "5"
    Name "Trihexyphenidyl"
    Targets "CHRM1_antagonist, CHRM2_antagonist, CHRM3_antagonist, CHRM4_antagonist, CHRM5_antagonist"
    TherapeuticTargetsDatabase "DAP001532"
  ]
  node [
    id 89
    label "DB01058"
    KEGGDrug "D00471"
    PubChemSubstance "46507082"
    Carriers ""
    Wikipedia "Praziquantel"
    HBondAcceptorCount "2"
    ChemSpider "4722"
    ATCcode "P02BA01"
    Polarizability "34.84"
    KEGGCompound "C07367"
    logS "-2.9"
    logP "2.3"
    Refractivity "88.79"
    pKastrongestbasic "-0.22"
    Bioavailability "1"
    DrugClass "Tetrahydroisoquinolines"
    PathwayNames ""
    ChEMBL "CHEMBL976"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "19.38"
    NumberofRings "4"
    BindingDB "74574"
    MolecularWeight "312.4061"
    PhysiologicalCharge "0"
    Enzymes "CYP3A4_substrate, CYP1A2_substrate, CYP2C19_substrate, CYP3A43_substrate, CYP3A5_substrate, CYP3A7_substrate"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "40.62"
    MonoisotopicWeight "312.183778022"
    MDDRLikeRule "0"
    ChEBI "91583"
    WaterSolubility "3.81e-01"
    DrugsProductDatabaseDPD "2092"
    PharmGKB "PA164764583"
    Family "small molecule"
    MolecularFormula "C19H24N2O2"
    Transporters ""
    PubChemCompound "4891"
    HBondDonorCount "0"
    DrugSubClass "None"
    RotatableBondCount "1"
    Name "Praziquantel"
    Targets "Schistosome calcium ion (Ca2+) channels"
    TherapeuticTargetsDatabase "DAP000695"
  ]
  node [
    id 90
    label "DB06708"
    KEGGDrug "D03821"
    NumberofRings "4"
    Carriers ""
    PubChemSubstance "99443260"
    Wikipedia "Lumefantrine"
    HBondAcceptorCount "2"
    ChemSpider "4941944"
    ATCcode "P01BF01"
    Polarizability "60.69"
    logS "-7.2"
    logP "9.19"
    pKastrongestbasic "9.78"
    Bioavailability "0"
    DrugClass "Fluorenes"
    PathwayNames ""
    ChEMBL "CHEMBL38827"
    RuleofFive "0"
    Approved "True"
    pKastrongestacidic "14.1"
    Refractivity "160.81"
    BindingDB "50123012"
    MolecularWeight "528.94"
    PhysiologicalCharge "1"
    Enzymes "CYP3A4_substrate, CYP3A4_inducer, CYP2D6_inhibitor"
    GhoseFilter "0"
    PolarSurfaceAreaPSA "23.47"
    MonoisotopicWeight "527.154947772"
    MDDRLikeRule "1"
    ChEBI "156095"
    WaterSolubility "3.09e-05"
    PharmGKB "PA165111722"
    Family "small molecule"
    MolecularFormula "C30H32Cl3NO"
    Transporters ""
    PubChemCompound "6437380"
    HBondDonorCount "1"
    DrugSubClass "None"
    RotatableBondCount "10"
    Name "Lumefantrine"
    Targets ""
  ]
  node [
    id 91
    label "DB00273"
    KEGGDrug "D00537"
    PubChemSubstance "46508334"
    Carriers ""
    WaterSolubility "6.80e+00"
    Wikipedia "Topiramate"
    HBondAcceptorCount "8"
    ChemSpider "4447672"
    ATCcode "N03AX11"
    Polarizability "32.42"
    KEGGCompound "C07502"
    logS "-1.7"
    logP "0.13"
    Refractivity "72.3"
    pKastrongestbasic "-3.7"
    Bioavailability "1"
    DrugClass "Dioxolopyrans"
    PathwayNames ""
    ChEMBL "CHEMBL220492"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "11.09"
    NumberofRings "3"
    BindingDB "10887"
    MolecularWeight "339.362"
    PhysiologicalCharge "0"
    Enzymes "CYP2C19_inhibitor, CYP3A4_inducer"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "115.54"
    MonoisotopicWeight "339.098787343"
    MDDRLikeRule "0"
    ChEBI "63631"
    PDB "TOR"
    DrugsProductDatabaseDPD "11384"
    PharmGKB "PA451728"
    Family "small molecule"
    MolecularFormula "C12H21NO8S"
    Transporters ""
    PubChemCompound "5284627"
    HBondDonorCount "1"
    DrugSubClass "None"
    RotatableBondCount "3"
    Name "Topiramate"
    Targets "GABRA1_agonist, SCN1A_inhibitor, GRIK1_antagonist, CA2_inhibitor, CA4_inhibitor, GABRA1_positive allosteric modulator, CA1_inhibitor, CA3_inhibitor"
    TherapeuticTargetsDatabase "DAP000137"
  ]
  node [
    id 92
    label "DB01273"
    PubChemSubstance "46505502"
    Carriers ""
    Wikipedia "Varenicline"
    HBondAcceptorCount "3"
    ChemSpider "4470510"
    ATCcode "N07BA03"
    Polarizability "23.12"
    PolarSurfaceAreaPSA "37.81"
    logS "-3.4"
    logP "1.01"
    Refractivity "61.3"
    pKastrongestbasic "9.73"
    Bioavailability "1"
    DrugClass "Benzazepines"
    ChEMBL "CHEMBL1076903"
    RuleofFive "1"
    Approved "True"
    MolecularWeight "211.2624"
    NumberofRings "4"
    BindingDB "221048"
    Name "Varenicline"
    PhysiologicalCharge "1"
    Enzymes ""
    GhoseFilter "1"
    PubChemCompound "5310966"
    MonoisotopicWeight "211.110947431"
    MDDRLikeRule "0"
    ChEBI "84500"
    PDB "QMR"
    DrugsProductDatabaseDPD "20097"
    PharmGKB "PA164781343"
    Family "small molecule"
    MolecularFormula "C13H13N3"
    Transporters ""
    PathwayNames ""
    HBondDonorCount "1"
    DrugSubClass "None"
    RotatableBondCount "0"
    WaterSolubility "8.77e-02"
    Targets "CHRNA4_partial agonist, CHRNA7_agonist, CHRNA3_partial agonist, CHRNA6_partial agonist, CHRNB2_partial agonist"
    TherapeuticTargetsDatabase "DAP001535"
  ]
  node [
    id 93
    label "DB01275"
    KEGGDrug "D08044"
    PubChemSubstance "46507533"
    Carriers ""
    WaterSolubility "2.61e+00"
    Wikipedia "Hydralazine"
    HBondAcceptorCount "4"
    ChemSpider "3511"
    ATCcode "C02DB02, C02LG02"
    Polarizability "16.06"
    KEGGCompound "C07040"
    logS "-1.8"
    logP "0.75"
    Refractivity "50.23"
    pKastrongestbasic "6.4"
    Bioavailability "1"
    DrugClass "Diazanaphthalenes"
    PathwayNames ""
    ChEMBL "CHEMBL276832"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "17.69"
    NumberofRings "2"
    BindingDB "81461"
    MolecularWeight "160.1759"
    PhysiologicalCharge "0"
    Enzymes "CYP3A4_inhibitor"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "63.83"
    MonoisotopicWeight "160.074896276"
    MDDRLikeRule "0"
    ChEBI "5775"
    PDB "HLZ"
    DrugsProductDatabaseDPD "6436"
    PharmGKB "PA449894"
    Family "small molecule"
    MolecularFormula "C8H8N4"
    Transporters ""
    PubChemCompound "3637"
    HBondDonorCount "2"
    DrugSubClass "Benzodiazines"
    RotatableBondCount "1"
    Name "Hydralazine"
    Targets "AOC3_inhibitor, P4HA1_inhibitor"
    TherapeuticTargetsDatabase "DAP000728"
  ]
  node [
    id 94
    label "DB00313"
    KEGGDrug "D00399"
    PubChemSubstance "46505925"
    Carriers "ALB"
    WaterSolubility "2.36e+00"
    Wikipedia "Valproic_Acid"
    HBondAcceptorCount "2"
    ChemSpider "3009"
    ATCcode "N03AG01"
    Polarizability "17"
    KEGGCompound "C07185"
    logS "-1.8"
    logP "2.8"
    Refractivity "40.25"
    Bioavailability "1"
    DrugClass "Fatty Acyls"
    PathwayNames "Valproic Acid Metabolism Pathway_SMP00635"
    ChEMBL "CHEMBL109"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "5.14"
    NumberofRings "0"
    BindingDB "50003616"
    MolecularWeight "144.2114"
    PhysiologicalCharge "-1"
    Enzymes "CYP2A6_substrate, CYP2A6_inducer, CYP2B6_substrate, CYP2C9_substrate, CYP2C9_inhibitor, CYP3A5_substrate, PTGS1_substrate, CYP1A2_inhibitor, CYP2C18_inhibitor, CYP2C19_substrate, CYP2C19_inhibitor, CYP2C8_inhibitor, CYP3A4_substrate, CYP3A4_inhibitor, UGT1A4_substrate, UGT1A8_substrate, UGT1A10_substrate, UGT1A6_substrate, UGT1A3_substrate, UGT2B7_substrate, UGT2B15_substrate, UGT1A9_substrate, UGT1A1_substrate, UGT1A1_inhibitor"
    GhoseFilter "0"
    PolarSurfaceAreaPSA "37.3"
    MonoisotopicWeight "144.115029756"
    MDDRLikeRule "0"
    ChEBI "39867"
    PDB "2PP"
    DrugsProductDatabaseDPD "2115"
    PharmGKB "PA451846"
    Family "small molecule"
    MolecularFormula "C8H16O2"
    Transporters "SLC22A6_inhibitor, SLC22A5_inhibitor, SLC22A8_substrate, SLC22A8_inhibitor, SLC16A1_substrate, SLC22A7_substrate"
    PubChemCompound "3121"
    HBondDonorCount "1"
    DrugSubClass "Fatty acids and conjugates"
    RotatableBondCount "5"
    Name "Valproic Acid"
    Targets "HDAC9_inhibitor, ABAT_inhibitor, ACADSB_inhibitor, OGDH_inhibitor, ALDH5A1_inhibitor, SCN1A_inhibitor, HDAC2_inhibitor, PPARA_Unkown, PPARD_Unkown, PPARG_Unkown"
    TherapeuticTargetsDatabase "DNC001659"
  ]
  node [
    id 95
    label "DB00275"
    KEGGDrug "D01204"
    NumberofRings "4"
    Carriers ""
    PubChemSubstance "46508275"
    WaterSolubility "1.05e-02"
    Wikipedia "Olmesartan"
    HBondAcceptorCount "7"
    ChemSpider "139674"
    ATCcode "C09DA08, C09DX03, C09CA08, C09DB02"
    Polarizability "47.46"
    logS "-4.6"
    logP "2.14"
    pKastrongestbasic "5.57"
    Bioavailability "1"
    DrugClass "Benzene and substituted derivatives"
    PathwayNames "Olmesartan Action Pathway_SMP00163"
    ChEMBL "CHEMBL1516"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "0.91"
    Refractivity "137.32"
    BindingDB "50241364"
    MolecularWeight "446.5016"
    PhysiologicalCharge "-2"
    Enzymes ""
    GhoseFilter "0"
    PolarSurfaceAreaPSA "129.81"
    MonoisotopicWeight "446.206638728"
    MDDRLikeRule "1"
    ChEBI "48416"
    PDB "OLM"
    DrugsProductDatabaseDPD "20396"
    PharmGKB "PA164742950"
    Family "small molecule"
    MolecularFormula "C24H26N6O3"
    Transporters "ABCC2_substrate, ABCC2_inducer, SLCO1B3_substrate, SLCO1B1_substrate"
    PubChemCompound "158781"
    HBondDonorCount "3"
    DrugSubClass "Biphenyls and derivatives"
    RotatableBondCount "8"
    Name "Olmesartan"
    Targets "AGTR1_antagonist"
    TherapeuticTargetsDatabase "DAP001412"
  ]
  node [
    id 96
    label "DB01051"
    PubChemSubstance "46507250"
    Carriers ""
    WaterSolubility "9.66e-03"
    Wikipedia "Novobiocin"
    HBondAcceptorCount "9"
    ChemSpider "10226117"
    ATCcode ""
    Polarizability "63.97"
    KEGGCompound "C05080"
    logS "-4.8"
    logP "3.26"
    Refractivity "158.24"
    pKastrongestbasic "-3.9"
    Bioavailability "1"
    DrugClass "Coumarins and derivatives"
    PathwayNames ""
    ChEMBL "CHEMBL36506"
    RuleofFive "0"
    Approved "True"
    pKastrongestacidic "6.96"
    NumberofRings "4"
    BindingDB "50226181"
    MolecularWeight "612.6243"
    PhysiologicalCharge "-1"
    Enzymes ""
    GhoseFilter "0"
    PolarSurfaceAreaPSA "196.1"
    MonoisotopicWeight "612.231910004"
    MDDRLikeRule "1"
    ChEBI "28368"
    PDB "NOV"
    DrugsProductDatabaseDPD "8547"
    PharmGKB "PA164768819"
    Family "small molecule"
    MolecularFormula "C31H36N2O11"
    Transporters "SLC22A6_inhibitor, SLC22A8_inhibitor, SLC22A11_inhibitor, ABCG2_inhibitor"
    PubChemCompound "54675769"
    HBondDonorCount "5"
    DrugSubClass "Coumarin glycosides"
    RotatableBondCount "9"
    Name "Novobiocin"
    Targets "gyrB_inhibitor, topA_inhibitor"
    TherapeuticTargetsDatabase "DAP001002"
  ]
  node [
    id 97
    label "DB01119"
    KEGGDrug "D00294"
    PubChemSubstance "46508027"
    Carriers ""
    WaterSolubility "5.52e-01"
    Wikipedia "Diazoxide"
    GuidetoPharmacology "2409"
    HBondAcceptorCount "4"
    ChemSpider "2911"
    ATCcode "V03AH01, C02DA01, G01AE10"
    Polarizability "20.98"
    KEGGCompound "C06949"
    logS "-2.6"
    logP "1"
    Refractivity "54.84"
    pKastrongestbasic "1.33"
    Bioavailability "1"
    DrugClass "Thiadiazines"
    PathwayNames ""
    ChEMBL "CHEMBL181"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "10.48"
    NumberofRings "2"
    BindingDB "86248"
    MolecularWeight "230.671"
    PhysiologicalCharge "0"
    Enzymes "GLUL_inhibitor"
    IUPHAR "2409"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "58.53"
    MonoisotopicWeight "229.991675875"
    MDDRLikeRule "0"
    ChEBI "4495"
    PDB "20J"
    DrugsProductDatabaseDPD "9557"
    PharmGKB "PA449285"
    Family "small molecule"
    MolecularFormula "C8H7ClN2O2S"
    Transporters ""
    PubChemCompound "3019"
    HBondDonorCount "1"
    DrugSubClass "Benzothiadiazines"
    RotatableBondCount "0"
    Name "Diazoxide"
    Targets "KCNJ11_inducer, CA1_inhibitor, CA2_inhibitor, ATP1A1_other, KCNMA1_other, SLC12A3_unknown"
    TherapeuticTargetsDatabase "DAP000956"
  ]
  node [
    id 98
    label "DB00968"
    KEGGDrug "D08205"
    PubChemSubstance "46508535"
    Carriers ""
    Wikipedia "Methyldopa"
    HBondAcceptorCount "5"
    ChemSpider "35562"
    ATCcode ""
    Polarizability "20.73"
    KEGGCompound "C07194"
    logS "-2"
    logP "-1.4"
    Refractivity "53.79"
    pKastrongestbasic "9.85"
    Bioavailability "1"
    DrugClass "Phenylpropanoic acids"
    PathwayNames ""
    ChEMBL "CHEMBL459"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "1.73"
    NumberofRings "1"
    BindingDB "48449"
    MolecularWeight "211.2145"
    PhysiologicalCharge "0"
    Enzymes "COMT_substrate"
    GhoseFilter "0"
    PolarSurfaceAreaPSA "103.78"
    MonoisotopicWeight "211.084457909"
    MDDRLikeRule "0"
    ChEBI "61058"
    WaterSolubility "2.26e+00"
    DrugsProductDatabaseDPD "20297"
    PharmGKB "PA450453"
    Family "small molecule"
    MolecularFormula "C10H13NO4"
    Transporters "SLC15A1_inhibitor"
    PubChemCompound "38853"
    HBondDonorCount "4"
    DrugSubClass "None"
    RotatableBondCount "3"
    Name "Methyldopa"
    Targets "ADRA2A_Unkown, DDC_inhibitor"
    TherapeuticTargetsDatabase "DAP000226"
  ]
  node [
    id 99
    label "DB00219"
    PubChemSubstance "46508840"
    Carriers ""
    Wikipedia "Oxyphenonium"
    HBondAcceptorCount "2"
    ChemSpider "5547"
    ATCcode "A03AB53, A03AB03"
    Name "Oxyphenonium"
    PolarSurfaceAreaPSA "46.53"
    logS "-6.4"
    logP "-0.2"
    Refractivity "112.61"
    pKastrongestbasic "-4.3"
    Bioavailability "1"
    DrugClass "Benzene and substituted derivatives"
    ChEMBL "CHEMBL1201286"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "11.53"
    NumberofRings "2"
    MolecularWeight "348.4996"
    PhysiologicalCharge "1"
    Enzymes ""
    GhoseFilter "1"
    PubChemCompound "5749"
    MonoisotopicWeight "348.253868959"
    MDDRLikeRule "0"
    ChEBI "94329"
    Polarizability "40.65"
    PharmGKB "PA164752252"
    Family "small molecule"
    MolecularFormula "C21H34NO3"
    Transporters ""
    PathwayNames ""
    HBondDonorCount "1"
    DrugSubClass "None"
    RotatableBondCount "9"
    WaterSolubility "1.36e-04"
    Targets "CHRM1_antagonist"
    TherapeuticTargetsDatabase "DAP001124"
  ]
  node [
    id 100
    label "DB01611"
    KEGGDrug "D08050"
    PubChemSubstance "46508459"
    Carriers ""
    Wikipedia "Hydroxychloroquine"
    HBondAcceptorCount "4"
    ChemSpider "3526"
    ATCcode "P01BA02"
    Polarizability "38.3"
    KEGGCompound "C07043"
    logS "-4.1"
    logP "2.89"
    Refractivity "97.97"
    pKastrongestbasic "9.76"
    Bioavailability "1"
    DrugClass "Quinolines and derivatives"
    PathwayNames ""
    ChEMBL "CHEMBL1535"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "15.59"
    NumberofRings "2"
    MolecularWeight "335.872"
    PhysiologicalCharge "2"
    Enzymes "CYP2D6_inhibitor"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "48.39"
    MonoisotopicWeight "335.176440176"
    MDDRLikeRule "0"
    ChEBI "5801"
    WaterSolubility "2.61e-02"
    DrugsProductDatabaseDPD "6506"
    PharmGKB "PA164777036"
    Family "small molecule"
    MolecularFormula "C18H26ClN3O"
    Transporters ""
    PubChemCompound "3652"
    HBondDonorCount "2"
    DrugSubClass "Aminoquinolines and derivatives"
    RotatableBondCount "9"
    Name "Hydroxychloroquine"
    Targets "DNA, TLR7_antagonist, TLR9_antagonist"
    TherapeuticTargetsDatabase "DAP000878"
  ]
  node [
    id 101
    label "DB00962"
    KEGGDrug "D00530"
    Refractivity "97.24"
    Carriers ""
    PubChemSubstance "46508267"
    Wikipedia "Zaleplon"
    HBondAcceptorCount "4"
    ChemSpider "5517"
    ATCcode "N05CF03"
    MolecularWeight "305.3339"
    KEGGCompound "C07484"
    logS "-3.9"
    logP "1.53"
    Polarizability "32.09"
    pKastrongestbasic "0.3"
    Bioavailability "1"
    DrugClass "Diazines"
    PathwayNames ""
    ChEMBL "CHEMBL1521"
    RuleofFive "1"
    Approved "True"
    NumberofRings "3"
    BindingDB "86521"
    Name "Zaleplon"
    PhysiologicalCharge "0"
    Enzymes "CYP3A4_substrate, CYP3A5_substrate, CYP3A7_substrate, AOX1_substrate"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "74.29"
    MonoisotopicWeight "305.127660127"
    MDDRLikeRule "0"
    ChEBI "10102"
    DrugsProductDatabaseDPD "11989"
    PharmGKB "PA451952"
    Family "small molecule"
    MolecularFormula "C17H15N5O"
    Transporters ""
    PubChemCompound "5719"
    HBondDonorCount "0"
    DrugSubClass "Pyrimidines and pyrimidine derivatives"
    RotatableBondCount "3"
    WaterSolubility "4.03e-02"
    Targets "GABRA1_potentiator, TSPO_other"
    TherapeuticTargetsDatabase "DAP000266"
  ]
  node [
    id 102
    label "DB00353"
    KEGGDrug "D00680"
    NumberofRings "4"
    Carriers ""
    PubChemSubstance "46507746"
    Wikipedia "Methylergonovine"
    HBondAcceptorCount "3"
    ChemSpider "7933"
    ATCcode "G02AC01, G02AB01"
    Polarizability "38.73"
    logS "-3.2"
    logP "1.59"
    pKastrongestbasic "7.93"
    Bioavailability "1"
    DrugClass "Ergoline and derivatives"
    PathwayNames ""
    ChEMBL "CHEMBL1201356"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "15"
    Refractivity "99.58"
    BindingDB "50330860"
    MolecularWeight "339.4314"
    PhysiologicalCharge "1"
    Enzymes "CYP3A4_substrate, CYP3A4_inhibitor"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "68.36"
    MonoisotopicWeight "339.194677059"
    MDDRLikeRule "0"
    ChEBI "92607"
    WaterSolubility "2.04e-01"
    PharmGKB "PA450461"
    Family "small molecule"
    MolecularFormula "C20H25N3O2"
    Transporters ""
    PubChemCompound "8226"
    HBondDonorCount "3"
    DrugSubClass "Lysergic acids and derivatives"
    RotatableBondCount "4"
    Name "Methylergometrine"
    Targets "DRD1_antagonist, HTR2B_Unkown"
    TherapeuticTargetsDatabase "DAP000978"
  ]
  node [
    id 103
    label "DB00744"
    KEGGDrug "D00414"
    NumberofRings "2"
    Carriers "ALB"
    PubChemSubstance "46506394"
    Wikipedia "Zileuton"
    HBondAcceptorCount "2"
    ChemSpider "54531"
    ATCcode ""
    Polarizability "24.14"
    logS "-3.6"
    logP "2.01"
    pKastrongestbasic "-5.5"
    Bioavailability "1"
    DrugClass "Benzothiophenes"
    PathwayNames ""
    ChEMBL "CHEMBL93"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "8.84"
    Refractivity "61.96"
    BindingDB "50000541"
    MolecularWeight "236.29"
    PhysiologicalCharge "0"
    Enzymes "CYP2C9_substrate, CYP1A2_substrate, CYP1A2_inhibitor, CYP3A4_substrate, PTGS1_substrate, UGT1A9_substrate"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "66.56"
    MonoisotopicWeight "236.061948328"
    MDDRLikeRule "0"
    ChEBI "10112"
    WaterSolubility "5.39e-02"
    PharmGKB "PA451955"
    Family "small molecule"
    MolecularFormula "C11H12N2O2S"
    Transporters ""
    PubChemCompound "60490"
    HBondDonorCount "2"
    DrugSubClass "1-benzothiophenes"
    RotatableBondCount "2"
    Name "Zileuton"
    Targets "ALOX5_inhibitor"
    TherapeuticTargetsDatabase "DAP000591"
  ]
  node [
    id 104
    label "DB00585"
    KEGGDrug "D00440"
    Refractivity "95.84"
    Carriers ""
    PubChemSubstance "46507554"
    Wikipedia "Nizatidine"
    HBondAcceptorCount "6"
    ChemSpider "4356"
    ATCcode "A02BA04"
    MolecularWeight "331.45"
    KEGGCompound "C07270"
    logS "-3.9"
    logP "0.77"
    pKastrongestbasic "6.54"
    Bioavailability "1"
    DrugClass "Azoles"
    PathwayNames "Nizatidine Action Pathway_SMP00233"
    ChEMBL "CHEMBL3183075"
    RuleofFive "1"
    Approved "True"
    NumberofRings "1"
    Polarizability "35.54"
    Name "Nizatidine"
    PhysiologicalCharge "0"
    Enzymes "BCHE_inhibitor"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "83.33"
    MonoisotopicWeight "331.113667284"
    MDDRLikeRule "0"
    ChEBI "7601"
    DrugsProductDatabaseDPD "1305"
    PharmGKB "PA164752234"
    Family "small molecule"
    MolecularFormula "C12H21N5O2S2"
    Transporters "ABCB1_substrate"
    PubChemCompound "3033637"
    HBondDonorCount "2"
    DrugSubClass "Thiazoles"
    RotatableBondCount "10"
    WaterSolubility "3.86e-02"
    Targets "HRH2_antagonist"
    TherapeuticTargetsDatabase "DAP000339"
  ]
  node [
    id 105
    label "DB00740"
    KEGGDrug "D00775"
    PubChemSubstance "46508094"
    Carriers ""
    WaterSolubility "3.95e-02"
    Wikipedia "Riluzole"
    GuidetoPharmacology "2326"
    HBondAcceptorCount "3"
    ChemSpider "4892"
    ATCcode "N07XX02"
    Polarizability "18.59"
    KEGGCompound "C07937"
    logS "-3.8"
    logP "3.4"
    Refractivity "44.37"
    pKastrongestbasic "4.57"
    Bioavailability "1"
    DrugClass "Benzothiazoles"
    PathwayNames ""
    ChEMBL "CHEMBL744"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "16.44"
    NumberofRings "2"
    BindingDB "30705"
    MolecularWeight "234.198"
    PhysiologicalCharge "0"
    Enzymes "CYP1A2_substrate, CYP1A1_substrate"
    IUPHAR "2326"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "48.14"
    MonoisotopicWeight "234.007468097"
    MDDRLikeRule "0"
    ChEBI "8863"
    PDB "657"
    DrugsProductDatabaseDPD "12026"
    PharmGKB "PA451251"
    Family "small molecule"
    MolecularFormula "C8H5F3N2OS"
    Transporters "ABCG2_substrate"
    PubChemCompound "5070"
    HBondDonorCount "1"
    DrugSubClass "None"
    RotatableBondCount "2"
    Name "Riluzole"
    Targets "SCN5A_inhibitor, SLC7A11_inducer"
    TherapeuticTargetsDatabase "DAP000527"
  ]
  node [
    id 106
    label "DB01117"
    KEGGDrug "D00236"
    PubChemSubstance "46507298"
    Carriers ""
    WaterSolubility "7.96e-04"
    Wikipedia "Atovaquone"
    HBondAcceptorCount "3"
    ChemSpider "10482034"
    ATCcode "P01AX06"
    Polarizability "39.55"
    KEGGCompound "C06835"
    logS "-5.7"
    logP "5"
    Refractivity "103.11"
    pKastrongestbasic "-4.1"
    Bioavailability "1"
    DrugClass "Naphthalenes"
    PathwayNames ""
    ChEMBL "CHEMBL1450"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "8.23"
    NumberofRings "4"
    BindingDB "16301"
    MolecularWeight "366.837"
    PhysiologicalCharge "0"
    Enzymes "CYP2C9_inhibitor"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "54.37"
    MonoisotopicWeight "366.102272181"
    MDDRLikeRule "0"
    ChEBI "575568"
    PDB "AOQ"
    DrugsProductDatabaseDPD "8317"
    PharmGKB "PA448502"
    Family "small molecule"
    MolecularFormula "C22H19ClO3"
    Transporters ""
    PubChemCompound "74989"
    HBondDonorCount "1"
    DrugSubClass "Naphthoquinones"
    RotatableBondCount "2"
    Name "Atovaquone"
    Targets "MT-CYB_inhibitor, MT-CYB_inhibitor, DHODH_inhibitor"
    TherapeuticTargetsDatabase "DAP000156"
  ]
  node [
    id 107
    label "DB02546"
    PubChemSubstance "46508989"
    Carriers ""
    Wikipedia "Vorinostat"
    HBondAcceptorCount "3"
    ChemSpider "5120"
    ATCcode "L01XX38"
    Name "Vorinostat"
    PolarSurfaceAreaPSA "78.43"
    logS "-3.6"
    logP "2"
    Polarizability "28.39"
    Refractivity "73.81"
    pKastrongestbasic "-3.5"
    Bioavailability "1"
    DrugClass "Benzene and substituted derivatives"
    ChEMBL "CHEMBL98"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "8.91"
    NumberofRings "1"
    BindingDB "19149"
    MolecularWeight "264.3202"
    PhysiologicalCharge "0"
    Enzymes ""
    GhoseFilter "1"
    PubChemCompound "5311"
    MonoisotopicWeight "264.147392516"
    MDDRLikeRule "0"
    ChEBI "45716"
    PDB "SHH"
    DrugsProductDatabaseDPD "20475"
    PharmGKB "PA164748224"
    Family "small molecule"
    MolecularFormula "C14H20N2O3"
    Transporters ""
    PathwayNames ""
    HBondDonorCount "3"
    DrugSubClass "None"
    RotatableBondCount "8"
    WaterSolubility "7.16e-02"
    Targets "HDAC1_inhibitor, HDAC2_inhibitor, HDAC3_inhibitor, HDAC6_inhibitor, HDAC8_Unkown, acuC1_Unkown"
    TherapeuticTargetsDatabase "DAP001082"
  ]
  node [
    id 108
    label "DB00291"
    KEGGDrug "D00266"
    PubChemSubstance "46506842"
    Carriers ""
    WaterSolubility "7.73e-02"
    Wikipedia "Chlorambucil"
    HBondAcceptorCount "3"
    ChemSpider "2607"
    ATCcode "L01AA02"
    Polarizability "31.98"
    KEGGCompound "C06900"
    logS "-3.6"
    logP "3.94"
    Refractivity "79.68"
    pKastrongestbasic "1.72"
    Bioavailability "1"
    DrugClass "Organonitrogen compounds"
    PathwayNames ""
    ChEMBL "CHEMBL515"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "4.46"
    NumberofRings "1"
    BindingDB "50003677"
    MolecularWeight "304.212"
    PhysiologicalCharge "-1"
    Enzymes "GSTP1_substrate"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "40.54"
    MonoisotopicWeight "303.079284271"
    MDDRLikeRule "0"
    ChEBI "28830"
    PDB "CBL"
    DrugsProductDatabaseDPD "10153"
    PharmGKB "PA448926"
    Family "small molecule"
    MolecularFormula "C14H19Cl2NO2"
    Transporters "SLCO1A2_Unkown"
    PubChemCompound "2708"
    HBondDonorCount "1"
    DrugSubClass "Nitrogen mustard compounds"
    RotatableBondCount "9"
    Name "Chlorambucil"
    Targets "DNA"
    TherapeuticTargetsDatabase "DNC001110"
  ]
  node [
    id 109
    label "DB00292"
    KEGGDrug "D00548"
    Refractivity "69.59"
    Carriers "SLC2A1"
    PubChemSubstance "46507012"
    Wikipedia "Etomidate"
    HBondAcceptorCount "2"
    ChemSpider "580864"
    ATCcode "N01AX07"
    MolecularWeight "244.289"
    KEGGCompound "C07522"
    logS "-2.7"
    logP "2.5"
    pKastrongestbasic "4.54"
    Bioavailability "1"
    DrugClass "Azoles"
    PathwayNames ""
    ChEMBL "CHEMBL681"
    RuleofFive "1"
    Approved "True"
    NumberofRings "2"
    BindingDB "50125935"
    Name "Etomidate"
    PhysiologicalCharge "0"
    Enzymes "CYP11B1_inhibitor, CYP11B2_inhibitor, CYP19A1_inhibitor"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "44.12"
    MonoisotopicWeight "244.121177766"
    MDDRLikeRule "0"
    ChEBI "4910"
    Polarizability "26.43"
    PharmGKB "PA164743987"
    Family "small molecule"
    MolecularFormula "C14H16N2O2"
    Transporters ""
    PubChemCompound "667484"
    HBondDonorCount "0"
    DrugSubClass "Imidazoles"
    RotatableBondCount "5"
    WaterSolubility "4.77e-01"
    Targets "GABRA1_agonist, ADRA2B_agonist, GABRA1_positive allosteric modulator"
    TherapeuticTargetsDatabase "DAP000669"
  ]
  node [
    id 110
    label "DB04855"
    KEGGDrug "D02537"
    NumberofRings "3"
    Carriers "ALB"
    PubChemSubstance "175426865"
    Wikipedia "Dronedarone"
    HBondAcceptorCount "5"
    ChemSpider "180996"
    ATCcode "C01BD07"
    Polarizability "66.05"
    logS "-5.4"
    logP "5.28"
    pKastrongestbasic "9.79"
    Bioavailability "0"
    DrugClass "Organooxygen compounds"
    PathwayNames ""
    ChEMBL "CHEMBL184412"
    RuleofFive "0"
    Approved "True"
    pKastrongestacidic "9.08"
    Refractivity "158.13"
    BindingDB "50151864"
    MolecularWeight "556.756"
    PhysiologicalCharge "1"
    Enzymes "CYP3A4_substrate, CYP3A4_inhibitor, CYP2D6_substrate, CYP2D6_inhibitor"
    GhoseFilter "0"
    PolarSurfaceAreaPSA "88.85"
    MonoisotopicWeight "556.297093218"
    MDDRLikeRule "1"
    ChEBI "50659"
    WaterSolubility "2.01e-03"
    DrugsProductDatabaseDPD "20511"
    PharmGKB "PA153619853"
    Family "small molecule"
    MolecularFormula "C31H44N2O5S"
    Transporters "ABCB1_inhibitor"
    PubChemCompound "208898"
    HBondDonorCount "1"
    DrugSubClass "Carbonyl compounds"
    RotatableBondCount "17"
    Name "Dronedarone"
    Targets "ADRA1A_antagonist, ADRA1B_antagonist, ADRA1D_Unkown, ADRA2A_Unkown, ADRA2B_Unkown, ADRA2C_Unkown, ADRB1_Unkown, KCNH2_Unkown, CACNA1C_Unkown, CACNA1D_Unkown, CACNA1F_Unkown, CACNA1S_Unkown, CACNB1_Unkown, CACNB2_Unkown, CACNB3_Unkown, CACNB4_Unkown, SCN1A_inhibitor, KCNK2_inhibitor"
  ]
  node [
    id 111
    label "DB01213"
    KEGGDrug "D00707"
    PubChemSubstance "46508566"
    Carriers ""
    WaterSolubility "5.59e+02"
    Wikipedia "Fomepizole"
    HBondAcceptorCount "1"
    ChemSpider "3289"
    ATCcode "V03AB34"
    Polarizability "8.58"
    KEGGCompound "C07837"
    logS "0.83"
    logP "0.79"
    Refractivity "24.79"
    pKastrongestbasic "2.13"
    Bioavailability "1"
    DrugClass "Azoles"
    PathwayNames ""
    ChEMBL "CHEMBL1308"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "15.82"
    NumberofRings "1"
    MolecularWeight "82.1038"
    PhysiologicalCharge "0"
    Enzymes "CYP2E1_inhibitor, CYP2A6_inhibitor"
    GhoseFilter "0"
    PolarSurfaceAreaPSA "28.68"
    MonoisotopicWeight "82.053098202"
    MDDRLikeRule "0"
    ChEBI "5141"
    PDB "4PZ"
    DrugsProductDatabaseDPD "12038"
    PharmGKB "PA449697"
    Family "small molecule"
    MolecularFormula "C4H6N2"
    Transporters ""
    PubChemCompound "3406"
    HBondDonorCount "1"
    DrugSubClass "Pyrazoles"
    RotatableBondCount "0"
    Name "Fomepizole"
    Targets "ADH1A_inhibitor, ADH1B_inhibitor, ADH1C_inhibitor, CAT_inhibitor"
    TherapeuticTargetsDatabase "DAP000568"
  ]
  node [
    id 112
    label "DB00267"
    KEGGDrug "D01739"
    NumberofRings "4"
    Carriers ""
    PubChemSubstance "46506246"
    Wikipedia "Cefmenoxime"
    HBondAcceptorCount "11"
    ChemSpider "7845223"
    ATCcode "J01DD05"
    Name "Cefmenoxime"
    logS "-3.1"
    logP "-0.83"
    pKastrongestbasic "4.14"
    Bioavailability "0"
    DrugClass "Lactams"
    PathwayNames ""
    ChEMBL "CHEMBL1201224"
    Polarizability "47.04"
    Approved "True"
    pKastrongestacidic "3.04"
    Refractivity "133.51"
    MolecularWeight "511.558"
    PhysiologicalCharge "-1"
    Enzymes ""
    GhoseFilter "0"
    PolarSurfaceAreaPSA "190.81"
    MonoisotopicWeight "511.051476769"
    MDDRLikeRule "1"
    ChEBI "55490"
    PharmGKB "PA164750569"
    Family "small molecule"
    MolecularFormula "C16H17N9O5S3"
    Transporters ""
    RuleofFive "0"
    PubChemCompound "9570757"
    HBondDonorCount "3"
    DrugSubClass "Beta lactams"
    RotatableBondCount "8"
    WaterSolubility "4.46e-01"
    Targets "pbpA_inhibitor, ftsI_inhibitor"
    TherapeuticTargetsDatabase "DAP001178"
  ]
  node [
    id 113
    label "DB00458"
    PubChemSubstance "46507351"
    Carriers "ORM1, ALB"
    Wikipedia "Imipramine"
    GuidetoPharmacology "357"
    HBondAcceptorCount "2"
    ChemSpider "3568"
    ATCcode "N06AA02"
    RuleofFive "1"
    KEGGCompound "C07049"
    PolarSurfaceAreaPSA "6.48"
    logS "-3.6"
    logP "4.28"
    Refractivity "90.61"
    pKastrongestbasic "9.2"
    Bioavailability "1"
    DrugClass "Benzazepines"
    ChEMBL "CHEMBL11"
    Polarizability "33.39"
    Approved "True"
    MolecularWeight "280.4073"
    NumberofRings "3"
    BindingDB "50010859"
    Name "Imipramine"
    PhysiologicalCharge "1"
    Enzymes "CYP2D6_substrate, CYP2D6_inhibitor, CYP2C19_substrate, CYP2C19_inhibitor, CYP1A2_substrate, CYP1A2_inhibitor, CYP3A4_substrate, CYP3A7_substrate, CYP2B6_substrate, CYP2C18_substrate, CYP2E1_inhibitor"
    IUPHAR "357"
    GhoseFilter "1"
    PubChemCompound "3696"
    MonoisotopicWeight "280.193948778"
    MDDRLikeRule "0"
    ChEBI "47499"
    PDB "IXX"
    DrugsProductDatabaseDPD "9267"
    PharmGKB "PA449969"
    Family "small molecule"
    MolecularFormula "C19H24N2"
    Transporters "ABCB1_substrate, SLC22A1_inhibitor, SLC22A2_inhibitor, SLC22A3_inhibitor, SLC22A4_inhibitor"
    PathwayNames "Imipramine Action Pathway_SMP00422, Imipramine Metabolism Pathway_SMP00625"
    HBondDonorCount "0"
    DrugSubClass "Dibenzazepines"
    RotatableBondCount "4"
    WaterSolubility "6.64e-02"
    Targets "SLC6A2_inhibitor, SLC6A4_inhibitor, HTR2A_antagonist, HRH1_antagonist, ADRA1A_antagonist, ADRA1D_antagonist, CHRM1_antagonist, CHRM2_antagonist, CHRM3_antagonist, CHRM4_antagonist, CHRM5_antagonist, KCND2_inhibitor, KCND3_inhibitor, HTR2C_antagonist, HTR2C_binder, ADRA1B_antagonist, HTR7_antagonist, DRD1_binder, DRD2_binder, KCNH2_inhibitor, SLC6A3_inhibitor, HTR1A_activator, HTR6_binder, KCNH1_Unkown, ORM2_Unkown"
    TherapeuticTargetsDatabase "DAP001154"
  ]
  node [
    id 114
    label "DB00459"
    KEGGDrug "D02754"
    NumberofRings "1"
    Carriers "ALB"
    PubChemSubstance "46509178"
    Wikipedia "Acitretin"
    HBondAcceptorCount "3"
    ChemSpider "4447573"
    ATCcode "D05BB02"
    Polarizability "38.54"
    logS "-5.8"
    logP "5.59"
    pKastrongestbasic "-4.8"
    Bioavailability "1"
    DrugClass "Prenol lipids"
    PathwayNames ""
    ChEMBL "CHEMBL1131"
    RuleofFive "0"
    Approved "True"
    pKastrongestacidic "5.01"
    Refractivity "104.17"
    BindingDB "50088429"
    MolecularWeight "326.4293"
    PhysiologicalCharge "-1"
    Enzymes "CYP26A1_substrate"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "46.53"
    MonoisotopicWeight "326.188194698"
    MDDRLikeRule "0"
    ChEBI "50173"
    WaterSolubility "4.78e-04"
    DrugsProductDatabaseDPD "1209"
    PharmGKB "PA448039"
    Family "small molecule"
    MolecularFormula "C21H26O3"
    Transporters ""
    PubChemCompound "5284513"
    HBondDonorCount "1"
    DrugSubClass "Retinoids"
    RotatableBondCount "6"
    Name "Acitretin"
    Targets "RXRA_agonist, RARA_agonist, RARB_agonist, RARG_agonist, RXRB_agonist, RXRG_agonist, RBP1_agonist"
    TherapeuticTargetsDatabase "DAP000743"
  ]
  node [
    id 115
    label "DB01261"
    PubChemSubstance "46505822"
    Carriers ""
    Wikipedia "Sitagliptin"
    HBondAcceptorCount "4"
    ChemSpider "3571948"
    ATCcode "A10BH51, A10BD12, A10BH01, A10BD07"
    Polarizability "32.66"
    PolarSurfaceAreaPSA "77.04"
    logS "-4.1"
    logP "1.26"
    Refractivity "87.49"
    pKastrongestbasic "8.78"
    Bioavailability "1"
    DrugClass "Carboxylic acids and derivatives"
    ChEMBL "CHEMBL1422"
    RuleofFive "1"
    Approved "True"
    MolecularWeight "407.3136"
    NumberofRings "3"
    BindingDB "11162"
    Name "Sitagliptin"
    PhysiologicalCharge "1"
    Enzymes "CYP3A4_substrate, CYP2C8_substrate"
    GhoseFilter "1"
    PubChemCompound "4369359"
    MonoisotopicWeight "407.118079357"
    MDDRLikeRule "0"
    ChEBI "40237"
    PDB "715"
    DrugsProductDatabaseDPD "20179"
    PharmGKB "PA164748978"
    Family "small molecule"
    MolecularFormula "C16H15F6N5O"
    Transporters "ABCB1_substrate, SLC22A8_substrate"
    PathwayNames ""
    HBondDonorCount "1"
    DrugSubClass "Amino acids, peptides, and analogues"
    RotatableBondCount "5"
    WaterSolubility "3.40e-02"
    Targets "DPP4_inhibitor"
    TherapeuticTargetsDatabase "DAP000639"
  ]
  node [
    id 116
    label "DB00848"
    KEGGDrug "D08114"
    Refractivity "60.08"
    Carriers ""
    PubChemSubstance "46509052"
    Wikipedia "Levamisole"
    HBondAcceptorCount "2"
    ChemSpider "25037"
    ATCcode "P02CE01"
    MolecularWeight "204.291"
    KEGGCompound "C07070"
    logS "-2.2"
    logP "2.36"
    Polarizability "22.35"
    pKastrongestbasic "6.98"
    Bioavailability "1"
    DrugClass "Imidazothiazoles"
    PathwayNames ""
    ChEMBL "CHEMBL1454"
    RuleofFive "1"
    Approved "True"
    NumberofRings "3"
    BindingDB "50241179"
    Name "Levamisole"
    PhysiologicalCharge "0"
    Enzymes ""
    GhoseFilter "1"
    PolarSurfaceAreaPSA "15.6"
    MonoisotopicWeight "204.072119084"
    MDDRLikeRule "0"
    ChEBI "6432"
    DrugsProductDatabaseDPD "2801"
    PharmGKB "PA450205"
    Family "small molecule"
    MolecularFormula "C11H12N2S"
    Transporters ""
    PubChemCompound "26879"
    HBondDonorCount "0"
    DrugSubClass "None"
    RotatableBondCount "1"
    WaterSolubility "1.44e+00"
    Targets "CHRNA3_agonist, ALPPL2_inhibitor, unc-38_activator, unc-63_activator, lev-1_activator, unc-29_activator"
    TherapeuticTargetsDatabase "DAP000570"
  ]
  node [
    id 117
    label "DB00518"
    KEGGDrug "D00134"
    PubChemSubstance "46506472"
    Carriers ""
    WaterSolubility "2.28e-02"
    Wikipedia "Albendazole"
    HBondAcceptorCount "3"
    ChemSpider "1998"
    ATCcode "P02CA03"
    Polarizability "29.3"
    KEGGCompound "C01779"
    logS "-4.1"
    logP "3.2"
    Refractivity "73.01"
    pKastrongestbasic "4.27"
    Bioavailability "1"
    DrugClass "Benzimidazoles"
    PathwayNames ""
    ChEMBL "CHEMBL1483"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "9.51"
    NumberofRings "2"
    BindingDB "50241293"
    MolecularWeight "265.331"
    PhysiologicalCharge "0"
    Enzymes "CYP3A4_substrate, CYP1A1_inducer, CYP1A2_substrate, CYP1A2_inhibitor, CYP1A2_inducer"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "67.01"
    MonoisotopicWeight "265.088497429"
    MDDRLikeRule "0"
    ChEBI "16664"
    PDB "ALW"
    DrugsProductDatabaseDPD "1263"
    PharmGKB "PA164746058"
    Family "small molecule"
    MolecularFormula "C12H15N3O2S"
    Transporters "ABCB1_inhibitor"
    PubChemCompound "2082"
    HBondDonorCount "2"
    DrugSubClass "2-benzimidazolylcarbamic acid esters"
    RotatableBondCount "5"
    Name "Albendazole"
    Targets "CHRM3_inhibitor, TUBA1A_inhibitor, TUBB4B_inhibitor, TUBB4B_inhibitor"
    TherapeuticTargetsDatabase "DAP000951"
  ]
  node [
    id 118
    label "DB01268"
    KEGGDrug "D06402"
    NumberofRings "3"
    Carriers ""
    PubChemSubstance "46507140"
    WaterSolubility "3.08e-02"
    Wikipedia "Sunitinib"
    HBondAcceptorCount "3"
    ChemSpider "4486264"
    ATCcode "L01XE04"
    Polarizability "44.32"
    logS "-4.1"
    logP "2.93"
    pKastrongestbasic "9.04"
    Bioavailability "1"
    DrugClass "Indoles and derivatives"
    PathwayNames ""
    ChEMBL "CHEMBL535"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "11.46"
    Refractivity "116.27"
    BindingDB "4814"
    MolecularWeight "398.4738"
    PhysiologicalCharge "1"
    Enzymes "CYP3A5_substrate, CYP3A7_substrate, CYP3A4_substrate"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "77.23"
    MonoisotopicWeight "398.211804333"
    MDDRLikeRule "1"
    ChEBI "38940"
    PDB "B49"
    DrugsProductDatabaseDPD "19249"
    PharmGKB "PA162372840"
    Family "small molecule"
    MolecularFormula "C22H27FN4O2"
    Transporters "ABCC4_inhibitor, ABCB1_inhibitor, ABCC2_inhibitor, ABCG2_inhibitor"
    PubChemCompound "5329102"
    HBondDonorCount "3"
    DrugSubClass "Indolines"
    RotatableBondCount "7"
    Name "Sunitinib"
    Targets "PDGFRB_inhibitor, FLT1_inhibitor, KIT_inhibitor, KDR_inhibitor, FLT4_inhibitor, FLT3_inhibitor, CSF1R_inhibitor, PDGFRA_inhibitor"
    TherapeuticTargetsDatabase "DCL000646"
  ]
  node [
    id 119
    label "DB00508"
    KEGGDrug "D00390"
    NumberofRings "3"
    Carriers ""
    PubChemSubstance "46507344"
    Wikipedia "Triflupromazine"
    GuidetoPharmacology "4330"
    HBondAcceptorCount "2"
    ChemSpider "5367"
    ATCcode "N05AA05"
    Polarizability "35.29"
    logS "-5.3"
    logP "4.81"
    pKastrongestbasic "9.2"
    Bioavailability "1"
    DrugClass "Benzothiazines"
    PathwayNames ""
    ChEMBL "CHEMBL570"
    RuleofFive "1"
    Approved "True"
    MolecularWeight "352.417"
    Refractivity "94.93"
    BindingDB "67544"
    Name "Triflupromazine"
    PhysiologicalCharge "1"
    Enzymes "BCHE_inhibitor"
    IUPHAR "4330"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "6.48"
    MonoisotopicWeight "352.122103923"
    MDDRLikeRule "0"
    ChEBI "9711"
    PharmGKB "PA451773"
    Family "small molecule"
    MolecularFormula "C18H19F3N2S"
    Transporters "ABCB1_inhibitor"
    PubChemCompound "5568"
    HBondDonorCount "0"
    DrugSubClass "Phenothiazines"
    RotatableBondCount "5"
    WaterSolubility "1.80e-03"
    Targets "DRD1_antagonist, DRD2_antagonist, HTR2B_antagonist, CHRM1_antagonist, CHRM2_antagonist"
    TherapeuticTargetsDatabase "DAP000294"
  ]
  node [
    id 120
    label "DB05482"
    PubChemSubstance "175427017"
    Carriers ""
    HBondAcceptorCount "5"
    ChemSpider "94634"
    ATCcode ""
    Name "7-ethyl-10-hydroxycamptothecin"
    KEGGCompound "C11173"
    PolarSurfaceAreaPSA "99.96"
    logS "-3.1"
    logP "1.87"
    Refractivity "106.12"
    pKastrongestbasic "3.91"
    Bioavailability "1"
    DrugClass "Camptothecins"
    ChEMBL "CHEMBL837"
    RuleofFive "1"
    Approved "False"
    pKastrongestacidic "9.68"
    NumberofRings "5"
    BindingDB "50418088"
    MolecularWeight "392.4046"
    PhysiologicalCharge "0"
    Enzymes ""
    GhoseFilter "1"
    PubChemCompound "104842"
    MonoisotopicWeight "392.13722176"
    MDDRLikeRule "0"
    ChEBI "8988"
    Polarizability "41.43"
    Family "small molecule"
    MolecularFormula "C22H20N2O5"
    Transporters ""
    PathwayNames "Irinotecan Metabolism Pathway_SMP00600, Irinotecan Action Pathway_SMP00433"
    HBondDonorCount "2"
    DrugSubClass "None"
    RotatableBondCount "2"
    WaterSolubility "2.90e-01"
    Targets "TOP1_Unkown"
  ]
  node [
    id 121
    label "DB06803"
    KEGGDrug "D00436"
    NumberofRings "2"
    Carriers ""
    PubChemSubstance "99443295"
    Wikipedia "Niclosamide"
    HBondAcceptorCount "4"
    ChemSpider "4322"
    ATCcode "P02DA01"
    Polarizability "28.47"
    logS "-4.6"
    logP "3.91"
    pKastrongestbasic "-4.4"
    Bioavailability "1"
    DrugClass "Benzene and substituted derivatives"
    PathwayNames ""
    ChEMBL "CHEMBL1448"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "6.89"
    Refractivity "80.51"
    BindingDB "11242"
    MolecularWeight "327.12"
    PhysiologicalCharge "-1"
    Enzymes "CYP2C9_substrate, CYP1A2_inhibitor"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "95.15"
    MonoisotopicWeight "325.986112168"
    MDDRLikeRule "0"
    ChEBI "7553"
    WaterSolubility "7.99e-03"
    PharmGKB "PA165958408"
    Family "small molecule"
    MolecularFormula "C13H8Cl2N2O4"
    Transporters ""
    PubChemCompound "4477"
    HBondDonorCount "2"
    DrugSubClass "Anilides"
    RotatableBondCount "3"
    Name "Niclosamide"
    Targets "DNA"
  ]
  node [
    id 122
    label "DB00367"
    KEGGDrug "D00950"
    PubChemSubstance "46508082"
    Carriers ""
    WaterSolubility "5.83e-03"
    Wikipedia "Levonorgestrel"
    GuidetoPharmacology "2881"
    HBondAcceptorCount "2"
    ChemSpider "12560"
    ATCcode "G03FA11, G03AC03, G03FB09, G03AB03, G03AA07, G03AD01"
    Polarizability "36.73"
    KEGGCompound "C08153"
    logS "-4.7"
    logP "3.66"
    Refractivity "92.03"
    pKastrongestbasic "-1.5"
    Bioavailability "1"
    DrugClass "Steroids and steroid derivatives"
    PathwayNames ""
    ChEMBL "CHEMBL1389"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "17.91"
    NumberofRings "4"
    BindingDB "50410522"
    MolecularWeight "312.4458"
    PhysiologicalCharge "0"
    Enzymes "CYP3A4_substrate, CYP19A1_inhibitor"
    IUPHAR "2881"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "37.3"
    MonoisotopicWeight "312.20893014"
    MDDRLikeRule "0"
    ChEBI "6443"
    PDB "NOG"
    DrugsProductDatabaseDPD "7490"
    PharmGKB "PA450218"
    Family "small molecule"
    MolecularFormula "C21H28O2"
    Transporters ""
    PubChemCompound "13109"
    HBondDonorCount "1"
    DrugSubClass "Estrane steroids"
    RotatableBondCount "1"
    Name "Levonorgestrel"
    Targets "PGR_binder, SRD5A1_inhibitor, ESR1_other, AR_agonist, SHBG_Unkown"
    TherapeuticTargetsDatabase "DAP001207"
  ]
  node [
    id 123
    label "DB01097"
    KEGGDrug "D00749"
    PubChemSubstance "46506013"
    Carriers ""
    Wikipedia "Leflunomide"
    HBondAcceptorCount "2"
    ChemSpider "3762"
    ATCcode "L04AA13"
    Polarizability "23.11"
    KEGGCompound "C07905"
    logS "-3.5"
    logP "2.51"
    Refractivity "64.16"
    pKastrongestbasic "-0.45"
    Bioavailability "1"
    DrugClass "Benzene and substituted derivatives"
    PathwayNames ""
    ChEMBL "CHEMBL960"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "10.41"
    NumberofRings "2"
    BindingDB "50054601"
    MolecularWeight "270.2073"
    PhysiologicalCharge "0"
    Enzymes "CYP2C9_substrate, CYP2C9_inhibitor, CYP1A2_substrate"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "55.13"
    MonoisotopicWeight "270.061612157"
    MDDRLikeRule "0"
    ChEBI "6402"
    WaterSolubility "8.44e-02"
    DrugsProductDatabaseDPD "11980"
    PharmGKB "PA450192"
    Family "small molecule"
    MolecularFormula "C12H9F3N2O2"
    Transporters "ABCG2_substrate"
    PubChemCompound "3899"
    HBondDonorCount "1"
    DrugSubClass "Anilides"
    RotatableBondCount "3"
    Name "Leflunomide"
    Targets "DHODH_inhibitor, AHR_agonist, PTK2B_antagonist"
    TherapeuticTargetsDatabase "DAP000636"
  ]
  node [
    id 124
    label "DB06589"
    KEGGDrug "D05380"
    NumberofRings "4"
    Carriers ""
    PubChemSubstance "175427074"
    Wikipedia "Pazopanib"
    HBondAcceptorCount "7"
    ChemSpider "8289501"
    ATCcode "L01XE11"
    Polarizability "45.41"
    logS "-4"
    logP "3.55"
    pKastrongestbasic "5.07"
    Bioavailability "1"
    DrugClass "Organonitrogen compounds"
    PathwayNames ""
    ChEMBL "CHEMBL477772"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "10.41"
    Refractivity "132.18"
    BindingDB "26474"
    MolecularWeight "437.518"
    PhysiologicalCharge "0"
    Enzymes "CYP3A4_substrate, CYP3A4_inhibitor, CYP2D6_substrate, CYP2D6_inhibitor, CYP2C8_substrate, CYP1A2_substrate"
    GhoseFilter "0"
    PolarSurfaceAreaPSA "119.03"
    MonoisotopicWeight "437.163393705"
    MDDRLikeRule "0"
    ChEBI "71219"
    WaterSolubility "4.33e-02"
    DrugsProductDatabaseDPD "20595"
    Family "small molecule"
    MolecularFormula "C21H23N7O2S"
    Transporters "ABCB1_substrate, ABCG2_substrate, SLCO1B1_inhibitor, UGT1A1_inhibitor"
    PubChemCompound "10113978"
    HBondDonorCount "2"
    DrugSubClass "Amines"
    RotatableBondCount "5"
    Name "Pazopanib"
    Targets "FLT1_inhibitor, KDR_inhibitor, FLT4_Unkown, PDGFRA_inhibitor, PDGFRB_inhibitor, KIT_inhibitor, FGFR3_inhibitor, ITK_inhibitor, FGF1_inhibitor, SH2B3_inhibitor"
  ]
  node [
    id 125
    label "DB00738"
    PubChemSubstance "46508562"
    Carriers ""
    Wikipedia "Pentamidine"
    HBondAcceptorCount "6"
    ChemSpider "4573"
    ATCcode "P01CX01"
    RuleofFive "1"
    KEGGCompound "C07420"
    PolarSurfaceAreaPSA "118.2"
    logS "-4.2"
    logP "2.32"
    Refractivity "120.53"
    pKastrongestbasic "12.13"
    Bioavailability "1"
    DrugClass "Phenol ethers"
    ChEMBL "CHEMBL55"
    Polarizability "38.85"
    Approved "True"
    MolecularWeight "340.4195"
    NumberofRings "2"
    BindingDB "45440"
    Name "Pentamidine"
    PhysiologicalCharge "2"
    Enzymes "CYP2C19_substrate, CYP1A1_substrate, CYP2D6_substrate, CYP3A5_substrate, CYP4A11_substrate, CYP1A2_substrate, CYP2C8_substrate, CYP3A4_substrate"
    GhoseFilter "1"
    PubChemCompound "4735"
    MonoisotopicWeight "340.189926032"
    MDDRLikeRule "0"
    ChEBI "45081"
    PDB "PNT"
    DrugsProductDatabaseDPD "20144"
    PharmGKB "PA450850"
    Family "small molecule"
    MolecularFormula "C19H24N4O2"
    Transporters ""
    PathwayNames ""
    HBondDonorCount "4"
    DrugSubClass "None"
    RotatableBondCount "10"
    WaterSolubility "2.36e-02"
    Targets "DNA, TRDMT1_other"
    TherapeuticTargetsDatabase "DAP000764"
  ]
  node [
    id 126
    label "DB04854"
    KEGGDrug "D01206"
    NumberofRings "2"
    Carriers ""
    PubChemSubstance "310264854"
    WaterSolubility "1.83e-02"
    Wikipedia "Febuxostat"
    HBondAcceptorCount "5"
    ChemSpider "118173"
    ATCcode "M04AA03"
    Polarizability "33.88"
    logS "-4.2"
    logP "3.52"
    pKastrongestbasic "0.39"
    Bioavailability "1"
    DrugClass "Azoles"
    PathwayNames ""
    ChEMBL "CHEMBL1164729"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "3.08"
    Refractivity "93.93"
    BindingDB "50320491"
    MolecularWeight "316.375"
    PhysiologicalCharge "-1"
    Enzymes ""
    GhoseFilter "1"
    PolarSurfaceAreaPSA "83.21"
    MonoisotopicWeight "316.088163078"
    MDDRLikeRule "0"
    ChEBI "31596"
    PDB "TEI"
    DrugsProductDatabaseDPD "13271"
    PharmGKB "PA165958521"
    Family "small molecule"
    MolecularFormula "C16H16N2O3S"
    Transporters ""
    PubChemCompound "134018"
    HBondDonorCount "1"
    DrugSubClass "Thiazoles"
    RotatableBondCount "5"
    Name "Febuxostat"
    Targets "XDH_inhibitor"
  ]
  node [
    id 127
    label "DB01048"
    KEGGDrug "D07057"
    PubChemSubstance "46505718"
    Carriers ""
    WaterSolubility "1.21e+00"
    Wikipedia "Abacavir"
    HBondAcceptorCount "6"
    ChemSpider "390063"
    ATCcode "J05AR02, J05AR13, J05AR04, J05AF06"
    Polarizability "30.43"
    KEGGCompound "C07624"
    logS "-2.4"
    logP "0.39"
    Refractivity "82.62"
    pKastrongestbasic "5.77"
    Bioavailability "1"
    DrugClass "Nucleoside and nucleotide analogues"
    PathwayNames "Abacavir Action Pathway_SMP00737"
    ChEMBL "CHEMBL1380"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "15.41"
    NumberofRings "4"
    BindingDB "50366816"
    MolecularWeight "286.3323"
    PhysiologicalCharge "0"
    Enzymes "ADH6_substrate, UGT1A1_substrate, ADK_substrate"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "101.88"
    MonoisotopicWeight "286.154209228"
    MDDRLikeRule "0"
    ChEBI "421707"
    PDB "1KX"
    DrugsProductDatabaseDPD "11893"
    PharmGKB "PA448004"
    Family "small molecule"
    MolecularFormula "C14H18N6O"
    Transporters ""
    PubChemCompound "441300"
    HBondDonorCount "3"
    DrugSubClass "Cyclopentyl nucleosides"
    RotatableBondCount "4"
    Name "Abacavir"
    Targets "pol_inhibitor, HLA-B_Unkown"
    TherapeuticTargetsDatabase "DAP000704"
  ]
  node [
    id 128
    label "DB01046"
    KEGGDrug "D04790"
    PubChemSubstance "46505874"
    Carriers ""
    Wikipedia "Lubiprostone"
    HBondAcceptorCount "5"
    ChemSpider "138948"
    ATCcode "A06AX03"
    Polarizability "42.35"
    KEGGCompound "C13707"
    logS "-4.2"
    logP "4.56"
    Refractivity "95.6"
    pKastrongestbasic "-4.4"
    Bioavailability "1"
    DrugClass "Fatty Acyls"
    PathwayNames ""
    ChEMBL "CHEMBL1201134"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "4.3"
    NumberofRings "2"
    MolecularWeight "390.468"
    PhysiologicalCharge "-1"
    Enzymes "CBR1_substrate"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "83.83"
    MonoisotopicWeight "390.221780456"
    MDDRLikeRule "0"
    WaterSolubility "2.56e-02"
    DrugsProductDatabaseDPD "22650"
    PharmGKB "PA164777012"
    Family "small molecule"
    MolecularFormula "C20H32F2O5"
    Transporters ""
    PubChemCompound "157920"
    HBondDonorCount "2"
    DrugSubClass "Eicosanoids"
    RotatableBondCount "11"
    Name "Lubiprostone"
    Targets "CLCN2_inducer"
    TherapeuticTargetsDatabase "DAP000208"
  ]
  node [
    id 129
    label "DB00731"
    KEGGDrug "D01111"
    PubChemSubstance "46504836"
    Carriers "ALB, ORM1"
    Wikipedia "Nateglinide"
    HBondAcceptorCount "4"
    ChemSpider "10482084"
    ATCcode "A10BX03"
    Polarizability "35.76"
    KEGGCompound "C12508"
    logS "-4.7"
    logP "4.85"
    Refractivity "89.98"
    pKastrongestbasic "1.53"
    Bioavailability "1"
    DrugClass "Carboxylic acids and derivatives"
    PathwayNames "Nateglinide Action Pathway_SMP00453"
    ChEMBL "CHEMBL783"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "4.06"
    NumberofRings "2"
    BindingDB "50344967"
    MolecularWeight "317.429"
    PhysiologicalCharge "-1"
    Enzymes "CYP2C9_substrate, CYP3A4_substrate, CYP3A5_substrate, CYP3A7_substrate, PTGS1_substrate, UGT1A9_substrate, CYP2D6_substrate"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "69.89"
    MonoisotopicWeight "317.199093733"
    MDDRLikeRule "0"
    ChEBI "31897"
    WaterSolubility "6.88e-03"
    DrugsProductDatabaseDPD "12683"
    PharmGKB "PA450600"
    Family "small molecule"
    MolecularFormula "C19H27NO3"
    Transporters "ABCC4_substrate, SLC16A1_substrate, SLC15A1_inhibitor, SLC15A2_inhibitor, SLC22A6_inhibitor"
    PubChemCompound "5311309"
    HBondDonorCount "2"
    DrugSubClass "Amino acids, peptides, and analogues"
    RotatableBondCount "6"
    Name "Nateglinide"
    Targets "ABCC8_inhibitor, PPARG_agonist"
    TherapeuticTargetsDatabase "DAP000918"
  ]
  node [
    id 130
    label "DB00730"
    KEGGDrug "D00372"
    PubChemSubstance "46505131"
    Carriers ""
    WaterSolubility "1.38e-01"
    Wikipedia "Thiabendazole"
    HBondAcceptorCount "2"
    ChemSpider "5237"
    ATCcode "D01AC06, P02CA02"
    Polarizability "21.02"
    KEGGCompound "C07131"
    logS "-3.2"
    logP "2.33"
    Refractivity "64.91"
    pKastrongestbasic "4.08"
    Bioavailability "1"
    DrugClass "Benzimidazoles"
    PathwayNames ""
    ChEMBL "CHEMBL625"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "10.28"
    NumberofRings "3"
    BindingDB "50121347"
    MolecularWeight "201.248"
    PhysiologicalCharge "0"
    Enzymes "CYP1A2_substrate, CYP1A2_inhibitor, CYP1A1_inducer"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "41.57"
    MonoisotopicWeight "201.036067929"
    MDDRLikeRule "0"
    ChEBI "45979"
    PDB "TMG"
    DrugsProductDatabaseDPD "9707"
    PharmGKB "PA164746466"
    Family "small molecule"
    MolecularFormula "C10H7N3S"
    Transporters ""
    PubChemCompound "5430"
    HBondDonorCount "1"
    DrugSubClass "None"
    RotatableBondCount "1"
    Name "Thiabendazole"
    Targets "frdA_inhibitor"
    TherapeuticTargetsDatabase "DAP000664"
  ]
  node [
    id 131
    label "DB06201"
    KEGGDrug "D05775"
    NumberofRings "2"
    Carriers "ALB"
    PubChemSubstance "175427055"
    Wikipedia "Rufinamide"
    HBondAcceptorCount "3"
    ChemSpider "114471"
    ATCcode "N03AF03"
    Name "Rufinamide"
    logS "-2.6"
    logP "1.27"
    pKastrongestbasic "-1.1"
    Bioavailability "1"
    DrugClass "Carboxylic acids and derivatives"
    PathwayNames ""
    ChEMBL "CHEMBL1201754"
    Polarizability "20.42"
    Approved "True"
    pKastrongestacidic "12.69"
    Refractivity "67.07"
    MolecularWeight "238.1935"
    PhysiologicalCharge "0"
    Enzymes "CES1_substrate, CYP2E1_inhibitor, CYP3A4_inducer"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "73.8"
    MonoisotopicWeight "238.066617308"
    MDDRLikeRule "0"
    ChEBI "134966"
    DrugsProductDatabaseDPD "20811"
    PharmGKB "PA166131606"
    Family "small molecule"
    MolecularFormula "C10H8F2N4O"
    Transporters ""
    RuleofFive "1"
    PubChemCompound "129228"
    HBondDonorCount "1"
    DrugSubClass "Carboxylic acid derivatives"
    RotatableBondCount "3"
    WaterSolubility "6.42e-01"
    Targets "GRM5_inhibitor, SCN9A_modulator"
  ]
  node [
    id 132
    label "DB01043"
    PubChemSubstance "46506702"
    Carriers ""
    Wikipedia "Memantine"
    HBondAcceptorCount "1"
    ChemSpider "3914"
    ATCcode "N06DX01, N06DA53, N06DA52"
    RuleofFive "1"
    KEGGCompound "C13736"
    PolarSurfaceAreaPSA "26.02"
    logS "-3.6"
    logP "2.07"
    Refractivity "54.49"
    pKastrongestbasic "10.7"
    Bioavailability "1"
    DrugClass "Organonitrogen compounds"
    ChEMBL "CHEMBL807"
    Polarizability "21.82"
    Approved "True"
    MolecularWeight "179.3018"
    NumberofRings "3"
    BindingDB "50062599"
    Name "Memantine"
    PhysiologicalCharge "1"
    Enzymes "CYP2B6_inhibitor, CYP2A6_inhibitor, CYP2C19_inhibitor"
    GhoseFilter "1"
    PubChemCompound "4054"
    MonoisotopicWeight "179.167399677"
    MDDRLikeRule "0"
    ChEBI "64312"
    DrugsProductDatabaseDPD "13366"
    PharmGKB "PA10364"
    Family "small molecule"
    MolecularFormula "C12H21N"
    Transporters "SLC22A2_substrate"
    PathwayNames ""
    HBondDonorCount "1"
    DrugSubClass "Amines"
    RotatableBondCount "0"
    WaterSolubility "4.55e-02"
    Targets "GRIN3A_antagonist, GRIN2A_antagonist, GRIN2B_antagonist, HTR3A_antagonist, CHRNA7_antagonist, DRD2_agonist, GRIN1_binder"
    TherapeuticTargetsDatabase "DAP000493"
  ]
  node [
    id 133
    label "DB00734"
    KEGGDrug "D00426"
    NumberofRings "5"
    Carriers ""
    PubChemSubstance "46505850"
    Wikipedia "Risperidone"
    GuidetoPharmacology "96"
    HBondAcceptorCount "4"
    ChemSpider "4895"
    ATCcode "N05AX08"
    Polarizability "45.27"
    logS "-3.4"
    logP "2.63"
    pKastrongestbasic "8.76"
    Bioavailability "1"
    DrugClass "Pyridopyrimidines"
    PathwayNames ""
    ChEMBL "CHEMBL85"
    RuleofFive "1"
    Approved "True"
    MolecularWeight "410.4845"
    Refractivity "114.55"
    BindingDB "50001885"
    Name "Risperidone"
    PhysiologicalCharge "1"
    Enzymes "CYP2D6_substrate, CYP2D6_inhibitor, CYP3A4_substrate, CYP3A4_inhibitor, CYP3A5_substrate, CYP3A7_substrate"
    IUPHAR "96"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "61.94"
    MonoisotopicWeight "410.211804333"
    MDDRLikeRule "0"
    ChEBI "8871"
    PDB "8NU"
    DrugsProductDatabaseDPD "723"
    PharmGKB "PA451257"
    Family "small molecule"
    MolecularFormula "C23H27FN4O2"
    Transporters ""
    PubChemCompound "5073"
    HBondDonorCount "0"
    DrugSubClass "None"
    RotatableBondCount "4"
    WaterSolubility "1.71e-01"
    Targets "HTR2A_antagonist, DRD2_antagonist, DRD3_antagonist, DRD4_antagonist, ADRA1A_antagonist, ADRA1B_antagonist, HTR1D_antagonist, HRH1_antagonist, ADRA2A_antagonist, ADRA2B_antagonist, ADRA2B_agonist, ADRA2C_agonist, HTR2C_antagonist, HTR1A_antagonist, DRD1_antagonist, HTR7_Unkown"
    TherapeuticTargetsDatabase "DAP000003"
  ]
  node [
    id 134
    label "DB01108"
    KEGGDrug "D01180"
    PubChemSubstance "46507062"
    Carriers ""
    Wikipedia "Trilostane"
    HBondAcceptorCount "4"
    ChemSpider "570949"
    ATCcode "H02CA01"
    Polarizability "36.96"
    KEGGCompound "C12580"
    logS "-3.8"
    logP "2.3"
    Refractivity "90.17"
    pKastrongestbasic "-0.88"
    Bioavailability "1"
    DrugClass "Steroids and steroid derivatives"
    PathwayNames ""
    ChEMBL "CHEMBL1200907"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "5.23"
    NumberofRings "5"
    MolecularWeight "329.4333"
    PhysiologicalCharge "-1"
    Enzymes ""
    GhoseFilter "1"
    PolarSurfaceAreaPSA "76.78"
    MonoisotopicWeight "329.199093735"
    MDDRLikeRule "0"
    ChEBI "32260"
    WaterSolubility "5.93e-02"
    DrugsProductDatabaseDPD "7334"
    PharmGKB "PA164748507"
    Family "small molecule"
    MolecularFormula "C20H27NO3"
    Transporters ""
    PubChemCompound "656583"
    HBondDonorCount "2"
    DrugSubClass "Estrane steroids"
    RotatableBondCount "0"
    Name "Trilostane"
    Targets "HSD3B1_inhibitor, HSD3B2_inhibitor, ESR1_allosteric modulator, ESR2_allosteric modulator"
    TherapeuticTargetsDatabase "DAP000148"
  ]
  node [
    id 135
    label "DB01590"
    KEGGDrug "D02714"
    NumberofRings "4"
    Carriers ""
    PubChemSubstance "46505248"
    Wikipedia "Everolimus"
    HBondAcceptorCount "13"
    ChemSpider "21106307"
    ATCcode "L01XE10, L04AA18"
    Name "Everolimus"
    logS "-5.8"
    logP "7.4"
    pKastrongestbasic "-2.7"
    Bioavailability "0"
    DrugClass "Macrolide lactams"
    PathwayNames ""
    ChEMBL "CHEMBL1908360"
    Polarizability "106.61"
    Approved "True"
    pKastrongestacidic "9.96"
    Refractivity "261.71"
    MolecularWeight "958.24"
    PhysiologicalCharge "0"
    Enzymes "CYP3A4_substrate"
    GhoseFilter "0"
    PolarSurfaceAreaPSA "204.66"
    MonoisotopicWeight "957.581356357"
    MDDRLikeRule "1"
    ChEBI "68478"
    DrugsProductDatabaseDPD "13238"
    PharmGKB "PA164746311"
    Family "small molecule"
    MolecularFormula "C53H83NO14"
    Transporters ""
    RuleofFive "0"
    PubChemCompound "6442177"
    HBondDonorCount "3"
    DrugSubClass "None"
    RotatableBondCount "9"
    WaterSolubility "1.63e-03"
    Targets "MTOR_inhibitor"
    TherapeuticTargetsDatabase "DAP001223"
  ]
  node [
    id 136
    label "DB08867"
    KEGGDrug "D09567"
    NumberofRings "5"
    Carriers "ALB, ORM1"
    PubChemSubstance "310264902"
    Wikipedia "Ulipristal_acetate"
    HBondAcceptorCount "4"
    ChemSpider "19349271"
    ATCcode "G03AD02, G03XB02"
    Name "Ulipristal"
    logS "-4.7"
    logP "4.18"
    pKastrongestbasic "4.89"
    Bioavailability "1"
    DrugClass "Steroids and steroid derivatives"
    PathwayNames ""
    ChEMBL "CHEMBL2103846"
    Polarizability "49.66"
    Approved "True"
    pKastrongestacidic "12.7"
    Refractivity "129.29"
    MolecularWeight "433.592"
    PhysiologicalCharge "0"
    Enzymes "CYP3A4_substrate, CYP1A2_substrate"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "57.61"
    MonoisotopicWeight "433.261693991"
    MDDRLikeRule "0"
    ChEBI "71025"
    DrugsProductDatabaseDPD "22109"
    Family "small molecule"
    MolecularFormula "C28H35NO3"
    Transporters ""
    RuleofFive "1"
    PubChemCompound "13559281"
    HBondDonorCount "1"
    DrugSubClass "Oxosteroids"
    RotatableBondCount "3"
    WaterSolubility "9.43e-03"
    Targets "PGR_modulator, NR3C1_antagonist, AR_Unkown"
  ]
  node [
    id 137
    label "DB06697"
    KEGGDrug "D02483"
    NumberofRings "4"
    Carriers ""
    PubChemSubstance "99443251"
    Wikipedia "Artemether"
    HBondAcceptorCount "5"
    ChemSpider "62138"
    ATCcode "P01BE02, P01BF01"
    Polarizability "32.12"
    logS "-2.8"
    logP "3.48"
    pKastrongestbasic "-3.9"
    Bioavailability "1"
    DrugClass "Prenol lipids"
    PathwayNames "Artemether Metabolism Pathway_SMP00651"
    ChEMBL "CHEMBL566534"
    RuleofFive "1"
    Approved "True"
    MolecularWeight "298.3746"
    Refractivity "74.66"
    BindingDB "50022886"
    Name "Artemether"
    PhysiologicalCharge "0"
    Enzymes "CYP3A4_substrate, CYP3A4_inducer, CYP3A5_substrate, CYP2B6_substrate, CYP2B6_inducer, CYP2C9_substrate, CYP2C19_substrate, CYP2C19_inducer, CYP2D6_substrate, CYP2D6_inhibitor"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "46.15"
    MonoisotopicWeight "298.178023942"
    MDDRLikeRule "0"
    ChEBI "195280"
    PharmGKB "PA165111698"
    Family "small molecule"
    MolecularFormula "C16H26O5"
    Transporters ""
    PubChemCompound "68911"
    HBondDonorCount "0"
    DrugSubClass "Sesquiterpenoids"
    RotatableBondCount "1"
    WaterSolubility "4.57e-01"
    Targets ""
  ]
  node [
    id 138
    label "DB00277"
    KEGGDrug "D00371"
    PubChemSubstance "46505949"
    Carriers ""
    WaterSolubility "2.29e+01"
    Wikipedia "Theophylline"
    GuidetoPharmacology "413"
    HBondAcceptorCount "3"
    ChemSpider "2068"
    ATCcode "R03DA54, R03DA74, R03DA20, R03DB04, R03DA04"
    Polarizability "16.86"
    KEGGCompound "C07130"
    logS "-0.9"
    logP "-0.77"
    Refractivity "44.93"
    pKastrongestbasic "-0.78"
    Bioavailability "1"
    DrugClass "Imidazopyrimidines"
    PathwayNames "Caffeine Metabolism_SMP63604, Caffeine Metabolism_SMP00028"
    ChEMBL "CHEMBL190"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "7.82"
    NumberofRings "2"
    BindingDB "10847"
    MolecularWeight "180.164"
    PhysiologicalCharge "0"
    Enzymes "CYP3A4_substrate, CYP1A2_substrate, CYP1A2_inhibitor, ADA_inhibitor, ADA_inducer, CYP2E1_substrate, CYP1A1_substrate, CYP1A1_inhibitor, CYP1B1_substrate, CYP2C8_substrate, CYP2C9_substrate, CYP2D6_substrate"
    IUPHAR "413"
    GhoseFilter "0"
    PolarSurfaceAreaPSA "69.3"
    MonoisotopicWeight "180.06472552"
    MDDRLikeRule "0"
    ChEBI "28177"
    PDB "TEP"
    DrugsProductDatabaseDPD "231"
    PharmGKB "PA451647"
    Family "small molecule"
    MolecularFormula "C7H8N4O2"
    Transporters "SLC22A7_inhibitor"
    PubChemCompound "2153"
    HBondDonorCount "1"
    DrugSubClass "Purines and purine derivatives"
    RotatableBondCount "0"
    Name "Theophylline"
    Targets "ADORA1_antagonist, ADORA2A_antagonist, ADORA2B_antagonist, PDE4B_inhibitor, PDE5A_inhibitor, PDE4A_inhibitor, PDE3A_inhibitor, HDAC2_activator, CPNE1_Unkown, HM13_Unkown, NOMO1_Unkown, PARP1_Unkown, RIC3_Unkown, TTLL3_Unkown"
    TherapeuticTargetsDatabase "DAP000002"
  ]
  node [
    id 139
    label "DB01599"
    KEGGDrug "D00476"
    PubChemSubstance "46508876"
    Carriers ""
    Wikipedia "Probucol"
    HBondAcceptorCount "2"
    ChemSpider "4743"
    ATCcode "C10AX02"
    Polarizability "62.35"
    KEGGCompound "C07373"
    logS "-7.1"
    logP "10.57"
    Refractivity "159.26"
    pKastrongestbasic "-5.1"
    Bioavailability "0"
    DrugClass "Benzene and substituted derivatives"
    PathwayNames ""
    ChEMBL "CHEMBL608"
    RuleofFive "0"
    Approved "True"
    pKastrongestacidic "10.29"
    NumberofRings "2"
    BindingDB "50007260"
    MolecularWeight "516.842"
    PhysiologicalCharge "0"
    Enzymes ""
    GhoseFilter "0"
    PolarSurfaceAreaPSA "40.46"
    MonoisotopicWeight "516.30957216"
    MDDRLikeRule "0"
    ChEBI "8427"
    WaterSolubility "4.18e-05"
    DrugsProductDatabaseDPD "2169"
    PharmGKB "PA451107"
    Family "small molecule"
    MolecularFormula "C31H48O2S2"
    Transporters ""
    PubChemCompound "4912"
    HBondDonorCount "2"
    DrugSubClass "Phenylpropanes"
    RotatableBondCount "8"
    Name "Probucol"
    Targets "ABCA1_inhibitor, CES1_Unkown"
    TherapeuticTargetsDatabase "DAP000916"
  ]
  node [
    id 140
    label "DB00911"
    KEGGDrug "D01426"
    NumberofRings "1"
    Carriers ""
    PubChemSubstance "46506396"
    Wikipedia "Tinidazole"
    HBondAcceptorCount "5"
    ChemSpider "5279"
    ATCcode "J01RA11, J01RA13, P01AB02, J01XD02, A02BD09, G01AF20"
    Polarizability "23.27"
    logS "-1.9"
    logP "-0.58"
    pKastrongestbasic "3.1"
    Bioavailability "1"
    DrugClass "Azoles"
    PathwayNames ""
    ChEMBL "CHEMBL1220"
    RuleofFive "1"
    Approved "True"
    MolecularWeight "247.272"
    Refractivity "57.66"
    Name "Tinidazole"
    PhysiologicalCharge "0"
    Enzymes "CYP3A4_substrate"
    GhoseFilter "0"
    PolarSurfaceAreaPSA "97.78"
    MonoisotopicWeight "247.062676609"
    MDDRLikeRule "0"
    ChEBI "63627"
    PharmGKB "PA10813"
    Family "small molecule"
    MolecularFormula "C8H13N3O4S"
    Transporters ""
    PubChemCompound "5479"
    HBondDonorCount "0"
    DrugSubClass "Imidazoles"
    RotatableBondCount "5"
    WaterSolubility "3.03e+00"
    Targets "DNA"
  ]
  node [
    id 141
    label "DB00997"
    KEGGDrug "D03899"
    PubChemSubstance "46507641"
    Carriers "ALB"
    WaterSolubility "1.18e+00"
    Wikipedia "Doxorubicin"
    HBondAcceptorCount "12"
    ChemSpider "29400"
    ATCcode "L01DB01"
    Polarizability "53.87"
    KEGGCompound "C01661"
    logS "-2.7"
    logP "0.92"
    Refractivity "134.59"
    pKastrongestbasic "8.94"
    Bioavailability "0"
    DrugClass "Anthracyclines"
    PathwayNames "Doxorubicin Metabolism Pathway_SMP00650"
    ChEMBL "CHEMBL53463"
    RuleofFive "0"
    Approved "True"
    pKastrongestacidic "9.53"
    NumberofRings "5"
    BindingDB "22984"
    MolecularWeight "543.5193"
    PhysiologicalCharge "1"
    Enzymes "CYP3A4_substrate, CYP3A4_inhibitor, CYP2D6_substrate, CYP2D6_inhibitor, CYP2B6_inhibitor, CYP1B1_inhibitor, CBR1_substrate, CBR3_substrate, AKR1A1_substrate, AKR1C3_substrate, NQO1_substrate, XDH_substrate, NOS1_substrate, NOS2_substrate, NOS3_substrate, POR_substrate"
    GhoseFilter "0"
    PolarSurfaceAreaPSA "206.07"
    MonoisotopicWeight "543.174060775"
    MDDRLikeRule "0"
    ChEBI "28748"
    PDB "DM2"
    DrugsProductDatabaseDPD "2298"
    PharmGKB "PA449412"
    Family "small molecule"
    MolecularFormula "C27H29NO11"
    Transporters "ABCB1_substrate, ABCB1_inhibitor, ABCB1_inducer, ABCC1_substrate, ABCC1_inhibitor, ABCC3_inhibitor, ABCC6_substrate, ABCC6_inhibitor, ABCG2_substrate, SLC22A16_substrate, ABCC10_inhibitor, ABCB8_substrate, ABCB11_substrate, RALBP1_substrate, ABCC2_substrate"
    PubChemCompound "31703"
    HBondDonorCount "6"
    DrugSubClass "None"
    RotatableBondCount "5"
    Name "Doxorubicin"
    Targets "DNA, TOP2A_inhibitor, NOLC1_Unkown, NDUFS2_Unkown, NDUFS3_Unkown, NDUFS7_Unkown"
    TherapeuticTargetsDatabase "DNC000163"
  ]
  node [
    id 142
    label "DB00996"
    KEGGDrug "D00332"
    NumberofRings "1"
    Carriers ""
    PubChemSubstance "46506529"
    WaterSolubility "4.34e+00"
    Wikipedia "Gabapentin"
    HBondAcceptorCount "3"
    ChemSpider "3328"
    ATCcode "N03AX12"
    Polarizability "18.92"
    logS "-1.6"
    logP "-1.3"
    pKastrongestbasic "9.91"
    Bioavailability "1"
    DrugClass "Carboxylic acids and derivatives"
    PathwayNames ""
    ChEMBL "CHEMBL940"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "4.63"
    Refractivity "46.33"
    BindingDB "50080153"
    MolecularWeight "171.2368"
    PhysiologicalCharge "0"
    Enzymes "BCAT1_inhibitor"
    GhoseFilter "0"
    PolarSurfaceAreaPSA "63.32"
    MonoisotopicWeight "171.125928793"
    MDDRLikeRule "0"
    ChEBI "42797"
    PDB "GBN"
    DrugsProductDatabaseDPD "470"
    PharmGKB "PA449720"
    Family "small molecule"
    MolecularFormula "C9H17NO2"
    Transporters ""
    PubChemCompound "3446"
    HBondDonorCount "2"
    DrugSubClass "Amino acids, peptides, and analogues"
    RotatableBondCount "3"
    Name "Gabapentin"
    Targets "CACNA2D1_inhibitor, CACNA2D2_inhibitor, CACNA1B_inhibitor, ADORA1_agonist, GRIN1_inhibitor, GABBR1_Unkown, GABBR2_Unkown"
    TherapeuticTargetsDatabase "DNC000670"
  ]
  node [
    id 143
    label "DB00995"
    KEGGDrug "D00237"
    NumberofRings "1"
    Carriers "ALB"
    PubChemSubstance "46507010"
    Wikipedia "Auranofin"
    HBondAcceptorCount "5"
    ChemSpider "5293650"
    ATCcode "M01CB03"
    Polarizability "50.82"
    logS "-3.6"
    logP "-1"
    pKastrongestbasic "-4.3"
    Bioavailability "0"
    DrugClass "Carboxylic acids and derivatives"
    PathwayNames ""
    ChEMBL "CHEMBL1366"
    RuleofFive "0"
    Approved "True"
    MolecularWeight "678.484"
    Refractivity "114.88"
    BindingDB "50153291"
    Name "Auranofin"
    PhysiologicalCharge "0"
    Enzymes ""
    GhoseFilter "0"
    PolarSurfaceAreaPSA "114.43"
    MonoisotopicWeight "678.132666497"
    MDDRLikeRule "0"
    ChEBI "2922"
    DrugsProductDatabaseDPD "1898"
    PharmGKB "PA448510"
    Family "small molecule"
    MolecularFormula "C20H34AuO9PS"
    Transporters ""
    PubChemCompound "70788951"
    HBondDonorCount "0"
    DrugSubClass "Tetracarboxylic acids and derivatives"
    RotatableBondCount "15"
    WaterSolubility "1.51e-01"
    Targets "PRDX5_inhibitor, IKBKB_inhibitor"
    TherapeuticTargetsDatabase "DAP000757"
  ]
  node [
    id 144
    label "DB01217"
    KEGGDrug "D00960"
    Refractivity "97.47"
    Carriers ""
    PubChemSubstance "46504987"
    Wikipedia "Anastrozole"
    HBondAcceptorCount "4"
    ChemSpider "2102"
    ATCcode "L02BG03"
    MolecularWeight "293.3663"
    KEGGCompound "C08159"
    logS "-3.6"
    logP "3.03"
    Polarizability "31.97"
    pKastrongestbasic "2.25"
    Bioavailability "1"
    DrugClass "Benzene and substituted derivatives"
    PathwayNames ""
    ChEMBL "CHEMBL1399"
    RuleofFive "1"
    Approved "True"
    NumberofRings "2"
    BindingDB "10015"
    Name "Anastrozole"
    PhysiologicalCharge "0"
    Enzymes "CYP19A1_inhibitor, CYP1A2_inhibitor, CYP2C9_inhibitor, CYP3A4_inhibitor"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "78.29"
    MonoisotopicWeight "293.164045633"
    MDDRLikeRule "0"
    ChEBI "2704"
    DrugsProductDatabaseDPD "27"
    PharmGKB "PA448432"
    Family "small molecule"
    MolecularFormula "C17H19N5"
    Transporters ""
    PubChemCompound "2187"
    HBondDonorCount "0"
    DrugSubClass "Phenylpropanes"
    RotatableBondCount "4"
    WaterSolubility "6.61e-02"
    Targets "CYP19A1_inhibitor"
    TherapeuticTargetsDatabase "DAP000627"
  ]
  node [
    id 145
    label "DB00507"
    KEGGDrug "D02486"
    NumberofRings "2"
    Carriers "SLC19A1"
    PubChemSubstance "46507813"
    WaterSolubility "7.55e-03"
    Wikipedia "Nitazoxanide"
    HBondAcceptorCount "5"
    ChemSpider "38037"
    ATCcode "P01AX11"
    Polarizability "27.54"
    logS "-4.6"
    logP "2.12"
    pKastrongestbasic "-4.2"
    Bioavailability "1"
    DrugClass "Benzene and substituted derivatives"
    PathwayNames ""
    ChEMBL "CHEMBL1401"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "8.3"
    Refractivity "73.89"
    BindingDB "50075050"
    MolecularWeight "307.282"
    PhysiologicalCharge "0"
    Enzymes "por_inhibitor"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "114.11"
    MonoisotopicWeight "307.026291103"
    MDDRLikeRule "0"
    ChEBI "94807"
    PDB "NTI"
    PharmGKB "PA164754874"
    Family "small molecule"
    MolecularFormula "C12H9N3O5S"
    Transporters ""
    PubChemCompound "41684"
    HBondDonorCount "1"
    DrugSubClass "Benzoic acids and derivatives"
    RotatableBondCount "5"
    Name "Nitazoxanide"
    Targets "por_antagonist, por_inhibitor"
    TherapeuticTargetsDatabase "DAP001293"
  ]
  node [
    id 146
    label "DB00856"
    PubChemSubstance "46504714"
    Carriers ""
    Wikipedia "Chlorphenesin"
    HBondAcceptorCount "3"
    ChemSpider "7411"
    ATCcode "D01AE07"
    Name "Chlorphenesin"
    KEGGCompound "C07928"
    PolarSurfaceAreaPSA "49.69"
    logS "-1.3"
    logP "1.1"
    Refractivity "49.58"
    pKastrongestbasic "-3"
    Bioavailability "1"
    DrugClass "Phenol ethers"
    ChEMBL "CHEMBL388751"
    Polarizability "20.1"
    Approved "True"
    pKastrongestacidic "13.62"
    NumberofRings "1"
    MolecularWeight "202.635"
    PhysiologicalCharge "0"
    Enzymes "CYP2B_inducer, CYP19A1_inducer, CYP3A4_inducer, XDH_inhibitor, PTGS2_inhibitor, BCHE_inducer"
    GhoseFilter "1"
    PubChemCompound "7697"
    MonoisotopicWeight "202.039671925"
    MDDRLikeRule "0"
    ChEBI "3642"
    DrugsProductDatabaseDPD "5969"
    PharmGKB "PA164784022"
    Family "small molecule"
    MolecularFormula "C9H11ClO3"
    Transporters ""
    RuleofFive "1"
    PathwayNames ""
    HBondDonorCount "2"
    DrugSubClass "None"
    RotatableBondCount "4"
    WaterSolubility "1.04e+01"
    Targets ""
  ]
  node [
    id 147
    label "DB00916"
    KEGGDrug "D00409"
    PubChemSubstance "46508911"
    Carriers ""
    WaterSolubility "5.92e+00"
    Wikipedia "Metronidazole"
    HBondAcceptorCount "4"
    ChemSpider "4029"
    ATCcode "A02BD08, P01AB01, G01AF01, D06BX01, A02BD01, A01AB17, A02BD03, A02BD02, G01AF20, A02BD11, P01AB51, J01RA04, J01RA10, J01RA03, J01XD01"
    Polarizability "15.82"
    KEGGCompound "C07203"
    logS "-1.5"
    logP "-0.46"
    Refractivity "41.22"
    pKastrongestbasic "3.09"
    Bioavailability "1"
    DrugClass "Azoles"
    PathwayNames ""
    ChEMBL "CHEMBL137"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "15.44"
    NumberofRings "1"
    BindingDB "50375309"
    MolecularWeight "171.154"
    PhysiologicalCharge "0"
    Enzymes "CYP2C9_substrate, CYP2C9_inhibitor, CYP3A4_substrate, CYP3A4_inhibitor, CYP2C8_inhibitor, UGT1A1_substrate"
    GhoseFilter "0"
    PolarSurfaceAreaPSA "83.87"
    MonoisotopicWeight "171.064391169"
    MDDRLikeRule "0"
    ChEBI "6909"
    PDB "2MN"
    DrugsProductDatabaseDPD "9880"
    PharmGKB "PA450484"
    Family "small molecule"
    MolecularFormula "C6H9N3O3"
    Transporters ""
    PubChemCompound "4173"
    HBondDonorCount "1"
    DrugSubClass "Imidazoles"
    RotatableBondCount "3"
    Name "Metronidazole"
    Targets "DNA, rdxA_potentiator, rdxA_inhibitor, CYP51A1_Unkown"
    TherapeuticTargetsDatabase "DAP000534"
  ]
  node [
    id 148
    label "DB01219"
    KEGGDrug "D02347"
    PubChemSubstance "46504976"
    Carriers ""
    Wikipedia "Dantrolene"
    GuidetoPharmacology "4172"
    HBondAcceptorCount "5"
    ChemSpider "5290202"
    ATCcode "M03CA01"
    Polarizability "29.98"
    KEGGCompound "C06939"
    logS "-3.6"
    logP "1.26"
    Refractivity "78.87"
    pKastrongestbasic "-1.4"
    Bioavailability "1"
    DrugClass "Azolidines"
    PathwayNames ""
    ChEMBL "CHEMBL1201288"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "9.23"
    NumberofRings "3"
    MolecularWeight "314.253"
    PhysiologicalCharge "0"
    Enzymes "CYP3A4_substrate"
    IUPHAR "4172"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "120.73"
    MonoisotopicWeight "314.06511945"
    MDDRLikeRule "0"
    ChEBI "4317"
    WaterSolubility "8.05e-02"
    DrugsProductDatabaseDPD "2402"
    PharmGKB "PA449208"
    Family "small molecule"
    MolecularFormula "C14H10N4O5"
    Transporters ""
    PubChemCompound "6914273"
    HBondDonorCount "1"
    DrugSubClass "Imidazolidines"
    RotatableBondCount "4"
    Name "Dantrolene"
    Targets "RYR1_antagonist"
    TherapeuticTargetsDatabase "DNC001623"
  ]
  node [
    id 149
    label "DB01218"
    PubChemSubstance "46506753"
    Carriers ""
    Wikipedia "Halofantrine"
    HBondAcceptorCount "2"
    ChemSpider "34303"
    ATCcode "P01BX01"
    Polarizability "51.53"
    KEGGCompound "C07634"
    logS "-6.7"
    logP "8.06"
    Refractivity "131.66"
    pKastrongestbasic "10.05"
    Bioavailability "0"
    DrugClass "Phenanthrenes and derivatives"
    PathwayNames ""
    ChEMBL "CHEMBL1107"
    RuleofFive "0"
    Approved "True"
    pKastrongestacidic "14.47"
    NumberofRings "3"
    BindingDB "79214"
    MolecularWeight "500.424"
    PhysiologicalCharge "1"
    Enzymes "CYP2D6_substrate, CYP2D6_inhibitor, CYP3A4_substrate, CYP3A5_substrate, CYP2C8_substrate"
    GhoseFilter "0"
    PolarSurfaceAreaPSA "23.47"
    MonoisotopicWeight "499.165654616"
    MDDRLikeRule "1"
    ChEBI "94392"
    WaterSolubility "1.11e-04"
    DrugsProductDatabaseDPD "900"
    PharmGKB "PA449839"
    Family "small molecule"
    MolecularFormula "C26H30Cl2F3NO"
    Transporters ""
    PubChemCompound "37393"
    HBondDonorCount "1"
    DrugSubClass "None"
    RotatableBondCount "11"
    Name "Halofantrine"
    Targets "Fe(II)-protoporphyrin IX, KCNH2_inhibitor, KCNH2_inhibitor"
    TherapeuticTargetsDatabase "DAP000953"
  ]
  node [
    id 150
    label "DB01356"
    PubChemSubstance "46505392"
    Carriers ""
    Wikipedia "Lithium"
    HBondAcceptorCount "0"
    ChemSpider "26502"
    Polarizability "1.78"
    KEGGCompound "C15473"
    PolarSurfaceAreaPSA "0"
    logP "0"
    Refractivity "0"
    Bioavailability "1"
    DrugClass "Homogeneous alkali metal compounds"
    PathwayNames "galactose metabolism_SMP00841, inner membrane transport_SMP00808"
    ChEMBL "CHEMBL1234004"
    RuleofFive "1"
    Approved "True"
    MolecularWeight "6.941"
    NumberofRings "0"
    Name "Lithium"
    PhysiologicalCharge "1"
    Enzymes ""
    GhoseFilter "0"
    PubChemCompound "28486"
    MonoisotopicWeight "7.016004049"
    MDDRLikeRule "0"
    ChEBI "49713"
    PDB "LI"
    DrugsProductDatabaseDPD "1399"
    PharmGKB "PA450243"
    Family "small molecule"
    MolecularFormula "Li"
    Transporters ""
    ATCcode "D11AX04, N05AN01"
    HBondDonorCount "0"
    DrugSubClass "None"
    RotatableBondCount "0"
    Targets "GSK3B_inhibitor, IMPA1_inhibitor, IMPA2_inhibitor, GRIA3_potentiator"
    TherapeuticTargetsDatabase "DNC000879"
  ]
  node [
    id 151
    label "DB00853"
    KEGGDrug "D06067"
    NumberofRings "2"
    Carriers ""
    PubChemSubstance "46507934"
    Wikipedia "Temozolomide"
    HBondAcceptorCount "5"
    ChemSpider "5201"
    ATCcode "L01AX03"
    Polarizability "16.88"
    logS "-1.6"
    logP "-0.28"
    pKastrongestbasic "-3.6"
    Bioavailability "1"
    DrugClass "Imidazotetrazines"
    PathwayNames ""
    ChEMBL "CHEMBL810"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "10.51"
    Refractivity "47.86"
    BindingDB "50034562"
    MolecularWeight "194.1508"
    PhysiologicalCharge "0"
    Enzymes "CYP3A4_inducer"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "105.94"
    MonoisotopicWeight "194.055223466"
    MDDRLikeRule "0"
    ChEBI "72564"
    WaterSolubility "5.09e+00"
    DrugsProductDatabaseDPD "11923"
    PharmGKB "PA451609"
    Family "small molecule"
    MolecularFormula "C6H6N6O2"
    Transporters ""
    PubChemCompound "5394"
    HBondDonorCount "1"
    DrugSubClass "None"
    RotatableBondCount "1"
    Name "Temozolomide"
    Targets "DNA"
    TherapeuticTargetsDatabase "DAP000987"
  ]
  node [
    id 152
    label "DB00625"
    KEGGDrug "D00896"
    PubChemSubstance "46506827"
    Carriers "ALB"
    WaterSolubility "8.55e-03"
    Wikipedia "Efavirenz"
    HBondAcceptorCount "2"
    ChemSpider "57715"
    ATCcode "J05AR06, J05AG03, J05AR11"
    Polarizability "26.81"
    KEGGCompound "C08088"
    logS "-4.6"
    logP "4.46"
    Refractivity "71.34"
    pKastrongestbasic "-1.5"
    Bioavailability "1"
    DrugClass "Benzoxazines"
    PathwayNames "Efavirenz Action Pathway_SMP00740"
    ChEMBL "CHEMBL223228"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "12.52"
    NumberofRings "3"
    BindingDB "2483"
    MolecularWeight "315.675"
    PhysiologicalCharge "0"
    Enzymes "CYP2C19_inhibitor, CYP2C9_inhibitor, CYP2B6_substrate, CYP2B6_inhibitor, CYP2B6_inducer, CYP3A4_substrate, CYP3A4_inhibitor, CYP3A4_inducer, CYP3A5_inhibitor, CYP3A5_inducer, CYP3A7_inhibitor, CYP3A7_inducer, CYP1A2_inhibitor, CYP2D6_inhibitor, CYP2C8_inhibitor, UGT1A1_inducer"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "38.33"
    MonoisotopicWeight "315.027390859"
    MDDRLikeRule "0"
    ChEBI "119486"
    PDB "EFZ"
    DrugsProductDatabaseDPD "11857"
    PharmGKB "PA449441"
    Family "small molecule"
    MolecularFormula "C14H9ClF3NO2"
    Transporters ""
    PubChemCompound "64139"
    HBondDonorCount "1"
    DrugSubClass "None"
    RotatableBondCount "3"
    Name "Efavirenz"
    Targets "pol_inhibitor"
    TherapeuticTargetsDatabase "DAP000709"
  ]
  node [
    id 153
    label "DB00624"
    KEGGDrug "D00075"
    PubChemSubstance "46505691"
    Carriers "ALB, SHBG"
    WaterSolubility "3.33e-02"
    Wikipedia "Testosterone"
    GuidetoPharmacology "2858"
    HBondAcceptorCount "2"
    ChemSpider "5791"
    ATCcode "G03EA02, G03BA03"
    Polarizability "34.02"
    KEGGCompound "C00535"
    logS "-3.9"
    logP "3.37"
    Refractivity "84.43"
    pKastrongestbasic "-0.88"
    Bioavailability "1"
    DrugClass "Steroids and steroid derivatives"
    PathwayNames "Androgen and Estrogen Metabolism_SMP63594, Aromatase deficiency_SMP00565, 17-beta Hydroxysteroid Dehydrogenase III Deficiency_SMP00356, Androstenedione Metabolism_SMP30406, Androgen and Estrogen Metabolism_SMP00068, Androstenedione Metabolism_SMP63688"
    ChEMBL "CHEMBL386630"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "19.09"
    NumberofRings "4"
    BindingDB "8885"
    MolecularWeight "288.4244"
    PhysiologicalCharge "0"
    Enzymes "CYP3A5_substrate, CYP19A1_substrate, CYP11A1_inhibitor, MAOA_inducer, CYP3A7_substrate, CYP3A4_substrate, CYP3A4_inhibitor, CYP3A4_inducer, CYP1A1_substrate, CYP1B1_substrate, CYP2A13_substrate, CYP2B6_substrate, CYP2B6_inducer, CYP2C19_substrate, CYP2C8_substrate, CYP2C9_substrate, CYP3A43_substrate"
    IUPHAR "2858"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "37.3"
    MonoisotopicWeight "288.20893014"
    MDDRLikeRule "0"
    ChEBI "17347"
    PDB "TES"
    DrugsProductDatabaseDPD "7478"
    PharmGKB "PA451627"
    Family "small molecule"
    MolecularFormula "C19H28O2"
    Transporters "SLCO1A2_inhibitor, SLCO1A2_inducer, SLC22A8_inducer, SLC22A7_inducer, SLC22A1_inhibitor, ABCB1_inhibitor, SLC10A1_inhibitor, SLC22A3_substrate, SLC22A4_substrate, ABCG2_substrate"
    PubChemCompound "6013"
    HBondDonorCount "1"
    DrugSubClass "Androstane steroids"
    RotatableBondCount "0"
    Name "Testosterone"
    Targets "AR_agonist, ESR1_Unkown, NR3C2_Unkown"
    TherapeuticTargetsDatabase "DAP000841"
  ]
  node [
    id 154
    label "DB00701"
    KEGGDrug "D00894"
    PubChemSubstance "46507537"
    Carriers ""
    WaterSolubility "4.91e-02"
    Wikipedia "Amprenavir"
    HBondAcceptorCount "6"
    ChemSpider "58532"
    ATCcode "J05AE05"
    Polarizability "53.6"
    KEGGCompound "C08086"
    logS "-4"
    logP "2.43"
    Refractivity "134.08"
    pKastrongestbasic "2.39"
    Bioavailability "0"
    DrugClass "Benzene and substituted derivatives"
    PathwayNames ""
    ChEMBL "CHEMBL116"
    RuleofFive "0"
    Approved "True"
    pKastrongestacidic "13.61"
    NumberofRings "3"
    BindingDB "577"
    MolecularWeight "505.627"
    PhysiologicalCharge "0"
    Enzymes "CYP3A4_substrate, CYP3A4_inhibitor, CYP2B6_inhibitor, CYP2C19_inhibitor, CYP2C8_substrate, CYP2C9_substrate, CYP2D6_substrate, CYP3A5_substrate"
    GhoseFilter "0"
    PolarSurfaceAreaPSA "131.19"
    MonoisotopicWeight "505.224656557"
    MDDRLikeRule "1"
    ChEBI "40050"
    PDB "478"
    DrugsProductDatabaseDPD "12083"
    PharmGKB "PA448422"
    Family "small molecule"
    MolecularFormula "C25H35N3O6S"
    Transporters "ABCB1_substrate, ABCB1_inducer, ABCC1_inhibitor"
    PubChemCompound "65016"
    HBondDonorCount "3"
    DrugSubClass "Benzenesulfonamides"
    RotatableBondCount "11"
    Name "Amprenavir"
    Targets "pol_inhibitor"
    TherapeuticTargetsDatabase "DAP000170"
  ]
  node [
    id 155
    label "DB00188"
    KEGGDrug "D03150"
    NumberofRings "2"
    Carriers ""
    PubChemSubstance "46508736"
    WaterSolubility "5.32e-02"
    Wikipedia "Bortezomib"
    HBondAcceptorCount "6"
    ChemSpider "343402"
    ATCcode "L01XX32"
    Polarizability "40.48"
    logS "-3.9"
    logP "1.53"
    pKastrongestbasic "-0.7"
    Bioavailability "1"
    DrugClass "Carboxylic acids and derivatives"
    PathwayNames ""
    ChEMBL "CHEMBL325041"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "13.04"
    Refractivity "99.37"
    BindingDB "50069989"
    MolecularWeight "384.237"
    PhysiologicalCharge "0"
    Enzymes "CYP3A4_substrate, CYP3A4_inhibitor, CYP2C19_substrate, CYP2C19_inhibitor, CYP2D6_substrate, CYP1A2_substrate, CYP1A2_inhibitor, CYP2C9_substrate, CYP2C9_inhibitor"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "124.44"
    MonoisotopicWeight "384.196885774"
    MDDRLikeRule "0"
    ChEBI "52717"
    PDB "BO2"
    DrugsProductDatabaseDPD "13053"
    PharmGKB "PA10252"
    Family "small molecule"
    MolecularFormula "C19H25BN4O4"
    Transporters ""
    PubChemCompound "387447"
    HBondDonorCount "4"
    DrugSubClass "Amino acids, peptides, and analogues"
    RotatableBondCount "9"
    Name "Bortezomib"
    Targets "PSMB5_inhibitor, PSMB1_inhibitor"
    TherapeuticTargetsDatabase "DAP001318"
  ]
  node [
    id 156
    label "DB00358"
    KEGGDrug "D04895"
    PubChemSubstance "46505610"
    Carriers ""
    Wikipedia "Mefloquine"
    HBondAcceptorCount "3"
    ChemSpider "3906"
    ATCcode "P01BF02, P01BC02"
    Polarizability "31.73"
    KEGGCompound "C07633"
    logS "-4"
    logP "4.11"
    Refractivity "82.58"
    pKastrongestbasic "9.46"
    Bioavailability "1"
    DrugClass "Quinolines and derivatives"
    PathwayNames ""
    ChEMBL "CHEMBL416956"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "13.79"
    NumberofRings "3"
    BindingDB "50022889"
    MolecularWeight "378.3122"
    PhysiologicalCharge "1"
    Enzymes "CYP3A4_substrate, CYP3A4_inhibitor, BCHE_inhibitor, CYP19A1_inhibitor, CYP2D6_inhibitor, ACHE_inhibitor"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "45.15"
    MonoisotopicWeight "378.116682374"
    MDDRLikeRule "0"
    ChEBI "63681"
    WaterSolubility "3.80e-02"
    DrugsProductDatabaseDPD "11386"
    PharmGKB "PA450348"
    Family "small molecule"
    MolecularFormula "C17H16F6N2O"
    Transporters "ABCB1_inhibitor"
    PubChemCompound "4046"
    HBondDonorCount "2"
    DrugSubClass "4-quinolinemethanols"
    RotatableBondCount "4"
    Name "Mefloquine"
    Targets "Fe(II)-protoporphyrin IX, HBA1_antagonist, ADORA2A_antagonist"
    TherapeuticTargetsDatabase "DAP001310"
  ]
  node [
    id 157
    label "DB06413"
    KEGGDrug "D03215"
    NumberofRings "2"
    Carriers ""
    PubChemSubstance "310264870"
    Wikipedia "Armodafinil"
    HBondAcceptorCount "2"
    ChemSpider "7962943"
    ATCcode "N06BA13"
    Polarizability "28.2"
    logS "-2.6"
    logP "1.53"
    pKastrongestbasic "-4.4"
    Bioavailability "1"
    DrugClass "Benzene and substituted derivatives"
    PathwayNames ""
    ChEMBL "CHEMBL1201192"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "8.84"
    Refractivity "77.39"
    BindingDB "50336892"
    MolecularWeight "273.35"
    PhysiologicalCharge "0"
    Enzymes "CYP2C19_inhibitor, CYP3A4_inducer, CYP3A5_inducer, CYP1A2_inducer, CYP2B6_inducer, CYP2C9_inhibitor"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "60.16"
    MonoisotopicWeight "273.082349901"
    MDDRLikeRule "0"
    ChEBI "77590"
    WaterSolubility "6.22e-01"
    Family "small molecule"
    MolecularFormula "C15H15NO2S"
    Transporters ""
    PubChemCompound "9690109"
    HBondDonorCount "1"
    DrugSubClass "Diphenylmethanes"
    RotatableBondCount "5"
    Name "Armodafinil"
    Targets "SLC6A3_antagonist, SLC6A3_inhibitor"
  ]
  node [
    id 158
    label "DB00592"
    KEGGDrug "D00807"
    NumberofRings "1"
    Carriers ""
    PubChemSubstance "46507642"
    Wikipedia "Piperazine"
    HBondAcceptorCount "2"
    ChemSpider "13835459"
    ATCcode "P02CB01"
    MolecularWeight "86.1356"
    KEGGCompound "C07973"
    logS "0.63"
    logP "-0.73"
    pKastrongestbasic "9.56"
    Bioavailability "1"
    DrugClass "Diazinanes"
    PathwayNames ""
    ChEMBL "CHEMBL1412"
    RuleofFive "1"
    Approved "True"
    Refractivity "25.45"
    Polarizability "9.97"
    Name "Piperazine"
    PhysiologicalCharge "1"
    Enzymes "CYP2D6_substrate"
    GhoseFilter "0"
    PolarSurfaceAreaPSA "24.06"
    MonoisotopicWeight "86.08439833"
    MDDRLikeRule "0"
    ChEBI "28568"
    PDB "PZE"
    DrugsProductDatabaseDPD "7153"
    PharmGKB "PA450977"
    Family "small molecule"
    MolecularFormula "C4H10N2"
    Transporters ""
    PubChemCompound "4837"
    HBondDonorCount "2"
    DrugSubClass "Piperazines"
    RotatableBondCount "0"
    WaterSolubility "3.71e+02"
    Targets "GABRB3_agonist"
    TherapeuticTargetsDatabase "DAP001418"
  ]
  node [
    id 159
    label "DB00185"
    KEGGDrug "D00661"
    NumberofRings "3"
    Carriers ""
    PubChemSubstance "46507202"
    Wikipedia "Cevimeline"
    HBondAcceptorCount "2"
    ChemSpider "21864737"
    ATCcode "N07AX03"
    Polarizability "21.89"
    logS "-1.9"
    logP "1"
    pKastrongestbasic "8.59"
    Bioavailability "1"
    DrugClass "Azaspirodecane derivatives"
    PathwayNames ""
    RuleofFive "1"
    Approved "True"
    MolecularWeight "199.313"
    Refractivity "55.92"
    Name "Cevimeline"
    PhysiologicalCharge "1"
    Enzymes "CYP2D6_substrate, CYP3A4_substrate, FMO1_substrate"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "12.47"
    MonoisotopicWeight "199.103084861"
    MDDRLikeRule "0"
    ChEBI "3568"
    PharmGKB "PA164754754"
    Family "small molecule"
    MolecularFormula "C10H17NOS"
    Transporters ""
    PubChemCompound "25137844"
    HBondDonorCount "0"
    DrugSubClass "None"
    RotatableBondCount "0"
    WaterSolubility "2.41e+00"
    Targets "CHRM3_agonist, CHRM1_agonist"
    TherapeuticTargetsDatabase "DAP000075"
  ]
  node [
    id 160
    label "DB00356"
    KEGGDrug "D00771"
    PubChemSubstance "46507755"
    Carriers ""
    WaterSolubility "2.96e+00"
    Wikipedia "Chlorzoxazone"
    GuidetoPharmacology "2322"
    HBondAcceptorCount "2"
    ChemSpider "2632"
    ATCcode "M03BB73, M03BB03, M03BB53"
    Polarizability "14.94"
    KEGGCompound "C07931"
    logS "-1.8"
    logP "1.94"
    Refractivity "41.07"
    pKastrongestbasic "-2.2"
    Bioavailability "1"
    DrugClass "Benzoxazoles"
    PathwayNames ""
    ChEMBL "CHEMBL1371"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "9.39"
    NumberofRings "2"
    BindingDB "50290811"
    MolecularWeight "169.565"
    PhysiologicalCharge "0"
    Enzymes "CYP2E1_substrate, CYP2E1_inhibitor, CYP1A1_substrate, CYP1A2_substrate, CYP2A6_substrate, CYP3A4_substrate, CYP3A4_inhibitor, CYP2D6_substrate"
    IUPHAR "2322"
    GhoseFilter "0"
    PolarSurfaceAreaPSA "38.33"
    MonoisotopicWeight "168.993056084"
    MDDRLikeRule "0"
    ChEBI "3655"
    PDB "CLW"
    DrugsProductDatabaseDPD "5883"
    PharmGKB "PA448971"
    Family "small molecule"
    MolecularFormula "C7H4ClNO2"
    Transporters ""
    PubChemCompound "2733"
    HBondDonorCount "1"
    DrugSubClass "Benzoxazolones"
    RotatableBondCount "0"
    Name "Chlorzoxazone"
    Targets "KCNMA1_Unkown"
    TherapeuticTargetsDatabase "DAP000952"
  ]
  node [
    id 161
    label "DB00350"
    KEGGDrug "D00418"
    PubChemSubstance "46508344"
    Carriers ""
    WaterSolubility "1.99e+01"
    Wikipedia "Minoxidil"
    GuidetoPharmacology "4254"
    HBondAcceptorCount "5"
    ChemSpider "10438564"
    ATCcode "D11AX01, C02DC01"
    Polarizability "21.93"
    logS "-1"
    logP "1.3"
    Refractivity "60.74"
    pKastrongestbasic "4.34"
    Bioavailability "1"
    DrugClass "Organonitrogen compounds"
    PathwayNames ""
    ChEMBL "CHEMBL802"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "14.22"
    NumberofRings "2"
    MolecularWeight "209.2483"
    PhysiologicalCharge "0"
    Enzymes ""
    IUPHAR "4254"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "93.63"
    MonoisotopicWeight "209.127660127"
    MDDRLikeRule "0"
    ChEBI "6942"
    PDB "MXD"
    DrugsProductDatabaseDPD "2011"
    PharmGKB "PA450521"
    Family "small molecule"
    MolecularFormula "C9H15N5O"
    Transporters ""
    PubChemCompound "4201"
    HBondDonorCount "2"
    DrugSubClass "Amines"
    RotatableBondCount "1"
    Name "Minoxidil"
    Targets "KCNJ1_inducer, PTGS1_inducer, REN_Unkown"
    TherapeuticTargetsDatabase "DAP000143"
  ]
  node [
    id 162
    label "DB00421"
    KEGGDrug "D00443"
    PubChemSubstance "46508525"
    Carriers ""
    WaterSolubility "1.98e-03"
    Wikipedia "Spironolactone"
    GuidetoPharmacology "2875"
    HBondAcceptorCount "3"
    ChemSpider "5628"
    ATCcode "C03DA01"
    Polarizability "46.03"
    KEGGCompound "C07310"
    logS "-5.3"
    logP "3.64"
    Refractivity "113.5"
    pKastrongestbasic "-4.9"
    Bioavailability "1"
    DrugClass "Steroids and steroid derivatives"
    PathwayNames "Spironolactone Action Pathway_SMP00134"
    ChEMBL "CHEMBL1393"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "18.01"
    NumberofRings "5"
    BindingDB "50228080"
    MolecularWeight "416.573"
    PhysiologicalCharge "0"
    Enzymes "CYP2C8_inhibitor, CYP11B1_inhibitor, CYP11B1_inducer"
    IUPHAR "2875"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "60.44"
    MonoisotopicWeight "416.202130202"
    MDDRLikeRule "0"
    ChEBI "9241"
    PDB "SNL"
    DrugsProductDatabaseDPD "7408"
    PharmGKB "PA451483"
    Family "small molecule"
    MolecularFormula "C24H32O4S"
    Transporters "ABCC2_inducer, ABCB1_inducer, SLCO1A2_inhibitor"
    PubChemCompound "5833"
    HBondDonorCount "0"
    DrugSubClass "Steroid lactones"
    RotatableBondCount "2"
    Name "Spironolactone"
    Targets "NR3C2_antagonist, AR_antagonist, PGR_agonist, NR3C1_antagonist, CYP11B2_antagonist, 17alpha-hydroxylase, 17,20-desmolase, SRD5A1_antagonist, SHBG_binder, CACNG1_inhibitor, Dihydrotestosterone receptor, NR1I2_Unkown"
    TherapeuticTargetsDatabase "DAP000297"
  ]
  node [
    id 163
    label "DB06218"
    KEGGDrug "D07299"
    NumberofRings "1"
    Carriers ""
    PubChemSubstance "175427063"
    Wikipedia "Lacosamide"
    HBondAcceptorCount "3"
    ChemSpider "189902"
    ATCcode "N03AX18"
    Polarizability "26.68"
    logS "-2.7"
    logP "-0.022"
    pKastrongestbasic "-1.5"
    Bioavailability "1"
    DrugClass "Carboxylic acids and derivatives"
    PathwayNames ""
    ChEMBL "CHEMBL58323"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "12.47"
    Refractivity "67.57"
    BindingDB "50300204"
    MolecularWeight "250.2936"
    PhysiologicalCharge "0"
    Enzymes ""
    GhoseFilter "1"
    PolarSurfaceAreaPSA "67.43"
    MonoisotopicWeight "250.131742452"
    MDDRLikeRule "0"
    ChEBI "135939"
    WaterSolubility "4.65e-01"
    DrugsProductDatabaseDPD "20636"
    PharmGKB "PA166160048"
    Family "small molecule"
    MolecularFormula "C13H18N2O3"
    Transporters ""
    PubChemCompound "219078"
    HBondDonorCount "2"
    DrugSubClass "Amino acids, peptides, and analogues"
    RotatableBondCount "6"
    Name "Lacosamide"
    Targets "SCN9A_Unkown, SCN3A_Unkown, SCN10A_Unkown"
  ]
  node [
    id 164
    label "DB00643"
    KEGGDrug "D00368"
    NumberofRings "3"
    Carriers ""
    PubChemSubstance "46508807"
    Wikipedia "Mebendazole"
    HBondAcceptorCount "4"
    ChemSpider "3890"
    ATCcode "P02CA01, P02CA51"
    Polarizability "31.1"
    logS "-3.9"
    logP "3.26"
    pKastrongestbasic "3.93"
    Bioavailability "1"
    DrugClass "Benzene and substituted derivatives"
    PathwayNames ""
    ChEMBL "CHEMBL685"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "8.44"
    Refractivity "81.5"
    BindingDB "50180753"
    MolecularWeight "295.2927"
    PhysiologicalCharge "0"
    Enzymes "CYP3A4_substrate, CYP1A1_inducer"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "84.08"
    MonoisotopicWeight "295.095691297"
    MDDRLikeRule "0"
    ChEBI "6704"
    WaterSolubility "3.87e-02"
    DrugsProductDatabaseDPD "2434"
    PharmGKB "PA164776669"
    Family "small molecule"
    MolecularFormula "C16H13N3O3"
    Transporters ""
    PubChemCompound "4030"
    HBondDonorCount "2"
    DrugSubClass "Benzophenones"
    RotatableBondCount "4"
    Name "Mebendazole"
    Targets "TUBA1A_inhibitor, TUBB4B_inhibitor"
    TherapeuticTargetsDatabase "DAP000950"
  ]
  node [
    id 165
    label "DB00339"
    KEGGDrug "D00144"
    PubChemSubstance "46507478"
    Carriers ""
    WaterSolubility "9.37e+01"
    Wikipedia "Pyrazinamide"
    HBondAcceptorCount "3"
    ChemSpider "1017"
    ATCcode "J04AM06, J04AM05, J04AK01"
    Polarizability "11.13"
    KEGGCompound "C01956"
    logS "-0.12"
    logP "-1.2"
    Refractivity "30.45"
    pKastrongestbasic "-0.68"
    Bioavailability "1"
    DrugClass "Diazines"
    PathwayNames ""
    ChEMBL "CHEMBL614"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "13.06"
    NumberofRings "1"
    BindingDB "228814"
    MolecularWeight "123.1127"
    PhysiologicalCharge "0"
    Enzymes "XDH_substrate, AOX1_substrate, CYP1A2_substrate, CYP3A4_substrate"
    GhoseFilter "0"
    PolarSurfaceAreaPSA "68.87"
    MonoisotopicWeight "123.043261797"
    MDDRLikeRule "0"
    ChEBI "45285"
    PDB "PZA"
    DrugsProductDatabaseDPD "5937"
    PharmGKB "PA451182"
    Family "small molecule"
    MolecularFormula "C5H5N3O"
    Transporters ""
    PubChemCompound "1046"
    HBondDonorCount "1"
    DrugSubClass "Pyrazines"
    RotatableBondCount "1"
    Name "Pyrazinamide"
    Targets "Fatty acid synthetase I (FASI)"
    TherapeuticTargetsDatabase "DAP000660"
  ]
  node [
    id 166
    label "DB06212"
    KEGGDrug "D01213"
    NumberofRings "4"
    Carriers ""
    PubChemSubstance "175427060"
    Wikipedia "Tolvaptan"
    HBondAcceptorCount "3"
    ChemSpider "391976"
    ATCcode "C03XA01"
    Name "Tolvaptan"
    logS "-5.6"
    logP "5.35"
    pKastrongestbasic "-2.1"
    Bioavailability "1"
    DrugClass "Benzene and substituted derivatives"
    PathwayNames ""
    ChEMBL "CHEMBL344159"
    Polarizability "48.16"
    Approved "True"
    pKastrongestacidic "11.76"
    Refractivity "129.16"
    MolecularWeight "448.941"
    PhysiologicalCharge "0"
    Enzymes "CYP3A4_substrate"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "69.64"
    MonoisotopicWeight "448.155370383"
    MDDRLikeRule "0"
    DrugsProductDatabaseDPD "20872"
    Family "small molecule"
    MolecularFormula "C26H25ClN2O3"
    Transporters "ABCB1_substrate, ABCB1_inhibitor"
    RuleofFive "0"
    PubChemCompound "443894"
    HBondDonorCount "2"
    DrugSubClass "Anilides"
    RotatableBondCount "3"
    WaterSolubility "1.24e-03"
    Targets "AVPR2_antagonist, AVPR1A_antagonist"
  ]
  node [
    id 167
    label "DB00203"
    KEGGDrug "D08514"
    PubChemSubstance "46508371"
    Carriers ""
    WaterSolubility "4.33e-01"
    Wikipedia "Sildenafil"
    HBondAcceptorCount "8"
    ChemSpider "5023"
    ATCcode "G04BE03, G01AE10"
    Polarizability "51.18"
    KEGGCompound "C07259"
    logS "-3"
    logP "1.65"
    Refractivity "139.44"
    pKastrongestbasic "5.97"
    Bioavailability "1"
    DrugClass "Benzene and substituted derivatives"
    PathwayNames ""
    ChEMBL "CHEMBL192"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "7.27"
    NumberofRings "4"
    BindingDB "14390"
    MolecularWeight "474.576"
    PhysiologicalCharge "0"
    Enzymes "CYP3A4_substrate, CYP3A5_substrate, CYP3A7_substrate, CYP2C9_substrate, CYP2C9_inhibitor, CYP2C19_substrate, CYP2C19_inhibitor, CYP2D6_substrate, CYP2D6_inhibitor, CYP1A1_inhibitor, CYP2E1_substrate, CYP2E1_inhibitor"
    GhoseFilter "0"
    PolarSurfaceAreaPSA "109.13"
    MonoisotopicWeight "474.204924168"
    MDDRLikeRule "1"
    ChEBI "9139"
    PDB "VIA"
    DrugsProductDatabaseDPD "11854"
    PharmGKB "PA451346"
    Family "small molecule"
    MolecularFormula "C22H30N6O4S"
    Transporters "ABCC4_inhibitor, ABCC5_inhibitor, ABCC10_inhibitor"
    PubChemCompound "5212"
    HBondDonorCount "1"
    DrugSubClass "Benzenesulfonamides"
    RotatableBondCount "6"
    Name "Sildenafil"
    Targets "PDE5A_inhibitor, PDE6G_inhibitor, PDE6H_inhibitor"
    TherapeuticTargetsDatabase "DAP000614"
  ]
  node [
    id 168
    label "DB00335"
    KEGGDrug "D00235"
    PubChemSubstance "46506915"
    Carriers ""
    Wikipedia "Atenolol"
    GuidetoPharmacology "548"
    HBondAcceptorCount "4"
    ChemSpider "2162"
    ATCcode "C07CB03, C07DB01, C07FB03, C07BB03, C07CB53, C07AB03"
    Polarizability "29.98"
    logS "-2.8"
    logP "0.43"
    Refractivity "73.51"
    pKastrongestbasic "9.67"
    Bioavailability "1"
    DrugClass "Benzene and substituted derivatives"
    PathwayNames "Atenolol Action Pathway_SMP00298"
    ChEMBL "CHEMBL24"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "14.08"
    NumberofRings "1"
    BindingDB "25753"
    MolecularWeight "266.3361"
    PhysiologicalCharge "1"
    Enzymes ""
    IUPHAR "548"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "84.58"
    MonoisotopicWeight "266.16304258"
    MDDRLikeRule "0"
    ChEBI "2904"
    WaterSolubility "4.29e-01"
    DrugsProductDatabaseDPD "2041"
    PharmGKB "PA448499"
    Family "small molecule"
    MolecularFormula "C14H22N2O3"
    Transporters "ABCB1_substrate"
    PubChemCompound "2249"
    HBondDonorCount "3"
    DrugSubClass "Phenylacetamides"
    RotatableBondCount "8"
    Name "Atenolol"
    Targets "ADRB1_antagonist, ADRB2_inhibitor"
    TherapeuticTargetsDatabase "DAP000482"
  ]
  node [
    id 169
    label "DB06216"
    KEGGDrug "D02995"
    NumberofRings "4"
    Carriers ""
    PubChemSubstance "175427062"
    Wikipedia "Asenapine"
    HBondAcceptorCount "1"
    ChemSpider "10128588"
    ATCcode "N05AH05"
    Polarizability "30.9"
    logP "3.72"
    pKastrongestbasic "7.29"
    Bioavailability "1"
    DrugClass "Benzoxepines"
    PathwayNames ""
    ChEMBL "CHEMBL3544974"
    RuleofFive "1"
    Approved "True"
    MolecularWeight "401.84"
    Refractivity "81.65"
    Name "Asenapine"
    PhysiologicalCharge "1"
    Enzymes "CYP1A2_substrate, CYP2D6_inhibitor, UGT1A4_substrate, CYP3A4_substrate"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "12.47"
    MonoisotopicWeight "401.103000462"
    MDDRLikeRule "0"
    ChEBI "71253"
    DrugsProductDatabaseDPD "21015"
    Family "small molecule"
    MolecularFormula "C21H20ClNO5"
    Transporters ""
    PubChemCompound "11954293"
    HBondDonorCount "0"
    DrugSubClass "Dibenzoxepines"
    RotatableBondCount "2"
    Targets "DRD2_antagonist, HTR2A_antagonist, HTR1A_antagonist, HTR1B_antagonist, HTR2B_antagonist, HTR2C_antagonist, HTR5A_antagonist, HTR6_antagonist, HTR7_antagonist, ADRA2A_antagonist, ADRA2B_antagonist, ADRA2C_antagonist, ADRA1A_antagonist, DRD1_antagonist, DRD3_antagonist, DRD4_antagonist, HRH1_antagonist, HRH2_antagonist, ADRB1_antagonist, ADRB2_antagonist"
  ]
  node [
    id 170
    label "DB00331"
    KEGGDrug "D04966"
    NumberofRings "0"
    Carriers ""
    PubChemSubstance "46507752"
    Wikipedia "Metformin"
    HBondAcceptorCount "5"
    ChemSpider "3949"
    ATCcode "A10BA02, A10BD13, A10BD18, A10BD02, A10BD03, A10BD10, A10BD16, A10BD14, A10BD15, A10BD08, A10BD05, A10BD17, A10BD07, A10BD20, A10BD11"
    RuleofFive "1"
    KEGGCompound "C07151"
    logS "-2"
    logP "-0.92"
    pKastrongestbasic "12.33"
    Bioavailability "1"
    DrugClass "Organonitrogen compounds"
    PathwayNames ""
    ChEMBL "CHEMBL1431"
    Polarizability "13.43"
    Approved "True"
    MolecularWeight "129.1636"
    Refractivity "56.64"
    BindingDB "50229665"
    Name "Metformin"
    PhysiologicalCharge "2"
    Enzymes ""
    GhoseFilter "0"
    PolarSurfaceAreaPSA "88.99"
    MonoisotopicWeight "129.101445377"
    MDDRLikeRule "0"
    ChEBI "6801"
    PDB "MF8"
    DrugsProductDatabaseDPD "10147"
    PharmGKB "PA450395"
    Family "small molecule"
    MolecularFormula "C4H11N5"
    Transporters "SLC22A1_substrate, SLC22A1_inhibitor, SLC22A2_substrate, SLC22A2_inhibitor, SLC22A3_substrate, SLC47A1_inhibitor, SLC29A4_substrate"
    PubChemCompound "4091"
    HBondDonorCount "4"
    DrugSubClass "Guanidines"
    RotatableBondCount "0"
    WaterSolubility "1.38e+00"
    Targets "PRKAB1_inducer"
    TherapeuticTargetsDatabase "DAP000205"
  ]
  node [
    id 171
    label "DB00648"
    KEGGDrug "D00420"
    PubChemSubstance "46508319"
    Carriers "SHBG, SERPINA6"
    Wikipedia "Mitotane"
    HBondAcceptorCount "0"
    ChemSpider "4066"
    ATCcode "L01XX23"
    Polarizability "29.93"
    PolarSurfaceAreaPSA "0"
    logS "-7.5"
    logP "6.11"
    Refractivity "79.97"
    Bioavailability "1"
    DrugClass "Benzene and substituted derivatives"
    ChEMBL "CHEMBL1670"
    RuleofFive "0"
    Approved "True"
    MolecularWeight "320.041"
    NumberofRings "2"
    Name "Mitotane"
    PhysiologicalCharge "0"
    Enzymes "CYP3A4_inducer"
    GhoseFilter "0"
    PubChemCompound "4211"
    MonoisotopicWeight "317.953661148"
    MDDRLikeRule "0"
    ChEBI "6954"
    DrugsProductDatabaseDPD "2100"
    PharmGKB "PA164746157"
    Family "small molecule"
    MolecularFormula "C14H10Cl4"
    Transporters ""
    PathwayNames ""
    HBondDonorCount "0"
    DrugSubClass "Diphenylmethanes"
    RotatableBondCount "3"
    WaterSolubility "9.42e-06"
    Targets "CYP11B1_inducer, FDX1_unknown, ESR1_Unkown, PGR_Unkown, AR_antagonist"
    TherapeuticTargetsDatabase "DAP000033"
  ]
  node [
    id 172
    label "DB02600"
    PubChemSubstance "46509088"
    Carriers ""
    WaterSolubility "6.35e-01"
    HBondAcceptorCount "6"
    ChemSpider "395929"
    ATCcode ""
    Polarizability "30.79"
    logS "-2.6"
    logP "-1"
    Refractivity "75.21"
    pKastrongestbasic "9.98"
    Bioavailability "1"
    DrugClass "Carboxylic acids and derivatives"
    ChEMBL "CHEMBL674"
    RuleofFive "1"
    Approved "False"
    MolecularWeight "284.3514"
    NumberofRings "1"
    BindingDB "4994"
    PolarSurfaceAreaPSA "105.14"
    PhysiologicalCharge "1"
    Enzymes ""
    GhoseFilter "0"
    PubChemCompound "449381"
    MonoisotopicWeight "284.173607266"
    MDDRLikeRule "0"
    ChEBI "73139"
    PDB "G39"
    Family "small molecule"
    MolecularFormula "C14H24N2O4"
    Transporters ""
    PathwayNames ""
    HBondDonorCount "3"
    DrugSubClass "Amino acids, peptides, and analogues"
    RotatableBondCount "6"
    pKastrongestacidic "4.35"
    Name "5-N-Acetyl-3-(1-Ethylpropyl)-1-Cyclohexene-1-Carboxylic Acid"
    Targets "NA_Unkown"
  ]
  node [
    id 173
    label "DB00906"
    PubChemSubstance "46505560"
    Carriers ""
    Wikipedia "Tiagabine"
    HBondAcceptorCount "3"
    ChemSpider "54661"
    ATCcode "N03AG06"
    Polarizability "41.7"
    KEGGCompound "C07503"
    logS "-4.2"
    logP "2.6"
    Refractivity "115.32"
    pKastrongestbasic "9.26"
    Bioavailability "1"
    DrugClass "Piperidines"
    PathwayNames ""
    ChEMBL "CHEMBL1027"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "4.14"
    NumberofRings "3"
    BindingDB "50368628"
    MolecularWeight "375.548"
    PhysiologicalCharge "0"
    Enzymes "CYP3A4_substrate, UGT1A1_substrate"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "40.54"
    MonoisotopicWeight "375.132670429"
    MDDRLikeRule "1"
    ChEBI "9586"
    WaterSolubility "2.11e-02"
    PharmGKB "PA451682"
    Family "small molecule"
    MolecularFormula "C20H25NO2S2"
    Transporters ""
    PubChemCompound "60648"
    HBondDonorCount "1"
    DrugSubClass "Piperidinecarboxylic acids and derivatives"
    RotatableBondCount "6"
    Name "Tiagabine"
    Targets "SLC6A1_inhibitor"
    TherapeuticTargetsDatabase "DAP000164"
  ]
  node [
    id 174
    label "DB01104"
    KEGGDrug "D02360"
    NumberofRings "3"
    Carriers "ALB"
    PubChemSubstance "46505341"
    Wikipedia "Sertraline"
    HBondAcceptorCount "1"
    ChemSpider "61881"
    ATCcode "N06AB06"
    RuleofFive "0"
    KEGGCompound "C07246"
    logS "-6.3"
    logP "5.15"
    pKastrongestbasic "9.85"
    Bioavailability "1"
    DrugClass "Tetralins"
    PathwayNames ""
    ChEMBL "CHEMBL809"
    Polarizability "32.44"
    Approved "True"
    MolecularWeight "306.23"
    Refractivity "85.74"
    BindingDB "50028094"
    Name "Sertraline"
    PhysiologicalCharge "1"
    Enzymes "CYP3A4_substrate, CYP3A4_inhibitor, CYP2D6_substrate, CYP2D6_inhibitor, CYP2C19_substrate, CYP2C19_inhibitor, CYP2C9_substrate, CYP2C9_inhibitor, CYP2B6_substrate, CYP2B6_inhibitor, CYP1A2_substrate, CYP1A2_inhibitor, MAOB_substrate, MAOA_substrate, CYP2B_inhibitor"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "12.03"
    MonoisotopicWeight "305.073804963"
    MDDRLikeRule "0"
    ChEBI "9123"
    PDB "SRE"
    DrugsProductDatabaseDPD "11168"
    PharmGKB "PA451333"
    Family "small molecule"
    MolecularFormula "C17H17Cl2N"
    Transporters "ABCB1_inhibitor"
    PubChemCompound "68617"
    HBondDonorCount "1"
    DrugSubClass "Tametralines"
    RotatableBondCount "2"
    WaterSolubility "1.45e-04"
    Targets "SLC6A4_inhibitor, SLC6A3_inhibitor, PGRMC1_antagonist"
    TherapeuticTargetsDatabase "DAP000051"
  ]
  node [
    id 175
    label "DB04835"
    PubChemSubstance "46508040"
    Carriers ""
    WaterSolubility "8.83e-03"
    Wikipedia "Maraviroc"
    GuidetoPharmacology "806"
    HBondAcceptorCount "5"
    ChemSpider "20078004"
    ATCcode "J05AX09"
    RuleofFive "0"
    logS "-4.8"
    logP "1.89"
    Refractivity "143.4"
    pKastrongestbasic "10.13"
    Bioavailability "1"
    DrugClass "Tropane alkaloids"
    PathwayNames ""
    ChEMBL "CHEMBL1201187"
    Polarizability "56.84"
    Approved "True"
    pKastrongestacidic "7.02"
    NumberofRings "5"
    BindingDB "50334986"
    MolecularWeight "513.6655"
    PhysiologicalCharge "2"
    Enzymes "CYP3A4_substrate"
    IUPHAR "806"
    GhoseFilter "0"
    PolarSurfaceAreaPSA "66.54"
    MonoisotopicWeight "513.327917369"
    MDDRLikeRule "1"
    ChEBI "63608"
    PDB "MRV"
    DrugsProductDatabaseDPD "20160"
    PharmGKB "PA164768835"
    Family "small molecule"
    MolecularFormula "C29H41F2N5O"
    Transporters ""
    PubChemCompound "3002977"
    HBondDonorCount "1"
    DrugSubClass "None"
    RotatableBondCount "8"
    Name "Maraviroc"
    Targets "CCR5_antagonist"
    TherapeuticTargetsDatabase "DNC001487"
  ]
  node [
    id 176
    label "DB00987"
    KEGGDrug "D00168"
    PubChemSubstance "46505879"
    Carriers ""
    WaterSolubility "4.38e+01"
    Wikipedia "Cytarabine"
    HBondAcceptorCount "7"
    ChemSpider "6017"
    ATCcode "L01BC01"
    Polarizability "22.21"
    KEGGCompound "C02961"
    logS "-0.74"
    logP "-2.8"
    Refractivity "54.54"
    pKastrongestbasic "-0.55"
    Bioavailability "1"
    DrugClass "Pyrimidine nucleosides"
    PathwayNames ""
    ChEMBL "CHEMBL803"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "12.55"
    NumberofRings "2"
    BindingDB "50087289"
    MolecularWeight "243.2166"
    PhysiologicalCharge "0"
    Enzymes "CDA_substrate, CYP3A4_substrate, DCK_substrate, NT5E_substrate, DCTD_substrate"
    GhoseFilter "0"
    PolarSurfaceAreaPSA "128.61"
    MonoisotopicWeight "243.085520541"
    MDDRLikeRule "0"
    ChEBI "28680"
    PDB "AR3"
    DrugsProductDatabaseDPD "2953"
    PharmGKB "PA449177"
    Family "small molecule"
    MolecularFormula "C9H13N3O5"
    Transporters "SLC22A1_substrate, ABCC10_substrate, SLC29A1_substrate"
    PubChemCompound "6253"
    HBondDonorCount "4"
    DrugSubClass "None"
    RotatableBondCount "2"
    Name "Cytarabine"
    Targets "POLB_inhibitor, DNA"
    TherapeuticTargetsDatabase "DNC001551"
  ]
  node [
    id 177
    label "DB01204"
    PubChemSubstance "46504608"
    Carriers ""
    WaterSolubility "7.34e-01"
    Wikipedia "Mitoxantrone"
    HBondAcceptorCount "10"
    ChemSpider "4067"
    ATCcode "L01DB07"
    Polarizability "48.49"
    KEGGCompound "C11195"
    logS "-2.8"
    logP "1.19"
    Refractivity "123.53"
    pKastrongestbasic "9.08"
    Bioavailability "0"
    DrugClass "Anthracenes"
    PathwayNames ""
    ChEMBL "CHEMBL58"
    RuleofFive "0"
    Approved "True"
    pKastrongestacidic "9.78"
    NumberofRings "3"
    BindingDB "67690"
    MolecularWeight "444.4809"
    PhysiologicalCharge "2"
    Enzymes "CYP2E1_substrate, CYP1B1_inhibitor, CYP3A4_inhibitor"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "163.18"
    MonoisotopicWeight "444.200884648"
    MDDRLikeRule "1"
    ChEBI "50729"
    PDB "MIX"
    DrugsProductDatabaseDPD "11343"
    PharmGKB "PA450526"
    Family "small molecule"
    MolecularFormula "C22H28N4O6"
    Transporters "ABCB1_substrate, ABCB1_inhibitor, ABCB1_inducer, ABCC1_substrate, ABCC1_inhibitor, ABCG2_substrate"
    PubChemCompound "4212"
    HBondDonorCount "8"
    DrugSubClass "Anthraquinones"
    RotatableBondCount "12"
    Name "Mitoxantrone"
    Targets "DNA, TOP2A_inhibitor"
    TherapeuticTargetsDatabase "DAP000057"
  ]
  node [
    id 178
    label "DB01205"
    KEGGDrug "D00697"
    NumberofRings "3"
    Carriers ""
    PubChemSubstance "46507438"
    Wikipedia "Flumazenil"
    HBondAcceptorCount "3"
    ChemSpider "3256"
    ATCcode "V03AB25"
    RuleofFive "1"
    KEGGCompound "C07825"
    logS "-2.5"
    logP "0.33"
    pKastrongestbasic "3.27"
    Bioavailability "1"
    DrugClass "Benzodiazepines"
    PathwayNames ""
    ChEMBL "CHEMBL407"
    Polarizability "29.97"
    Approved "True"
    MolecularWeight "303.2884"
    Refractivity "87.93"
    BindingDB "26263"
    Name "Flumazenil"
    PhysiologicalCharge "0"
    Enzymes ""
    GhoseFilter "1"
    PolarSurfaceAreaPSA "64.43"
    MonoisotopicWeight "303.101919534"
    MDDRLikeRule "0"
    ChEBI "5103"
    PDB "FYP"
    DrugsProductDatabaseDPD "1227"
    PharmGKB "PA449659"
    Family "small molecule"
    MolecularFormula "C15H14FN3O3"
    Transporters ""
    PubChemCompound "3373"
    HBondDonorCount "0"
    DrugSubClass "1,4-benzodiazepines"
    RotatableBondCount "3"
    WaterSolubility "1.04e+00"
    Targets "GABRA1_antagonist, GABRG2_antagonist, GABRA5_antagonist, GABRA1_positive allosteric modulator"
    TherapeuticTargetsDatabase "DAP000685"
  ]
  node [
    id 179
    label "DB01597"
    PubChemSubstance "46505611"
    Carriers ""
    WaterSolubility "1.00e-01"
    Wikipedia "Cilastatin"
    HBondAcceptorCount "6"
    ChemSpider "4940183"
    ATCcode ""
    Polarizability "38.28"
    KEGGCompound "C01675"
    logS "-3.6"
    logP "-1.3"
    Refractivity "92.85"
    pKastrongestbasic "9.14"
    Bioavailability "1"
    DrugClass "Carboxylic acids and derivatives"
    PathwayNames ""
    ChEMBL "CHEMBL766"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "2.53"
    NumberofRings "1"
    BindingDB "50367502"
    MolecularWeight "358.453"
    PhysiologicalCharge "-1"
    Enzymes ""
    GhoseFilter "0"
    PolarSurfaceAreaPSA "129.72"
    MonoisotopicWeight "358.156242642"
    MDDRLikeRule "0"
    ChEBI "3697"
    PDB "CIL"
    DrugsProductDatabaseDPD "11321"
    PharmGKB "PA448998"
    Family "small molecule"
    MolecularFormula "C16H26N2O5S"
    Transporters "SLC22A6_inhibitor, SLC22A8_inhibitor"
    PubChemCompound "6435415"
    HBondDonorCount "4"
    DrugSubClass "Amino acids, peptides, and analogues"
    RotatableBondCount "11"
    Name "Cilastatin"
    Targets "DPEP1_inhibitor"
    TherapeuticTargetsDatabase "DAP000632"
  ]
  node [
    id 180
    label "DB00822"
    KEGGDrug "D00131"
    PubChemSubstance "46506008"
    Carriers ""
    Wikipedia "Disulfiram"
    HBondAcceptorCount "0"
    ChemSpider "3005"
    ATCcode "P03AA54, P03AA04, N07BB01"
    RuleofFive "1"
    KEGGCompound "C01692"
    PolarSurfaceAreaPSA "6.48"
    logS "-4.4"
    logP "4.16"
    Refractivity "88.24"
    Bioavailability "1"
    DrugClass "Organonitrogen compounds"
    ChEMBL "CHEMBL964"
    Polarizability "31.6"
    Approved "True"
    MolecularWeight "296.539"
    NumberofRings "0"
    BindingDB "50058655"
    Name "Disulfiram"
    PhysiologicalCharge "0"
    Enzymes "CYP2E1_inhibitor, CYP2C9_inhibitor, CYP3A4_substrate, CYP3A5_substrate, CYP1A2_inhibitor"
    GhoseFilter "1"
    PubChemCompound "3117"
    MonoisotopicWeight "296.05093141"
    MDDRLikeRule "0"
    ChEBI "4659"
    DrugsProductDatabaseDPD "5805"
    PharmGKB "PA449376"
    Family "small molecule"
    MolecularFormula "C10H20N2S4"
    Transporters ""
    PathwayNames "Disulfiram Action Pathway_SMP00429"
    HBondDonorCount "0"
    DrugSubClass "Amines"
    RotatableBondCount "7"
    WaterSolubility "1.26e-02"
    Targets "ALDH2_inhibitor, DBH_inhibitor"
    TherapeuticTargetsDatabase "DAP000012"
  ]
  node [
    id 181
    label "DB00988"
    KEGGDrug "D07870"
    PubChemSubstance "46506043"
    Carriers ""
    WaterSolubility "7.43e+00"
    Wikipedia "Dopamine"
    GuidetoPharmacology "940"
    HBondAcceptorCount "3"
    ChemSpider "661"
    ATCcode "C01CA04"
    Polarizability "16.21"
    KEGGCompound "C03758"
    logS "-1.3"
    logP "0.03"
    Refractivity "43.25"
    pKastrongestbasic "9.27"
    Bioavailability "1"
    DrugClass "Phenols"
    PathwayNames "Catecholamine Biosynthesis_SMP00012, Prilocaine Action Pathway_SMP00401, Heroin Action Pathway_SMP00407, Methadone Action Pathway_SMP00408, Alfentanil Action Pathway_SMP00413, Carfentanil Action Pathway_SMP00414, Tramadol Action Action Pathway_SMP00671, Levallorphan Action Pathway_SMP00683, Tyrosine Metabolism_SMP00006, Dibucaine Action Pathway_SMP00396, Procaine Action Pathway_SMP00402, Codeine Action Pathway_SMP00405, Hydromorphone Action Pathway_SMP00410, Remifentanil Action Pathway_SMP00416, Imipramine Action Pathway_SMP00422, Tyrosinemia, transient, of the newborn_SMP00494, Propoxyphene Action Pathway_SMP00672, Diphenoxylate Action Pathway_SMP00675, 3-Methylthiofentanyl Action Pathway_SMP00679, Ethylmorphine Action Pathway_SMP00681, Aromatic L-Aminoacid Decarboxylase Deficiency_SMP00170, Dopamine Activation of Neurological Reward System_SMP00308, Levobupivacaine Action Pathway_SMP00397, Oxymorphone Action Pathway_SMP00412, Fentanyl Action Pathway_SMP00415, Fluoxetine Action Pathway_SMP00426, Nicotine Action Pathway_SMP00431, Levorphanol Action Pathway_SMP00673, Anileridine Action Pathway_SMP00674, Methadyl Acetate Action Pathway_SMP00678"
    ChEMBL "CHEMBL59"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "10.01"
    NumberofRings "1"
    BindingDB "55121"
    MolecularWeight "153.1784"
    PhysiologicalCharge "1"
    Enzymes "MAOA_substrate, MAOB_substrate, COMT_substrate, DBH_substrate, CYP1A2_inhibitor, CYP2C19_substrate, CYP2C9_substrate, CYP2D6_substrate"
    IUPHAR "940"
    GhoseFilter "0"
    PolarSurfaceAreaPSA "66.48"
    MonoisotopicWeight "153.078978601"
    MDDRLikeRule "0"
    ChEBI "18243"
    PDB "LDP"
    DrugsProductDatabaseDPD "2322"
    PharmGKB "PA449396"
    Family "small molecule"
    MolecularFormula "C8H11NO2"
    Transporters "SLC22A2_substrate, SLC22A2_inhibitor, SLC22A1_substrate, SLC22A1_inhibitor, SLC22A3_inhibitor, SLC22A5_inhibitor, POU5F1_substrate"
    PubChemCompound "681"
    HBondDonorCount "3"
    DrugSubClass "Benzenediols"
    RotatableBondCount "2"
    Name "Dopamine"
    Targets "DRD2_agonist, DRD1_agonist, DRD5_agonist, DRD3_agonist, DRD4_agonist, SLC6A3_inducer, DBH_ligand, HTR1A_binder, HTR7_binder, DRD1_agonist, SLC6A2_inhibitor, SLC6A4_inhibitor, HTR3A_Unkown, HTR3B_Unkown, SOD1_Unkown, SLC18A2_Unkown"
    TherapeuticTargetsDatabase "DAP000212"
  ]
  node [
    id 182
    label "DB00532"
    KEGGDrug "D00375"
    NumberofRings "2"
    Carriers ""
    PubChemSubstance "46508677"
    Wikipedia "Mephenytoin"
    HBondAcceptorCount "2"
    ChemSpider "3920"
    ATCcode "N03AB04, N03AB54"
    Name "Mephenytoin"
    logS "-2.4"
    logP "1.67"
    pKastrongestbasic "-8.1"
    Bioavailability "1"
    DrugClass "Azolidines"
    PathwayNames ""
    ChEMBL "CHEMBL861"
    Polarizability "22.67"
    Approved "False"
    pKastrongestacidic "11.18"
    Refractivity "59.54"
    MolecularWeight "218.2518"
    PhysiologicalCharge "0"
    Enzymes "CYP2C19_substrate, CYP2C19_inhibitor, CYP2B6_substrate, CYP1A2_substrate, CYP2D6_substrate, CYP2C8_substrate, CYP2C9_substrate"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "49.41"
    MonoisotopicWeight "218.105527702"
    MDDRLikeRule "0"
    ChEBI "6757"
    PharmGKB "PA450373"
    Family "small molecule"
    MolecularFormula "C12H14N2O2"
    Transporters ""
    RuleofFive "1"
    PubChemCompound "4060"
    HBondDonorCount "1"
    DrugSubClass "Imidazolidines"
    RotatableBondCount "2"
    WaterSolubility "9.70e-01"
    Targets "SCN5A_inhibitor, NR1I2_activator"
    TherapeuticTargetsDatabase "DAP000508"
  ]
  node [
    id 183
    label "DB06821"
    KEGGDrug "D02517"
    NumberofRings "2"
    Carriers ""
    Wikipedia "Sulfametoxydiazine"
    HBondAcceptorCount "6"
    ChemSpider "5135"
    PolarSurfaceAreaPSA "107.2"
    logS "-3"
    logP "0.23"
    pKastrongestbasic "1.98"
    Bioavailability "1"
    DrugClass "Benzene and substituted derivatives"
    ChEMBL "CHEMBL1200359"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "7.06"
    Refractivity "70.66"
    MolecularWeight "280.3"
    PhysiologicalCharge "0"
    Enzymes ""
    GhoseFilter "1"
    PathwayNames ""
    MonoisotopicWeight "280.063011436"
    MDDRLikeRule "0"
    ChEBI "53727"
    WaterSolubility "3.13e-01"
    Polarizability "26.24"
    Family "small molecule"
    MolecularFormula "C11H12N4O3S"
    Transporters ""
    ATCcode "J01ED04, G01AE10"
    HBondDonorCount "2"
    DrugSubClass "Benzenesulfonamides"
    RotatableBondCount "3"
    Name "Sulfameter"
    Targets "folP_inhibitor"
  ]
  node [
    id 184
    label "DB00633"
    KEGGDrug "D00514"
    PubChemSubstance "46507406"
    Carriers ""
    Wikipedia "Dexmedetomidine"
    HBondAcceptorCount "1"
    ChemSpider "4470605"
    ATCcode "N05CM18"
    Polarizability "23.32"
    KEGGCompound "C07450"
    logS "-3.1"
    logP "3.39"
    Refractivity "62.98"
    pKastrongestbasic "6.54"
    Bioavailability "1"
    DrugClass "Benzene and substituted derivatives"
    PathwayNames ""
    ChEMBL "CHEMBL778"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "14.09"
    NumberofRings "2"
    BindingDB "50085683"
    MolecularWeight "200.2795"
    PhysiologicalCharge "0"
    Enzymes "CYP2E1_substrate, CYP1A2_inhibitor, CYP1A1_inhibitor, CYP2D6_inhibitor"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "28.68"
    MonoisotopicWeight "200.131348522"
    MDDRLikeRule "0"
    ChEBI "4466"
    WaterSolubility "1.74e-01"
    DrugsProductDatabaseDPD "20565"
    PharmGKB "PA449256"
    Family "small molecule"
    MolecularFormula "C13H16N2"
    Transporters ""
    PubChemCompound "5311068"
    HBondDonorCount "1"
    DrugSubClass "Xylenes"
    RotatableBondCount "2"
    Name "Dexmedetomidine"
    Targets "ADRA2A_agonist"
    TherapeuticTargetsDatabase "DAP000233"
  ]
  node [
    id 185
    label "DB00348"
    PubChemSubstance "46507380"
    Carriers ""
    Wikipedia "Nitisinone"
    HBondAcceptorCount "5"
    ChemSpider "103195"
    ATCcode "A16AX04"
    Name "Nitisinone"
    PolarSurfaceAreaPSA "97.03"
    logS "-4.6"
    logP "3.13"
    Polarizability "26.74"
    Refractivity "72.35"
    pKastrongestbasic "-7.3"
    Bioavailability "1"
    DrugClass "Organooxygen compounds"
    ChEMBL "CHEMBL1337"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "2.71"
    NumberofRings "2"
    BindingDB "50088804"
    MolecularWeight "329.2281"
    PhysiologicalCharge "-1"
    Enzymes ""
    GhoseFilter "1"
    PubChemCompound "115355"
    MonoisotopicWeight "329.05110705"
    MDDRLikeRule "0"
    ChEBI "50378"
    DrugsProductDatabaseDPD "22811"
    PharmGKB "PA164777037"
    Family "small molecule"
    MolecularFormula "C14H10F3NO5"
    Transporters ""
    PathwayNames ""
    HBondDonorCount "0"
    DrugSubClass "Carbonyl compounds"
    RotatableBondCount "4"
    WaterSolubility "8.11e-03"
    Targets "HPD_inhibitor"
    TherapeuticTargetsDatabase "DAP000774"
  ]
  node [
    id 186
    label "DB01126"
    KEGGDrug "D03820"
    NumberofRings "5"
    Carriers ""
    PubChemSubstance "46504830"
    Wikipedia "Dutasteride"
    HBondAcceptorCount "2"
    ChemSpider "5293502"
    ATCcode "G04CB02, G04CA52"
    Polarizability "50.13"
    logS "-5.8"
    logP "5.79"
    pKastrongestbasic "2.17"
    Bioavailability "0"
    DrugClass "Steroids and steroid derivatives"
    PathwayNames ""
    ChEMBL "CHEMBL1200969"
    RuleofFive "0"
    Approved "True"
    pKastrongestacidic "12.56"
    Refractivity "127.9"
    BindingDB "50340481"
    MolecularWeight "528.5297"
    PhysiologicalCharge "0"
    Enzymes "CYP3A4_substrate, CYP3A5_substrate"
    GhoseFilter "0"
    PolarSurfaceAreaPSA "58.2"
    MonoisotopicWeight "528.221147444"
    MDDRLikeRule "0"
    ChEBI "521033"
    WaterSolubility "9.08e-04"
    DrugsProductDatabaseDPD "12580"
    PharmGKB "PA164749300"
    Family "small molecule"
    MolecularFormula "C27H30F6N2O2"
    Transporters ""
    PubChemCompound "6918296"
    HBondDonorCount "2"
    DrugSubClass "Androstane steroids"
    RotatableBondCount "4"
    Name "Dutasteride"
    Targets "SRD5A2_inhibitor, SRD5A1_inhibitor"
    TherapeuticTargetsDatabase "DAP000044"
  ]
  node [
    id 187
    label "DB00636"
    KEGGDrug "D00279"
    Refractivity "62.14"
    Carriers ""
    PubChemSubstance "46504748"
    Wikipedia "Clofibrate"
    HBondAcceptorCount "2"
    ChemSpider "2694"
    ATCcode "C10AB01"
    MolecularWeight "242.699"
    KEGGCompound "C06916"
    logS "-3.9"
    logP "3.4"
    Polarizability "24.7"
    pKastrongestbasic "-4.9"
    Bioavailability "1"
    DrugClass "Benzene and substituted derivatives"
    PathwayNames ""
    ChEMBL "CHEMBL565"
    RuleofFive "1"
    Approved "True"
    NumberofRings "1"
    BindingDB "50085047"
    Name "Clofibrate"
    PhysiologicalCharge "0"
    Enzymes "CYP2E1_inducer, GSTA2_inhibitor, CYP3A4_substrate, CYP3A4_inducer, CYP1A1_inducer, CYP2A6_inhibitor, CYP2B6_inducer, CYP4A11_substrate, CYP4A11_inducer"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "35.53"
    MonoisotopicWeight "242.070972053"
    MDDRLikeRule "0"
    ChEBI "3750"
    DrugsProductDatabaseDPD "9842"
    PharmGKB "PA449045"
    Family "small molecule"
    MolecularFormula "C12H15ClO3"
    Transporters ""
    PubChemCompound "2796"
    HBondDonorCount "0"
    DrugSubClass "Phenoxyacetic acid derivatives"
    RotatableBondCount "5"
    WaterSolubility "2.90e-02"
    Targets "PPARA_agonist"
    TherapeuticTargetsDatabase "DAP000262"
  ]
  node [
    id 188
    label "DB00439"
    PubChemSubstance "46505877"
    Carriers ""
    WaterSolubility "4.19e-03"
    Wikipedia "Cerivastatin"
    HBondAcceptorCount "6"
    ChemSpider "393588"
    ATCcode "C10AA06"
    Polarizability "50.23"
    KEGGCompound "C07966"
    logS "-5"
    logP "2.67"
    Refractivity "126.82"
    pKastrongestbasic "5.58"
    Bioavailability "1"
    DrugClass "Pyridines and derivatives"
    PathwayNames "Cerivastatin Action Pathway_SMP00111"
    ChEMBL "CHEMBL1477"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "4.05"
    NumberofRings "2"
    BindingDB "18376"
    MolecularWeight "459.5503"
    PhysiologicalCharge "-1"
    Enzymes "CYP3A4_substrate, CYP3A4_inhibitor, CYP3A4_inducer, CYP3A5_substrate, CYP3A7_substrate, CYP2C8_substrate, CYP2C8_inhibitor, CYP2D6_inhibitor, CYP2C19_inhibitor, CYP2C9_inhibitor, CYP2C9_inducer, CYP2B6_inducer, UGT1A1_substrate"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "99.88"
    MonoisotopicWeight "459.242101408"
    MDDRLikeRule "0"
    ChEBI "3558"
    PDB "116"
    DrugsProductDatabaseDPD "11747"
    PharmGKB "PA448897"
    Family "small molecule"
    MolecularFormula "C26H34FNO5"
    Transporters "ABCB1_substrate, ABCC2_substrate, ABCG2_substrate, SLCO1B1_substrate"
    PubChemCompound "446156"
    HBondDonorCount "3"
    DrugSubClass "Phenylpyridines"
    RotatableBondCount "11"
    Name "Cerivastatin"
    Targets "HMGCR_inhibitor"
    TherapeuticTargetsDatabase "DNC000403"
  ]
  node [
    id 189
    label "DB00233"
    KEGGDrug "D00162"
    PubChemSubstance "46505572"
    Carriers ""
    WaterSolubility "1.18e+01"
    Wikipedia "4-Aminosalicylic_acid"
    HBondAcceptorCount "4"
    ChemSpider "4488"
    ATCcode "J04AA02, J04AA01, J04AA03"
    Polarizability "14.29"
    KEGGCompound "C02518"
    logS "-1.1"
    logP "0.83"
    Refractivity "40"
    pKastrongestbasic "2.19"
    Bioavailability "1"
    DrugClass "Benzene and substituted derivatives"
    PathwayNames ""
    ChEMBL "CHEMBL1169"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "3.68"
    NumberofRings "1"
    BindingDB "48319"
    MolecularWeight "153.1354"
    PhysiologicalCharge "-1"
    Enzymes "MPO_inhibitor"
    GhoseFilter "0"
    PolarSurfaceAreaPSA "83.55"
    MonoisotopicWeight "153.042593095"
    MDDRLikeRule "0"
    ChEBI "27565"
    PDB "BHA"
    DrugsProductDatabaseDPD "6620"
    PharmGKB "PA448382"
    Family "small molecule"
    MolecularFormula "C7H7NO3"
    Transporters ""
    PubChemCompound "4649"
    HBondDonorCount "3"
    DrugSubClass "Benzoic acids and derivatives"
    RotatableBondCount "1"
    Name "Aminosalicylic Acid"
    Targets "PTGS2_inhibitor, CHUK_inhibitor, ALOX5_inhibitor, PLA2G2E_unknown, folK_unknown"
  ]
  node [
    id 190
    label "DB00437"
    KEGGDrug "D00224"
    NumberofRings "2"
    Carriers ""
    PubChemSubstance "46508516"
    WaterSolubility "5.88e+00"
    Wikipedia "Allopurinol"
    HBondAcceptorCount "5"
    ChemSpider "2010"
    ATCcode "M04AA01, M04AA51"
    Polarizability "11.67"
    logS "-1.4"
    logP "-1.8"
    pKastrongestbasic "2.57"
    Bioavailability "1"
    DrugClass "Pyrazolopyrimidines"
    PathwayNames ""
    ChEMBL "CHEMBL1467"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "7.83"
    Refractivity "54.24"
    BindingDB "181133"
    MolecularWeight "136.1115"
    PhysiologicalCharge "0"
    Enzymes "AOX1_substrate, XDH_substrate"
    GhoseFilter "0"
    PolarSurfaceAreaPSA "65.85"
    MonoisotopicWeight "136.03851077"
    MDDRLikeRule "0"
    ChEBI "40279"
    PDB "7HP"
    DrugsProductDatabaseDPD "9388"
    PharmGKB "PA448320"
    Family "small molecule"
    MolecularFormula "C5H4N4O"
    Transporters "SLC22A8_substrate, SLC22A7_substrate"
    PubChemCompound "2094"
    HBondDonorCount "2"
    DrugSubClass "Pyrazolo[3,4-d]pyrimidines"
    RotatableBondCount "0"
    Name "Allopurinol"
    Targets "XDH_inhibitor"
    TherapeuticTargetsDatabase "DAP000773"
  ]
  node [
    id 191
    label "DB00656"
    PubChemSubstance "46506648"
    Carriers "ORM1"
    Wikipedia "Trazodone"
    GuidetoPharmacology "213"
    HBondAcceptorCount "4"
    ChemSpider "5332"
    ATCcode "N06AX05"
    RuleofFive "1"
    KEGGCompound "C07156"
    PolarSurfaceAreaPSA "42.39"
    logS "-3.1"
    logP "3.13"
    Refractivity "105.88"
    pKastrongestbasic "7.09"
    Bioavailability "1"
    DrugClass "Diazinanes"
    ChEMBL "CHEMBL621"
    Polarizability "40.12"
    Approved "True"
    MolecularWeight "371.864"
    NumberofRings "4"
    BindingDB "50073444"
    Name "Trazodone"
    PhysiologicalCharge "1"
    Enzymes "CYP3A4_substrate, CYP3A5_substrate, CYP3A7_substrate, CYP2D6_substrate"
    IUPHAR "213"
    GhoseFilter "1"
    PubChemCompound "5533"
    MonoisotopicWeight "371.151288058"
    MDDRLikeRule "0"
    ChEBI "9654"
    DrugsProductDatabaseDPD "11748"
    PharmGKB "PA451744"
    Family "small molecule"
    MolecularFormula "C19H22ClN5O"
    Transporters "ABCB1_inducer"
    PathwayNames ""
    HBondDonorCount "0"
    DrugSubClass "Piperazines"
    RotatableBondCount "5"
    WaterSolubility "2.90e-01"
    Targets "HTR2A_antagonist, HTR2C_agonist, SLC6A4_inhibitor, HTR1A_partial agonist, HRH1_antagonist, ADRA1A_antagonist, ADRA2A_antagonist"
    TherapeuticTargetsDatabase "DAP000104"
  ]
  node [
    id 192
    label "DB00657"
    PubChemSubstance "46508607"
    Carriers ""
    Wikipedia "Mecamylamine"
    GuidetoPharmacology "3990"
    HBondAcceptorCount "1"
    ChemSpider "3892"
    ATCcode "C02BB01"
    RuleofFive "1"
    KEGGCompound "C07511"
    PolarSurfaceAreaPSA "12.03"
    logS "-3.1"
    logP "2.37"
    Refractivity "51.83"
    pKastrongestbasic "10.88"
    Bioavailability "1"
    DrugClass "Prenol lipids"
    ChEMBL "CHEMBL267936"
    Polarizability "20.74"
    Approved "True"
    MolecularWeight "167.2911"
    NumberofRings "2"
    BindingDB "50061565"
    Name "Mecamylamine"
    PhysiologicalCharge "1"
    Enzymes ""
    IUPHAR "3990"
    GhoseFilter "1"
    PubChemCompound "4032"
    MonoisotopicWeight "167.167399677"
    MDDRLikeRule "0"
    ChEBI "6706"
    PharmGKB "PA450334"
    Family "small molecule"
    MolecularFormula "C11H21N"
    Transporters ""
    PathwayNames ""
    HBondDonorCount "1"
    DrugSubClass "Monoterpenoids"
    RotatableBondCount "1"
    WaterSolubility "1.24e-01"
    Targets "CHRNA2_antagonist, CHRNA7_Unkown, CHRNA4_Unkown, CHRNB2_Unkown"
    TherapeuticTargetsDatabase "DAP000027"
  ]
  node [
    id 193
    label "DB00499"
    KEGGDrug "D00586"
    PubChemSubstance "46508874"
    Carriers ""
    WaterSolubility "5.66e-03"
    Wikipedia "Flutamide"
    HBondAcceptorCount "3"
    ChemSpider "3280"
    ATCcode "L02BB01"
    Polarizability "23.2"
    KEGGCompound "C07653"
    logS "-4.7"
    logP "3.27"
    Refractivity "63.42"
    pKastrongestbasic "-3.7"
    Bioavailability "1"
    DrugClass "Benzene and substituted derivatives"
    PathwayNames ""
    ChEMBL "CHEMBL806"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "13.17"
    NumberofRings "1"
    BindingDB "50131270"
    MolecularWeight "276.2118"
    PhysiologicalCharge "0"
    Enzymes "CYP3A4_substrate, CYP1A2_substrate, CYP1A2_inhibitor, CYP1A1_substrate, CYP1B1_substrate, CYP1B1_inhibitor, CYP2C19_substrate, CYP3A5_substrate"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "74.92"
    MonoisotopicWeight "276.072176843"
    MDDRLikeRule "0"
    ChEBI "5132"
    PDB "HFT"
    DrugsProductDatabaseDPD "1847"
    PharmGKB "PA449685"
    Family "small molecule"
    MolecularFormula "C11H11F3N2O3"
    Transporters ""
    PubChemCompound "3397"
    HBondDonorCount "1"
    DrugSubClass "Trifluoromethylbenzenes"
    RotatableBondCount "4"
    Name "Flutamide"
    Targets "AR_antagonist, AHR_agonist, NR1I2_Unkown"
    TherapeuticTargetsDatabase "DAP000301"
  ]
  node [
    id 194
    label "DB01626"
    PubChemSubstance "46507368"
    Carriers ""
    Wikipedia "Pargyline"
    HBondAcceptorCount "1"
    ChemSpider "4526"
    ATCcode "C02LL01, C02KC01"
    RuleofFive "1"
    KEGGCompound "C07414"
    PolarSurfaceAreaPSA "3.24"
    logS "-3.2"
    logP "2.14"
    Refractivity "52.18"
    pKastrongestbasic "8.13"
    Bioavailability "1"
    DrugClass "Benzene and substituted derivatives"
    ChEMBL "CHEMBL673"
    Polarizability "18.78"
    Approved "True"
    MolecularWeight "159.2276"
    NumberofRings "1"
    BindingDB "50172756"
    Name "Pargyline"
    PhysiologicalCharge "1"
    Enzymes ""
    GhoseFilter "0"
    PubChemCompound "4688"
    MonoisotopicWeight "159.104799421"
    MDDRLikeRule "0"
    ChEBI "7930"
    PharmGKB "PA450797"
    Family "small molecule"
    MolecularFormula "C11H13N"
    Transporters ""
    PathwayNames ""
    HBondDonorCount "0"
    DrugSubClass "Phenylmethylamines"
    RotatableBondCount "3"
    WaterSolubility "9.98e-02"
    Targets "MAOB_inhibitor, MAOA_inhibitor"
    TherapeuticTargetsDatabase "DAP000580"
  ]
  node [
    id 195
    label "DB00494"
    KEGGDrug "D00781"
    PubChemSubstance "46508734"
    Carriers ""
    Wikipedia "Entacapone"
    HBondAcceptorCount "6"
    ChemSpider "4444537"
    ATCcode "N04BX02"
    Polarizability "29.48"
    KEGGCompound "C07943"
    logS "-3.6"
    logP "1.63"
    Refractivity "80.51"
    pKastrongestbasic "-0.036"
    Bioavailability "1"
    DrugClass "Cinnamic acids and derivatives"
    PathwayNames ""
    ChEMBL "CHEMBL953"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "5.68"
    NumberofRings "1"
    BindingDB "50108879"
    MolecularWeight "305.286"
    PhysiologicalCharge "-1"
    Enzymes "COMT_inhibitor, UGT1A9_substrate, CYP1A2_inhibitor, CYP2D6_inhibitor"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "130.38"
    MonoisotopicWeight "305.101170605"
    MDDRLikeRule "0"
    ChEBI "4798"
    WaterSolubility "7.97e-02"
    DrugsProductDatabaseDPD "12126"
    PharmGKB "PA164748726"
    Family "small molecule"
    MolecularFormula "C14H15N3O5"
    Transporters ""
    PubChemCompound "5281081"
    HBondDonorCount "2"
    DrugSubClass "Hydroxycinnamic acids and derivatives"
    RotatableBondCount "5"
    Name "Entacapone"
    Targets "COMT_inhibitor"
    TherapeuticTargetsDatabase "DAP000608"
  ]
  node [
    id 196
    label "DB00320"
    PubChemSubstance "46507711"
    Carriers ""
    WaterSolubility "2.29e-01"
    Wikipedia "Dihydroergotamine"
    HBondAcceptorCount "6"
    ChemSpider "10091"
    ATCcode "N02CA01, N02CA51"
    Polarizability "63.3"
    KEGGCompound "C07798"
    logS "-3.4"
    logP "2.71"
    Refractivity "159.39"
    pKastrongestbasic "8.39"
    Bioavailability "1"
    DrugClass "Ergoline and derivatives"
    PathwayNames ""
    ChEMBL "CHEMBL1732"
    RuleofFive "0"
    Approved "True"
    pKastrongestacidic "9.71"
    NumberofRings "8"
    BindingDB "50295557"
    MolecularWeight "583.6774"
    PhysiologicalCharge "1"
    Enzymes "CYP3A4_substrate, CYP3A4_inhibitor"
    GhoseFilter "0"
    PolarSurfaceAreaPSA "118.21"
    MonoisotopicWeight "583.279469319"
    MDDRLikeRule "0"
    ChEBI "4562"
    PDB "2GM"
    DrugsProductDatabaseDPD "3359"
    PharmGKB "PA164743028"
    Family "small molecule"
    MolecularFormula "C33H37N5O5"
    Transporters "ABCB1_inhibitor"
    PubChemCompound "10531"
    HBondDonorCount "3"
    DrugSubClass "Lysergic acids and derivatives"
    RotatableBondCount "4"
    Name "Dihydroergotamine"
    Targets "HTR1D_agonist, HTR1B_agonist, ADRA2A_agonist, HTR2B_agonist"
    TherapeuticTargetsDatabase "DAP000078"
  ]
  node [
    id 197
    label "DB00490"
    PubChemSubstance "46508113"
    Carriers ""
    Wikipedia "Buspirone"
    GuidetoPharmacology "36"
    HBondAcceptorCount "6"
    ChemSpider "2383"
    ATCcode "N05BE01"
    RuleofFive "1"
    KEGGCompound "C06861"
    PolarSurfaceAreaPSA "69.64"
    logS "-2.8"
    logP "1.78"
    Refractivity "108.89"
    pKastrongestbasic "7.62"
    Bioavailability "1"
    DrugClass "Diazinanes"
    ChEMBL "CHEMBL49"
    Polarizability "44.12"
    Approved "True"
    MolecularWeight "385.5031"
    NumberofRings "4"
    BindingDB "50001859"
    Name "Buspirone"
    PhysiologicalCharge "1"
    Enzymes "CYP3A4_substrate, CYP3A5_substrate, CYP3A7_substrate, CYP2D6_substrate"
    IUPHAR "36"
    GhoseFilter "1"
    PubChemCompound "2477"
    MonoisotopicWeight "385.247775261"
    MDDRLikeRule "1"
    ChEBI "3223"
    DrugsProductDatabaseDPD "1890"
    PharmGKB "PA448689"
    Family "small molecule"
    MolecularFormula "C21H31N5O2"
    Transporters "ABCB1_inhibitor"
    PathwayNames ""
    HBondDonorCount "0"
    DrugSubClass "Piperazines"
    RotatableBondCount "6"
    WaterSolubility "5.88e-01"
    Targets "HTR1A_partial agonist, DRD2_antagonist"
    TherapeuticTargetsDatabase "DAP000031"
  ]
  node [
    id 198
    label "DB00491"
    KEGGDrug "D00625"
    PubChemSubstance "46504492"
    Carriers ""
    WaterSolubility "6.10e+02"
    Wikipedia "Miglitol"
    HBondAcceptorCount "6"
    ChemSpider "390074"
    ATCcode "A10BF02"
    Polarizability "20.81"
    KEGGCompound "C07708"
    logS "0.47"
    logP "-3.2"
    Refractivity "48.16"
    pKastrongestbasic "7.6"
    Bioavailability "1"
    DrugClass "Piperidines"
    PathwayNames ""
    ChEMBL "CHEMBL1561"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "12.9"
    NumberofRings "1"
    BindingDB "50242271"
    MolecularWeight "207.2243"
    PhysiologicalCharge "1"
    Enzymes ""
    GhoseFilter "0"
    PolarSurfaceAreaPSA "104.39"
    MonoisotopicWeight "207.110672659"
    MDDRLikeRule "0"
    ChEBI "6935"
    PDB "MIG"
    PharmGKB "PA164776726"
    Family "small molecule"
    MolecularFormula "C8H17NO5"
    Transporters ""
    PubChemCompound "441314"
    HBondDonorCount "5"
    DrugSubClass "None"
    RotatableBondCount "3"
    Name "Miglitol"
    Targets "MGAM_antagonist, MGAM_inhibitor, GAA_antagonist, GANAB_antagonist, GANC_antagonist, AMY2A_Unkown"
    TherapeuticTargetsDatabase "DAP000712"
  ]
  node [
    id 199
    label "DB00939"
    KEGGDrug "D02341"
    PubChemSubstance "46507887"
    Carriers ""
    WaterSolubility "3.66e-03"
    Wikipedia "Meclofenamic_acid"
    HBondAcceptorCount "3"
    ChemSpider "3897"
    ATCcode "M01AG04, M02AA18"
    Polarizability "28.44"
    KEGGCompound "C07117"
    logS "-4.9"
    logP "6.09"
    Refractivity "76.45"
    pKastrongestbasic "-3.6"
    Bioavailability "1"
    DrugClass "Benzene and substituted derivatives"
    PathwayNames ""
    ChEMBL "CHEMBL509"
    RuleofFive "0"
    Approved "True"
    pKastrongestacidic "3.79"
    NumberofRings "2"
    BindingDB "22971"
    MolecularWeight "296.149"
    PhysiologicalCharge "-1"
    Enzymes ""
    GhoseFilter "0"
    PolarSurfaceAreaPSA "49.33"
    MonoisotopicWeight "295.016684015"
    MDDRLikeRule "0"
    ChEBI "6710"
    PDB "JMS"
    DrugsProductDatabaseDPD "2114"
    PharmGKB "PA450341"
    Family "small molecule"
    MolecularFormula "C14H11Cl2NO2"
    Transporters "SLC22A6_inhibitor, SLCO1C1_inhibitor"
    PubChemCompound "4037"
    HBondDonorCount "2"
    DrugSubClass "Benzoic acids and derivatives"
    RotatableBondCount "3"
    Name "Meclofenamic acid"
    Targets "PTGS1_inhibitor, PTGS2_inhibitor, ALOX5_inhibitor, KCNQ2_other, KCNQ3_other"
    TherapeuticTargetsDatabase "DNC000919"
  ]
  node [
    id 200
    label "DB00943"
    KEGGDrug "D00412"
    PubChemSubstance "46507879"
    Carriers "ALB"
    Wikipedia "Zalcitabine"
    HBondAcceptorCount "5"
    ChemSpider "22498"
    ATCcode "J05AF03"
    Polarizability "20.86"
    KEGGCompound "C07207"
    logS "-1.5"
    logP "-1.2"
    Refractivity "52.24"
    pKastrongestbasic "0.18"
    Bioavailability "1"
    DrugClass "Pyrimidine nucleosides"
    PathwayNames "Zalcitabine Action Pathway_SMP00746"
    ChEMBL "CHEMBL853"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "14.67"
    NumberofRings "2"
    BindingDB "50145605"
    MolecularWeight "211.2178"
    PhysiologicalCharge "0"
    Enzymes "DCK_substrate, CYP2C9_substrate, CYP2D6_substrate, CYP3A4_substrate, CYP3A43_substrate, CYP3A5_substrate, CYP3A7_substrate"
    GhoseFilter "0"
    PolarSurfaceAreaPSA "88.15"
    MonoisotopicWeight "211.095691297"
    MDDRLikeRule "0"
    ChEBI "10101"
    WaterSolubility "7.05e+00"
    DrugsProductDatabaseDPD "884"
    PharmGKB "PA451950"
    Family "small molecule"
    MolecularFormula "C9H13N3O3"
    Transporters "SLC22A6_substrate, SLC22A7_substrate, SLC29A1_Unkown, SLC29A2_Unkown"
    PubChemCompound "24066"
    HBondDonorCount "2"
    DrugSubClass "Pyrimidine 2',3'-dideoxyribonucleosides"
    RotatableBondCount "2"
    Name "Zalcitabine"
    Targets "pol_inhibitor"
    TherapeuticTargetsDatabase "DNC000527"
  ]
  node [
    id 201
    label "DB09026"
    KEGGDrug "D03208"
    NumberofRings "1"
    Carriers ""
    PubChemSubstance "310264980"
    WaterSolubility "2.10e-03"
    Wikipedia "Aliskiren"
    HBondAcceptorCount "7"
    ChemSpider "4591452"
    ATCcode "C09DX02, C09XA02, C09XA52, C09XA53, C09XA54"
    Polarizability "64.25"
    logS "-5.4"
    logP "3.12"
    pKastrongestbasic "9.57"
    Bioavailability "0"
    DrugClass "Carboxylic acids and derivatives"
    PathwayNames ""
    ChEMBL "CHEMBL1639"
    RuleofFive "0"
    Approved "True"
    pKastrongestacidic "14.56"
    Refractivity "154.32"
    BindingDB "17950"
    MolecularWeight "551.7583"
    PhysiologicalCharge "1"
    Enzymes "CYP3A4_substrate"
    GhoseFilter "0"
    PolarSurfaceAreaPSA "146.13"
    MonoisotopicWeight "551.393436443"
    MDDRLikeRule "0"
    ChEBI "601027"
    PDB "C41"
    DrugsProductDatabaseDPD "20175"
    PharmGKB "PA143487910"
    Family "small molecule"
    MolecularFormula "C30H53N3O6"
    Transporters ""
    PubChemCompound "5493444"
    HBondDonorCount "4"
    DrugSubClass "Amino acids, peptides, and analogues"
    RotatableBondCount "19"
    Name "Aliskiren"
    Targets "REN_inhibitor"
  ]
  node [
    id 202
    label "DB00934"
    KEGGDrug "D02566"
    PubChemSubstance "46508358"
    Carriers "ORM1"
    Wikipedia "Maprotiline"
    GuidetoPharmacology "2402"
    HBondAcceptorCount "1"
    ChemSpider "3871"
    ATCcode "N06AA21"
    RuleofFive "1"
    KEGGCompound "C07107"
    PolarSurfaceAreaPSA "12.03"
    logS "-6.3"
    logP "4.37"
    Refractivity "99.3"
    pKastrongestbasic "10.54"
    Bioavailability "1"
    DrugClass "Anthracenes"
    ChEMBL "CHEMBL21731"
    Polarizability "33.57"
    Approved "True"
    MolecularWeight "277.4033"
    NumberofRings "4"
    BindingDB "35228"
    Name "Maprotiline"
    PhysiologicalCharge "1"
    Enzymes "CYP2D6_substrate, CYP1A2_substrate"
    IUPHAR "2402"
    GhoseFilter "1"
    PubChemCompound "4011"
    MonoisotopicWeight "277.183049741"
    MDDRLikeRule "0"
    ChEBI "6690"
    DrugsProductDatabaseDPD "2274"
    PharmGKB "PA450322"
    Family "small molecule"
    MolecularFormula "C20H23N"
    Transporters ""
    PathwayNames ""
    HBondDonorCount "1"
    DrugSubClass "None"
    RotatableBondCount "4"
    WaterSolubility "1.50e-04"
    Targets "SLC6A2_inhibitor, HRH1_antagonist, CHRM1_antagonist, CHRM2_antagonist, CHRM3_antagonist, CHRM4_antagonist, CHRM5_antagonist, ADRA1A_antagonist, HTR2A_binder, HTR2C_binder, HTR7_antagonist, DRD2_binder, ADRA2A_antagonist"
    TherapeuticTargetsDatabase "DAP001150"
  ]
  node [
    id 203
    label "DB00958"
    KEGGDrug "D01363"
    NumberofRings "2"
    Carriers ""
    PubChemSubstance "46507170"
    Wikipedia "Carboplatin"
    HBondAcceptorCount "2"
    ChemSpider "8514637"
    ATCcode "L01XA02"
    Polarizability "14.06"
    logP "1.06"
    pKastrongestbasic "-6.6"
    Bioavailability "1"
    DrugClass "Carboxylic acids and derivatives"
    PathwayNames ""
    ChEMBL "CHEMBL1351"
    RuleofFive "1"
    Approved "True"
    MolecularWeight "371.254"
    Refractivity "29.01"
    Name "Carboplatin"
    PhysiologicalCharge "0"
    Enzymes "XDH_inducer, MPO_substrate, GSTT1_substrate, MT1A_substrate, MT2A_substrate, GSTP1_substrate, GSTM1_substrate, NQO1_substrate"
    GhoseFilter "0"
    PolarSurfaceAreaPSA "52.6"
    MonoisotopicWeight "371.044481331"
    MDDRLikeRule "0"
    ChEBI "31355"
    DrugsProductDatabaseDPD "1755"
    PharmGKB "PA448803"
    Family "small molecule"
    MolecularFormula "C6H12N2O4Pt"
    Transporters "SLC31A1_substrate, SLC31A2_substrate, ATP7A_substrate, ATP7B_substrate, ABCG2_substrate, ABCC2_substrate"
    PubChemCompound "38904"
    HBondDonorCount "0"
    DrugSubClass "Dicarboxylic acids and derivatives"
    RotatableBondCount "0"
    Targets "DNA, SOD1_Unkown"
    TherapeuticTargetsDatabase "DAP000535"
  ]
  node [
    id 204
    label "DB03585"
    PubChemSubstance "46507285"
    Carriers "ALB"
    WaterSolubility "2.56e-01"
    Wikipedia "Oxyphenbutazone"
    HBondAcceptorCount "3"
    ChemSpider "4480"
    ATCcode "S01BC02, M01AA03, M02AA04"
    Polarizability "35.14"
    KEGGCompound "C19494"
    logS "-3.1"
    logP "3.83"
    Refractivity "90.74"
    pKastrongestbasic "-6"
    Bioavailability "1"
    DrugClass "Phenols"
    PathwayNames ""
    ChEMBL "CHEMBL1228"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "4.87"
    NumberofRings "3"
    BindingDB "200298"
    MolecularWeight "324.3737"
    PhysiologicalCharge "-1"
    Enzymes ""
    GhoseFilter "1"
    PolarSurfaceAreaPSA "60.85"
    MonoisotopicWeight "324.147392516"
    MDDRLikeRule "0"
    ChEBI "76258"
    PDB "OPB"
    DrugsProductDatabaseDPD "9266"
    PharmGKB "PA450750"
    Family "small molecule"
    MolecularFormula "C19H20N2O3"
    Transporters "SLC22A6_inhibitor"
    PubChemCompound "4641"
    HBondDonorCount "1"
    DrugSubClass "1-hydroxy-2-unsubstituted benzenoids"
    RotatableBondCount "5"
    Name "Oxyphenbutazone"
    Targets "PLA2G2E_Unkown"
  ]
  node [
    id 205
    label "DB00529"
    KEGGDrug "D00579"
    PubChemSubstance "46507873"
    Carriers ""
    WaterSolubility "1.68e+01"
    Wikipedia "Foscarnet"
    HBondAcceptorCount "5"
    ChemSpider "3297"
    ATCcode "J05AD01"
    Polarizability "7.89"
    KEGGCompound "C06456"
    logS "-0.88"
    logP "-0.83"
    Refractivity "19.07"
    Bioavailability "1"
    DrugClass "Organic phosphonic acids and derivatives"
    PathwayNames ""
    ChEMBL "CHEMBL666"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "-0.096"
    NumberofRings "0"
    BindingDB "50011181"
    MolecularWeight "126.0053"
    PhysiologicalCharge "-3"
    Enzymes ""
    GhoseFilter "0"
    PolarSurfaceAreaPSA "94.83"
    MonoisotopicWeight "125.971809718"
    MDDRLikeRule "0"
    ChEBI "127780"
    PDB "PPF"
    PharmGKB "PA449706"
    Family "small molecule"
    MolecularFormula "CH3O5P"
    Transporters "SLC22A6_inhibitor, SLC16A1_substrate"
    PubChemCompound "3415"
    HBondDonorCount "3"
    DrugSubClass "Organic phosphonic acids"
    RotatableBondCount "1"
    Name "Foscarnet"
    Targets "UL54_inhibitor, UL54_inhibitor"
    TherapeuticTargetsDatabase "DAP001383"
  ]
  node [
    id 206
    label "DB01238"
    KEGGDrug "D01164"
    PubChemSubstance "46505745"
    Carriers ""
    Wikipedia "Aripiprazole"
    GuidetoPharmacology "34"
    HBondAcceptorCount "4"
    ChemSpider "54790"
    ATCcode "N05AX12"
    Polarizability "49.23"
    KEGGCompound "C12564"
    logS "-4.8"
    logP "4.9"
    Refractivity "124.34"
    pKastrongestbasic "7.46"
    Bioavailability "1"
    DrugClass "Diazinanes"
    PathwayNames ""
    ChEMBL "CHEMBL1112"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "13.51"
    NumberofRings "4"
    BindingDB "50130293"
    MolecularWeight "448.385"
    PhysiologicalCharge "1"
    Enzymes "CYP3A5_substrate, CYP3A7_substrate, CYP2D6_substrate, CYP2D6_inhibitor, CYP2D6_inducer, CYP3A4_substrate"
    IUPHAR "34"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "44.81"
    MonoisotopicWeight "447.148032537"
    MDDRLikeRule "1"
    ChEBI "31236"
    WaterSolubility "7.77e-03"
    DrugsProductDatabaseDPD "20435"
    PharmGKB "PA10026"
    Family "small molecule"
    MolecularFormula "C23H27Cl2N3O2"
    Transporters ""
    PubChemCompound "60795"
    HBondDonorCount "1"
    DrugSubClass "Piperazines"
    RotatableBondCount "7"
    Name "Aripiprazole"
    Targets "HTR2A_antagonist, DRD2_antagonist, DRD2_partial agonist, HTR1A_antagonist, HTR1A_partial agonist, HTR1B_antagonist, HTR1D_antagonist, HTR1E_antagonist, HTR2C_antagonist, HTR3A_antagonist, HTR6_antagonist, HTR7_antagonist, DRD1_antagonist, DRD1_partial agonist, DRD5_antagonist, DRD5_partial agonist, DRD3_antagonist, DRD3_partial agonist, DRD4_antagonist, DRD4_partial agonist, HRH1_antagonist, ADRA1A_antagonist, ADRA1B_antagonist, ADRA2A_antagonist, ADRA2B_antagonist, ADRA2C_antagonist, ADRA2C_other/unknown, CHRM1_antagonist, CHRM2_antagonist, CHRM3_antagonist, CHRM4_antagonist, CHRM5_antagonist"
    TherapeuticTargetsDatabase "DAP000076"
  ]
  node [
    id 207
    label "DB00909"
    KEGGDrug "D00538"
    PubChemSubstance "46505278"
    Carriers ""
    WaterSolubility "2.09e+00"
    Wikipedia "Zonisamide"
    HBondAcceptorCount "3"
    ChemSpider "5532"
    ATCcode "N03AX15"
    Polarizability "19.48"
    KEGGCompound "C07504"
    logS "-2"
    logP "0.11"
    Refractivity "50.3"
    pKastrongestbasic "-1.8"
    Bioavailability "1"
    DrugClass "Benzisoxazoles"
    PathwayNames ""
    ChEMBL "CHEMBL750"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "9.84"
    NumberofRings "2"
    BindingDB "10888"
    MolecularWeight "212.226"
    PhysiologicalCharge "0"
    Enzymes "CYP3A4_substrate, AOX1_substrate, CYP2C19_inhibitor, UGT1A1_substrate"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "86.19"
    MonoisotopicWeight "212.025562822"
    MDDRLikeRule "0"
    ChEBI "10127"
    PDB "ZON"
    PharmGKB "PA451978"
    Family "small molecule"
    MolecularFormula "C8H8N2O3S"
    Transporters ""
    PubChemCompound "5734"
    HBondDonorCount "1"
    DrugSubClass "None"
    RotatableBondCount "2"
    Name "Zonisamide"
    Targets "SCN1A_inhibitor, SCN2A_inhibitor, SCN3A_inhibitor, SCN4A_inhibitor, SCN5A_inhibitor, SCN9A_inhibitor, SCN11A_inhibitor, SCN1B_inhibitor, SCN2B_inhibitor, SCN3B_inhibitor, SCN4B_inhibitor, CACNA1G_inhibitor, CACNA1H_inhibitor, CACNA1I_inhibitor, CA1_inhibitor, CA2_inhibitor, CA3_inhibitor, CA4_inhibitor, CA5A_inhibitor, CA5B_inhibitor, CA6_inhibitor, CA7_inhibitor, CA8_inhibitor, CA9_inhibitor, CA10_inhibitor, CA11_inhibitor, CA12_inhibitor, CA13_inhibitor, CA14_inhibitor, MAOB_inhibitor, MAOA_inhibitor"
    TherapeuticTargetsDatabase "DAP000500"
  ]
  node [
    id 208
    label "DB00831"
    PubChemSubstance "46507961"
    Carriers ""
    Wikipedia "Trifluoperazine"
    GuidetoPharmacology "214"
    HBondAcceptorCount "3"
    ChemSpider "5365"
    ATCcode "N05AB06"
    RuleofFive "1"
    KEGGCompound "C07168"
    PolarSurfaceAreaPSA "9.72"
    logS "-4.7"
    logP "4.66"
    Refractivity "110.98"
    pKastrongestbasic "8.39"
    Bioavailability "1"
    DrugClass "Benzothiazines"
    ChEMBL "CHEMBL422"
    Polarizability "41.94"
    Approved "True"
    MolecularWeight "407.496"
    NumberofRings "4"
    BindingDB "79181"
    Name "Trifluoperazine"
    PhysiologicalCharge "1"
    Enzymes "XDH_conversion inhibitor, UGT1A4_substrate, CYP1A2_substrate"
    IUPHAR "214"
    GhoseFilter "1"
    PubChemCompound "5566"
    MonoisotopicWeight "407.164303088"
    MDDRLikeRule "0"
    ChEBI "45951"
    PDB "TFP"
    DrugsProductDatabaseDPD "7997"
    PharmGKB "PA451771"
    Family "small molecule"
    MolecularFormula "C21H24F3N3S"
    Transporters "ABCB1_inhibitor"
    PathwayNames ""
    HBondDonorCount "0"
    DrugSubClass "Phenothiazines"
    RotatableBondCount "5"
    WaterSolubility "8.76e-03"
    Targets "DRD2_antagonist, CALY_antagonist, ADRA1A_antagonist, CALM1_inhibitor, TNNC1_Unkown, S100A4_inhibitor"
    TherapeuticTargetsDatabase "DAP000034"
  ]
  node [
    id 209
    label "DB06775"
    KEGGDrug "D07130"
    NumberofRings "0"
    Carriers ""
    PubChemSubstance "99443290"
    HBondAcceptorCount "5"
    ChemSpider "108351"
    ATCcode "A16AA05"
    Name "Carglumic Acid"
    KEGGCompound "C05829"
    PolarSurfaceAreaPSA "129.72"
    logS "-1"
    logP "-1.4"
    pKastrongestbasic "-2.3"
    Bioavailability "1"
    DrugClass "Carboxylic acids and derivatives"
    ChEMBL "CHEMBL1201780"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "3.36"
    Refractivity "39.41"
    Polarizability "16.78"
    MolecularWeight "190.154"
    PhysiologicalCharge "-2"
    Enzymes ""
    GhoseFilter "0"
    PubChemCompound "121396"
    MonoisotopicWeight "190.05897144"
    MDDRLikeRule "0"
    ChEBI "71028"
    DrugsProductDatabaseDPD "22593"
    PharmGKB "PA165958402"
    Family "small molecule"
    MolecularFormula "C6H10N2O5"
    Transporters ""
    PathwayNames ""
    HBondDonorCount "4"
    DrugSubClass "Amino acids, peptides, and analogues"
    RotatableBondCount "5"
    WaterSolubility "1.91e+01"
    Targets "CPS1_allosteric modulator"
  ]
  node [
    id 210
    label "DB13679"
    PubChemSubstance "347829309"
    Carriers ""
    Wikipedia "Dexchlorpheniramine"
    HBondAcceptorCount "2"
    ChemSpider "30576"
    ATCcode "R06AB02, R06AB52"
    Polarizability "30.82"
    KEGGCompound "C06946"
    PolarSurfaceAreaPSA "16.13"
    logS "-3.7"
    logP "3.58"
    Refractivity "80.85"
    pKastrongestbasic "9.47"
    Bioavailability "1"
    DrugClass "Pyridines and derivatives"
    ChEMBL "CHEMBL1201353"
    RuleofFive "1"
    Approved "False"
    MolecularWeight "274.79"
    NumberofRings "2"
    Name "Dexchlorpheniramine"
    PhysiologicalCharge "1"
    Enzymes ""
    GhoseFilter "1"
    PubChemCompound "33036"
    MonoisotopicWeight "274.1236763"
    MDDRLikeRule "0"
    ChEBI "4464"
    Family "small molecule"
    MolecularFormula "C16H19ClN2"
    Transporters ""
    PathwayNames "Dexchlorpheniramine H1-Antihistamine Action_SMP56811"
    HBondDonorCount "0"
    DrugSubClass "Pheniramines"
    RotatableBondCount "5"
    WaterSolubility "5.19e-02"
    Targets ""
  ]
  node [
    id 211
    label "DB01231"
    KEGGDrug "D03858"
    PubChemSubstance "46506486"
    Carriers ""
    Wikipedia "Diphenidol"
    HBondAcceptorCount "2"
    ChemSpider "2947"
    ATCcode ""
    Polarizability "36.66"
    KEGGCompound "C06961"
    logS "-4.7"
    logP "4.22"
    Refractivity "96.92"
    pKastrongestbasic "9.23"
    Bioavailability "1"
    DrugClass "Benzene and substituted derivatives"
    PathwayNames ""
    ChEMBL "CHEMBL936"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "13.4"
    NumberofRings "3"
    MolecularWeight "309.4452"
    PhysiologicalCharge "1"
    Enzymes ""
    GhoseFilter "1"
    PolarSurfaceAreaPSA "23.47"
    MonoisotopicWeight "309.209264491"
    MDDRLikeRule "1"
    ChEBI "4638"
    WaterSolubility "5.87e-03"
    PharmGKB "PA164746037"
    Family "small molecule"
    MolecularFormula "C21H27NO"
    Transporters ""
    PubChemCompound "3055"
    HBondDonorCount "1"
    DrugSubClass "Diphenylmethanes"
    RotatableBondCount "6"
    Name "Diphenidol"
    Targets "CHRM1_antagonist, CHRM3_antagonist, CHRM2_antagonist"
    TherapeuticTargetsDatabase "DAP001133"
  ]
  node [
    id 212
    label "DB00836"
    KEGGDrug "D08144"
    PubChemSubstance "46504591"
    Carriers ""
    Wikipedia "Loperamide"
    HBondAcceptorCount "3"
    ChemSpider "3818"
    ATCcode "A07DA03, A07DA53, A07DA05"
    Polarizability "52.67"
    KEGGCompound "C07080"
    logS "-5.7"
    logP "4.77"
    Refractivity "139.32"
    pKastrongestbasic "9.41"
    Bioavailability "1"
    DrugClass "Benzene and substituted derivatives"
    PathwayNames ""
    ChEMBL "CHEMBL841"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "13.96"
    NumberofRings "4"
    BindingDB "50017698"
    MolecularWeight "477.038"
    PhysiologicalCharge "1"
    Enzymes "CYP3A4_substrate, CYP2C8_substrate, CYP2B6_substrate, CYP2D6_substrate"
    GhoseFilter "0"
    PolarSurfaceAreaPSA "43.78"
    MonoisotopicWeight "476.223056017"
    MDDRLikeRule "1"
    ChEBI "6532"
    WaterSolubility "8.60e-04"
    DrugsProductDatabaseDPD "2251"
    PharmGKB "PA450262"
    Family "small molecule"
    MolecularFormula "C29H33ClN2O2"
    Transporters "ABCB1_substrate"
    PubChemCompound "3955"
    HBondDonorCount "1"
    DrugSubClass "Diphenylmethanes"
    RotatableBondCount "7"
    Name "Loperamide"
    Targets "OPRM1_agonist, OPRD1_agonist, OPRK1_agonist, CACNA1A_inhibitor, POMC_modulator, CALM1_inhibitor, NR1I3_Unkown"
    TherapeuticTargetsDatabase "DAP000425"
  ]
  node [
    id 213
    label "DB01033"
    KEGGDrug "D04931"
    PubChemSubstance "46506988"
    Carriers ""
    WaterSolubility "7.35e-01"
    Wikipedia "Mercaptopurine"
    HBondAcceptorCount "3"
    ChemSpider "580869"
    ATCcode "L01BB02"
    Polarizability "14.04"
    KEGGCompound "C02380"
    logS "-2.3"
    logP "-0.12"
    Refractivity "43.6"
    pKastrongestbasic "2.99"
    Bioavailability "1"
    DrugClass "Imidazopyrimidines"
    PathwayNames "Azathioprine Metabolism Pathway_SMP00645, Azathioprine Action Pathway_SMP00427, Mercaptopurine Metabolism Pathway_SMP00609, Mercaptopurine Action Pathway_SMP00428, Thioguanine Action Pathway_SMP00430"
    ChEMBL "CHEMBL1425"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "9.5"
    NumberofRings "2"
    BindingDB "50423778"
    MolecularWeight "152.177"
    PhysiologicalCharge "0"
    Enzymes "TPMT_substrate, XDH_substrate, AOX1_substrate"
    GhoseFilter "0"
    PolarSurfaceAreaPSA "53.07"
    MonoisotopicWeight "152.015666838"
    MDDRLikeRule "0"
    ChEBI "94796"
    PDB "PM6"
    DrugsProductDatabaseDPD "11804"
    PharmGKB "PA450379"
    Family "small molecule"
    MolecularFormula "C5H4N4S"
    Transporters "SLC22A8_substrate, SLC22A8_inhibitor, ABCC4_substrate, ABCC5_substrate, SLC28A2_substrate, SLC28A3_substrate, SLC29A1_substrate, SLC29A2_substrate"
    PubChemCompound "667490"
    HBondDonorCount "2"
    DrugSubClass "Purines and purine derivatives"
    RotatableBondCount "0"
    Name "Mercaptopurine"
    Targets "HPRT1_inhibitor, PPAT_inhibitor, IMPDH1_inhibitor"
    TherapeuticTargetsDatabase "DAP000147"
  ]
  node [
    id 214
    label "DB01131"
    PubChemSubstance "46506228"
    Carriers ""
    Wikipedia "Proguanil"
    HBondAcceptorCount "5"
    ChemSpider "4754"
    ATCcode "P01BB51, P01BB01"
    Name "Proguanil"
    KEGGCompound "C07631"
    PolarSurfaceAreaPSA "88.79"
    logS "-3"
    logP "1.89"
    Refractivity "71.07"
    pKastrongestbasic "10.12"
    Bioavailability "1"
    DrugClass "Organonitrogen compounds"
    ChEMBL "CHEMBL1377"
    Polarizability "26.84"
    Approved "True"
    pKastrongestacidic "19.77"
    NumberofRings "1"
    MolecularWeight "253.731"
    PhysiologicalCharge "1"
    Enzymes "CYP2C19_substrate, CYP2D6_inhibitor, CYP1A2_substrate, CYP2C9_substrate, CYP2E1_substrate, CYP3A4_substrate"
    GhoseFilter "1"
    PubChemCompound "4923"
    MonoisotopicWeight "253.109423244"
    MDDRLikeRule "0"
    ChEBI "8455"
    DrugsProductDatabaseDPD "11436"
    PharmGKB "PA451124"
    Family "small molecule"
    MolecularFormula "C11H16ClN5"
    Transporters ""
    RuleofFive "1"
    PathwayNames ""
    HBondDonorCount "3"
    DrugSubClass "Guanidines"
    RotatableBondCount "2"
    WaterSolubility "2.86e-01"
    Targets "DHFR_inhibitor, DHFR_inhibitor"
    TherapeuticTargetsDatabase "DAP000634"
  ]
  node [
    id 215
    label "DB00232"
    KEGGDrug "D00656"
    PubChemSubstance "46509197"
    Carriers ""
    Wikipedia "Methyclothiazide"
    HBondAcceptorCount "5"
    ChemSpider "3978"
    ATCcode "C03AA08, C03AB08, G01AE10"
    Polarizability "31.65"
    KEGGCompound "C07765"
    logS "-2.6"
    logP "0.53"
    Refractivity "77.28"
    pKastrongestbasic "-3.4"
    Bioavailability "1"
    DrugClass "Thiadiazines"
    PathwayNames "Methyclothiazide Action Pathway_SMP00081"
    ChEMBL "CHEMBL1577"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "9.29"
    NumberofRings "2"
    MolecularWeight "360.237"
    PhysiologicalCharge "0"
    Enzymes ""
    GhoseFilter "1"
    PolarSurfaceAreaPSA "109.57"
    MonoisotopicWeight "358.956802649"
    MDDRLikeRule "0"
    ChEBI "6847"
    WaterSolubility "8.24e-01"
    DrugsProductDatabaseDPD "10199"
    PharmGKB "PA164748094"
    Family "small molecule"
    MolecularFormula "C9H11Cl2N3O4S2"
    Transporters ""
    PubChemCompound "4121"
    HBondDonorCount "2"
    DrugSubClass "Benzothiadiazines"
    RotatableBondCount "2"
    Name "Methyclothiazide"
    Targets "SLC12A1_inhibitor, CA1_inhibitor, CA2_inhibitor, CA4_inhibitor"
    TherapeuticTargetsDatabase "DAP000746"
  ]
  node [
    id 216
    label "DB01339"
    PubChemSubstance "46507656"
    Carriers ""
    Wikipedia "Vecuronium"
    GuidetoPharmacology "4002"
    HBondAcceptorCount "3"
    ChemSpider "36358"
    ATCcode "M03AC03"
    RuleofFive "0"
    KEGGCompound "C07553"
    PolarSurfaceAreaPSA "55.84"
    logS "-7.5"
    logP "0.89"
    Refractivity "169.31"
    pKastrongestbasic "9.65"
    Bioavailability "1"
    DrugClass "Steroids and steroid derivatives"
    ChEMBL "CHEMBL1201219"
    Polarizability "66.85"
    Approved "True"
    MolecularWeight "557.8274"
    NumberofRings "6"
    BindingDB "50424713"
    Name "Vecuronium"
    PhysiologicalCharge "2"
    Enzymes ""
    IUPHAR "4002"
    GhoseFilter "0"
    PubChemCompound "39765"
    MonoisotopicWeight "557.431833322"
    MDDRLikeRule "1"
    ChEBI "9939"
    DrugsProductDatabaseDPD "1777"
    PharmGKB "PA164748865"
    Family "small molecule"
    MolecularFormula "C34H57N2O4"
    Transporters "SLC22A1_inhibitor, ABCB1_substrate"
    PathwayNames ""
    HBondDonorCount "0"
    DrugSubClass "Steroid esters"
    RotatableBondCount "6"
    WaterSolubility "1.86e-05"
    Targets "CHRNA2_antagonist"
    TherapeuticTargetsDatabase "DAP000354"
  ]
  node [
    id 217
    label "DB01134"
    PubChemSubstance "46506381"
    Carriers ""
    Wikipedia "Desoxycorticosterone_Pivalate"
    HBondAcceptorCount "3"
    ChemSpider "10050591"
    ATCcode ""
    RuleofFive "0"
    PolarSurfaceAreaPSA "60.44"
    logS "-5.5"
    logP "5.57"
    Refractivity "117.26"
    pKastrongestbasic "-4.8"
    Bioavailability "1"
    DrugClass "Steroids and steroid derivatives"
    ChEMBL "CHEMBL1200592"
    Polarizability "48.3"
    Approved "False"
    MolecularWeight "414.586"
    NumberofRings "4"
    Name "Desoxycorticosterone Pivalate"
    PhysiologicalCharge "0"
    Enzymes ""
    GhoseFilter "1"
    PubChemCompound "11876263"
    MonoisotopicWeight "414.277009704"
    MDDRLikeRule "0"
    ChEBI "50782"
    DrugsProductDatabaseDPD "22599"
    PharmGKB "PA449245"
    Family "small molecule"
    MolecularFormula "C26H38O4"
    Transporters ""
    PathwayNames ""
    HBondDonorCount "0"
    DrugSubClass "Pregnane steroids"
    RotatableBondCount "5"
    pKastrongestacidic "17.19"
    WaterSolubility "1.41e-03"
    Targets "NR3C2_agonist"
    TherapeuticTargetsDatabase "DAP001106"
  ]
  node [
    id 218
    label "DB00488"
    PubChemSubstance "46505760"
    Carriers ""
    Wikipedia "Altretamine"
    HBondAcceptorCount "6"
    ChemSpider "2038"
    ATCcode "L01XX03"
    Polarizability "23.7"
    PolarSurfaceAreaPSA "48.39"
    logS "-1.8"
    logP "2.22"
    Refractivity "65.65"
    pKastrongestbasic "7.75"
    Bioavailability "1"
    DrugClass "Organonitrogen compounds"
    ChEMBL "CHEMBL1455"
    RuleofFive "1"
    Approved "True"
    MolecularWeight "210.2794"
    NumberofRings "1"
    BindingDB "37631"
    Name "Altretamine"
    PhysiologicalCharge "1"
    Enzymes ""
    GhoseFilter "1"
    PubChemCompound "2123"
    MonoisotopicWeight "210.159294606"
    MDDRLikeRule "0"
    ChEBI "24564"
    DrugsProductDatabaseDPD "1757"
    PharmGKB "PA164743136"
    Family "small molecule"
    MolecularFormula "C9H18N6"
    Transporters ""
    PathwayNames ""
    HBondDonorCount "0"
    DrugSubClass "Amines"
    RotatableBondCount "3"
    WaterSolubility "3.10e+00"
    Targets "DNA"
    TherapeuticTargetsDatabase "DAP000989"
  ]
  node [
    id 219
    label "DB00401"
    KEGGDrug "D00618"
    PubChemSubstance "46504546"
    Carriers ""
    Wikipedia "Nisoldipine"
    GuidetoPharmacology "2524"
    HBondAcceptorCount "5"
    ChemSpider "4343"
    ATCcode "C08CA07"
    RuleofFive "1"
    KEGGCompound "C07699"
    PolarSurfaceAreaPSA "110.45"
    logS "-4.8"
    logP "3.06"
    Refractivity "105.91"
    pKastrongestbasic "5.32"
    Bioavailability "1"
    DrugClass "Pyridines and derivatives"
    ChEMBL "CHEMBL1726"
    Polarizability "39.72"
    Approved "True"
    MolecularWeight "388.4144"
    NumberofRings "2"
    BindingDB "50011689"
    Name "Nisoldipine"
    PhysiologicalCharge "0"
    Enzymes "CYP3A4_substrate, CYP3A4_inhibitor, CYP3A5_substrate, CYP3A7_substrate, CYP1A2_inhibitor"
    IUPHAR "2524"
    GhoseFilter "1"
    PubChemCompound "4499"
    MonoisotopicWeight "388.16343651"
    MDDRLikeRule "0"
    ChEBI "76917"
    PharmGKB "PA450634"
    Family "small molecule"
    MolecularFormula "C20H24N2O6"
    Transporters "ABCB1_inhibitor"
    PathwayNames "Nisoldipine Action Pathway_SMP00381"
    HBondDonorCount "1"
    DrugSubClass "Hydropyridines"
    RotatableBondCount "8"
    WaterSolubility "5.77e-03"
    Targets "CACNA1C_inhibitor, CACNA2D1_inhibitor, CACNB2_inhibitor, CACNA1D_inhibitor, CACNA1S_inhibitor"
    TherapeuticTargetsDatabase "DAP000595"
  ]
  node [
    id 220
    label "DB01138"
    KEGGDrug "D00449"
    PubChemSubstance "46504918"
    Carriers "FABP2"
    Wikipedia "Sulfinpyrazone"
    HBondAcceptorCount "3"
    ChemSpider "5149"
    ATCcode "M04AB02"
    Polarizability "42.15"
    KEGGCompound "C07317"
    logS "-3.1"
    logP "3.19"
    Refractivity "113.62"
    pKastrongestbasic "-6.7"
    Bioavailability "1"
    DrugClass "Benzene and substituted derivatives"
    PathwayNames ""
    ChEMBL "CHEMBL832"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "3.41"
    NumberofRings "4"
    MolecularWeight "404.482"
    PhysiologicalCharge "-1"
    Enzymes "CYP2C9_substrate, CYP2C9_inhibitor, CYP3A4_substrate, CYP3A4_inhibitor, CYP3A4_inducer, CYP2B6_inducer, CYP2C8_substrate"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "57.69"
    MonoisotopicWeight "404.119463206"
    MDDRLikeRule "1"
    ChEBI "9342"
    WaterSolubility "3.23e-01"
    DrugsProductDatabaseDPD "8151"
    PharmGKB "PA451550"
    Family "small molecule"
    MolecularFormula "C23H20N2O3S"
    Transporters "ABCC3_inhibitor, ABCC4_inhibitor, ABCC5_inhibitor, ABCC6_inhibitor, ABCC1_inhibitor, ABCC2_substrate, ABCC2_inhibitor"
    PubChemCompound "5342"
    HBondDonorCount "0"
    DrugSubClass "Phenyl sulfoxides"
    RotatableBondCount "6"
    Name "Sulfinpyrazone"
    Targets "ABCC2_inhibitor, ABCC1_inhibitor, SLC22A12_inhibitor, NR1I2_activator"
    TherapeuticTargetsDatabase "DAP000794"
  ]
  node [
    id 221
    label "DB05259"
    PubChemSubstance "46505299"
    Name "Glatiramer"
    Carriers ""
    Enzymes ""
    Wikipedia "Glatiramer_acetate"
    ATCcode "L03AX13"
    DrugsProductDatabaseDPD "11533"
    PharmGKB "PA449760"
    Family "biotech"
    Transporters ""
    PathwayNames ""
    Approved "True"
    DrugSubClass "Amino Acids, Peptides, and Analogues"
    DrugClass "Carboxylic Acids and Derivatives"
    ChEMBL "CHEMBL1201507"
    Targets "HLA-DRB1_binder"
    TherapeuticTargetsDatabase "DAP001315"
  ]
  node [
    id 222
    label "DB00660"
    KEGGDrug "D00773"
    PubChemSubstance "46506253"
    Carriers ""
    Wikipedia "Metaxalone"
    HBondAcceptorCount "2"
    ChemSpider "14709"
    ATCcode ""
    Polarizability "23.74"
    KEGGCompound "C07934"
    logS "-2.2"
    logP "2.37"
    Refractivity "59.32"
    pKastrongestbasic "-4.9"
    Bioavailability "1"
    DrugClass "Phenol ethers"
    PathwayNames ""
    ChEMBL "CHEMBL1079604"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "13.14"
    NumberofRings "2"
    MolecularWeight "221.2524"
    PhysiologicalCharge "0"
    Enzymes ""
    GhoseFilter "1"
    PolarSurfaceAreaPSA "47.56"
    MonoisotopicWeight "221.105193351"
    MDDRLikeRule "0"
    ChEBI "6797"
    WaterSolubility "1.28e+00"
    PharmGKB "PA164747189"
    Family "small molecule"
    MolecularFormula "C12H15NO3"
    Transporters ""
    PubChemCompound "15459"
    HBondDonorCount "1"
    DrugSubClass "None"
    RotatableBondCount "3"
    Name "Metaxalone"
    Targets ""
  ]
  node [
    id 223
    label "DB00662"
    PubChemSubstance "46507787"
    Carriers ""
    Wikipedia "Trimethobenzamide"
    HBondAcceptorCount "6"
    ChemSpider "5375"
    ATCcode "R06AA10"
    Name "Trimethobenzamide"
    KEGGCompound "C07178"
    PolarSurfaceAreaPSA "69.26"
    logS "-4"
    logP "2.16"
    Refractivity "108.52"
    pKastrongestbasic "8.77"
    Bioavailability "1"
    DrugClass "Benzene and substituted derivatives"
    ChEMBL "CHEMBL1201256"
    Polarizability "43.19"
    Approved "True"
    pKastrongestacidic "14.36"
    NumberofRings "2"
    MolecularWeight "388.4574"
    PhysiologicalCharge "1"
    Enzymes ""
    GhoseFilter "1"
    PubChemCompound "5577"
    MonoisotopicWeight "388.199822016"
    MDDRLikeRule "0"
    ChEBI "27796"
    PharmGKB "PA164764516"
    Family "small molecule"
    MolecularFormula "C21H28N2O5"
    Transporters ""
    RuleofFive "1"
    PathwayNames ""
    HBondDonorCount "1"
    DrugSubClass "Benzoic acids and derivatives"
    RotatableBondCount "10"
    WaterSolubility "3.98e-02"
    Targets ""
  ]
  node [
    id 224
    label "DB00669"
    KEGGDrug "D00451"
    PubChemSubstance "46506520"
    Carriers ""
    Wikipedia "Sumatriptan"
    GuidetoPharmacology "119"
    HBondAcceptorCount "3"
    ChemSpider "5165"
    ATCcode "N02CC01, G01AE10"
    Polarizability "32.31"
    KEGGCompound "C07319"
    logS "-3.4"
    logP "0.74"
    Refractivity "82.08"
    pKastrongestbasic "9.54"
    Bioavailability "1"
    DrugClass "Indoles and derivatives"
    PathwayNames ""
    ChEMBL "CHEMBL128"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "11.24"
    NumberofRings "2"
    BindingDB "50005835"
    MolecularWeight "295.4"
    PhysiologicalCharge "1"
    Enzymes "MAOA_substrate"
    IUPHAR "119"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "65.2"
    MonoisotopicWeight "295.135447621"
    MDDRLikeRule "0"
    ChEBI "10650"
    WaterSolubility "1.27e-01"
    DrugsProductDatabaseDPD "11323"
    PharmGKB "PA451566"
    Family "small molecule"
    MolecularFormula "C14H21N3O2S"
    Transporters "SLCO1A2_inducer, ABCB1_substrate, ABCG2_substrate, SLCO1B1_substrate"
    PubChemCompound "5358"
    HBondDonorCount "2"
    DrugSubClass "Tryptamines and derivatives"
    RotatableBondCount "5"
    Name "Sumatriptan"
    Targets "HTR1D_agonist, HTR1B_agonist, HTR1F_agonist, HTR1A_agonist"
    TherapeuticTargetsDatabase "DNC001649"
  ]
  node [
    id 225
    label "DB00668"
    KEGGDrug "D00095"
    PubChemSubstance "46509097"
    Carriers ""
    WaterSolubility "1.86e+01"
    Wikipedia "Epinephrine"
    GuidetoPharmacology "479"
    HBondAcceptorCount "4"
    ChemSpider "5611"
    ATCcode "R03AK01, R01AA14, C01CA24, S01EA51, B02BC09, A01AD01, R03AA01, S01EA01"
    Polarizability "19.04"
    KEGGCompound "C00788"
    logS "-0.99"
    logP "-0.43"
    Refractivity "49.23"
    pKastrongestbasic "8.91"
    Bioavailability "1"
    DrugClass "Phenols"
    PathwayNames "Catecholamine Biosynthesis_SMP00012, Tyrosine Metabolism_SMP00006, Tyrosinemia, transient, of the newborn_SMP00494, Aromatic L-Aminoacid Decarboxylase Deficiency_SMP00170, Catecholamine Biosynthesis_SMP63606, Tyrosine Metabolism_SMP63684, Tyrosinemia Type I_SMP00218, Disulfiram Action Pathway_SMP00429, Tyrosine hydroxylase deficiency_SMP00497, Epinephrine Action Pathway_SMP00661, Alkaptonuria_SMP00169, Hawkinsinuria_SMP00190, Dopamine beta-hydroxylase deficiency_SMP00498, Monoamine oxidase-a deficiency (MAO-A)_SMP00533"
    ChEMBL "CHEMBL679"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "9.69"
    NumberofRings "1"
    BindingDB "50029050"
    MolecularWeight "183.2044"
    PhysiologicalCharge "1"
    Enzymes "CYP1A2_inhibitor, CYP2C9_inhibitor, CYP3A4_inhibitor"
    IUPHAR "479"
    GhoseFilter "0"
    PolarSurfaceAreaPSA "72.72"
    MonoisotopicWeight "183.089543287"
    MDDRLikeRule "0"
    ChEBI "28918"
    PDB "ALE"
    DrugsProductDatabaseDPD "8921"
    PharmGKB "PA449470"
    Family "small molecule"
    MolecularFormula "C9H13NO3"
    Transporters "SLC22A2_substrate, SLC22A2_inhibitor, SLC22A1_substrate, SLC22A1_inhibitor, SLC22A5_inhibitor"
    PubChemCompound "5816"
    HBondDonorCount "4"
    DrugSubClass "Benzenediols"
    RotatableBondCount "3"
    Name "Epinephrine"
    Targets "ADRA1A_agonist, ADRA1B_agonist, ADRB1_agonist, ADRB2_agonist, ADRA2A_agonist, ADRA2B_agonist, ADRA1D_antagonist, PAH_antagonist, ADRA2C_agonist, ADRB3_agonist, TNF_antagonist, SOD1_Unkown"
    TherapeuticTargetsDatabase "DAP000066"
  ]
  node [
    id 226
    label "DB00887"
    KEGGDrug "D00247"
    NumberofRings "2"
    Carriers ""
    PubChemSubstance "46508147"
    Wikipedia "Bumetanide"
    HBondAcceptorCount "5"
    ChemSpider "2377"
    ATCcode "C03EB02, C03CB02, C03CA02, G01AE10"
    Polarizability "37.21"
    logS "-4.2"
    logP "2.42"
    pKastrongestbasic "2.7"
    Bioavailability "1"
    DrugClass "Benzene and substituted derivatives"
    PathwayNames "Bumetanide Action Pathway_SMP00088"
    ChEMBL "CHEMBL1072"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "4.69"
    Refractivity "95.78"
    BindingDB "25903"
    MolecularWeight "364.416"
    PhysiologicalCharge "-1"
    Enzymes "PTGS2_inducer"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "118.72"
    MonoisotopicWeight "364.10929245"
    MDDRLikeRule "0"
    ChEBI "3213"
    WaterSolubility "2.57e-02"
    DrugsProductDatabaseDPD "1374"
    PharmGKB "PA448682"
    Family "small molecule"
    MolecularFormula "C17H20N2O5S"
    Transporters "SLC10A1_substrate, SLC10A1_inhibitor, SLC22A6_substrate, SLC22A6_inhibitor, SLC22A8_inhibitor, SLC22A11_inhibitor, SLC22A7_inhibitor, SLCO1A2_substrate"
    PubChemCompound "2471"
    HBondDonorCount "3"
    DrugSubClass "Diphenylethers"
    RotatableBondCount "8"
    Name "Bumetanide"
    Targets "SLC12A1_inhibitor, SLC12A2_inhibitor, SLC12A4_inhibitor, SLC12A5_inhibitor, CFTR_antagonist"
    TherapeuticTargetsDatabase "DAP000361"
  ]
  node [
    id 227
    label "DB00198"
    KEGGDrug "D00900"
    PubChemSubstance "46507602"
    Carriers ""
    Wikipedia "Oseltamivir"
    HBondAcceptorCount "4"
    ChemSpider "58540"
    ATCcode "J05AH02"
    Polarizability "34.65"
    KEGGCompound "C08092"
    logS "-2.7"
    logP "1.16"
    Refractivity "84.2"
    pKastrongestbasic "9.31"
    Bioavailability "1"
    DrugClass "Carboxylic acids and derivatives"
    PathwayNames ""
    ChEMBL "CHEMBL1229"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "14.03"
    NumberofRings "1"
    BindingDB "5025"
    MolecularWeight "312.4045"
    PhysiologicalCharge "1"
    Enzymes ""
    GhoseFilter "1"
    PolarSurfaceAreaPSA "90.65"
    MonoisotopicWeight "312.204907394"
    MDDRLikeRule "0"
    ChEBI "7798"
    WaterSolubility "6.86e-01"
    DrugsProductDatabaseDPD "11956"
    PharmGKB "PA450721"
    Family "small molecule"
    MolecularFormula "C16H28N2O4"
    Transporters "ABCC4_substrate, SLC15A1_substrate, SLC22A8_substrate"
    PubChemCompound "65028"
    HBondDonorCount "2"
    DrugSubClass "Amino acids, peptides, and analogues"
    RotatableBondCount "8"
    Name "Oseltamivir"
    Targets "NA_inhibitor, CES1_other, NEU1_inhibitor, NEU2_inhibitor"
    TherapeuticTargetsDatabase "DAP000714"
  ]
  node [
    id 228
    label "DB01158"
    KEGGDrug "D00645"
    PubChemSubstance "46505320"
    Carriers ""
    Wikipedia "Bretylium"
    HBondAcceptorCount "0"
    ChemSpider "2337"
    ATCcode ""
    Name "Bretylium"
    KEGGCompound "C06855"
    PolarSurfaceAreaPSA "0"
    logS "-6.3"
    logP "-1.1"
    Refractivity "72.89"
    Bioavailability "1"
    DrugClass "Benzene and substituted derivatives"
    ChEMBL "CHEMBL1199080"
    Polarizability "23.24"
    Approved "True"
    pKastrongestacidic "17.58"
    NumberofRings "1"
    MolecularWeight "243.163"
    PhysiologicalCharge "1"
    Enzymes ""
    GhoseFilter "0"
    PubChemCompound "2431"
    MonoisotopicWeight "242.054437196"
    MDDRLikeRule "0"
    ChEBI "3172"
    DrugsProductDatabaseDPD "5917"
    PharmGKB "PA448662"
    Family "small molecule"
    MolecularFormula "C11H17BrN"
    Transporters ""
    RuleofFive "1"
    PathwayNames ""
    HBondDonorCount "0"
    DrugSubClass "Phenylmethylamines"
    RotatableBondCount "3"
    WaterSolubility "1.54e-04"
    Targets "ATP1A1_inhibitor"
    TherapeuticTargetsDatabase "DAP000939"
  ]
  node [
    id 229
    label "DB01421"
    PubChemSubstance "46505391"
    Carriers ""
    Wikipedia "Paromomycin_sulfate"
    HBondAcceptorCount "19"
    ChemSpider "145115"
    ATCcode "A07AA06"
    Name "Paromomycin"
    KEGGCompound "C00832"
    PolarSurfaceAreaPSA "347.32"
    logS "-0.89"
    logP "-8.3"
    Refractivity "134.24"
    pKastrongestbasic "9.94"
    Bioavailability "0"
    DrugClass "Organooxygen compounds"
    ChEMBL "CHEMBL370143"
    Polarizability "60.4"
    Approved "True"
    pKastrongestacidic "12.23"
    NumberofRings "4"
    MolecularWeight "615.6285"
    PhysiologicalCharge "5"
    Enzymes ""
    GhoseFilter "0"
    PubChemCompound "165580"
    MonoisotopicWeight "615.296301173"
    MDDRLikeRule "1"
    ChEBI "7934"
    PDB "PAR"
    DrugsProductDatabaseDPD "8625"
    PharmGKB "PA164784023"
    Family "small molecule"
    MolecularFormula "C23H45N5O14"
    Transporters ""
    RuleofFive "0"
    PathwayNames "Paromomycin Action Pathway_SMP00714"
    HBondDonorCount "13"
    DrugSubClass "Carbohydrates and carbohydrate conjugates"
    RotatableBondCount "9"
    WaterSolubility "7.97e+01"
    Targets "rpsJ_inhibitor, 16S rRNA"
    TherapeuticTargetsDatabase "DAP000407"
  ]
  node [
    id 230
    label "DB00883"
    KEGGDrug "D00516"
    NumberofRings "2"
    Carriers ""
    PubChemSubstance "46506412"
    HBondAcceptorCount "8"
    ChemSpider "6619"
    ATCcode "C01DA58, C05AE02, C01DA08"
    Polarizability "18.07"
    KEGGCompound "C07456"
    logS "-2.4"
    logP "0.44"
    pKastrongestbasic "-3.9"
    Bioavailability "1"
    DrugClass "Furofurans"
    ChEMBL "CHEMBL6622"
    RuleofFive "1"
    Approved "True"
    MolecularWeight "236.1363"
    Refractivity "44.77"
    PolarSurfaceAreaPSA "128.56"
    PhysiologicalCharge "0"
    Enzymes "CYP3A4_substrate, CYP2E1_inhibitor"
    GhoseFilter "1"
    PubChemCompound "6883"
    MonoisotopicWeight "236.028065242"
    MDDRLikeRule "0"
    ChEBI "6061"
    WaterSolubility "9.38e-01"
    DrugsProductDatabaseDPD "9627"
    PharmGKB "PA450125"
    Family "small molecule"
    MolecularFormula "C6H8N2O8"
    Transporters ""
    PathwayNames ""
    HBondDonorCount "0"
    DrugSubClass "Isosorbides"
    RotatableBondCount "4"
    Name "Isosorbide Dinitrate"
    Targets "NPR1_agonist"
    TherapeuticTargetsDatabase "DAP001057"
  ]
  node [
    id 231
    label "DB00395"
    KEGGDrug "D00768"
    PubChemSubstance "46506377"
    Carriers ""
    Wikipedia "Carisoprodol"
    HBondAcceptorCount "2"
    ChemSpider "2478"
    ATCcode "M03BA52, M03BA02, M03BA72"
    Name "Carisoprodol"
    KEGGCompound "C07927"
    PolarSurfaceAreaPSA "90.65"
    logS "-2.5"
    logP "1.92"
    Refractivity "67.1"
    Bioavailability "1"
    DrugClass "Carboxylic acids and derivatives"
    ChEMBL "CHEMBL1233"
    Polarizability "28.77"
    Approved "True"
    pKastrongestacidic "15.06"
    NumberofRings "0"
    MolecularWeight "260.33"
    PhysiologicalCharge "0"
    Enzymes "CYP2C19_substrate"
    GhoseFilter "1"
    PubChemCompound "2576"
    MonoisotopicWeight "260.173607266"
    MDDRLikeRule "0"
    ChEBI "3419"
    DrugsProductDatabaseDPD "9924"
    PharmGKB "PA448809"
    Family "small molecule"
    MolecularFormula "C12H24N2O4"
    Transporters ""
    RuleofFive "1"
    PathwayNames ""
    HBondDonorCount "2"
    DrugSubClass "Amino acids, peptides, and analogues"
    RotatableBondCount "9"
    WaterSolubility "7.92e-01"
    Targets "GABRA1_Unkown, GABRB2_Unkown, GABRG2_Unkown"
  ]
  node [
    id 232
    label "DB00398"
    KEGGDrug "D08524"
    NumberofRings "3"
    Carriers ""
    PubChemSubstance "46505329"
    WaterSolubility "1.71e-03"
    Wikipedia "Sorafenib"
    HBondAcceptorCount "3"
    ChemSpider "187440"
    ATCcode "L01XE05"
    Polarizability "41.11"
    logS "-5.4"
    logP "4.34"
    pKastrongestbasic "2.03"
    Bioavailability "1"
    DrugClass "Organooxygen compounds"
    PathwayNames "Sorafenib Metabolism Pathway_SMP00648"
    ChEMBL "CHEMBL1336"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "11.55"
    Refractivity "114.52"
    BindingDB "16673"
    MolecularWeight "464.825"
    PhysiologicalCharge "0"
    Enzymes "CYP2C9_inhibitor, CYP3A5_substrate, CYP3A7_substrate, CYP3A4_substrate, CYP3A4_inhibitor, CYP2B6_substrate, CYP2B6_inhibitor, CYP2C8_substrate, CYP2C8_inhibitor, CYP1A2_inhibitor, CYP2C19_inhibitor, CYP2D6_inhibitor, UGT1A9_substrate, UGT1A9_inhibitor, UGT1A1_inhibitor"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "92.35"
    MonoisotopicWeight "464.08630272"
    MDDRLikeRule "1"
    ChEBI "50924"
    PDB "BAX"
    DrugsProductDatabaseDPD "15231"
    PharmGKB "PA7000"
    Family "small molecule"
    MolecularFormula "C21H16ClF3N4O3"
    Transporters "ABCG2_substrate, ABCG2_inhibitor, ABCC4_inhibitor, ABCB1_substrate, ABCB1_inhibitor, ABCC2_inhibitor, RALBP1_substrate"
    PubChemCompound "216239"
    HBondDonorCount "3"
    DrugSubClass "Ethers"
    RotatableBondCount "6"
    Name "Sorafenib"
    Targets "BRAF_inhibitor, RAF1_inhibitor, FLT4_antagonist, KDR_antagonist, FLT3_antagonist, PDGFRB_antagonist, KIT_antagonist, FGFR1_inhibitor, RET_inhibitor, FLT1_inhibitor"
    TherapeuticTargetsDatabase "DAP000006"
  ]
  node [
    id 233
    label "DB00330"
    PubChemSubstance "46504788"
    Carriers ""
    WaterSolubility "7.58e+00"
    Wikipedia "Ethambutol"
    HBondAcceptorCount "4"
    ChemSpider "13433"
    ATCcode "J04AM06, J04AK02, J04AM03"
    Polarizability "24.47"
    KEGGCompound "C06984"
    logS "-1.4"
    logP "-0.059"
    Refractivity "57.89"
    pKastrongestbasic "9.55"
    Bioavailability "1"
    DrugClass "Organonitrogen compounds"
    PathwayNames ""
    ChEMBL "CHEMBL44884"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "14.82"
    NumberofRings "0"
    BindingDB "50448407"
    MolecularWeight "204.3098"
    PhysiologicalCharge "1"
    Enzymes ""
    GhoseFilter "1"
    PolarSurfaceAreaPSA "64.52"
    MonoisotopicWeight "204.183778022"
    MDDRLikeRule "0"
    ChEBI "4877"
    PDB "95E"
    DrugsProductDatabaseDPD "20261"
    PharmGKB "PA164784021"
    Family "small molecule"
    MolecularFormula "C10H24N2O2"
    Transporters ""
    PubChemCompound "14052"
    HBondDonorCount "4"
    DrugSubClass "Amines"
    RotatableBondCount "9"
    Name "Ethambutol"
    Targets "embC_inhibitor, embB_inhibitor, embA_inhibitor"
    TherapeuticTargetsDatabase "DAP000055"
  ]
  node [
    id 234
    label "DB00555"
    KEGGDrug "D00354"
    PubChemSubstance "46505408"
    Carriers ""
    Wikipedia "Lamotrigine"
    GuidetoPharmacology "2622"
    HBondAcceptorCount "5"
    ChemSpider "3741"
    ATCcode "N03AX09"
    Polarizability "23.1"
    logS "-2.7"
    logP "1.93"
    Refractivity "66.62"
    pKastrongestbasic "5.87"
    Bioavailability "1"
    DrugClass "Benzene and substituted derivatives"
    PathwayNames ""
    ChEMBL "CHEMBL741"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "14.98"
    NumberofRings "2"
    BindingDB "50031299"
    MolecularWeight "256.091"
    PhysiologicalCharge "0"
    Enzymes "UGT1A4_substrate, DHFR_inhibitor, UGT1A3_substrate, UGT1A1_substrate, UGT1A1_inducer"
    IUPHAR "2622"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "90.71"
    MonoisotopicWeight "255.007850663"
    MDDRLikeRule "0"
    ChEBI "6367"
    WaterSolubility "4.88e-01"
    DrugsProductDatabaseDPD "238"
    PharmGKB "PA450164"
    Family "small molecule"
    MolecularFormula "C9H7Cl2N5"
    Transporters "ABCB1_substrate"
    PubChemCompound "3878"
    HBondDonorCount "2"
    DrugSubClass "Halobenzenes"
    RotatableBondCount "1"
    Name "Lamotrigine"
    Targets "CACNA1E_inhibitor, SCN2A_inhibitor, ADORA1_inhibitor, ADORA2A_inhibitor, ADRA1A_inhibitor, ADRA2A_inhibitor, ADRB1_inhibitor, DRD1_inhibitor, DRD2_inhibitor, GABRA1_inhibitor, GABRA1_inhibitor, HRH1_inhibitor, OPRK1_inhibitor, CHRM1_inhibitor, HTR2A_inhibitor, HTR3A_inhibitor"
    TherapeuticTargetsDatabase "DAP000039"
  ]
  node [
    id 235
    label "DB00448"
    KEGGDrug "D00355"
    NumberofRings "3"
    Carriers ""
    PubChemSubstance "46508975"
    Wikipedia "Lansoprazole"
    HBondAcceptorCount "4"
    ChemSpider "3746"
    ATCcode "A02BC53, A02BD10, A02BC03, A02BD03, A02BD02, A02BD09, A02BD07"
    Polarizability "34.59"
    logS "-3.2"
    logP "3.03"
    pKastrongestbasic "4.16"
    Bioavailability "1"
    DrugClass "Benzimidazoles"
    PathwayNames "Lansoprazole Action Pathway_SMP00227, Lansoprazole Metabolism Pathway_SMP00614"
    ChEMBL "CHEMBL480"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "9.35"
    Refractivity "87.61"
    BindingDB "47032"
    MolecularWeight "369.361"
    PhysiologicalCharge "0"
    Enzymes "CYP3A4_substrate, CYP3A4_inhibitor, CYP3A4_inducer, CYP2C19_substrate, CYP2C19_inhibitor, CYP2C9_substrate, CYP2C9_inhibitor, CYP2C9_inducer, CYP1A1_inducer, CYP1A2_inducer, CYP1B1_inducer, CYP2C18_substrate, CYP2C8_substrate, CYP2C8_inhibitor, CYP2D6_inhibitor, CYP4A11_inducer"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "67.87"
    MonoisotopicWeight "369.075882012"
    MDDRLikeRule "1"
    ChEBI "6375"
    WaterSolubility "2.50e-01"
    DrugsProductDatabaseDPD "180"
    PharmGKB "PA450180"
    Family "small molecule"
    MolecularFormula "C16H14F3N3O2S"
    Transporters "ABCB1_substrate, ABCB1_inhibitor, ABCG2_inhibitor"
    PubChemCompound "3883"
    HBondDonorCount "1"
    DrugSubClass "Sulfinylbenzimidazoles"
    RotatableBondCount "6"
    Name "Lansoprazole"
    Targets "ATP4A_inhibitor, MAPT_Unkown"
    TherapeuticTargetsDatabase "DAP000725"
  ]
  node [
    id 236
    label "DB00414"
    KEGGDrug "D00219"
    PubChemSubstance "46505821"
    Carriers "ALB"
    Wikipedia "Acetohexamide"
    HBondAcceptorCount "4"
    ChemSpider "1912"
    ATCcode "A10BB31"
    Polarizability "33.97"
    KEGGCompound "C06806"
    logS "-3.8"
    logP "1.81"
    Refractivity "82.77"
    pKastrongestbasic "-7.4"
    Bioavailability "1"
    DrugClass "Organooxygen compounds"
    PathwayNames ""
    ChEMBL "CHEMBL1589"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "4.31"
    NumberofRings "2"
    MolecularWeight "324.395"
    PhysiologicalCharge "-1"
    Enzymes "CBR1_substrate"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "92.34"
    MonoisotopicWeight "324.114377828"
    MDDRLikeRule "0"
    ChEBI "28052"
    WaterSolubility "4.83e-02"
    DrugsProductDatabaseDPD "9737"
    PharmGKB "PA164777011"
    Family "small molecule"
    MolecularFormula "C15H20N2O4S"
    Transporters ""
    PubChemCompound "1989"
    HBondDonorCount "2"
    DrugSubClass "Carbonyl compounds"
    RotatableBondCount "3"
    Name "Acetohexamide"
    Targets "KCNJ1_inhibitor"
    TherapeuticTargetsDatabase "DAP000922"
  ]
  node [
    id 237
    label "DB00412"
    KEGGDrug "D00596"
    PubChemSubstance "46504556"
    Carriers "ALB"
    WaterSolubility "3.80e-02"
    Wikipedia "Rosiglitazone"
    GuidetoPharmacology "1056"
    HBondAcceptorCount "5"
    ChemSpider "70383"
    ATCcode "A10BD03, A10BG02, A10BD04"
    Polarizability "37.8"
    logS "-4"
    logP "2.45"
    Refractivity "97.79"
    pKastrongestbasic "6.23"
    Bioavailability "1"
    DrugClass "Phenol ethers"
    PathwayNames "Rosiglitazone Metabolism Pathway_SMP00653"
    ChEMBL "CHEMBL121"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "6.84"
    NumberofRings "3"
    BindingDB "28681"
    MolecularWeight "357.427"
    PhysiologicalCharge "-1"
    Enzymes "CYP2C8_substrate, CYP2C8_inhibitor, CYP2C9_substrate, CYP2C9_inhibitor, PTGS1_substrate, CYP1A2_inhibitor, CYP2A6_inhibitor, CYP2C19_inhibitor, CYP2D6_inhibitor"
    IUPHAR "1056"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "71.53"
    MonoisotopicWeight "357.114712179"
    MDDRLikeRule "1"
    ChEBI "50122"
    PDB "BRL"
    DrugsProductDatabaseDPD "11925"
    PharmGKB "PA451283"
    Family "small molecule"
    MolecularFormula "C18H19N3O3S"
    Transporters "SLCO1B1_inhibitor"
    PubChemCompound "77999"
    HBondDonorCount "1"
    DrugSubClass "None"
    RotatableBondCount "7"
    Name "Rosiglitazone"
    Targets "PPARG_agonist, ACSL4_inhibitor, PPARA_Unkown, PPARD_Unkown, RXRA_Unkown, RXRB_Unkown, RXRG_Unkown"
    TherapeuticTargetsDatabase "DAP000271"
  ]
  node [
    id 238
    label "DB00413"
    KEGGDrug "D00559"
    PubChemSubstance "46505897"
    Carriers ""
    Wikipedia "Pramipexole"
    GuidetoPharmacology "953"
    HBondAcceptorCount "3"
    ChemSpider "106770"
    ATCcode "N04BC05"
    Polarizability "24.47"
    logS "-3.2"
    logP "1.76"
    Refractivity "59.77"
    pKastrongestbasic "10.31"
    Bioavailability "1"
    DrugClass "Organonitrogen compounds"
    PathwayNames ""
    ChEMBL "CHEMBL301265"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "17.66"
    NumberofRings "2"
    BindingDB "50116766"
    MolecularWeight "211.327"
    PhysiologicalCharge "1"
    Enzymes ""
    IUPHAR "953"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "50.94"
    MonoisotopicWeight "211.114318249"
    MDDRLikeRule "0"
    ChEBI "8356"
    WaterSolubility "1.40e-01"
    DrugsProductDatabaseDPD "11733"
    PharmGKB "PA164742949"
    Family "small molecule"
    MolecularFormula "C10H17N3S"
    Transporters "SLC22A2_substrate, SLC22A1_substrate"
    PubChemCompound "119570"
    HBondDonorCount "2"
    DrugSubClass "Amines"
    RotatableBondCount "3"
    Name "Pramipexole"
    Targets "DRD3_agonist, DRD2_agonist, DRD4_agonist, ADRA2B_unknown, HTR1A_unknown, HTR1D_unknown, ADRA2A_partial agonist, HTR1B_unknown, HTR2A_unknown, HTR2B_unknown, HTR2C_unknown, ADRA2C_unknown, DRD1_unknown, DRD5_unknown"
    TherapeuticTargetsDatabase "DAP000019"
  ]
  node [
    id 239
    label "DB00411"
    KEGGDrug "D00524"
    PubChemSubstance "46509115"
    Carriers ""
    Wikipedia "Carbachol"
    GuidetoPharmacology "298"
    HBondAcceptorCount "1"
    ChemSpider "5626"
    ATCcode "N07AB01, S01EB02"
    Name "Carbachol"
    PolarSurfaceAreaPSA "52.32"
    logS "-2.3"
    logP "-4.6"
    Refractivity "50.02"
    Bioavailability "1"
    DrugClass "Organonitrogen compounds"
    ChEMBL "CHEMBL14"
    Polarizability "16.02"
    Approved "True"
    pKastrongestacidic "15.23"
    NumberofRings "0"
    MolecularWeight "182.649"
    PhysiologicalCharge "1"
    Enzymes "PLA2G4A_inducer"
    IUPHAR "298"
    GhoseFilter "0"
    PubChemCompound "5831"
    MonoisotopicWeight "182.082205441"
    MDDRLikeRule "0"
    ChEBI "3385"
    PDB "CCE"
    DrugsProductDatabaseDPD "9622"
    PharmGKB "PA448784"
    Family "small molecule"
    MolecularFormula "C6H15ClN2O2"
    Transporters ""
    RuleofFive "1"
    PathwayNames ""
    HBondDonorCount "1"
    DrugSubClass "Quaternary ammonium salts"
    RotatableBondCount "4"
    WaterSolubility "9.48e-01"
    Targets "CHRM1_agonist, CHRM2_agonist, CHRNA2_agonist, ACHE_Unkown, CHRM3_Unkown, CHRM4_Unkown"
    TherapeuticTargetsDatabase "DAP000347"
  ]
  node [
    id 240
    label "DB00794"
    KEGGDrug "D00474"
    PubChemSubstance "46507775"
    Carriers ""
    Wikipedia "Primidone"
    HBondAcceptorCount "2"
    ChemSpider "4740"
    ATCcode "N03AA03, N05CB01"
    Polarizability "22.44"
    KEGGCompound "C07371"
    logS "-2.3"
    logP "1.12"
    Refractivity "59.04"
    pKastrongestbasic "-6.2"
    Bioavailability "1"
    DrugClass "Diazines"
    PathwayNames ""
    ChEMBL "CHEMBL856"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "11.5"
    NumberofRings "2"
    MolecularWeight "218.2518"
    PhysiologicalCharge "0"
    Enzymes "CYP2C19_substrate, CYP2C19_inducer, CYP2C9_inducer, CYP3A4_inducer, CYP1A2_inducer, CYP2B6_inducer, CYP2C8_inducer, UGT1A1_inducer"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "58.2"
    MonoisotopicWeight "218.105527702"
    MDDRLikeRule "0"
    ChEBI "8412"
    WaterSolubility "1.04e+00"
    DrugsProductDatabaseDPD "8265"
    PharmGKB "PA451105"
    Family "small molecule"
    MolecularFormula "C12H14N2O2"
    Transporters ""
    PubChemCompound "4909"
    HBondDonorCount "2"
    DrugSubClass "Pyrimidines and pyrimidine derivatives"
    RotatableBondCount "2"
    Name "Primidone"
    Targets "GABRA1_potentiator, GABRA2_potentiator, GABRA3_potentiator, GABRA4_potentiator, GABRA5_potentiator, GABRA6_potentiator, CHRNA4_antagonist, CHRNA7_antagonist, GRIA2_antagonist, GRIK2_antagonist, GABRA1_positive allosteric modulator"
    TherapeuticTargetsDatabase "DAP000678"
  ]
  node [
    id 241
    label "DB00797"
    PubChemSubstance "46505641"
    Carriers ""
    Wikipedia "Tolazoline"
    HBondAcceptorCount "2"
    ChemSpider "5303"
    ATCcode "C04AB02, M02AX02"
    RuleofFive "1"
    KEGGCompound "C07147"
    PolarSurfaceAreaPSA "24.39"
    logS "-2.1"
    logP "1.2"
    Refractivity "49.07"
    pKastrongestbasic "10.25"
    Bioavailability "1"
    DrugClass "Benzene and substituted derivatives"
    ChEMBL "CHEMBL770"
    Polarizability "17.94"
    Approved "True"
    MolecularWeight "160.2157"
    NumberofRings "2"
    BindingDB "55436"
    Name "Tolazoline"
    PhysiologicalCharge "1"
    Enzymes ""
    GhoseFilter "1"
    PubChemCompound "5504"
    MonoisotopicWeight "160.100048394"
    MDDRLikeRule "0"
    ChEBI "28502"
    DrugsProductDatabaseDPD "6010"
    PharmGKB "PA451716"
    Family "small molecule"
    MolecularFormula "C10H12N2"
    Transporters ""
    PathwayNames ""
    HBondDonorCount "1"
    DrugSubClass "None"
    RotatableBondCount "2"
    WaterSolubility "1.36e+00"
    Targets "ADRA1A_antagonist, ADRA2A_antagonist, HRH1_agonist, HRH2_agonist, ADRA2C_binder, ADRA2B_binder"
    TherapeuticTargetsDatabase "DAP000477"
  ]
  node [
    id 242
    label "DB00302"
    KEGGDrug "D01136"
    NumberofRings "1"
    Carriers ""
    PubChemSubstance "46508089"
    HBondAcceptorCount "3"
    ChemSpider "10482000"
    ATCcode "B02AA02"
    Name "Tranexamic Acid"
    PolarSurfaceAreaPSA "63.32"
    logS "-0.94"
    logP "-1.6"
    Polarizability "17.28"
    pKastrongestbasic "10.22"
    Bioavailability "1"
    DrugClass "Carboxylic acids and derivatives"
    ChEMBL "CHEMBL877"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "4.56"
    Refractivity "41.9"
    BindingDB "50428067"
    MolecularWeight "157.2102"
    PhysiologicalCharge "0"
    Enzymes ""
    GhoseFilter "0"
    PubChemCompound "5526"
    MonoisotopicWeight "157.110278729"
    MDDRLikeRule "0"
    ChEBI "48669"
    PDB "AMH"
    DrugsProductDatabaseDPD "1988"
    PharmGKB "PA164750514"
    Family "small molecule"
    MolecularFormula "C8H15NO2"
    Transporters "SLC15A2_Unkown"
    PathwayNames "Tranexamic Acid Action Pathway_SMP00287"
    HBondDonorCount "2"
    DrugSubClass "Amino acids, peptides, and analogues"
    RotatableBondCount "2"
    WaterSolubility "1.82e+01"
    Targets "PLG_inhibitor"
    TherapeuticTargetsDatabase "DAP000199"
  ]
  node [
    id 243
    label "DB00419"
    PubChemSubstance "46506350"
    Carriers ""
    Wikipedia "Miglustat"
    HBondAcceptorCount "5"
    ChemSpider "46764"
    ATCcode "A16AX06"
    Name "Miglustat"
    PolarSurfaceAreaPSA "84.16"
    logS "0.18"
    logP "-1.2"
    Polarizability "23.99"
    Refractivity "55.74"
    pKastrongestbasic "8.49"
    Bioavailability "1"
    DrugClass "Piperidines"
    ChEMBL "CHEMBL1029"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "12.9"
    NumberofRings "1"
    BindingDB "18355"
    MolecularWeight "219.278"
    PhysiologicalCharge "1"
    Enzymes ""
    GhoseFilter "0"
    PubChemCompound "51634"
    MonoisotopicWeight "219.147058165"
    MDDRLikeRule "0"
    ChEBI "50381"
    PDB "NBV"
    DrugsProductDatabaseDPD "13313"
    PharmGKB "PA10140"
    Family "small molecule"
    MolecularFormula "C10H21NO4"
    Transporters ""
    PathwayNames ""
    HBondDonorCount "4"
    DrugSubClass "None"
    RotatableBondCount "4"
    WaterSolubility "3.31e+02"
    Targets "UGCG_inhibitor"
    TherapeuticTargetsDatabase "DAP000609"
  ]
  node [
    id 244
    label "DB00243"
    PubChemSubstance "46505145"
    Carriers ""
    Wikipedia "Ranolazine"
    HBondAcceptorCount "6"
    ChemSpider "51354"
    ATCcode "C01EB18"
    Name "Ranolazine"
    PolarSurfaceAreaPSA "74.27"
    logS "-3.6"
    logP "2.83"
    Refractivity "123.46"
    pKastrongestbasic "7.17"
    Bioavailability "1"
    DrugClass "Phenol ethers"
    ChEMBL "CHEMBL1404"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "13.6"
    NumberofRings "3"
    MolecularWeight "427.5365"
    PhysiologicalCharge "1"
    Enzymes "CYP3A4_substrate, CYP2D6_inhibitor"
    GhoseFilter "1"
    PubChemCompound "56959"
    MonoisotopicWeight "427.247106559"
    MDDRLikeRule "1"
    ChEBI "87690"
    Polarizability "47.22"
    PharmGKB "PA164746007"
    Family "small molecule"
    MolecularFormula "C24H33N3O4"
    Transporters ""
    PathwayNames ""
    HBondDonorCount "2"
    DrugSubClass "Anisoles"
    RotatableBondCount "9"
    WaterSolubility "1.10e-01"
    Targets "SCN5A_inhibitor, SCN9A_inhibitor"
    TherapeuticTargetsDatabase "DAP000875"
  ]
  node [
    id 245
    label "DB00711"
    KEGGDrug "D00803"
    Refractivity "58.28"
    Carriers ""
    PubChemSubstance "46506830"
    Wikipedia "Diethylcarbamazine"
    HBondAcceptorCount "2"
    ChemSpider "2944"
    ATCcode "P02CB02"
    MolecularWeight "199.2932"
    KEGGCompound "C07968"
    logS "0.07"
    logP "0.092"
    Polarizability "22.89"
    pKastrongestbasic "6.9"
    Bioavailability "1"
    DrugClass "Diazinanes"
    PathwayNames ""
    ChEMBL "CHEMBL684"
    RuleofFive "1"
    Approved "True"
    NumberofRings "1"
    BindingDB "50024883"
    Name "Diethylcarbamazine"
    PhysiologicalCharge "0"
    Enzymes "BCHE_inhibitor"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "26.79"
    MonoisotopicWeight "199.168462309"
    MDDRLikeRule "0"
    ChEBI "4527"
    DrugsProductDatabaseDPD "3436"
    PharmGKB "PA164748883"
    Family "small molecule"
    MolecularFormula "C10H21N3O"
    Transporters ""
    PubChemCompound "3052"
    HBondDonorCount "0"
    DrugSubClass "Piperazines"
    RotatableBondCount "2"
    WaterSolubility "2.36e+02"
    Targets "ALOX5_inhibitor, PTGS1_inhibitor"
    TherapeuticTargetsDatabase "DAP000914"
  ]
  node [
    id 246
    label "DB00559"
    KEGGDrug "D01227"
    NumberofRings "4"
    Carriers ""
    PubChemSubstance "46507154"
    WaterSolubility "9.04e-03"
    Wikipedia "Bosentan"
    HBondAcceptorCount "9"
    ChemSpider "94651"
    ATCcode "C02KX01"
    Polarizability "57.89"
    logS "-4.8"
    logP "4.94"
    pKastrongestbasic "-0.43"
    Bioavailability "1"
    DrugClass "Diazines"
    PathwayNames ""
    ChEMBL "CHEMBL957"
    RuleofFive "0"
    Approved "True"
    pKastrongestacidic "5.8"
    Refractivity "166.66"
    BindingDB "50061101"
    MolecularWeight "551.614"
    PhysiologicalCharge "-1"
    Enzymes "CYP3A4_substrate, CYP3A4_inducer, CYP2C9_substrate, CYP2C9_inducer"
    GhoseFilter "0"
    PolarSurfaceAreaPSA "145.65"
    MonoisotopicWeight "551.183854375"
    MDDRLikeRule "1"
    ChEBI "51450"
    PDB "K86"
    DrugsProductDatabaseDPD "12538"
    PharmGKB "PA10034"
    Family "small molecule"
    MolecularFormula "C27H29N5O6S"
    Transporters "ABCB11_inhibitor"
    PubChemCompound "104865"
    HBondDonorCount "2"
    DrugSubClass "Pyrimidines and pyrimidine derivatives"
    RotatableBondCount "10"
    Name "Bosentan"
    Targets "EDNRA_antagonist, EDNRB_antagonist"
    TherapeuticTargetsDatabase "DNC000341"
  ]
  node [
    id 247
    label "DB00244"
    KEGGDrug "D00377"
    PubChemSubstance "46509142"
    Carriers ""
    Wikipedia "Mesalazine"
    GuidetoPharmacology "2700"
    HBondAcceptorCount "4"
    ChemSpider "3933"
    ATCcode "A07EC02"
    Polarizability "14.26"
    logS "-1.1"
    logP "-0.29"
    Refractivity "40"
    pKastrongestbasic "5.87"
    Bioavailability "1"
    DrugClass "Benzene and substituted derivatives"
    PathwayNames ""
    ChEMBL "CHEMBL704"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "2.02"
    NumberofRings "1"
    BindingDB "60918"
    MolecularWeight "153.1354"
    PhysiologicalCharge "-1"
    Enzymes ""
    IUPHAR "2700"
    GhoseFilter "0"
    PolarSurfaceAreaPSA "83.55"
    MonoisotopicWeight "153.042593095"
    MDDRLikeRule "0"
    ChEBI "6775"
    WaterSolubility "1.22e+01"
    DrugsProductDatabaseDPD "14088"
    PharmGKB "PA450384"
    Family "small molecule"
    MolecularFormula "C7H7NO3"
    Transporters ""
    PubChemCompound "4075"
    HBondDonorCount "3"
    DrugSubClass "Benzoic acids and derivatives"
    RotatableBondCount "1"
    Name "Mesalazine"
    Targets "PTGS2_inhibitor, PTGS1_inhibitor, ALOX5_inhibitor, PPARG_agonist, CHUK_inhibitor, IKBKB_inhibitor, MPO_Unkown, nat_Unkown"
    TherapeuticTargetsDatabase "DAP000729"
  ]
  node [
    id 248
    label "DB00928"
    KEGGDrug "D03021"
    PubChemSubstance "46509032"
    Carriers ""
    WaterSolubility "1.21e+01"
    Wikipedia "Azacitidine"
    HBondAcceptorCount "8"
    ChemSpider "9072"
    ATCcode "L01BC07"
    Polarizability "21.5"
    KEGGCompound "C11262"
    logS "-1.3"
    logP "-3.1"
    Refractivity "52.19"
    pKastrongestbasic "-0.38"
    Bioavailability "1"
    DrugClass "Organooxygen compounds"
    PathwayNames ""
    ChEMBL "CHEMBL1489"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "12.55"
    NumberofRings "2"
    BindingDB "50424715"
    MolecularWeight "244.2047"
    PhysiologicalCharge "0"
    Enzymes "CDA_substrate"
    GhoseFilter "0"
    PolarSurfaceAreaPSA "140.97"
    MonoisotopicWeight "244.080769514"
    MDDRLikeRule "0"
    ChEBI "2038"
    PDB "5AE"
    DrugsProductDatabaseDPD "20554"
    PharmGKB "PA451996"
    Family "small molecule"
    MolecularFormula "C8H12N4O5"
    Transporters ""
    PubChemCompound "9444"
    HBondDonorCount "4"
    DrugSubClass "Carbohydrates and carbohydrate conjugates"
    RotatableBondCount "2"
    Name "Azacitidine"
    Targets "DNMT1_inhibitor, RNA, DNA"
    TherapeuticTargetsDatabase "DAP000640"
  ]
  node [
    id 249
    label "DB00975"
    KEGGDrug "D00302"
    NumberofRings "4"
    Carriers ""
    PubChemSubstance "46506292"
    Wikipedia "Dipyridamole"
    HBondAcceptorCount "12"
    ChemSpider "2997"
    ATCcode "B01AC07"
    Polarizability "56.94"
    logS "-2.7"
    logP "1.81"
    pKastrongestbasic "6.59"
    Bioavailability "0"
    DrugClass "Organonitrogen compounds"
    PathwayNames "Dipyridamole (Antiplatelet) Action Pathway_SMP00264"
    ChEMBL "CHEMBL932"
    RuleofFive "0"
    Approved "True"
    pKastrongestacidic "14.97"
    Refractivity "142.78"
    BindingDB "23620"
    MolecularWeight "504.6256"
    PhysiologicalCharge "0"
    Enzymes ""
    GhoseFilter "0"
    PolarSurfaceAreaPSA "145.44"
    MonoisotopicWeight "504.317251808"
    MDDRLikeRule "1"
    ChEBI "4653"
    WaterSolubility "9.22e-01"
    DrugsProductDatabaseDPD "7219"
    PharmGKB "PA449367"
    Family "small molecule"
    MolecularFormula "C24H40N8O4"
    Transporters "ABCC4_inhibitor, ABCC5_inhibitor, ABCB1_substrate, ABCB1_inhibitor"
    PubChemCompound "3108"
    HBondDonorCount "4"
    DrugSubClass "Amines"
    RotatableBondCount "12"
    Name "Dipyridamole"
    Targets "PDE10A_inhibitor, ADA_inhibitor, PDE5A_inhibitor, PDE4A_inhibitor, RCAN1_Unkown, ORM1_Unkown"
    TherapeuticTargetsDatabase "DNC001625"
  ]
  node [
    id 250
    label "DB00719"
    PubChemSubstance "46507958"
    Carriers ""
    Wikipedia "Azatadine"
    HBondAcceptorCount "2"
    ChemSpider "18709"
    ATCcode "R06AX09"
    RuleofFive "1"
    KEGGCompound "C07774"
    PolarSurfaceAreaPSA "16.13"
    logS "-3.4"
    logP "3.75"
    Refractivity "101.53"
    pKastrongestbasic "7.91"
    Bioavailability "1"
    DrugClass "Benzocycloheptapyridines"
    ChEMBL "CHEMBL946"
    Polarizability "34.01"
    Approved "True"
    MolecularWeight "290.4021"
    NumberofRings "4"
    BindingDB "22868"
    Name "Azatadine"
    PhysiologicalCharge "1"
    Enzymes "CYP3A4_inducer"
    GhoseFilter "1"
    PubChemCompound "19861"
    MonoisotopicWeight "290.178298714"
    MDDRLikeRule "0"
    ChEBI "2946"
    DrugsProductDatabaseDPD "2291"
    PharmGKB "PA164747157"
    Family "small molecule"
    MolecularFormula "C20H22N2"
    Transporters ""
    PathwayNames "Azatadine H1-Antihistamine Action_SMP59865"
    HBondDonorCount "0"
    DrugSubClass "None"
    RotatableBondCount "0"
    WaterSolubility "1.13e-01"
    Targets "HRH1_antagonist"
    TherapeuticTargetsDatabase "DAP001079"
  ]
  node [
    id 251
    label "DB00552"
    KEGGDrug "D00155"
    PubChemSubstance "46507116"
    Carriers ""
    WaterSolubility "1.07e+01"
    Wikipedia "Pentostatin"
    HBondAcceptorCount "7"
    ChemSpider "388759"
    ATCcode "L01XX08"
    Polarizability "26.44"
    KEGGCompound "C02267"
    logS "-1.4"
    logP "-2"
    Refractivity "64.98"
    pKastrongestbasic "8.33"
    Bioavailability "1"
    DrugClass "Imidazodiazepines"
    PathwayNames ""
    ChEMBL "CHEMBL1580"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "13.06"
    NumberofRings "3"
    BindingDB "22925"
    MolecularWeight "268.2691"
    PhysiologicalCharge "1"
    Enzymes ""
    GhoseFilter "0"
    PolarSurfaceAreaPSA "112.13"
    MonoisotopicWeight "268.11715502"
    MDDRLikeRule "0"
    PDB "DCF"
    DrugsProductDatabaseDPD "1740"
    PharmGKB "PA450863"
    Family "small molecule"
    MolecularFormula "C11H16N4O4"
    Transporters ""
    PubChemCompound "439693"
    HBondDonorCount "4"
    DrugSubClass "None"
    RotatableBondCount "2"
    Name "Pentostatin"
    Targets "ADA_inhibitor"
    TherapeuticTargetsDatabase "DAP000566"
  ]
  node [
    id 252
    label "DB00551"
    KEGGDrug "D00220"
    PubChemSubstance "46508546"
    Carriers ""
    WaterSolubility "5.09e+02"
    Wikipedia "Acetohydroxamic_acid"
    HBondAcceptorCount "2"
    ChemSpider "1913"
    ATCcode "G04BX03"
    Polarizability "6.6"
    KEGGCompound "C06808"
    logS "0.83"
    logP "-1"
    Refractivity "16.23"
    pKastrongestbasic "-5.4"
    Bioavailability "1"
    DrugClass "Carboxylic acids and derivatives"
    PathwayNames ""
    ChEMBL "CHEMBL734"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "8.94"
    NumberofRings "0"
    BindingDB "50099857"
    MolecularWeight "75.0666"
    PhysiologicalCharge "0"
    Enzymes ""
    GhoseFilter "0"
    PolarSurfaceAreaPSA "49.33"
    MonoisotopicWeight "75.032028409"
    MDDRLikeRule "0"
    ChEBI "49029"
    PDB "HAE"
    PharmGKB "PA164749213"
    Family "small molecule"
    MolecularFormula "C2H5NO2"
    Transporters ""
    PubChemCompound "1990"
    HBondDonorCount "2"
    DrugSubClass "Carboxylic acid derivatives"
    RotatableBondCount "0"
    Name "Acetohydroxamic Acid"
    Targets "ureC_inhibitor, MMP12_inhibitor"
    TherapeuticTargetsDatabase "DAP001277"
  ]
  node [
    id 253
    label "DB00550"
    KEGGDrug "D00562"
    PubChemSubstance "46505181"
    Carriers ""
    WaterSolubility "4.66e-01"
    Wikipedia "Propylthiouracil"
    HBondAcceptorCount "1"
    ChemSpider "571424"
    ATCcode "H03BA02"
    Polarizability "17.79"
    KEGGCompound "C07569"
    logS "-2.6"
    logP "1.2"
    Refractivity "48.9"
    pKastrongestbasic "-2.7"
    Bioavailability "1"
    DrugClass "Diazines"
    PathwayNames ""
    ChEMBL "CHEMBL1518"
    RuleofFive "1"
    Approved "True"
    pKastrongestacidic "8.09"
    NumberofRings "1"
    BindingDB "50133597"
    MolecularWeight "170.232"
    PhysiologicalCharge "0"
    Enzymes "MPO_inhibitor, DBH_inhibitor"
    GhoseFilter "1"
    PolarSurfaceAreaPSA "41.13"
    MonoisotopicWeight "170.051383642"
    MDDRLikeRule "0"
    ChEBI "8502"
    PDB "3CJ"
    DrugsProductDatabaseDPD "9439"
    PharmGKB "PA451156"
    Family "small molecule"
    MolecularFormula "C7H10N2OS"
    Transporters ""
    PubChemCompound "657298"
    HBondDonorCount "2"
    DrugSubClass "Pyrimidines and pyrimidine derivatives"
    RotatableBondCount "2"
    Name "Propylthiouracil"
    Targets "TPO_inhibitor"
    TherapeuticTargetsDatabase "DAP001247"
  ]
  edge [
    source 0
    target 53
    int "The metabolism of Vinblastine can be decreased when combined with Isoniazid."
  ]
  edge [
    source 0
    target 61
    int "The metabolism of Imatinib can be decreased when combined with Isoniazid."
  ]
  edge [
    source 0
    target 64
    int "The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Isoniazid resulting in a loss in efficacy."
  ]
  edge [
    source 0
    target 66
    int "The serum concentration of Amodiaquine can be increased when it is combined with Isoniazid."
  ]
  edge [
    source 0
    target 167
    int "The metabolism of Sildenafil can be decreased when combined with Isoniazid."
  ]
  edge [
    source 0
    target 68
    int "Rifabutin may increase the hepatotoxic activities of Isoniazid."
  ]
  edge [
    source 0
    target 110
    int "The metabolism of Dronedarone can be decreased when combined with Isoniazid."
  ]
  edge [
    source 0
    target 137
    int "The metabolism of Artemether can be decreased when combined with Isoniazid."
  ]
  edge [
    source 0
    target 141
    int "The metabolism of Doxorubicin can be decreased when combined with Isoniazid."
  ]
  edge [
    source 0
    target 149
    int "The metabolism of Halofantrine can be decreased when combined with Isoniazid."
  ]
  edge [
    source 0
    target 154
    int "The metabolism of Amprenavir can be decreased when combined with Isoniazid."
  ]
  edge [
    source 0
    target 197
    int "The metabolism of Buspirone can be decreased when combined with Isoniazid."
  ]
  edge [
    source 0
    target 182
    int "The metabolism of Mephenytoin can be decreased when combined with Isoniazid."
  ]
  edge [
    source 0
    target 193
    int "The metabolism of Flutamide can be decreased when combined with Isoniazid."
  ]
  edge [
    source 0
    target 196
    int "The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Isoniazid."
  ]
  edge [
    source 0
    target 177
    int "The metabolism of Mitoxantrone can be decreased when combined with Isoniazid."
  ]
  edge [
    source 0
    target 214
    int "The metabolism of Proguanil can be decreased when combined with Isoniazid."
  ]
  edge [
    source 0
    target 217
    int "The serum concentration of Isoniazid can be decreased when it is combined with Desoxycorticosterone Pivalate."
  ]
  edge [
    source 0
    target 231
    int "The metabolism of Carisoprodol can be decreased when combined with Isoniazid."
  ]
  edge [
    source 0
    target 47
    int "The serum concentration of Isoniazid can be decreased when it is combined with Prednisolone."
  ]
  edge [
    source 0
    target 158
    int "The metabolism of Piperazine can be decreased when combined with Isoniazid."
  ]
  edge [
    source 0
    target 174
    int "The metabolism of Sertraline can be decreased when combined with Isoniazid."
  ]
  edge [
    source 0
    target 235
    int "The metabolism of Lansoprazole can be decreased when combined with Isoniazid."
  ]
  edge [
    source 0
    target 138
    int "The serum concentration of Theophylline can be increased when it is combined with Isoniazid."
  ]
  edge [
    source 0
    target 41
    int "The serum concentration of Citalopram can be increased when it is combined with Isoniazid."
  ]
  edge [
    source 0
    target 153
    int "The metabolism of Testosterone can be decreased when combined with Isoniazid."
  ]
  edge [
    source 0
    target 155
    int "The metabolism of Bortezomib can be decreased when combined with Isoniazid."
  ]
  edge [
    source 0
    target 159
    int "The metabolism of Cevimeline can be decreased when combined with Isoniazid."
  ]
  edge [
    source 0
    target 42
    int "The metabolism of Ramelteon can be decreased when combined with Isoniazid."
  ]
  edge [
    source 0
    target 181
    int "The metabolism of Dopamine can be decreased when combined with Isoniazid."
  ]
  edge [
    source 0
    target 94
    int "The metabolism of Valproic Acid can be decreased when combined with Isoniazid."
  ]
  edge [
    source 0
    target 48
    int "The metabolism of Gefitinib can be decreased when combined with Isoniazid."
  ]
  edge [
    source 0
    target 240
    int "The metabolism of Primidone can be decreased when combined with Isoniazid."
  ]
  edge [
    source 0
    target 5
    int "The metabolism of Galantamine can be decreased when combined with Isoniazid."
  ]
  edge [
    source 0
    target 6
    int "The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Isoniazid resulting in a loss in efficacy."
  ]
  edge [
    source 0
    target 8
    int "The metabolism of Aprepitant can be decreased when combined with Isoniazid."
  ]
  edge [
    source 0
    target 49
    int "The metabolism of Fluvoxamine can be decreased when combined with Isoniazid."
  ]
  edge [
    source 0
    target 188
    int "The serum concentration of Cerivastatin can be increased when it is combined with Isoniazid."
  ]
  edge [
    source 0
    target 89
    int "The metabolism of Praziquantel can be decreased when combined with Isoniazid."
  ]
  edge [
    source 0
    target 125
    int "The metabolism of Pentamidine can be decreased when combined with Isoniazid."
  ]
  edge [
    source 0
    target 129
    int "The metabolism of Nateglinide can be decreased when combined with Isoniazid."
  ]
  edge [
    source 0
    target 133
    int "The metabolism of Risperidone can be decreased when combined with Isoniazid."
  ]
  edge [
    source 0
    target 160
    int "The metabolism of Chlorzoxazone can be decreased when combined with Isoniazid."
  ]
  edge [
    source 0
    target 102
    int "The risk or severity of adverse effects can be increased when Methylergometrine is combined with Isoniazid."
  ]
  edge [
    source 0
    target 166
    int "The serum concentration of Tolvaptan can be increased when it is combined with Isoniazid."
  ]
  edge [
    source 0
    target 184
    int "The metabolism of Dexmedetomidine can be decreased when combined with Isoniazid."
  ]
  edge [
    source 0
    target 33
    int "The metabolism of Chloroquine can be decreased when combined with Isoniazid."
  ]
  edge [
    source 0
    target 206
    int "The serum concentration of Aripiprazole can be increased when it is combined with Isoniazid."
  ]
  edge [
    source 0
    target 212
    int "The metabolism of Loperamide can be decreased when combined with Isoniazid."
  ]
  edge [
    source 0
    target 124
    int "The metabolism of Pazopanib can be decreased when combined with Isoniazid."
  ]
  edge [
    source 0
    target 180
    int "The risk or severity of adverse effects can be increased when Disulfiram is combined with Isoniazid."
  ]
  edge [
    source 0
    target 3
    int "The serum concentration of Itraconazole can be decreased when it is combined with Isoniazid."
  ]
  edge [
    source 0
    target 20
    int "The metabolism of Quinine can be decreased when combined with Isoniazid."
  ]
  edge [
    source 0
    target 30
    int "The metabolism of Amoxapine can be decreased when combined with Isoniazid."
  ]
  edge [
    source 0
    target 200
    int "The metabolism of Zalcitabine can be decreased when combined with Isoniazid."
  ]
  edge [
    source 0
    target 37
    int "The metabolism of Felbamate can be decreased when combined with Isoniazid."
  ]
  edge [
    source 0
    target 39
    int "The metabolism of Cisapride can be decreased when combined with Isoniazid."
  ]
  edge [
    source 0
    target 57
    int "The risk or severity of adverse effects can be increased when Isoniazid is combined with Cycloserine."
  ]
  edge [
    source 0
    target 72
    int "The metabolism of Tetrabenazine can be decreased when combined with Isoniazid."
  ]
  edge [
    source 0
    target 43
    int "The metabolism of Thalidomide can be decreased when combined with Isoniazid."
  ]
  edge [
    source 0
    target 191
    int "The metabolism of Trazodone can be decreased when combined with Isoniazid."
  ]
  edge [
    source 0
    target 202
    int "The metabolism of Maprotiline can be decreased when combined with Isoniazid."
  ]
  edge [
    source 0
    target 113
    int "The metabolism of Imipramine can be decreased when combined with Isoniazid."
  ]
  edge [
    source 1
    target 62
    int "The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Terazosin."
  ]
  edge [
    source 1
    target 167
    int "Sildenafil may increase the hypotensive activities of Terazosin."
  ]
  edge [
    source 1
    target 138
    int "Theophylline may increase the hypotensive activities of Terazosin."
  ]
  edge [
    source 1
    target 95
    int "The risk or severity of adverse effects can be increased when Olmesartan is combined with Terazosin."
  ]
  edge [
    source 1
    target 109
    int "Terazosin may decrease the vasoconstricting activities of Etomidate."
  ]
  edge [
    source 1
    target 110
    int "Terazosin may increase the antihypertensive activities of Dronedarone."
  ]
  edge [
    source 1
    target 11
    int "The risk or severity of adverse effects can be increased when Diclofenamide is combined with Terazosin."
  ]
  edge [
    source 1
    target 141
    int "The serum concentration of Doxorubicin can be increased when it is combined with Terazosin."
  ]
  edge [
    source 1
    target 142
    int "The risk or severity of hypotension can be increased when Terazosin is combined with Gabapentin."
  ]
  edge [
    source 1
    target 219
    int "The risk or severity of hypotension can be increased when Terazosin is combined with Nisoldipine."
  ]
  edge [
    source 1
    target 225
    int "Terazosin may increase the antihypertensive activities of Epinephrine."
  ]
  edge [
    source 1
    target 226
    int "The risk or severity of adverse effects can be increased when Bumetanide is combined with Terazosin."
  ]
  edge [
    source 1
    target 230
    int "The risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Terazosin."
  ]
  edge [
    source 1
    target 244
    int "The serum concentration of Ranolazine can be increased when it is combined with Terazosin."
  ]
  edge [
    source 1
    target 45
    int "The risk or severity of adverse effects can be increased when Iloprost is combined with Terazosin."
  ]
  edge [
    source 1
    target 60
    int "Terazosin may decrease the vasoconstricting activities of Isoprenaline."
  ]
  edge [
    source 1
    target 70
    int "The risk or severity of adverse effects can be increased when Amiloride is combined with Terazosin."
  ]
  edge [
    source 1
    target 98
    int "Terazosin may decrease the vasoconstricting activities of Methyldopa."
  ]
  edge [
    source 1
    target 249
    int "Dipyridamole may increase the hypotensive activities of Terazosin."
  ]
  edge [
    source 1
    target 155
    int "The risk or severity of adverse effects can be increased when Bortezomib is combined with Terazosin."
  ]
  edge [
    source 1
    target 238
    int "The risk or severity of adverse effects can be increased when Pramipexole is combined with Terazosin."
  ]
  edge [
    source 1
    target 240
    int "Primidone may increase the hypotensive activities of Terazosin."
  ]
  edge [
    source 1
    target 241
    int "Terazosin may increase the antihypertensive activities of Tolazoline."
  ]
  edge [
    source 1
    target 234
    int "The risk or severity of hypotension can be increased when Terazosin is combined with Lamotrigine."
  ]
  edge [
    source 1
    target 12
    int "The risk or severity of adverse effects can be increased when Triamterene is combined with Terazosin."
  ]
  edge [
    source 1
    target 93
    int "The risk or severity of adverse effects can be increased when Terazosin is combined with Hydralazine."
  ]
  edge [
    source 1
    target 113
    int "Terazosin may increase the antihypertensive activities of Imipramine."
  ]
  edge [
    source 1
    target 133
    int "Terazosin may increase the hypotensive activities of Risperidone."
  ]
  edge [
    source 1
    target 135
    int "The serum concentration of Everolimus can be increased when it is combined with Terazosin."
  ]
  edge [
    source 1
    target 196
    int "Terazosin may decrease the vasoconstricting activities of Dihydroergotamine."
  ]
  edge [
    source 1
    target 161
    int "The risk or severity of adverse effects can be increased when Minoxidil is combined with Terazosin."
  ]
  edge [
    source 1
    target 162
    int "The risk or severity of adverse effects can be increased when Spironolactone is combined with Terazosin."
  ]
  edge [
    source 1
    target 169
    int "Terazosin may increase the antihypertensive activities of Asenapine."
  ]
  edge [
    source 1
    target 207
    int "The risk or severity of hypotension can be increased when Terazosin is combined with Zonisamide."
  ]
  edge [
    source 1
    target 184
    int "Terazosin may decrease the vasoconstricting activities of Dexmedetomidine."
  ]
  edge [
    source 1
    target 87
    int "The risk or severity of adverse effects can be increased when Clofarabine is combined with Terazosin."
  ]
  edge [
    source 1
    target 201
    int "The risk or severity of adverse effects can be increased when Terazosin is combined with Aliskiren."
  ]
  edge [
    source 1
    target 206
    int "Aripiprazole may increase the hypotensive activities of Terazosin."
  ]
  edge [
    source 1
    target 208
    int "Terazosin may increase the antihypertensive activities of Trifluoperazine."
  ]
  edge [
    source 1
    target 212
    int "The risk or severity of hypotension can be increased when Terazosin is combined with Loperamide."
  ]
  edge [
    source 1
    target 124
    int "The serum concentration of Pazopanib can be increased when it is combined with Terazosin."
  ]
  edge [
    source 1
    target 30
    int "Terazosin may increase the antihypertensive activities of Amoxapine."
  ]
  edge [
    source 1
    target 56
    int "The risk or severity of adverse effects can be increased when Enalaprilat is combined with Terazosin."
  ]
  edge [
    source 1
    target 228
    int "The risk or severity of adverse effects can be increased when Bretylium is combined with Terazosin."
  ]
  edge [
    source 1
    target 43
    int "The risk or severity of adverse effects can be increased when Thalidomide is combined with Terazosin."
  ]
  edge [
    source 1
    target 168
    int "Atenolol may increase the orthostatic hypotensive activities of Terazosin."
  ]
  edge [
    source 1
    target 191
    int "Terazosin may increase the antihypertensive activities of Trazodone."
  ]
  edge [
    source 1
    target 192
    int "The risk or severity of adverse effects can be increased when Mecamylamine is combined with Terazosin."
  ]
  edge [
    source 1
    target 215
    int "The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Terazosin."
  ]
  edge [
    source 3
    target 8
    int "The serum concentration of Itraconazole can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 3
    target 53
    int "The serum concentration of Vinblastine can be increased when it is combined with Itraconazole."
  ]
  edge [
    source 3
    target 54
    int "The serum concentration of Busulfan can be increased when it is combined with Itraconazole."
  ]
  edge [
    source 3
    target 61
    int "The serum concentration of Imatinib can be increased when it is combined with Itraconazole."
  ]
  edge [
    source 3
    target 76
    int "The metabolism of Tetracycline can be decreased when combined with Itraconazole."
  ]
  edge [
    source 3
    target 64
    int "The metabolism of Clopidogrel can be decreased when combined with Itraconazole."
  ]
  edge [
    source 3
    target 167
    int "The serum concentration of Sildenafil can be increased when it is combined with Itraconazole."
  ]
  edge [
    source 3
    target 68
    int "The serum concentration of Itraconazole can be decreased when it is combined with Rifabutin."
  ]
  edge [
    source 3
    target 86
    int "The metabolism of Argatroban can be decreased when combined with Itraconazole."
  ]
  edge [
    source 3
    target 103
    int "The metabolism of Zileuton can be decreased when combined with Itraconazole."
  ]
  edge [
    source 3
    target 110
    int "The serum concentration of Dronedarone can be increased when it is combined with Itraconazole."
  ]
  edge [
    source 3
    target 137
    int "The metabolism of Artemether can be decreased when combined with Itraconazole."
  ]
  edge [
    source 3
    target 141
    int "The metabolism of Doxorubicin can be decreased when combined with Itraconazole."
  ]
  edge [
    source 3
    target 142
    int "The therapeutic efficacy of Itraconazole can be increased when used in combination with Gabapentin."
  ]
  edge [
    source 3
    target 148
    int "The metabolism of Dantrolene can be decreased when combined with Itraconazole."
  ]
  edge [
    source 3
    target 149
    int "The serum concentration of Halofantrine can be increased when it is combined with Itraconazole."
  ]
  edge [
    source 3
    target 74
    int "The serum concentration of Saxagliptin can be increased when it is combined with Itraconazole."
  ]
  edge [
    source 3
    target 154
    int "The metabolism of Amprenavir can be decreased when combined with Itraconazole."
  ]
  edge [
    source 3
    target 197
    int "The metabolism of Buspirone can be decreased when combined with Itraconazole."
  ]
  edge [
    source 3
    target 193
    int "The metabolism of Flutamide can be decreased when combined with Itraconazole."
  ]
  edge [
    source 3
    target 196
    int "The serum concentration of Dihydroergotamine can be increased when it is combined with Itraconazole."
  ]
  edge [
    source 3
    target 214
    int "The metabolism of Proguanil can be decreased when combined with Itraconazole."
  ]
  edge [
    source 3
    target 219
    int "The serum concentration of Nisoldipine can be increased when it is combined with Itraconazole."
  ]
  edge [
    source 3
    target 220
    int "The metabolism of Sulfinpyrazone can be decreased when combined with Itraconazole."
  ]
  edge [
    source 3
    target 122
    int "The metabolism of Levonorgestrel can be decreased when combined with Itraconazole."
  ]
  edge [
    source 3
    target 230
    int "The metabolism of Isosorbide Dinitrate can be decreased when combined with Itraconazole."
  ]
  edge [
    source 3
    target 232
    int "The serum concentration of Sorafenib can be increased when it is combined with Itraconazole."
  ]
  edge [
    source 3
    target 206
    int "The serum concentration of Aripiprazole can be increased when it is combined with Itraconazole."
  ]
  edge [
    source 3
    target 244
    int "The serum concentration of Ranolazine can be increased when it is combined with Itraconazole."
  ]
  edge [
    source 3
    target 23
    int "The metabolism of Pinacidil can be decreased when combined with Itraconazole."
  ]
  edge [
    source 3
    target 65
    int "The metabolism of Ethinyl Estradiol can be decreased when combined with Itraconazole."
  ]
  edge [
    source 3
    target 217
    int "The serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Itraconazole."
  ]
  edge [
    source 3
    target 46
    int "The serum concentration of Tacrolimus can be increased when it is combined with Itraconazole."
  ]
  edge [
    source 3
    target 50
    int "The metabolism of Docetaxel can be decreased when combined with Itraconazole."
  ]
  edge [
    source 3
    target 174
    int "The metabolism of Sertraline can be decreased when combined with Itraconazole."
  ]
  edge [
    source 3
    target 235
    int "The serum concentration of Itraconazole can be decreased when it is combined with Lansoprazole."
  ]
  edge [
    source 3
    target 84
    int "The metabolism of Trimethoprim can be decreased when combined with Itraconazole."
  ]
  edge [
    source 3
    target 85
    int "The serum concentration of Digitoxin can be increased when it is combined with Itraconazole."
  ]
  edge [
    source 3
    target 101
    int "The metabolism of Zaleplon can be decreased when combined with Itraconazole."
  ]
  edge [
    source 3
    target 41
    int "The metabolism of Citalopram can be decreased when combined with Itraconazole."
  ]
  edge [
    source 3
    target 147
    int "The metabolism of Metronidazole can be decreased when combined with Itraconazole."
  ]
  edge [
    source 3
    target 6
    int "The metabolism of Tamoxifen can be decreased when combined with Itraconazole."
  ]
  edge [
    source 3
    target 140
    int "The metabolism of Tinidazole can be decreased when combined with Itraconazole."
  ]
  edge [
    source 3
    target 152
    int "The serum concentration of Itraconazole can be decreased when it is combined with Efavirenz."
  ]
  edge [
    source 3
    target 153
    int "The metabolism of Testosterone can be decreased when combined with Itraconazole."
  ]
  edge [
    source 3
    target 155
    int "The serum concentration of Bortezomib can be increased when it is combined with Itraconazole."
  ]
  edge [
    source 3
    target 159
    int "The metabolism of Cevimeline can be decreased when combined with Itraconazole."
  ]
  edge [
    source 3
    target 175
    int "The serum concentration of Maraviroc can be increased when it is combined with Itraconazole."
  ]
  edge [
    source 3
    target 176
    int "The metabolism of Cytarabine can be decreased when combined with Itraconazole."
  ]
  edge [
    source 3
    target 42
    int "The serum concentration of Ramelteon can be increased when it is combined with Itraconazole."
  ]
  edge [
    source 3
    target 180
    int "The metabolism of Disulfiram can be decreased when combined with Itraconazole."
  ]
  edge [
    source 3
    target 48
    int "The metabolism of Gefitinib can be decreased when combined with Itraconazole."
  ]
  edge [
    source 3
    target 240
    int "The serum concentration of Itraconazole can be decreased when it is combined with Primidone."
  ]
  edge [
    source 3
    target 246
    int "The serum concentration of Itraconazole can be decreased when it is combined with Bosentan."
  ]
  edge [
    source 3
    target 72
    int "Itraconazole may increase the QTc-prolonging activities of Tetrabenazine."
  ]
  edge [
    source 3
    target 234
    int "The therapeutic efficacy of Itraconazole can be increased when used in combination with Lamotrigine."
  ]
  edge [
    source 3
    target 5
    int "The metabolism of Galantamine can be decreased when combined with Itraconazole."
  ]
  edge [
    source 3
    target 49
    int "The metabolism of Itraconazole can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 3
    target 89
    int "The metabolism of Praziquantel can be decreased when combined with Itraconazole."
  ]
  edge [
    source 3
    target 104
    int "The serum concentration of Itraconazole can be decreased when it is combined with Nizatidine."
  ]
  edge [
    source 3
    target 113
    int "The metabolism of Imipramine can be decreased when combined with Itraconazole."
  ]
  edge [
    source 3
    target 117
    int "The metabolism of Albendazole can be decreased when combined with Itraconazole."
  ]
  edge [
    source 3
    target 125
    int "The metabolism of Pentamidine can be decreased when combined with Itraconazole."
  ]
  edge [
    source 3
    target 133
    int "The metabolism of Risperidone can be decreased when combined with Itraconazole."
  ]
  edge [
    source 3
    target 135
    int "The serum concentration of Everolimus can be increased when it is combined with Itraconazole."
  ]
  edge [
    source 3
    target 136
    int "The serum concentration of Ulipristal can be increased when it is combined with Itraconazole."
  ]
  edge [
    source 3
    target 156
    int "The metabolism of Mefloquine can be decreased when combined with Itraconazole."
  ]
  edge [
    source 3
    target 160
    int "The metabolism of Chlorzoxazone can be decreased when combined with Itraconazole."
  ]
  edge [
    source 3
    target 102
    int "The serum concentration of Methylergometrine can be increased when it is combined with Itraconazole."
  ]
  edge [
    source 3
    target 163
    int "The serum concentration of Lacosamide can be increased when it is combined with Itraconazole."
  ]
  edge [
    source 3
    target 164
    int "The metabolism of Mebendazole can be decreased when combined with Itraconazole."
  ]
  edge [
    source 3
    target 166
    int "The serum concentration of Tolvaptan can be increased when it is combined with Itraconazole."
  ]
  edge [
    source 3
    target 169
    int "The serum concentration of Itraconazole can be decreased when it is combined with Asenapine."
  ]
  edge [
    source 3
    target 171
    int "The serum concentration of Itraconazole can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 3
    target 207
    int "The metabolism of Zonisamide can be decreased when combined with Itraconazole."
  ]
  edge [
    source 3
    target 173
    int "The metabolism of Tiagabine can be decreased when combined with Itraconazole."
  ]
  edge [
    source 3
    target 187
    int "The metabolism of Clofibrate can be decreased when combined with Itraconazole."
  ]
  edge [
    source 3
    target 33
    int "The metabolism of Chloroquine can be decreased when combined with Itraconazole."
  ]
  edge [
    source 3
    target 201
    int "The serum concentration of Aliskiren can be increased when it is combined with Itraconazole."
  ]
  edge [
    source 3
    target 35
    int "The serum concentration of Irinotecan can be increased when it is combined with Itraconazole."
  ]
  edge [
    source 3
    target 212
    int "The metabolism of Loperamide can be decreased when combined with Itraconazole."
  ]
  edge [
    source 3
    target 124
    int "The serum concentration of Pazopanib can be increased when it is combined with Itraconazole."
  ]
  edge [
    source 3
    target 39
    int "The serum concentration of Cisapride can be increased when it is combined with Itraconazole."
  ]
  edge [
    source 3
    target 63
    int "The metabolism of Azithromycin can be decreased when combined with Itraconazole."
  ]
  edge [
    source 3
    target 20
    int "The metabolism of Quinine can be decreased when combined with Itraconazole."
  ]
  edge [
    source 3
    target 24
    int "The metabolism of Zafirlukast can be decreased when combined with Itraconazole."
  ]
  edge [
    source 3
    target 26
    int "The metabolism of Cinacalcet can be decreased when combined with Itraconazole."
  ]
  edge [
    source 3
    target 129
    int "The metabolism of Nateglinide can be decreased when combined with Itraconazole."
  ]
  edge [
    source 3
    target 200
    int "The metabolism of Zalcitabine can be decreased when combined with Itraconazole."
  ]
  edge [
    source 3
    target 21
    int "The serum concentration of Phenprocoumon can be increased when it is combined with Itraconazole."
  ]
  edge [
    source 3
    target 37
    int "The metabolism of Felbamate can be decreased when combined with Itraconazole."
  ]
  edge [
    source 3
    target 47
    int "The serum concentration of Prednisolone can be increased when it is combined with Itraconazole."
  ]
  edge [
    source 3
    target 90
    int "The serum concentration of Lumefantrine can be increased when it is combined with Itraconazole."
  ]
  edge [
    source 3
    target 115
    int "The metabolism of Sitagliptin can be decreased when combined with Itraconazole."
  ]
  edge [
    source 3
    target 118
    int "The metabolism of Sunitinib can be decreased when combined with Itraconazole."
  ]
  edge [
    source 3
    target 58
    int "Itraconazole may increase the QTc-prolonging activities of Ibutilide."
  ]
  edge [
    source 3
    target 138
    int "The metabolism of Theophylline can be decreased when combined with Itraconazole."
  ]
  edge [
    source 3
    target 165
    int "The metabolism of Pyrazinamide can be decreased when combined with Itraconazole."
  ]
  edge [
    source 3
    target 186
    int "The serum concentration of Dutasteride can be increased when it is combined with Itraconazole."
  ]
  edge [
    source 3
    target 188
    int "The serum concentration of Cerivastatin can be increased when it is combined with Itraconazole."
  ]
  edge [
    source 3
    target 191
    int "The metabolism of Trazodone can be decreased when combined with Itraconazole."
  ]
  edge [
    source 4
    target 123
    int "The risk or severity of adverse effects can be increased when Procarbazine is combined with Leflunomide."
  ]
  edge [
    source 4
    target 62
    int "The risk or severity of adverse effects can be increased when Procarbazine is combined with Tranylcypromine."
  ]
  edge [
    source 4
    target 67
    int "Furazolidone may increase the hypertensive activities of Procarbazine."
  ]
  edge [
    source 4
    target 95
    int "Procarbazine may increase the hypotensive activities of Olmesartan."
  ]
  edge [
    source 4
    target 195
    int "The risk or severity of adverse effects can be increased when Entacapone is combined with Procarbazine."
  ]
  edge [
    source 4
    target 197
    int "The risk or severity of adverse effects can be increased when Procarbazine is combined with Buspirone."
  ]
  edge [
    source 4
    target 194
    int "Pargyline may increase the hypertensive activities of Procarbazine."
  ]
  edge [
    source 4
    target 198
    int "Procarbazine may increase the hypoglycemic activities of Miglitol."
  ]
  edge [
    source 4
    target 118
    int "Procarbazine may increase the hypoglycemic activities of Sunitinib."
  ]
  edge [
    source 4
    target 219
    int "Procarbazine may increase the hypotensive activities of Nisoldipine."
  ]
  edge [
    source 4
    target 224
    int "The serum concentration of Sumatriptan can be increased when it is combined with Procarbazine."
  ]
  edge [
    source 4
    target 225
    int "Procarbazine may increase the hypertensive activities of Epinephrine."
  ]
  edge [
    source 4
    target 23
    int "Procarbazine may increase the hypotensive activities of Pinacidil."
  ]
  edge [
    source 4
    target 46
    int "Tacrolimus may increase the immunosuppressive activities of Procarbazine."
  ]
  edge [
    source 4
    target 50
    int "The risk or severity of adverse effects can be increased when Docetaxel is combined with Procarbazine."
  ]
  edge [
    source 4
    target 60
    int "The risk or severity of adverse effects can be increased when Procarbazine is combined with Isoprenaline."
  ]
  edge [
    source 4
    target 174
    int "The risk or severity of adverse effects can be increased when Sertraline is combined with Procarbazine."
  ]
  edge [
    source 4
    target 74
    int "Procarbazine may increase the hypoglycemic activities of Saxagliptin."
  ]
  edge [
    source 4
    target 81
    int "Procarbazine may increase the hypertensive activities of Doxapram."
  ]
  edge [
    source 4
    target 98
    int "The risk or severity of hypertension can be increased when Procarbazine is combined with Methyldopa."
  ]
  edge [
    source 4
    target 41
    int "The risk or severity of adverse effects can be increased when Citalopram is combined with Procarbazine."
  ]
  edge [
    source 4
    target 218
    int "Altretamine may increase the orthostatic hypotensive activities of Procarbazine."
  ]
  edge [
    source 4
    target 168
    int "Procarbazine may increase the hypotensive activities of Atenolol."
  ]
  edge [
    source 4
    target 228
    int "Procarbazine may increase the hypotensive activities of Bretylium."
  ]
  edge [
    source 4
    target 170
    int "Procarbazine may increase the hypoglycemic activities of Metformin."
  ]
  edge [
    source 4
    target 237
    int "Procarbazine may increase the hypoglycemic activities of Rosiglitazone."
  ]
  edge [
    source 4
    target 241
    int "Procarbazine may increase the hypotensive activities of Tolazoline."
  ]
  edge [
    source 4
    target 246
    int "Procarbazine may increase the hypotensive activities of Bosentan."
  ]
  edge [
    source 4
    target 234
    int "The risk or severity of adverse effects can be increased when Procarbazine is combined with Lamotrigine."
  ]
  edge [
    source 4
    target 49
    int "The risk or severity of adverse effects can be increased when Fluvoxamine is combined with Procarbazine."
  ]
  edge [
    source 4
    target 180
    int "The risk or severity of convulsion can be increased when Procarbazine is combined with Disulfiram."
  ]
  edge [
    source 4
    target 97
    int "Procarbazine may increase the hypotensive activities of Diazoxide."
  ]
  edge [
    source 4
    target 93
    int "Procarbazine may increase the hypotensive activities of Hydralazine."
  ]
  edge [
    source 4
    target 113
    int "Procarbazine may increase the serotonergic activities of Imipramine."
  ]
  edge [
    source 4
    target 125
    int "Procarbazine may increase the hypoglycemic activities of Pentamidine."
  ]
  edge [
    source 4
    target 129
    int "Procarbazine may increase the hypoglycemic activities of Nateglinide."
  ]
  edge [
    source 4
    target 133
    int "The risk or severity of adverse effects can be increased when Procarbazine is combined with Risperidone."
  ]
  edge [
    source 4
    target 196
    int "The metabolism of Dihydroergotamine can be decreased when combined with Procarbazine."
  ]
  edge [
    source 4
    target 161
    int "Procarbazine may increase the hypotensive activities of Minoxidil."
  ]
  edge [
    source 4
    target 169
    int "The risk or severity of adverse effects can be increased when Procarbazine is combined with Asenapine."
  ]
  edge [
    source 4
    target 30
    int "Procarbazine may increase the serotonergic activities of Amoxapine."
  ]
  edge [
    source 4
    target 31
    int "Procarbazine may increase the hypotensive activities of Metyrosine."
  ]
  edge [
    source 4
    target 201
    int "Procarbazine may increase the hypotensive activities of Aliskiren."
  ]
  edge [
    source 4
    target 206
    int "The risk or severity of adverse effects can be increased when Procarbazine is combined with Aripiprazole."
  ]
  edge [
    source 4
    target 208
    int "The risk or severity of adverse effects can be increased when Procarbazine is combined with Trifluoperazine."
  ]
  edge [
    source 4
    target 85
    int "Digitoxin may decrease the cardiotoxic activities of Procarbazine."
  ]
  edge [
    source 4
    target 20
    int "Procarbazine may increase the hypoglycemic activities of Quinine."
  ]
  edge [
    source 4
    target 32
    int "Procarbazine may increase the hypotensive activities of Guanadrel."
  ]
  edge [
    source 4
    target 56
    int "Procarbazine may increase the hypotensive activities of Enalaprilat."
  ]
  edge [
    source 4
    target 72
    int "The risk or severity of adverse effects can be increased when Procarbazine is combined with Tetrabenazine."
  ]
  edge [
    source 4
    target 73
    int "Procarbazine may increase the hypoglycemic activities of Acarbose."
  ]
  edge [
    source 4
    target 115
    int "Procarbazine may increase the hypoglycemic activities of Sitagliptin."
  ]
  edge [
    source 4
    target 150
    int "The risk or severity of adverse effects can be increased when Procarbazine is combined with Lithium."
  ]
  edge [
    source 4
    target 119
    int "The risk or severity of adverse effects can be increased when Procarbazine is combined with Triflupromazine."
  ]
  edge [
    source 4
    target 191
    int "Procarbazine may increase the serotonergic activities of Trazodone."
  ]
  edge [
    source 4
    target 192
    int "Procarbazine may increase the hypotensive activities of Mecamylamine."
  ]
  edge [
    source 4
    target 202
    int "The risk or severity of adverse effects can be increased when Procarbazine is combined with Maprotiline."
  ]
  edge [
    source 5
    target 90
    int "Galantamine may increase the QTc-prolonging activities of Lumefantrine."
  ]
  edge [
    source 5
    target 61
    int "The metabolism of Galantamine can be decreased when combined with Imatinib."
  ]
  edge [
    source 5
    target 62
    int "The metabolism of Galantamine can be decreased when combined with Tranylcypromine."
  ]
  edge [
    source 5
    target 249
    int "The therapeutic efficacy of Galantamine can be decreased when used in combination with Dipyridamole."
  ]
  edge [
    source 5
    target 167
    int "The metabolism of Galantamine can be decreased when combined with Sildenafil."
  ]
  edge [
    source 5
    target 71
    int "The serum concentration of Succinylcholine can be increased when it is combined with Galantamine."
  ]
  edge [
    source 5
    target 88
    int "The therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Galantamine."
  ]
  edge [
    source 5
    target 110
    int "Galantamine may increase the QTc-prolonging activities of Dronedarone."
  ]
  edge [
    source 5
    target 137
    int "Galantamine may increase the QTc-prolonging activities of Artemether."
  ]
  edge [
    source 5
    target 196
    int "The metabolism of Galantamine can be decreased when combined with Dihydroergotamine."
  ]
  edge [
    source 5
    target 217
    int "The risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Galantamine."
  ]
  edge [
    source 5
    target 47
    int "The risk or severity of adverse effects can be increased when Prednisolone is combined with Galantamine."
  ]
  edge [
    source 5
    target 174
    int "The metabolism of Galantamine can be decreased when combined with Sertraline."
  ]
  edge [
    source 5
    target 98
    int "Galantamine may increase the bradycardic activities of Methyldopa."
  ]
  edge [
    source 5
    target 99
    int "The therapeutic efficacy of Oxyphenonium can be decreased when used in combination with Galantamine."
  ]
  edge [
    source 5
    target 41
    int "The metabolism of Galantamine can be decreased when combined with Citalopram."
  ]
  edge [
    source 5
    target 63
    int "Galantamine may increase the QTc-prolonging activities of Azithromycin."
  ]
  edge [
    source 5
    target 155
    int "The metabolism of Galantamine can be decreased when combined with Bortezomib."
  ]
  edge [
    source 5
    target 159
    int "The risk or severity of adverse effects can be increased when Galantamine is combined with Cevimeline."
  ]
  edge [
    source 5
    target 68
    int "The metabolism of Galantamine can be increased when combined with Rifabutin."
  ]
  edge [
    source 5
    target 244
    int "The metabolism of Galantamine can be decreased when combined with Ranolazine."
  ]
  edge [
    source 5
    target 216
    int "The therapeutic efficacy of Vecuronium can be decreased when used in combination with Galantamine."
  ]
  edge [
    source 5
    target 228
    int "Bretylium may increase the bradycardic activities of Galantamine."
  ]
  edge [
    source 5
    target 239
    int "The risk or severity of adverse effects can be increased when Galantamine is combined with Carbachol."
  ]
  edge [
    source 5
    target 240
    int "The metabolism of Galantamine can be increased when combined with Primidone."
  ]
  edge [
    source 5
    target 246
    int "The serum concentration of Galantamine can be decreased when it is combined with Bosentan."
  ]
  edge [
    source 5
    target 8
    int "The serum concentration of Galantamine can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 5
    target 49
    int "The metabolism of Galantamine can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 5
    target 92
    int "The risk or severity of adverse effects can be increased when Galantamine is combined with Varenicline."
  ]
  edge [
    source 5
    target 113
    int "The metabolism of Galantamine can be decreased when combined with Imipramine."
  ]
  edge [
    source 5
    target 125
    int "Galantamine may increase the QTc-prolonging activities of Pentamidine."
  ]
  edge [
    source 5
    target 163
    int "Galantamine may increase the atrioventricular blocking (AV block) activities of Lacosamide."
  ]
  edge [
    source 5
    target 169
    int "Galantamine may increase the QTc-prolonging activities of Asenapine."
  ]
  edge [
    source 5
    target 171
    int "The serum concentration of Galantamine can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 5
    target 184
    int "Dexmedetomidine may increase the bradycardic activities of Galantamine."
  ]
  edge [
    source 5
    target 124
    int "Galantamine may increase the QTc-prolonging activities of Pazopanib."
  ]
  edge [
    source 5
    target 39
    int "Galantamine may increase the QTc-prolonging activities of Cisapride."
  ]
  edge [
    source 5
    target 20
    int "Galantamine may increase the QTc-prolonging activities of Quinine."
  ]
  edge [
    source 5
    target 26
    int "The metabolism of Galantamine can be decreased when combined with Cinacalcet."
  ]
  edge [
    source 5
    target 33
    int "The metabolism of Galantamine can be decreased when combined with Chloroquine."
  ]
  edge [
    source 5
    target 72
    int "Galantamine may increase the QTc-prolonging activities of Tetrabenazine."
  ]
  edge [
    source 5
    target 58
    int "Galantamine may increase the QTc-prolonging activities of Ibutilide."
  ]
  edge [
    source 5
    target 168
    int "Galantamine may increase the bradycardic activities of Atenolol."
  ]
  edge [
    source 5
    target 192
    int "The therapeutic efficacy of Mecamylamine can be decreased when used in combination with Galantamine."
  ]
  edge [
    source 6
    target 157
    int "The metabolism of Tamoxifen can be decreased when combined with Armodafinil."
  ]
  edge [
    source 6
    target 123
    int "The metabolism of Tamoxifen can be decreased when combined with Leflunomide."
  ]
  edge [
    source 6
    target 61
    int "The metabolism of Tamoxifen can be decreased when combined with Imatinib."
  ]
  edge [
    source 6
    target 62
    int "The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Tranylcypromine resulting in a loss in efficacy."
  ]
  edge [
    source 6
    target 63
    int "The metabolism of Tamoxifen can be decreased when combined with Azithromycin."
  ]
  edge [
    source 6
    target 64
    int "The metabolism of Tamoxifen can be decreased when combined with Clopidogrel."
  ]
  edge [
    source 6
    target 167
    int "The metabolism of Tamoxifen can be decreased when combined with Sildenafil."
  ]
  edge [
    source 6
    target 68
    int "The metabolism of Tamoxifen can be increased when combined with Rifabutin."
  ]
  edge [
    source 6
    target 75
    int "The serum concentration of Tamoxifen can be decreased when it is combined with Teriflunomide."
  ]
  edge [
    source 6
    target 91
    int "The metabolism of Tamoxifen can be decreased when combined with Topiramate."
  ]
  edge [
    source 6
    target 138
    int "The metabolism of Tamoxifen can be decreased when combined with Theophylline."
  ]
  edge [
    source 6
    target 110
    int "The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Dronedarone resulting in a loss in efficacy."
  ]
  edge [
    source 6
    target 137
    int "The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Artemether resulting in a loss in efficacy."
  ]
  edge [
    source 6
    target 141
    int "The metabolism of Tamoxifen can be decreased when combined with Doxorubicin."
  ]
  edge [
    source 6
    target 144
    int "The serum concentration of Anastrozole can be decreased when it is combined with Tamoxifen."
  ]
  edge [
    source 6
    target 149
    int "The metabolism of Halofantrine can be decreased when combined with Tamoxifen."
  ]
  edge [
    source 6
    target 182
    int "The metabolism of Mephenytoin can be decreased when combined with Tamoxifen."
  ]
  edge [
    source 6
    target 196
    int "The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Tamoxifen."
  ]
  edge [
    source 6
    target 220
    int "The metabolism of Sulfinpyrazone can be decreased when combined with Tamoxifen."
  ]
  edge [
    source 6
    target 232
    int "The metabolism of Tamoxifen can be decreased when combined with Sorafenib."
  ]
  edge [
    source 6
    target 50
    int "The risk or severity of adverse effects can be increased when Docetaxel is combined with Tamoxifen."
  ]
  edge [
    source 6
    target 174
    int "The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Sertraline resulting in a loss in efficacy."
  ]
  edge [
    source 6
    target 74
    int "The serum concentration of Saxagliptin can be decreased when it is combined with Tamoxifen."
  ]
  edge [
    source 6
    target 235
    int "The metabolism of Lansoprazole can be decreased when combined with Tamoxifen."
  ]
  edge [
    source 6
    target 84
    int "The metabolism of Tamoxifen can be decreased when combined with Trimethoprim."
  ]
  edge [
    source 6
    target 41
    int "The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Citalopram resulting in a loss in efficacy."
  ]
  edge [
    source 6
    target 152
    int "The metabolism of Tamoxifen can be decreased when combined with Efavirenz."
  ]
  edge [
    source 6
    target 153
    int "The metabolism of Testosterone can be decreased when combined with Tamoxifen."
  ]
  edge [
    source 6
    target 155
    int "The metabolism of Tamoxifen can be decreased when combined with Bortezomib."
  ]
  edge [
    source 6
    target 66
    int "The metabolism of Amodiaquine can be decreased when combined with Tamoxifen."
  ]
  edge [
    source 6
    target 244
    int "The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Ranolazine resulting in a loss in efficacy."
  ]
  edge [
    source 6
    target 94
    int "The metabolism of Tamoxifen can be decreased when combined with Valproic Acid."
  ]
  edge [
    source 6
    target 240
    int "The metabolism of Tamoxifen can be increased when combined with Primidone."
  ]
  edge [
    source 6
    target 246
    int "The serum concentration of Tamoxifen can be decreased when it is combined with Bosentan."
  ]
  edge [
    source 6
    target 8
    int "The serum concentration of Tamoxifen can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 6
    target 154
    int "The metabolism of Amprenavir can be decreased when combined with Tamoxifen."
  ]
  edge [
    source 6
    target 49
    int "The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Fluvoxamine resulting in a loss in efficacy."
  ]
  edge [
    source 6
    target 125
    int "The metabolism of Pentamidine can be decreased when combined with Tamoxifen."
  ]
  edge [
    source 6
    target 135
    int "The serum concentration of Everolimus can be increased when it is combined with Tamoxifen."
  ]
  edge [
    source 6
    target 102
    int "The risk or severity of adverse effects can be increased when Methylergometrine is combined with Tamoxifen."
  ]
  edge [
    source 6
    target 166
    int "The serum concentration of Tolvaptan can be increased when it is combined with Tamoxifen."
  ]
  edge [
    source 6
    target 169
    int "Tamoxifen may increase the QTc-prolonging activities of Asenapine."
  ]
  edge [
    source 6
    target 171
    int "The serum concentration of Tamoxifen can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 6
    target 206
    int "The serum concentration of Aripiprazole can be decreased when it is combined with Tamoxifen."
  ]
  edge [
    source 6
    target 212
    int "The metabolism of Loperamide can be decreased when combined with Tamoxifen."
  ]
  edge [
    source 6
    target 124
    int "The serum concentration of Pazopanib can be increased when it is combined with Tamoxifen."
  ]
  edge [
    source 6
    target 85
    int "Digitoxin may decrease the cardiotoxic activities of Tamoxifen."
  ]
  edge [
    source 6
    target 39
    int "Tamoxifen may increase the QTc-prolonging activities of Cisapride."
  ]
  edge [
    source 6
    target 20
    int "The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Quinine resulting in a loss in efficacy."
  ]
  edge [
    source 6
    target 24
    int "The metabolism of Tamoxifen can be decreased when combined with Zafirlukast."
  ]
  edge [
    source 6
    target 26
    int "The serum concentration of Tamoxifen can be increased when it is combined with Cinacalcet."
  ]
  edge [
    source 6
    target 27
    int "The metabolism of Tamoxifen can be decreased when combined with Fluorouracil."
  ]
  edge [
    source 6
    target 33
    int "The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Chloroquine resulting in a loss in efficacy."
  ]
  edge [
    source 6
    target 21
    int "Tamoxifen may increase the anticoagulant activities of Phenprocoumon."
  ]
  edge [
    source 6
    target 72
    int "Tamoxifen may increase the QTc-prolonging activities of Tetrabenazine."
  ]
  edge [
    source 6
    target 90
    int "The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Lumefantrine resulting in a loss in efficacy."
  ]
  edge [
    source 6
    target 115
    int "The metabolism of Sitagliptin can be decreased when combined with Tamoxifen."
  ]
  edge [
    source 6
    target 58
    int "Tamoxifen may increase the QTc-prolonging activities of Ibutilide."
  ]
  edge [
    source 6
    target 237
    int "The metabolism of Rosiglitazone can be decreased when combined with Tamoxifen."
  ]
  edge [
    source 6
    target 188
    int "The serum concentration of Cerivastatin can be increased when it is combined with Tamoxifen."
  ]
  edge [
    source 6
    target 113
    int "The serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Imipramine resulting in a loss in efficacy."
  ]
  edge [
    source 7
    target 21
    int "Eptifibatide may increase the anticoagulant activities of Phenprocoumon."
  ]
  edge [
    source 7
    target 45
    int "Eptifibatide may increase the anticoagulant activities of Iloprost."
  ]
  edge [
    source 7
    target 249
    int "Eptifibatide may increase the anticoagulant activities of Dipyridamole."
  ]
  edge [
    source 7
    target 64
    int "Eptifibatide may increase the anticoagulant activities of Clopidogrel."
  ]
  edge [
    source 7
    target 86
    int "Eptifibatide may increase the anticoagulant activities of Argatroban."
  ]
  edge [
    source 7
    target 22
    int "Milrinone may increase the anticoagulant activities of Eptifibatide."
  ]
  edge [
    source 7
    target 189
    int "The risk or severity of adverse effects can be increased when Eptifibatide is combined with Aminosalicylic Acid."
  ]
  edge [
    source 7
    target 237
    int "Eptifibatide may increase the anticoagulant activities of Rosiglitazone."
  ]
  edge [
    source 7
    target 247
    int "The risk or severity of adverse effects can be increased when Eptifibatide is combined with Mesalazine."
  ]
  edge [
    source 8
    target 157
    int "The metabolism of Aprepitant can be decreased when combined with Armodafinil."
  ]
  edge [
    source 8
    target 123
    int "The metabolism of Leflunomide can be increased when combined with Aprepitant."
  ]
  edge [
    source 8
    target 53
    int "The serum concentration of Vinblastine can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 54
    int "The serum concentration of Busulfan can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 61
    int "The serum concentration of Imatinib can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 62
    int "The metabolism of Aprepitant can be decreased when combined with Tranylcypromine."
  ]
  edge [
    source 8
    target 76
    int "The serum concentration of Tetracycline can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 64
    int "The serum concentration of Clopidogrel can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 167
    int "The serum concentration of Sildenafil can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 68
    int "The serum concentration of Rifabutin can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 75
    int "The serum concentration of Aprepitant can be decreased when it is combined with Teriflunomide."
  ]
  edge [
    source 8
    target 86
    int "The serum concentration of Argatroban can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 91
    int "The metabolism of Aprepitant can be decreased when combined with Topiramate."
  ]
  edge [
    source 8
    target 103
    int "The serum concentration of Zileuton can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 110
    int "The serum concentration of Dronedarone can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 137
    int "The serum concentration of Artemether can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 141
    int "The serum concentration of Doxorubicin can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 148
    int "The serum concentration of Dantrolene can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 149
    int "The serum concentration of Halofantrine can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 74
    int "The serum concentration of Saxagliptin can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 154
    int "The serum concentration of Amprenavir can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 197
    int "The serum concentration of Buspirone can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 182
    int "The metabolism of Mephenytoin can be increased when combined with Aprepitant."
  ]
  edge [
    source 8
    target 193
    int "The serum concentration of Flutamide can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 196
    int "The serum concentration of Dihydroergotamine can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 214
    int "The serum concentration of Proguanil can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 217
    int "The serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 219
    int "The serum concentration of Nisoldipine can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 220
    int "The serum concentration of Sulfinpyrazone can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 122
    int "The serum concentration of Levonorgestrel can be decreased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 232
    int "The serum concentration of Sorafenib can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 206
    int "The serum concentration of Aripiprazole can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 244
    int "The serum concentration of Ranolazine can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 23
    int "The serum concentration of Pinacidil can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 65
    int "The serum concentration of Ethinyl Estradiol can be decreased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 46
    int "The serum concentration of Tacrolimus can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 50
    int "The serum concentration of Docetaxel can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 174
    int "The serum concentration of Sertraline can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 235
    int "The serum concentration of Lansoprazole can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 84
    int "The serum concentration of Trimethoprim can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 101
    int "The serum concentration of Zaleplon can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 41
    int "The serum concentration of Citalopram can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 230
    int "The serum concentration of Isosorbide Dinitrate can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 121
    int "The metabolism of Niclosamide can be increased when combined with Aprepitant."
  ]
  edge [
    source 8
    target 147
    int "The serum concentration of Metronidazole can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 140
    int "The serum concentration of Tinidazole can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 152
    int "The serum concentration of Efavirenz can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 153
    int "The serum concentration of Testosterone can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 155
    int "The serum concentration of Bortezomib can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 159
    int "The serum concentration of Cevimeline can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 175
    int "The serum concentration of Maraviroc can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 176
    int "The serum concentration of Cytarabine can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 42
    int "The serum concentration of Ramelteon can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 180
    int "The serum concentration of Disulfiram can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 181
    int "The metabolism of Dopamine can be increased when combined with Aprepitant."
  ]
  edge [
    source 8
    target 94
    int "The metabolism of Valproic Acid can be increased when combined with Aprepitant."
  ]
  edge [
    source 8
    target 48
    int "The serum concentration of Gefitinib can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 237
    int "The metabolism of Rosiglitazone can be increased when combined with Aprepitant."
  ]
  edge [
    source 8
    target 240
    int "The metabolism of Aprepitant can be increased when combined with Primidone."
  ]
  edge [
    source 8
    target 246
    int "The serum concentration of Bosentan can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 49
    int "The metabolism of Aprepitant can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 8
    target 188
    int "The serum concentration of Cerivastatin can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 89
    int "The serum concentration of Praziquantel can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 113
    int "The serum concentration of Imipramine can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 117
    int "The serum concentration of Albendazole can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 125
    int "The serum concentration of Pentamidine can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 133
    int "The serum concentration of Risperidone can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 135
    int "The serum concentration of Everolimus can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 136
    int "The serum concentration of Ulipristal can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 156
    int "The serum concentration of Mefloquine can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 160
    int "The serum concentration of Chlorzoxazone can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 164
    int "The serum concentration of Mebendazole can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 166
    int "The serum concentration of Tolvaptan can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 169
    int "The serum concentration of Asenapine can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 171
    int "The serum concentration of Aprepitant can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 8
    target 207
    int "The serum concentration of Zonisamide can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 173
    int "The serum concentration of Tiagabine can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 187
    int "The serum concentration of Clofibrate can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 33
    int "The serum concentration of Chloroquine can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 201
    int "The serum concentration of Aliskiren can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 35
    int "The serum concentration of Irinotecan can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 212
    int "The serum concentration of Loperamide can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 124
    int "The serum concentration of Pazopanib can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 85
    int "The serum concentration of Digitoxin can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 39
    int "The serum concentration of Cisapride can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 63
    int "The serum concentration of Azithromycin can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 20
    int "The serum concentration of Quinine can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 24
    int "The serum concentration of Zafirlukast can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 26
    int "The serum concentration of Cinacalcet can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 129
    int "The serum concentration of Nateglinide can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 200
    int "The serum concentration of Zalcitabine can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 21
    int "The serum concentration of Phenprocoumon can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 37
    int "The serum concentration of Felbamate can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 47
    int "The serum concentration of Prednisolone can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 90
    int "The serum concentration of Lumefantrine can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 115
    int "The serum concentration of Sitagliptin can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 118
    int "The serum concentration of Sunitinib can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 43
    int "The metabolism of Thalidomide can be increased when combined with Aprepitant."
  ]
  edge [
    source 8
    target 138
    int "The serum concentration of Theophylline can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 165
    int "The serum concentration of Pyrazinamide can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 186
    int "The serum concentration of Dutasteride can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 8
    target 191
    int "The serum concentration of Trazodone can be increased when it is combined with Aprepitant."
  ]
  edge [
    source 9
    target 200
    int "Ribavirin may increase the hepatotoxic activities of Zalcitabine."
  ]
  edge [
    source 9
    target 127
    int "Ribavirin may increase the hepatotoxic activities of Abacavir."
  ]
  edge [
    source 10
    target 85
    int "Digitoxin may decrease the cardiotoxic activities of Afimoxifene."
  ]
  edge [
    source 10
    target 50
    int "The risk or severity of adverse effects can be increased when Docetaxel is combined with Afimoxifene."
  ]
  edge [
    source 11
    target 12
    int "The risk or severity of adverse effects can be increased when Triamterene is combined with Diclofenamide."
  ]
  edge [
    source 11
    target 13
    int "The risk or severity of adverse effects can be increased when Acetazolamide is combined with Diclofenamide."
  ]
  edge [
    source 11
    target 45
    int "The risk or severity of adverse effects can be increased when Iloprost is combined with Diclofenamide."
  ]
  edge [
    source 11
    target 132
    int "Diclofenamide may decrease the excretion rate of Memantine which could result in a higher serum level."
  ]
  edge [
    source 11
    target 219
    int "The risk or severity of adverse effects can be increased when Nisoldipine is combined with Diclofenamide."
  ]
  edge [
    source 11
    target 133
    int "Diclofenamide may increase the hypotensive activities of Risperidone."
  ]
  edge [
    source 11
    target 56
    int "The risk or severity of adverse effects can be increased when Enalaprilat is combined with Diclofenamide."
  ]
  edge [
    source 11
    target 70
    int "The risk or severity of adverse effects can be increased when Amiloride is combined with Diclofenamide."
  ]
  edge [
    source 11
    target 93
    int "The risk or severity of adverse effects can be increased when Diclofenamide is combined with Hydralazine."
  ]
  edge [
    source 11
    target 95
    int "The risk or severity of adverse effects can be increased when Olmesartan is combined with Diclofenamide."
  ]
  edge [
    source 11
    target 98
    int "The risk or severity of adverse effects can be increased when Methyldopa is combined with Diclofenamide."
  ]
  edge [
    source 11
    target 150
    int "The serum concentration of Lithium can be decreased when it is combined with Diclofenamide."
  ]
  edge [
    source 11
    target 43
    int "The risk or severity of adverse effects can be increased when Thalidomide is combined with Diclofenamide."
  ]
  edge [
    source 11
    target 62
    int "The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Diclofenamide."
  ]
  edge [
    source 11
    target 192
    int "The risk or severity of adverse effects can be increased when Diclofenamide is combined with Mecamylamine."
  ]
  edge [
    source 11
    target 249
    int "The risk or severity of adverse effects can be increased when Dipyridamole is combined with Diclofenamide."
  ]
  edge [
    source 11
    target 155
    int "The risk or severity of adverse effects can be increased when Bortezomib is combined with Diclofenamide."
  ]
  edge [
    source 11
    target 161
    int "The risk or severity of adverse effects can be increased when Minoxidil is combined with Diclofenamide."
  ]
  edge [
    source 11
    target 162
    int "The risk or severity of adverse effects can be increased when Spironolactone is combined with Diclofenamide."
  ]
  edge [
    source 11
    target 168
    int "The risk or severity of adverse effects can be increased when Atenolol is combined with Diclofenamide."
  ]
  edge [
    source 11
    target 113
    int "The risk or severity of adverse effects can be increased when Imipramine is combined with Diclofenamide."
  ]
  edge [
    source 11
    target 170
    int "The risk or severity of adverse effects can be increased when Diclofenamide is combined with Metformin."
  ]
  edge [
    source 11
    target 184
    int "The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Diclofenamide."
  ]
  edge [
    source 11
    target 87
    int "The risk or severity of adverse effects can be increased when Clofarabine is combined with Diclofenamide."
  ]
  edge [
    source 11
    target 201
    int "The risk or severity of adverse effects can be increased when Diclofenamide is combined with Aliskiren."
  ]
  edge [
    source 11
    target 206
    int "Aripiprazole may increase the hypotensive activities of Diclofenamide."
  ]
  edge [
    source 11
    target 215
    int "The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Diclofenamide."
  ]
  edge [
    source 11
    target 189
    int "The risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Diclofenamide."
  ]
  edge [
    source 11
    target 226
    int "The risk or severity of adverse effects can be increased when Bumetanide is combined with Diclofenamide."
  ]
  edge [
    source 11
    target 228
    int "The risk or severity of adverse effects can be increased when Diclofenamide is combined with Bretylium."
  ]
  edge [
    source 11
    target 230
    int "The risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Diclofenamide."
  ]
  edge [
    source 11
    target 238
    int "The risk or severity of adverse effects can be increased when Pramipexole is combined with Diclofenamide."
  ]
  edge [
    source 11
    target 240
    int "The risk or severity of adverse effects can be increased when Diclofenamide is combined with Primidone."
  ]
  edge [
    source 11
    target 241
    int "The risk or severity of adverse effects can be increased when Tolazoline is combined with Diclofenamide."
  ]
  edge [
    source 11
    target 247
    int "The risk or severity of adverse effects can be increased when Mesalazine is combined with Diclofenamide."
  ]
  edge [
    source 12
    target 123
    int "Leflunomide may decrease the antihypertensive activities of Triamterene."
  ]
  edge [
    source 12
    target 19
    int "Fenoprofen may decrease the antihypertensive activities of Triamterene."
  ]
  edge [
    source 12
    target 62
    int "The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Triamterene."
  ]
  edge [
    source 12
    target 249
    int "The risk or severity of adverse effects can be increased when Triamterene is combined with Dipyridamole."
  ]
  edge [
    source 12
    target 103
    int "Zileuton may decrease the antihypertensive activities of Triamterene."
  ]
  edge [
    source 12
    target 95
    int "Olmesartan may increase the hyperkalemic activities of Triamterene."
  ]
  edge [
    source 12
    target 219
    int "The risk or severity of adverse effects can be increased when Triamterene is combined with Nisoldipine."
  ]
  edge [
    source 12
    target 226
    int "The risk or severity of adverse effects can be increased when Triamterene is combined with Bumetanide."
  ]
  edge [
    source 12
    target 230
    int "The risk or severity of adverse effects can be increased when Triamterene is combined with Isosorbide Dinitrate."
  ]
  edge [
    source 12
    target 247
    int "Mesalazine may decrease the antihypertensive activities of Triamterene."
  ]
  edge [
    source 12
    target 45
    int "The risk or severity of adverse effects can be increased when Iloprost is combined with Triamterene."
  ]
  edge [
    source 12
    target 46
    int "The risk or severity of hyperkalemia can be increased when Triamterene is combined with Tacrolimus."
  ]
  edge [
    source 12
    target 70
    int "The risk or severity of adverse effects can be increased when Triamterene is combined with Amiloride."
  ]
  edge [
    source 12
    target 98
    int "The risk or severity of adverse effects can be increased when Triamterene is combined with Methyldopa."
  ]
  edge [
    source 12
    target 41
    int "The metabolism of Triamterene can be decreased when combined with Citalopram."
  ]
  edge [
    source 12
    target 63
    int "The metabolism of Triamterene can be decreased when combined with Azithromycin."
  ]
  edge [
    source 12
    target 155
    int "The metabolism of Triamterene can be decreased when combined with Bortezomib."
  ]
  edge [
    source 12
    target 75
    int "The serum concentration of Triamterene can be decreased when it is combined with Teriflunomide."
  ]
  edge [
    source 12
    target 168
    int "The risk or severity of adverse effects can be increased when Atenolol is combined with Triamterene."
  ]
  edge [
    source 12
    target 228
    int "The risk or severity of adverse effects can be increased when Triamterene is combined with Bretylium."
  ]
  edge [
    source 12
    target 238
    int "The risk or severity of adverse effects can be increased when Pramipexole is combined with Triamterene."
  ]
  edge [
    source 12
    target 240
    int "Primidone may increase the hypotensive activities of Triamterene."
  ]
  edge [
    source 12
    target 241
    int "The risk or severity of adverse effects can be increased when Tolazoline is combined with Triamterene."
  ]
  edge [
    source 12
    target 138
    int "The metabolism of Triamterene can be decreased when combined with Theophylline."
  ]
  edge [
    source 12
    target 49
    int "The metabolism of Triamterene can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 12
    target 93
    int "The risk or severity of adverse effects can be increased when Triamterene is combined with Hydralazine."
  ]
  edge [
    source 12
    target 133
    int "Triamterene may increase the hypotensive activities of Risperidone."
  ]
  edge [
    source 12
    target 161
    int "The risk or severity of adverse effects can be increased when Minoxidil is combined with Triamterene."
  ]
  edge [
    source 12
    target 162
    int "Triamterene may increase the hyperkalemic activities of Spironolactone."
  ]
  edge [
    source 12
    target 166
    int "Tolvaptan may increase the hyperkalemic activities of Triamterene."
  ]
  edge [
    source 12
    target 38
    int "Mycophenolic acid may decrease the antihypertensive activities of Triamterene."
  ]
  edge [
    source 12
    target 113
    int "The risk or severity of adverse effects can be increased when Imipramine is combined with Triamterene."
  ]
  edge [
    source 12
    target 184
    int "The risk or severity of adverse effects can be increased when Triamterene is combined with Dexmedetomidine."
  ]
  edge [
    source 12
    target 87
    int "The risk or severity of adverse effects can be increased when Clofarabine is combined with Triamterene."
  ]
  edge [
    source 12
    target 204
    int "Oxyphenbutazone may decrease the antihypertensive activities of Triamterene."
  ]
  edge [
    source 12
    target 201
    int "The risk or severity of adverse effects can be increased when Triamterene is combined with Aliskiren."
  ]
  edge [
    source 12
    target 206
    int "Aripiprazole may increase the hypotensive activities of Triamterene."
  ]
  edge [
    source 12
    target 85
    int "The therapeutic efficacy of Digitoxin can be decreased when used in combination with Triamterene."
  ]
  edge [
    source 12
    target 33
    int "Chloroquine may decrease the antihypertensive activities of Triamterene."
  ]
  edge [
    source 12
    target 56
    int "Triamterene may increase the hyperkalemic activities of Enalaprilat."
  ]
  edge [
    source 12
    target 43
    int "The risk or severity of adverse effects can be increased when Thalidomide is combined with Triamterene."
  ]
  edge [
    source 12
    target 192
    int "The risk or severity of adverse effects can be increased when Triamterene is combined with Mecamylamine."
  ]
  edge [
    source 12
    target 199
    int "Meclofenamic acid may decrease the antihypertensive activities of Triamterene."
  ]
  edge [
    source 12
    target 215
    int "The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Triamterene."
  ]
  edge [
    source 13
    target 150
    int "The serum concentration of Lithium can be decreased when it is combined with Acetazolamide."
  ]
  edge [
    source 13
    target 132
    int "Acetazolamide may decrease the excretion rate of Memantine which could result in a higher serum level."
  ]
  edge [
    source 13
    target 156
    int "The therapeutic efficacy of Acetazolamide can be decreased when used in combination with Mefloquine."
  ]
  edge [
    source 13
    target 102
    int "The risk or severity of adverse effects can be increased when Methylergometrine is combined with Acetazolamide."
  ]
  edge [
    source 13
    target 166
    int "The serum concentration of Tolvaptan can be increased when it is combined with Acetazolamide."
  ]
  edge [
    source 13
    target 196
    int "The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Acetazolamide."
  ]
  edge [
    source 13
    target 170
    int "The risk or severity of adverse effects can be increased when Acetazolamide is combined with Metformin."
  ]
  edge [
    source 13
    target 188
    int "The serum concentration of Cerivastatin can be increased when it is combined with Acetazolamide."
  ]
  edge [
    source 13
    target 189
    int "The risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Acetazolamide."
  ]
  edge [
    source 13
    target 240
    int "The risk or severity of adverse effects can be increased when Acetazolamide is combined with Primidone."
  ]
  edge [
    source 13
    target 247
    int "The risk or severity of adverse effects can be increased when Mesalazine is combined with Acetazolamide."
  ]
  edge [
    source 14
    target 47
    int "The risk or severity of adverse effects can be increased when Prednisolone is combined with Tacrine."
  ]
  edge [
    source 14
    target 49
    int "The metabolism of Tacrine can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 14
    target 249
    int "The therapeutic efficacy of Tacrine can be decreased when used in combination with Dipyridamole."
  ]
  edge [
    source 14
    target 75
    int "The serum concentration of Tacrine can be decreased when it is combined with Teriflunomide."
  ]
  edge [
    source 14
    target 88
    int "The therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Tacrine."
  ]
  edge [
    source 14
    target 41
    int "The metabolism of Tacrine can be decreased when combined with Citalopram."
  ]
  edge [
    source 14
    target 138
    int "The metabolism of Tacrine can be decreased when combined with Theophylline."
  ]
  edge [
    source 14
    target 99
    int "The therapeutic efficacy of Oxyphenonium can be decreased when used in combination with Tacrine."
  ]
  edge [
    source 14
    target 135
    int "The serum concentration of Everolimus can be increased when it is combined with Tacrine."
  ]
  edge [
    source 14
    target 141
    int "The serum concentration of Doxorubicin can be increased when it is combined with Tacrine."
  ]
  edge [
    source 14
    target 155
    int "The metabolism of Tacrine can be decreased when combined with Bortezomib."
  ]
  edge [
    source 14
    target 159
    int "The risk or severity of adverse effects can be increased when Tacrine is combined with Cevimeline."
  ]
  edge [
    source 14
    target 168
    int "Tacrine may increase the bradycardic activities of Atenolol."
  ]
  edge [
    source 14
    target 169
    int "Tacrine may increase the bradycardic activities of Asenapine."
  ]
  edge [
    source 14
    target 71
    int "The serum concentration of Succinylcholine can be increased when it is combined with Tacrine."
  ]
  edge [
    source 14
    target 239
    int "The risk or severity of adverse effects can be increased when Tacrine is combined with Carbachol."
  ]
  edge [
    source 14
    target 92
    int "The risk or severity of adverse effects can be increased when Tacrine is combined with Varenicline."
  ]
  edge [
    source 14
    target 192
    int "The therapeutic efficacy of Mecamylamine can be decreased when used in combination with Tacrine."
  ]
  edge [
    source 14
    target 124
    int "The serum concentration of Pazopanib can be increased when it is combined with Tacrine."
  ]
  edge [
    source 14
    target 216
    int "The therapeutic efficacy of Vecuronium can be decreased when used in combination with Tacrine."
  ]
  edge [
    source 14
    target 217
    int "The risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Tacrine."
  ]
  edge [
    source 14
    target 244
    int "The serum concentration of Ranolazine can be increased when it is combined with Tacrine."
  ]
  edge [
    source 14
    target 63
    int "The metabolism of Tacrine can be decreased when combined with Azithromycin."
  ]
  edge [
    source 16
    target 123
    int "Leflunomide may increase the neuroexcitatory activities of Enoxacin."
  ]
  edge [
    source 16
    target 19
    int "Fenoprofen may increase the neuroexcitatory activities of Enoxacin."
  ]
  edge [
    source 16
    target 138
    int "The metabolism of Theophylline can be decreased when combined with Enoxacin."
  ]
  edge [
    source 16
    target 44
    int "The serum concentration of Enoxacin can be increased when it is combined with Probenecid."
  ]
  edge [
    source 16
    target 198
    int "Enoxacin may increase the hypoglycemic activities of Miglitol."
  ]
  edge [
    source 16
    target 217
    int "The risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Enoxacin."
  ]
  edge [
    source 16
    target 47
    int "The risk or severity of adverse effects can be increased when Prednisolone is combined with Enoxacin."
  ]
  edge [
    source 16
    target 50
    int "The risk or severity of adverse effects can be increased when Docetaxel is combined with Enoxacin."
  ]
  edge [
    source 16
    target 74
    int "Enoxacin may increase the hypoglycemic activities of Saxagliptin."
  ]
  edge [
    source 16
    target 103
    int "Zileuton may increase the neuroexcitatory activities of Enoxacin."
  ]
  edge [
    source 16
    target 75
    int "Teriflunomide may increase the neuroexcitatory activities of Enoxacin."
  ]
  edge [
    source 16
    target 38
    int "The serum concentration of Mycophenolic acid can be decreased when it is combined with Enoxacin."
  ]
  edge [
    source 16
    target 247
    int "Mesalazine may increase the neuroexcitatory activities of Enoxacin."
  ]
  edge [
    source 16
    target 237
    int "Enoxacin may increase the hypoglycemic activities of Rosiglitazone."
  ]
  edge [
    source 16
    target 92
    int "The serum concentration of Varenicline can be increased when it is combined with Enoxacin."
  ]
  edge [
    source 16
    target 125
    int "Enoxacin may increase the hypoglycemic activities of Pentamidine."
  ]
  edge [
    source 16
    target 204
    int "Oxyphenbutazone may increase the neuroexcitatory activities of Enoxacin."
  ]
  edge [
    source 16
    target 85
    int "Digitoxin may decrease the cardiotoxic activities of Enoxacin."
  ]
  edge [
    source 16
    target 20
    int "Enoxacin may increase the hypoglycemic activities of Quinine."
  ]
  edge [
    source 16
    target 129
    int "Enoxacin may increase the hypoglycemic activities of Nateglinide."
  ]
  edge [
    source 16
    target 33
    int "Chloroquine may increase the neuroexcitatory activities of Enoxacin."
  ]
  edge [
    source 16
    target 21
    int "Enoxacin may increase the anticoagulant activities of Phenprocoumon."
  ]
  edge [
    source 16
    target 73
    int "Enoxacin may increase the hypoglycemic activities of Acarbose."
  ]
  edge [
    source 16
    target 115
    int "Enoxacin may increase the hypoglycemic activities of Sitagliptin."
  ]
  edge [
    source 16
    target 118
    int "Enoxacin may increase the hypoglycemic activities of Sunitinib."
  ]
  edge [
    source 16
    target 170
    int "Enoxacin may increase the hypoglycemic activities of Metformin."
  ]
  edge [
    source 16
    target 199
    int "Meclofenamic acid may increase the neuroexcitatory activities of Enoxacin."
  ]
  edge [
    source 17
    target 68
    int "The serum concentration of Raltegravir can be decreased when it is combined with Rifabutin."
  ]
  edge [
    source 17
    target 235
    int "The serum concentration of Raltegravir can be increased when it is combined with Lansoprazole."
  ]
  edge [
    source 17
    target 187
    int "Raltegravir may increase the myopathic rhabdomyolysis activities of Clofibrate."
  ]
  edge [
    source 17
    target 188
    int "Raltegravir may increase the myopathic rhabdomyolysis activities of Cerivastatin."
  ]
  edge [
    source 19
    target 123
    int "The risk or severity of adverse effects can be increased when Leflunomide is combined with Fenoprofen."
  ]
  edge [
    source 19
    target 75
    int "The risk or severity of adverse effects can be increased when Teriflunomide is combined with Fenoprofen."
  ]
  edge [
    source 19
    target 86
    int "Fenoprofen may increase the anticoagulant activities of Argatroban."
  ]
  edge [
    source 19
    target 103
    int "The risk or severity of adverse effects can be increased when Zileuton is combined with Fenoprofen."
  ]
  edge [
    source 19
    target 95
    int "The risk or severity of adverse effects can be increased when Olmesartan is combined with Fenoprofen."
  ]
  edge [
    source 19
    target 146
    int "The risk or severity of adverse effects can be increased when Fenoprofen is combined with Chlorphenesin."
  ]
  edge [
    source 19
    target 150
    int "The serum concentration of Lithium can be increased when it is combined with Fenoprofen."
  ]
  edge [
    source 19
    target 44
    int "The serum concentration of Fenoprofen can be increased when it is combined with Probenecid."
  ]
  edge [
    source 19
    target 217
    int "The risk or severity of adverse effects can be increased when Fenoprofen is combined with Desoxycorticosterone Pivalate."
  ]
  edge [
    source 19
    target 226
    int "The therapeutic efficacy of Bumetanide can be decreased when used in combination with Fenoprofen."
  ]
  edge [
    source 19
    target 247
    int "The risk or severity of adverse effects can be increased when Mesalazine is combined with Fenoprofen."
  ]
  edge [
    source 19
    target 45
    int "The therapeutic efficacy of Iloprost can be decreased when used in combination with Fenoprofen."
  ]
  edge [
    source 19
    target 46
    int "Fenoprofen may increase the nephrotoxic activities of Tacrolimus."
  ]
  edge [
    source 19
    target 47
    int "The risk or severity of adverse effects can be increased when Fenoprofen is combined with Prednisolone."
  ]
  edge [
    source 19
    target 70
    int "Fenoprofen may decrease the antihypertensive activities of Amiloride."
  ]
  edge [
    source 19
    target 65
    int "Fenoprofen may increase the thrombogenic activities of Ethinyl Estradiol."
  ]
  edge [
    source 19
    target 38
    int "The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Fenoprofen."
  ]
  edge [
    source 19
    target 41
    int "Citalopram may increase the antiplatelet activities of Fenoprofen."
  ]
  edge [
    source 19
    target 49
    int "Fluvoxamine may increase the antiplatelet activities of Fenoprofen."
  ]
  edge [
    source 19
    target 93
    int "Fenoprofen may decrease the antihypertensive activities of Hydralazine."
  ]
  edge [
    source 19
    target 162
    int "Fenoprofen may decrease the antihypertensive activities of Spironolactone."
  ]
  edge [
    source 19
    target 169
    int "Fenoprofen may decrease the antihypertensive activities of Asenapine."
  ]
  edge [
    source 19
    target 204
    int "The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Fenoprofen."
  ]
  edge [
    source 19
    target 201
    int "Fenoprofen may decrease the antihypertensive activities of Aliskiren."
  ]
  edge [
    source 19
    target 229
    int "Fenoprofen may decrease the excretion rate of Paromomycin which could result in a higher serum level."
  ]
  edge [
    source 19
    target 33
    int "The risk or severity of adverse effects can be increased when Chloroquine is combined with Fenoprofen."
  ]
  edge [
    source 19
    target 21
    int "Fenoprofen may increase the anticoagulant activities of Phenprocoumon."
  ]
  edge [
    source 19
    target 56
    int "The risk or severity of adverse effects can be increased when Fenoprofen is combined with Enalaprilat."
  ]
  edge [
    source 19
    target 128
    int "The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Fenoprofen."
  ]
  edge [
    source 19
    target 168
    int "Fenoprofen may decrease the antihypertensive activities of Atenolol."
  ]
  edge [
    source 19
    target 174
    int "Sertraline may increase the antiplatelet activities of Fenoprofen."
  ]
  edge [
    source 19
    target 199
    int "The risk or severity of adverse effects can be increased when Fenoprofen is combined with Meclofenamic acid."
  ]
  edge [
    source 19
    target 215
    int "The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Fenoprofen."
  ]
  edge [
    source 19
    target 189
    int "The risk or severity of adverse effects can be increased when Fenoprofen is combined with Aminosalicylic Acid."
  ]
  edge [
    source 19
    target 80
    int "The serum concentration of Methotrexate can be increased when it is combined with Fenoprofen."
  ]
  edge [
    source 20
    target 157
    int "The metabolism of Quinine can be decreased when combined with Armodafinil."
  ]
  edge [
    source 20
    target 237
    int "The metabolism of Rosiglitazone can be decreased when combined with Quinine."
  ]
  edge [
    source 20
    target 123
    int "The metabolism of Leflunomide can be decreased when combined with Quinine."
  ]
  edge [
    source 20
    target 53
    int "The metabolism of Vinblastine can be decreased when combined with Quinine."
  ]
  edge [
    source 20
    target 61
    int "The metabolism of Quinine can be decreased when combined with Imatinib."
  ]
  edge [
    source 20
    target 62
    int "The metabolism of Quinine can be decreased when combined with Tranylcypromine."
  ]
  edge [
    source 20
    target 76
    int "The serum concentration of Quinine can be increased when it is combined with Tetracycline."
  ]
  edge [
    source 20
    target 64
    int "The metabolism of Clopidogrel can be decreased when combined with Quinine."
  ]
  edge [
    source 20
    target 67
    int "Furazolidone may increase the hypoglycemic activities of Quinine."
  ]
  edge [
    source 20
    target 68
    int "The metabolism of Quinine can be increased when combined with Rifabutin."
  ]
  edge [
    source 20
    target 75
    int "The serum concentration of Quinine can be decreased when it is combined with Teriflunomide."
  ]
  edge [
    source 20
    target 91
    int "The metabolism of Quinine can be decreased when combined with Topiramate."
  ]
  edge [
    source 20
    target 95
    int "Quinine may increase the hypotensive activities of Olmesartan."
  ]
  edge [
    source 20
    target 110
    int "The risk or severity of QTc prolongation can be increased when Quinine is combined with Dronedarone."
  ]
  edge [
    source 20
    target 196
    int "The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Quinine."
  ]
  edge [
    source 20
    target 137
    int "The risk or severity of QTc prolongation can be increased when Quinine is combined with Artemether."
  ]
  edge [
    source 20
    target 141
    int "The metabolism of Doxorubicin can be decreased when combined with Quinine."
  ]
  edge [
    source 20
    target 149
    int "The risk or severity of adverse effects can be increased when Quinine is combined with Halofantrine."
  ]
  edge [
    source 20
    target 150
    int "Lithium may increase the QTc-prolonging activities of Quinine."
  ]
  edge [
    source 20
    target 194
    int "Quinine may increase the hypotensive activities of Pargyline."
  ]
  edge [
    source 20
    target 79
    int "Quinine may increase the neuromuscular blocking activities of Cisatracurium."
  ]
  edge [
    source 20
    target 197
    int "The metabolism of Buspirone can be decreased when combined with Quinine."
  ]
  edge [
    source 20
    target 198
    int "Miglitol may increase the hypoglycemic activities of Quinine."
  ]
  edge [
    source 20
    target 182
    int "The metabolism of Mephenytoin can be decreased when combined with Quinine."
  ]
  edge [
    source 20
    target 214
    int "The metabolism of Proguanil can be decreased when combined with Quinine."
  ]
  edge [
    source 20
    target 219
    int "Quinine may increase the hypotensive activities of Nisoldipine."
  ]
  edge [
    source 20
    target 220
    int "The metabolism of Sulfinpyrazone can be decreased when combined with Quinine."
  ]
  edge [
    source 20
    target 232
    int "Sorafenib may increase the QTc-prolonging activities of Quinine."
  ]
  edge [
    source 20
    target 244
    int "The serum concentration of Ranolazine can be increased when it is combined with Quinine."
  ]
  edge [
    source 20
    target 247
    int "Mesalazine may increase the hypoglycemic activities of Quinine."
  ]
  edge [
    source 20
    target 23
    int "Quinine may increase the hypotensive activities of Pinacidil."
  ]
  edge [
    source 20
    target 158
    int "The metabolism of Piperazine can be decreased when combined with Quinine."
  ]
  edge [
    source 20
    target 174
    int "Sertraline may increase the QTc-prolonging activities of Quinine."
  ]
  edge [
    source 20
    target 74
    int "The serum concentration of Saxagliptin can be decreased when it is combined with Quinine."
  ]
  edge [
    source 20
    target 235
    int "The metabolism of Lansoprazole can be decreased when combined with Quinine."
  ]
  edge [
    source 20
    target 84
    int "Trimethoprim may increase the QTc-prolonging activities of Quinine."
  ]
  edge [
    source 20
    target 98
    int "Quinine may increase the hypotensive activities of Methyldopa."
  ]
  edge [
    source 20
    target 41
    int "The risk or severity of QTc prolongation can be increased when Citalopram is combined with Quinine."
  ]
  edge [
    source 20
    target 107
    int "Vorinostat may increase the QTc-prolonging activities of Quinine."
  ]
  edge [
    source 20
    target 121
    int "The metabolism of Niclosamide can be decreased when combined with Quinine."
  ]
  edge [
    source 20
    target 147
    int "Metronidazole may increase the QTc-prolonging activities of Quinine."
  ]
  edge [
    source 20
    target 83
    int "Amantadine may increase the QTc-prolonging activities of Quinine."
  ]
  edge [
    source 20
    target 97
    int "Quinine may increase the hypotensive activities of Diazoxide."
  ]
  edge [
    source 20
    target 152
    int "The metabolism of Quinine can be decreased when combined with Efavirenz."
  ]
  edge [
    source 20
    target 153
    int "The metabolism of Testosterone can be decreased when combined with Quinine."
  ]
  edge [
    source 20
    target 155
    int "Bortezomib may increase the QTc-prolonging activities of Quinine."
  ]
  edge [
    source 20
    target 66
    int "The metabolism of Amodiaquine can be decreased when combined with Quinine."
  ]
  edge [
    source 20
    target 167
    int "The metabolism of Quinine can be decreased when combined with Sildenafil."
  ]
  edge [
    source 20
    target 71
    int "Quinine may increase the neuromuscular blocking activities of Succinylcholine."
  ]
  edge [
    source 20
    target 159
    int "The metabolism of Cevimeline can be decreased when combined with Quinine."
  ]
  edge [
    source 20
    target 181
    int "The metabolism of Dopamine can be decreased when combined with Quinine."
  ]
  edge [
    source 20
    target 216
    int "Quinine may increase the neuromuscular blocking activities of Vecuronium."
  ]
  edge [
    source 20
    target 168
    int "Quinine may increase the hypotensive activities of Atenolol."
  ]
  edge [
    source 20
    target 94
    int "The metabolism of Valproic Acid can be decreased when combined with Quinine."
  ]
  edge [
    source 20
    target 48
    int "The metabolism of Gefitinib can be decreased when combined with Quinine."
  ]
  edge [
    source 20
    target 170
    int "Metformin may increase the hypoglycemic activities of Quinine."
  ]
  edge [
    source 20
    target 236
    int "Acetohexamide may increase the hypoglycemic activities of Quinine."
  ]
  edge [
    source 20
    target 240
    int "The metabolism of Quinine can be increased when combined with Primidone."
  ]
  edge [
    source 20
    target 243
    int "Miglustat may increase the hypoglycemic activities of Quinine."
  ]
  edge [
    source 20
    target 246
    int "The serum concentration of Bosentan can be increased when it is combined with Quinine."
  ]
  edge [
    source 20
    target 154
    int "The metabolism of Amprenavir can be decreased when combined with Quinine."
  ]
  edge [
    source 20
    target 138
    int "The serum concentration of Theophylline can be increased when it is combined with Quinine."
  ]
  edge [
    source 20
    target 49
    int "The metabolism of Quinine can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 20
    target 55
    int "Stanozolol may increase the hypoglycemic activities of Quinine."
  ]
  edge [
    source 20
    target 93
    int "Quinine may increase the hypotensive activities of Hydralazine."
  ]
  edge [
    source 20
    target 113
    int "Imipramine may increase the QTc-prolonging activities of Quinine."
  ]
  edge [
    source 20
    target 125
    int "Pentamidine may increase the QTc-prolonging activities of Quinine."
  ]
  edge [
    source 20
    target 129
    int "The metabolism of Nateglinide can be decreased when combined with Quinine."
  ]
  edge [
    source 20
    target 32
    int "Quinine may increase the hypotensive activities of Guanadrel."
  ]
  edge [
    source 20
    target 135
    int "The serum concentration of Everolimus can be increased when it is combined with Quinine."
  ]
  edge [
    source 20
    target 156
    int "The risk or severity of adverse effects can be increased when Quinine is combined with Mefloquine."
  ]
  edge [
    source 20
    target 102
    int "The risk or severity of adverse effects can be increased when Methylergometrine is combined with Quinine."
  ]
  edge [
    source 20
    target 166
    int "The serum concentration of Tolvaptan can be increased when it is combined with Quinine."
  ]
  edge [
    source 20
    target 26
    int "The metabolism of Quinine can be decreased when combined with Cinacalcet."
  ]
  edge [
    source 20
    target 169
    int "The risk or severity of QTc prolongation can be increased when Quinine is combined with Asenapine."
  ]
  edge [
    source 20
    target 171
    int "The serum concentration of Quinine can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 20
    target 201
    int "Quinine may increase the hypotensive activities of Aliskiren."
  ]
  edge [
    source 20
    target 33
    int "Chloroquine may increase the QTc-prolonging activities of Quinine."
  ]
  edge [
    source 20
    target 206
    int "The serum concentration of Aripiprazole can be decreased when it is combined with Quinine."
  ]
  edge [
    source 20
    target 208
    int "The serum concentration of Trifluoperazine can be increased when it is combined with Quinine."
  ]
  edge [
    source 20
    target 212
    int "The metabolism of Loperamide can be decreased when combined with Quinine."
  ]
  edge [
    source 20
    target 124
    int "The serum concentration of Pazopanib can be increased when it is combined with Quinine."
  ]
  edge [
    source 20
    target 37
    int "Felbamate may increase the QTc-prolonging activities of Quinine."
  ]
  edge [
    source 20
    target 205
    int "Foscarnet may increase the QTc-prolonging activities of Quinine."
  ]
  edge [
    source 20
    target 39
    int "The risk or severity of QTc prolongation can be increased when Quinine is combined with Cisapride."
  ]
  edge [
    source 20
    target 63
    int "The serum concentration of Quinine can be increased when it is combined with Azithromycin."
  ]
  edge [
    source 20
    target 24
    int "The metabolism of Quinine can be decreased when combined with Zafirlukast."
  ]
  edge [
    source 20
    target 27
    int "The metabolism of Quinine can be decreased when combined with Fluorouracil."
  ]
  edge [
    source 20
    target 30
    int "Amoxapine may increase the QTc-prolonging activities of Quinine."
  ]
  edge [
    source 20
    target 31
    int "Quinine may increase the hypotensive activities of Metyrosine."
  ]
  edge [
    source 20
    target 200
    int "The metabolism of Zalcitabine can be decreased when combined with Quinine."
  ]
  edge [
    source 20
    target 21
    int "Quinine may increase the anticoagulant activities of Phenprocoumon."
  ]
  edge [
    source 20
    target 133
    int "Risperidone may increase the QTc-prolonging activities of Quinine."
  ]
  edge [
    source 20
    target 56
    int "Quinine may increase the hypotensive activities of Enalaprilat."
  ]
  edge [
    source 20
    target 58
    int "The risk or severity of QTc prolongation can be increased when Ibutilide is combined with Quinine."
  ]
  edge [
    source 20
    target 72
    int "The risk or severity of QTc prolongation can be increased when Quinine is combined with Tetrabenazine."
  ]
  edge [
    source 20
    target 73
    int "Acarbose may increase the hypoglycemic activities of Quinine."
  ]
  edge [
    source 20
    target 90
    int "The risk or severity of QTc prolongation can be increased when Quinine is combined with Lumefantrine."
  ]
  edge [
    source 20
    target 228
    int "Quinine may increase the hypotensive activities of Bretylium."
  ]
  edge [
    source 20
    target 115
    int "The metabolism of Sitagliptin can be decreased when combined with Quinine."
  ]
  edge [
    source 20
    target 118
    int "Sunitinib may increase the QTc-prolonging activities of Quinine."
  ]
  edge [
    source 20
    target 188
    int "The serum concentration of Cerivastatin can be increased when it is combined with Quinine."
  ]
  edge [
    source 20
    target 43
    int "The metabolism of Thalidomide can be decreased when combined with Quinine."
  ]
  edge [
    source 20
    target 119
    int "The serum concentration of Triflupromazine can be increased when it is combined with Quinine."
  ]
  edge [
    source 20
    target 160
    int "The metabolism of Chlorzoxazone can be decreased when combined with Quinine."
  ]
  edge [
    source 20
    target 161
    int "Quinine may increase the hypotensive activities of Minoxidil."
  ]
  edge [
    source 20
    target 241
    int "Quinine may increase the hypotensive activities of Tolazoline."
  ]
  edge [
    source 20
    target 191
    int "Trazodone may increase the QTc-prolonging activities of Quinine."
  ]
  edge [
    source 20
    target 192
    int "Quinine may increase the hypotensive activities of Mecamylamine."
  ]
  edge [
    source 20
    target 202
    int "Maprotiline may increase the QTc-prolonging activities of Quinine."
  ]
  edge [
    source 20
    target 189
    int "Aminosalicylic Acid may increase the hypoglycemic activities of Quinine."
  ]
  edge [
    source 20
    target 103
    int "The metabolism of Zileuton can be decreased when combined with Quinine."
  ]
  edge [
    source 21
    target 61
    int "The metabolism of Phenprocoumon can be decreased when combined with Imatinib."
  ]
  edge [
    source 21
    target 76
    int "Tetracycline may increase the anticoagulant activities of Phenprocoumon."
  ]
  edge [
    source 21
    target 64
    int "Clopidogrel may increase the anticoagulant activities of Phenprocoumon."
  ]
  edge [
    source 21
    target 167
    int "The metabolism of Phenprocoumon can be decreased when combined with Sildenafil."
  ]
  edge [
    source 21
    target 68
    int "The metabolism of Phenprocoumon can be increased when combined with Rifabutin."
  ]
  edge [
    source 21
    target 86
    int "Argatroban may increase the anticoagulant activities of Phenprocoumon."
  ]
  edge [
    source 21
    target 110
    int "The serum concentration of Phenprocoumon can be increased when it is combined with Dronedarone."
  ]
  edge [
    source 21
    target 123
    int "Leflunomide may increase the anticoagulant activities of Phenprocoumon."
  ]
  edge [
    source 21
    target 146
    int "Chlorphenesin may increase the anticoagulant activities of Phenprocoumon."
  ]
  edge [
    source 21
    target 247
    int "Mesalazine may increase the anticoagulant activities of Phenprocoumon."
  ]
  edge [
    source 21
    target 213
    int "Mercaptopurine may decrease the anticoagulant activities of Phenprocoumon."
  ]
  edge [
    source 21
    target 196
    int "The metabolism of Phenprocoumon can be decreased when combined with Dihydroergotamine."
  ]
  edge [
    source 21
    target 220
    int "The metabolism of Phenprocoumon can be decreased when combined with Sulfinpyrazone."
  ]
  edge [
    source 21
    target 122
    int "Levonorgestrel may decrease the anticoagulant activities of Phenprocoumon."
  ]
  edge [
    source 21
    target 232
    int "The metabolism of Phenprocoumon can be decreased when combined with Sorafenib."
  ]
  edge [
    source 21
    target 45
    int "Iloprost may increase the anticoagulant activities of Phenprocoumon."
  ]
  edge [
    source 21
    target 174
    int "Sertraline may increase the anticoagulant activities of Phenprocoumon."
  ]
  edge [
    source 21
    target 235
    int "The serum concentration of Phenprocoumon can be increased when it is combined with Lansoprazole."
  ]
  edge [
    source 21
    target 84
    int "The metabolism of Phenprocoumon can be decreased when combined with Trimethoprim."
  ]
  edge [
    source 21
    target 41
    int "Citalopram may increase the anticoagulant activities of Phenprocoumon."
  ]
  edge [
    source 21
    target 103
    int "Zileuton may increase the anticoagulant activities of Phenprocoumon."
  ]
  edge [
    source 21
    target 107
    int "Vorinostat may increase the anticoagulant activities of Phenprocoumon."
  ]
  edge [
    source 21
    target 147
    int "The serum concentration of Phenprocoumon can be increased when it is combined with Metronidazole."
  ]
  edge [
    source 21
    target 152
    int "The serum concentration of Phenprocoumon can be decreased when it is combined with Efavirenz."
  ]
  edge [
    source 21
    target 249
    int "Dipyridamole may increase the anticoagulant activities of Phenprocoumon."
  ]
  edge [
    source 21
    target 155
    int "The metabolism of Phenprocoumon can be decreased when combined with Bortezomib."
  ]
  edge [
    source 21
    target 65
    int "Ethinyl Estradiol may decrease the anticoagulant activities of Phenprocoumon."
  ]
  edge [
    source 21
    target 153
    int "Testosterone may increase the anticoagulant activities of Phenprocoumon."
  ]
  edge [
    source 21
    target 180
    int "The serum concentration of Phenprocoumon can be increased when it is combined with Disulfiram."
  ]
  edge [
    source 21
    target 75
    int "Teriflunomide may increase the anticoagulant activities of Phenprocoumon."
  ]
  edge [
    source 21
    target 38
    int "Mycophenolic acid may increase the anticoagulant activities of Phenprocoumon."
  ]
  edge [
    source 21
    target 244
    int "The metabolism of Phenprocoumon can be decreased when combined with Ranolazine."
  ]
  edge [
    source 21
    target 94
    int "The metabolism of Phenprocoumon can be decreased when combined with Valproic Acid."
  ]
  edge [
    source 21
    target 236
    int "Acetohexamide may increase the anticoagulant activities of Phenprocoumon."
  ]
  edge [
    source 21
    target 237
    int "Rosiglitazone may increase the anticoagulant activities of Phenprocoumon."
  ]
  edge [
    source 21
    target 240
    int "The metabolism of Phenprocoumon can be increased when combined with Primidone."
  ]
  edge [
    source 21
    target 246
    int "The metabolism of Phenprocoumon can be increased when combined with Bosentan."
  ]
  edge [
    source 21
    target 253
    int "Propylthiouracil may decrease the anticoagulant activities of Phenprocoumon."
  ]
  edge [
    source 21
    target 49
    int "The metabolism of Phenprocoumon can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 21
    target 55
    int "Stanozolol may increase the anticoagulant activities of Phenprocoumon."
  ]
  edge [
    source 21
    target 136
    int "Ulipristal may decrease the anticoagulant activities of Phenprocoumon."
  ]
  edge [
    source 21
    target 113
    int "Imipramine may increase the anticoagulant activities of Phenprocoumon."
  ]
  edge [
    source 21
    target 171
    int "The serum concentration of Phenprocoumon can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 21
    target 187
    int "Clofibrate may increase the anticoagulant activities of Phenprocoumon."
  ]
  edge [
    source 21
    target 30
    int "Amoxapine may increase the anticoagulant activities of Phenprocoumon."
  ]
  edge [
    source 21
    target 204
    int "Oxyphenbutazone may increase the anticoagulant activities of Phenprocoumon."
  ]
  edge [
    source 21
    target 63
    int "The serum concentration of Phenprocoumon can be increased when it is combined with Azithromycin."
  ]
  edge [
    source 21
    target 24
    int "The serum concentration of Phenprocoumon can be increased when it is combined with Zafirlukast."
  ]
  edge [
    source 21
    target 27
    int "The serum concentration of Phenprocoumon can be increased when it is combined with Fluorouracil."
  ]
  edge [
    source 21
    target 33
    int "Chloroquine may increase the anticoagulant activities of Phenprocoumon."
  ]
  edge [
    source 21
    target 112
    int "Cefmenoxime may increase the anticoagulant activities of Phenprocoumon."
  ]
  edge [
    source 21
    target 48
    int "Gefitinib may increase the anticoagulant activities of Phenprocoumon."
  ]
  edge [
    source 21
    target 190
    int "Allopurinol may increase the anticoagulant activities of Phenprocoumon."
  ]
  edge [
    source 21
    target 199
    int "Meclofenamic acid may increase the anticoagulant activities of Phenprocoumon."
  ]
  edge [
    source 21
    target 22
    int "Milrinone may increase the anticoagulant activities of Phenprocoumon."
  ]
  edge [
    source 21
    target 189
    int "Aminosalicylic Acid may increase the anticoagulant activities of Phenprocoumon."
  ]
  edge [
    source 22
    target 45
    int "Milrinone may increase the anticoagulant activities of Iloprost."
  ]
  edge [
    source 22
    target 249
    int "Milrinone may increase the anticoagulant activities of Dipyridamole."
  ]
  edge [
    source 22
    target 86
    int "Milrinone may increase the anticoagulant activities of Argatroban."
  ]
  edge [
    source 22
    target 64
    int "Milrinone may increase the anticoagulant activities of Clopidogrel."
  ]
  edge [
    source 22
    target 189
    int "The risk or severity of adverse effects can be increased when Milrinone is combined with Aminosalicylic Acid."
  ]
  edge [
    source 22
    target 237
    int "Milrinone may increase the anticoagulant activities of Rosiglitazone."
  ]
  edge [
    source 22
    target 247
    int "The risk or severity of adverse effects can be increased when Milrinone is combined with Mesalazine."
  ]
  edge [
    source 23
    target 31
    int "Pinacidil may increase the hypotensive activities of Metyrosine."
  ]
  edge [
    source 23
    target 45
    int "Iloprost may increase the hypotensive activities of Pinacidil."
  ]
  edge [
    source 23
    target 49
    int "The metabolism of Pinacidil can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 23
    target 56
    int "Pinacidil may increase the hypotensive activities of Enalaprilat."
  ]
  edge [
    source 23
    target 61
    int "The metabolism of Pinacidil can be decreased when combined with Imatinib."
  ]
  edge [
    source 23
    target 249
    int "Dipyridamole may increase the antihypertensive activities of Pinacidil."
  ]
  edge [
    source 23
    target 67
    int "Furazolidone may increase the hypotensive activities of Pinacidil."
  ]
  edge [
    source 23
    target 68
    int "The metabolism of Pinacidil can be increased when combined with Rifabutin."
  ]
  edge [
    source 23
    target 138
    int "Theophylline may increase the antihypertensive activities of Pinacidil."
  ]
  edge [
    source 23
    target 93
    int "Hydralazine may increase the hypotensive activities of Pinacidil."
  ]
  edge [
    source 23
    target 95
    int "Pinacidil may increase the hypotensive activities of Olmesartan."
  ]
  edge [
    source 23
    target 98
    int "Pinacidil may increase the hypotensive activities of Methyldopa."
  ]
  edge [
    source 23
    target 110
    int "The metabolism of Pinacidil can be decreased when combined with Dronedarone."
  ]
  edge [
    source 23
    target 32
    int "Pinacidil may increase the hypotensive activities of Guanadrel."
  ]
  edge [
    source 23
    target 62
    int "Tranylcypromine may increase the hypotensive activities of Pinacidil."
  ]
  edge [
    source 23
    target 167
    int "Sildenafil may increase the antihypertensive activities of Pinacidil."
  ]
  edge [
    source 23
    target 97
    int "Diazoxide may increase the hypotensive activities of Pinacidil."
  ]
  edge [
    source 23
    target 155
    int "The metabolism of Pinacidil can be decreased when combined with Bortezomib."
  ]
  edge [
    source 23
    target 196
    int "The metabolism of Pinacidil can be decreased when combined with Dihydroergotamine."
  ]
  edge [
    source 23
    target 168
    int "Pinacidil may increase the hypotensive activities of Atenolol."
  ]
  edge [
    source 23
    target 171
    int "The serum concentration of Pinacidil can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 23
    target 161
    int "Minoxidil may increase the hypotensive activities of Pinacidil."
  ]
  edge [
    source 23
    target 192
    int "Mecamylamine may increase the hypotensive activities of Pinacidil."
  ]
  edge [
    source 23
    target 201
    int "Pinacidil may increase the hypotensive activities of Aliskiren."
  ]
  edge [
    source 23
    target 194
    int "Pargyline may increase the hypotensive activities of Pinacidil."
  ]
  edge [
    source 23
    target 219
    int "Pinacidil may increase the hypotensive activities of Nisoldipine."
  ]
  edge [
    source 23
    target 228
    int "Pinacidil may increase the hypotensive activities of Bretylium."
  ]
  edge [
    source 23
    target 240
    int "The metabolism of Pinacidil can be increased when combined with Primidone."
  ]
  edge [
    source 23
    target 241
    int "Pinacidil may increase the hypotensive activities of Tolazoline."
  ]
  edge [
    source 23
    target 244
    int "The metabolism of Pinacidil can be decreased when combined with Ranolazine."
  ]
  edge [
    source 23
    target 246
    int "The serum concentration of Pinacidil can be decreased when it is combined with Bosentan."
  ]
  edge [
    source 24
    target 123
    int "The metabolism of Leflunomide can be decreased when combined with Zafirlukast."
  ]
  edge [
    source 24
    target 61
    int "The metabolism of Zafirlukast can be decreased when combined with Imatinib."
  ]
  edge [
    source 24
    target 64
    int "The metabolism of Clopidogrel can be decreased when combined with Zafirlukast."
  ]
  edge [
    source 24
    target 167
    int "The metabolism of Zafirlukast can be decreased when combined with Sildenafil."
  ]
  edge [
    source 24
    target 68
    int "The metabolism of Zafirlukast can be increased when combined with Rifabutin."
  ]
  edge [
    source 24
    target 75
    int "The metabolism of Zafirlukast can be decreased when combined with Teriflunomide."
  ]
  edge [
    source 24
    target 110
    int "The metabolism of Zafirlukast can be decreased when combined with Dronedarone."
  ]
  edge [
    source 24
    target 137
    int "The metabolism of Artemether can be decreased when combined with Zafirlukast."
  ]
  edge [
    source 24
    target 182
    int "The metabolism of Mephenytoin can be decreased when combined with Zafirlukast."
  ]
  edge [
    source 24
    target 196
    int "The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Zafirlukast."
  ]
  edge [
    source 24
    target 214
    int "The metabolism of Proguanil can be decreased when combined with Zafirlukast."
  ]
  edge [
    source 24
    target 220
    int "The metabolism of Sulfinpyrazone can be decreased when combined with Zafirlukast."
  ]
  edge [
    source 24
    target 232
    int "The metabolism of Zafirlukast can be decreased when combined with Sorafenib."
  ]
  edge [
    source 24
    target 244
    int "The metabolism of Zafirlukast can be decreased when combined with Ranolazine."
  ]
  edge [
    source 24
    target 174
    int "The metabolism of Sertraline can be decreased when combined with Zafirlukast."
  ]
  edge [
    source 24
    target 235
    int "The metabolism of Lansoprazole can be decreased when combined with Zafirlukast."
  ]
  edge [
    source 24
    target 84
    int "The metabolism of Trimethoprim can be decreased when combined with Zafirlukast."
  ]
  edge [
    source 24
    target 103
    int "The metabolism of Zileuton can be decreased when combined with Zafirlukast."
  ]
  edge [
    source 24
    target 121
    int "The metabolism of Niclosamide can be decreased when combined with Zafirlukast."
  ]
  edge [
    source 24
    target 147
    int "The metabolism of Metronidazole can be decreased when combined with Zafirlukast."
  ]
  edge [
    source 24
    target 152
    int "The metabolism of Zafirlukast can be decreased when combined with Efavirenz."
  ]
  edge [
    source 24
    target 153
    int "The metabolism of Testosterone can be decreased when combined with Zafirlukast."
  ]
  edge [
    source 24
    target 155
    int "The metabolism of Zafirlukast can be decreased when combined with Bortezomib."
  ]
  edge [
    source 24
    target 66
    int "The serum concentration of Amodiaquine can be increased when it is combined with Zafirlukast."
  ]
  edge [
    source 24
    target 181
    int "The metabolism of Dopamine can be decreased when combined with Zafirlukast."
  ]
  edge [
    source 24
    target 94
    int "The metabolism of Valproic Acid can be decreased when combined with Zafirlukast."
  ]
  edge [
    source 24
    target 237
    int "The metabolism of Rosiglitazone can be decreased when combined with Zafirlukast."
  ]
  edge [
    source 24
    target 240
    int "The metabolism of Zafirlukast can be increased when combined with Primidone."
  ]
  edge [
    source 24
    target 246
    int "The serum concentration of Bosentan can be increased when it is combined with Zafirlukast."
  ]
  edge [
    source 24
    target 154
    int "The metabolism of Amprenavir can be decreased when combined with Zafirlukast."
  ]
  edge [
    source 24
    target 138
    int "The serum concentration of Zafirlukast can be decreased when it is combined with Theophylline."
  ]
  edge [
    source 24
    target 49
    int "The metabolism of Zafirlukast can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 24
    target 129
    int "The metabolism of Nateglinide can be decreased when combined with Zafirlukast."
  ]
  edge [
    source 24
    target 102
    int "The risk or severity of adverse effects can be increased when Methylergometrine is combined with Zafirlukast."
  ]
  edge [
    source 24
    target 166
    int "The serum concentration of Tolvaptan can be increased when it is combined with Zafirlukast."
  ]
  edge [
    source 24
    target 171
    int "The serum concentration of Zafirlukast can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 24
    target 27
    int "The metabolism of Zafirlukast can be decreased when combined with Fluorouracil."
  ]
  edge [
    source 24
    target 30
    int "The therapeutic efficacy of Zafirlukast can be decreased when used in combination with Amoxapine."
  ]
  edge [
    source 24
    target 200
    int "The metabolism of Zalcitabine can be decreased when combined with Zafirlukast."
  ]
  edge [
    source 24
    target 39
    int "The metabolism of Cisapride can be decreased when combined with Zafirlukast."
  ]
  edge [
    source 24
    target 43
    int "The metabolism of Thalidomide can be decreased when combined with Zafirlukast."
  ]
  edge [
    source 24
    target 188
    int "The serum concentration of Cerivastatin can be increased when it is combined with Zafirlukast."
  ]
  edge [
    source 25
    target 135
    int "The serum concentration of Everolimus can be increased when it is combined with Naltrexone."
  ]
  edge [
    source 25
    target 141
    int "The serum concentration of Doxorubicin can be increased when it is combined with Naltrexone."
  ]
  edge [
    source 25
    target 244
    int "The serum concentration of Ranolazine can be increased when it is combined with Naltrexone."
  ]
  edge [
    source 25
    target 124
    int "The serum concentration of Pazopanib can be increased when it is combined with Naltrexone."
  ]
  edge [
    source 26
    target 125
    int "The metabolism of Pentamidine can be decreased when combined with Cinacalcet."
  ]
  edge [
    source 26
    target 160
    int "The metabolism of Chlorzoxazone can be decreased when combined with Cinacalcet."
  ]
  edge [
    source 26
    target 154
    int "The metabolism of Amprenavir can be decreased when combined with Cinacalcet."
  ]
  edge [
    source 26
    target 30
    int "The serum concentration of Amoxapine can be increased when it is combined with Cinacalcet."
  ]
  edge [
    source 26
    target 46
    int "The serum concentration of Tacrolimus can be decreased when it is combined with Cinacalcet."
  ]
  edge [
    source 26
    target 167
    int "The metabolism of Sildenafil can be decreased when combined with Cinacalcet."
  ]
  edge [
    source 26
    target 49
    int "The metabolism of Cinacalcet can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 26
    target 53
    int "The metabolism of Vinblastine can be decreased when combined with Cinacalcet."
  ]
  edge [
    source 26
    target 63
    int "The metabolism of Cinacalcet can be decreased when combined with Azithromycin."
  ]
  edge [
    source 26
    target 158
    int "The metabolism of Piperazine can be decreased when combined with Cinacalcet."
  ]
  edge [
    source 26
    target 68
    int "The metabolism of Cinacalcet can be increased when combined with Rifabutin."
  ]
  edge [
    source 26
    target 72
    int "The serum concentration of Tetrabenazine can be increased when it is combined with Cinacalcet."
  ]
  edge [
    source 26
    target 182
    int "The metabolism of Mephenytoin can be decreased when combined with Cinacalcet."
  ]
  edge [
    source 26
    target 171
    int "The serum concentration of Cinacalcet can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 26
    target 246
    int "The serum concentration of Cinacalcet can be decreased when it is combined with Bosentan."
  ]
  edge [
    source 26
    target 75
    int "The serum concentration of Cinacalcet can be decreased when it is combined with Teriflunomide."
  ]
  edge [
    source 26
    target 41
    int "The metabolism of Citalopram can be decreased when combined with Cinacalcet."
  ]
  edge [
    source 26
    target 110
    int "The metabolism of Dronedarone can be decreased when combined with Cinacalcet."
  ]
  edge [
    source 26
    target 61
    int "The metabolism of Imatinib can be decreased when combined with Cinacalcet."
  ]
  edge [
    source 26
    target 129
    int "The metabolism of Nateglinide can be decreased when combined with Cinacalcet."
  ]
  edge [
    source 26
    target 133
    int "The metabolism of Risperidone can be decreased when combined with Cinacalcet."
  ]
  edge [
    source 26
    target 137
    int "The metabolism of Artemether can be decreased when combined with Cinacalcet."
  ]
  edge [
    source 26
    target 138
    int "The metabolism of Theophylline can be decreased when combined with Cinacalcet."
  ]
  edge [
    source 26
    target 141
    int "The metabolism of Doxorubicin can be decreased when combined with Cinacalcet."
  ]
  edge [
    source 26
    target 149
    int "The metabolism of Halofantrine can be decreased when combined with Cinacalcet."
  ]
  edge [
    source 26
    target 155
    int "The metabolism of Bortezomib can be decreased when combined with Cinacalcet."
  ]
  edge [
    source 26
    target 159
    int "The metabolism of Cevimeline can be decreased when combined with Cinacalcet."
  ]
  edge [
    source 26
    target 174
    int "The metabolism of Sertraline can be decreased when combined with Cinacalcet."
  ]
  edge [
    source 26
    target 240
    int "The metabolism of Cinacalcet can be increased when combined with Primidone."
  ]
  edge [
    source 26
    target 191
    int "The metabolism of Trazodone can be decreased when combined with Cinacalcet."
  ]
  edge [
    source 26
    target 196
    int "The metabolism of Cinacalcet can be decreased when combined with Dihydroergotamine."
  ]
  edge [
    source 26
    target 197
    int "The metabolism of Buspirone can be decreased when combined with Cinacalcet."
  ]
  edge [
    source 26
    target 33
    int "The metabolism of Chloroquine can be decreased when combined with Cinacalcet."
  ]
  edge [
    source 26
    target 202
    int "The metabolism of Maprotiline can be decreased when combined with Cinacalcet."
  ]
  edge [
    source 26
    target 244
    int "The metabolism of Cinacalcet can be decreased when combined with Ranolazine."
  ]
  edge [
    source 26
    target 206
    int "The serum concentration of Aripiprazole can be increased when it is combined with Cinacalcet."
  ]
  edge [
    source 26
    target 212
    int "The metabolism of Loperamide can be decreased when combined with Cinacalcet."
  ]
  edge [
    source 26
    target 124
    int "The metabolism of Pazopanib can be decreased when combined with Cinacalcet."
  ]
  edge [
    source 26
    target 181
    int "The metabolism of Dopamine can be decreased when combined with Cinacalcet."
  ]
  edge [
    source 26
    target 48
    int "The metabolism of Gefitinib can be decreased when combined with Cinacalcet."
  ]
  edge [
    source 26
    target 200
    int "The metabolism of Zalcitabine can be decreased when combined with Cinacalcet."
  ]
  edge [
    source 26
    target 113
    int "The serum concentration of Imipramine can be increased when it is combined with Cinacalcet."
  ]
  edge [
    source 27
    target 237
    int "The metabolism of Rosiglitazone can be decreased when combined with Fluorouracil."
  ]
  edge [
    source 27
    target 123
    int "The risk or severity of adverse effects can be increased when Fluorouracil is combined with Leflunomide."
  ]
  edge [
    source 27
    target 154
    int "The metabolism of Amprenavir can be decreased when combined with Fluorouracil."
  ]
  edge [
    source 27
    target 214
    int "The metabolism of Proguanil can be decreased when combined with Fluorouracil."
  ]
  edge [
    source 27
    target 46
    int "Tacrolimus may increase the immunosuppressive activities of Fluorouracil."
  ]
  edge [
    source 27
    target 49
    int "The metabolism of Fluorouracil can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 27
    target 61
    int "The metabolism of Imatinib can be decreased when combined with Fluorouracil."
  ]
  edge [
    source 27
    target 63
    int "The metabolism of Fluorouracil can be decreased when combined with Azithromycin."
  ]
  edge [
    source 27
    target 64
    int "The metabolism of Clopidogrel can be decreased when combined with Fluorouracil."
  ]
  edge [
    source 27
    target 167
    int "The metabolism of Sildenafil can be decreased when combined with Fluorouracil."
  ]
  edge [
    source 27
    target 174
    int "The metabolism of Sertraline can be decreased when combined with Fluorouracil."
  ]
  edge [
    source 27
    target 75
    int "The serum concentration of Fluorouracil can be decreased when it is combined with Teriflunomide."
  ]
  edge [
    source 27
    target 137
    int "The metabolism of Artemether can be decreased when combined with Fluorouracil."
  ]
  edge [
    source 27
    target 235
    int "The metabolism of Lansoprazole can be decreased when combined with Fluorouracil."
  ]
  edge [
    source 27
    target 181
    int "The metabolism of Dopamine can be decreased when combined with Fluorouracil."
  ]
  edge [
    source 27
    target 84
    int "The metabolism of Trimethoprim can be decreased when combined with Fluorouracil."
  ]
  edge [
    source 27
    target 50
    int "The risk or severity of adverse effects can be increased when Docetaxel is combined with Fluorouracil."
  ]
  edge [
    source 27
    target 103
    int "The metabolism of Zileuton can be decreased when combined with Fluorouracil."
  ]
  edge [
    source 27
    target 41
    int "The metabolism of Fluorouracil can be decreased when combined with Citalopram."
  ]
  edge [
    source 27
    target 85
    int "Digitoxin may decrease the cardiotoxic activities of Fluorouracil."
  ]
  edge [
    source 27
    target 129
    int "The metabolism of Nateglinide can be decreased when combined with Fluorouracil."
  ]
  edge [
    source 27
    target 43
    int "The metabolism of Thalidomide can be decreased when combined with Fluorouracil."
  ]
  edge [
    source 27
    target 147
    int "The serum concentration of Fluorouracil can be increased when it is combined with Metronidazole."
  ]
  edge [
    source 27
    target 138
    int "The metabolism of Theophylline can be decreased when combined with Fluorouracil."
  ]
  edge [
    source 27
    target 153
    int "The metabolism of Testosterone can be decreased when combined with Fluorouracil."
  ]
  edge [
    source 27
    target 152
    int "The metabolism of Fluorouracil can be decreased when combined with Efavirenz."
  ]
  edge [
    source 27
    target 155
    int "The metabolism of Bortezomib can be decreased when combined with Fluorouracil."
  ]
  edge [
    source 27
    target 163
    int "The serum concentration of Lacosamide can be increased when it is combined with Fluorouracil."
  ]
  edge [
    source 27
    target 42
    int "The serum concentration of Ramelteon can be increased when it is combined with Fluorouracil."
  ]
  edge [
    source 27
    target 182
    int "The metabolism of Mephenytoin can be decreased when combined with Fluorouracil."
  ]
  edge [
    source 27
    target 240
    int "The metabolism of Fluorouracil can be increased when combined with Primidone."
  ]
  edge [
    source 27
    target 121
    int "The metabolism of Niclosamide can be decreased when combined with Fluorouracil."
  ]
  edge [
    source 27
    target 220
    int "The metabolism of Sulfinpyrazone can be decreased when combined with Fluorouracil."
  ]
  edge [
    source 27
    target 94
    int "The metabolism of Valproic Acid can be decreased when combined with Fluorouracil."
  ]
  edge [
    source 27
    target 200
    int "The metabolism of Zalcitabine can be decreased when combined with Fluorouracil."
  ]
  edge [
    source 27
    target 232
    int "The serum concentration of Fluorouracil can be decreased when it is combined with Sorafenib."
  ]
  edge [
    source 27
    target 39
    int "The metabolism of Cisapride can be decreased when combined with Fluorouracil."
  ]
  edge [
    source 27
    target 246
    int "The serum concentration of Bosentan can be increased when it is combined with Fluorouracil."
  ]
  edge [
    source 28
    target 47
    int "The risk or severity of adverse effects can be increased when Prednisolone is combined with Pyridostigmine."
  ]
  edge [
    source 28
    target 249
    int "The therapeutic efficacy of Pyridostigmine can be decreased when used in combination with Dipyridamole."
  ]
  edge [
    source 28
    target 74
    int "The serum concentration of Saxagliptin can be decreased when it is combined with Pyridostigmine."
  ]
  edge [
    source 28
    target 88
    int "The therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Pyridostigmine."
  ]
  edge [
    source 28
    target 92
    int "The risk or severity of adverse effects can be increased when Pyridostigmine is combined with Varenicline."
  ]
  edge [
    source 28
    target 99
    int "The therapeutic efficacy of Oxyphenonium can be decreased when used in combination with Pyridostigmine."
  ]
  edge [
    source 28
    target 159
    int "The risk or severity of adverse effects can be increased when Pyridostigmine is combined with Cevimeline."
  ]
  edge [
    source 28
    target 168
    int "Pyridostigmine may increase the bradycardic activities of Atenolol."
  ]
  edge [
    source 28
    target 169
    int "Pyridostigmine may increase the bradycardic activities of Asenapine."
  ]
  edge [
    source 28
    target 71
    int "The serum concentration of Succinylcholine can be increased when it is combined with Pyridostigmine."
  ]
  edge [
    source 28
    target 239
    int "The risk or severity of adverse effects can be increased when Pyridostigmine is combined with Carbachol."
  ]
  edge [
    source 28
    target 192
    int "The therapeutic efficacy of Mecamylamine can be decreased when used in combination with Pyridostigmine."
  ]
  edge [
    source 28
    target 206
    int "The serum concentration of Aripiprazole can be decreased when it is combined with Pyridostigmine."
  ]
  edge [
    source 28
    target 216
    int "The therapeutic efficacy of Vecuronium can be decreased when used in combination with Pyridostigmine."
  ]
  edge [
    source 28
    target 217
    int "The risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Pyridostigmine."
  ]
  edge [
    source 30
    target 62
    int "Tranylcypromine may increase the serotonergic activities of Amoxapine."
  ]
  edge [
    source 30
    target 67
    int "Furazolidone may increase the serotonergic activities of Amoxapine."
  ]
  edge [
    source 30
    target 86
    int "The serum concentration of Amoxapine can be increased when it is combined with Argatroban."
  ]
  edge [
    source 30
    target 91
    int "The risk or severity of adverse effects can be increased when Topiramate is combined with Amoxapine."
  ]
  edge [
    source 30
    target 103
    int "The therapeutic efficacy of Zileuton can be decreased when used in combination with Amoxapine."
  ]
  edge [
    source 30
    target 109
    int "Amoxapine may decrease the antihypertensive activities of Etomidate."
  ]
  edge [
    source 30
    target 110
    int "Dronedarone may increase the antihypertensive activities of Amoxapine."
  ]
  edge [
    source 30
    target 137
    int "Amoxapine may increase the QTc-prolonging activities of Artemether."
  ]
  edge [
    source 30
    target 142
    int "The risk or severity of adverse effects can be increased when Gabapentin is combined with Amoxapine."
  ]
  edge [
    source 30
    target 150
    int "Lithium may increase the neurotoxic activities of Amoxapine."
  ]
  edge [
    source 30
    target 194
    int "Pargyline may increase the serotonergic activities of Amoxapine."
  ]
  edge [
    source 30
    target 154
    int "The serum concentration of Amoxapine can be increased when it is combined with Amprenavir."
  ]
  edge [
    source 30
    target 195
    int "The risk or severity of adverse effects can be increased when Entacapone is combined with Amoxapine."
  ]
  edge [
    source 30
    target 197
    int "Buspirone may increase the serotonergic activities of Amoxapine."
  ]
  edge [
    source 30
    target 115
    int "The serum concentration of Amoxapine can be increased when it is combined with Sitagliptin."
  ]
  edge [
    source 30
    target 196
    int "Amoxapine may decrease the antihypertensive activities of Dihydroergotamine."
  ]
  edge [
    source 30
    target 219
    int "The risk or severity of hypotension can be increased when Amoxapine is combined with Nisoldipine."
  ]
  edge [
    source 30
    target 222
    int "The risk or severity of adverse effects can be increased when Amoxapine is combined with Metaxalone."
  ]
  edge [
    source 30
    target 224
    int "The risk or severity of adverse effects can be increased when Amoxapine is combined with Sumatriptan."
  ]
  edge [
    source 30
    target 231
    int "The risk or severity of adverse effects can be increased when Carisoprodol is combined with Amoxapine."
  ]
  edge [
    source 30
    target 249
    int "Dipyridamole may increase the hypotensive activities of Amoxapine."
  ]
  edge [
    source 30
    target 46
    int "The metabolism of Tacrolimus can be decreased when combined with Amoxapine."
  ]
  edge [
    source 30
    target 60
    int "The risk or severity of adverse effects can be increased when Amoxapine is combined with Isoprenaline."
  ]
  edge [
    source 30
    target 174
    int "The risk or severity of adverse effects can be increased when Sertraline is combined with Amoxapine."
  ]
  edge [
    source 30
    target 74
    int "The serum concentration of Amoxapine can be increased when it is combined with Saxagliptin."
  ]
  edge [
    source 30
    target 225
    int "Amoxapine may increase the antihypertensive activities of Epinephrine."
  ]
  edge [
    source 30
    target 98
    int "Amoxapine may decrease the antihypertensive activities of Methyldopa."
  ]
  edge [
    source 30
    target 101
    int "The risk or severity of adverse effects can be increased when Zaleplon is combined with Amoxapine."
  ]
  edge [
    source 30
    target 41
    int "The risk or severity of adverse effects can be increased when Amoxapine is combined with Citalopram."
  ]
  edge [
    source 30
    target 131
    int "The risk or severity of adverse effects can be increased when Rufinamide is combined with Amoxapine."
  ]
  edge [
    source 30
    target 152
    int "The risk or severity of adverse effects can be increased when Amoxapine is combined with Efavirenz."
  ]
  edge [
    source 30
    target 34
    int "The risk or severity of adverse effects can be increased when Baclofen is combined with Amoxapine."
  ]
  edge [
    source 30
    target 167
    int "Sildenafil may increase the hypotensive activities of Amoxapine."
  ]
  edge [
    source 30
    target 42
    int "The risk or severity of adverse effects can be increased when Amoxapine is combined with Ramelteon."
  ]
  edge [
    source 30
    target 244
    int "The metabolism of Amoxapine can be decreased when combined with Ranolazine."
  ]
  edge [
    source 30
    target 218
    int "Altretamine may increase the orthostatic hypotensive activities of Amoxapine."
  ]
  edge [
    source 30
    target 168
    int "Atenolol may increase the orthostatic hypotensive activities of Amoxapine."
  ]
  edge [
    source 30
    target 94
    int "The serum concentration of Amoxapine can be increased when it is combined with Valproic Acid."
  ]
  edge [
    source 30
    target 238
    int "Amoxapine may increase the sedative activities of Pramipexole."
  ]
  edge [
    source 30
    target 240
    int "The metabolism of Amoxapine can be increased when combined with Primidone."
  ]
  edge [
    source 30
    target 241
    int "Tolazoline may increase the antihypertensive activities of Amoxapine."
  ]
  edge [
    source 30
    target 138
    int "Theophylline may increase the hypotensive activities of Amoxapine."
  ]
  edge [
    source 30
    target 49
    int "The risk or severity of adverse effects can be increased when Fluvoxamine is combined with Amoxapine."
  ]
  edge [
    source 30
    target 113
    int "Imipramine may increase the antihypertensive activities of Amoxapine."
  ]
  edge [
    source 30
    target 125
    int "Amoxapine may increase the QTc-prolonging activities of Pentamidine."
  ]
  edge [
    source 30
    target 133
    int "Risperidone may increase the antihypertensive activities of Amoxapine."
  ]
  edge [
    source 30
    target 179
    int "The serum concentration of Amoxapine can be increased when it is combined with Cilastatin."
  ]
  edge [
    source 30
    target 160
    int "The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Amoxapine."
  ]
  edge [
    source 30
    target 169
    int "Asenapine may increase the antihypertensive activities of Amoxapine."
  ]
  edge [
    source 30
    target 207
    int "The risk or severity of adverse effects can be increased when Amoxapine is combined with Zonisamide."
  ]
  edge [
    source 30
    target 173
    int "The risk or severity of adverse effects can be increased when Amoxapine is combined with Tiagabine."
  ]
  edge [
    source 30
    target 184
    int "Amoxapine may decrease the antihypertensive activities of Dexmedetomidine."
  ]
  edge [
    source 30
    target 31
    int "The risk or severity of adverse effects can be increased when Metyrosine is combined with Amoxapine."
  ]
  edge [
    source 30
    target 206
    int "Aripiprazole may increase the antihypertensive activities of Amoxapine."
  ]
  edge [
    source 30
    target 208
    int "Trifluoperazine may increase the antihypertensive activities of Amoxapine."
  ]
  edge [
    source 30
    target 212
    int "The risk or severity of hypotension can be increased when Amoxapine is combined with Loperamide."
  ]
  edge [
    source 30
    target 124
    int "Amoxapine may increase the QTc-prolonging activities of Pazopanib."
  ]
  edge [
    source 30
    target 37
    int "The risk or severity of adverse effects can be increased when Amoxapine is combined with Felbamate."
  ]
  edge [
    source 30
    target 63
    int "Amoxapine may increase the QTc-prolonging activities of Azithromycin."
  ]
  edge [
    source 30
    target 33
    int "The metabolism of Amoxapine can be decreased when combined with Chloroquine."
  ]
  edge [
    source 30
    target 39
    int "Amoxapine may increase the QTc-prolonging activities of Cisapride."
  ]
  edge [
    source 30
    target 56
    int "The serum concentration of Amoxapine can be increased when it is combined with Enalaprilat."
  ]
  edge [
    source 30
    target 72
    int "Amoxapine may increase the QTc-prolonging activities of Tetrabenazine."
  ]
  edge [
    source 30
    target 90
    int "Amoxapine may increase the QTc-prolonging activities of Lumefantrine."
  ]
  edge [
    source 30
    target 58
    int "Amoxapine may increase the QTc-prolonging activities of Ibutilide."
  ]
  edge [
    source 30
    target 148
    int "The risk or severity of adverse effects can be increased when Amoxapine is combined with Dantrolene."
  ]
  edge [
    source 30
    target 43
    int "Amoxapine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide."
  ]
  edge [
    source 30
    target 119
    int "The risk or severity of adverse effects can be increased when Triflupromazine is combined with Amoxapine."
  ]
  edge [
    source 30
    target 191
    int "Trazodone may increase the antihypertensive activities of Amoxapine."
  ]
  edge [
    source 30
    target 202
    int "The risk or severity of adverse effects can be increased when Amoxapine is combined with Maprotiline."
  ]
  edge [
    source 30
    target 234
    int "The risk or severity of adverse effects can be increased when Amoxapine is combined with Lamotrigine."
  ]
  edge [
    source 31
    target 62
    int "Tranylcypromine may increase the sedative activities of Metyrosine."
  ]
  edge [
    source 31
    target 249
    int "Dipyridamole may increase the antihypertensive activities of Metyrosine."
  ]
  edge [
    source 31
    target 167
    int "Sildenafil may increase the antihypertensive activities of Metyrosine."
  ]
  edge [
    source 31
    target 101
    int "Zaleplon may increase the sedative activities of Metyrosine."
  ]
  edge [
    source 31
    target 91
    int "Topiramate may increase the sedative activities of Metyrosine."
  ]
  edge [
    source 31
    target 109
    int "Etomidate may increase the sedative activities of Metyrosine."
  ]
  edge [
    source 31
    target 142
    int "Gabapentin may increase the sedative activities of Metyrosine."
  ]
  edge [
    source 31
    target 148
    int "Dantrolene may increase the sedative activities of Metyrosine."
  ]
  edge [
    source 31
    target 150
    int "Lithium may increase the sedative activities of Metyrosine."
  ]
  edge [
    source 31
    target 195
    int "Entacapone may increase the sedative activities of Metyrosine."
  ]
  edge [
    source 31
    target 197
    int "Buspirone may increase the sedative activities of Metyrosine."
  ]
  edge [
    source 31
    target 194
    int "Pargyline may increase the hypotensive activities of Metyrosine."
  ]
  edge [
    source 31
    target 219
    int "Nisoldipine may increase the hypotensive activities of Metyrosine."
  ]
  edge [
    source 31
    target 222
    int "Metaxalone may increase the sedative activities of Metyrosine."
  ]
  edge [
    source 31
    target 231
    int "Carisoprodol may increase the sedative activities of Metyrosine."
  ]
  edge [
    source 31
    target 45
    int "Iloprost may increase the hypotensive activities of Metyrosine."
  ]
  edge [
    source 31
    target 174
    int "The risk or severity of adverse effects can be increased when Metyrosine is combined with Sertraline."
  ]
  edge [
    source 31
    target 49
    int "Fluvoxamine may increase the sedative activities of Metyrosine."
  ]
  edge [
    source 31
    target 98
    int "Methyldopa may increase the hypotensive activities of Metyrosine."
  ]
  edge [
    source 31
    target 41
    int "The risk or severity of adverse effects can be increased when Metyrosine is combined with Citalopram."
  ]
  edge [
    source 31
    target 152
    int "Efavirenz may increase the sedative activities of Metyrosine."
  ]
  edge [
    source 31
    target 34
    int "Baclofen may increase the sedative activities of Metyrosine."
  ]
  edge [
    source 31
    target 67
    int "Furazolidone may increase the hypotensive activities of Metyrosine."
  ]
  edge [
    source 31
    target 42
    int "Ramelteon may increase the sedative activities of Metyrosine."
  ]
  edge [
    source 31
    target 168
    int "Atenolol may increase the hypotensive activities of Metyrosine."
  ]
  edge [
    source 31
    target 94
    int "Valproic Acid may increase the sedative activities of Metyrosine."
  ]
  edge [
    source 31
    target 228
    int "Bretylium may increase the hypotensive activities of Metyrosine."
  ]
  edge [
    source 31
    target 240
    int "Primidone may increase the sedative activities of Metyrosine."
  ]
  edge [
    source 31
    target 241
    int "Tolazoline may increase the hypotensive activities of Metyrosine."
  ]
  edge [
    source 31
    target 246
    int "Bosentan may increase the hypotensive activities of Metyrosine."
  ]
  edge [
    source 31
    target 234
    int "Lamotrigine may increase the sedative activities of Metyrosine."
  ]
  edge [
    source 31
    target 138
    int "Theophylline may increase the antihypertensive activities of Metyrosine."
  ]
  edge [
    source 31
    target 95
    int "Olmesartan may increase the hypotensive activities of Metyrosine."
  ]
  edge [
    source 31
    target 93
    int "Hydralazine may increase the hypotensive activities of Metyrosine."
  ]
  edge [
    source 31
    target 97
    int "Diazoxide may increase the hypotensive activities of Metyrosine."
  ]
  edge [
    source 31
    target 113
    int "The risk or severity of adverse effects can be increased when Metyrosine is combined with Imipramine."
  ]
  edge [
    source 31
    target 32
    int "Guanadrel may increase the hypotensive activities of Metyrosine."
  ]
  edge [
    source 31
    target 160
    int "Chlorzoxazone may increase the sedative activities of Metyrosine."
  ]
  edge [
    source 31
    target 161
    int "Minoxidil may increase the hypotensive activities of Metyrosine."
  ]
  edge [
    source 31
    target 169
    int "Asenapine may increase the sedative activities of Metyrosine."
  ]
  edge [
    source 31
    target 207
    int "Zonisamide may increase the sedative activities of Metyrosine."
  ]
  edge [
    source 31
    target 173
    int "Tiagabine may increase the sedative activities of Metyrosine."
  ]
  edge [
    source 31
    target 184
    int "Dexmedetomidine may increase the sedative activities of Metyrosine."
  ]
  edge [
    source 31
    target 201
    int "Aliskiren may increase the hypotensive activities of Metyrosine."
  ]
  edge [
    source 31
    target 206
    int "Aripiprazole may increase the sedative activities of Metyrosine."
  ]
  edge [
    source 31
    target 208
    int "Trifluoperazine may increase the sedative activities of Metyrosine."
  ]
  edge [
    source 31
    target 37
    int "Felbamate may increase the sedative activities of Metyrosine."
  ]
  edge [
    source 31
    target 133
    int "Risperidone may increase the sedative activities of Metyrosine."
  ]
  edge [
    source 31
    target 56
    int "Enalaprilat may increase the hypotensive activities of Metyrosine."
  ]
  edge [
    source 31
    target 72
    int "The risk or severity of adverse effects can be increased when Metyrosine is combined with Tetrabenazine."
  ]
  edge [
    source 31
    target 43
    int "Thalidomide may increase the sedative activities of Metyrosine."
  ]
  edge [
    source 31
    target 119
    int "Triflupromazine may increase the sedative activities of Metyrosine."
  ]
  edge [
    source 31
    target 191
    int "Trazodone may increase the sedative activities of Metyrosine."
  ]
  edge [
    source 31
    target 192
    int "Mecamylamine may increase the hypotensive activities of Metyrosine."
  ]
  edge [
    source 31
    target 202
    int "Maprotiline may increase the sedative activities of Metyrosine."
  ]
  edge [
    source 32
    target 45
    int "Iloprost may increase the hypotensive activities of Guanadrel."
  ]
  edge [
    source 32
    target 56
    int "Guanadrel may increase the hypotensive activities of Enalaprilat."
  ]
  edge [
    source 32
    target 97
    int "Diazoxide may increase the hypotensive activities of Guanadrel."
  ]
  edge [
    source 32
    target 249
    int "Dipyridamole may increase the antihypertensive activities of Guanadrel."
  ]
  edge [
    source 32
    target 167
    int "Sildenafil may increase the antihypertensive activities of Guanadrel."
  ]
  edge [
    source 32
    target 138
    int "Theophylline may increase the antihypertensive activities of Guanadrel."
  ]
  edge [
    source 32
    target 93
    int "Hydralazine may increase the hypotensive activities of Guanadrel."
  ]
  edge [
    source 32
    target 95
    int "Guanadrel may increase the hypotensive activities of Olmesartan."
  ]
  edge [
    source 32
    target 98
    int "Guanadrel may increase the hypotensive activities of Methyldopa."
  ]
  edge [
    source 32
    target 62
    int "Tranylcypromine may increase the hypotensive activities of Guanadrel."
  ]
  edge [
    source 32
    target 161
    int "Minoxidil may increase the hypotensive activities of Guanadrel."
  ]
  edge [
    source 32
    target 168
    int "Guanadrel may increase the hypotensive activities of Atenolol."
  ]
  edge [
    source 32
    target 192
    int "Mecamylamine may increase the hypotensive activities of Guanadrel."
  ]
  edge [
    source 32
    target 194
    int "Pargyline may increase the hypotensive activities of Guanadrel."
  ]
  edge [
    source 32
    target 201
    int "Guanadrel may increase the hypotensive activities of Aliskiren."
  ]
  edge [
    source 32
    target 219
    int "Guanadrel may increase the hypotensive activities of Nisoldipine."
  ]
  edge [
    source 32
    target 228
    int "Guanadrel may increase the hypotensive activities of Bretylium."
  ]
  edge [
    source 32
    target 241
    int "Guanadrel may increase the hypotensive activities of Tolazoline."
  ]
  edge [
    source 32
    target 67
    int "Furazolidone may increase the hypotensive activities of Guanadrel."
  ]
  edge [
    source 32
    target 246
    int "Bosentan may increase the hypotensive activities of Guanadrel."
  ]
  edge [
    source 33
    target 123
    int "The risk or severity of adverse effects can be increased when Chloroquine is combined with Leflunomide."
  ]
  edge [
    source 33
    target 244
    int "The serum concentration of Ranolazine can be increased when it is combined with Chloroquine."
  ]
  edge [
    source 33
    target 53
    int "The metabolism of Vinblastine can be decreased when combined with Chloroquine."
  ]
  edge [
    source 33
    target 61
    int "The metabolism of Chloroquine can be decreased when combined with Imatinib."
  ]
  edge [
    source 33
    target 62
    int "The metabolism of Chloroquine can be decreased when combined with Tranylcypromine."
  ]
  edge [
    source 33
    target 63
    int "Azithromycin may increase the QTc-prolonging activities of Chloroquine."
  ]
  edge [
    source 33
    target 167
    int "The metabolism of Chloroquine can be decreased when combined with Sildenafil."
  ]
  edge [
    source 33
    target 68
    int "The metabolism of Chloroquine can be increased when combined with Rifabutin."
  ]
  edge [
    source 33
    target 86
    int "Chloroquine may increase the anticoagulant activities of Argatroban."
  ]
  edge [
    source 33
    target 103
    int "The risk or severity of adverse effects can be increased when Chloroquine is combined with Zileuton."
  ]
  edge [
    source 33
    target 95
    int "The risk or severity of adverse effects can be increased when Olmesartan is combined with Chloroquine."
  ]
  edge [
    source 33
    target 110
    int "Chloroquine may increase the QTc-prolonging activities of Dronedarone."
  ]
  edge [
    source 33
    target 141
    int "The metabolism of Doxorubicin can be decreased when combined with Chloroquine."
  ]
  edge [
    source 33
    target 146
    int "The risk or severity of adverse effects can be increased when Chloroquine is combined with Chlorphenesin."
  ]
  edge [
    source 33
    target 149
    int "The metabolism of Halofantrine can be decreased when combined with Chloroquine."
  ]
  edge [
    source 33
    target 150
    int "The serum concentration of Lithium can be increased when it is combined with Chloroquine."
  ]
  edge [
    source 33
    target 154
    int "The metabolism of Amprenavir can be decreased when combined with Chloroquine."
  ]
  edge [
    source 33
    target 247
    int "The risk or severity of adverse effects can be increased when Chloroquine is combined with Mesalazine."
  ]
  edge [
    source 33
    target 197
    int "The metabolism of Buspirone can be decreased when combined with Chloroquine."
  ]
  edge [
    source 33
    target 182
    int "The metabolism of Mephenytoin can be decreased when combined with Chloroquine."
  ]
  edge [
    source 33
    target 116
    int "The serum concentration of Levamisole can be decreased when it is combined with Chloroquine."
  ]
  edge [
    source 33
    target 196
    int "The metabolism of Chloroquine can be decreased when combined with Dihydroergotamine."
  ]
  edge [
    source 33
    target 217
    int "The risk or severity of adverse effects can be increased when Chloroquine is combined with Desoxycorticosterone Pivalate."
  ]
  edge [
    source 33
    target 226
    int "The therapeutic efficacy of Bumetanide can be decreased when used in combination with Chloroquine."
  ]
  edge [
    source 33
    target 232
    int "Sorafenib may increase the QTc-prolonging activities of Chloroquine."
  ]
  edge [
    source 33
    target 245
    int "The serum concentration of Diethylcarbamazine can be decreased when it is combined with Chloroquine."
  ]
  edge [
    source 33
    target 44
    int "The serum concentration of Chloroquine can be increased when it is combined with Probenecid."
  ]
  edge [
    source 33
    target 45
    int "The therapeutic efficacy of Iloprost can be decreased when used in combination with Chloroquine."
  ]
  edge [
    source 33
    target 47
    int "The risk or severity of adverse effects can be increased when Chloroquine is combined with Prednisolone."
  ]
  edge [
    source 33
    target 158
    int "The metabolism of Piperazine can be decreased when combined with Chloroquine."
  ]
  edge [
    source 33
    target 174
    int "The metabolism of Chloroquine can be decreased when combined with Sertraline."
  ]
  edge [
    source 33
    target 80
    int "The serum concentration of Methotrexate can be increased when it is combined with Chloroquine."
  ]
  edge [
    source 33
    target 84
    int "The metabolism of Chloroquine can be decreased when combined with Trimethoprim."
  ]
  edge [
    source 33
    target 85
    int "The serum concentration of Digitoxin can be increased when it is combined with Chloroquine."
  ]
  edge [
    source 33
    target 100
    int "The serum concentration of Chloroquine can be decreased when it is combined with Hydroxychloroquine."
  ]
  edge [
    source 33
    target 41
    int "Chloroquine may increase the QTc-prolonging activities of Citalopram."
  ]
  edge [
    source 33
    target 107
    int "Vorinostat may increase the QTc-prolonging activities of Chloroquine."
  ]
  edge [
    source 33
    target 121
    int "The serum concentration of Niclosamide can be decreased when it is combined with Chloroquine."
  ]
  edge [
    source 33
    target 137
    int "The risk or severity of QTc prolongation can be increased when Chloroquine is combined with Artemether."
  ]
  edge [
    source 33
    target 147
    int "Metronidazole may increase the QTc-prolonging activities of Chloroquine."
  ]
  edge [
    source 33
    target 83
    int "Amantadine may increase the QTc-prolonging activities of Chloroquine."
  ]
  edge [
    source 33
    target 152
    int "The metabolism of Chloroquine can be decreased when combined with Efavirenz."
  ]
  edge [
    source 33
    target 155
    int "The metabolism of Chloroquine can be decreased when combined with Bortezomib."
  ]
  edge [
    source 33
    target 66
    int "The serum concentration of Chloroquine can be decreased when it is combined with Amodiaquine."
  ]
  edge [
    source 33
    target 159
    int "The metabolism of Cevimeline can be decreased when combined with Chloroquine."
  ]
  edge [
    source 33
    target 75
    int "The metabolism of Chloroquine can be decreased when combined with Teriflunomide."
  ]
  edge [
    source 33
    target 38
    int "The risk or severity of adverse effects can be increased when Chloroquine is combined with Mycophenolic acid."
  ]
  edge [
    source 33
    target 168
    int "The metabolism of Atenolol can be decreased when combined with Chloroquine."
  ]
  edge [
    source 33
    target 246
    int "The serum concentration of Chloroquine can be decreased when it is combined with Bosentan."
  ]
  edge [
    source 33
    target 72
    int "Chloroquine may increase the QTc-prolonging activities of Tetrabenazine."
  ]
  edge [
    source 33
    target 49
    int "The metabolism of Chloroquine can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 33
    target 181
    int "The metabolism of Dopamine can be decreased when combined with Chloroquine."
  ]
  edge [
    source 33
    target 93
    int "Chloroquine may decrease the antihypertensive activities of Hydralazine."
  ]
  edge [
    source 33
    target 89
    int "The serum concentration of Praziquantel can be decreased when it is combined with Chloroquine."
  ]
  edge [
    source 33
    target 117
    int "The serum concentration of Albendazole can be decreased when it is combined with Chloroquine."
  ]
  edge [
    source 33
    target 125
    int "Chloroquine may increase the QTc-prolonging activities of Pentamidine."
  ]
  edge [
    source 33
    target 129
    int "The metabolism of Nateglinide can be decreased when combined with Chloroquine."
  ]
  edge [
    source 33
    target 130
    int "The serum concentration of Thiabendazole can be decreased when it is combined with Chloroquine."
  ]
  edge [
    source 33
    target 133
    int "The metabolism of Risperidone can be decreased when combined with Chloroquine."
  ]
  edge [
    source 33
    target 135
    int "The serum concentration of Everolimus can be increased when it is combined with Chloroquine."
  ]
  edge [
    source 33
    target 156
    int "The risk or severity of adverse effects can be increased when Chloroquine is combined with Mefloquine."
  ]
  edge [
    source 33
    target 162
    int "Chloroquine may decrease the antihypertensive activities of Spironolactone."
  ]
  edge [
    source 33
    target 164
    int "The serum concentration of Mebendazole can be decreased when it is combined with Chloroquine."
  ]
  edge [
    source 33
    target 169
    int "Chloroquine may increase the QTc-prolonging activities of Asenapine."
  ]
  edge [
    source 33
    target 171
    int "The serum concentration of Chloroquine can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 33
    target 201
    int "Chloroquine may decrease the antihypertensive activities of Aliskiren."
  ]
  edge [
    source 33
    target 204
    int "The risk or severity of adverse effects can be increased when Chloroquine is combined with Oxyphenbutazone."
  ]
  edge [
    source 33
    target 200
    int "The metabolism of Zalcitabine can be decreased when combined with Chloroquine."
  ]
  edge [
    source 33
    target 206
    int "The serum concentration of Aripiprazole can be increased when it is combined with Chloroquine."
  ]
  edge [
    source 33
    target 208
    int "The serum concentration of Trifluoperazine can be increased when it is combined with Chloroquine."
  ]
  edge [
    source 33
    target 212
    int "The metabolism of Loperamide can be decreased when combined with Chloroquine."
  ]
  edge [
    source 33
    target 124
    int "The serum concentration of Pazopanib can be increased when it is combined with Chloroquine."
  ]
  edge [
    source 33
    target 229
    int "Chloroquine may decrease the excretion rate of Paromomycin which could result in a higher serum level."
  ]
  edge [
    source 33
    target 205
    int "Foscarnet may increase the QTc-prolonging activities of Chloroquine."
  ]
  edge [
    source 33
    target 39
    int "Chloroquine may increase the QTc-prolonging activities of Cisapride."
  ]
  edge [
    source 33
    target 160
    int "The metabolism of Chlorzoxazone can be decreased when combined with Chloroquine."
  ]
  edge [
    source 33
    target 113
    int "The metabolism of Chloroquine can be decreased when combined with Imipramine."
  ]
  edge [
    source 33
    target 37
    int "Felbamate may increase the QTc-prolonging activities of Chloroquine."
  ]
  edge [
    source 33
    target 46
    int "Chloroquine may increase the nephrotoxic activities of Tacrolimus."
  ]
  edge [
    source 33
    target 56
    int "The risk or severity of adverse effects can be increased when Chloroquine is combined with Enalaprilat."
  ]
  edge [
    source 33
    target 90
    int "The risk or severity of QTc prolongation can be increased when Chloroquine is combined with Lumefantrine."
  ]
  edge [
    source 33
    target 48
    int "The metabolism of Gefitinib can be decreased when combined with Chloroquine."
  ]
  edge [
    source 33
    target 58
    int "Chloroquine may increase the QTc-prolonging activities of Ibutilide."
  ]
  edge [
    source 33
    target 128
    int "The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Chloroquine."
  ]
  edge [
    source 33
    target 138
    int "The metabolism of Theophylline can be decreased when combined with Chloroquine."
  ]
  edge [
    source 33
    target 119
    int "The serum concentration of Triflupromazine can be increased when it is combined with Chloroquine."
  ]
  edge [
    source 33
    target 237
    int "The metabolism of Chloroquine can be decreased when combined with Rosiglitazone."
  ]
  edge [
    source 33
    target 70
    int "Chloroquine may decrease the antihypertensive activities of Amiloride."
  ]
  edge [
    source 33
    target 240
    int "The metabolism of Chloroquine can be increased when combined with Primidone."
  ]
  edge [
    source 33
    target 191
    int "The metabolism of Trazodone can be decreased when combined with Chloroquine."
  ]
  edge [
    source 33
    target 199
    int "The risk or severity of adverse effects can be increased when Chloroquine is combined with Meclofenamic acid."
  ]
  edge [
    source 33
    target 202
    int "The metabolism of Maprotiline can be decreased when combined with Chloroquine."
  ]
  edge [
    source 33
    target 118
    int "Sunitinib may increase the QTc-prolonging activities of Chloroquine."
  ]
  edge [
    source 33
    target 215
    int "The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Chloroquine."
  ]
  edge [
    source 33
    target 189
    int "The risk or severity of adverse effects can be increased when Chloroquine is combined with Aminosalicylic Acid."
  ]
  edge [
    source 34
    target 62
    int "The risk or severity of adverse effects can be increased when Baclofen is combined with Tranylcypromine."
  ]
  edge [
    source 34
    target 91
    int "The risk or severity of adverse effects can be increased when Baclofen is combined with Topiramate."
  ]
  edge [
    source 34
    target 109
    int "The risk or severity of adverse effects can be increased when Baclofen is combined with Etomidate."
  ]
  edge [
    source 34
    target 142
    int "The risk or severity of adverse effects can be increased when Gabapentin is combined with Baclofen."
  ]
  edge [
    source 34
    target 148
    int "The risk or severity of adverse effects can be increased when Baclofen is combined with Dantrolene."
  ]
  edge [
    source 34
    target 150
    int "The risk or severity of adverse effects can be increased when Baclofen is combined with Lithium."
  ]
  edge [
    source 34
    target 197
    int "The risk or severity of adverse effects can be increased when Buspirone is combined with Baclofen."
  ]
  edge [
    source 34
    target 195
    int "The risk or severity of adverse effects can be increased when Baclofen is combined with Entacapone."
  ]
  edge [
    source 34
    target 222
    int "The risk or severity of adverse effects can be increased when Baclofen is combined with Metaxalone."
  ]
  edge [
    source 34
    target 231
    int "The risk or severity of adverse effects can be increased when Baclofen is combined with Carisoprodol."
  ]
  edge [
    source 34
    target 174
    int "The risk or severity of adverse effects can be increased when Baclofen is combined with Sertraline."
  ]
  edge [
    source 34
    target 101
    int "The risk or severity of adverse effects can be increased when Zaleplon is combined with Baclofen."
  ]
  edge [
    source 34
    target 41
    int "The risk or severity of adverse effects can be increased when Baclofen is combined with Citalopram."
  ]
  edge [
    source 34
    target 119
    int "The risk or severity of adverse effects can be increased when Baclofen is combined with Triflupromazine."
  ]
  edge [
    source 34
    target 131
    int "The risk or severity of adverse effects can be increased when Rufinamide is combined with Baclofen."
  ]
  edge [
    source 34
    target 152
    int "The risk or severity of adverse effects can be increased when Baclofen is combined with Efavirenz."
  ]
  edge [
    source 34
    target 42
    int "The risk or severity of adverse effects can be increased when Baclofen is combined with Ramelteon."
  ]
  edge [
    source 34
    target 94
    int "The risk or severity of adverse effects can be increased when Baclofen is combined with Valproic Acid."
  ]
  edge [
    source 34
    target 238
    int "Baclofen may increase the sedative activities of Pramipexole."
  ]
  edge [
    source 34
    target 240
    int "The risk or severity of adverse effects can be increased when Baclofen is combined with Primidone."
  ]
  edge [
    source 34
    target 234
    int "The risk or severity of adverse effects can be increased when Baclofen is combined with Lamotrigine."
  ]
  edge [
    source 34
    target 49
    int "The risk or severity of adverse effects can be increased when Baclofen is combined with Fluvoxamine."
  ]
  edge [
    source 34
    target 113
    int "The risk or severity of adverse effects can be increased when Baclofen is combined with Imipramine."
  ]
  edge [
    source 34
    target 133
    int "The risk or severity of adverse effects can be increased when Risperidone is combined with Baclofen."
  ]
  edge [
    source 34
    target 160
    int "The risk or severity of adverse effects can be increased when Baclofen is combined with Chlorzoxazone."
  ]
  edge [
    source 34
    target 169
    int "The risk or severity of adverse effects can be increased when Asenapine is combined with Baclofen."
  ]
  edge [
    source 34
    target 207
    int "The risk or severity of adverse effects can be increased when Baclofen is combined with Zonisamide."
  ]
  edge [
    source 34
    target 173
    int "The risk or severity of adverse effects can be increased when Baclofen is combined with Tiagabine."
  ]
  edge [
    source 34
    target 184
    int "The risk or severity of adverse effects can be increased when Baclofen is combined with Dexmedetomidine."
  ]
  edge [
    source 34
    target 206
    int "The risk or severity of adverse effects can be increased when Aripiprazole is combined with Baclofen."
  ]
  edge [
    source 34
    target 208
    int "The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Baclofen."
  ]
  edge [
    source 34
    target 202
    int "The risk or severity of adverse effects can be increased when Baclofen is combined with Maprotiline."
  ]
  edge [
    source 34
    target 37
    int "The risk or severity of adverse effects can be increased when Baclofen is combined with Felbamate."
  ]
  edge [
    source 34
    target 72
    int "The risk or severity of adverse effects can be increased when Baclofen is combined with Tetrabenazine."
  ]
  edge [
    source 34
    target 43
    int "Baclofen may increase the central nervous system depressant (CNS depressant) activities of Thalidomide."
  ]
  edge [
    source 34
    target 191
    int "The risk or severity of adverse effects can be increased when Baclofen is combined with Trazodone."
  ]
  edge [
    source 35
    target 123
    int "The risk or severity of adverse effects can be increased when Irinotecan is combined with Leflunomide."
  ]
  edge [
    source 35
    target 46
    int "Tacrolimus may increase the immunosuppressive activities of Irinotecan."
  ]
  edge [
    source 35
    target 49
    int "The metabolism of Irinotecan can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 35
    target 61
    int "The metabolism of Irinotecan can be decreased when combined with Imatinib."
  ]
  edge [
    source 35
    target 64
    int "The metabolism of Irinotecan can be decreased when combined with Clopidogrel."
  ]
  edge [
    source 35
    target 167
    int "The metabolism of Irinotecan can be decreased when combined with Sildenafil."
  ]
  edge [
    source 35
    target 68
    int "The serum concentration of Irinotecan can be decreased when it is combined with Rifabutin."
  ]
  edge [
    source 35
    target 174
    int "The metabolism of Irinotecan can be decreased when combined with Sertraline."
  ]
  edge [
    source 35
    target 75
    int "The serum concentration of Irinotecan can be increased when it is combined with Teriflunomide."
  ]
  edge [
    source 35
    target 50
    int "The risk or severity of adverse effects can be increased when Docetaxel is combined with Irinotecan."
  ]
  edge [
    source 35
    target 141
    int "The metabolism of Irinotecan can be decreased when combined with Doxorubicin."
  ]
  edge [
    source 35
    target 41
    int "The metabolism of Irinotecan can be decreased when combined with Citalopram."
  ]
  edge [
    source 35
    target 110
    int "The metabolism of Irinotecan can be decreased when combined with Dronedarone."
  ]
  edge [
    source 35
    target 155
    int "The metabolism of Irinotecan can be decreased when combined with Bortezomib."
  ]
  edge [
    source 35
    target 102
    int "The risk or severity of adverse effects can be increased when Methylergometrine is combined with Irinotecan."
  ]
  edge [
    source 35
    target 171
    int "The serum concentration of Irinotecan can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 35
    target 188
    int "The serum concentration of Cerivastatin can be increased when it is combined with Irinotecan."
  ]
  edge [
    source 35
    target 240
    int "The serum concentration of Irinotecan can be decreased when it is combined with Primidone."
  ]
  edge [
    source 35
    target 196
    int "The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Irinotecan."
  ]
  edge [
    source 35
    target 244
    int "The serum concentration of Irinotecan can be increased when it is combined with Ranolazine."
  ]
  edge [
    source 35
    target 166
    int "The serum concentration of Tolvaptan can be increased when it is combined with Irinotecan."
  ]
  edge [
    source 35
    target 124
    int "The serum concentration of SN-38, an active metabolite of Irinotecan, can be increased when used in combination with Pazopanib."
  ]
  edge [
    source 35
    target 85
    int "Digitoxin may decrease the cardiotoxic activities of Irinotecan."
  ]
  edge [
    source 35
    target 232
    int "The serum concentration of Irinotecan can be increased when it is combined with Sorafenib."
  ]
  edge [
    source 35
    target 246
    int "The serum concentration of Irinotecan can be decreased when it is combined with Bosentan."
  ]
  edge [
    source 37
    target 62
    int "The risk or severity of adverse effects can be increased when Felbamate is combined with Tranylcypromine."
  ]
  edge [
    source 37
    target 63
    int "Felbamate may increase the QTc-prolonging activities of Azithromycin."
  ]
  edge [
    source 37
    target 65
    int "The serum concentration of Ethinyl Estradiol can be decreased when it is combined with Felbamate."
  ]
  edge [
    source 37
    target 167
    int "The metabolism of Felbamate can be decreased when combined with Sildenafil."
  ]
  edge [
    source 37
    target 68
    int "The metabolism of Felbamate can be increased when combined with Rifabutin."
  ]
  edge [
    source 37
    target 41
    int "Felbamate may increase the QTc-prolonging activities of Citalopram."
  ]
  edge [
    source 37
    target 91
    int "The risk or severity of adverse effects can be increased when Topiramate is combined with Felbamate."
  ]
  edge [
    source 37
    target 109
    int "The risk or severity of adverse effects can be increased when Felbamate is combined with Etomidate."
  ]
  edge [
    source 37
    target 110
    int "Felbamate may increase the QTc-prolonging activities of Dronedarone."
  ]
  edge [
    source 37
    target 137
    int "Felbamate may increase the QTc-prolonging activities of Artemether."
  ]
  edge [
    source 37
    target 142
    int "The risk or severity of adverse effects can be increased when Gabapentin is combined with Felbamate."
  ]
  edge [
    source 37
    target 148
    int "The risk or severity of adverse effects can be increased when Felbamate is combined with Dantrolene."
  ]
  edge [
    source 37
    target 150
    int "The risk or severity of adverse effects can be increased when Felbamate is combined with Lithium."
  ]
  edge [
    source 37
    target 197
    int "The risk or severity of adverse effects can be increased when Buspirone is combined with Felbamate."
  ]
  edge [
    source 37
    target 195
    int "The risk or severity of adverse effects can be increased when Entacapone is combined with Felbamate."
  ]
  edge [
    source 37
    target 196
    int "The metabolism of Felbamate can be decreased when combined with Dihydroergotamine."
  ]
  edge [
    source 37
    target 222
    int "The risk or severity of adverse effects can be increased when Metaxalone is combined with Felbamate."
  ]
  edge [
    source 37
    target 231
    int "The risk or severity of adverse effects can be increased when Carisoprodol is combined with Felbamate."
  ]
  edge [
    source 37
    target 244
    int "The metabolism of Felbamate can be decreased when combined with Ranolazine."
  ]
  edge [
    source 37
    target 174
    int "The risk or severity of adverse effects can be increased when Felbamate is combined with Sertraline."
  ]
  edge [
    source 37
    target 74
    int "The serum concentration of Saxagliptin can be decreased when it is combined with Felbamate."
  ]
  edge [
    source 37
    target 101
    int "The risk or severity of adverse effects can be increased when Zaleplon is combined with Felbamate."
  ]
  edge [
    source 37
    target 122
    int "The serum concentration of Levonorgestrel can be decreased when it is combined with Felbamate."
  ]
  edge [
    source 37
    target 61
    int "The metabolism of Felbamate can be decreased when combined with Imatinib."
  ]
  edge [
    source 37
    target 131
    int "The risk or severity of adverse effects can be increased when Rufinamide is combined with Felbamate."
  ]
  edge [
    source 37
    target 152
    int "The risk or severity of adverse effects can be increased when Efavirenz is combined with Felbamate."
  ]
  edge [
    source 37
    target 155
    int "The metabolism of Felbamate can be decreased when combined with Bortezomib."
  ]
  edge [
    source 37
    target 42
    int "The risk or severity of adverse effects can be increased when Felbamate is combined with Ramelteon."
  ]
  edge [
    source 37
    target 94
    int "The serum concentration of Valproic Acid can be increased when it is combined with Felbamate."
  ]
  edge [
    source 37
    target 238
    int "Felbamate may increase the sedative activities of Pramipexole."
  ]
  edge [
    source 37
    target 240
    int "The serum concentration of the active metabolites of Primidone can be increased when Primidone is used in combination with Felbamate."
  ]
  edge [
    source 37
    target 246
    int "The serum concentration of Felbamate can be decreased when it is combined with Bosentan."
  ]
  edge [
    source 37
    target 49
    int "The metabolism of Felbamate can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 37
    target 113
    int "The risk or severity of adverse effects can be increased when Imipramine is combined with Felbamate."
  ]
  edge [
    source 37
    target 125
    int "Felbamate may increase the QTc-prolonging activities of Pentamidine."
  ]
  edge [
    source 37
    target 133
    int "The risk or severity of adverse effects can be increased when Risperidone is combined with Felbamate."
  ]
  edge [
    source 37
    target 136
    int "The serum concentration of Ulipristal can be decreased when it is combined with Felbamate."
  ]
  edge [
    source 37
    target 156
    int "The therapeutic efficacy of Felbamate can be decreased when used in combination with Mefloquine."
  ]
  edge [
    source 37
    target 160
    int "The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Felbamate."
  ]
  edge [
    source 37
    target 169
    int "Felbamate may increase the QTc-prolonging activities of Asenapine."
  ]
  edge [
    source 37
    target 171
    int "The serum concentration of Felbamate can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 37
    target 207
    int "The risk or severity of adverse effects can be increased when Zonisamide is combined with Felbamate."
  ]
  edge [
    source 37
    target 173
    int "The risk or severity of adverse effects can be increased when Tiagabine is combined with Felbamate."
  ]
  edge [
    source 37
    target 184
    int "The risk or severity of adverse effects can be increased when Felbamate is combined with Dexmedetomidine."
  ]
  edge [
    source 37
    target 206
    int "The serum concentration of Aripiprazole can be decreased when it is combined with Felbamate."
  ]
  edge [
    source 37
    target 208
    int "The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Felbamate."
  ]
  edge [
    source 37
    target 124
    int "Felbamate may increase the QTc-prolonging activities of Pazopanib."
  ]
  edge [
    source 37
    target 39
    int "Felbamate may increase the QTc-prolonging activities of Cisapride."
  ]
  edge [
    source 37
    target 72
    int "Felbamate may increase the QTc-prolonging activities of Tetrabenazine."
  ]
  edge [
    source 37
    target 90
    int "Felbamate may increase the QTc-prolonging activities of Lumefantrine."
  ]
  edge [
    source 37
    target 58
    int "Felbamate may increase the QTc-prolonging activities of Ibutilide."
  ]
  edge [
    source 37
    target 132
    int "The risk or severity of adverse effects can be increased when Felbamate is combined with Memantine."
  ]
  edge [
    source 37
    target 43
    int "Felbamate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide."
  ]
  edge [
    source 37
    target 119
    int "The risk or severity of adverse effects can be increased when Felbamate is combined with Triflupromazine."
  ]
  edge [
    source 37
    target 191
    int "The risk or severity of adverse effects can be increased when Felbamate is combined with Trazodone."
  ]
  edge [
    source 37
    target 202
    int "The risk or severity of adverse effects can be increased when Maprotiline is combined with Felbamate."
  ]
  edge [
    source 37
    target 234
    int "The risk or severity of adverse effects can be increased when Lamotrigine is combined with Felbamate."
  ]
  edge [
    source 38
    target 123
    int "The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Leflunomide."
  ]
  edge [
    source 38
    target 51
    int "The serum concentration of Ganciclovir can be increased when it is combined with Mycophenolic acid."
  ]
  edge [
    source 38
    target 86
    int "Mycophenolic acid may increase the anticoagulant activities of Argatroban."
  ]
  edge [
    source 38
    target 95
    int "The risk or severity of adverse effects can be increased when Olmesartan is combined with Mycophenolic acid."
  ]
  edge [
    source 38
    target 146
    int "The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Chlorphenesin."
  ]
  edge [
    source 38
    target 150
    int "The serum concentration of Lithium can be increased when it is combined with Mycophenolic acid."
  ]
  edge [
    source 38
    target 44
    int "The serum concentration of Mycophenolic acid can be increased when it is combined with Probenecid."
  ]
  edge [
    source 38
    target 80
    int "The serum concentration of Methotrexate can be increased when it is combined with Mycophenolic acid."
  ]
  edge [
    source 38
    target 201
    int "Mycophenolic acid may decrease the antihypertensive activities of Aliskiren."
  ]
  edge [
    source 38
    target 217
    int "The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Desoxycorticosterone Pivalate."
  ]
  edge [
    source 38
    target 226
    int "The therapeutic efficacy of Bumetanide can be decreased when used in combination with Mycophenolic acid."
  ]
  edge [
    source 38
    target 247
    int "The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Mesalazine."
  ]
  edge [
    source 38
    target 45
    int "The therapeutic efficacy of Iloprost can be decreased when used in combination with Mycophenolic acid."
  ]
  edge [
    source 38
    target 46
    int "Tacrolimus may increase the immunosuppressive activities of Mycophenolic acid."
  ]
  edge [
    source 38
    target 47
    int "The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Prednisolone."
  ]
  edge [
    source 38
    target 50
    int "The risk or severity of adverse effects can be increased when Docetaxel is combined with Mycophenolic acid."
  ]
  edge [
    source 38
    target 70
    int "Mycophenolic acid may decrease the antihypertensive activities of Amiloride."
  ]
  edge [
    source 38
    target 235
    int "The serum concentration of Mycophenolic acid can be decreased when it is combined with Lansoprazole."
  ]
  edge [
    source 38
    target 103
    int "The risk or severity of adverse effects can be increased when Zileuton is combined with Mycophenolic acid."
  ]
  edge [
    source 38
    target 122
    int "The serum concentration of Levonorgestrel can be decreased when it is combined with Mycophenolic acid."
  ]
  edge [
    source 38
    target 147
    int "The serum concentration of Mycophenolic acid can be decreased when it is combined with Metronidazole."
  ]
  edge [
    source 38
    target 65
    int "The serum concentration of Ethinyl Estradiol can be decreased when it is combined with Mycophenolic acid."
  ]
  edge [
    source 38
    target 75
    int "The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Teriflunomide."
  ]
  edge [
    source 38
    target 168
    int "Mycophenolic acid may decrease the antihypertensive activities of Atenolol."
  ]
  edge [
    source 38
    target 93
    int "Mycophenolic acid may decrease the antihypertensive activities of Hydralazine."
  ]
  edge [
    source 38
    target 136
    int "The serum concentration of Ulipristal can be decreased when it is combined with Mycophenolic acid."
  ]
  edge [
    source 38
    target 162
    int "Mycophenolic acid may decrease the antihypertensive activities of Spironolactone."
  ]
  edge [
    source 38
    target 169
    int "Mycophenolic acid may decrease the antihypertensive activities of Asenapine."
  ]
  edge [
    source 38
    target 204
    int "The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Oxyphenbutazone."
  ]
  edge [
    source 38
    target 85
    int "Digitoxin may decrease the cardiotoxic activities of Mycophenolic acid."
  ]
  edge [
    source 38
    target 229
    int "Mycophenolic acid may decrease the excretion rate of Paromomycin which could result in a higher serum level."
  ]
  edge [
    source 38
    target 56
    int "The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Enalaprilat."
  ]
  edge [
    source 38
    target 128
    int "The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Mycophenolic acid."
  ]
  edge [
    source 38
    target 199
    int "The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Meclofenamic acid."
  ]
  edge [
    source 38
    target 215
    int "The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Mycophenolic acid."
  ]
  edge [
    source 38
    target 189
    int "The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Aminosalicylic Acid."
  ]
  edge [
    source 39
    target 157
    int "The metabolism of Cisapride can be decreased when combined with Armodafinil."
  ]
  edge [
    source 39
    target 123
    int "The metabolism of Cisapride can be decreased when combined with Leflunomide."
  ]
  edge [
    source 39
    target 61
    int "The metabolism of Cisapride can be decreased when combined with Imatinib."
  ]
  edge [
    source 39
    target 62
    int "The metabolism of Cisapride can be decreased when combined with Tranylcypromine."
  ]
  edge [
    source 39
    target 63
    int "Azithromycin may increase the QTc-prolonging activities of Cisapride."
  ]
  edge [
    source 39
    target 64
    int "The metabolism of Cisapride can be decreased when combined with Clopidogrel."
  ]
  edge [
    source 39
    target 167
    int "The metabolism of Cisapride can be decreased when combined with Sildenafil."
  ]
  edge [
    source 39
    target 68
    int "The metabolism of Cisapride can be increased when combined with Rifabutin."
  ]
  edge [
    source 39
    target 75
    int "The serum concentration of Cisapride can be decreased when it is combined with Teriflunomide."
  ]
  edge [
    source 39
    target 91
    int "The metabolism of Cisapride can be decreased when combined with Topiramate."
  ]
  edge [
    source 39
    target 138
    int "The metabolism of Cisapride can be decreased when combined with Theophylline."
  ]
  edge [
    source 39
    target 110
    int "The risk or severity of QTc prolongation can be increased when Cisapride is combined with Dronedarone."
  ]
  edge [
    source 39
    target 137
    int "The serum concentration of Cisapride can be increased when it is combined with Artemether."
  ]
  edge [
    source 39
    target 141
    int "The metabolism of Cisapride can be decreased when combined with Doxorubicin."
  ]
  edge [
    source 39
    target 150
    int "Lithium may increase the QTc-prolonging activities of Cisapride."
  ]
  edge [
    source 39
    target 196
    int "The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Cisapride."
  ]
  edge [
    source 39
    target 118
    int "Sunitinib may increase the QTc-prolonging activities of Cisapride."
  ]
  edge [
    source 39
    target 232
    int "Sorafenib may increase the QTc-prolonging activities of Cisapride."
  ]
  edge [
    source 39
    target 244
    int "Ranolazine may increase the QTc-prolonging activities of Cisapride."
  ]
  edge [
    source 39
    target 174
    int "Sertraline may increase the QTc-prolonging activities of Cisapride."
  ]
  edge [
    source 39
    target 84
    int "Trimethoprim may increase the QTc-prolonging activities of Cisapride."
  ]
  edge [
    source 39
    target 41
    int "The risk or severity of QTc prolongation can be increased when Citalopram is combined with Cisapride."
  ]
  edge [
    source 39
    target 107
    int "Vorinostat may increase the QTc-prolonging activities of Cisapride."
  ]
  edge [
    source 39
    target 147
    int "Metronidazole may increase the QTc-prolonging activities of Cisapride."
  ]
  edge [
    source 39
    target 83
    int "Amantadine may increase the QTc-prolonging activities of Cisapride."
  ]
  edge [
    source 39
    target 152
    int "The metabolism of Cisapride can be decreased when combined with Efavirenz."
  ]
  edge [
    source 39
    target 155
    int "Bortezomib may increase the QTc-prolonging activities of Cisapride."
  ]
  edge [
    source 39
    target 205
    int "Foscarnet may increase the QTc-prolonging activities of Cisapride."
  ]
  edge [
    source 39
    target 94
    int "The metabolism of Cisapride can be decreased when combined with Valproic Acid."
  ]
  edge [
    source 39
    target 237
    int "The metabolism of Cisapride can be decreased when combined with Rosiglitazone."
  ]
  edge [
    source 39
    target 240
    int "The metabolism of Cisapride can be increased when combined with Primidone."
  ]
  edge [
    source 39
    target 246
    int "The serum concentration of Cisapride can be decreased when it is combined with Bosentan."
  ]
  edge [
    source 39
    target 49
    int "The metabolism of Cisapride can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 39
    target 113
    int "Imipramine may increase the QTc-prolonging activities of Cisapride."
  ]
  edge [
    source 39
    target 125
    int "The serum concentration of Cisapride can be increased when it is combined with Pentamidine."
  ]
  edge [
    source 39
    target 133
    int "Risperidone may increase the QTc-prolonging activities of Cisapride."
  ]
  edge [
    source 39
    target 156
    int "Mefloquine may increase the QTc-prolonging activities of Cisapride."
  ]
  edge [
    source 39
    target 102
    int "The risk or severity of adverse effects can be increased when Methylergometrine is combined with Cisapride."
  ]
  edge [
    source 39
    target 166
    int "The serum concentration of Tolvaptan can be increased when it is combined with Cisapride."
  ]
  edge [
    source 39
    target 169
    int "The risk or severity of QTc prolongation can be increased when Cisapride is combined with Asenapine."
  ]
  edge [
    source 39
    target 171
    int "The serum concentration of Cisapride can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 39
    target 206
    int "Aripiprazole may increase the QTc-prolonging activities of Cisapride."
  ]
  edge [
    source 39
    target 124
    int "Pazopanib may increase the QTc-prolonging activities of Cisapride."
  ]
  edge [
    source 39
    target 72
    int "The risk or severity of QTc prolongation can be increased when Cisapride is combined with Tetrabenazine."
  ]
  edge [
    source 39
    target 90
    int "The risk or severity of QTc prolongation can be increased when Cisapride is combined with Lumefantrine."
  ]
  edge [
    source 39
    target 58
    int "The risk or severity of QTc prolongation can be increased when Ibutilide is combined with Cisapride."
  ]
  edge [
    source 39
    target 188
    int "The serum concentration of Cerivastatin can be increased when it is combined with Cisapride."
  ]
  edge [
    source 39
    target 191
    int "Trazodone may increase the QTc-prolonging activities of Cisapride."
  ]
  edge [
    source 39
    target 202
    int "Maprotiline may increase the QTc-prolonging activities of Cisapride."
  ]
  edge [
    source 41
    target 157
    int "The serum concentration of Citalopram can be increased when it is combined with Armodafinil."
  ]
  edge [
    source 41
    target 123
    int "The metabolism of Leflunomide can be decreased when combined with Citalopram."
  ]
  edge [
    source 41
    target 206
    int "The serum concentration of Aripiprazole can be increased when it is combined with Citalopram."
  ]
  edge [
    source 41
    target 61
    int "The metabolism of Citalopram can be decreased when combined with Imatinib."
  ]
  edge [
    source 41
    target 62
    int "The serum concentration of Citalopram can be increased when it is combined with Tranylcypromine."
  ]
  edge [
    source 41
    target 63
    int "Azithromycin may increase the QTc-prolonging activities of Citalopram."
  ]
  edge [
    source 41
    target 64
    int "The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Citalopram resulting in a loss in efficacy."
  ]
  edge [
    source 41
    target 67
    int "Furazolidone may increase the serotonergic activities of Citalopram."
  ]
  edge [
    source 41
    target 68
    int "The metabolism of Citalopram can be increased when combined with Rifabutin."
  ]
  edge [
    source 41
    target 222
    int "The risk or severity of adverse effects can be increased when Metaxalone is combined with Citalopram."
  ]
  edge [
    source 41
    target 91
    int "The serum concentration of Citalopram can be increased when it is combined with Topiramate."
  ]
  edge [
    source 41
    target 138
    int "The metabolism of Theophylline can be decreased when combined with Citalopram."
  ]
  edge [
    source 41
    target 109
    int "The risk or severity of adverse effects can be increased when Etomidate is combined with Citalopram."
  ]
  edge [
    source 41
    target 110
    int "The risk or severity of QTc prolongation can be increased when Citalopram is combined with Dronedarone."
  ]
  edge [
    source 41
    target 137
    int "The risk or severity of QTc prolongation can be increased when Citalopram is combined with Artemether."
  ]
  edge [
    source 41
    target 141
    int "The metabolism of Doxorubicin can be decreased when combined with Citalopram."
  ]
  edge [
    source 41
    target 142
    int "The risk or severity of adverse effects can be increased when Gabapentin is combined with Citalopram."
  ]
  edge [
    source 41
    target 146
    int "Citalopram may increase the antiplatelet activities of Chlorphenesin."
  ]
  edge [
    source 41
    target 148
    int "The risk or severity of adverse effects can be increased when Dantrolene is combined with Citalopram."
  ]
  edge [
    source 41
    target 194
    int "Pargyline may increase the serotonergic activities of Citalopram."
  ]
  edge [
    source 41
    target 195
    int "The risk or severity of adverse effects can be increased when Entacapone is combined with Citalopram."
  ]
  edge [
    source 41
    target 196
    int "The risk or severity of adverse effects can be increased when Citalopram is combined with Dihydroergotamine."
  ]
  edge [
    source 41
    target 198
    int "Citalopram may increase the hypoglycemic activities of Miglitol."
  ]
  edge [
    source 41
    target 182
    int "The metabolism of Mephenytoin can be decreased when combined with Citalopram."
  ]
  edge [
    source 41
    target 197
    int "Buspirone may increase the serotonergic activities of Citalopram."
  ]
  edge [
    source 41
    target 193
    int "The metabolism of Flutamide can be decreased when combined with Citalopram."
  ]
  edge [
    source 41
    target 214
    int "The metabolism of Proguanil can be decreased when combined with Citalopram."
  ]
  edge [
    source 41
    target 224
    int "The risk or severity of adverse effects can be increased when Citalopram is combined with Sumatriptan."
  ]
  edge [
    source 41
    target 231
    int "The metabolism of Carisoprodol can be decreased when combined with Citalopram."
  ]
  edge [
    source 41
    target 232
    int "Sorafenib may increase the QTc-prolonging activities of Citalopram."
  ]
  edge [
    source 41
    target 244
    int "The serum concentration of Ranolazine can be increased when it is combined with Citalopram."
  ]
  edge [
    source 41
    target 247
    int "Citalopram may increase the antiplatelet activities of Mesalazine."
  ]
  edge [
    source 41
    target 212
    int "The metabolism of Loperamide can be decreased when combined with Citalopram."
  ]
  edge [
    source 41
    target 46
    int "The metabolism of Tacrolimus can be decreased when combined with Citalopram."
  ]
  edge [
    source 41
    target 158
    int "The metabolism of Piperazine can be decreased when combined with Citalopram."
  ]
  edge [
    source 41
    target 174
    int "The serum concentration of Citalopram can be increased when it is combined with Sertraline."
  ]
  edge [
    source 41
    target 74
    int "Citalopram may increase the hypoglycemic activities of Saxagliptin."
  ]
  edge [
    source 41
    target 235
    int "The metabolism of Lansoprazole can be decreased when combined with Citalopram."
  ]
  edge [
    source 41
    target 84
    int "Trimethoprim may increase the QTc-prolonging activities of Citalopram."
  ]
  edge [
    source 41
    target 101
    int "The risk or severity of adverse effects can be increased when Zaleplon is combined with Citalopram."
  ]
  edge [
    source 41
    target 103
    int "The metabolism of Zileuton can be decreased when combined with Citalopram."
  ]
  edge [
    source 41
    target 105
    int "The metabolism of Riluzole can be decreased when combined with Citalopram."
  ]
  edge [
    source 41
    target 147
    int "Metronidazole may increase the QTc-prolonging activities of Citalopram."
  ]
  edge [
    source 41
    target 83
    int "Amantadine may increase the QTc-prolonging activities of Citalopram."
  ]
  edge [
    source 41
    target 152
    int "The serum concentration of Citalopram can be increased when it is combined with Efavirenz."
  ]
  edge [
    source 41
    target 153
    int "The metabolism of Testosterone can be decreased when combined with Citalopram."
  ]
  edge [
    source 41
    target 155
    int "The serum concentration of Citalopram can be increased when it is combined with Bortezomib."
  ]
  edge [
    source 41
    target 159
    int "The metabolism of Cevimeline can be decreased when combined with Citalopram."
  ]
  edge [
    source 41
    target 167
    int "The metabolism of Citalopram can be decreased when combined with Sildenafil."
  ]
  edge [
    source 41
    target 42
    int "The metabolism of Ramelteon can be decreased when combined with Citalopram."
  ]
  edge [
    source 41
    target 181
    int "The metabolism of Dopamine can be decreased when combined with Citalopram."
  ]
  edge [
    source 41
    target 205
    int "Foscarnet may increase the QTc-prolonging activities of Citalopram."
  ]
  edge [
    source 41
    target 94
    int "The metabolism of Valproic Acid can be decreased when combined with Citalopram."
  ]
  edge [
    source 41
    target 48
    int "The metabolism of Gefitinib can be decreased when combined with Citalopram."
  ]
  edge [
    source 41
    target 237
    int "Citalopram may increase the hypoglycemic activities of Rosiglitazone."
  ]
  edge [
    source 41
    target 240
    int "The metabolism of Citalopram can be increased when combined with Primidone."
  ]
  edge [
    source 41
    target 246
    int "The serum concentration of Citalopram can be decreased when it is combined with Bosentan."
  ]
  edge [
    source 41
    target 72
    int "The risk or severity of QTc prolongation can be increased when Citalopram is combined with Tetrabenazine."
  ]
  edge [
    source 41
    target 234
    int "The risk or severity of adverse effects can be increased when Citalopram is combined with Lamotrigine."
  ]
  edge [
    source 41
    target 90
    int "The risk or severity of QTc prolongation can be increased when Citalopram is combined with Lumefantrine."
  ]
  edge [
    source 41
    target 154
    int "The metabolism of Amprenavir can be decreased when combined with Citalopram."
  ]
  edge [
    source 41
    target 49
    int "The serum concentration of Citalopram can be increased when it is combined with Fluvoxamine."
  ]
  edge [
    source 41
    target 150
    int "Lithium may increase the serotonergic activities of Citalopram."
  ]
  edge [
    source 41
    target 89
    int "The metabolism of Praziquantel can be decreased when combined with Citalopram."
  ]
  edge [
    source 41
    target 113
    int "The risk or severity of adverse effects can be increased when Imipramine is combined with Citalopram."
  ]
  edge [
    source 41
    target 117
    int "The metabolism of Albendazole can be decreased when combined with Citalopram."
  ]
  edge [
    source 41
    target 125
    int "Pentamidine may increase the QTc-prolonging activities of Citalopram."
  ]
  edge [
    source 41
    target 129
    int "The metabolism of Nateglinide can be decreased when combined with Citalopram."
  ]
  edge [
    source 41
    target 133
    int "The metabolism of Risperidone can be decreased when combined with Citalopram."
  ]
  edge [
    source 41
    target 135
    int "The serum concentration of Everolimus can be increased when it is combined with Citalopram."
  ]
  edge [
    source 41
    target 136
    int "The metabolism of Ulipristal can be decreased when combined with Citalopram."
  ]
  edge [
    source 41
    target 156
    int "Mefloquine may increase the QTc-prolonging activities of Citalopram."
  ]
  edge [
    source 41
    target 169
    int "The risk or severity of QTc prolongation can be increased when Citalopram is combined with Asenapine."
  ]
  edge [
    source 41
    target 171
    int "The serum concentration of Citalopram can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 41
    target 207
    int "The risk or severity of adverse effects can be increased when Zonisamide is combined with Citalopram."
  ]
  edge [
    source 41
    target 173
    int "The risk or severity of adverse effects can be increased when Tiagabine is combined with Citalopram."
  ]
  edge [
    source 41
    target 184
    int "The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Citalopram."
  ]
  edge [
    source 41
    target 130
    int "The metabolism of Thiabendazole can be decreased when combined with Citalopram."
  ]
  edge [
    source 41
    target 208
    int "The metabolism of Trifluoperazine can be decreased when combined with Citalopram."
  ]
  edge [
    source 41
    target 124
    int "The serum concentration of Pazopanib can be increased when it is combined with Citalopram."
  ]
  edge [
    source 41
    target 160
    int "The metabolism of Chlorzoxazone can be decreased when combined with Citalopram."
  ]
  edge [
    source 41
    target 53
    int "The metabolism of Vinblastine can be decreased when combined with Citalopram."
  ]
  edge [
    source 41
    target 200
    int "The metabolism of Zalcitabine can be decreased when combined with Citalopram."
  ]
  edge [
    source 41
    target 58
    int "The risk or severity of QTc prolongation can be increased when Citalopram is combined with Ibutilide."
  ]
  edge [
    source 41
    target 59
    int "The metabolism of Carmustine can be decreased when combined with Citalopram."
  ]
  edge [
    source 41
    target 191
    int "Citalopram may increase the serotonergic activities of Trazodone."
  ]
  edge [
    source 41
    target 73
    int "Citalopram may increase the hypoglycemic activities of Acarbose."
  ]
  edge [
    source 41
    target 119
    int "The risk or severity of adverse effects can be increased when Triflupromazine is combined with Citalopram."
  ]
  edge [
    source 41
    target 115
    int "Citalopram may increase the hypoglycemic activities of Sitagliptin."
  ]
  edge [
    source 41
    target 118
    int "Sunitinib may increase the QTc-prolonging activities of Citalopram."
  ]
  edge [
    source 41
    target 149
    int "The metabolism of Halofantrine can be decreased when combined with Citalopram."
  ]
  edge [
    source 41
    target 43
    int "The metabolism of Thalidomide can be decreased when combined with Citalopram."
  ]
  edge [
    source 41
    target 165
    int "The metabolism of Pyrazinamide can be decreased when combined with Citalopram."
  ]
  edge [
    source 41
    target 170
    int "Citalopram may increase the hypoglycemic activities of Metformin."
  ]
  edge [
    source 41
    target 199
    int "Citalopram may increase the antiplatelet activities of Meclofenamic acid."
  ]
  edge [
    source 41
    target 202
    int "Maprotiline may increase the QTc-prolonging activities of Citalopram."
  ]
  edge [
    source 41
    target 215
    int "Citalopram may increase the hyponatremic activities of Methyclothiazide."
  ]
  edge [
    source 41
    target 189
    int "Citalopram may increase the antiplatelet activities of Aminosalicylic Acid."
  ]
  edge [
    source 41
    target 107
    int "Vorinostat may increase the QTc-prolonging activities of Citalopram."
  ]
  edge [
    source 42
    target 157
    int "The metabolism of Ramelteon can be decreased when combined with Armodafinil."
  ]
  edge [
    source 42
    target 62
    int "The metabolism of Ramelteon can be decreased when combined with Tranylcypromine."
  ]
  edge [
    source 42
    target 63
    int "The metabolism of Ramelteon can be decreased when combined with Azithromycin."
  ]
  edge [
    source 42
    target 167
    int "The metabolism of Ramelteon can be decreased when combined with Sildenafil."
  ]
  edge [
    source 42
    target 68
    int "The metabolism of Ramelteon can be increased when combined with Rifabutin."
  ]
  edge [
    source 42
    target 75
    int "The serum concentration of Ramelteon can be decreased when it is combined with Teriflunomide."
  ]
  edge [
    source 42
    target 91
    int "The metabolism of Ramelteon can be decreased when combined with Topiramate."
  ]
  edge [
    source 42
    target 138
    int "The metabolism of Ramelteon can be decreased when combined with Theophylline."
  ]
  edge [
    source 42
    target 109
    int "The risk or severity of adverse effects can be increased when Ramelteon is combined with Etomidate."
  ]
  edge [
    source 42
    target 110
    int "The metabolism of Ramelteon can be decreased when combined with Dronedarone."
  ]
  edge [
    source 42
    target 142
    int "The risk or severity of adverse effects can be increased when Gabapentin is combined with Ramelteon."
  ]
  edge [
    source 42
    target 148
    int "The risk or severity of adverse effects can be increased when Ramelteon is combined with Dantrolene."
  ]
  edge [
    source 42
    target 150
    int "The risk or severity of adverse effects can be increased when Ramelteon is combined with Lithium."
  ]
  edge [
    source 42
    target 197
    int "The risk or severity of adverse effects can be increased when Buspirone is combined with Ramelteon."
  ]
  edge [
    source 42
    target 195
    int "The risk or severity of adverse effects can be increased when Entacapone is combined with Ramelteon."
  ]
  edge [
    source 42
    target 196
    int "The metabolism of Ramelteon can be decreased when combined with Dihydroergotamine."
  ]
  edge [
    source 42
    target 222
    int "The risk or severity of adverse effects can be increased when Metaxalone is combined with Ramelteon."
  ]
  edge [
    source 42
    target 231
    int "The risk or severity of adverse effects can be increased when Carisoprodol is combined with Ramelteon."
  ]
  edge [
    source 42
    target 244
    int "The metabolism of Ramelteon can be decreased when combined with Ranolazine."
  ]
  edge [
    source 42
    target 174
    int "The metabolism of Ramelteon can be decreased when combined with Sertraline."
  ]
  edge [
    source 42
    target 101
    int "The risk or severity of adverse effects can be increased when Zaleplon is combined with Ramelteon."
  ]
  edge [
    source 42
    target 61
    int "The metabolism of Ramelteon can be decreased when combined with Imatinib."
  ]
  edge [
    source 42
    target 131
    int "The risk or severity of adverse effects can be increased when Rufinamide is combined with Ramelteon."
  ]
  edge [
    source 42
    target 152
    int "The metabolism of Ramelteon can be decreased when combined with Efavirenz."
  ]
  edge [
    source 42
    target 155
    int "The metabolism of Ramelteon can be decreased when combined with Bortezomib."
  ]
  edge [
    source 42
    target 178
    int "Flumazenil may decrease the sedative activities of Ramelteon."
  ]
  edge [
    source 42
    target 94
    int "The risk or severity of adverse effects can be increased when Ramelteon is combined with Valproic Acid."
  ]
  edge [
    source 42
    target 238
    int "Ramelteon may increase the sedative activities of Pramipexole."
  ]
  edge [
    source 42
    target 240
    int "The metabolism of Ramelteon can be increased when combined with Primidone."
  ]
  edge [
    source 42
    target 246
    int "The serum concentration of Ramelteon can be decreased when it is combined with Bosentan."
  ]
  edge [
    source 42
    target 234
    int "The risk or severity of adverse effects can be increased when Lamotrigine is combined with Ramelteon."
  ]
  edge [
    source 42
    target 49
    int "The serum concentration of Ramelteon can be increased when it is combined with Fluvoxamine."
  ]
  edge [
    source 42
    target 113
    int "The risk or severity of adverse effects can be increased when Imipramine is combined with Ramelteon."
  ]
  edge [
    source 42
    target 133
    int "The risk or severity of adverse effects can be increased when Risperidone is combined with Ramelteon."
  ]
  edge [
    source 42
    target 160
    int "The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Ramelteon."
  ]
  edge [
    source 42
    target 169
    int "The risk or severity of adverse effects can be increased when Asenapine is combined with Ramelteon."
  ]
  edge [
    source 42
    target 171
    int "The serum concentration of Ramelteon can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 42
    target 207
    int "The risk or severity of adverse effects can be increased when Zonisamide is combined with Ramelteon."
  ]
  edge [
    source 42
    target 173
    int "The risk or severity of adverse effects can be increased when Tiagabine is combined with Ramelteon."
  ]
  edge [
    source 42
    target 184
    int "The risk or severity of adverse effects can be increased when Ramelteon is combined with Dexmedetomidine."
  ]
  edge [
    source 42
    target 206
    int "The risk or severity of adverse effects can be increased when Aripiprazole is combined with Ramelteon."
  ]
  edge [
    source 42
    target 208
    int "The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ramelteon."
  ]
  edge [
    source 42
    target 72
    int "The risk or severity of adverse effects can be increased when Ramelteon is combined with Tetrabenazine."
  ]
  edge [
    source 42
    target 43
    int "Ramelteon may increase the central nervous system depressant (CNS depressant) activities of Thalidomide."
  ]
  edge [
    source 42
    target 119
    int "The risk or severity of adverse effects can be increased when Ramelteon is combined with Triflupromazine."
  ]
  edge [
    source 42
    target 191
    int "The risk or severity of adverse effects can be increased when Ramelteon is combined with Trazodone."
  ]
  edge [
    source 42
    target 202
    int "The risk or severity of adverse effects can be increased when Maprotiline is combined with Ramelteon."
  ]
  edge [
    source 43
    target 157
    int "The metabolism of Thalidomide can be decreased when combined with Armodafinil."
  ]
  edge [
    source 43
    target 123
    int "The risk or severity of adverse effects can be increased when Thalidomide is combined with Leflunomide."
  ]
  edge [
    source 43
    target 62
    int "Tranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide."
  ]
  edge [
    source 43
    target 249
    int "The risk or severity of adverse effects can be increased when Thalidomide is combined with Dipyridamole."
  ]
  edge [
    source 43
    target 167
    int "The metabolism of Thalidomide can be decreased when combined with Sildenafil."
  ]
  edge [
    source 43
    target 75
    int "The serum concentration of Thalidomide can be decreased when it is combined with Teriflunomide."
  ]
  edge [
    source 43
    target 101
    int "Zaleplon may increase the central nervous system depressant (CNS depressant) activities of Thalidomide."
  ]
  edge [
    source 43
    target 91
    int "Topiramate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide."
  ]
  edge [
    source 43
    target 138
    int "The metabolism of Thalidomide can be decreased when combined with Theophylline."
  ]
  edge [
    source 43
    target 95
    int "The risk or severity of adverse effects can be increased when Thalidomide is combined with Olmesartan."
  ]
  edge [
    source 43
    target 109
    int "Etomidate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide."
  ]
  edge [
    source 43
    target 142
    int "Gabapentin may increase the central nervous system depressant (CNS depressant) activities of Thalidomide."
  ]
  edge [
    source 43
    target 150
    int "Lithium may increase the central nervous system depressant (CNS depressant) activities of Thalidomide."
  ]
  edge [
    source 43
    target 195
    int "Entacapone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide."
  ]
  edge [
    source 43
    target 197
    int "Buspirone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide."
  ]
  edge [
    source 43
    target 219
    int "The risk or severity of adverse effects can be increased when Thalidomide is combined with Nisoldipine."
  ]
  edge [
    source 43
    target 222
    int "Metaxalone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide."
  ]
  edge [
    source 43
    target 230
    int "The risk or severity of adverse effects can be increased when Thalidomide is combined with Isosorbide Dinitrate."
  ]
  edge [
    source 43
    target 231
    int "Carisoprodol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide."
  ]
  edge [
    source 43
    target 232
    int "The metabolism of Thalidomide can be decreased when combined with Sorafenib."
  ]
  edge [
    source 43
    target 65
    int "Ethinyl Estradiol may increase the thrombogenic activities of Thalidomide."
  ]
  edge [
    source 43
    target 45
    int "The risk or severity of adverse effects can be increased when Iloprost is combined with Thalidomide."
  ]
  edge [
    source 43
    target 46
    int "Tacrolimus may increase the immunosuppressive activities of Thalidomide."
  ]
  edge [
    source 43
    target 50
    int "The risk or severity of adverse effects can be increased when Docetaxel is combined with Thalidomide."
  ]
  edge [
    source 43
    target 70
    int "The risk or severity of adverse effects can be increased when Thalidomide is combined with Amiloride."
  ]
  edge [
    source 43
    target 74
    int "The serum concentration of Saxagliptin can be decreased when it is combined with Thalidomide."
  ]
  edge [
    source 43
    target 84
    int "The metabolism of Thalidomide can be decreased when combined with Trimethoprim."
  ]
  edge [
    source 43
    target 226
    int "The risk or severity of adverse effects can be increased when Thalidomide is combined with Bumetanide."
  ]
  edge [
    source 43
    target 98
    int "The risk or severity of adverse effects can be increased when Thalidomide is combined with Methyldopa."
  ]
  edge [
    source 43
    target 122
    int "Levonorgestrel may increase the thrombogenic activities of Thalidomide."
  ]
  edge [
    source 43
    target 131
    int "The risk or severity of adverse effects can be increased when Rufinamide is combined with Thalidomide."
  ]
  edge [
    source 43
    target 152
    int "Efavirenz may increase the central nervous system depressant (CNS depressant) activities of Thalidomide."
  ]
  edge [
    source 43
    target 63
    int "The metabolism of Thalidomide can be decreased when combined with Azithromycin."
  ]
  edge [
    source 43
    target 155
    int "The metabolism of Thalidomide can be decreased when combined with Bortezomib."
  ]
  edge [
    source 43
    target 168
    int "The risk or severity of adverse effects can be increased when Thalidomide is combined with Atenolol."
  ]
  edge [
    source 43
    target 94
    int "Valproic Acid may increase the central nervous system depressant (CNS depressant) activities of Thalidomide."
  ]
  edge [
    source 43
    target 228
    int "The risk or severity of adverse effects can be increased when Thalidomide is combined with Bretylium."
  ]
  edge [
    source 43
    target 238
    int "Thalidomide may increase the sedative activities of Pramipexole."
  ]
  edge [
    source 43
    target 240
    int "Primidone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide."
  ]
  edge [
    source 43
    target 241
    int "The risk or severity of adverse effects can be increased when Thalidomide is combined with Tolazoline."
  ]
  edge [
    source 43
    target 234
    int "Lamotrigine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide."
  ]
  edge [
    source 43
    target 49
    int "Fluvoxamine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide."
  ]
  edge [
    source 43
    target 148
    int "Dantrolene may increase the central nervous system depressant (CNS depressant) activities of Thalidomide."
  ]
  edge [
    source 43
    target 93
    int "The risk or severity of adverse effects can be increased when Thalidomide is combined with Hydralazine."
  ]
  edge [
    source 43
    target 113
    int "Imipramine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide."
  ]
  edge [
    source 43
    target 133
    int "Risperidone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide."
  ]
  edge [
    source 43
    target 136
    int "Ulipristal may increase the thrombogenic activities of Thalidomide."
  ]
  edge [
    source 43
    target 160
    int "Chlorzoxazone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide."
  ]
  edge [
    source 43
    target 161
    int "The risk or severity of adverse effects can be increased when Thalidomide is combined with Minoxidil."
  ]
  edge [
    source 43
    target 162
    int "The risk or severity of adverse effects can be increased when Thalidomide is combined with Spironolactone."
  ]
  edge [
    source 43
    target 169
    int "Asenapine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide."
  ]
  edge [
    source 43
    target 207
    int "Zonisamide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide."
  ]
  edge [
    source 43
    target 173
    int "Tiagabine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide."
  ]
  edge [
    source 43
    target 184
    int "Dexmedetomidine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide."
  ]
  edge [
    source 43
    target 87
    int "The risk or severity of adverse effects can be increased when Clofarabine is combined with Thalidomide."
  ]
  edge [
    source 43
    target 201
    int "The risk or severity of adverse effects can be increased when Thalidomide is combined with Aliskiren."
  ]
  edge [
    source 43
    target 206
    int "Aripiprazole may increase the central nervous system depressant (CNS depressant) activities of Thalidomide."
  ]
  edge [
    source 43
    target 208
    int "Trifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide."
  ]
  edge [
    source 43
    target 85
    int "Digitoxin may decrease the cardiotoxic activities of Thalidomide."
  ]
  edge [
    source 43
    target 56
    int "The risk or severity of adverse effects can be increased when Enalaprilat is combined with Thalidomide."
  ]
  edge [
    source 43
    target 119
    int "Triflupromazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide."
  ]
  edge [
    source 43
    target 174
    int "The metabolism of Thalidomide can be decreased when combined with Sertraline."
  ]
  edge [
    source 43
    target 72
    int "Tetrabenazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide."
  ]
  edge [
    source 43
    target 191
    int "Trazodone may increase the central nervous system depressant (CNS depressant) activities of Thalidomide."
  ]
  edge [
    source 43
    target 192
    int "The risk or severity of adverse effects can be increased when Thalidomide is combined with Mecamylamine."
  ]
  edge [
    source 43
    target 202
    int "Maprotiline may increase the central nervous system depressant (CNS depressant) activities of Thalidomide."
  ]
  edge [
    source 43
    target 215
    int "The risk or severity of adverse effects can be increased when Thalidomide is combined with Methyclothiazide."
  ]
  edge [
    source 44
    target 123
    int "The serum concentration of Leflunomide can be increased when it is combined with Probenecid."
  ]
  edge [
    source 44
    target 124
    int "The serum concentration of Pazopanib can be increased when it is combined with Probenecid."
  ]
  edge [
    source 44
    target 138
    int "The serum concentration of Theophylline can be increased when it is combined with Probenecid."
  ]
  edge [
    source 44
    target 51
    int "The serum concentration of Ganciclovir can be increased when it is combined with Probenecid."
  ]
  edge [
    source 44
    target 74
    int "The serum concentration of Saxagliptin can be decreased when it is combined with Probenecid."
  ]
  edge [
    source 44
    target 80
    int "The serum concentration of Methotrexate can be increased when it is combined with Probenecid."
  ]
  edge [
    source 44
    target 103
    int "The serum concentration of Zileuton can be increased when it is combined with Probenecid."
  ]
  edge [
    source 44
    target 112
    int "The serum concentration of Cefmenoxime can be increased when it is combined with Probenecid."
  ]
  edge [
    source 44
    target 227
    int "The serum concentration of the active metabolites of Oseltamivir can be increased when Oseltamivir is used in combination with Probenecid."
  ]
  edge [
    source 44
    target 135
    int "The serum concentration of Everolimus can be increased when it is combined with Probenecid."
  ]
  edge [
    source 44
    target 141
    int "The serum concentration of Doxorubicin can be increased when it is combined with Probenecid."
  ]
  edge [
    source 44
    target 161
    int "The serum concentration of Minoxidil can be increased when it is combined with Probenecid."
  ]
  edge [
    source 44
    target 236
    int "The protein binding of Acetohexamide can be decreased when combined with Probenecid."
  ]
  edge [
    source 44
    target 226
    int "The risk or severity of adverse effects can be increased when Probenecid is combined with Bumetanide."
  ]
  edge [
    source 44
    target 75
    int "The serum concentration of Teriflunomide can be increased when it is combined with Probenecid."
  ]
  edge [
    source 44
    target 192
    int "The risk or severity of adverse effects can be increased when Probenecid is combined with Mecamylamine."
  ]
  edge [
    source 44
    target 204
    int "The serum concentration of Oxyphenbutazone can be increased when it is combined with Probenecid."
  ]
  edge [
    source 44
    target 199
    int "The serum concentration of Meclofenamic acid can be increased when it is combined with Probenecid."
  ]
  edge [
    source 44
    target 206
    int "The serum concentration of Aripiprazole can be decreased when it is combined with Probenecid."
  ]
  edge [
    source 44
    target 215
    int "The risk or severity of adverse effects can be increased when Probenecid is combined with Methyclothiazide."
  ]
  edge [
    source 44
    target 189
    int "The therapeutic efficacy of Probenecid can be decreased when used in combination with Aminosalicylic Acid."
  ]
  edge [
    source 44
    target 247
    int "The therapeutic efficacy of Probenecid can be decreased when used in combination with Mesalazine."
  ]
  edge [
    source 44
    target 244
    int "The serum concentration of Ranolazine can be increased when it is combined with Probenecid."
  ]
  edge [
    source 45
    target 62
    int "The risk or severity of adverse effects can be increased when Iloprost is combined with Tranylcypromine."
  ]
  edge [
    source 45
    target 249
    int "Dipyridamole may increase the anticoagulant activities of Iloprost."
  ]
  edge [
    source 45
    target 86
    int "Iloprost may increase the anticoagulant activities of Argatroban."
  ]
  edge [
    source 45
    target 95
    int "The risk or severity of adverse effects can be increased when Iloprost is combined with Olmesartan."
  ]
  edge [
    source 45
    target 123
    int "The therapeutic efficacy of Iloprost can be decreased when used in combination with Leflunomide."
  ]
  edge [
    source 45
    target 230
    int "The risk or severity of adverse effects can be increased when Iloprost is combined with Isosorbide Dinitrate."
  ]
  edge [
    source 45
    target 194
    int "Iloprost may increase the hypotensive activities of Pargyline."
  ]
  edge [
    source 45
    target 219
    int "The risk or severity of adverse effects can be increased when Iloprost is combined with Nisoldipine."
  ]
  edge [
    source 45
    target 226
    int "The risk or severity of adverse effects can be increased when Iloprost is combined with Bumetanide."
  ]
  edge [
    source 45
    target 247
    int "The risk or severity of adverse effects can be increased when Iloprost is combined with Mesalazine."
  ]
  edge [
    source 45
    target 70
    int "The risk or severity of adverse effects can be increased when Iloprost is combined with Amiloride."
  ]
  edge [
    source 45
    target 98
    int "The risk or severity of adverse effects can be increased when Iloprost is combined with Methyldopa."
  ]
  edge [
    source 45
    target 103
    int "The therapeutic efficacy of Iloprost can be decreased when used in combination with Zileuton."
  ]
  edge [
    source 45
    target 155
    int "The risk or severity of adverse effects can be increased when Bortezomib is combined with Iloprost."
  ]
  edge [
    source 45
    target 64
    int "Clopidogrel may increase the anticoagulant activities of Iloprost."
  ]
  edge [
    source 45
    target 75
    int "The therapeutic efficacy of Iloprost can be decreased when used in combination with Teriflunomide."
  ]
  edge [
    source 45
    target 237
    int "Iloprost may increase the anticoagulant activities of Rosiglitazone."
  ]
  edge [
    source 45
    target 238
    int "The risk or severity of adverse effects can be increased when Iloprost is combined with Pramipexole."
  ]
  edge [
    source 45
    target 240
    int "Primidone may increase the hypotensive activities of Iloprost."
  ]
  edge [
    source 45
    target 241
    int "The risk or severity of adverse effects can be increased when Iloprost is combined with Tolazoline."
  ]
  edge [
    source 45
    target 246
    int "Iloprost may increase the hypotensive activities of Bosentan."
  ]
  edge [
    source 45
    target 97
    int "Iloprost may increase the hypotensive activities of Diazoxide."
  ]
  edge [
    source 45
    target 93
    int "The risk or severity of adverse effects can be increased when Iloprost is combined with Hydralazine."
  ]
  edge [
    source 45
    target 113
    int "The risk or severity of adverse effects can be increased when Iloprost is combined with Imipramine."
  ]
  edge [
    source 45
    target 133
    int "Iloprost may increase the hypotensive activities of Risperidone."
  ]
  edge [
    source 45
    target 161
    int "The risk or severity of adverse effects can be increased when Iloprost is combined with Minoxidil."
  ]
  edge [
    source 45
    target 162
    int "The risk or severity of adverse effects can be increased when Iloprost is combined with Spironolactone."
  ]
  edge [
    source 45
    target 184
    int "The risk or severity of adverse effects can be increased when Iloprost is combined with Dexmedetomidine."
  ]
  edge [
    source 45
    target 87
    int "The risk or severity of adverse effects can be increased when Clofarabine is combined with Iloprost."
  ]
  edge [
    source 45
    target 204
    int "The therapeutic efficacy of Iloprost can be decreased when used in combination with Oxyphenbutazone."
  ]
  edge [
    source 45
    target 201
    int "The risk or severity of adverse effects can be increased when Iloprost is combined with Aliskiren."
  ]
  edge [
    source 45
    target 206
    int "Aripiprazole may increase the hypotensive activities of Iloprost."
  ]
  edge [
    source 45
    target 215
    int "The risk or severity of adverse effects can be increased when Iloprost is combined with Methyclothiazide."
  ]
  edge [
    source 45
    target 56
    int "The risk or severity of adverse effects can be increased when Enalaprilat is combined with Iloprost."
  ]
  edge [
    source 45
    target 228
    int "The risk or severity of adverse effects can be increased when Iloprost is combined with Bretylium."
  ]
  edge [
    source 45
    target 168
    int "The risk or severity of adverse effects can be increased when Iloprost is combined with Atenolol."
  ]
  edge [
    source 45
    target 192
    int "The risk or severity of adverse effects can be increased when Iloprost is combined with Mecamylamine."
  ]
  edge [
    source 45
    target 199
    int "The therapeutic efficacy of Iloprost can be decreased when used in combination with Meclofenamic acid."
  ]
  edge [
    source 45
    target 189
    int "The risk or severity of adverse effects can be increased when Iloprost is combined with Aminosalicylic Acid."
  ]
  edge [
    source 46
    target 123
    int "Tacrolimus may increase the immunosuppressive activities of Leflunomide."
  ]
  edge [
    source 46
    target 70
    int "The risk or severity of hyperkalemia can be increased when Amiloride is combined with Tacrolimus."
  ]
  edge [
    source 46
    target 52
    int "Tacrolimus may increase the immunosuppressive activities of Hydroxyurea."
  ]
  edge [
    source 46
    target 53
    int "Tacrolimus may increase the immunosuppressive activities of Vinblastine."
  ]
  edge [
    source 46
    target 61
    int "Tacrolimus may increase the immunosuppressive activities of Imatinib."
  ]
  edge [
    source 46
    target 167
    int "The metabolism of Tacrolimus can be decreased when combined with Sildenafil."
  ]
  edge [
    source 46
    target 86
    int "The metabolism of Tacrolimus can be decreased when combined with Argatroban."
  ]
  edge [
    source 46
    target 108
    int "Tacrolimus may increase the immunosuppressive activities of Chlorambucil."
  ]
  edge [
    source 46
    target 110
    int "Tacrolimus may increase the QTc-prolonging activities of Dronedarone."
  ]
  edge [
    source 46
    target 102
    int "The risk or severity of adverse effects can be increased when Methylergometrine is combined with Tacrolimus."
  ]
  edge [
    source 46
    target 141
    int "The serum concentration of Doxorubicin can be increased when it is combined with Tacrolimus."
  ]
  edge [
    source 46
    target 151
    int "Tacrolimus may increase the immunosuppressive activities of Temozolomide."
  ]
  edge [
    source 46
    target 247
    int "Mesalazine may increase the nephrotoxic activities of Tacrolimus."
  ]
  edge [
    source 46
    target 213
    int "Tacrolimus may increase the immunosuppressive activities of Mercaptopurine."
  ]
  edge [
    source 46
    target 196
    int "The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Tacrolimus."
  ]
  edge [
    source 46
    target 80
    int "Tacrolimus may increase the immunosuppressive activities of Methotrexate."
  ]
  edge [
    source 46
    target 198
    int "The therapeutic efficacy of Miglitol can be decreased when used in combination with Tacrolimus."
  ]
  edge [
    source 46
    target 118
    int "Tacrolimus may increase the immunosuppressive activities of Sunitinib."
  ]
  edge [
    source 46
    target 219
    int "The serum concentration of Tacrolimus can be increased when it is combined with Nisoldipine."
  ]
  edge [
    source 46
    target 232
    int "Tacrolimus may increase the immunosuppressive activities of Sorafenib."
  ]
  edge [
    source 46
    target 47
    int "Tacrolimus may increase the immunosuppressive activities of Prednisolone."
  ]
  edge [
    source 46
    target 50
    int "Tacrolimus may increase the immunosuppressive activities of Docetaxel."
  ]
  edge [
    source 46
    target 74
    int "The metabolism of Tacrolimus can be decreased when combined with Saxagliptin."
  ]
  edge [
    source 46
    target 235
    int "The serum concentration of Tacrolimus can be increased when it is combined with Lansoprazole."
  ]
  edge [
    source 46
    target 103
    int "Zileuton may increase the nephrotoxic activities of Tacrolimus."
  ]
  edge [
    source 46
    target 248
    int "Tacrolimus may increase the immunosuppressive activities of Azacitidine."
  ]
  edge [
    source 46
    target 54
    int "Tacrolimus may increase the immunosuppressive activities of Busulfan."
  ]
  edge [
    source 46
    target 152
    int "The serum concentration of Tacrolimus can be decreased when it is combined with Efavirenz."
  ]
  edge [
    source 46
    target 63
    int "The serum concentration of Tacrolimus can be increased when it is combined with Azithromycin."
  ]
  edge [
    source 46
    target 155
    int "The metabolism of Tacrolimus can be decreased when combined with Bortezomib."
  ]
  edge [
    source 46
    target 68
    int "The serum concentration of Tacrolimus can be decreased when it is combined with Rifabutin."
  ]
  edge [
    source 46
    target 176
    int "Tacrolimus may increase the immunosuppressive activities of Cytarabine."
  ]
  edge [
    source 46
    target 75
    int "Tacrolimus may increase the immunosuppressive activities of Teriflunomide."
  ]
  edge [
    source 46
    target 244
    int "The serum concentration of Tacrolimus can be increased when it is combined with Ranolazine."
  ]
  edge [
    source 46
    target 205
    int "Foscarnet may increase the nephrotoxic activities of Tacrolimus."
  ]
  edge [
    source 46
    target 221
    int "Tacrolimus may increase the immunosuppressive activities of Glatiramer Acetate."
  ]
  edge [
    source 46
    target 236
    int "The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Tacrolimus."
  ]
  edge [
    source 46
    target 237
    int "The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Tacrolimus."
  ]
  edge [
    source 46
    target 240
    int "The metabolism of Tacrolimus can be increased when combined with Primidone."
  ]
  edge [
    source 46
    target 243
    int "The therapeutic efficacy of Miglustat can be decreased when used in combination with Tacrolimus."
  ]
  edge [
    source 46
    target 246
    int "The serum concentration of Tacrolimus can be decreased when it is combined with Bosentan."
  ]
  edge [
    source 46
    target 203
    int "Tacrolimus may increase the immunosuppressive activities of Carboplatin."
  ]
  edge [
    source 46
    target 154
    int "The metabolism of Tacrolimus can be decreased when combined with Amprenavir."
  ]
  edge [
    source 46
    target 177
    int "Tacrolimus may increase the immunosuppressive activities of Mitoxantrone."
  ]
  edge [
    source 46
    target 49
    int "The metabolism of Tacrolimus can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 46
    target 125
    int "The metabolism of Tacrolimus can be decreased when combined with Pentamidine."
  ]
  edge [
    source 46
    target 129
    int "The therapeutic efficacy of Nateglinide can be decreased when used in combination with Tacrolimus."
  ]
  edge [
    source 46
    target 179
    int "The metabolism of Tacrolimus can be decreased when combined with Cilastatin."
  ]
  edge [
    source 46
    target 135
    int "Tacrolimus may increase the immunosuppressive activities of Everolimus."
  ]
  edge [
    source 46
    target 162
    int "The risk or severity of hyperkalemia can be increased when Spironolactone is combined with Tacrolimus."
  ]
  edge [
    source 46
    target 166
    int "The serum concentration of Tolvaptan can be increased when it is combined with Tacrolimus."
  ]
  edge [
    source 46
    target 171
    int "The serum concentration of Tacrolimus can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 46
    target 59
    int "Tacrolimus may increase the immunosuppressive activities of Carmustine."
  ]
  edge [
    source 46
    target 87
    int "Tacrolimus may increase the immunosuppressive activities of Clofarabine."
  ]
  edge [
    source 46
    target 204
    int "Oxyphenbutazone may increase the nephrotoxic activities of Tacrolimus."
  ]
  edge [
    source 46
    target 124
    int "The serum concentration of Pazopanib can be increased when it is combined with Tacrolimus."
  ]
  edge [
    source 46
    target 56
    int "The metabolism of Tacrolimus can be decreased when combined with Enalaprilat."
  ]
  edge [
    source 46
    target 137
    int "The metabolism of Tacrolimus can be decreased when combined with Artemether."
  ]
  edge [
    source 46
    target 115
    int "The metabolism of Tacrolimus can be decreased when combined with Sitagliptin."
  ]
  edge [
    source 46
    target 188
    int "The serum concentration of Cerivastatin can be increased when it is combined with Tacrolimus."
  ]
  edge [
    source 46
    target 218
    int "Tacrolimus may increase the immunosuppressive activities of Altretamine."
  ]
  edge [
    source 46
    target 170
    int "The therapeutic efficacy of Metformin can be decreased when used in combination with Tacrolimus."
  ]
  edge [
    source 46
    target 174
    int "The metabolism of Tacrolimus can be decreased when combined with Sertraline."
  ]
  edge [
    source 46
    target 73
    int "The therapeutic efficacy of Acarbose can be decreased when used in combination with Tacrolimus."
  ]
  edge [
    source 46
    target 191
    int "The metabolism of Tacrolimus can be decreased when combined with Trazodone."
  ]
  edge [
    source 46
    target 199
    int "Meclofenamic acid may increase the nephrotoxic activities of Tacrolimus."
  ]
  edge [
    source 46
    target 251
    int "Tacrolimus may increase the immunosuppressive activities of Pentostatin."
  ]
  edge [
    source 47
    target 123
    int "The risk or severity of adverse effects can be increased when Prednisolone is combined with Leflunomide."
  ]
  edge [
    source 47
    target 61
    int "The metabolism of Prednisolone can be decreased when combined with Imatinib."
  ]
  edge [
    source 47
    target 65
    int "The serum concentration of Prednisolone can be increased when it is combined with Ethinyl Estradiol."
  ]
  edge [
    source 47
    target 167
    int "The metabolism of Prednisolone can be decreased when combined with Sildenafil."
  ]
  edge [
    source 47
    target 68
    int "The serum concentration of Prednisolone can be decreased when it is combined with Rifabutin."
  ]
  edge [
    source 47
    target 110
    int "The metabolism of Prednisolone can be decreased when combined with Dronedarone."
  ]
  edge [
    source 47
    target 146
    int "The risk or severity of adverse effects can be increased when Prednisolone is combined with Chlorphenesin."
  ]
  edge [
    source 47
    target 196
    int "The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Prednisolone."
  ]
  edge [
    source 47
    target 198
    int "The therapeutic efficacy of Miglitol can be decreased when used in combination with Prednisolone."
  ]
  edge [
    source 47
    target 226
    int "Prednisolone may increase the hypokalemic activities of Bumetanide."
  ]
  edge [
    source 47
    target 244
    int "The serum concentration of Prednisolone can be increased when it is combined with Ranolazine."
  ]
  edge [
    source 47
    target 247
    int "The risk or severity of adverse effects can be increased when Mesalazine is combined with Prednisolone."
  ]
  edge [
    source 47
    target 50
    int "The risk or severity of adverse effects can be increased when Docetaxel is combined with Prednisolone."
  ]
  edge [
    source 47
    target 74
    int "The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Prednisolone."
  ]
  edge [
    source 47
    target 103
    int "The risk or severity of adverse effects can be increased when Zileuton is combined with Prednisolone."
  ]
  edge [
    source 47
    target 153
    int "Prednisolone may increase the fluid retaining activities of Testosterone."
  ]
  edge [
    source 47
    target 155
    int "The metabolism of Prednisolone can be decreased when combined with Bortezomib."
  ]
  edge [
    source 47
    target 75
    int "The risk or severity of adverse effects can be increased when Teriflunomide is combined with Prednisolone."
  ]
  edge [
    source 47
    target 236
    int "The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Prednisolone."
  ]
  edge [
    source 47
    target 237
    int "The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Prednisolone."
  ]
  edge [
    source 47
    target 240
    int "The serum concentration of Prednisolone can be decreased when it is combined with Primidone."
  ]
  edge [
    source 47
    target 243
    int "The therapeutic efficacy of Miglustat can be decreased when used in combination with Prednisolone."
  ]
  edge [
    source 47
    target 246
    int "The serum concentration of Prednisolone can be decreased when it is combined with Bosentan."
  ]
  edge [
    source 47
    target 49
    int "The metabolism of Prednisolone can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 47
    target 55
    int "Prednisolone may increase the fluid retaining activities of Stanozolol."
  ]
  edge [
    source 47
    target 129
    int "The therapeutic efficacy of Nateglinide can be decreased when used in combination with Prednisolone."
  ]
  edge [
    source 47
    target 156
    int "The risk or severity of adverse effects can be increased when Prednisolone is combined with Mefloquine."
  ]
  edge [
    source 47
    target 102
    int "The risk or severity of adverse effects can be increased when Methylergometrine is combined with Prednisolone."
  ]
  edge [
    source 47
    target 166
    int "The serum concentration of Tolvaptan can be increased when it is combined with Prednisolone."
  ]
  edge [
    source 47
    target 171
    int "The serum concentration of Prednisolone can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 47
    target 204
    int "The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Prednisolone."
  ]
  edge [
    source 47
    target 85
    int "Digitoxin may decrease the cardiotoxic activities of Prednisolone."
  ]
  edge [
    source 47
    target 73
    int "The therapeutic efficacy of Acarbose can be decreased when used in combination with Prednisolone."
  ]
  edge [
    source 47
    target 115
    int "The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Prednisolone."
  ]
  edge [
    source 47
    target 188
    int "The serum concentration of Cerivastatin can be increased when it is combined with Prednisolone."
  ]
  edge [
    source 47
    target 132
    int "The risk or severity of adverse effects can be increased when Prednisolone is combined with Memantine."
  ]
  edge [
    source 47
    target 170
    int "The therapeutic efficacy of Metformin can be decreased when used in combination with Prednisolone."
  ]
  edge [
    source 47
    target 199
    int "The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Prednisolone."
  ]
  edge [
    source 47
    target 215
    int "Prednisolone may increase the hypokalemic activities of Methyclothiazide."
  ]
  edge [
    source 47
    target 189
    int "The risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Prednisolone."
  ]
  edge [
    source 48
    target 68
    int "The serum concentration of Gefitinib can be decreased when it is combined with Rifabutin."
  ]
  edge [
    source 48
    target 113
    int "The metabolism of Gefitinib can be decreased when combined with Imipramine."
  ]
  edge [
    source 48
    target 49
    int "The metabolism of Gefitinib can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 48
    target 61
    int "The metabolism of Gefitinib can be decreased when combined with Imatinib."
  ]
  edge [
    source 48
    target 62
    int "The metabolism of Gefitinib can be decreased when combined with Tranylcypromine."
  ]
  edge [
    source 48
    target 167
    int "The metabolism of Gefitinib can be decreased when combined with Sildenafil."
  ]
  edge [
    source 48
    target 174
    int "The metabolism of Gefitinib can be decreased when combined with Sertraline."
  ]
  edge [
    source 48
    target 75
    int "The serum concentration of Gefitinib can be increased when it is combined with Teriflunomide."
  ]
  edge [
    source 48
    target 235
    int "The serum concentration of Gefitinib can be decreased when it is combined with Lansoprazole."
  ]
  edge [
    source 48
    target 90
    int "The metabolism of Gefitinib can be decreased when combined with Lumefantrine."
  ]
  edge [
    source 48
    target 50
    int "The risk or severity of adverse effects can be increased when Docetaxel is combined with Gefitinib."
  ]
  edge [
    source 48
    target 110
    int "The metabolism of Gefitinib can be decreased when combined with Dronedarone."
  ]
  edge [
    source 48
    target 135
    int "The serum concentration of Everolimus can be increased when it is combined with Gefitinib."
  ]
  edge [
    source 48
    target 137
    int "The metabolism of Gefitinib can be decreased when combined with Artemether."
  ]
  edge [
    source 48
    target 141
    int "The serum concentration of Doxorubicin can be increased when it is combined with Gefitinib."
  ]
  edge [
    source 48
    target 155
    int "The metabolism of Gefitinib can be decreased when combined with Bortezomib."
  ]
  edge [
    source 48
    target 169
    int "The serum concentration of Gefitinib can be decreased when it is combined with Asenapine."
  ]
  edge [
    source 48
    target 171
    int "The serum concentration of Gefitinib can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 48
    target 196
    int "The metabolism of Gefitinib can be decreased when combined with Dihydroergotamine."
  ]
  edge [
    source 48
    target 104
    int "The serum concentration of Gefitinib can be decreased when it is combined with Nizatidine."
  ]
  edge [
    source 48
    target 124
    int "The serum concentration of Pazopanib can be increased when it is combined with Gefitinib."
  ]
  edge [
    source 48
    target 85
    int "Digitoxin may decrease the cardiotoxic activities of Gefitinib."
  ]
  edge [
    source 48
    target 240
    int "The serum concentration of Gefitinib can be decreased when it is combined with Primidone."
  ]
  edge [
    source 48
    target 244
    int "The serum concentration of Ranolazine can be increased when it is combined with Gefitinib."
  ]
  edge [
    source 48
    target 246
    int "The serum concentration of Gefitinib can be decreased when it is combined with Bosentan."
  ]
  edge [
    source 49
    target 122
    int "The metabolism of Levonorgestrel can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 123
    int "The metabolism of Leflunomide can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 61
    int "The serum concentration of Imatinib can be increased when it is combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 62
    int "The risk or severity of adverse effects can be increased when Fluvoxamine is combined with Tranylcypromine."
  ]
  edge [
    source 49
    target 76
    int "The metabolism of Tetracycline can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 64
    int "The risk or severity of adverse effects can be increased when Fluvoxamine is combined with Clopidogrel."
  ]
  edge [
    source 49
    target 67
    int "Furazolidone may increase the serotonergic activities of Fluvoxamine."
  ]
  edge [
    source 49
    target 68
    int "The metabolism of Rifabutin can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 75
    int "The serum concentration of Fluvoxamine can be decreased when it is combined with Teriflunomide."
  ]
  edge [
    source 49
    target 222
    int "The risk or severity of adverse effects can be increased when Metaxalone is combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 86
    int "The metabolism of Argatroban can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 91
    int "The risk or severity of adverse effects can be increased when Topiramate is combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 186
    int "The metabolism of Dutasteride can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 103
    int "The metabolism of Zileuton can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 109
    int "The risk or severity of adverse effects can be increased when Fluvoxamine is combined with Etomidate."
  ]
  edge [
    source 49
    target 110
    int "The metabolism of Dronedarone can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 137
    int "The metabolism of Artemether can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 142
    int "The risk or severity of adverse effects can be increased when Gabapentin is combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 146
    int "Fluvoxamine may increase the antiplatelet activities of Chlorphenesin."
  ]
  edge [
    source 49
    target 194
    int "Pargyline may increase the serotonergic activities of Fluvoxamine."
  ]
  edge [
    source 49
    target 74
    int "The serum concentration of Saxagliptin can be increased when it is combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 154
    int "The metabolism of Amprenavir can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 195
    int "The risk or severity of adverse effects can be increased when Entacapone is combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 196
    int "The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 197
    int "Buspirone may increase the serotonergic activities of Fluvoxamine."
  ]
  edge [
    source 49
    target 198
    int "Fluvoxamine may increase the hypoglycemic activities of Miglitol."
  ]
  edge [
    source 49
    target 182
    int "The metabolism of Mephenytoin can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 193
    int "The metabolism of Flutamide can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 214
    int "The metabolism of Proguanil can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 219
    int "The metabolism of Nisoldipine can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 121
    int "The metabolism of Niclosamide can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 220
    int "The metabolism of Sulfinpyrazone can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 224
    int "The risk or severity of adverse effects can be increased when Fluvoxamine is combined with Sumatriptan."
  ]
  edge [
    source 49
    target 231
    int "The metabolism of Carisoprodol can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 232
    int "The metabolism of Sorafenib can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 244
    int "The serum concentration of Ranolazine can be increased when it is combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 247
    int "Fluvoxamine may increase the antiplatelet activities of Mesalazine."
  ]
  edge [
    source 49
    target 150
    int "Lithium may increase the serotonergic activities of Fluvoxamine."
  ]
  edge [
    source 49
    target 65
    int "The metabolism of Ethinyl Estradiol can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 50
    int "The metabolism of Docetaxel can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 158
    int "The metabolism of Piperazine can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 174
    int "The metabolism of Sertraline can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 235
    int "The metabolism of Lansoprazole can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 84
    int "The metabolism of Trimethoprim can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 101
    int "The metabolism of Zaleplon can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 105
    int "The metabolism of Riluzole can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 230
    int "The metabolism of Isosorbide Dinitrate can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 53
    int "The metabolism of Vinblastine can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 54
    int "The metabolism of Busulfan can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 131
    int "The risk or severity of adverse effects can be increased when Rufinamide is combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 147
    int "The metabolism of Metronidazole can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 140
    int "The metabolism of Tinidazole can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 152
    int "The metabolism of Efavirenz can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 153
    int "The metabolism of Testosterone can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 155
    int "The metabolism of Bortezomib can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 159
    int "The metabolism of Cevimeline can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 167
    int "The metabolism of Sildenafil can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 175
    int "The metabolism of Maraviroc can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 176
    int "The metabolism of Cytarabine can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 181
    int "The metabolism of Dopamine can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 94
    int "The metabolism of Valproic Acid can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 170
    int "Fluvoxamine may increase the hypoglycemic activities of Metformin."
  ]
  edge [
    source 49
    target 237
    int "The metabolism of Rosiglitazone can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 238
    int "Fluvoxamine may increase the sedative activities of Pramipexole."
  ]
  edge [
    source 49
    target 240
    int "The metabolism of Primidone can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 246
    int "The serum concentration of Bosentan can be increased when it is combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 72
    int "The metabolism of Tetrabenazine can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 234
    int "The risk or severity of adverse effects can be increased when Fluvoxamine is combined with Lamotrigine."
  ]
  edge [
    source 49
    target 90
    int "The metabolism of Lumefantrine can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 180
    int "The metabolism of Disulfiram can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 89
    int "The metabolism of Praziquantel can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 63
    int "The metabolism of Azithromycin can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 113
    int "The risk or severity of adverse effects can be increased when Fluvoxamine is combined with Imipramine."
  ]
  edge [
    source 49
    target 117
    int "The metabolism of Albendazole can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 125
    int "The metabolism of Pentamidine can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 129
    int "The metabolism of Nateglinide can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 133
    int "The metabolism of Risperidone can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 135
    int "The serum concentration of Everolimus can be increased when it is combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 136
    int "The serum concentration of Ulipristal can be increased when it is combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 160
    int "The metabolism of Chlorzoxazone can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 102
    int "The risk or severity of adverse effects can be increased when Methylergometrine is combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 164
    int "The metabolism of Mebendazole can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 166
    int "The serum concentration of Tolvaptan can be increased when it is combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 169
    int "The serum concentration of Asenapine can be increased when it is combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 207
    int "The metabolism of Zonisamide can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 173
    int "The metabolism of Tiagabine can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 184
    int "The risk or severity of adverse effects can be increased when Fluvoxamine is combined with Dexmedetomidine."
  ]
  edge [
    source 49
    target 187
    int "The metabolism of Clofibrate can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 200
    int "The metabolism of Zalcitabine can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 201
    int "The metabolism of Aliskiren can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 208
    int "The metabolism of Trifluoperazine can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 212
    int "The metabolism of Loperamide can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 124
    int "The serum concentration of Pazopanib can be increased when it is combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 85
    int "The metabolism of Digitoxin can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 130
    int "The metabolism of Thiabendazole can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 191
    int "Fluvoxamine may increase the serotonergic activities of Trazodone."
  ]
  edge [
    source 49
    target 73
    int "Fluvoxamine may increase the hypoglycemic activities of Acarbose."
  ]
  edge [
    source 49
    target 119
    int "The risk or severity of adverse effects can be increased when Triflupromazine is combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 141
    int "The metabolism of Doxorubicin can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 188
    int "The serum concentration of Cerivastatin can be increased when it is combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 115
    int "The metabolism of Sitagliptin can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 118
    int "The metabolism of Sunitinib can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 59
    int "The metabolism of Carmustine can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 148
    int "The metabolism of Dantrolene can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 149
    int "The serum concentration of Halofantrine can be increased when it is combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 138
    int "The metabolism of Theophylline can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 156
    int "The metabolism of Mefloquine can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 165
    int "The metabolism of Pyrazinamide can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 199
    int "Fluvoxamine may increase the antiplatelet activities of Meclofenamic acid."
  ]
  edge [
    source 49
    target 202
    int "The metabolism of Maprotiline can be decreased when combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 206
    int "The serum concentration of Aripiprazole can be increased when it is combined with Fluvoxamine."
  ]
  edge [
    source 49
    target 215
    int "Fluvoxamine may increase the hyponatremic activities of Methyclothiazide."
  ]
  edge [
    source 49
    target 189
    int "Fluvoxamine may increase the antiplatelet activities of Aminosalicylic Acid."
  ]
  edge [
    source 50
    target 123
    int "The risk or severity of adverse effects can be increased when Docetaxel is combined with Leflunomide."
  ]
  edge [
    source 50
    target 203
    int "Carboplatin may increase the myelosuppressive activities of Docetaxel."
  ]
  edge [
    source 50
    target 53
    int "The risk or severity of adverse effects can be increased when Docetaxel is combined with Vinblastine."
  ]
  edge [
    source 50
    target 54
    int "The risk or severity of adverse effects can be increased when Docetaxel is combined with Busulfan."
  ]
  edge [
    source 50
    target 61
    int "The risk or severity of adverse effects can be increased when Docetaxel is combined with Imatinib."
  ]
  edge [
    source 50
    target 167
    int "The metabolism of Docetaxel can be decreased when combined with Sildenafil."
  ]
  edge [
    source 50
    target 75
    int "The serum concentration of Docetaxel can be increased when it is combined with Teriflunomide."
  ]
  edge [
    source 50
    target 108
    int "The risk or severity of adverse effects can be increased when Docetaxel is combined with Chlorambucil."
  ]
  edge [
    source 50
    target 110
    int "The serum concentration of Docetaxel can be increased when it is combined with Dronedarone."
  ]
  edge [
    source 50
    target 141
    int "The risk or severity of adverse effects can be increased when Docetaxel is combined with Doxorubicin."
  ]
  edge [
    source 50
    target 151
    int "The risk or severity of adverse effects can be increased when Docetaxel is combined with Temozolomide."
  ]
  edge [
    source 50
    target 213
    int "The risk or severity of adverse effects can be increased when Docetaxel is combined with Mercaptopurine."
  ]
  edge [
    source 50
    target 193
    int "The risk or severity of adverse effects can be increased when Docetaxel is combined with Flutamide."
  ]
  edge [
    source 50
    target 196
    int "The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Docetaxel."
  ]
  edge [
    source 50
    target 118
    int "The risk or severity of adverse effects can be increased when Docetaxel is combined with Sunitinib."
  ]
  edge [
    source 50
    target 248
    int "The risk or severity of adverse effects can be increased when Docetaxel is combined with Azacitidine."
  ]
  edge [
    source 50
    target 232
    int "The serum concentration of Docetaxel can be increased when it is combined with Sorafenib."
  ]
  edge [
    source 50
    target 244
    int "The serum concentration of Docetaxel can be increased when it is combined with Ranolazine."
  ]
  edge [
    source 50
    target 77
    int "The risk or severity of adverse effects can be increased when Docetaxel is combined with Eflornithine."
  ]
  edge [
    source 50
    target 134
    int "The risk or severity of adverse effects can be increased when Docetaxel is combined with Trilostane."
  ]
  edge [
    source 50
    target 80
    int "The risk or severity of adverse effects can be increased when Docetaxel is combined with Methotrexate."
  ]
  edge [
    source 50
    target 52
    int "The risk or severity of adverse effects can be increased when Docetaxel is combined with Hydroxyurea."
  ]
  edge [
    source 50
    target 155
    int "The risk or severity of adverse effects can be increased when Docetaxel is combined with Bortezomib."
  ]
  edge [
    source 50
    target 68
    int "The metabolism of Docetaxel can be increased when combined with Rifabutin."
  ]
  edge [
    source 50
    target 176
    int "The risk or severity of adverse effects can be increased when Docetaxel is combined with Cytarabine."
  ]
  edge [
    source 50
    target 218
    int "The risk or severity of adverse effects can be increased when Docetaxel is combined with Altretamine."
  ]
  edge [
    source 50
    target 246
    int "The serum concentration of Docetaxel can be decreased when it is combined with Bosentan."
  ]
  edge [
    source 50
    target 251
    int "The risk or severity of adverse effects can be increased when Docetaxel is combined with Pentostatin."
  ]
  edge [
    source 50
    target 177
    int "The risk or severity of adverse effects can be increased when Docetaxel is combined with Mitoxantrone."
  ]
  edge [
    source 50
    target 125
    int "The metabolism of Docetaxel can be decreased when combined with Pentamidine."
  ]
  edge [
    source 50
    target 135
    int "The risk or severity of adverse effects can be increased when Docetaxel is combined with Everolimus."
  ]
  edge [
    source 50
    target 102
    int "The risk or severity of adverse effects can be increased when Methylergometrine is combined with Docetaxel."
  ]
  edge [
    source 50
    target 166
    int "The serum concentration of Tolvaptan can be increased when it is combined with Docetaxel."
  ]
  edge [
    source 50
    target 171
    int "The serum concentration of Docetaxel can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 50
    target 59
    int "The risk or severity of adverse effects can be increased when Docetaxel is combined with Carmustine."
  ]
  edge [
    source 50
    target 87
    int "The risk or severity of adverse effects can be increased when Docetaxel is combined with Clofarabine."
  ]
  edge [
    source 50
    target 117
    int "The risk or severity of adverse effects can be increased when Docetaxel is combined with Albendazole."
  ]
  edge [
    source 50
    target 124
    int "The risk or severity of adverse effects can be increased when Docetaxel is combined with Pazopanib."
  ]
  edge [
    source 50
    target 85
    int "Digitoxin may decrease the cardiotoxic activities of Docetaxel."
  ]
  edge [
    source 50
    target 137
    int "The metabolism of Docetaxel can be decreased when combined with Artemether."
  ]
  edge [
    source 50
    target 144
    int "The risk or severity of adverse effects can be increased when Docetaxel is combined with Anastrozole."
  ]
  edge [
    source 50
    target 188
    int "The serum concentration of Cerivastatin can be increased when it is combined with Docetaxel."
  ]
  edge [
    source 50
    target 240
    int "The metabolism of Docetaxel can be increased when combined with Primidone."
  ]
  edge [
    source 50
    target 164
    int "The risk or severity of adverse effects can be increased when Docetaxel is combined with Mebendazole."
  ]
  edge [
    source 50
    target 107
    int "The risk or severity of adverse effects can be increased when Docetaxel is combined with Vorinostat."
  ]
  edge [
    source 51
    target 200
    int "The risk or severity of adverse effects can be increased when Ganciclovir is combined with Zalcitabine."
  ]
  edge [
    source 51
    target 127
    int "The risk or severity of adverse effects can be increased when Ganciclovir is combined with Abacavir."
  ]
  edge [
    source 52
    target 85
    int "Digitoxin may decrease the cardiotoxic activities of Hydroxyurea."
  ]
  edge [
    source 52
    target 123
    int "The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Leflunomide."
  ]
  edge [
    source 53
    target 123
    int "The risk or severity of adverse effects can be increased when Vinblastine is combined with Leflunomide."
  ]
  edge [
    source 53
    target 240
    int "The metabolism of Vinblastine can be increased when combined with Primidone."
  ]
  edge [
    source 53
    target 61
    int "The metabolism of Vinblastine can be decreased when combined with Imatinib."
  ]
  edge [
    source 53
    target 167
    int "The metabolism of Vinblastine can be decreased when combined with Sildenafil."
  ]
  edge [
    source 53
    target 68
    int "The metabolism of Vinblastine can be increased when combined with Rifabutin."
  ]
  edge [
    source 53
    target 174
    int "The metabolism of Vinblastine can be decreased when combined with Sertraline."
  ]
  edge [
    source 53
    target 90
    int "The metabolism of Vinblastine can be decreased when combined with Lumefantrine."
  ]
  edge [
    source 53
    target 141
    int "The serum concentration of Doxorubicin can be increased when it is combined with Vinblastine."
  ]
  edge [
    source 53
    target 135
    int "The serum concentration of Everolimus can be increased when it is combined with Vinblastine."
  ]
  edge [
    source 53
    target 137
    int "The metabolism of Vinblastine can be decreased when combined with Artemether."
  ]
  edge [
    source 53
    target 155
    int "The metabolism of Vinblastine can be decreased when combined with Bortezomib."
  ]
  edge [
    source 53
    target 102
    int "The risk or severity of adverse effects can be increased when Methylergometrine is combined with Vinblastine."
  ]
  edge [
    source 53
    target 113
    int "The metabolism of Vinblastine can be decreased when combined with Imipramine."
  ]
  edge [
    source 53
    target 171
    int "The serum concentration of Vinblastine can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 53
    target 62
    int "The metabolism of Vinblastine can be decreased when combined with Tranylcypromine."
  ]
  edge [
    source 53
    target 188
    int "The serum concentration of Cerivastatin can be increased when it is combined with Vinblastine."
  ]
  edge [
    source 53
    target 196
    int "The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Vinblastine."
  ]
  edge [
    source 53
    target 166
    int "The serum concentration of Tolvaptan can be increased when it is combined with Vinblastine."
  ]
  edge [
    source 53
    target 124
    int "The serum concentration of Pazopanib can be increased when it is combined with Vinblastine."
  ]
  edge [
    source 53
    target 110
    int "The metabolism of Vinblastine can be decreased when combined with Dronedarone."
  ]
  edge [
    source 53
    target 85
    int "Digitoxin may decrease the cardiotoxic activities of Vinblastine."
  ]
  edge [
    source 53
    target 244
    int "The serum concentration of Ranolazine can be increased when it is combined with Vinblastine."
  ]
  edge [
    source 53
    target 246
    int "The serum concentration of Vinblastine can be decreased when it is combined with Bosentan."
  ]
  edge [
    source 54
    target 123
    int "The risk or severity of adverse effects can be increased when Busulfan is combined with Leflunomide."
  ]
  edge [
    source 54
    target 61
    int "The metabolism of Busulfan can be decreased when combined with Imatinib."
  ]
  edge [
    source 54
    target 167
    int "The metabolism of Busulfan can be decreased when combined with Sildenafil."
  ]
  edge [
    source 54
    target 68
    int "The metabolism of Busulfan can be increased when combined with Rifabutin."
  ]
  edge [
    source 54
    target 110
    int "The metabolism of Busulfan can be decreased when combined with Dronedarone."
  ]
  edge [
    source 54
    target 137
    int "The serum concentration of Busulfan can be increased when it is combined with Artemether."
  ]
  edge [
    source 54
    target 125
    int "The serum concentration of Busulfan can be increased when it is combined with Pentamidine."
  ]
  edge [
    source 54
    target 147
    int "The serum concentration of Busulfan can be increased when it is combined with Metronidazole."
  ]
  edge [
    source 54
    target 155
    int "The metabolism of Busulfan can be decreased when combined with Bortezomib."
  ]
  edge [
    source 54
    target 171
    int "The serum concentration of Busulfan can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 54
    target 240
    int "The metabolism of Busulfan can be increased when combined with Primidone."
  ]
  edge [
    source 54
    target 196
    int "The metabolism of Busulfan can be decreased when combined with Dihydroergotamine."
  ]
  edge [
    source 54
    target 85
    int "Digitoxin may decrease the cardiotoxic activities of Busulfan."
  ]
  edge [
    source 54
    target 244
    int "The metabolism of Busulfan can be decreased when combined with Ranolazine."
  ]
  edge [
    source 54
    target 246
    int "The serum concentration of Busulfan can be decreased when it is combined with Bosentan."
  ]
  edge [
    source 55
    target 73
    int "Stanozolol may increase the hypoglycemic activities of Acarbose."
  ]
  edge [
    source 55
    target 74
    int "Stanozolol may increase the hypoglycemic activities of Saxagliptin."
  ]
  edge [
    source 55
    target 118
    int "Stanozolol may increase the hypoglycemic activities of Sunitinib."
  ]
  edge [
    source 55
    target 125
    int "Stanozolol may increase the hypoglycemic activities of Pentamidine."
  ]
  edge [
    source 55
    target 129
    int "Stanozolol may increase the hypoglycemic activities of Nateglinide."
  ]
  edge [
    source 55
    target 170
    int "Stanozolol may increase the hypoglycemic activities of Metformin."
  ]
  edge [
    source 55
    target 115
    int "Stanozolol may increase the hypoglycemic activities of Sitagliptin."
  ]
  edge [
    source 55
    target 198
    int "Stanozolol may increase the hypoglycemic activities of Miglitol."
  ]
  edge [
    source 55
    target 217
    int "Desoxycorticosterone Pivalate may increase the fluid retaining activities of Stanozolol."
  ]
  edge [
    source 55
    target 237
    int "Stanozolol may increase the hypoglycemic activities of Rosiglitazone."
  ]
  edge [
    source 56
    target 123
    int "The risk or severity of adverse effects can be increased when Leflunomide is combined with Enalaprilat."
  ]
  edge [
    source 56
    target 62
    int "Tranylcypromine may increase the hypotensive activities of Enalaprilat."
  ]
  edge [
    source 56
    target 249
    int "The risk or severity of adverse effects can be increased when Enalaprilat is combined with Dipyridamole."
  ]
  edge [
    source 56
    target 67
    int "Furazolidone may increase the hypotensive activities of Enalaprilat."
  ]
  edge [
    source 56
    target 138
    int "The serum concentration of Theophylline can be decreased when it is combined with Enalaprilat."
  ]
  edge [
    source 56
    target 95
    int "The risk or severity of adverse effects can be increased when Olmesartan is combined with Enalaprilat."
  ]
  edge [
    source 56
    target 150
    int "The serum concentration of Lithium can be increased when it is combined with Enalaprilat."
  ]
  edge [
    source 56
    target 196
    int "The serum concentration of Dihydroergotamine can be increased when it is combined with Enalaprilat."
  ]
  edge [
    source 56
    target 194
    int "Pargyline may increase the hypotensive activities of Enalaprilat."
  ]
  edge [
    source 56
    target 219
    int "Nisoldipine may increase the hypotensive activities of Enalaprilat."
  ]
  edge [
    source 56
    target 226
    int "Bumetanide may increase the hypotensive activities of Enalaprilat."
  ]
  edge [
    source 56
    target 230
    int "The risk or severity of adverse effects can be increased when Enalaprilat is combined with Isosorbide Dinitrate."
  ]
  edge [
    source 56
    target 247
    int "The therapeutic efficacy of Enalaprilat can be decreased when used in combination with Mesalazine."
  ]
  edge [
    source 56
    target 70
    int "Amiloride may increase the hyperkalemic activities of Enalaprilat."
  ]
  edge [
    source 56
    target 74
    int "The risk or severity of adverse effects can be increased when Saxagliptin is combined with Enalaprilat."
  ]
  edge [
    source 56
    target 84
    int "Trimethoprim may increase the hyperkalemic activities of Enalaprilat."
  ]
  edge [
    source 56
    target 98
    int "Methyldopa may increase the hypotensive activities of Enalaprilat."
  ]
  edge [
    source 56
    target 103
    int "The risk or severity of adverse effects can be increased when Zileuton is combined with Enalaprilat."
  ]
  edge [
    source 56
    target 155
    int "The risk or severity of adverse effects can be increased when Bortezomib is combined with Enalaprilat."
  ]
  edge [
    source 56
    target 65
    int "The serum concentration of Ethinyl Estradiol can be decreased when it is combined with Enalaprilat."
  ]
  edge [
    source 56
    target 167
    int "The serum concentration of Sildenafil can be increased when it is combined with Enalaprilat."
  ]
  edge [
    source 56
    target 75
    int "The risk or severity of adverse effects can be increased when Teriflunomide is combined with Enalaprilat."
  ]
  edge [
    source 56
    target 168
    int "Atenolol may increase the hypotensive activities of Enalaprilat."
  ]
  edge [
    source 56
    target 94
    int "The serum concentration of Valproic Acid can be decreased when it is combined with Enalaprilat."
  ]
  edge [
    source 56
    target 228
    int "Bretylium may increase the hypotensive activities of Enalaprilat."
  ]
  edge [
    source 56
    target 238
    int "The risk or severity of adverse effects can be increased when Enalaprilat is combined with Pramipexole."
  ]
  edge [
    source 56
    target 240
    int "Primidone may increase the hypotensive activities of Enalaprilat."
  ]
  edge [
    source 56
    target 241
    int "Tolazoline may increase the hypotensive activities of Enalaprilat."
  ]
  edge [
    source 56
    target 246
    int "Bosentan may increase the hypotensive activities of Enalaprilat."
  ]
  edge [
    source 56
    target 97
    int "Diazoxide may increase the hypotensive activities of Enalaprilat."
  ]
  edge [
    source 56
    target 93
    int "Hydralazine may increase the hypotensive activities of Enalaprilat."
  ]
  edge [
    source 56
    target 113
    int "The serum concentration of Imipramine can be increased when it is combined with Enalaprilat."
  ]
  edge [
    source 56
    target 135
    int "The risk or severity of adverse effects can be increased when Everolimus is combined with Enalaprilat."
  ]
  edge [
    source 56
    target 161
    int "Minoxidil may increase the hypotensive activities of Enalaprilat."
  ]
  edge [
    source 56
    target 102
    int "The serum concentration of Methylergometrine can be increased when it is combined with Enalaprilat."
  ]
  edge [
    source 56
    target 166
    int "Tolvaptan may increase the hyperkalemic activities of Enalaprilat."
  ]
  edge [
    source 56
    target 184
    int "The risk or severity of adverse effects can be increased when Enalaprilat is combined with Dexmedetomidine."
  ]
  edge [
    source 56
    target 87
    int "The risk or severity of adverse effects can be increased when Clofarabine is combined with Enalaprilat."
  ]
  edge [
    source 56
    target 204
    int "The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Enalaprilat."
  ]
  edge [
    source 56
    target 201
    int "Aliskiren may increase the hypotensive, nephrotoxic, and hyperkalemic activities of Enalaprilat."
  ]
  edge [
    source 56
    target 206
    int "Aripiprazole may increase the hypotensive activities of Enalaprilat."
  ]
  edge [
    source 56
    target 133
    int "Enalaprilat may increase the hypotensive activities of Risperidone."
  ]
  edge [
    source 56
    target 115
    int "The risk or severity of adverse effects can be increased when Sitagliptin is combined with Enalaprilat."
  ]
  edge [
    source 56
    target 127
    int "The serum concentration of Abacavir can be decreased when it is combined with Enalaprilat."
  ]
  edge [
    source 56
    target 162
    int "The risk or severity of adverse effects can be increased when Enalaprilat is combined with Spironolactone."
  ]
  edge [
    source 56
    target 190
    int "The risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Enalaprilat."
  ]
  edge [
    source 56
    target 192
    int "Mecamylamine may increase the hypotensive activities of Enalaprilat."
  ]
  edge [
    source 56
    target 199
    int "The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Enalaprilat."
  ]
  edge [
    source 56
    target 215
    int "The risk or severity of hypotension can be increased when Methyclothiazide is combined with Enalaprilat."
  ]
  edge [
    source 56
    target 189
    int "The therapeutic efficacy of Enalaprilat can be decreased when used in combination with Aminosalicylic Acid."
  ]
  edge [
    source 58
    target 63
    int "Azithromycin may increase the QTc-prolonging activities of Ibutilide."
  ]
  edge [
    source 58
    target 174
    int "Sertraline may increase the QTc-prolonging activities of Ibutilide."
  ]
  edge [
    source 58
    target 72
    int "The risk or severity of QTc prolongation can be increased when Ibutilide is combined with Tetrabenazine."
  ]
  edge [
    source 58
    target 84
    int "Trimethoprim may increase the QTc-prolonging activities of Ibutilide."
  ]
  edge [
    source 58
    target 90
    int "The risk or severity of QTc prolongation can be increased when Ibutilide is combined with Lumefantrine."
  ]
  edge [
    source 58
    target 107
    int "Vorinostat may increase the QTc-prolonging activities of Ibutilide."
  ]
  edge [
    source 58
    target 110
    int "The risk or severity of QTc prolongation can be increased when Ibutilide is combined with Dronedarone."
  ]
  edge [
    source 58
    target 113
    int "Imipramine may increase the QTc-prolonging activities of Ibutilide."
  ]
  edge [
    source 58
    target 137
    int "The risk or severity of QTc prolongation can be increased when Ibutilide is combined with Artemether."
  ]
  edge [
    source 58
    target 125
    int "Pentamidine may increase the QTc-prolonging activities of Ibutilide."
  ]
  edge [
    source 58
    target 133
    int "Risperidone may increase the QTc-prolonging activities of Ibutilide."
  ]
  edge [
    source 58
    target 232
    int "Sorafenib may increase the QTc-prolonging activities of Ibutilide."
  ]
  edge [
    source 58
    target 147
    int "Metronidazole may increase the QTc-prolonging activities of Ibutilide."
  ]
  edge [
    source 58
    target 83
    int "Amantadine may increase the QTc-prolonging activities of Ibutilide."
  ]
  edge [
    source 58
    target 150
    int "Lithium may increase the QTc-prolonging activities of Ibutilide."
  ]
  edge [
    source 58
    target 155
    int "Bortezomib may increase the QTc-prolonging activities of Ibutilide."
  ]
  edge [
    source 58
    target 156
    int "Mefloquine may increase the QTc-prolonging activities of Ibutilide."
  ]
  edge [
    source 58
    target 118
    int "Sunitinib may increase the QTc-prolonging activities of Ibutilide."
  ]
  edge [
    source 58
    target 191
    int "Trazodone may increase the QTc-prolonging activities of Ibutilide."
  ]
  edge [
    source 58
    target 202
    int "Maprotiline may increase the QTc-prolonging activities of Ibutilide."
  ]
  edge [
    source 58
    target 244
    int "Ranolazine may increase the QTc-prolonging activities of Ibutilide."
  ]
  edge [
    source 58
    target 205
    int "Foscarnet may increase the QTc-prolonging activities of Ibutilide."
  ]
  edge [
    source 58
    target 206
    int "Aripiprazole may increase the QTc-prolonging activities of Ibutilide."
  ]
  edge [
    source 58
    target 124
    int "Pazopanib may increase the QTc-prolonging activities of Ibutilide."
  ]
  edge [
    source 58
    target 169
    int "The risk or severity of QTc prolongation can be increased when Ibutilide is combined with Asenapine."
  ]
  edge [
    source 59
    target 123
    int "The risk or severity of adverse effects can be increased when Carmustine is combined with Leflunomide."
  ]
  edge [
    source 59
    target 63
    int "The metabolism of Carmustine can be decreased when combined with Azithromycin."
  ]
  edge [
    source 59
    target 75
    int "The serum concentration of Carmustine can be decreased when it is combined with Teriflunomide."
  ]
  edge [
    source 59
    target 138
    int "The metabolism of Carmustine can be decreased when combined with Theophylline."
  ]
  edge [
    source 59
    target 155
    int "The metabolism of Carmustine can be decreased when combined with Bortezomib."
  ]
  edge [
    source 59
    target 85
    int "Digitoxin may decrease the cardiotoxic activities of Carmustine."
  ]
  edge [
    source 60
    target 225
    int "The risk or severity of adverse effects can be increased when Epinephrine is combined with Isoprenaline."
  ]
  edge [
    source 60
    target 67
    int "The risk or severity of adverse effects can be increased when Furazolidone is combined with Isoprenaline."
  ]
  edge [
    source 60
    target 138
    int "The serum concentration of Theophylline can be decreased when it is combined with Isoprenaline."
  ]
  edge [
    source 60
    target 110
    int "Dronedarone may decrease the vasoconstricting activities of Isoprenaline."
  ]
  edge [
    source 60
    target 133
    int "Risperidone may decrease the vasoconstricting activities of Isoprenaline."
  ]
  edge [
    source 60
    target 62
    int "The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Isoprenaline."
  ]
  edge [
    source 60
    target 196
    int "Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Isoprenaline."
  ]
  edge [
    source 60
    target 162
    int "Spironolactone may decrease the vasoconstricting activities of Isoprenaline."
  ]
  edge [
    source 60
    target 168
    int "Atenolol may decrease the bronchodilatory activities of Isoprenaline."
  ]
  edge [
    source 60
    target 169
    int "Asenapine may decrease the vasoconstricting activities of Isoprenaline."
  ]
  edge [
    source 60
    target 113
    int "The risk or severity of adverse effects can be increased when Imipramine is combined with Isoprenaline."
  ]
  edge [
    source 60
    target 181
    int "The risk or severity of adverse effects can be increased when Dopamine is combined with Isoprenaline."
  ]
  edge [
    source 60
    target 102
    int "Methylergometrine may increase the hypertensive and vasoconstricting activities of Isoprenaline."
  ]
  edge [
    source 60
    target 191
    int "Trazodone may decrease the vasoconstricting activities of Isoprenaline."
  ]
  edge [
    source 60
    target 194
    int "The risk or severity of adverse effects can be increased when Pargyline is combined with Isoprenaline."
  ]
  edge [
    source 60
    target 206
    int "Aripiprazole may decrease the vasoconstricting activities of Isoprenaline."
  ]
  edge [
    source 60
    target 208
    int "Trifluoperazine may decrease the vasoconstricting activities of Isoprenaline."
  ]
  edge [
    source 60
    target 215
    int "Isoprenaline may increase the hypokalemic activities of Methyclothiazide."
  ]
  edge [
    source 60
    target 226
    int "Isoprenaline may increase the hypokalemic activities of Bumetanide."
  ]
  edge [
    source 60
    target 241
    int "Tolazoline may decrease the vasoconstricting activities of Isoprenaline."
  ]
  edge [
    source 61
    target 157
    int "The metabolism of Imatinib can be decreased when combined with Armodafinil."
  ]
  edge [
    source 61
    target 123
    int "The risk or severity of adverse effects can be increased when Imatinib is combined with Leflunomide."
  ]
  edge [
    source 61
    target 62
    int "The metabolism of Imatinib can be decreased when combined with Tranylcypromine."
  ]
  edge [
    source 61
    target 76
    int "The metabolism of Tetracycline can be decreased when combined with Imatinib."
  ]
  edge [
    source 61
    target 64
    int "The metabolism of Clopidogrel can be decreased when combined with Imatinib."
  ]
  edge [
    source 61
    target 167
    int "The serum concentration of Imatinib can be increased when it is combined with Sildenafil."
  ]
  edge [
    source 61
    target 68
    int "The serum concentration of Imatinib can be decreased when it is combined with Rifabutin."
  ]
  edge [
    source 61
    target 75
    int "The serum concentration of Imatinib can be decreased when it is combined with Teriflunomide."
  ]
  edge [
    source 61
    target 86
    int "The metabolism of Argatroban can be decreased when combined with Imatinib."
  ]
  edge [
    source 61
    target 91
    int "The metabolism of Imatinib can be decreased when combined with Topiramate."
  ]
  edge [
    source 61
    target 103
    int "The metabolism of Zileuton can be decreased when combined with Imatinib."
  ]
  edge [
    source 61
    target 110
    int "The serum concentration of Imatinib can be increased when it is combined with Dronedarone."
  ]
  edge [
    source 61
    target 137
    int "The metabolism of Artemether can be decreased when combined with Imatinib."
  ]
  edge [
    source 61
    target 141
    int "The metabolism of Doxorubicin can be decreased when combined with Imatinib."
  ]
  edge [
    source 61
    target 148
    int "The metabolism of Dantrolene can be decreased when combined with Imatinib."
  ]
  edge [
    source 61
    target 149
    int "The serum concentration of Halofantrine can be increased when it is combined with Imatinib."
  ]
  edge [
    source 61
    target 74
    int "The serum concentration of Saxagliptin can be increased when it is combined with Imatinib."
  ]
  edge [
    source 61
    target 197
    int "The metabolism of Buspirone can be decreased when combined with Imatinib."
  ]
  edge [
    source 61
    target 193
    int "The metabolism of Flutamide can be decreased when combined with Imatinib."
  ]
  edge [
    source 61
    target 196
    int "The serum concentration of Imatinib can be increased when it is combined with Dihydroergotamine."
  ]
  edge [
    source 61
    target 214
    int "The metabolism of Proguanil can be decreased when combined with Imatinib."
  ]
  edge [
    source 61
    target 219
    int "The metabolism of Nisoldipine can be decreased when combined with Imatinib."
  ]
  edge [
    source 61
    target 220
    int "The metabolism of Sulfinpyrazone can be decreased when combined with Imatinib."
  ]
  edge [
    source 61
    target 122
    int "The metabolism of Levonorgestrel can be decreased when combined with Imatinib."
  ]
  edge [
    source 61
    target 230
    int "The metabolism of Isosorbide Dinitrate can be decreased when combined with Imatinib."
  ]
  edge [
    source 61
    target 232
    int "The metabolism of Sorafenib can be decreased when combined with Imatinib."
  ]
  edge [
    source 61
    target 206
    int "The serum concentration of Aripiprazole can be increased when it is combined with Imatinib."
  ]
  edge [
    source 61
    target 244
    int "The serum concentration of Ranolazine can be increased when it is combined with Imatinib."
  ]
  edge [
    source 61
    target 65
    int "The metabolism of Ethinyl Estradiol can be decreased when combined with Imatinib."
  ]
  edge [
    source 61
    target 174
    int "The metabolism of Sertraline can be decreased when combined with Imatinib."
  ]
  edge [
    source 61
    target 235
    int "Lansoprazole may increase the dermatologic adverse activities of Imatinib."
  ]
  edge [
    source 61
    target 84
    int "The metabolism of Trimethoprim can be decreased when combined with Imatinib."
  ]
  edge [
    source 61
    target 85
    int "Digitoxin may decrease the cardiotoxic activities of Imatinib."
  ]
  edge [
    source 61
    target 101
    int "The metabolism of Zaleplon can be decreased when combined with Imatinib."
  ]
  edge [
    source 61
    target 147
    int "The metabolism of Metronidazole can be decreased when combined with Imatinib."
  ]
  edge [
    source 61
    target 140
    int "The metabolism of Tinidazole can be decreased when combined with Imatinib."
  ]
  edge [
    source 61
    target 152
    int "The metabolism of Efavirenz can be decreased when combined with Imatinib."
  ]
  edge [
    source 61
    target 153
    int "The metabolism of Testosterone can be decreased when combined with Imatinib."
  ]
  edge [
    source 61
    target 155
    int "The serum concentration of Imatinib can be increased when it is combined with Bortezomib."
  ]
  edge [
    source 61
    target 159
    int "The metabolism of Cevimeline can be decreased when combined with Imatinib."
  ]
  edge [
    source 61
    target 175
    int "The metabolism of Maraviroc can be decreased when combined with Imatinib."
  ]
  edge [
    source 61
    target 176
    int "The metabolism of Cytarabine can be decreased when combined with Imatinib."
  ]
  edge [
    source 61
    target 180
    int "The metabolism of Disulfiram can be decreased when combined with Imatinib."
  ]
  edge [
    source 61
    target 94
    int "The metabolism of Imatinib can be decreased when combined with Valproic Acid."
  ]
  edge [
    source 61
    target 240
    int "The serum concentration of Imatinib can be decreased when it is combined with Primidone."
  ]
  edge [
    source 61
    target 246
    int "The serum concentration of Bosentan can be increased when it is combined with Imatinib."
  ]
  edge [
    source 61
    target 154
    int "The metabolism of Amprenavir can be decreased when combined with Imatinib."
  ]
  edge [
    source 61
    target 89
    int "The metabolism of Praziquantel can be decreased when combined with Imatinib."
  ]
  edge [
    source 61
    target 117
    int "The metabolism of Albendazole can be decreased when combined with Imatinib."
  ]
  edge [
    source 61
    target 125
    int "The metabolism of Pentamidine can be decreased when combined with Imatinib."
  ]
  edge [
    source 61
    target 129
    int "The metabolism of Nateglinide can be decreased when combined with Imatinib."
  ]
  edge [
    source 61
    target 133
    int "The metabolism of Risperidone can be decreased when combined with Imatinib."
  ]
  edge [
    source 61
    target 135
    int "The serum concentration of Everolimus can be increased when it is combined with Imatinib."
  ]
  edge [
    source 61
    target 136
    int "The serum concentration of Ulipristal can be increased when it is combined with Imatinib."
  ]
  edge [
    source 61
    target 156
    int "The metabolism of Mefloquine can be decreased when combined with Imatinib."
  ]
  edge [
    source 61
    target 160
    int "The metabolism of Chlorzoxazone can be decreased when combined with Imatinib."
  ]
  edge [
    source 61
    target 102
    int "The risk or severity of adverse effects can be increased when Methylergometrine is combined with Imatinib."
  ]
  edge [
    source 61
    target 164
    int "The metabolism of Mebendazole can be decreased when combined with Imatinib."
  ]
  edge [
    source 61
    target 166
    int "The serum concentration of Tolvaptan can be increased when it is combined with Imatinib."
  ]
  edge [
    source 61
    target 169
    int "The metabolism of Asenapine can be decreased when combined with Imatinib."
  ]
  edge [
    source 61
    target 113
    int "The metabolism of Imipramine can be decreased when combined with Imatinib."
  ]
  edge [
    source 61
    target 171
    int "The serum concentration of Imatinib can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 61
    target 207
    int "The metabolism of Zonisamide can be decreased when combined with Imatinib."
  ]
  edge [
    source 61
    target 173
    int "The metabolism of Tiagabine can be decreased when combined with Imatinib."
  ]
  edge [
    source 61
    target 187
    int "The metabolism of Clofibrate can be decreased when combined with Imatinib."
  ]
  edge [
    source 61
    target 201
    int "The metabolism of Aliskiren can be decreased when combined with Imatinib."
  ]
  edge [
    source 61
    target 212
    int "The metabolism of Loperamide can be decreased when combined with Imatinib."
  ]
  edge [
    source 61
    target 124
    int "The serum concentration of Pazopanib can be increased when it is combined with Imatinib."
  ]
  edge [
    source 61
    target 63
    int "The metabolism of Azithromycin can be decreased when combined with Imatinib."
  ]
  edge [
    source 61
    target 200
    int "The metabolism of Zalcitabine can be decreased when combined with Imatinib."
  ]
  edge [
    source 61
    target 90
    int "The metabolism of Lumefantrine can be decreased when combined with Imatinib."
  ]
  edge [
    source 61
    target 115
    int "The metabolism of Sitagliptin can be decreased when combined with Imatinib."
  ]
  edge [
    source 61
    target 118
    int "The metabolism of Sunitinib can be decreased when combined with Imatinib."
  ]
  edge [
    source 61
    target 138
    int "The metabolism of Theophylline can be decreased when combined with Imatinib."
  ]
  edge [
    source 61
    target 165
    int "The metabolism of Pyrazinamide can be decreased when combined with Imatinib."
  ]
  edge [
    source 61
    target 186
    int "The metabolism of Dutasteride can be decreased when combined with Imatinib."
  ]
  edge [
    source 61
    target 188
    int "The serum concentration of Cerivastatin can be increased when it is combined with Imatinib."
  ]
  edge [
    source 61
    target 191
    int "The metabolism of Trazodone can be decreased when combined with Imatinib."
  ]
  edge [
    source 62
    target 64
    int "The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Tranylcypromine resulting in a loss in efficacy."
  ]
  edge [
    source 62
    target 67
    int "Tranylcypromine may increase the hypertensive activities of Furazolidone."
  ]
  edge [
    source 62
    target 91
    int "The risk or severity of adverse effects can be increased when Topiramate is combined with Tranylcypromine."
  ]
  edge [
    source 62
    target 95
    int "Tranylcypromine may increase the hypotensive activities of Olmesartan."
  ]
  edge [
    source 62
    target 109
    int "The risk or severity of adverse effects can be increased when Etomidate is combined with Tranylcypromine."
  ]
  edge [
    source 62
    target 110
    int "The metabolism of Dronedarone can be decreased when combined with Tranylcypromine."
  ]
  edge [
    source 62
    target 228
    int "Tranylcypromine may increase the hypotensive activities of Bretylium."
  ]
  edge [
    source 62
    target 137
    int "The metabolism of Artemether can be decreased when combined with Tranylcypromine."
  ]
  edge [
    source 62
    target 141
    int "The metabolism of Doxorubicin can be decreased when combined with Tranylcypromine."
  ]
  edge [
    source 62
    target 142
    int "The risk or severity of adverse effects can be increased when Gabapentin is combined with Tranylcypromine."
  ]
  edge [
    source 62
    target 150
    int "The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Lithium."
  ]
  edge [
    source 62
    target 194
    int "Tranylcypromine may increase the hypertensive activities of Pargyline."
  ]
  edge [
    source 62
    target 195
    int "The risk or severity of adverse effects can be increased when Entacapone is combined with Tranylcypromine."
  ]
  edge [
    source 62
    target 197
    int "The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Buspirone."
  ]
  edge [
    source 62
    target 198
    int "Tranylcypromine may increase the hypoglycemic activities of Miglitol."
  ]
  edge [
    source 62
    target 182
    int "The metabolism of Mephenytoin can be decreased when combined with Tranylcypromine."
  ]
  edge [
    source 62
    target 193
    int "The metabolism of Flutamide can be decreased when combined with Tranylcypromine."
  ]
  edge [
    source 62
    target 196
    int "The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Tranylcypromine."
  ]
  edge [
    source 62
    target 214
    int "The metabolism of Proguanil can be decreased when combined with Tranylcypromine."
  ]
  edge [
    source 62
    target 219
    int "Tranylcypromine may increase the hypotensive activities of Nisoldipine."
  ]
  edge [
    source 62
    target 222
    int "The risk or severity of adverse effects can be increased when Metaxalone is combined with Tranylcypromine."
  ]
  edge [
    source 62
    target 224
    int "The serum concentration of Sumatriptan can be increased when it is combined with Tranylcypromine."
  ]
  edge [
    source 62
    target 225
    int "Tranylcypromine may increase the hypertensive activities of Epinephrine."
  ]
  edge [
    source 62
    target 230
    int "The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Isosorbide Dinitrate."
  ]
  edge [
    source 62
    target 231
    int "The metabolism of Carisoprodol can be decreased when combined with Tranylcypromine."
  ]
  edge [
    source 62
    target 158
    int "The metabolism of Piperazine can be decreased when combined with Tranylcypromine."
  ]
  edge [
    source 62
    target 249
    int "The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Dipyridamole."
  ]
  edge [
    source 62
    target 174
    int "The risk or severity of adverse effects can be increased when Sertraline is combined with Tranylcypromine."
  ]
  edge [
    source 62
    target 74
    int "Tranylcypromine may increase the hypoglycemic activities of Saxagliptin."
  ]
  edge [
    source 62
    target 235
    int "The metabolism of Lansoprazole can be decreased when combined with Tranylcypromine."
  ]
  edge [
    source 62
    target 81
    int "Tranylcypromine may increase the hypertensive activities of Doxapram."
  ]
  edge [
    source 62
    target 98
    int "The risk or severity of hypertension can be increased when Tranylcypromine is combined with Methyldopa."
  ]
  edge [
    source 62
    target 101
    int "The risk or severity of adverse effects can be increased when Zaleplon is combined with Tranylcypromine."
  ]
  edge [
    source 62
    target 131
    int "The risk or severity of adverse effects can be increased when Rufinamide is combined with Tranylcypromine."
  ]
  edge [
    source 62
    target 97
    int "Tranylcypromine may increase the hypotensive activities of Diazoxide."
  ]
  edge [
    source 62
    target 152
    int "The risk or severity of adverse effects can be increased when Efavirenz is combined with Tranylcypromine."
  ]
  edge [
    source 62
    target 153
    int "The metabolism of Testosterone can be decreased when combined with Tranylcypromine."
  ]
  edge [
    source 62
    target 155
    int "The metabolism of Bortezomib can be decreased when combined with Tranylcypromine."
  ]
  edge [
    source 62
    target 159
    int "The metabolism of Cevimeline can be decreased when combined with Tranylcypromine."
  ]
  edge [
    source 62
    target 167
    int "The metabolism of Sildenafil can be decreased when combined with Tranylcypromine."
  ]
  edge [
    source 62
    target 218
    int "Altretamine may increase the orthostatic hypotensive activities of Tranylcypromine."
  ]
  edge [
    source 62
    target 181
    int "The metabolism of Dopamine can be decreased when combined with Tranylcypromine."
  ]
  edge [
    source 62
    target 226
    int "The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Bumetanide."
  ]
  edge [
    source 62
    target 168
    int "Tranylcypromine may increase the hypotensive activities of Atenolol."
  ]
  edge [
    source 62
    target 94
    int "The risk or severity of adverse effects can be increased when Valproic Acid is combined with Tranylcypromine."
  ]
  edge [
    source 62
    target 170
    int "Tranylcypromine may increase the hypoglycemic activities of Metformin."
  ]
  edge [
    source 62
    target 237
    int "Tranylcypromine may increase the hypoglycemic activities of Rosiglitazone."
  ]
  edge [
    source 62
    target 238
    int "Tranylcypromine may increase the sedative activities of Pramipexole."
  ]
  edge [
    source 62
    target 240
    int "The metabolism of Primidone can be decreased when combined with Tranylcypromine."
  ]
  edge [
    source 62
    target 246
    int "Tranylcypromine may increase the hypotensive activities of Bosentan."
  ]
  edge [
    source 62
    target 234
    int "The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Lamotrigine."
  ]
  edge [
    source 62
    target 154
    int "The metabolism of Amprenavir can be decreased when combined with Tranylcypromine."
  ]
  edge [
    source 62
    target 93
    int "Tranylcypromine may increase the hypotensive activities of Hydralazine."
  ]
  edge [
    source 62
    target 89
    int "The metabolism of Praziquantel can be decreased when combined with Tranylcypromine."
  ]
  edge [
    source 62
    target 125
    int "The metabolism of Pentamidine can be decreased when combined with Tranylcypromine."
  ]
  edge [
    source 62
    target 129
    int "The metabolism of Nateglinide can be decreased when combined with Tranylcypromine."
  ]
  edge [
    source 62
    target 160
    int "The metabolism of Chlorzoxazone can be decreased when combined with Tranylcypromine."
  ]
  edge [
    source 62
    target 161
    int "Tranylcypromine may increase the hypotensive activities of Minoxidil."
  ]
  edge [
    source 62
    target 162
    int "The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Spironolactone."
  ]
  edge [
    source 62
    target 166
    int "The serum concentration of Tolvaptan can be increased when it is combined with Tranylcypromine."
  ]
  edge [
    source 62
    target 169
    int "The risk or severity of adverse effects can be increased when Asenapine is combined with Tranylcypromine."
  ]
  edge [
    source 62
    target 113
    int "Tranylcypromine may increase the serotonergic activities of Imipramine."
  ]
  edge [
    source 62
    target 207
    int "The risk or severity of adverse effects can be increased when Zonisamide is combined with Tranylcypromine."
  ]
  edge [
    source 62
    target 173
    int "The risk or severity of adverse effects can be increased when Tiagabine is combined with Tranylcypromine."
  ]
  edge [
    source 62
    target 184
    int "The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Tranylcypromine."
  ]
  edge [
    source 62
    target 87
    int "The risk or severity of adverse effects can be increased when Clofarabine is combined with Tranylcypromine."
  ]
  edge [
    source 62
    target 201
    int "Tranylcypromine may increase the hypotensive activities of Aliskiren."
  ]
  edge [
    source 62
    target 206
    int "The serum concentration of Aripiprazole can be increased when it is combined with Tranylcypromine."
  ]
  edge [
    source 62
    target 208
    int "The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Tranylcypromine."
  ]
  edge [
    source 62
    target 212
    int "The metabolism of Loperamide can be decreased when combined with Tranylcypromine."
  ]
  edge [
    source 62
    target 124
    int "The metabolism of Pazopanib can be decreased when combined with Tranylcypromine."
  ]
  edge [
    source 62
    target 180
    int "The risk or severity of convulsion can be increased when Tranylcypromine is combined with Disulfiram."
  ]
  edge [
    source 62
    target 200
    int "The metabolism of Zalcitabine can be decreased when combined with Tranylcypromine."
  ]
  edge [
    source 62
    target 133
    int "Tranylcypromine may increase the hypotensive activities of Risperidone."
  ]
  edge [
    source 62
    target 102
    int "The risk or severity of adverse effects can be increased when Methylergometrine is combined with Tranylcypromine."
  ]
  edge [
    source 62
    target 72
    int "The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Tetrabenazine."
  ]
  edge [
    source 62
    target 73
    int "Tranylcypromine may increase the hypoglycemic activities of Acarbose."
  ]
  edge [
    source 62
    target 188
    int "The serum concentration of Cerivastatin can be increased when it is combined with Tranylcypromine."
  ]
  edge [
    source 62
    target 115
    int "Tranylcypromine may increase the hypoglycemic activities of Sitagliptin."
  ]
  edge [
    source 62
    target 118
    int "Tranylcypromine may increase the hypoglycemic activities of Sunitinib."
  ]
  edge [
    source 62
    target 148
    int "The risk or severity of adverse effects can be increased when Dantrolene is combined with Tranylcypromine."
  ]
  edge [
    source 62
    target 149
    int "The metabolism of Halofantrine can be decreased when combined with Tranylcypromine."
  ]
  edge [
    source 62
    target 138
    int "The metabolism of Theophylline can be decreased when combined with Tranylcypromine."
  ]
  edge [
    source 62
    target 119
    int "The risk or severity of adverse effects can be increased when Triflupromazine is combined with Tranylcypromine."
  ]
  edge [
    source 62
    target 70
    int "The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Amiloride."
  ]
  edge [
    source 62
    target 241
    int "Tranylcypromine may increase the hypotensive activities of Tolazoline."
  ]
  edge [
    source 62
    target 191
    int "Tranylcypromine may increase the serotonergic activities of Trazodone."
  ]
  edge [
    source 62
    target 192
    int "Tranylcypromine may increase the hypotensive activities of Mecamylamine."
  ]
  edge [
    source 62
    target 202
    int "The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Maprotiline."
  ]
  edge [
    source 62
    target 215
    int "The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Methyclothiazide."
  ]
  edge [
    source 63
    target 123
    int "The metabolism of Leflunomide can be decreased when combined with Azithromycin."
  ]
  edge [
    source 63
    target 64
    int "The metabolism of Clopidogrel can be decreased when combined with Azithromycin."
  ]
  edge [
    source 63
    target 167
    int "The metabolism of Azithromycin can be decreased when combined with Sildenafil."
  ]
  edge [
    source 63
    target 68
    int "The metabolism of Azithromycin can be increased when combined with Rifabutin."
  ]
  edge [
    source 63
    target 138
    int "The metabolism of Theophylline can be decreased when combined with Azithromycin."
  ]
  edge [
    source 63
    target 110
    int "Azithromycin may increase the QTc-prolonging activities of Dronedarone."
  ]
  edge [
    source 63
    target 137
    int "Azithromycin may increase the QTc-prolonging activities of Artemether."
  ]
  edge [
    source 63
    target 141
    int "The serum concentration of Doxorubicin can be increased when it is combined with Azithromycin."
  ]
  edge [
    source 63
    target 150
    int "Lithium may increase the QTc-prolonging activities of Azithromycin."
  ]
  edge [
    source 63
    target 182
    int "The metabolism of Mephenytoin can be decreased when combined with Azithromycin."
  ]
  edge [
    source 63
    target 193
    int "The metabolism of Flutamide can be decreased when combined with Azithromycin."
  ]
  edge [
    source 63
    target 196
    int "The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Azithromycin."
  ]
  edge [
    source 63
    target 118
    int "Sunitinib may increase the QTc-prolonging activities of Azithromycin."
  ]
  edge [
    source 63
    target 214
    int "The metabolism of Proguanil can be decreased when combined with Azithromycin."
  ]
  edge [
    source 63
    target 232
    int "Sorafenib may increase the QTc-prolonging activities of Azithromycin."
  ]
  edge [
    source 63
    target 244
    int "The serum concentration of Ranolazine can be increased when it is combined with Azithromycin."
  ]
  edge [
    source 63
    target 174
    int "The metabolism of Sertraline can be decreased when combined with Azithromycin."
  ]
  edge [
    source 63
    target 72
    int "Azithromycin may increase the QTc-prolonging activities of Tetrabenazine."
  ]
  edge [
    source 63
    target 84
    int "Trimethoprim may increase the QTc-prolonging activities of Azithromycin."
  ]
  edge [
    source 63
    target 103
    int "The metabolism of Zileuton can be decreased when combined with Azithromycin."
  ]
  edge [
    source 63
    target 105
    int "The metabolism of Riluzole can be decreased when combined with Azithromycin."
  ]
  edge [
    source 63
    target 107
    int "Vorinostat may increase the QTc-prolonging activities of Azithromycin."
  ]
  edge [
    source 63
    target 147
    int "Metronidazole may increase the QTc-prolonging activities of Azithromycin."
  ]
  edge [
    source 63
    target 83
    int "Amantadine may increase the QTc-prolonging activities of Azithromycin."
  ]
  edge [
    source 63
    target 155
    int "The metabolism of Azithromycin can be decreased when combined with Bortezomib."
  ]
  edge [
    source 63
    target 205
    int "Foscarnet may increase the QTc-prolonging activities of Azithromycin."
  ]
  edge [
    source 63
    target 240
    int "The metabolism of Azithromycin can be increased when combined with Primidone."
  ]
  edge [
    source 63
    target 246
    int "The serum concentration of Azithromycin can be decreased when it is combined with Bosentan."
  ]
  edge [
    source 63
    target 89
    int "The metabolism of Praziquantel can be decreased when combined with Azithromycin."
  ]
  edge [
    source 63
    target 117
    int "The metabolism of Albendazole can be decreased when combined with Azithromycin."
  ]
  edge [
    source 63
    target 125
    int "Azithromycin may increase the QTc-prolonging activities of Pentamidine."
  ]
  edge [
    source 63
    target 130
    int "The metabolism of Thiabendazole can be decreased when combined with Azithromycin."
  ]
  edge [
    source 63
    target 133
    int "Risperidone may increase the QTc-prolonging activities of Azithromycin."
  ]
  edge [
    source 63
    target 135
    int "The serum concentration of Everolimus can be increased when it is combined with Azithromycin."
  ]
  edge [
    source 63
    target 136
    int "The metabolism of Ulipristal can be decreased when combined with Azithromycin."
  ]
  edge [
    source 63
    target 156
    int "Mefloquine may increase the QTc-prolonging activities of Azithromycin."
  ]
  edge [
    source 63
    target 160
    int "The metabolism of Chlorzoxazone can be decreased when combined with Azithromycin."
  ]
  edge [
    source 63
    target 102
    int "The risk or severity of adverse effects can be increased when Methylergometrine is combined with Azithromycin."
  ]
  edge [
    source 63
    target 166
    int "The serum concentration of Tolvaptan can be increased when it is combined with Azithromycin."
  ]
  edge [
    source 63
    target 169
    int "Azithromycin may increase the QTc-prolonging activities of Asenapine."
  ]
  edge [
    source 63
    target 113
    int "The metabolism of Imipramine can be decreased when combined with Azithromycin."
  ]
  edge [
    source 63
    target 171
    int "The serum concentration of Azithromycin can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 63
    target 206
    int "Aripiprazole may increase the QTc-prolonging activities of Azithromycin."
  ]
  edge [
    source 63
    target 208
    int "The metabolism of Trifluoperazine can be decreased when combined with Azithromycin."
  ]
  edge [
    source 63
    target 124
    int "The serum concentration of Pazopanib can be increased when it is combined with Azithromycin."
  ]
  edge [
    source 63
    target 85
    int "The serum concentration of Digitoxin can be increased when it is combined with Azithromycin."
  ]
  edge [
    source 63
    target 90
    int "Azithromycin may increase the QTc-prolonging activities of Lumefantrine."
  ]
  edge [
    source 63
    target 165
    int "The metabolism of Pyrazinamide can be decreased when combined with Azithromycin."
  ]
  edge [
    source 63
    target 188
    int "The serum concentration of Cerivastatin can be increased when it is combined with Azithromycin."
  ]
  edge [
    source 63
    target 191
    int "Trazodone may increase the QTc-prolonging activities of Azithromycin."
  ]
  edge [
    source 63
    target 202
    int "The metabolism of Maprotiline can be decreased when combined with Azithromycin."
  ]
  edge [
    source 64
    target 157
    int "The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Armodafinil resulting in a loss in efficacy."
  ]
  edge [
    source 64
    target 249
    int "Dipyridamole may increase the anticoagulant activities of Clopidogrel."
  ]
  edge [
    source 64
    target 167
    int "The metabolism of Clopidogrel can be decreased when combined with Sildenafil."
  ]
  edge [
    source 64
    target 68
    int "The risk or severity of adverse effects can be increased when Rifabutin is combined with Clopidogrel."
  ]
  edge [
    source 64
    target 91
    int "The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Topiramate resulting in a loss in efficacy."
  ]
  edge [
    source 64
    target 138
    int "The metabolism of Clopidogrel can be decreased when combined with Theophylline."
  ]
  edge [
    source 64
    target 110
    int "The metabolism of Clopidogrel can be decreased when combined with Dronedarone."
  ]
  edge [
    source 64
    target 123
    int "The metabolism of Clopidogrel can be decreased when combined with Leflunomide."
  ]
  edge [
    source 64
    target 137
    int "The metabolism of Artemether can be decreased when combined with Clopidogrel."
  ]
  edge [
    source 64
    target 141
    int "The metabolism of Clopidogrel can be decreased when combined with Doxorubicin."
  ]
  edge [
    source 64
    target 142
    int "The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Gabapentin."
  ]
  edge [
    source 64
    target 182
    int "The metabolism of Mephenytoin can be decreased when combined with Clopidogrel."
  ]
  edge [
    source 64
    target 196
    int "The metabolism of Clopidogrel can be decreased when combined with Dihydroergotamine."
  ]
  edge [
    source 64
    target 219
    int "The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Nisoldipine."
  ]
  edge [
    source 64
    target 232
    int "The metabolism of Clopidogrel can be decreased when combined with Sorafenib."
  ]
  edge [
    source 64
    target 247
    int "The risk or severity of adverse effects can be increased when Clopidogrel is combined with Mesalazine."
  ]
  edge [
    source 64
    target 174
    int "The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Sertraline resulting in a loss in efficacy."
  ]
  edge [
    source 64
    target 235
    int "The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Lansoprazole resulting in a loss in efficacy."
  ]
  edge [
    source 64
    target 84
    int "The metabolism of Clopidogrel can be decreased when combined with Trimethoprim."
  ]
  edge [
    source 64
    target 152
    int "The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Efavirenz resulting in a loss in efficacy."
  ]
  edge [
    source 64
    target 153
    int "The metabolism of Testosterone can be decreased when combined with Clopidogrel."
  ]
  edge [
    source 64
    target 155
    int "The serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Bortezomib resulting in a loss in efficacy."
  ]
  edge [
    source 64
    target 66
    int "The serum concentration of Amodiaquine can be increased when it is combined with Clopidogrel."
  ]
  edge [
    source 64
    target 75
    int "The serum concentration of Clopidogrel can be decreased when it is combined with Teriflunomide."
  ]
  edge [
    source 64
    target 244
    int "The serum concentration of Clopidogrel can be increased when it is combined with Ranolazine."
  ]
  edge [
    source 64
    target 94
    int "The metabolism of Clopidogrel can be decreased when combined with Valproic Acid."
  ]
  edge [
    source 64
    target 237
    int "Clopidogrel may increase the anticoagulant activities of Rosiglitazone."
  ]
  edge [
    source 64
    target 240
    int "The metabolism of Clopidogrel can be increased when combined with Primidone."
  ]
  edge [
    source 64
    target 246
    int "The serum concentration of Clopidogrel can be decreased when it is combined with Bosentan."
  ]
  edge [
    source 64
    target 234
    int "The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Lamotrigine."
  ]
  edge [
    source 64
    target 86
    int "Clopidogrel may increase the anticoagulant activities of Argatroban."
  ]
  edge [
    source 64
    target 113
    int "The metabolism of Imipramine can be decreased when combined with Clopidogrel."
  ]
  edge [
    source 64
    target 171
    int "The serum concentration of Clopidogrel can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 64
    target 207
    int "The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Zonisamide."
  ]
  edge [
    source 64
    target 212
    int "The therapeutic efficacy of Clopidogrel can be decreased when used in combination with Loperamide."
  ]
  edge [
    source 64
    target 188
    int "The risk or severity of rhabdomyolysis can be increased when Clopidogrel is combined with Cerivastatin."
  ]
  edge [
    source 64
    target 189
    int "The risk or severity of adverse effects can be increased when Clopidogrel is combined with Aminosalicylic Acid."
  ]
  edge [
    source 65
    target 157
    int "The serum concentration of Ethinyl Estradiol can be decreased when it is combined with Armodafinil."
  ]
  edge [
    source 65
    target 167
    int "The metabolism of Ethinyl Estradiol can be decreased when combined with Sildenafil."
  ]
  edge [
    source 65
    target 68
    int "The metabolism of Ethinyl Estradiol can be increased when combined with Rifabutin."
  ]
  edge [
    source 65
    target 86
    int "The serum concentration of Ethinyl Estradiol can be decreased when it is combined with Argatroban."
  ]
  edge [
    source 65
    target 91
    int "The serum concentration of Ethinyl Estradiol can be decreased when it is combined with Topiramate."
  ]
  edge [
    source 65
    target 138
    int "The serum concentration of Theophylline can be increased when it is combined with Ethinyl Estradiol."
  ]
  edge [
    source 65
    target 110
    int "The metabolism of Ethinyl Estradiol can be decreased when combined with Dronedarone."
  ]
  edge [
    source 65
    target 137
    int "The serum concentration of Ethinyl Estradiol can be decreased when it is combined with Artemether."
  ]
  edge [
    source 65
    target 144
    int "The therapeutic efficacy of Anastrozole can be decreased when used in combination with Ethinyl Estradiol."
  ]
  edge [
    source 65
    target 146
    int "Chlorphenesin may increase the thrombogenic activities of Ethinyl Estradiol."
  ]
  edge [
    source 65
    target 154
    int "The serum concentration of Ethinyl Estradiol can be decreased when it is combined with Amprenavir."
  ]
  edge [
    source 65
    target 198
    int "The therapeutic efficacy of Miglitol can be decreased when used in combination with Ethinyl Estradiol."
  ]
  edge [
    source 65
    target 217
    int "The serum concentration of Desoxycorticosterone Pivalate can be increased when it is combined with Ethinyl Estradiol."
  ]
  edge [
    source 65
    target 244
    int "The serum concentration of Ethinyl Estradiol can be increased when it is combined with Ranolazine."
  ]
  edge [
    source 65
    target 247
    int "Mesalazine may increase the thrombogenic activities of Ethinyl Estradiol."
  ]
  edge [
    source 65
    target 74
    int "The serum concentration of Ethinyl Estradiol can be decreased when it is combined with Saxagliptin."
  ]
  edge [
    source 65
    target 131
    int "The serum concentration of Ethinyl Estradiol can be decreased when it is combined with Rufinamide."
  ]
  edge [
    source 65
    target 155
    int "The metabolism of Ethinyl Estradiol can be decreased when combined with Bortezomib."
  ]
  edge [
    source 65
    target 66
    int "The serum concentration of Amodiaquine can be increased when it is combined with Ethinyl Estradiol."
  ]
  edge [
    source 65
    target 236
    int "The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Ethinyl Estradiol."
  ]
  edge [
    source 65
    target 237
    int "The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Ethinyl Estradiol."
  ]
  edge [
    source 65
    target 240
    int "The metabolism of Ethinyl Estradiol can be increased when combined with Primidone."
  ]
  edge [
    source 65
    target 243
    int "The therapeutic efficacy of Miglustat can be decreased when used in combination with Ethinyl Estradiol."
  ]
  edge [
    source 65
    target 246
    int "The serum concentration of Ethinyl Estradiol can be decreased when it is combined with Bosentan."
  ]
  edge [
    source 65
    target 234
    int "The serum concentration of Lamotrigine can be decreased when it is combined with Ethinyl Estradiol."
  ]
  edge [
    source 65
    target 114
    int "The therapeutic efficacy of Ethinyl Estradiol can be decreased when used in combination with Acitretin."
  ]
  edge [
    source 65
    target 129
    int "The therapeutic efficacy of Nateglinide can be decreased when used in combination with Ethinyl Estradiol."
  ]
  edge [
    source 65
    target 179
    int "The serum concentration of Ethinyl Estradiol can be decreased when it is combined with Cilastatin."
  ]
  edge [
    source 65
    target 196
    int "The metabolism of Ethinyl Estradiol can be decreased when combined with Dihydroergotamine."
  ]
  edge [
    source 65
    target 171
    int "The serum concentration of Ethinyl Estradiol can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 65
    target 242
    int "Ethinyl Estradiol may increase the thrombogenic activities of Tranexamic Acid."
  ]
  edge [
    source 65
    target 73
    int "The therapeutic efficacy of Acarbose can be decreased when used in combination with Ethinyl Estradiol."
  ]
  edge [
    source 65
    target 115
    int "The serum concentration of Ethinyl Estradiol can be decreased when it is combined with Sitagliptin."
  ]
  edge [
    source 65
    target 170
    int "The therapeutic efficacy of Metformin can be decreased when used in combination with Ethinyl Estradiol."
  ]
  edge [
    source 65
    target 199
    int "Meclofenamic acid may increase the thrombogenic activities of Ethinyl Estradiol."
  ]
  edge [
    source 65
    target 189
    int "Aminosalicylic Acid may increase the thrombogenic activities of Ethinyl Estradiol."
  ]
  edge [
    source 66
    target 245
    int "The serum concentration of Diethylcarbamazine can be decreased when it is combined with Amodiaquine."
  ]
  edge [
    source 66
    target 75
    int "The metabolism of Amodiaquine can be decreased when combined with Teriflunomide."
  ]
  edge [
    source 66
    target 147
    int "The serum concentration of Amodiaquine can be increased when it is combined with Metronidazole."
  ]
  edge [
    source 66
    target 84
    int "Trimethoprim may increase the neutropenic activities of Amodiaquine."
  ]
  edge [
    source 66
    target 90
    int "The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Lumefantrine."
  ]
  edge [
    source 66
    target 89
    int "The serum concentration of Praziquantel can be decreased when it is combined with Amodiaquine."
  ]
  edge [
    source 66
    target 116
    int "The serum concentration of Levamisole can be decreased when it is combined with Amodiaquine."
  ]
  edge [
    source 66
    target 117
    int "The serum concentration of Albendazole can be decreased when it is combined with Amodiaquine."
  ]
  edge [
    source 66
    target 130
    int "The serum concentration of Thiabendazole can be decreased when it is combined with Amodiaquine."
  ]
  edge [
    source 66
    target 137
    int "The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Artemether."
  ]
  edge [
    source 66
    target 119
    int "The serum concentration of Triflupromazine can be increased when it is combined with Amodiaquine."
  ]
  edge [
    source 66
    target 152
    int "Efavirenz may increase the hepatotoxic activities of Amodiaquine."
  ]
  edge [
    source 66
    target 156
    int "The risk or severity of adverse effects can be increased when Amodiaquine is combined with Mefloquine."
  ]
  edge [
    source 66
    target 158
    int "The serum concentration of Piperazine can be decreased when it is combined with Amodiaquine."
  ]
  edge [
    source 66
    target 162
    int "The serum concentration of Amodiaquine can be increased when it is combined with Spironolactone."
  ]
  edge [
    source 66
    target 164
    int "The serum concentration of Mebendazole can be decreased when it is combined with Amodiaquine."
  ]
  edge [
    source 66
    target 168
    int "The metabolism of Atenolol can be decreased when combined with Amodiaquine."
  ]
  edge [
    source 66
    target 169
    int "The metabolism of Asenapine can be decreased when combined with Amodiaquine."
  ]
  edge [
    source 66
    target 188
    int "The serum concentration of Amodiaquine can be increased when it is combined with Cerivastatin."
  ]
  edge [
    source 66
    target 240
    int "The metabolism of Amodiaquine can be increased when combined with Primidone."
  ]
  edge [
    source 66
    target 208
    int "The serum concentration of Trifluoperazine can be increased when it is combined with Amodiaquine."
  ]
  edge [
    source 66
    target 121
    int "The serum concentration of Niclosamide can be decreased when it is combined with Amodiaquine."
  ]
  edge [
    source 66
    target 85
    int "The serum concentration of Digitoxin can be increased when it is combined with Amodiaquine."
  ]
  edge [
    source 66
    target 94
    int "The serum concentration of Amodiaquine can be increased when it is combined with Valproic Acid."
  ]
  edge [
    source 66
    target 232
    int "The serum concentration of Amodiaquine can be increased when it is combined with Sorafenib."
  ]
  edge [
    source 66
    target 235
    int "The serum concentration of Amodiaquine can be increased when it is combined with Lansoprazole."
  ]
  edge [
    source 66
    target 237
    int "The metabolism of Amodiaquine can be decreased when combined with Rosiglitazone."
  ]
  edge [
    source 67
    target 95
    int "Furazolidone may increase the hypotensive activities of Olmesartan."
  ]
  edge [
    source 67
    target 150
    int "The risk or severity of adverse effects can be increased when Furazolidone is combined with Lithium."
  ]
  edge [
    source 67
    target 196
    int "The metabolism of Dihydroergotamine can be decreased when combined with Furazolidone."
  ]
  edge [
    source 67
    target 197
    int "The risk or severity of adverse effects can be increased when Furazolidone is combined with Buspirone."
  ]
  edge [
    source 67
    target 194
    int "Pargyline may increase the hypertensive activities of Furazolidone."
  ]
  edge [
    source 67
    target 195
    int "The risk or severity of adverse effects can be increased when Entacapone is combined with Furazolidone."
  ]
  edge [
    source 67
    target 198
    int "Furazolidone may increase the hypoglycemic activities of Miglitol."
  ]
  edge [
    source 67
    target 219
    int "Furazolidone may increase the hypotensive activities of Nisoldipine."
  ]
  edge [
    source 67
    target 224
    int "The metabolism of Sumatriptan can be decreased when combined with Furazolidone."
  ]
  edge [
    source 67
    target 225
    int "Furazolidone may increase the hypertensive activities of Epinephrine."
  ]
  edge [
    source 67
    target 174
    int "Furazolidone may increase the serotonergic activities of Sertraline."
  ]
  edge [
    source 67
    target 74
    int "Furazolidone may increase the hypoglycemic activities of Saxagliptin."
  ]
  edge [
    source 67
    target 81
    int "Furazolidone may increase the hypertensive activities of Doxapram."
  ]
  edge [
    source 67
    target 98
    int "The risk or severity of hypertension can be increased when Furazolidone is combined with Methyldopa."
  ]
  edge [
    source 67
    target 218
    int "Altretamine may increase the orthostatic hypotensive activities of Furazolidone."
  ]
  edge [
    source 67
    target 168
    int "Furazolidone may increase the hypotensive activities of Atenolol."
  ]
  edge [
    source 67
    target 237
    int "Furazolidone may increase the hypoglycemic activities of Rosiglitazone."
  ]
  edge [
    source 67
    target 241
    int "Furazolidone may increase the hypotensive activities of Tolazoline."
  ]
  edge [
    source 67
    target 246
    int "Furazolidone may increase the hypotensive activities of Bosentan."
  ]
  edge [
    source 67
    target 180
    int "The risk or severity of convulsion can be increased when Furazolidone is combined with Disulfiram."
  ]
  edge [
    source 67
    target 97
    int "Furazolidone may increase the hypotensive activities of Diazoxide."
  ]
  edge [
    source 67
    target 93
    int "Furazolidone may increase the hypotensive activities of Hydralazine."
  ]
  edge [
    source 67
    target 113
    int "Furazolidone may increase the serotonergic activities of Imipramine."
  ]
  edge [
    source 67
    target 125
    int "Furazolidone may increase the hypoglycemic activities of Pentamidine."
  ]
  edge [
    source 67
    target 129
    int "Furazolidone may increase the hypoglycemic activities of Nateglinide."
  ]
  edge [
    source 67
    target 161
    int "Furazolidone may increase the hypotensive activities of Minoxidil."
  ]
  edge [
    source 67
    target 201
    int "Furazolidone may increase the hypotensive activities of Aliskiren."
  ]
  edge [
    source 67
    target 72
    int "The risk or severity of adverse effects can be increased when Furazolidone is combined with Tetrabenazine."
  ]
  edge [
    source 67
    target 73
    int "Furazolidone may increase the hypoglycemic activities of Acarbose."
  ]
  edge [
    source 67
    target 228
    int "Furazolidone may increase the hypotensive activities of Bretylium."
  ]
  edge [
    source 67
    target 115
    int "Furazolidone may increase the hypoglycemic activities of Sitagliptin."
  ]
  edge [
    source 67
    target 118
    int "Furazolidone may increase the hypoglycemic activities of Sunitinib."
  ]
  edge [
    source 67
    target 170
    int "Furazolidone may increase the hypoglycemic activities of Metformin."
  ]
  edge [
    source 67
    target 191
    int "Furazolidone may increase the serotonergic activities of Trazodone."
  ]
  edge [
    source 67
    target 192
    int "Furazolidone may increase the hypotensive activities of Mecamylamine."
  ]
  edge [
    source 67
    target 202
    int "The risk or severity of adverse effects can be increased when Furazolidone is combined with Maprotiline."
  ]
  edge [
    source 68
    target 76
    int "The metabolism of Tetracycline can be increased when combined with Rifabutin."
  ]
  edge [
    source 68
    target 167
    int "The metabolism of Sildenafil can be increased when combined with Rifabutin."
  ]
  edge [
    source 68
    target 86
    int "The metabolism of Argatroban can be increased when combined with Rifabutin."
  ]
  edge [
    source 68
    target 103
    int "The metabolism of Zileuton can be increased when combined with Rifabutin."
  ]
  edge [
    source 68
    target 110
    int "The serum concentration of Dronedarone can be decreased when it is combined with Rifabutin."
  ]
  edge [
    source 68
    target 137
    int "The metabolism of Artemether can be increased when combined with Rifabutin."
  ]
  edge [
    source 68
    target 141
    int "The metabolism of Doxorubicin can be increased when combined with Rifabutin."
  ]
  edge [
    source 68
    target 142
    int "The risk or severity of hypotension can be increased when Rifabutin is combined with Gabapentin."
  ]
  edge [
    source 68
    target 148
    int "The metabolism of Dantrolene can be increased when combined with Rifabutin."
  ]
  edge [
    source 68
    target 74
    int "The serum concentration of Saxagliptin can be decreased when it is combined with Rifabutin."
  ]
  edge [
    source 68
    target 154
    int "The serum concentration of Rifabutin can be increased when it is combined with Amprenavir."
  ]
  edge [
    source 68
    target 197
    int "The serum concentration of Buspirone can be decreased when it is combined with Rifabutin."
  ]
  edge [
    source 68
    target 193
    int "The metabolism of Flutamide can be increased when combined with Rifabutin."
  ]
  edge [
    source 68
    target 196
    int "The metabolism of Dihydroergotamine can be increased when combined with Rifabutin."
  ]
  edge [
    source 68
    target 214
    int "The metabolism of Proguanil can be increased when combined with Rifabutin."
  ]
  edge [
    source 68
    target 217
    int "The serum concentration of Desoxycorticosterone Pivalate can be decreased when it is combined with Rifabutin."
  ]
  edge [
    source 68
    target 219
    int "The metabolism of Nisoldipine can be increased when combined with Rifabutin."
  ]
  edge [
    source 68
    target 220
    int "The metabolism of Sulfinpyrazone can be increased when combined with Rifabutin."
  ]
  edge [
    source 68
    target 122
    int "The metabolism of Levonorgestrel can be increased when combined with Rifabutin."
  ]
  edge [
    source 68
    target 230
    int "The metabolism of Isosorbide Dinitrate can be increased when combined with Rifabutin."
  ]
  edge [
    source 68
    target 232
    int "The serum concentration of Sorafenib can be decreased when it is combined with Rifabutin."
  ]
  edge [
    source 68
    target 206
    int "The serum concentration of Aripiprazole can be decreased when it is combined with Rifabutin."
  ]
  edge [
    source 68
    target 244
    int "The metabolism of Ranolazine can be increased when combined with Rifabutin."
  ]
  edge [
    source 68
    target 174
    int "The metabolism of Sertraline can be increased when combined with Rifabutin."
  ]
  edge [
    source 68
    target 235
    int "The metabolism of Lansoprazole can be increased when combined with Rifabutin."
  ]
  edge [
    source 68
    target 84
    int "The metabolism of Trimethoprim can be increased when combined with Rifabutin."
  ]
  edge [
    source 68
    target 85
    int "The metabolism of Digitoxin can be increased when combined with Rifabutin."
  ]
  edge [
    source 68
    target 101
    int "The serum concentration of Zaleplon can be decreased when it is combined with Rifabutin."
  ]
  edge [
    source 68
    target 147
    int "The metabolism of Metronidazole can be increased when combined with Rifabutin."
  ]
  edge [
    source 68
    target 140
    int "The metabolism of Tinidazole can be increased when combined with Rifabutin."
  ]
  edge [
    source 68
    target 152
    int "The serum concentration of Rifabutin can be decreased when it is combined with Efavirenz."
  ]
  edge [
    source 68
    target 153
    int "The metabolism of Testosterone can be increased when combined with Rifabutin."
  ]
  edge [
    source 68
    target 155
    int "The serum concentration of Bortezomib can be decreased when it is combined with Rifabutin."
  ]
  edge [
    source 68
    target 159
    int "The metabolism of Cevimeline can be increased when combined with Rifabutin."
  ]
  edge [
    source 68
    target 175
    int "The serum concentration of Maraviroc can be decreased when it is combined with Rifabutin."
  ]
  edge [
    source 68
    target 176
    int "The metabolism of Cytarabine can be increased when combined with Rifabutin."
  ]
  edge [
    source 68
    target 75
    int "The serum concentration of Rifabutin can be decreased when it is combined with Teriflunomide."
  ]
  edge [
    source 68
    target 240
    int "The metabolism of Rifabutin can be increased when combined with Primidone."
  ]
  edge [
    source 68
    target 246
    int "The serum concentration of Rifabutin can be decreased when it is combined with Bosentan."
  ]
  edge [
    source 68
    target 234
    int "The risk or severity of hypotension can be increased when Rifabutin is combined with Lamotrigine."
  ]
  edge [
    source 68
    target 180
    int "The metabolism of Disulfiram can be increased when combined with Rifabutin."
  ]
  edge [
    source 68
    target 89
    int "The serum concentration of Praziquantel can be decreased when it is combined with Rifabutin."
  ]
  edge [
    source 68
    target 106
    int "The serum concentration of Atovaquone can be decreased when it is combined with Rifabutin."
  ]
  edge [
    source 68
    target 113
    int "The metabolism of Imipramine can be increased when combined with Rifabutin."
  ]
  edge [
    source 68
    target 117
    int "The metabolism of Albendazole can be increased when combined with Rifabutin."
  ]
  edge [
    source 68
    target 125
    int "The metabolism of Pentamidine can be increased when combined with Rifabutin."
  ]
  edge [
    source 68
    target 129
    int "The metabolism of Nateglinide can be increased when combined with Rifabutin."
  ]
  edge [
    source 68
    target 133
    int "The metabolism of Risperidone can be increased when combined with Rifabutin."
  ]
  edge [
    source 68
    target 135
    int "The serum concentration of Everolimus can be decreased when it is combined with Rifabutin."
  ]
  edge [
    source 68
    target 136
    int "The serum concentration of Ulipristal can be decreased when it is combined with Rifabutin."
  ]
  edge [
    source 68
    target 156
    int "The metabolism of Mefloquine can be increased when combined with Rifabutin."
  ]
  edge [
    source 68
    target 160
    int "The metabolism of Chlorzoxazone can be increased when combined with Rifabutin."
  ]
  edge [
    source 68
    target 164
    int "The metabolism of Mebendazole can be increased when combined with Rifabutin."
  ]
  edge [
    source 68
    target 166
    int "The serum concentration of Tolvaptan can be decreased when it is combined with Rifabutin."
  ]
  edge [
    source 68
    target 169
    int "The metabolism of Asenapine can be increased when combined with Rifabutin."
  ]
  edge [
    source 68
    target 171
    int "The serum concentration of Rifabutin can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 68
    target 207
    int "The metabolism of Zonisamide can be increased when combined with Rifabutin."
  ]
  edge [
    source 68
    target 173
    int "The metabolism of Tiagabine can be increased when combined with Rifabutin."
  ]
  edge [
    source 68
    target 187
    int "The metabolism of Clofibrate can be increased when combined with Rifabutin."
  ]
  edge [
    source 68
    target 201
    int "The metabolism of Aliskiren can be increased when combined with Rifabutin."
  ]
  edge [
    source 68
    target 212
    int "The metabolism of Loperamide can be increased when combined with Rifabutin."
  ]
  edge [
    source 68
    target 124
    int "The serum concentration of Pazopanib can be decreased when it is combined with Rifabutin."
  ]
  edge [
    source 68
    target 200
    int "The metabolism of Zalcitabine can be increased when combined with Rifabutin."
  ]
  edge [
    source 68
    target 90
    int "The metabolism of Lumefantrine can be increased when combined with Rifabutin."
  ]
  edge [
    source 68
    target 115
    int "The metabolism of Sitagliptin can be increased when combined with Rifabutin."
  ]
  edge [
    source 68
    target 118
    int "The serum concentration of Sunitinib can be decreased when it is combined with Rifabutin."
  ]
  edge [
    source 68
    target 149
    int "The metabolism of Halofantrine can be increased when combined with Rifabutin."
  ]
  edge [
    source 68
    target 138
    int "The metabolism of Theophylline can be increased when combined with Rifabutin."
  ]
  edge [
    source 68
    target 165
    int "The metabolism of Pyrazinamide can be increased when combined with Rifabutin."
  ]
  edge [
    source 68
    target 186
    int "The metabolism of Dutasteride can be increased when combined with Rifabutin."
  ]
  edge [
    source 68
    target 188
    int "The metabolism of Cerivastatin can be increased when combined with Rifabutin."
  ]
  edge [
    source 68
    target 191
    int "The metabolism of Trazodone can be increased when combined with Rifabutin."
  ]
  edge [
    source 69
    target 196
    int "The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Ezetimibe."
  ]
  edge [
    source 69
    target 75
    int "The serum concentration of Ezetimibe can be increased when it is combined with Teriflunomide."
  ]
  edge [
    source 69
    target 102
    int "The risk or severity of adverse effects can be increased when Methylergometrine is combined with Ezetimibe."
  ]
  edge [
    source 69
    target 166
    int "The serum concentration of Tolvaptan can be increased when it is combined with Ezetimibe."
  ]
  edge [
    source 69
    target 188
    int "The serum concentration of Cerivastatin can be increased when it is combined with Ezetimibe."
  ]
  edge [
    source 69
    target 244
    int "The serum concentration of Ezetimibe can be increased when it is combined with Ranolazine."
  ]
  edge [
    source 70
    target 123
    int "Leflunomide may decrease the antihypertensive activities of Amiloride."
  ]
  edge [
    source 70
    target 249
    int "The risk or severity of adverse effects can be increased when Amiloride is combined with Dipyridamole."
  ]
  edge [
    source 70
    target 75
    int "Teriflunomide may decrease the antihypertensive activities of Amiloride."
  ]
  edge [
    source 70
    target 103
    int "Zileuton may decrease the antihypertensive activities of Amiloride."
  ]
  edge [
    source 70
    target 95
    int "Olmesartan may increase the hyperkalemic activities of Amiloride."
  ]
  edge [
    source 70
    target 201
    int "The risk or severity of adverse effects can be increased when Amiloride is combined with Aliskiren."
  ]
  edge [
    source 70
    target 219
    int "The risk or severity of adverse effects can be increased when Nisoldipine is combined with Amiloride."
  ]
  edge [
    source 70
    target 226
    int "The risk or severity of adverse effects can be increased when Amiloride is combined with Bumetanide."
  ]
  edge [
    source 70
    target 230
    int "The risk or severity of adverse effects can be increased when Amiloride is combined with Isosorbide Dinitrate."
  ]
  edge [
    source 70
    target 247
    int "Mesalazine may decrease the antihypertensive activities of Amiloride."
  ]
  edge [
    source 70
    target 98
    int "The risk or severity of adverse effects can be increased when Amiloride is combined with Methyldopa."
  ]
  edge [
    source 70
    target 155
    int "The risk or severity of adverse effects can be increased when Bortezomib is combined with Amiloride."
  ]
  edge [
    source 70
    target 168
    int "The risk or severity of adverse effects can be increased when Atenolol is combined with Amiloride."
  ]
  edge [
    source 70
    target 228
    int "The risk or severity of adverse effects can be increased when Amiloride is combined with Bretylium."
  ]
  edge [
    source 70
    target 238
    int "The risk or severity of adverse effects can be increased when Pramipexole is combined with Amiloride."
  ]
  edge [
    source 70
    target 240
    int "Primidone may increase the hypotensive activities of Amiloride."
  ]
  edge [
    source 70
    target 241
    int "The risk or severity of adverse effects can be increased when Tolazoline is combined with Amiloride."
  ]
  edge [
    source 70
    target 93
    int "The risk or severity of adverse effects can be increased when Amiloride is combined with Hydralazine."
  ]
  edge [
    source 70
    target 133
    int "Amiloride may increase the hypotensive activities of Risperidone."
  ]
  edge [
    source 70
    target 161
    int "The risk or severity of adverse effects can be increased when Minoxidil is combined with Amiloride."
  ]
  edge [
    source 70
    target 162
    int "Amiloride may increase the hyperkalemic activities of Spironolactone."
  ]
  edge [
    source 70
    target 166
    int "Tolvaptan may increase the hyperkalemic activities of Amiloride."
  ]
  edge [
    source 70
    target 113
    int "The risk or severity of adverse effects can be increased when Imipramine is combined with Amiloride."
  ]
  edge [
    source 70
    target 184
    int "The risk or severity of adverse effects can be increased when Amiloride is combined with Dexmedetomidine."
  ]
  edge [
    source 70
    target 87
    int "The risk or severity of adverse effects can be increased when Clofarabine is combined with Amiloride."
  ]
  edge [
    source 70
    target 204
    int "Oxyphenbutazone may decrease the antihypertensive activities of Amiloride."
  ]
  edge [
    source 70
    target 206
    int "Aripiprazole may increase the hypotensive activities of Amiloride."
  ]
  edge [
    source 70
    target 85
    int "The therapeutic efficacy of Digitoxin can be decreased when used in combination with Amiloride."
  ]
  edge [
    source 70
    target 192
    int "The risk or severity of adverse effects can be increased when Amiloride is combined with Mecamylamine."
  ]
  edge [
    source 70
    target 199
    int "Meclofenamic acid may decrease the antihypertensive activities of Amiloride."
  ]
  edge [
    source 70
    target 215
    int "The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Amiloride."
  ]
  edge [
    source 71
    target 76
    int "Tetracycline may increase the neuromuscular blocking activities of Succinylcholine."
  ]
  edge [
    source 71
    target 132
    int "The serum concentration of Succinylcholine can be increased when it is combined with Memantine."
  ]
  edge [
    source 71
    target 150
    int "Lithium may increase the neuromuscular blocking activities of Succinylcholine."
  ]
  edge [
    source 71
    target 156
    int "The serum concentration of Succinylcholine can be increased when it is combined with Mefloquine."
  ]
  edge [
    source 71
    target 215
    int "Methyclothiazide may decrease the neuromuscular blocking activities of Succinylcholine."
  ]
  edge [
    source 71
    target 85
    int "Succinylcholine may increase the arrhythmogenic activities of Digitoxin."
  ]
  edge [
    source 71
    target 226
    int "Bumetanide may decrease the neuromuscular blocking activities of Succinylcholine."
  ]
  edge [
    source 71
    target 229
    int "Paromomycin may increase the respiratory depressant activities of Succinylcholine."
  ]
  edge [
    source 72
    target 222
    int "The risk or severity of adverse effects can be increased when Metaxalone is combined with Tetrabenazine."
  ]
  edge [
    source 72
    target 91
    int "The risk or severity of adverse effects can be increased when Topiramate is combined with Tetrabenazine."
  ]
  edge [
    source 72
    target 109
    int "The risk or severity of adverse effects can be increased when Tetrabenazine is combined with Etomidate."
  ]
  edge [
    source 72
    target 110
    int "The risk or severity of QTc prolongation can be increased when Tetrabenazine is combined with Dronedarone."
  ]
  edge [
    source 72
    target 137
    int "The risk or severity of QTc prolongation can be increased when Tetrabenazine is combined with Artemether."
  ]
  edge [
    source 72
    target 142
    int "The risk or severity of adverse effects can be increased when Gabapentin is combined with Tetrabenazine."
  ]
  edge [
    source 72
    target 148
    int "The risk or severity of adverse effects can be increased when Dantrolene is combined with Tetrabenazine."
  ]
  edge [
    source 72
    target 150
    int "The risk or severity of adverse effects can be increased when Tetrabenazine is combined with Lithium."
  ]
  edge [
    source 72
    target 194
    int "The risk or severity of adverse effects can be increased when Pargyline is combined with Tetrabenazine."
  ]
  edge [
    source 72
    target 195
    int "The risk or severity of adverse effects can be increased when Entacapone is combined with Tetrabenazine."
  ]
  edge [
    source 72
    target 197
    int "The risk or severity of adverse effects can be increased when Buspirone is combined with Tetrabenazine."
  ]
  edge [
    source 72
    target 118
    int "Sunitinib may increase the QTc-prolonging activities of Tetrabenazine."
  ]
  edge [
    source 72
    target 231
    int "The risk or severity of adverse effects can be increased when Carisoprodol is combined with Tetrabenazine."
  ]
  edge [
    source 72
    target 232
    int "Sorafenib may increase the QTc-prolonging activities of Tetrabenazine."
  ]
  edge [
    source 72
    target 244
    int "Ranolazine may increase the QTc-prolonging activities of Tetrabenazine."
  ]
  edge [
    source 72
    target 174
    int "Sertraline may increase the QTc-prolonging activities of Tetrabenazine."
  ]
  edge [
    source 72
    target 84
    int "Trimethoprim may increase the QTc-prolonging activities of Tetrabenazine."
  ]
  edge [
    source 72
    target 101
    int "The risk or severity of adverse effects can be increased when Zaleplon is combined with Tetrabenazine."
  ]
  edge [
    source 72
    target 107
    int "Vorinostat may increase the QTc-prolonging activities of Tetrabenazine."
  ]
  edge [
    source 72
    target 131
    int "The risk or severity of adverse effects can be increased when Rufinamide is combined with Tetrabenazine."
  ]
  edge [
    source 72
    target 147
    int "Metronidazole may increase the QTc-prolonging activities of Tetrabenazine."
  ]
  edge [
    source 72
    target 83
    int "Amantadine may increase the QTc-prolonging activities of Tetrabenazine."
  ]
  edge [
    source 72
    target 152
    int "The risk or severity of adverse effects can be increased when Efavirenz is combined with Tetrabenazine."
  ]
  edge [
    source 72
    target 155
    int "Bortezomib may increase the QTc-prolonging activities of Tetrabenazine."
  ]
  edge [
    source 72
    target 205
    int "Foscarnet may increase the QTc-prolonging activities of Tetrabenazine."
  ]
  edge [
    source 72
    target 94
    int "The risk or severity of adverse effects can be increased when Tetrabenazine is combined with Valproic Acid."
  ]
  edge [
    source 72
    target 238
    int "Tetrabenazine may increase the sedative activities of Pramipexole."
  ]
  edge [
    source 72
    target 240
    int "The risk or severity of adverse effects can be increased when Primidone is combined with Tetrabenazine."
  ]
  edge [
    source 72
    target 234
    int "The risk or severity of adverse effects can be increased when Lamotrigine is combined with Tetrabenazine."
  ]
  edge [
    source 72
    target 113
    int "Imipramine may increase the QTc-prolonging activities of Tetrabenazine."
  ]
  edge [
    source 72
    target 125
    int "Pentamidine may increase the QTc-prolonging activities of Tetrabenazine."
  ]
  edge [
    source 72
    target 133
    int "The risk or severity of adverse effects can be increased when Tetrabenazine is combined with Risperidone."
  ]
  edge [
    source 72
    target 156
    int "Mefloquine may increase the QTc-prolonging activities of Tetrabenazine."
  ]
  edge [
    source 72
    target 160
    int "The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Tetrabenazine."
  ]
  edge [
    source 72
    target 169
    int "The risk or severity of adverse effects can be increased when Tetrabenazine is combined with Asenapine."
  ]
  edge [
    source 72
    target 207
    int "The risk or severity of adverse effects can be increased when Zonisamide is combined with Tetrabenazine."
  ]
  edge [
    source 72
    target 173
    int "The risk or severity of adverse effects can be increased when Tiagabine is combined with Tetrabenazine."
  ]
  edge [
    source 72
    target 184
    int "The risk or severity of adverse effects can be increased when Tetrabenazine is combined with Dexmedetomidine."
  ]
  edge [
    source 72
    target 206
    int "The risk or severity of adverse effects can be increased when Tetrabenazine is combined with Aripiprazole."
  ]
  edge [
    source 72
    target 208
    int "The risk or severity of adverse effects can be increased when Tetrabenazine is combined with Trifluoperazine."
  ]
  edge [
    source 72
    target 124
    int "Pazopanib may increase the QTc-prolonging activities of Tetrabenazine."
  ]
  edge [
    source 72
    target 90
    int "The risk or severity of QTc prolongation can be increased when Tetrabenazine is combined with Lumefantrine."
  ]
  edge [
    source 72
    target 119
    int "The risk or severity of adverse effects can be increased when Tetrabenazine is combined with Triflupromazine."
  ]
  edge [
    source 72
    target 191
    int "Trazodone may increase the QTc-prolonging activities of Tetrabenazine."
  ]
  edge [
    source 72
    target 202
    int "Maprotiline may increase the QTc-prolonging activities of Tetrabenazine."
  ]
  edge [
    source 73
    target 129
    int "Acarbose may increase the hypoglycemic activities of Nateglinide."
  ]
  edge [
    source 73
    target 174
    int "Sertraline may increase the hypoglycemic activities of Acarbose."
  ]
  edge [
    source 73
    target 225
    int "The therapeutic efficacy of Acarbose can be decreased when used in combination with Epinephrine."
  ]
  edge [
    source 73
    target 97
    int "The therapeutic efficacy of Acarbose can be decreased when used in combination with Diazoxide."
  ]
  edge [
    source 73
    target 107
    int "The therapeutic efficacy of Acarbose can be decreased when used in combination with Vorinostat."
  ]
  edge [
    source 73
    target 118
    int "Acarbose may increase the hypoglycemic activities of Sunitinib."
  ]
  edge [
    source 73
    target 122
    int "The therapeutic efficacy of Acarbose can be decreased when used in combination with Levonorgestrel."
  ]
  edge [
    source 73
    target 125
    int "The therapeutic efficacy of Acarbose can be decreased when used in combination with Pentamidine."
  ]
  edge [
    source 73
    target 133
    int "The therapeutic efficacy of Acarbose can be decreased when used in combination with Risperidone."
  ]
  edge [
    source 73
    target 135
    int "The therapeutic efficacy of Acarbose can be decreased when used in combination with Everolimus."
  ]
  edge [
    source 73
    target 153
    int "Testosterone may increase the hypoglycemic activities of Acarbose."
  ]
  edge [
    source 73
    target 169
    int "The therapeutic efficacy of Acarbose can be decreased when used in combination with Asenapine."
  ]
  edge [
    source 73
    target 194
    int "Pargyline may increase the hypoglycemic activities of Acarbose."
  ]
  edge [
    source 73
    target 206
    int "The therapeutic efficacy of Acarbose can be decreased when used in combination with Aripiprazole."
  ]
  edge [
    source 73
    target 158
    int "The therapeutic efficacy of Acarbose can be decreased when used in combination with Piperazine."
  ]
  edge [
    source 73
    target 215
    int "The therapeutic efficacy of Acarbose can be decreased when used in combination with Methyclothiazide."
  ]
  edge [
    source 73
    target 189
    int "Aminosalicylic Acid may increase the hypoglycemic activities of Acarbose."
  ]
  edge [
    source 73
    target 226
    int "The therapeutic efficacy of Acarbose can be decreased when used in combination with Bumetanide."
  ]
  edge [
    source 73
    target 247
    int "Mesalazine may increase the hypoglycemic activities of Acarbose."
  ]
  edge [
    source 74
    target 157
    int "The serum concentration of Saxagliptin can be decreased when it is combined with Armodafinil."
  ]
  edge [
    source 74
    target 167
    int "The serum concentration of Sildenafil can be increased when it is combined with Saxagliptin."
  ]
  edge [
    source 74
    target 91
    int "The serum concentration of Saxagliptin can be decreased when it is combined with Topiramate."
  ]
  edge [
    source 74
    target 138
    int "The serum concentration of Theophylline can be decreased when it is combined with Saxagliptin."
  ]
  edge [
    source 74
    target 110
    int "The serum concentration of Saxagliptin can be increased when it is combined with Dronedarone."
  ]
  edge [
    source 74
    target 137
    int "The serum concentration of Saxagliptin can be decreased when it is combined with Artemether."
  ]
  edge [
    source 74
    target 146
    int "The serum concentration of Saxagliptin can be decreased when it is combined with Chlorphenesin."
  ]
  edge [
    source 74
    target 194
    int "Pargyline may increase the hypoglycemic activities of Saxagliptin."
  ]
  edge [
    source 74
    target 196
    int "The serum concentration of Saxagliptin can be increased when it is combined with Dihydroergotamine."
  ]
  edge [
    source 74
    target 220
    int "The serum concentration of Saxagliptin can be decreased when it is combined with Sulfinpyrazone."
  ]
  edge [
    source 74
    target 225
    int "The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Epinephrine."
  ]
  edge [
    source 74
    target 226
    int "The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Bumetanide."
  ]
  edge [
    source 74
    target 244
    int "The serum concentration of Saxagliptin can be increased when it is combined with Ranolazine."
  ]
  edge [
    source 74
    target 247
    int "Mesalazine may increase the hypoglycemic activities of Saxagliptin."
  ]
  edge [
    source 74
    target 250
    int "The serum concentration of Saxagliptin can be decreased when it is combined with Azatadine."
  ]
  edge [
    source 74
    target 158
    int "The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Piperazine."
  ]
  edge [
    source 74
    target 174
    int "Sertraline may increase the hypoglycemic activities of Saxagliptin."
  ]
  edge [
    source 74
    target 235
    int "The serum concentration of Saxagliptin can be decreased when it is combined with Lansoprazole."
  ]
  edge [
    source 74
    target 107
    int "The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Vorinostat."
  ]
  edge [
    source 74
    target 122
    int "The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Levonorgestrel."
  ]
  edge [
    source 74
    target 131
    int "The serum concentration of Saxagliptin can be decreased when it is combined with Rufinamide."
  ]
  edge [
    source 74
    target 152
    int "The serum concentration of Saxagliptin can be decreased when it is combined with Efavirenz."
  ]
  edge [
    source 74
    target 153
    int "The serum concentration of Saxagliptin can be decreased when it is combined with Testosterone."
  ]
  edge [
    source 74
    target 155
    int "The serum concentration of Saxagliptin can be increased when it is combined with Bortezomib."
  ]
  edge [
    source 74
    target 94
    int "The serum concentration of Valproic Acid can be decreased when it is combined with Saxagliptin."
  ]
  edge [
    source 74
    target 236
    int "Saxagliptin may increase the hypoglycemic activities of Acetohexamide."
  ]
  edge [
    source 74
    target 240
    int "The serum concentration of Saxagliptin can be decreased when it is combined with Primidone."
  ]
  edge [
    source 74
    target 246
    int "The serum concentration of Saxagliptin can be decreased when it is combined with Bosentan."
  ]
  edge [
    source 74
    target 188
    int "The serum concentration of Saxagliptin can be decreased when it is combined with Cerivastatin."
  ]
  edge [
    source 74
    target 97
    int "The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Diazoxide."
  ]
  edge [
    source 74
    target 125
    int "The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Pentamidine."
  ]
  edge [
    source 74
    target 129
    int "Saxagliptin may increase the hypoglycemic activities of Nateglinide."
  ]
  edge [
    source 74
    target 133
    int "The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Risperidone."
  ]
  edge [
    source 74
    target 135
    int "The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Everolimus."
  ]
  edge [
    source 74
    target 102
    int "The serum concentration of Methylergometrine can be increased when it is combined with Saxagliptin."
  ]
  edge [
    source 74
    target 169
    int "The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Asenapine."
  ]
  edge [
    source 74
    target 113
    int "The serum concentration of Imipramine can be increased when it is combined with Saxagliptin."
  ]
  edge [
    source 74
    target 171
    int "The serum concentration of Saxagliptin can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 74
    target 187
    int "The serum concentration of Saxagliptin can be decreased when it is combined with Clofibrate."
  ]
  edge [
    source 74
    target 206
    int "The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Aripiprazole."
  ]
  edge [
    source 74
    target 90
    int "The serum concentration of Saxagliptin can be decreased when it is combined with Lumefantrine."
  ]
  edge [
    source 74
    target 118
    int "Saxagliptin may increase the hypoglycemic activities of Sunitinib."
  ]
  edge [
    source 74
    target 127
    int "The serum concentration of Abacavir can be decreased when it is combined with Saxagliptin."
  ]
  edge [
    source 74
    target 215
    int "The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Methyclothiazide."
  ]
  edge [
    source 74
    target 189
    int "Aminosalicylic Acid may increase the hypoglycemic activities of Saxagliptin."
  ]
  edge [
    source 74
    target 151
    int "The serum concentration of Saxagliptin can be decreased when it is combined with Temozolomide."
  ]
  edge [
    source 75
    target 237
    int "The metabolism of Rosiglitazone can be decreased when combined with Teriflunomide."
  ]
  edge [
    source 75
    target 123
    int "The risk or severity of adverse effects can be increased when Leflunomide is combined with Teriflunomide."
  ]
  edge [
    source 75
    target 203
    int "The serum concentration of Carboplatin can be increased when it is combined with Teriflunomide."
  ]
  edge [
    source 75
    target 86
    int "Teriflunomide may increase the anticoagulant activities of Argatroban."
  ]
  edge [
    source 75
    target 95
    int "The serum concentration of Olmesartan can be increased when it is combined with Teriflunomide."
  ]
  edge [
    source 75
    target 224
    int "The serum concentration of Sumatriptan can be increased when it is combined with Teriflunomide."
  ]
  edge [
    source 75
    target 177
    int "The serum concentration of Mitoxantrone can be increased when it is combined with Teriflunomide."
  ]
  edge [
    source 75
    target 141
    int "The serum concentration of Doxorubicin can be increased when it is combined with Teriflunomide."
  ]
  edge [
    source 75
    target 146
    int "The risk or severity of adverse effects can be increased when Teriflunomide is combined with Chlorphenesin."
  ]
  edge [
    source 75
    target 149
    int "The metabolism of Halofantrine can be decreased when combined with Teriflunomide."
  ]
  edge [
    source 75
    target 150
    int "The serum concentration of Lithium can be increased when it is combined with Teriflunomide."
  ]
  edge [
    source 75
    target 154
    int "The metabolism of Amprenavir can be decreased when combined with Teriflunomide."
  ]
  edge [
    source 75
    target 115
    int "The metabolism of Sitagliptin can be decreased when combined with Teriflunomide."
  ]
  edge [
    source 75
    target 182
    int "The serum concentration of Mephenytoin can be decreased when it is combined with Teriflunomide."
  ]
  edge [
    source 75
    target 193
    int "The serum concentration of Flutamide can be decreased when it is combined with Teriflunomide."
  ]
  edge [
    source 75
    target 214
    int "The serum concentration of Proguanil can be decreased when it is combined with Teriflunomide."
  ]
  edge [
    source 75
    target 217
    int "The risk or severity of adverse effects can be increased when Teriflunomide is combined with Desoxycorticosterone Pivalate."
  ]
  edge [
    source 75
    target 220
    int "The metabolism of Sulfinpyrazone can be decreased when combined with Teriflunomide."
  ]
  edge [
    source 75
    target 226
    int "The therapeutic efficacy of Bumetanide can be decreased when used in combination with Teriflunomide."
  ]
  edge [
    source 75
    target 232
    int "The serum concentration of Sorafenib can be increased when it is combined with Teriflunomide."
  ]
  edge [
    source 75
    target 174
    int "The serum concentration of Sertraline can be decreased when it is combined with Teriflunomide."
  ]
  edge [
    source 75
    target 235
    int "The metabolism of Lansoprazole can be decreased when combined with Teriflunomide."
  ]
  edge [
    source 75
    target 84
    int "The metabolism of Trimethoprim can be decreased when combined with Teriflunomide."
  ]
  edge [
    source 75
    target 103
    int "The serum concentration of Zileuton can be decreased when it is combined with Teriflunomide."
  ]
  edge [
    source 75
    target 105
    int "The serum concentration of Riluzole can be decreased when it is combined with Teriflunomide."
  ]
  edge [
    source 75
    target 153
    int "The serum concentration of Testosterone can be increased when it is combined with Teriflunomide."
  ]
  edge [
    source 75
    target 155
    int "The serum concentration of Bortezomib can be decreased when it is combined with Teriflunomide."
  ]
  edge [
    source 75
    target 168
    int "Teriflunomide may decrease the antihypertensive activities of Atenolol."
  ]
  edge [
    source 75
    target 247
    int "The risk or severity of adverse effects can be increased when Teriflunomide is combined with Mesalazine."
  ]
  edge [
    source 75
    target 89
    int "The serum concentration of Praziquantel can be decreased when it is combined with Teriflunomide."
  ]
  edge [
    source 75
    target 93
    int "Teriflunomide may decrease the antihypertensive activities of Hydralazine."
  ]
  edge [
    source 75
    target 117
    int "The serum concentration of Albendazole can be decreased when it is combined with Teriflunomide."
  ]
  edge [
    source 75
    target 125
    int "The serum concentration of Pentamidine can be decreased when it is combined with Teriflunomide."
  ]
  edge [
    source 75
    target 130
    int "The serum concentration of Thiabendazole can be decreased when it is combined with Teriflunomide."
  ]
  edge [
    source 75
    target 136
    int "The serum concentration of Ulipristal can be decreased when it is combined with Teriflunomide."
  ]
  edge [
    source 75
    target 160
    int "The serum concentration of Chlorzoxazone can be decreased when it is combined with Teriflunomide."
  ]
  edge [
    source 75
    target 162
    int "Teriflunomide may decrease the antihypertensive activities of Spironolactone."
  ]
  edge [
    source 75
    target 169
    int "The serum concentration of Asenapine can be decreased when it is combined with Teriflunomide."
  ]
  edge [
    source 75
    target 113
    int "The serum concentration of Imipramine can be decreased when it is combined with Teriflunomide."
  ]
  edge [
    source 75
    target 87
    int "The serum concentration of Clofarabine can be increased when it is combined with Teriflunomide."
  ]
  edge [
    source 75
    target 201
    int "Teriflunomide may decrease the antihypertensive activities of Aliskiren."
  ]
  edge [
    source 75
    target 204
    int "The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Teriflunomide."
  ]
  edge [
    source 75
    target 200
    int "The serum concentration of Zalcitabine can be increased when it is combined with Teriflunomide."
  ]
  edge [
    source 75
    target 208
    int "The serum concentration of Trifluoperazine can be decreased when it is combined with Teriflunomide."
  ]
  edge [
    source 75
    target 212
    int "The metabolism of Loperamide can be decreased when combined with Teriflunomide."
  ]
  edge [
    source 75
    target 124
    int "The serum concentration of Pazopanib can be decreased when it is combined with Teriflunomide."
  ]
  edge [
    source 75
    target 229
    int "Teriflunomide may decrease the excretion rate of Paromomycin which could result in a higher serum level."
  ]
  edge [
    source 75
    target 128
    int "The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Teriflunomide."
  ]
  edge [
    source 75
    target 138
    int "The serum concentration of Theophylline can be decreased when it is combined with Teriflunomide."
  ]
  edge [
    source 75
    target 165
    int "The serum concentration of Pyrazinamide can be decreased when it is combined with Teriflunomide."
  ]
  edge [
    source 75
    target 188
    int "The serum concentration of Cerivastatin can be increased when it is combined with Teriflunomide."
  ]
  edge [
    source 75
    target 199
    int "The risk or severity of adverse effects can be increased when Teriflunomide is combined with Meclofenamic acid."
  ]
  edge [
    source 75
    target 202
    int "The serum concentration of Maprotiline can be decreased when it is combined with Teriflunomide."
  ]
  edge [
    source 75
    target 215
    int "The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Teriflunomide."
  ]
  edge [
    source 75
    target 189
    int "The risk or severity of adverse effects can be increased when Teriflunomide is combined with Aminosalicylic Acid."
  ]
  edge [
    source 75
    target 80
    int "The serum concentration of Methotrexate can be increased when it is combined with Teriflunomide."
  ]
  edge [
    source 76
    target 240
    int "The metabolism of Tetracycline can be increased when combined with Primidone."
  ]
  edge [
    source 76
    target 167
    int "The metabolism of Tetracycline can be decreased when combined with Sildenafil."
  ]
  edge [
    source 76
    target 79
    int "Tetracycline may increase the neuromuscular blocking activities of Cisatracurium."
  ]
  edge [
    source 76
    target 188
    int "The serum concentration of Cerivastatin can be increased when it is combined with Tetracycline."
  ]
  edge [
    source 76
    target 110
    int "The metabolism of Tetracycline can be decreased when combined with Dronedarone."
  ]
  edge [
    source 76
    target 114
    int "The risk or severity of adverse effects can be increased when Tetracycline is combined with Acitretin."
  ]
  edge [
    source 76
    target 155
    int "The metabolism of Tetracycline can be decreased when combined with Bortezomib."
  ]
  edge [
    source 76
    target 102
    int "The risk or severity of adverse effects can be increased when Methylergometrine is combined with Tetracycline."
  ]
  edge [
    source 76
    target 166
    int "The serum concentration of Tolvaptan can be increased when it is combined with Tetracycline."
  ]
  edge [
    source 76
    target 171
    int "The serum concentration of Tetracycline can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 76
    target 106
    int "The serum concentration of Atovaquone can be decreased when it is combined with Tetracycline."
  ]
  edge [
    source 76
    target 192
    int "Tetracycline may increase the neuromuscular blocking activities of Mecamylamine."
  ]
  edge [
    source 76
    target 196
    int "The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Tetracycline."
  ]
  edge [
    source 76
    target 216
    int "Tetracycline may increase the neuromuscular blocking activities of Vecuronium."
  ]
  edge [
    source 76
    target 244
    int "The metabolism of Tetracycline can be decreased when combined with Ranolazine."
  ]
  edge [
    source 76
    target 246
    int "The serum concentration of Tetracycline can be decreased when it is combined with Bosentan."
  ]
  edge [
    source 77
    target 85
    int "Digitoxin may decrease the cardiotoxic activities of Eflornithine."
  ]
  edge [
    source 78
    target 156
    int "The therapeutic efficacy of Phensuximide can be decreased when used in combination with Mefloquine."
  ]
  edge [
    source 79
    target 150
    int "Lithium may increase the neuromuscular blocking activities of Cisatracurium."
  ]
  edge [
    source 79
    target 85
    int "Cisatracurium may increase the arrhythmogenic activities of Digitoxin."
  ]
  edge [
    source 79
    target 215
    int "Methyclothiazide may decrease the neuromuscular blocking activities of Cisatracurium."
  ]
  edge [
    source 79
    target 226
    int "Bumetanide may decrease the neuromuscular blocking activities of Cisatracurium."
  ]
  edge [
    source 79
    target 229
    int "Paromomycin may increase the respiratory depressant activities of Cisatracurium."
  ]
  edge [
    source 80
    target 123
    int "The risk or severity of adverse effects can be increased when Methotrexate is combined with Leflunomide."
  ]
  edge [
    source 80
    target 205
    int "Foscarnet may increase the nephrotoxic activities of Methotrexate."
  ]
  edge [
    source 80
    target 235
    int "The serum concentration of Methotrexate can be increased when it is combined with Lansoprazole."
  ]
  edge [
    source 80
    target 84
    int "The risk or severity of adverse effects can be increased when Trimethoprim is combined with Methotrexate."
  ]
  edge [
    source 80
    target 138
    int "The serum concentration of Theophylline can be increased when it is combined with Methotrexate."
  ]
  edge [
    source 80
    target 103
    int "The serum concentration of Methotrexate can be increased when it is combined with Zileuton."
  ]
  edge [
    source 80
    target 114
    int "Acitretin may increase the hepatotoxic activities of Methotrexate."
  ]
  edge [
    source 80
    target 204
    int "The serum concentration of Methotrexate can be increased when it is combined with Oxyphenbutazone."
  ]
  edge [
    source 80
    target 199
    int "The serum concentration of Methotrexate can be increased when it is combined with Meclofenamic acid."
  ]
  edge [
    source 80
    target 215
    int "The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Methotrexate."
  ]
  edge [
    source 80
    target 189
    int "The serum concentration of Methotrexate can be increased when it is combined with Aminosalicylic Acid."
  ]
  edge [
    source 80
    target 226
    int "The therapeutic efficacy of Bumetanide can be decreased when used in combination with Methotrexate."
  ]
  edge [
    source 80
    target 247
    int "The serum concentration of Methotrexate can be increased when it is combined with Mesalazine."
  ]
  edge [
    source 80
    target 85
    int "Digitoxin may decrease the cardiotoxic activities of Methotrexate."
  ]
  edge [
    source 80
    target 244
    int "The serum concentration of Methotrexate can be increased when it is combined with Ranolazine."
  ]
  edge [
    source 81
    target 194
    int "Pargyline may increase the hypertensive activities of Doxapram."
  ]
  edge [
    source 83
    target 84
    int "The risk or severity of adverse effects can be increased when Trimethoprim is combined with Amantadine."
  ]
  edge [
    source 83
    target 90
    int "Amantadine may increase the QTc-prolonging activities of Lumefantrine."
  ]
  edge [
    source 83
    target 110
    int "Amantadine may increase the QTc-prolonging activities of Dronedarone."
  ]
  edge [
    source 83
    target 125
    int "Amantadine may increase the QTc-prolonging activities of Pentamidine."
  ]
  edge [
    source 83
    target 132
    int "The risk or severity of adverse effects can be increased when Amantadine is combined with Memantine."
  ]
  edge [
    source 83
    target 133
    int "The therapeutic efficacy of Amantadine can be decreased when used in combination with Risperidone."
  ]
  edge [
    source 83
    target 135
    int "The serum concentration of Everolimus can be increased when it is combined with Amantadine."
  ]
  edge [
    source 83
    target 137
    int "Amantadine may increase the QTc-prolonging activities of Artemether."
  ]
  edge [
    source 83
    target 141
    int "The serum concentration of Doxorubicin can be increased when it is combined with Amantadine."
  ]
  edge [
    source 83
    target 169
    int "The therapeutic efficacy of Amantadine can be decreased when used in combination with Asenapine."
  ]
  edge [
    source 83
    target 206
    int "The therapeutic efficacy of Amantadine can be decreased when used in combination with Aripiprazole."
  ]
  edge [
    source 83
    target 208
    int "The therapeutic efficacy of Trifluoperazine can be decreased when used in combination with Amantadine."
  ]
  edge [
    source 83
    target 124
    int "The serum concentration of Pazopanib can be increased when it is combined with Amantadine."
  ]
  edge [
    source 83
    target 244
    int "The serum concentration of Ranolazine can be increased when it is combined with Amantadine."
  ]
  edge [
    source 84
    target 237
    int "The metabolism of Rosiglitazone can be decreased when combined with Trimethoprim."
  ]
  edge [
    source 84
    target 123
    int "The metabolism of Leflunomide can be decreased when combined with Trimethoprim."
  ]
  edge [
    source 84
    target 167
    int "The metabolism of Trimethoprim can be decreased when combined with Sildenafil."
  ]
  edge [
    source 84
    target 138
    int "The metabolism of Theophylline can be decreased when combined with Trimethoprim."
  ]
  edge [
    source 84
    target 95
    int "Trimethoprim may increase the hyperkalemic activities of Olmesartan."
  ]
  edge [
    source 84
    target 110
    int "Trimethoprim may increase the QTc-prolonging activities of Dronedarone."
  ]
  edge [
    source 84
    target 137
    int "The risk or severity of QTc prolongation can be increased when Trimethoprim is combined with Artemether."
  ]
  edge [
    source 84
    target 141
    int "The serum concentration of Doxorubicin can be increased when it is combined with Trimethoprim."
  ]
  edge [
    source 84
    target 149
    int "The metabolism of Halofantrine can be decreased when combined with Trimethoprim."
  ]
  edge [
    source 84
    target 213
    int "Trimethoprim may increase the myelosuppressive activities of Mercaptopurine."
  ]
  edge [
    source 84
    target 182
    int "The metabolism of Mephenytoin can be decreased when combined with Trimethoprim."
  ]
  edge [
    source 84
    target 214
    int "The metabolism of Proguanil can be decreased when combined with Trimethoprim."
  ]
  edge [
    source 84
    target 220
    int "The metabolism of Sulfinpyrazone can be decreased when combined with Trimethoprim."
  ]
  edge [
    source 84
    target 232
    int "The metabolism of Trimethoprim can be decreased when combined with Sorafenib."
  ]
  edge [
    source 84
    target 244
    int "The serum concentration of Ranolazine can be increased when it is combined with Trimethoprim."
  ]
  edge [
    source 84
    target 196
    int "The metabolism of Trimethoprim can be decreased when combined with Dihydroergotamine."
  ]
  edge [
    source 84
    target 174
    int "The metabolism of Sertraline can be decreased when combined with Trimethoprim."
  ]
  edge [
    source 84
    target 235
    int "The metabolism of Lansoprazole can be decreased when combined with Trimethoprim."
  ]
  edge [
    source 84
    target 119
    int "The serum concentration of Triflupromazine can be increased when it is combined with Trimethoprim."
  ]
  edge [
    source 84
    target 121
    int "The metabolism of Niclosamide can be decreased when combined with Trimethoprim."
  ]
  edge [
    source 84
    target 147
    int "The metabolism of Metronidazole can be decreased when combined with Trimethoprim."
  ]
  edge [
    source 84
    target 152
    int "The metabolism of Trimethoprim can be decreased when combined with Efavirenz."
  ]
  edge [
    source 84
    target 153
    int "The metabolism of Testosterone can be decreased when combined with Trimethoprim."
  ]
  edge [
    source 84
    target 155
    int "The metabolism of Trimethoprim can be decreased when combined with Bortezomib."
  ]
  edge [
    source 84
    target 181
    int "The metabolism of Dopamine can be decreased when combined with Trimethoprim."
  ]
  edge [
    source 84
    target 94
    int "The metabolism of Trimethoprim can be decreased when combined with Valproic Acid."
  ]
  edge [
    source 84
    target 170
    int "The serum concentration of Metformin can be increased when it is combined with Trimethoprim."
  ]
  edge [
    source 84
    target 240
    int "The metabolism of Trimethoprim can be increased when combined with Primidone."
  ]
  edge [
    source 84
    target 246
    int "The serum concentration of Bosentan can be increased when it is combined with Trimethoprim."
  ]
  edge [
    source 84
    target 154
    int "The metabolism of Amprenavir can be decreased when combined with Trimethoprim."
  ]
  edge [
    source 84
    target 92
    int "The serum concentration of Varenicline can be increased when it is combined with Trimethoprim."
  ]
  edge [
    source 84
    target 188
    int "The metabolism of Cerivastatin can be decreased when combined with Trimethoprim."
  ]
  edge [
    source 84
    target 125
    int "The metabolism of Pentamidine can be decreased when combined with Trimethoprim."
  ]
  edge [
    source 84
    target 129
    int "The metabolism of Nateglinide can be decreased when combined with Trimethoprim."
  ]
  edge [
    source 84
    target 135
    int "The serum concentration of Everolimus can be increased when it is combined with Trimethoprim."
  ]
  edge [
    source 84
    target 162
    int "Trimethoprim may increase the hyperkalemic activities of Spironolactone."
  ]
  edge [
    source 84
    target 169
    int "Trimethoprim may increase the QTc-prolonging activities of Asenapine."
  ]
  edge [
    source 84
    target 171
    int "The serum concentration of Trimethoprim can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 84
    target 200
    int "The metabolism of Zalcitabine can be decreased when combined with Trimethoprim."
  ]
  edge [
    source 84
    target 208
    int "The serum concentration of Trifluoperazine can be increased when it is combined with Trimethoprim."
  ]
  edge [
    source 84
    target 212
    int "The metabolism of Loperamide can be decreased when combined with Trimethoprim."
  ]
  edge [
    source 84
    target 124
    int "The serum concentration of Pazopanib can be increased when it is combined with Trimethoprim."
  ]
  edge [
    source 84
    target 90
    int "The risk or severity of QTc prolongation can be increased when Trimethoprim is combined with Lumefantrine."
  ]
  edge [
    source 84
    target 115
    int "The metabolism of Sitagliptin can be decreased when combined with Trimethoprim."
  ]
  edge [
    source 84
    target 132
    int "The risk or severity of adverse effects can be increased when Trimethoprim is combined with Memantine."
  ]
  edge [
    source 84
    target 103
    int "The metabolism of Zileuton can be decreased when combined with Trimethoprim."
  ]
  edge [
    source 85
    target 123
    int "Digitoxin may decrease the cardiotoxic activities of Leflunomide."
  ]
  edge [
    source 85
    target 203
    int "Digitoxin may decrease the cardiotoxic activities of Carboplatin."
  ]
  edge [
    source 85
    target 167
    int "The metabolism of Digitoxin can be decreased when combined with Sildenafil."
  ]
  edge [
    source 85
    target 108
    int "Digitoxin may decrease the cardiotoxic activities of Chlorambucil."
  ]
  edge [
    source 85
    target 110
    int "The metabolism of Digitoxin can be decreased when combined with Dronedarone."
  ]
  edge [
    source 85
    target 141
    int "Digitoxin may decrease the cardiotoxic activities of Doxorubicin."
  ]
  edge [
    source 85
    target 151
    int "Digitoxin may decrease the cardiotoxic activities of Temozolomide."
  ]
  edge [
    source 85
    target 213
    int "Digitoxin may decrease the cardiotoxic activities of Mercaptopurine."
  ]
  edge [
    source 85
    target 193
    int "Digitoxin may decrease the cardiotoxic activities of Flutamide."
  ]
  edge [
    source 85
    target 196
    int "The metabolism of Digitoxin can be decreased when combined with Dihydroergotamine."
  ]
  edge [
    source 85
    target 226
    int "The risk or severity of adverse effects can be increased when Bumetanide is combined with Digitoxin."
  ]
  edge [
    source 85
    target 232
    int "Digitoxin may decrease the cardiotoxic activities of Sorafenib."
  ]
  edge [
    source 85
    target 244
    int "The serum concentration of Digitoxin can be increased when it is combined with Ranolazine."
  ]
  edge [
    source 85
    target 247
    int "The serum concentration of Digitoxin can be decreased when it is combined with Mesalazine."
  ]
  edge [
    source 85
    target 134
    int "Digitoxin may decrease the cardiotoxic activities of Trilostane."
  ]
  edge [
    source 85
    target 100
    int "The serum concentration of Digitoxin can be increased when it is combined with Hydroxychloroquine."
  ]
  edge [
    source 85
    target 248
    int "Digitoxin may decrease the cardiotoxic activities of Azacitidine."
  ]
  edge [
    source 85
    target 155
    int "Digitoxin may decrease the cardiotoxic activities of Bortezomib."
  ]
  edge [
    source 85
    target 216
    int "Vecuronium may increase the arrhythmogenic activities of Digitoxin."
  ]
  edge [
    source 85
    target 246
    int "The serum concentration of Digitoxin can be decreased when it is combined with Bosentan."
  ]
  edge [
    source 85
    target 251
    int "Digitoxin may decrease the cardiotoxic activities of Pentostatin."
  ]
  edge [
    source 85
    target 253
    int "The serum concentration of Digitoxin can be increased when it is combined with Propylthiouracil."
  ]
  edge [
    source 85
    target 176
    int "Digitoxin may decrease the cardiotoxic activities of Cytarabine."
  ]
  edge [
    source 85
    target 177
    int "Digitoxin may decrease the cardiotoxic activities of Mitoxantrone."
  ]
  edge [
    source 85
    target 117
    int "Digitoxin may decrease the cardiotoxic activities of Albendazole."
  ]
  edge [
    source 85
    target 135
    int "Digitoxin may decrease the cardiotoxic activities of Everolimus."
  ]
  edge [
    source 85
    target 164
    int "Digitoxin may decrease the cardiotoxic activities of Mebendazole."
  ]
  edge [
    source 85
    target 162
    int "The therapeutic efficacy of Digitoxin can be decreased when used in combination with Spironolactone."
  ]
  edge [
    source 85
    target 169
    int "Asenapine may increase the bradycardic activities of Digitoxin."
  ]
  edge [
    source 85
    target 171
    int "The serum concentration of Digitoxin can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 85
    target 87
    int "Digitoxin may decrease the cardiotoxic activities of Clofarabine."
  ]
  edge [
    source 85
    target 124
    int "Digitoxin may decrease the cardiotoxic activities of Pazopanib."
  ]
  edge [
    source 85
    target 229
    int "The serum concentration of Digitoxin can be decreased when it is combined with Paromomycin."
  ]
  edge [
    source 85
    target 144
    int "Digitoxin may decrease the cardiotoxic activities of Anastrozole."
  ]
  edge [
    source 85
    target 118
    int "Digitoxin may decrease the cardiotoxic activities of Sunitinib."
  ]
  edge [
    source 85
    target 218
    int "Digitoxin may decrease the cardiotoxic activities of Altretamine."
  ]
  edge [
    source 85
    target 168
    int "Atenolol may increase the bradycardic activities of Digitoxin."
  ]
  edge [
    source 85
    target 240
    int "The metabolism of Digitoxin can be increased when combined with Primidone."
  ]
  edge [
    source 85
    target 215
    int "The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Digitoxin."
  ]
  edge [
    source 85
    target 107
    int "Digitoxin may decrease the cardiotoxic activities of Vorinostat."
  ]
  edge [
    source 86
    target 123
    int "Leflunomide may increase the anticoagulant activities of Argatroban."
  ]
  edge [
    source 86
    target 249
    int "Dipyridamole may increase the anticoagulant activities of Argatroban."
  ]
  edge [
    source 86
    target 167
    int "The serum concentration of Sildenafil can be increased when it is combined with Argatroban."
  ]
  edge [
    source 86
    target 138
    int "The serum concentration of Theophylline can be decreased when it is combined with Argatroban."
  ]
  edge [
    source 86
    target 110
    int "The metabolism of Argatroban can be decreased when combined with Dronedarone."
  ]
  edge [
    source 86
    target 247
    int "The risk or severity of adverse effects can be increased when Argatroban is combined with Mesalazine."
  ]
  edge [
    source 86
    target 196
    int "The serum concentration of Dihydroergotamine can be increased when it is combined with Argatroban."
  ]
  edge [
    source 86
    target 244
    int "The metabolism of Argatroban can be decreased when combined with Ranolazine."
  ]
  edge [
    source 86
    target 103
    int "Zileuton may increase the anticoagulant activities of Argatroban."
  ]
  edge [
    source 86
    target 122
    int "The therapeutic efficacy of Argatroban can be decreased when used in combination with Levonorgestrel."
  ]
  edge [
    source 86
    target 155
    int "The metabolism of Argatroban can be decreased when combined with Bortezomib."
  ]
  edge [
    source 86
    target 94
    int "The serum concentration of Valproic Acid can be decreased when it is combined with Argatroban."
  ]
  edge [
    source 86
    target 237
    int "Rosiglitazone may increase the anticoagulant activities of Argatroban."
  ]
  edge [
    source 86
    target 240
    int "The metabolism of Argatroban can be increased when combined with Primidone."
  ]
  edge [
    source 86
    target 246
    int "The serum concentration of Argatroban can be decreased when it is combined with Bosentan."
  ]
  edge [
    source 86
    target 113
    int "The serum concentration of Imipramine can be increased when it is combined with Argatroban."
  ]
  edge [
    source 86
    target 102
    int "The serum concentration of Methylergometrine can be increased when it is combined with Argatroban."
  ]
  edge [
    source 86
    target 171
    int "The serum concentration of Argatroban can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 86
    target 204
    int "Oxyphenbutazone may increase the anticoagulant activities of Argatroban."
  ]
  edge [
    source 86
    target 127
    int "The serum concentration of Abacavir can be decreased when it is combined with Argatroban."
  ]
  edge [
    source 86
    target 199
    int "Meclofenamic acid may increase the anticoagulant activities of Argatroban."
  ]
  edge [
    source 86
    target 189
    int "The risk or severity of adverse effects can be increased when Argatroban is combined with Aminosalicylic Acid."
  ]
  edge [
    source 87
    target 113
    int "The risk or severity of adverse effects can be increased when Clofarabine is combined with Imipramine."
  ]
  edge [
    source 87
    target 123
    int "The risk or severity of adverse effects can be increased when Clofarabine is combined with Leflunomide."
  ]
  edge [
    source 87
    target 133
    int "Clofarabine may increase the hypotensive activities of Risperidone."
  ]
  edge [
    source 87
    target 93
    int "The risk or severity of adverse effects can be increased when Clofarabine is combined with Hydralazine."
  ]
  edge [
    source 87
    target 95
    int "The risk or severity of adverse effects can be increased when Clofarabine is combined with Olmesartan."
  ]
  edge [
    source 87
    target 98
    int "The risk or severity of adverse effects can be increased when Clofarabine is combined with Methyldopa."
  ]
  edge [
    source 87
    target 192
    int "The risk or severity of adverse effects can be increased when Clofarabine is combined with Mecamylamine."
  ]
  edge [
    source 87
    target 228
    int "The risk or severity of adverse effects can be increased when Clofarabine is combined with Bretylium."
  ]
  edge [
    source 87
    target 155
    int "The risk or severity of adverse effects can be increased when Bortezomib is combined with Clofarabine."
  ]
  edge [
    source 87
    target 161
    int "The risk or severity of adverse effects can be increased when Clofarabine is combined with Minoxidil."
  ]
  edge [
    source 87
    target 162
    int "The risk or severity of adverse effects can be increased when Clofarabine is combined with Spironolactone."
  ]
  edge [
    source 87
    target 168
    int "The risk or severity of adverse effects can be increased when Clofarabine is combined with Atenolol."
  ]
  edge [
    source 87
    target 184
    int "The risk or severity of adverse effects can be increased when Clofarabine is combined with Dexmedetomidine."
  ]
  edge [
    source 87
    target 240
    int "Primidone may increase the hypotensive activities of Clofarabine."
  ]
  edge [
    source 87
    target 201
    int "The risk or severity of adverse effects can be increased when Clofarabine is combined with Aliskiren."
  ]
  edge [
    source 87
    target 206
    int "Aripiprazole may increase the hypotensive activities of Clofarabine."
  ]
  edge [
    source 87
    target 215
    int "The risk or severity of adverse effects can be increased when Clofarabine is combined with Methyclothiazide."
  ]
  edge [
    source 87
    target 219
    int "The risk or severity of adverse effects can be increased when Clofarabine is combined with Nisoldipine."
  ]
  edge [
    source 87
    target 226
    int "The risk or severity of adverse effects can be increased when Clofarabine is combined with Bumetanide."
  ]
  edge [
    source 87
    target 230
    int "The risk or severity of adverse effects can be increased when Clofarabine is combined with Isosorbide Dinitrate."
  ]
  edge [
    source 87
    target 238
    int "The risk or severity of adverse effects can be increased when Clofarabine is combined with Pramipexole."
  ]
  edge [
    source 87
    target 241
    int "The risk or severity of adverse effects can be increased when Clofarabine is combined with Tolazoline."
  ]
  edge [
    source 87
    target 249
    int "The risk or severity of adverse effects can be increased when Clofarabine is combined with Dipyridamole."
  ]
  edge [
    source 88
    target 91
    int "The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Topiramate."
  ]
  edge [
    source 88
    target 99
    int "The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Oxyphenonium."
  ]
  edge [
    source 88
    target 132
    int "The therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Memantine."
  ]
  edge [
    source 88
    target 156
    int "The therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Mefloquine."
  ]
  edge [
    source 88
    target 192
    int "The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Mecamylamine."
  ]
  edge [
    source 88
    target 215
    int "The serum concentration of Methyclothiazide can be increased when it is combined with Trihexyphenidyl."
  ]
  edge [
    source 88
    target 216
    int "The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Vecuronium."
  ]
  edge [
    source 89
    target 157
    int "The metabolism of Praziquantel can be decreased when combined with Armodafinil."
  ]
  edge [
    source 89
    target 167
    int "The metabolism of Praziquantel can be decreased when combined with Sildenafil."
  ]
  edge [
    source 89
    target 174
    int "The metabolism of Praziquantel can be decreased when combined with Sertraline."
  ]
  edge [
    source 89
    target 91
    int "The metabolism of Praziquantel can be decreased when combined with Topiramate."
  ]
  edge [
    source 89
    target 138
    int "The metabolism of Praziquantel can be decreased when combined with Theophylline."
  ]
  edge [
    source 89
    target 100
    int "The serum concentration of Praziquantel can be decreased when it is combined with Hydroxychloroquine."
  ]
  edge [
    source 89
    target 110
    int "The metabolism of Praziquantel can be decreased when combined with Dronedarone."
  ]
  edge [
    source 89
    target 152
    int "The metabolism of Praziquantel can be decreased when combined with Efavirenz."
  ]
  edge [
    source 89
    target 155
    int "The metabolism of Praziquantel can be decreased when combined with Bortezomib."
  ]
  edge [
    source 89
    target 171
    int "The serum concentration of Praziquantel can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 89
    target 196
    int "The metabolism of Praziquantel can be decreased when combined with Dihydroergotamine."
  ]
  edge [
    source 89
    target 240
    int "The serum concentration of Praziquantel can be decreased when it is combined with Primidone."
  ]
  edge [
    source 89
    target 244
    int "The metabolism of Praziquantel can be decreased when combined with Ranolazine."
  ]
  edge [
    source 89
    target 246
    int "The serum concentration of Praziquantel can be decreased when it is combined with Bosentan."
  ]
  edge [
    source 90
    target 167
    int "The metabolism of Lumefantrine can be decreased when combined with Sildenafil."
  ]
  edge [
    source 90
    target 138
    int "The metabolism of Theophylline can be decreased when combined with Lumefantrine."
  ]
  edge [
    source 90
    target 110
    int "The risk or severity of QTc prolongation can be increased when Dronedarone is combined with Lumefantrine."
  ]
  edge [
    source 90
    target 137
    int "The risk or severity of QTc prolongation can be increased when Lumefantrine is combined with Artemether."
  ]
  edge [
    source 90
    target 141
    int "The metabolism of Doxorubicin can be decreased when combined with Lumefantrine."
  ]
  edge [
    source 90
    target 149
    int "Lumefantrine may increase the QTc-prolonging activities of Halofantrine."
  ]
  edge [
    source 90
    target 150
    int "Lithium may increase the QTc-prolonging activities of Lumefantrine."
  ]
  edge [
    source 90
    target 196
    int "The metabolism of Lumefantrine can be decreased when combined with Dihydroergotamine."
  ]
  edge [
    source 90
    target 197
    int "The metabolism of Buspirone can be decreased when combined with Lumefantrine."
  ]
  edge [
    source 90
    target 182
    int "The metabolism of Mephenytoin can be decreased when combined with Lumefantrine."
  ]
  edge [
    source 90
    target 214
    int "The risk or severity of QTc prolongation can be increased when Proguanil is combined with Lumefantrine."
  ]
  edge [
    source 90
    target 232
    int "Sorafenib may increase the QTc-prolonging activities of Lumefantrine."
  ]
  edge [
    source 90
    target 244
    int "Ranolazine may increase the QTc-prolonging activities of Lumefantrine."
  ]
  edge [
    source 90
    target 158
    int "The metabolism of Piperazine can be decreased when combined with Lumefantrine."
  ]
  edge [
    source 90
    target 174
    int "Sertraline may increase the QTc-prolonging activities of Lumefantrine."
  ]
  edge [
    source 90
    target 100
    int "The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Lumefantrine."
  ]
  edge [
    source 90
    target 107
    int "Vorinostat may increase the QTc-prolonging activities of Lumefantrine."
  ]
  edge [
    source 90
    target 147
    int "Metronidazole may increase the QTc-prolonging activities of Lumefantrine."
  ]
  edge [
    source 90
    target 155
    int "Bortezomib may increase the QTc-prolonging activities of Lumefantrine."
  ]
  edge [
    source 90
    target 159
    int "The metabolism of Cevimeline can be decreased when combined with Lumefantrine."
  ]
  edge [
    source 90
    target 181
    int "The metabolism of Dopamine can be decreased when combined with Lumefantrine."
  ]
  edge [
    source 90
    target 205
    int "Foscarnet may increase the QTc-prolonging activities of Lumefantrine."
  ]
  edge [
    source 90
    target 240
    int "The metabolism of Lumefantrine can be increased when combined with Primidone."
  ]
  edge [
    source 90
    target 246
    int "The serum concentration of Lumefantrine can be decreased when it is combined with Bosentan."
  ]
  edge [
    source 90
    target 154
    int "The metabolism of Amprenavir can be decreased when combined with Lumefantrine."
  ]
  edge [
    source 90
    target 106
    int "The risk or severity of QTc prolongation can be increased when Atovaquone is combined with Lumefantrine."
  ]
  edge [
    source 90
    target 113
    int "Imipramine may increase the QTc-prolonging activities of Lumefantrine."
  ]
  edge [
    source 90
    target 125
    int "Pentamidine may increase the QTc-prolonging activities of Lumefantrine."
  ]
  edge [
    source 90
    target 129
    int "The metabolism of Nateglinide can be decreased when combined with Lumefantrine."
  ]
  edge [
    source 90
    target 133
    int "Risperidone may increase the QTc-prolonging activities of Lumefantrine."
  ]
  edge [
    source 90
    target 156
    int "The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Lumefantrine."
  ]
  edge [
    source 90
    target 169
    int "The risk or severity of QTc prolongation can be increased when Asenapine is combined with Lumefantrine."
  ]
  edge [
    source 90
    target 171
    int "The serum concentration of Lumefantrine can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 90
    target 206
    int "The serum concentration of Aripiprazole can be decreased when it is combined with Lumefantrine."
  ]
  edge [
    source 90
    target 208
    int "The serum concentration of Trifluoperazine can be increased when it is combined with Lumefantrine."
  ]
  edge [
    source 90
    target 212
    int "The metabolism of Loperamide can be decreased when combined with Lumefantrine."
  ]
  edge [
    source 90
    target 124
    int "Pazopanib may increase the QTc-prolonging activities of Lumefantrine."
  ]
  edge [
    source 90
    target 200
    int "The metabolism of Zalcitabine can be decreased when combined with Lumefantrine."
  ]
  edge [
    source 90
    target 118
    int "Sunitinib may increase the QTc-prolonging activities of Lumefantrine."
  ]
  edge [
    source 90
    target 119
    int "The serum concentration of Triflupromazine can be increased when it is combined with Lumefantrine."
  ]
  edge [
    source 90
    target 160
    int "The metabolism of Chlorzoxazone can be decreased when combined with Lumefantrine."
  ]
  edge [
    source 90
    target 191
    int "Trazodone may increase the QTc-prolonging activities of Lumefantrine."
  ]
  edge [
    source 90
    target 202
    int "Maprotiline may increase the QTc-prolonging activities of Lumefantrine."
  ]
  edge [
    source 91
    target 167
    int "The metabolism of Sildenafil can be decreased when combined with Topiramate."
  ]
  edge [
    source 91
    target 101
    int "The risk or severity of adverse effects can be increased when Zaleplon is combined with Topiramate."
  ]
  edge [
    source 91
    target 109
    int "The risk or severity of adverse effects can be increased when Topiramate is combined with Etomidate."
  ]
  edge [
    source 91
    target 137
    int "The metabolism of Artemether can be decreased when combined with Topiramate."
  ]
  edge [
    source 91
    target 142
    int "The risk or severity of adverse effects can be increased when Gabapentin is combined with Topiramate."
  ]
  edge [
    source 91
    target 148
    int "The risk or severity of adverse effects can be increased when Topiramate is combined with Dantrolene."
  ]
  edge [
    source 91
    target 150
    int "The serum concentration of Lithium can be increased when it is combined with Topiramate."
  ]
  edge [
    source 91
    target 195
    int "The risk or severity of adverse effects can be increased when Topiramate is combined with Entacapone."
  ]
  edge [
    source 91
    target 197
    int "The risk or severity of adverse effects can be increased when Buspirone is combined with Topiramate."
  ]
  edge [
    source 91
    target 182
    int "The metabolism of Mephenytoin can be decreased when combined with Topiramate."
  ]
  edge [
    source 91
    target 193
    int "The metabolism of Flutamide can be decreased when combined with Topiramate."
  ]
  edge [
    source 91
    target 214
    int "The metabolism of Proguanil can be decreased when combined with Topiramate."
  ]
  edge [
    source 91
    target 231
    int "The metabolism of Carisoprodol can be decreased when combined with Topiramate."
  ]
  edge [
    source 91
    target 222
    int "The risk or severity of adverse effects can be increased when Topiramate is combined with Metaxalone."
  ]
  edge [
    source 91
    target 174
    int "The metabolism of Sertraline can be decreased when combined with Topiramate."
  ]
  edge [
    source 91
    target 235
    int "The metabolism of Lansoprazole can be decreased when combined with Topiramate."
  ]
  edge [
    source 91
    target 226
    int "The risk or severity of hypokalemia can be increased when Bumetanide is combined with Topiramate."
  ]
  edge [
    source 91
    target 99
    int "The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Topiramate."
  ]
  edge [
    source 91
    target 119
    int "The risk or severity of adverse effects can be increased when Topiramate is combined with Triflupromazine."
  ]
  edge [
    source 91
    target 122
    int "The serum concentration of Levonorgestrel can be decreased when it is combined with Topiramate."
  ]
  edge [
    source 91
    target 131
    int "The risk or severity of adverse effects can be increased when Rufinamide is combined with Topiramate."
  ]
  edge [
    source 91
    target 152
    int "The risk or severity of adverse effects can be increased when Topiramate is combined with Efavirenz."
  ]
  edge [
    source 91
    target 153
    int "The metabolism of Testosterone can be decreased when combined with Topiramate."
  ]
  edge [
    source 91
    target 155
    int "The metabolism of Bortezomib can be decreased when combined with Topiramate."
  ]
  edge [
    source 91
    target 181
    int "The metabolism of Dopamine can be decreased when combined with Topiramate."
  ]
  edge [
    source 91
    target 216
    int "The risk or severity of adverse effects can be increased when Vecuronium is combined with Topiramate."
  ]
  edge [
    source 91
    target 94
    int "The risk or severity of adverse effects can be increased when Topiramate is combined with Valproic Acid."
  ]
  edge [
    source 91
    target 170
    int "The risk or severity of adverse effects can be increased when Topiramate is combined with Metformin."
  ]
  edge [
    source 91
    target 238
    int "Topiramate may increase the sedative activities of Pramipexole."
  ]
  edge [
    source 91
    target 240
    int "The metabolism of Primidone can be decreased when combined with Topiramate."
  ]
  edge [
    source 91
    target 234
    int "The risk or severity of adverse effects can be increased when Topiramate is combined with Lamotrigine."
  ]
  edge [
    source 91
    target 125
    int "The metabolism of Pentamidine can be decreased when combined with Topiramate."
  ]
  edge [
    source 91
    target 133
    int "The risk or severity of adverse effects can be increased when Risperidone is combined with Topiramate."
  ]
  edge [
    source 91
    target 136
    int "The serum concentration of Ulipristal can be decreased when it is combined with Topiramate."
  ]
  edge [
    source 91
    target 156
    int "The therapeutic efficacy of Topiramate can be decreased when used in combination with Mefloquine."
  ]
  edge [
    source 91
    target 160
    int "The risk or severity of adverse effects can be increased when Topiramate is combined with Chlorzoxazone."
  ]
  edge [
    source 91
    target 169
    int "The risk or severity of adverse effects can be increased when Asenapine is combined with Topiramate."
  ]
  edge [
    source 91
    target 113
    int "The metabolism of Imipramine can be decreased when combined with Topiramate."
  ]
  edge [
    source 91
    target 207
    int "The risk or severity of adverse effects can be increased when Topiramate is combined with Zonisamide."
  ]
  edge [
    source 91
    target 173
    int "The risk or severity of adverse effects can be increased when Topiramate is combined with Tiagabine."
  ]
  edge [
    source 91
    target 184
    int "The risk or severity of adverse effects can be increased when Topiramate is combined with Dexmedetomidine."
  ]
  edge [
    source 91
    target 206
    int "The serum concentration of Aripiprazole can be decreased when it is combined with Topiramate."
  ]
  edge [
    source 91
    target 208
    int "The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Topiramate."
  ]
  edge [
    source 91
    target 191
    int "The risk or severity of adverse effects can be increased when Topiramate is combined with Trazodone."
  ]
  edge [
    source 91
    target 192
    int "The risk or severity of adverse effects can be increased when Mecamylamine is combined with Topiramate."
  ]
  edge [
    source 91
    target 202
    int "The risk or severity of adverse effects can be increased when Topiramate is combined with Maprotiline."
  ]
  edge [
    source 91
    target 215
    int "The risk or severity of hypokalemia can be increased when Methyclothiazide is combined with Topiramate."
  ]
  edge [
    source 92
    target 104
    int "The serum concentration of Varenicline can be increased when it is combined with Nizatidine."
  ]
  edge [
    source 92
    target 132
    int "The risk or severity of adverse effects can be increased when Memantine is combined with Varenicline."
  ]
  edge [
    source 92
    target 156
    int "The risk or severity of adverse effects can be increased when Mefloquine is combined with Varenicline."
  ]
  edge [
    source 92
    target 168
    int "The risk or severity of adverse effects can be increased when Atenolol is combined with Varenicline."
  ]
  edge [
    source 92
    target 169
    int "The serum concentration of Varenicline can be increased when it is combined with Asenapine."
  ]
  edge [
    source 93
    target 123
    int "Leflunomide may decrease the antihypertensive activities of Hydralazine."
  ]
  edge [
    source 93
    target 249
    int "The risk or severity of adverse effects can be increased when Dipyridamole is combined with Hydralazine."
  ]
  edge [
    source 93
    target 95
    int "Hydralazine may increase the hypotensive activities of Olmesartan."
  ]
  edge [
    source 93
    target 196
    int "The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Hydralazine."
  ]
  edge [
    source 93
    target 194
    int "Pargyline may increase the hypotensive activities of Hydralazine."
  ]
  edge [
    source 93
    target 219
    int "Hydralazine may increase the hypotensive activities of Nisoldipine."
  ]
  edge [
    source 93
    target 226
    int "The risk or severity of adverse effects can be increased when Bumetanide is combined with Hydralazine."
  ]
  edge [
    source 93
    target 230
    int "The risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Hydralazine."
  ]
  edge [
    source 93
    target 247
    int "Mesalazine may decrease the antihypertensive activities of Hydralazine."
  ]
  edge [
    source 93
    target 98
    int "Hydralazine may increase the hypotensive activities of Methyldopa."
  ]
  edge [
    source 93
    target 103
    int "Zileuton may decrease the antihypertensive activities of Hydralazine."
  ]
  edge [
    source 93
    target 155
    int "The risk or severity of adverse effects can be increased when Bortezomib is combined with Hydralazine."
  ]
  edge [
    source 93
    target 167
    int "Sildenafil may increase the antihypertensive activities of Hydralazine."
  ]
  edge [
    source 93
    target 168
    int "Hydralazine may increase the hypotensive activities of Atenolol."
  ]
  edge [
    source 93
    target 228
    int "Hydralazine may increase the hypotensive activities of Bretylium."
  ]
  edge [
    source 93
    target 238
    int "The risk or severity of adverse effects can be increased when Pramipexole is combined with Hydralazine."
  ]
  edge [
    source 93
    target 240
    int "Primidone may increase the hypotensive activities of Hydralazine."
  ]
  edge [
    source 93
    target 241
    int "Hydralazine may increase the hypotensive activities of Tolazoline."
  ]
  edge [
    source 93
    target 246
    int "Bosentan may increase the hypotensive activities of Hydralazine."
  ]
  edge [
    source 93
    target 138
    int "Theophylline may increase the antihypertensive activities of Hydralazine."
  ]
  edge [
    source 93
    target 188
    int "The serum concentration of Cerivastatin can be increased when it is combined with Hydralazine."
  ]
  edge [
    source 93
    target 113
    int "The risk or severity of adverse effects can be increased when Imipramine is combined with Hydralazine."
  ]
  edge [
    source 93
    target 162
    int "The risk or severity of adverse effects can be increased when Spironolactone is combined with Hydralazine."
  ]
  edge [
    source 93
    target 166
    int "The serum concentration of Tolvaptan can be increased when it is combined with Hydralazine."
  ]
  edge [
    source 93
    target 184
    int "The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Hydralazine."
  ]
  edge [
    source 93
    target 204
    int "Oxyphenbutazone may decrease the antihypertensive activities of Hydralazine."
  ]
  edge [
    source 93
    target 201
    int "Hydralazine may increase the hypotensive activities of Aliskiren."
  ]
  edge [
    source 93
    target 206
    int "Aripiprazole may increase the hypotensive activities of Hydralazine."
  ]
  edge [
    source 93
    target 97
    int "Diazoxide may increase the hypotensive activities of Hydralazine."
  ]
  edge [
    source 93
    target 133
    int "Hydralazine may increase the hypotensive activities of Risperidone."
  ]
  edge [
    source 93
    target 161
    int "Minoxidil may increase the hypotensive activities of Hydralazine."
  ]
  edge [
    source 93
    target 102
    int "The risk or severity of adverse effects can be increased when Methylergometrine is combined with Hydralazine."
  ]
  edge [
    source 93
    target 192
    int "Mecamylamine may increase the hypotensive activities of Hydralazine."
  ]
  edge [
    source 93
    target 199
    int "Meclofenamic acid may decrease the antihypertensive activities of Hydralazine."
  ]
  edge [
    source 93
    target 215
    int "The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Hydralazine."
  ]
  edge [
    source 94
    target 157
    int "The metabolism of Valproic Acid can be decreased when combined with Armodafinil."
  ]
  edge [
    source 94
    target 123
    int "The metabolism of Leflunomide can be decreased when combined with Valproic Acid."
  ]
  edge [
    source 94
    target 167
    int "The metabolism of Valproic Acid can be decreased when combined with Sildenafil."
  ]
  edge [
    source 94
    target 101
    int "The risk or severity of adverse effects can be increased when Zaleplon is combined with Valproic Acid."
  ]
  edge [
    source 94
    target 103
    int "The metabolism of Zileuton can be decreased when combined with Valproic Acid."
  ]
  edge [
    source 94
    target 109
    int "The risk or severity of adverse effects can be increased when Etomidate is combined with Valproic Acid."
  ]
  edge [
    source 94
    target 142
    int "The risk or severity of adverse effects can be increased when Gabapentin is combined with Valproic Acid."
  ]
  edge [
    source 94
    target 150
    int "The risk or severity of adverse effects can be increased when Valproic Acid is combined with Lithium."
  ]
  edge [
    source 94
    target 151
    int "The risk or severity of adverse effects can be increased when Valproic Acid is combined with Temozolomide."
  ]
  edge [
    source 94
    target 195
    int "The risk or severity of adverse effects can be increased when Entacapone is combined with Valproic Acid."
  ]
  edge [
    source 94
    target 196
    int "The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Valproic Acid."
  ]
  edge [
    source 94
    target 197
    int "The risk or severity of adverse effects can be increased when Buspirone is combined with Valproic Acid."
  ]
  edge [
    source 94
    target 182
    int "The metabolism of Mephenytoin can be decreased when combined with Valproic Acid."
  ]
  edge [
    source 94
    target 214
    int "The metabolism of Proguanil can be decreased when combined with Valproic Acid."
  ]
  edge [
    source 94
    target 220
    int "The metabolism of Sulfinpyrazone can be decreased when combined with Valproic Acid."
  ]
  edge [
    source 94
    target 222
    int "The risk or severity of adverse effects can be increased when Metaxalone is combined with Valproic Acid."
  ]
  edge [
    source 94
    target 231
    int "The risk or severity of adverse effects can be increased when Carisoprodol is combined with Valproic Acid."
  ]
  edge [
    source 94
    target 232
    int "The metabolism of Valproic Acid can be decreased when combined with Sorafenib."
  ]
  edge [
    source 94
    target 247
    int "The serum concentration of Valproic Acid can be increased when it is combined with Mesalazine."
  ]
  edge [
    source 94
    target 174
    int "The metabolism of Valproic Acid can be decreased when combined with Sertraline."
  ]
  edge [
    source 94
    target 235
    int "The metabolism of Lansoprazole can be decreased when combined with Valproic Acid."
  ]
  edge [
    source 94
    target 107
    int "Valproic Acid may increase the thrombocytopenic activities of Vorinostat."
  ]
  edge [
    source 94
    target 119
    int "The risk or severity of adverse effects can be increased when Valproic Acid is combined with Triflupromazine."
  ]
  edge [
    source 94
    target 121
    int "The metabolism of Niclosamide can be decreased when combined with Valproic Acid."
  ]
  edge [
    source 94
    target 137
    int "The metabolism of Artemether can be decreased when combined with Valproic Acid."
  ]
  edge [
    source 94
    target 131
    int "The serum concentration of Rufinamide can be increased when it is combined with Valproic Acid."
  ]
  edge [
    source 94
    target 147
    int "The metabolism of Metronidazole can be decreased when combined with Valproic Acid."
  ]
  edge [
    source 94
    target 152
    int "The metabolism of Valproic Acid can be decreased when combined with Efavirenz."
  ]
  edge [
    source 94
    target 153
    int "The metabolism of Testosterone can be decreased when combined with Valproic Acid."
  ]
  edge [
    source 94
    target 155
    int "The metabolism of Valproic Acid can be decreased when combined with Bortezomib."
  ]
  edge [
    source 94
    target 181
    int "The metabolism of Dopamine can be decreased when combined with Valproic Acid."
  ]
  edge [
    source 94
    target 237
    int "The metabolism of Rosiglitazone can be decreased when combined with Valproic Acid."
  ]
  edge [
    source 94
    target 238
    int "Valproic Acid may increase the sedative activities of Pramipexole."
  ]
  edge [
    source 94
    target 240
    int "The metabolism of Primidone can be decreased when combined with Valproic Acid."
  ]
  edge [
    source 94
    target 246
    int "The serum concentration of Bosentan can be increased when it is combined with Valproic Acid."
  ]
  edge [
    source 94
    target 234
    int "Valproic Acid may increase the excretion rate of Lamotrigine which could result in a lower serum level and potentially a reduction in efficacy."
  ]
  edge [
    source 94
    target 154
    int "The serum concentration of Valproic Acid can be decreased when it is combined with Amprenavir."
  ]
  edge [
    source 94
    target 138
    int "The metabolism of Theophylline can be decreased when combined with Valproic Acid."
  ]
  edge [
    source 94
    target 188
    int "The serum concentration of Cerivastatin can be increased when it is combined with Valproic Acid."
  ]
  edge [
    source 94
    target 113
    int "The serum concentration of Imipramine can be increased when it is combined with Valproic Acid."
  ]
  edge [
    source 94
    target 129
    int "The metabolism of Nateglinide can be decreased when combined with Valproic Acid."
  ]
  edge [
    source 94
    target 133
    int "The risk or severity of adverse effects can be increased when Valproic Acid is combined with Risperidone."
  ]
  edge [
    source 94
    target 179
    int "The serum concentration of Valproic Acid can be decreased when it is combined with Cilastatin."
  ]
  edge [
    source 94
    target 156
    int "The therapeutic efficacy of Valproic Acid can be decreased when used in combination with Mefloquine."
  ]
  edge [
    source 94
    target 160
    int "The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Valproic Acid."
  ]
  edge [
    source 94
    target 161
    int "The serum concentration of Minoxidil can be increased when it is combined with Valproic Acid."
  ]
  edge [
    source 94
    target 102
    int "The risk or severity of adverse effects can be increased when Methylergometrine is combined with Valproic Acid."
  ]
  edge [
    source 94
    target 166
    int "The serum concentration of Tolvaptan can be increased when it is combined with Valproic Acid."
  ]
  edge [
    source 94
    target 169
    int "The risk or severity of adverse effects can be increased when Asenapine is combined with Valproic Acid."
  ]
  edge [
    source 94
    target 207
    int "The risk or severity of adverse effects can be increased when Zonisamide is combined with Valproic Acid."
  ]
  edge [
    source 94
    target 173
    int "The risk or severity of adverse effects can be increased when Tiagabine is combined with Valproic Acid."
  ]
  edge [
    source 94
    target 184
    int "The risk or severity of adverse effects can be increased when Valproic Acid is combined with Dexmedetomidine."
  ]
  edge [
    source 94
    target 206
    int "The risk or severity of adverse effects can be increased when Aripiprazole is combined with Valproic Acid."
  ]
  edge [
    source 94
    target 208
    int "The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Valproic Acid."
  ]
  edge [
    source 94
    target 200
    int "The metabolism of Zalcitabine can be decreased when combined with Valproic Acid."
  ]
  edge [
    source 94
    target 141
    int "The metabolism of Valproic Acid can be decreased when combined with Doxorubicin."
  ]
  edge [
    source 94
    target 115
    int "The serum concentration of Valproic Acid can be decreased when it is combined with Sitagliptin."
  ]
  edge [
    source 94
    target 148
    int "The risk or severity of adverse effects can be increased when Dantrolene is combined with Valproic Acid."
  ]
  edge [
    source 94
    target 191
    int "The risk or severity of adverse effects can be increased when Valproic Acid is combined with Trazodone."
  ]
  edge [
    source 94
    target 202
    int "The risk or severity of adverse effects can be increased when Maprotiline is combined with Valproic Acid."
  ]
  edge [
    source 94
    target 189
    int "The serum concentration of Valproic Acid can be increased when it is combined with Aminosalicylic Acid."
  ]
  edge [
    source 95
    target 123
    int "The risk or severity of adverse effects can be increased when Olmesartan is combined with Leflunomide."
  ]
  edge [
    source 95
    target 249
    int "The risk or severity of adverse effects can be increased when Olmesartan is combined with Dipyridamole."
  ]
  edge [
    source 95
    target 138
    int "Theophylline may increase the antihypertensive activities of Olmesartan."
  ]
  edge [
    source 95
    target 150
    int "The serum concentration of Lithium can be increased when it is combined with Olmesartan."
  ]
  edge [
    source 95
    target 194
    int "Pargyline may increase the hypotensive activities of Olmesartan."
  ]
  edge [
    source 95
    target 219
    int "Olmesartan may increase the hypotensive activities of Nisoldipine."
  ]
  edge [
    source 95
    target 226
    int "The risk or severity of adverse effects can be increased when Olmesartan is combined with Bumetanide."
  ]
  edge [
    source 95
    target 230
    int "The risk or severity of adverse effects can be increased when Olmesartan is combined with Isosorbide Dinitrate."
  ]
  edge [
    source 95
    target 247
    int "The risk or severity of adverse effects can be increased when Olmesartan is combined with Mesalazine."
  ]
  edge [
    source 95
    target 98
    int "Olmesartan may increase the hypotensive activities of Methyldopa."
  ]
  edge [
    source 95
    target 103
    int "The risk or severity of adverse effects can be increased when Olmesartan is combined with Zileuton."
  ]
  edge [
    source 95
    target 155
    int "The risk or severity of adverse effects can be increased when Bortezomib is combined with Olmesartan."
  ]
  edge [
    source 95
    target 167
    int "Sildenafil may increase the antihypertensive activities of Olmesartan."
  ]
  edge [
    source 95
    target 168
    int "Olmesartan may increase the hypotensive activities of Atenolol."
  ]
  edge [
    source 95
    target 238
    int "The risk or severity of adverse effects can be increased when Pramipexole is combined with Olmesartan."
  ]
  edge [
    source 95
    target 240
    int "Primidone may increase the hypotensive activities of Olmesartan."
  ]
  edge [
    source 95
    target 241
    int "Olmesartan may increase the hypotensive activities of Tolazoline."
  ]
  edge [
    source 95
    target 246
    int "Bosentan may increase the hypotensive activities of Olmesartan."
  ]
  edge [
    source 95
    target 97
    int "Diazoxide may increase the hypotensive activities of Olmesartan."
  ]
  edge [
    source 95
    target 113
    int "The risk or severity of adverse effects can be increased when Imipramine is combined with Olmesartan."
  ]
  edge [
    source 95
    target 133
    int "Olmesartan may increase the hypotensive activities of Risperidone."
  ]
  edge [
    source 95
    target 161
    int "Minoxidil may increase the hypotensive activities of Olmesartan."
  ]
  edge [
    source 95
    target 162
    int "The risk or severity of adverse effects can be increased when Olmesartan is combined with Spironolactone."
  ]
  edge [
    source 95
    target 166
    int "Tolvaptan may increase the hyperkalemic activities of Olmesartan."
  ]
  edge [
    source 95
    target 184
    int "The risk or severity of adverse effects can be increased when Olmesartan is combined with Dexmedetomidine."
  ]
  edge [
    source 95
    target 204
    int "The risk or severity of adverse effects can be increased when Olmesartan is combined with Oxyphenbutazone."
  ]
  edge [
    source 95
    target 201
    int "Aliskiren may increase the hyperkalemic activities of Olmesartan."
  ]
  edge [
    source 95
    target 206
    int "Aripiprazole may increase the hypotensive activities of Olmesartan."
  ]
  edge [
    source 95
    target 228
    int "Olmesartan may increase the hypotensive activities of Bretylium."
  ]
  edge [
    source 95
    target 192
    int "Mecamylamine may increase the hypotensive activities of Olmesartan."
  ]
  edge [
    source 95
    target 199
    int "The risk or severity of adverse effects can be increased when Olmesartan is combined with Meclofenamic acid."
  ]
  edge [
    source 95
    target 215
    int "The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Olmesartan."
  ]
  edge [
    source 96
    target 124
    int "The serum concentration of Pazopanib can be increased when it is combined with Novobiocin."
  ]
  edge [
    source 97
    target 228
    int "Diazoxide may increase the hypotensive activities of Bretylium."
  ]
  edge [
    source 97
    target 249
    int "Dipyridamole may increase the antihypertensive activities of Diazoxide."
  ]
  edge [
    source 97
    target 98
    int "Diazoxide may increase the hypotensive activities of Methyldopa."
  ]
  edge [
    source 97
    target 115
    int "The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Diazoxide."
  ]
  edge [
    source 97
    target 129
    int "The therapeutic efficacy of Nateglinide can be decreased when used in combination with Diazoxide."
  ]
  edge [
    source 97
    target 138
    int "Theophylline may increase the antihypertensive activities of Diazoxide."
  ]
  edge [
    source 97
    target 167
    int "Sildenafil may increase the antihypertensive activities of Diazoxide."
  ]
  edge [
    source 97
    target 168
    int "Diazoxide may increase the hypotensive activities of Atenolol."
  ]
  edge [
    source 97
    target 170
    int "The therapeutic efficacy of Metformin can be decreased when used in combination with Diazoxide."
  ]
  edge [
    source 97
    target 161
    int "Diazoxide may increase the hypotensive activities of Minoxidil."
  ]
  edge [
    source 97
    target 192
    int "The risk or severity of adverse effects can be increased when Diazoxide is combined with Mecamylamine."
  ]
  edge [
    source 97
    target 201
    int "Diazoxide may increase the hypotensive activities of Aliskiren."
  ]
  edge [
    source 97
    target 194
    int "Diazoxide may increase the hypotensive activities of Pargyline."
  ]
  edge [
    source 97
    target 198
    int "The therapeutic efficacy of Miglitol can be decreased when used in combination with Diazoxide."
  ]
  edge [
    source 97
    target 215
    int "The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Diazoxide."
  ]
  edge [
    source 97
    target 219
    int "Diazoxide may increase the hypotensive activities of Nisoldipine."
  ]
  edge [
    source 97
    target 236
    int "The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Diazoxide."
  ]
  edge [
    source 97
    target 237
    int "The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Diazoxide."
  ]
  edge [
    source 97
    target 241
    int "Diazoxide may increase the hypotensive activities of Tolazoline."
  ]
  edge [
    source 97
    target 243
    int "The therapeutic efficacy of Miglustat can be decreased when used in combination with Diazoxide."
  ]
  edge [
    source 97
    target 246
    int "Diazoxide may increase the hypotensive activities of Bosentan."
  ]
  edge [
    source 98
    target 249
    int "The risk or severity of adverse effects can be increased when Methyldopa is combined with Dipyridamole."
  ]
  edge [
    source 98
    target 138
    int "Theophylline may increase the antihypertensive activities of Methyldopa."
  ]
  edge [
    source 98
    target 110
    int "Methyldopa may increase the bradycardic activities of Dronedarone."
  ]
  edge [
    source 98
    target 150
    int "The risk or severity of adverse effects can be increased when Methyldopa is combined with Lithium."
  ]
  edge [
    source 98
    target 195
    int "The metabolism of Methyldopa can be decreased when combined with Entacapone."
  ]
  edge [
    source 98
    target 201
    int "Methyldopa may increase the hypotensive activities of Aliskiren."
  ]
  edge [
    source 98
    target 194
    int "The risk or severity of hypertension can be increased when Pargyline is combined with Methyldopa."
  ]
  edge [
    source 98
    target 219
    int "Nisoldipine may increase the hypotensive activities of Methyldopa."
  ]
  edge [
    source 98
    target 225
    int "Epinephrine may decrease the vasoconstricting activities of Methyldopa."
  ]
  edge [
    source 98
    target 226
    int "The risk or severity of adverse effects can be increased when Bumetanide is combined with Methyldopa."
  ]
  edge [
    source 98
    target 230
    int "The risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Methyldopa."
  ]
  edge [
    source 98
    target 155
    int "The risk or severity of adverse effects can be increased when Bortezomib is combined with Methyldopa."
  ]
  edge [
    source 98
    target 167
    int "Sildenafil may increase the antihypertensive activities of Methyldopa."
  ]
  edge [
    source 98
    target 238
    int "The risk or severity of adverse effects can be increased when Pramipexole is combined with Methyldopa."
  ]
  edge [
    source 98
    target 240
    int "Primidone may increase the hypotensive activities of Methyldopa."
  ]
  edge [
    source 98
    target 241
    int "Tolazoline may increase the hypotensive activities of Methyldopa."
  ]
  edge [
    source 98
    target 246
    int "Bosentan may increase the hypotensive activities of Methyldopa."
  ]
  edge [
    source 98
    target 113
    int "Imipramine may decrease the antihypertensive activities of Methyldopa."
  ]
  edge [
    source 98
    target 133
    int "Methyldopa may increase the hypotensive activities of Risperidone."
  ]
  edge [
    source 98
    target 196
    int "Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Methyldopa."
  ]
  edge [
    source 98
    target 161
    int "Minoxidil may increase the hypotensive activities of Methyldopa."
  ]
  edge [
    source 98
    target 162
    int "Spironolactone may decrease the vasoconstricting activities of Methyldopa."
  ]
  edge [
    source 98
    target 169
    int "Methyldopa may increase the atrioventricular blocking (AV block) activities of Asenapine."
  ]
  edge [
    source 98
    target 184
    int "The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Methyldopa."
  ]
  edge [
    source 98
    target 206
    int "Aripiprazole may increase the hypotensive activities of Methyldopa."
  ]
  edge [
    source 98
    target 208
    int "Trifluoperazine may decrease the vasoconstricting activities of Methyldopa."
  ]
  edge [
    source 98
    target 228
    int "Bretylium may increase the bradycardic activities of Methyldopa."
  ]
  edge [
    source 98
    target 168
    int "Methyldopa may increase the atrioventricular blocking (AV block) activities of Atenolol."
  ]
  edge [
    source 98
    target 102
    int "Methylergometrine may increase the hypertensive and vasoconstricting activities of Methyldopa."
  ]
  edge [
    source 98
    target 191
    int "Trazodone may decrease the vasoconstricting activities of Methyldopa."
  ]
  edge [
    source 98
    target 192
    int "Mecamylamine may increase the hypotensive activities of Methyldopa."
  ]
  edge [
    source 98
    target 163
    int "Methyldopa may increase the atrioventricular blocking (AV block) activities of Lacosamide."
  ]
  edge [
    source 98
    target 215
    int "The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Methyldopa."
  ]
  edge [
    source 99
    target 132
    int "The therapeutic efficacy of Oxyphenonium can be decreased when used in combination with Memantine."
  ]
  edge [
    source 99
    target 156
    int "The therapeutic efficacy of Oxyphenonium can be decreased when used in combination with Mefloquine."
  ]
  edge [
    source 99
    target 192
    int "The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Mecamylamine."
  ]
  edge [
    source 99
    target 215
    int "The serum concentration of Methyclothiazide can be increased when it is combined with Oxyphenonium."
  ]
  edge [
    source 99
    target 216
    int "The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Vecuronium."
  ]
  edge [
    source 100
    target 158
    int "The serum concentration of Piperazine can be decreased when it is combined with Hydroxychloroquine."
  ]
  edge [
    source 100
    target 116
    int "The serum concentration of Levamisole can be decreased when it is combined with Hydroxychloroquine."
  ]
  edge [
    source 100
    target 121
    int "The serum concentration of Niclosamide can be decreased when it is combined with Hydroxychloroquine."
  ]
  edge [
    source 100
    target 130
    int "The serum concentration of Thiabendazole can be decreased when it is combined with Hydroxychloroquine."
  ]
  edge [
    source 100
    target 137
    int "The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Artemether."
  ]
  edge [
    source 100
    target 119
    int "The serum concentration of Triflupromazine can be increased when it is combined with Hydroxychloroquine."
  ]
  edge [
    source 100
    target 156
    int "The risk or severity of adverse effects can be increased when Hydroxychloroquine is combined with Mefloquine."
  ]
  edge [
    source 100
    target 164
    int "The serum concentration of Mebendazole can be decreased when it is combined with Hydroxychloroquine."
  ]
  edge [
    source 100
    target 168
    int "The metabolism of Atenolol can be decreased when combined with Hydroxychloroquine."
  ]
  edge [
    source 100
    target 169
    int "The metabolism of Asenapine can be decreased when combined with Hydroxychloroquine."
  ]
  edge [
    source 100
    target 117
    int "The serum concentration of Albendazole can be decreased when it is combined with Hydroxychloroquine."
  ]
  edge [
    source 100
    target 208
    int "The serum concentration of Trifluoperazine can be increased when it is combined with Hydroxychloroquine."
  ]
  edge [
    source 100
    target 245
    int "The serum concentration of Diethylcarbamazine can be decreased when it is combined with Hydroxychloroquine."
  ]
  edge [
    source 101
    target 167
    int "The metabolism of Zaleplon can be decreased when combined with Sildenafil."
  ]
  edge [
    source 101
    target 109
    int "The risk or severity of adverse effects can be increased when Zaleplon is combined with Etomidate."
  ]
  edge [
    source 101
    target 110
    int "The metabolism of Zaleplon can be decreased when combined with Dronedarone."
  ]
  edge [
    source 101
    target 142
    int "The risk or severity of adverse effects can be increased when Zaleplon is combined with Gabapentin."
  ]
  edge [
    source 101
    target 148
    int "The risk or severity of adverse effects can be increased when Zaleplon is combined with Dantrolene."
  ]
  edge [
    source 101
    target 150
    int "The risk or severity of adverse effects can be increased when Zaleplon is combined with Lithium."
  ]
  edge [
    source 101
    target 195
    int "The risk or severity of adverse effects can be increased when Zaleplon is combined with Entacapone."
  ]
  edge [
    source 101
    target 197
    int "The risk or severity of adverse effects can be increased when Buspirone is combined with Zaleplon."
  ]
  edge [
    source 101
    target 196
    int "The metabolism of Zaleplon can be decreased when combined with Dihydroergotamine."
  ]
  edge [
    source 101
    target 222
    int "The risk or severity of adverse effects can be increased when Zaleplon is combined with Metaxalone."
  ]
  edge [
    source 101
    target 231
    int "The risk or severity of adverse effects can be increased when Zaleplon is combined with Carisoprodol."
  ]
  edge [
    source 101
    target 174
    int "The risk or severity of adverse effects can be increased when Zaleplon is combined with Sertraline."
  ]
  edge [
    source 101
    target 119
    int "The risk or severity of adverse effects can be increased when Zaleplon is combined with Triflupromazine."
  ]
  edge [
    source 101
    target 131
    int "The risk or severity of adverse effects can be increased when Rufinamide is combined with Zaleplon."
  ]
  edge [
    source 101
    target 152
    int "The risk or severity of adverse effects can be increased when Zaleplon is combined with Efavirenz."
  ]
  edge [
    source 101
    target 155
    int "The metabolism of Zaleplon can be decreased when combined with Bortezomib."
  ]
  edge [
    source 101
    target 178
    int "Flumazenil may decrease the sedative activities of Zaleplon."
  ]
  edge [
    source 101
    target 244
    int "The metabolism of Zaleplon can be decreased when combined with Ranolazine."
  ]
  edge [
    source 101
    target 238
    int "Zaleplon may increase the sedative activities of Pramipexole."
  ]
  edge [
    source 101
    target 240
    int "The serum concentration of Zaleplon can be decreased when it is combined with Primidone."
  ]
  edge [
    source 101
    target 246
    int "The serum concentration of Zaleplon can be decreased when it is combined with Bosentan."
  ]
  edge [
    source 101
    target 234
    int "The risk or severity of adverse effects can be increased when Zaleplon is combined with Lamotrigine."
  ]
  edge [
    source 101
    target 113
    int "The risk or severity of adverse effects can be increased when Zaleplon is combined with Imipramine."
  ]
  edge [
    source 101
    target 133
    int "The risk or severity of adverse effects can be increased when Risperidone is combined with Zaleplon."
  ]
  edge [
    source 101
    target 156
    int "The therapeutic efficacy of Zaleplon can be decreased when used in combination with Mefloquine."
  ]
  edge [
    source 101
    target 160
    int "The risk or severity of adverse effects can be increased when Zaleplon is combined with Chlorzoxazone."
  ]
  edge [
    source 101
    target 169
    int "The risk or severity of adverse effects can be increased when Zaleplon is combined with Asenapine."
  ]
  edge [
    source 101
    target 171
    int "The serum concentration of Zaleplon can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 101
    target 207
    int "The risk or severity of adverse effects can be increased when Zaleplon is combined with Zonisamide."
  ]
  edge [
    source 101
    target 173
    int "The risk or severity of adverse effects can be increased when Zaleplon is combined with Tiagabine."
  ]
  edge [
    source 101
    target 184
    int "The risk or severity of adverse effects can be increased when Zaleplon is combined with Dexmedetomidine."
  ]
  edge [
    source 101
    target 206
    int "The risk or severity of adverse effects can be increased when Zaleplon is combined with Aripiprazole."
  ]
  edge [
    source 101
    target 208
    int "The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Zaleplon."
  ]
  edge [
    source 101
    target 191
    int "The risk or severity of adverse effects can be increased when Zaleplon is combined with Trazodone."
  ]
  edge [
    source 101
    target 202
    int "The risk or severity of adverse effects can be increased when Zaleplon is combined with Maprotiline."
  ]
  edge [
    source 102
    target 167
    int "The risk or severity of adverse effects can be increased when Methylergometrine is combined with Sildenafil."
  ]
  edge [
    source 102
    target 109
    int "Methylergometrine may increase the hypertensive and vasoconstricting activities of Etomidate."
  ]
  edge [
    source 102
    target 110
    int "The risk or severity of adverse effects can be increased when Methylergometrine is combined with Dronedarone."
  ]
  edge [
    source 102
    target 141
    int "The risk or severity of adverse effects can be increased when Methylergometrine is combined with Doxorubicin."
  ]
  edge [
    source 102
    target 144
    int "The risk or severity of adverse effects can be increased when Methylergometrine is combined with Anastrozole."
  ]
  edge [
    source 102
    target 196
    int "The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Methylergometrine."
  ]
  edge [
    source 102
    target 219
    int "The risk or severity of adverse effects can be increased when Methylergometrine is combined with Nisoldipine."
  ]
  edge [
    source 102
    target 220
    int "The risk or severity of adverse effects can be increased when Methylergometrine is combined with Sulfinpyrazone."
  ]
  edge [
    source 102
    target 224
    int "Methylergometrine may increase the vasoconstricting activities of Sumatriptan."
  ]
  edge [
    source 102
    target 232
    int "The risk or severity of adverse effects can be increased when Methylergometrine is combined with Sorafenib."
  ]
  edge [
    source 102
    target 244
    int "The risk or severity of adverse effects can be increased when Methylergometrine is combined with Ranolazine."
  ]
  edge [
    source 102
    target 174
    int "The risk or severity of adverse effects can be increased when Methylergometrine is combined with Sertraline."
  ]
  edge [
    source 102
    target 235
    int "The risk or severity of adverse effects can be increased when Methylergometrine is combined with Lansoprazole."
  ]
  edge [
    source 102
    target 225
    int "The risk or severity of adverse effects can be increased when Methylergometrine is combined with Epinephrine."
  ]
  edge [
    source 102
    target 147
    int "The risk or severity of adverse effects can be increased when Methylergometrine is combined with Metronidazole."
  ]
  edge [
    source 102
    target 153
    int "The risk or severity of adverse effects can be increased when Methylergometrine is combined with Testosterone."
  ]
  edge [
    source 102
    target 152
    int "The risk or severity of adverse effects can be increased when Methylergometrine is combined with Efavirenz."
  ]
  edge [
    source 102
    target 155
    int "The risk or severity of adverse effects can be increased when Methylergometrine is combined with Bortezomib."
  ]
  edge [
    source 102
    target 177
    int "The risk or severity of adverse effects can be increased when Methylergometrine is combined with Mitoxantrone."
  ]
  edge [
    source 102
    target 154
    int "The risk or severity of adverse effects can be increased when Methylergometrine is combined with Amprenavir."
  ]
  edge [
    source 102
    target 133
    int "The risk or severity of adverse effects can be increased when Methylergometrine is combined with Risperidone."
  ]
  edge [
    source 102
    target 179
    int "The serum concentration of Methylergometrine can be increased when it is combined with Cilastatin."
  ]
  edge [
    source 102
    target 156
    int "The risk or severity of adverse effects can be increased when Methylergometrine is combined with Mefloquine."
  ]
  edge [
    source 102
    target 160
    int "The risk or severity of adverse effects can be increased when Methylergometrine is combined with Chlorzoxazone."
  ]
  edge [
    source 102
    target 166
    int "The serum concentration of Tolvaptan can be increased when it is combined with Methylergometrine."
  ]
  edge [
    source 102
    target 169
    int "Asenapine may increase the vasoconstricting activities of Methylergometrine."
  ]
  edge [
    source 102
    target 184
    int "Methylergometrine may increase the hypertensive and vasoconstricting activities of Dexmedetomidine."
  ]
  edge [
    source 102
    target 124
    int "The risk or severity of adverse effects can be increased when Methylergometrine is combined with Pazopanib."
  ]
  edge [
    source 102
    target 115
    int "The serum concentration of Methylergometrine can be increased when it is combined with Sitagliptin."
  ]
  edge [
    source 102
    target 168
    int "Atenolol may increase the vasoconstricting activities of Methylergometrine."
  ]
  edge [
    source 102
    target 188
    int "The serum concentration of Cerivastatin can be increased when it is combined with Methylergometrine."
  ]
  edge [
    source 103
    target 123
    int "The metabolism of Zileuton can be decreased when combined with Leflunomide."
  ]
  edge [
    source 103
    target 167
    int "The metabolism of Zileuton can be decreased when combined with Sildenafil."
  ]
  edge [
    source 103
    target 138
    int "The serum concentration of Theophylline can be increased when it is combined with Zileuton."
  ]
  edge [
    source 103
    target 110
    int "The metabolism of Zileuton can be decreased when combined with Dronedarone."
  ]
  edge [
    source 103
    target 146
    int "The risk or severity of adverse effects can be increased when Zileuton is combined with Chlorphenesin."
  ]
  edge [
    source 103
    target 150
    int "The serum concentration of Lithium can be increased when it is combined with Zileuton."
  ]
  edge [
    source 103
    target 217
    int "The risk or severity of adverse effects can be increased when Zileuton is combined with Desoxycorticosterone Pivalate."
  ]
  edge [
    source 103
    target 226
    int "The therapeutic efficacy of Bumetanide can be decreased when used in combination with Zileuton."
  ]
  edge [
    source 103
    target 232
    int "The metabolism of Zileuton can be decreased when combined with Sorafenib."
  ]
  edge [
    source 103
    target 247
    int "The risk or severity of adverse effects can be increased when Zileuton is combined with Mesalazine."
  ]
  edge [
    source 103
    target 152
    int "The metabolism of Zileuton can be decreased when combined with Efavirenz."
  ]
  edge [
    source 103
    target 155
    int "The metabolism of Zileuton can be decreased when combined with Bortezomib."
  ]
  edge [
    source 103
    target 189
    int "The risk or severity of adverse effects can be increased when Zileuton is combined with Aminosalicylic Acid."
  ]
  edge [
    source 103
    target 244
    int "The metabolism of Zileuton can be decreased when combined with Ranolazine."
  ]
  edge [
    source 103
    target 240
    int "The metabolism of Zileuton can be increased when combined with Primidone."
  ]
  edge [
    source 103
    target 246
    int "The serum concentration of Zileuton can be decreased when it is combined with Bosentan."
  ]
  edge [
    source 103
    target 196
    int "The metabolism of Zileuton can be decreased when combined with Dihydroergotamine."
  ]
  edge [
    source 103
    target 162
    int "Zileuton may decrease the antihypertensive activities of Spironolactone."
  ]
  edge [
    source 103
    target 169
    int "Zileuton may decrease the antihypertensive activities of Asenapine."
  ]
  edge [
    source 103
    target 171
    int "The serum concentration of Zileuton can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 103
    target 204
    int "The risk or severity of adverse effects can be increased when Zileuton is combined with Oxyphenbutazone."
  ]
  edge [
    source 103
    target 201
    int "Zileuton may decrease the antihypertensive activities of Aliskiren."
  ]
  edge [
    source 103
    target 229
    int "Zileuton may decrease the excretion rate of Paromomycin which could result in a higher serum level."
  ]
  edge [
    source 103
    target 128
    int "The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Zileuton."
  ]
  edge [
    source 103
    target 168
    int "Zileuton may decrease the antihypertensive activities of Atenolol."
  ]
  edge [
    source 103
    target 199
    int "The risk or severity of adverse effects can be increased when Zileuton is combined with Meclofenamic acid."
  ]
  edge [
    source 103
    target 215
    int "The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Zileuton."
  ]
  edge [
    source 104
    target 244
    int "The serum concentration of Nizatidine can be increased when it is combined with Ranolazine."
  ]
  edge [
    source 104
    target 124
    int "Nizatidine can cause a decrease in the absorption of Pazopanib resulting in a reduced serum concentration and potentially a decrease in efficacy."
  ]
  edge [
    source 104
    target 247
    int "The therapeutic efficacy of Mesalazine can be decreased when used in combination with Nizatidine."
  ]
  edge [
    source 105
    target 155
    int "The metabolism of Riluzole can be decreased when combined with Bortezomib."
  ]
  edge [
    source 105
    target 156
    int "The therapeutic efficacy of Riluzole can be decreased when used in combination with Mefloquine."
  ]
  edge [
    source 105
    target 138
    int "The metabolism of Riluzole can be decreased when combined with Theophylline."
  ]
  edge [
    source 106
    target 137
    int "The risk or severity of QTc prolongation can be increased when Atovaquone is combined with Artemether."
  ]
  edge [
    source 106
    target 152
    int "The serum concentration of Atovaquone can be decreased when it is combined with Efavirenz."
  ]
  edge [
    source 106
    target 119
    int "The serum concentration of Triflupromazine can be increased when it is combined with Atovaquone."
  ]
  edge [
    source 106
    target 208
    int "The serum concentration of Trifluoperazine can be increased when it is combined with Atovaquone."
  ]
  edge [
    source 107
    target 110
    int "Vorinostat may increase the QTc-prolonging activities of Dronedarone."
  ]
  edge [
    source 107
    target 125
    int "Vorinostat may increase the QTc-prolonging activities of Pentamidine."
  ]
  edge [
    source 107
    target 129
    int "The therapeutic efficacy of Nateglinide can be decreased when used in combination with Vorinostat."
  ]
  edge [
    source 107
    target 137
    int "Vorinostat may increase the QTc-prolonging activities of Artemether."
  ]
  edge [
    source 107
    target 170
    int "The therapeutic efficacy of Metformin can be decreased when used in combination with Vorinostat."
  ]
  edge [
    source 107
    target 115
    int "The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Vorinostat."
  ]
  edge [
    source 107
    target 198
    int "The therapeutic efficacy of Miglitol can be decreased when used in combination with Vorinostat."
  ]
  edge [
    source 107
    target 124
    int "Vorinostat may increase the QTc-prolonging activities of Pazopanib."
  ]
  edge [
    source 107
    target 169
    int "Vorinostat may increase the QTc-prolonging activities of Asenapine."
  ]
  edge [
    source 107
    target 236
    int "The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Vorinostat."
  ]
  edge [
    source 107
    target 237
    int "The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Vorinostat."
  ]
  edge [
    source 107
    target 243
    int "The therapeutic efficacy of Miglustat can be decreased when used in combination with Vorinostat."
  ]
  edge [
    source 108
    target 123
    int "The risk or severity of adverse effects can be increased when Chlorambucil is combined with Leflunomide."
  ]
  edge [
    source 109
    target 110
    int "Dronedarone may decrease the vasoconstricting activities of Etomidate."
  ]
  edge [
    source 109
    target 142
    int "The risk or severity of adverse effects can be increased when Gabapentin is combined with Etomidate."
  ]
  edge [
    source 109
    target 148
    int "The risk or severity of adverse effects can be increased when Dantrolene is combined with Etomidate."
  ]
  edge [
    source 109
    target 150
    int "The risk or severity of adverse effects can be increased when Etomidate is combined with Lithium."
  ]
  edge [
    source 109
    target 196
    int "Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Etomidate."
  ]
  edge [
    source 109
    target 197
    int "The risk or severity of adverse effects can be increased when Buspirone is combined with Etomidate."
  ]
  edge [
    source 109
    target 195
    int "The risk or severity of adverse effects can be increased when Entacapone is combined with Etomidate."
  ]
  edge [
    source 109
    target 222
    int "The risk or severity of adverse effects can be increased when Metaxalone is combined with Etomidate."
  ]
  edge [
    source 109
    target 225
    int "Epinephrine may decrease the vasoconstricting activities of Etomidate."
  ]
  edge [
    source 109
    target 231
    int "The risk or severity of adverse effects can be increased when Carisoprodol is combined with Etomidate."
  ]
  edge [
    source 109
    target 174
    int "The risk or severity of adverse effects can be increased when Etomidate is combined with Sertraline."
  ]
  edge [
    source 109
    target 131
    int "The risk or severity of adverse effects can be increased when Rufinamide is combined with Etomidate."
  ]
  edge [
    source 109
    target 152
    int "The risk or severity of adverse effects can be increased when Efavirenz is combined with Etomidate."
  ]
  edge [
    source 109
    target 238
    int "Etomidate may increase the sedative activities of Pramipexole."
  ]
  edge [
    source 109
    target 240
    int "The risk or severity of adverse effects can be increased when Primidone is combined with Etomidate."
  ]
  edge [
    source 109
    target 241
    int "Tolazoline may decrease the vasoconstricting activities of Etomidate."
  ]
  edge [
    source 109
    target 234
    int "The risk or severity of adverse effects can be increased when Lamotrigine is combined with Etomidate."
  ]
  edge [
    source 109
    target 113
    int "Imipramine may decrease the antihypertensive activities of Etomidate."
  ]
  edge [
    source 109
    target 133
    int "The risk or severity of adverse effects can be increased when Risperidone is combined with Etomidate."
  ]
  edge [
    source 109
    target 160
    int "The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Etomidate."
  ]
  edge [
    source 109
    target 162
    int "Spironolactone may decrease the vasoconstricting activities of Etomidate."
  ]
  edge [
    source 109
    target 169
    int "Etomidate may increase the atrioventricular blocking (AV block) activities of Asenapine."
  ]
  edge [
    source 109
    target 207
    int "The risk or severity of adverse effects can be increased when Zonisamide is combined with Etomidate."
  ]
  edge [
    source 109
    target 173
    int "The risk or severity of adverse effects can be increased when Tiagabine is combined with Etomidate."
  ]
  edge [
    source 109
    target 184
    int "The risk or severity of adverse effects can be increased when Etomidate is combined with Dexmedetomidine."
  ]
  edge [
    source 109
    target 206
    int "The risk or severity of adverse effects can be increased when Aripiprazole is combined with Etomidate."
  ]
  edge [
    source 109
    target 208
    int "The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Etomidate."
  ]
  edge [
    source 109
    target 119
    int "The risk or severity of adverse effects can be increased when Etomidate is combined with Triflupromazine."
  ]
  edge [
    source 109
    target 168
    int "Etomidate may increase the atrioventricular blocking (AV block) activities of Atenolol."
  ]
  edge [
    source 109
    target 191
    int "The risk or severity of adverse effects can be increased when Etomidate is combined with Trazodone."
  ]
  edge [
    source 109
    target 202
    int "The risk or severity of adverse effects can be increased when Maprotiline is combined with Etomidate."
  ]
  edge [
    source 110
    target 167
    int "Sildenafil may increase the hypotensive activities of Dronedarone."
  ]
  edge [
    source 110
    target 137
    int "The risk or severity of QTc prolongation can be increased when Dronedarone is combined with Artemether."
  ]
  edge [
    source 110
    target 141
    int "The metabolism of Doxorubicin can be decreased when combined with Dronedarone."
  ]
  edge [
    source 110
    target 142
    int "The risk or severity of hypotension can be increased when Dronedarone is combined with Gabapentin."
  ]
  edge [
    source 110
    target 148
    int "The metabolism of Dantrolene can be decreased when combined with Dronedarone."
  ]
  edge [
    source 110
    target 149
    int "The serum concentration of Halofantrine can be increased when it is combined with Dronedarone."
  ]
  edge [
    source 110
    target 196
    int "The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Dronedarone."
  ]
  edge [
    source 110
    target 197
    int "The metabolism of Buspirone can be decreased when combined with Dronedarone."
  ]
  edge [
    source 110
    target 182
    int "The metabolism of Mephenytoin can be decreased when combined with Dronedarone."
  ]
  edge [
    source 110
    target 193
    int "The metabolism of Flutamide can be decreased when combined with Dronedarone."
  ]
  edge [
    source 110
    target 214
    int "The metabolism of Proguanil can be decreased when combined with Dronedarone."
  ]
  edge [
    source 110
    target 219
    int "The metabolism of Nisoldipine can be decreased when combined with Dronedarone."
  ]
  edge [
    source 110
    target 220
    int "The metabolism of Sulfinpyrazone can be decreased when combined with Dronedarone."
  ]
  edge [
    source 110
    target 122
    int "The metabolism of Levonorgestrel can be decreased when combined with Dronedarone."
  ]
  edge [
    source 110
    target 230
    int "The metabolism of Isosorbide Dinitrate can be decreased when combined with Dronedarone."
  ]
  edge [
    source 110
    target 232
    int "Sorafenib may increase the QTc-prolonging activities of Dronedarone."
  ]
  edge [
    source 110
    target 206
    int "The serum concentration of Aripiprazole can be increased when it is combined with Dronedarone."
  ]
  edge [
    source 110
    target 244
    int "The serum concentration of Ranolazine can be increased when it is combined with Dronedarone."
  ]
  edge [
    source 110
    target 249
    int "Dipyridamole may increase the hypotensive activities of Dronedarone."
  ]
  edge [
    source 110
    target 158
    int "The metabolism of Piperazine can be decreased when combined with Dronedarone."
  ]
  edge [
    source 110
    target 174
    int "Sertraline may increase the QTc-prolonging activities of Dronedarone."
  ]
  edge [
    source 110
    target 235
    int "The metabolism of Lansoprazole can be decreased when combined with Dronedarone."
  ]
  edge [
    source 110
    target 225
    int "Dronedarone may increase the antihypertensive activities of Epinephrine."
  ]
  edge [
    source 110
    target 147
    int "Metronidazole may increase the QTc-prolonging activities of Dronedarone."
  ]
  edge [
    source 110
    target 140
    int "The metabolism of Tinidazole can be decreased when combined with Dronedarone."
  ]
  edge [
    source 110
    target 152
    int "The metabolism of Efavirenz can be decreased when combined with Dronedarone."
  ]
  edge [
    source 110
    target 153
    int "The metabolism of Testosterone can be decreased when combined with Dronedarone."
  ]
  edge [
    source 110
    target 155
    int "Bortezomib may increase the QTc-prolonging activities of Dronedarone."
  ]
  edge [
    source 110
    target 159
    int "The metabolism of Cevimeline can be decreased when combined with Dronedarone."
  ]
  edge [
    source 110
    target 175
    int "The metabolism of Maraviroc can be decreased when combined with Dronedarone."
  ]
  edge [
    source 110
    target 176
    int "The metabolism of Cytarabine can be decreased when combined with Dronedarone."
  ]
  edge [
    source 110
    target 180
    int "The metabolism of Disulfiram can be decreased when combined with Dronedarone."
  ]
  edge [
    source 110
    target 205
    int "Foscarnet may increase the QTc-prolonging activities of Dronedarone."
  ]
  edge [
    source 110
    target 228
    int "Bretylium may increase the bradycardic activities of Dronedarone."
  ]
  edge [
    source 110
    target 240
    int "The serum concentration of Dronedarone can be decreased when it is combined with Primidone."
  ]
  edge [
    source 110
    target 246
    int "The serum concentration of Bosentan can be increased when it is combined with Dronedarone."
  ]
  edge [
    source 110
    target 234
    int "The risk or severity of hypotension can be increased when Dronedarone is combined with Lamotrigine."
  ]
  edge [
    source 110
    target 154
    int "The metabolism of Amprenavir can be decreased when combined with Dronedarone."
  ]
  edge [
    source 110
    target 138
    int "Theophylline may increase the hypotensive activities of Dronedarone."
  ]
  edge [
    source 110
    target 150
    int "Lithium may increase the QTc-prolonging activities of Dronedarone."
  ]
  edge [
    source 110
    target 181
    int "The metabolism of Dopamine can be decreased when combined with Dronedarone."
  ]
  edge [
    source 110
    target 113
    int "Dronedarone may increase the antihypertensive activities of Imipramine."
  ]
  edge [
    source 110
    target 117
    int "The metabolism of Albendazole can be decreased when combined with Dronedarone."
  ]
  edge [
    source 110
    target 125
    int "Pentamidine may increase the QTc-prolonging activities of Dronedarone."
  ]
  edge [
    source 110
    target 129
    int "The metabolism of Nateglinide can be decreased when combined with Dronedarone."
  ]
  edge [
    source 110
    target 133
    int "Risperidone may increase the antihypertensive activities of Dronedarone."
  ]
  edge [
    source 110
    target 135
    int "The serum concentration of Everolimus can be increased when it is combined with Dronedarone."
  ]
  edge [
    source 110
    target 136
    int "The serum concentration of Ulipristal can be increased when it is combined with Dronedarone."
  ]
  edge [
    source 110
    target 156
    int "Mefloquine may increase the QTc-prolonging activities of Dronedarone."
  ]
  edge [
    source 110
    target 160
    int "The metabolism of Chlorzoxazone can be decreased when combined with Dronedarone."
  ]
  edge [
    source 110
    target 163
    int "Dronedarone may increase the atrioventricular blocking (AV block) activities of Lacosamide."
  ]
  edge [
    source 110
    target 164
    int "The metabolism of Mebendazole can be decreased when combined with Dronedarone."
  ]
  edge [
    source 110
    target 166
    int "The serum concentration of Tolvaptan can be increased when it is combined with Dronedarone."
  ]
  edge [
    source 110
    target 169
    int "Dronedarone may increase the bradycardic activities of Asenapine."
  ]
  edge [
    source 110
    target 171
    int "The serum concentration of Dronedarone can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 110
    target 207
    int "The metabolism of Zonisamide can be decreased when combined with Dronedarone."
  ]
  edge [
    source 110
    target 173
    int "The metabolism of Tiagabine can be decreased when combined with Dronedarone."
  ]
  edge [
    source 110
    target 184
    int "Dexmedetomidine may increase the bradycardic activities of Dronedarone."
  ]
  edge [
    source 110
    target 187
    int "The metabolism of Clofibrate can be decreased when combined with Dronedarone."
  ]
  edge [
    source 110
    target 201
    int "The metabolism of Aliskiren can be decreased when combined with Dronedarone."
  ]
  edge [
    source 110
    target 208
    int "Trifluoperazine may increase the antihypertensive activities of Dronedarone."
  ]
  edge [
    source 110
    target 212
    int "The metabolism of Loperamide can be decreased when combined with Dronedarone."
  ]
  edge [
    source 110
    target 124
    int "The serum concentration of Pazopanib can be increased when it is combined with Dronedarone."
  ]
  edge [
    source 110
    target 200
    int "The metabolism of Zalcitabine can be decreased when combined with Dronedarone."
  ]
  edge [
    source 110
    target 115
    int "The metabolism of Sitagliptin can be decreased when combined with Dronedarone."
  ]
  edge [
    source 110
    target 118
    int "Sunitinib may increase the QTc-prolonging activities of Dronedarone."
  ]
  edge [
    source 110
    target 165
    int "The metabolism of Pyrazinamide can be decreased when combined with Dronedarone."
  ]
  edge [
    source 110
    target 168
    int "Dronedarone may increase the bradycardic activities of Atenolol."
  ]
  edge [
    source 110
    target 186
    int "The metabolism of Dutasteride can be decreased when combined with Dronedarone."
  ]
  edge [
    source 110
    target 188
    int "The serum concentration of Cerivastatin can be increased when it is combined with Dronedarone."
  ]
  edge [
    source 110
    target 241
    int "Tolazoline may increase the antihypertensive activities of Dronedarone."
  ]
  edge [
    source 110
    target 191
    int "Trazodone may increase the antihypertensive activities of Dronedarone."
  ]
  edge [
    source 110
    target 202
    int "Maprotiline may increase the QTc-prolonging activities of Dronedarone."
  ]
  edge [
    source 112
    target 229
    int "Cefmenoxime may increase the nephrotoxic activities of Paromomycin."
  ]
  edge [
    source 113
    target 157
    int "The metabolism of Imipramine can be decreased when combined with Armodafinil."
  ]
  edge [
    source 113
    target 228
    int "The risk or severity of adverse effects can be increased when Imipramine is combined with Bretylium."
  ]
  edge [
    source 113
    target 137
    int "Imipramine may increase the QTc-prolonging activities of Artemether."
  ]
  edge [
    source 113
    target 141
    int "The metabolism of Doxorubicin can be decreased when combined with Imipramine."
  ]
  edge [
    source 113
    target 142
    int "The risk or severity of adverse effects can be increased when Gabapentin is combined with Imipramine."
  ]
  edge [
    source 113
    target 150
    int "Lithium may increase the neurotoxic activities of Imipramine."
  ]
  edge [
    source 113
    target 194
    int "Pargyline may increase the serotonergic activities of Imipramine."
  ]
  edge [
    source 113
    target 154
    int "The serum concentration of Imipramine can be increased when it is combined with Amprenavir."
  ]
  edge [
    source 113
    target 195
    int "The risk or severity of adverse effects can be increased when Imipramine is combined with Entacapone."
  ]
  edge [
    source 113
    target 197
    int "The risk or severity of adverse effects can be increased when Imipramine is combined with Buspirone."
  ]
  edge [
    source 113
    target 115
    int "The serum concentration of Imipramine can be increased when it is combined with Sitagliptin."
  ]
  edge [
    source 113
    target 182
    int "The metabolism of Mephenytoin can be decreased when combined with Imipramine."
  ]
  edge [
    source 113
    target 196
    int "Imipramine may decrease the antihypertensive activities of Dihydroergotamine."
  ]
  edge [
    source 113
    target 219
    int "The risk or severity of adverse effects can be increased when Imipramine is combined with Nisoldipine."
  ]
  edge [
    source 113
    target 222
    int "The risk or severity of adverse effects can be increased when Imipramine is combined with Metaxalone."
  ]
  edge [
    source 113
    target 224
    int "The risk or severity of adverse effects can be increased when Imipramine is combined with Sumatriptan."
  ]
  edge [
    source 113
    target 231
    int "The risk or severity of adverse effects can be increased when Carisoprodol is combined with Imipramine."
  ]
  edge [
    source 113
    target 232
    int "The metabolism of Imipramine can be decreased when combined with Sorafenib."
  ]
  edge [
    source 113
    target 158
    int "The metabolism of Piperazine can be decreased when combined with Imipramine."
  ]
  edge [
    source 113
    target 249
    int "Dipyridamole may increase the hypotensive activities of Imipramine."
  ]
  edge [
    source 113
    target 174
    int "The risk or severity of adverse effects can be increased when Sertraline is combined with Imipramine."
  ]
  edge [
    source 113
    target 225
    int "Imipramine may increase the antihypertensive activities of Epinephrine."
  ]
  edge [
    source 113
    target 230
    int "The risk or severity of adverse effects can be increased when Imipramine is combined with Isosorbide Dinitrate."
  ]
  edge [
    source 113
    target 131
    int "The risk or severity of adverse effects can be increased when Rufinamide is combined with Imipramine."
  ]
  edge [
    source 113
    target 152
    int "The metabolism of Imipramine can be decreased when combined with Efavirenz."
  ]
  edge [
    source 113
    target 155
    int "The metabolism of Imipramine can be decreased when combined with Bortezomib."
  ]
  edge [
    source 113
    target 159
    int "The metabolism of Cevimeline can be decreased when combined with Imipramine."
  ]
  edge [
    source 113
    target 167
    int "Sildenafil may increase the hypotensive activities of Imipramine."
  ]
  edge [
    source 113
    target 218
    int "Altretamine may increase the orthostatic hypotensive activities of Imipramine."
  ]
  edge [
    source 113
    target 226
    int "The risk or severity of adverse effects can be increased when Imipramine is combined with Bumetanide."
  ]
  edge [
    source 113
    target 244
    int "The serum concentration of Ranolazine can be increased when it is combined with Imipramine."
  ]
  edge [
    source 113
    target 168
    int "Atenolol may increase the orthostatic hypotensive activities of Imipramine."
  ]
  edge [
    source 113
    target 238
    int "Imipramine may increase the sedative activities of Pramipexole."
  ]
  edge [
    source 113
    target 240
    int "The metabolism of Imipramine can be increased when combined with Primidone."
  ]
  edge [
    source 113
    target 246
    int "The serum concentration of Imipramine can be decreased when it is combined with Bosentan."
  ]
  edge [
    source 113
    target 138
    int "Theophylline may increase the hypotensive activities of Imipramine."
  ]
  edge [
    source 113
    target 181
    int "The metabolism of Dopamine can be decreased when combined with Imipramine."
  ]
  edge [
    source 113
    target 125
    int "The metabolism of Pentamidine can be decreased when combined with Imipramine."
  ]
  edge [
    source 113
    target 129
    int "The metabolism of Nateglinide can be decreased when combined with Imipramine."
  ]
  edge [
    source 113
    target 133
    int "Imipramine may increase the hypotensive activities of Risperidone."
  ]
  edge [
    source 113
    target 179
    int "The serum concentration of Imipramine can be increased when it is combined with Cilastatin."
  ]
  edge [
    source 113
    target 135
    int "The serum concentration of Everolimus can be increased when it is combined with Imipramine."
  ]
  edge [
    source 113
    target 162
    int "The risk or severity of adverse effects can be increased when Imipramine is combined with Spironolactone."
  ]
  edge [
    source 113
    target 169
    int "Asenapine may increase the antihypertensive activities of Imipramine."
  ]
  edge [
    source 113
    target 171
    int "The serum concentration of Imipramine can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 113
    target 207
    int "The risk or severity of adverse effects can be increased when Imipramine is combined with Zonisamide."
  ]
  edge [
    source 113
    target 173
    int "The risk or severity of adverse effects can be increased when Imipramine is combined with Tiagabine."
  ]
  edge [
    source 113
    target 184
    int "Imipramine may decrease the antihypertensive activities of Dexmedetomidine."
  ]
  edge [
    source 113
    target 200
    int "The metabolism of Zalcitabine can be decreased when combined with Imipramine."
  ]
  edge [
    source 113
    target 201
    int "The risk or severity of adverse effects can be increased when Imipramine is combined with Aliskiren."
  ]
  edge [
    source 113
    target 206
    int "The serum concentration of Aripiprazole can be increased when it is combined with Imipramine."
  ]
  edge [
    source 113
    target 208
    int "Trifluoperazine may increase the antihypertensive activities of Imipramine."
  ]
  edge [
    source 113
    target 212
    int "The metabolism of Loperamide can be decreased when combined with Imipramine."
  ]
  edge [
    source 113
    target 124
    int "The serum concentration of Pazopanib can be increased when it is combined with Imipramine."
  ]
  edge [
    source 113
    target 160
    int "The metabolism of Chlorzoxazone can be decreased when combined with Imipramine."
  ]
  edge [
    source 113
    target 234
    int "The risk or severity of adverse effects can be increased when Imipramine is combined with Lamotrigine."
  ]
  edge [
    source 113
    target 148
    int "The risk or severity of adverse effects can be increased when Imipramine is combined with Dantrolene."
  ]
  edge [
    source 113
    target 149
    int "The metabolism of Halofantrine can be decreased when combined with Imipramine."
  ]
  edge [
    source 113
    target 119
    int "The risk or severity of adverse effects can be increased when Imipramine is combined with Triflupromazine."
  ]
  edge [
    source 113
    target 161
    int "The risk or severity of adverse effects can be increased when Imipramine is combined with Minoxidil."
  ]
  edge [
    source 113
    target 241
    int "Tolazoline may increase the antihypertensive activities of Imipramine."
  ]
  edge [
    source 113
    target 191
    int "Trazodone may increase the antihypertensive activities of Imipramine."
  ]
  edge [
    source 113
    target 192
    int "The risk or severity of adverse effects can be increased when Imipramine is combined with Mecamylamine."
  ]
  edge [
    source 113
    target 202
    int "The risk or severity of adverse effects can be increased when Imipramine is combined with Maprotiline."
  ]
  edge [
    source 113
    target 215
    int "The risk or severity of adverse effects can be increased when Imipramine is combined with Methyclothiazide."
  ]
  edge [
    source 114
    target 122
    int "The therapeutic efficacy of Levonorgestrel can be decreased when used in combination with Acitretin."
  ]
  edge [
    source 115
    target 167
    int "The serum concentration of Sildenafil can be increased when it is combined with Sitagliptin."
  ]
  edge [
    source 115
    target 138
    int "The serum concentration of Theophylline can be decreased when it is combined with Sitagliptin."
  ]
  edge [
    source 115
    target 194
    int "Pargyline may increase the hypoglycemic activities of Sitagliptin."
  ]
  edge [
    source 115
    target 196
    int "The serum concentration of Dihydroergotamine can be increased when it is combined with Sitagliptin."
  ]
  edge [
    source 115
    target 225
    int "The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Epinephrine."
  ]
  edge [
    source 115
    target 226
    int "The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Bumetanide."
  ]
  edge [
    source 115
    target 244
    int "The serum concentration of Sitagliptin can be increased when it is combined with Ranolazine."
  ]
  edge [
    source 115
    target 247
    int "Mesalazine may increase the hypoglycemic activities of Sitagliptin."
  ]
  edge [
    source 115
    target 158
    int "The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Piperazine."
  ]
  edge [
    source 115
    target 174
    int "Sertraline may increase the hypoglycemic activities of Sitagliptin."
  ]
  edge [
    source 115
    target 122
    int "The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Levonorgestrel."
  ]
  edge [
    source 115
    target 152
    int "The metabolism of Sitagliptin can be decreased when combined with Efavirenz."
  ]
  edge [
    source 115
    target 153
    int "Testosterone may increase the hypoglycemic activities of Sitagliptin."
  ]
  edge [
    source 115
    target 155
    int "The metabolism of Sitagliptin can be decreased when combined with Bortezomib."
  ]
  edge [
    source 115
    target 236
    int "Sitagliptin may increase the hypoglycemic activities of Acetohexamide."
  ]
  edge [
    source 115
    target 237
    int "The metabolism of Sitagliptin can be decreased when combined with Rosiglitazone."
  ]
  edge [
    source 115
    target 240
    int "The metabolism of Sitagliptin can be increased when combined with Primidone."
  ]
  edge [
    source 115
    target 246
    int "The serum concentration of Sitagliptin can be decreased when it is combined with Bosentan."
  ]
  edge [
    source 115
    target 125
    int "The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Pentamidine."
  ]
  edge [
    source 115
    target 129
    int "Sitagliptin may increase the hypoglycemic activities of Nateglinide."
  ]
  edge [
    source 115
    target 133
    int "The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Risperidone."
  ]
  edge [
    source 115
    target 135
    int "The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Everolimus."
  ]
  edge [
    source 115
    target 169
    int "The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Asenapine."
  ]
  edge [
    source 115
    target 171
    int "The serum concentration of Sitagliptin can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 115
    target 206
    int "The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Aripiprazole."
  ]
  edge [
    source 115
    target 118
    int "Sitagliptin may increase the hypoglycemic activities of Sunitinib."
  ]
  edge [
    source 115
    target 127
    int "The serum concentration of Abacavir can be decreased when it is combined with Sitagliptin."
  ]
  edge [
    source 115
    target 215
    int "The therapeutic efficacy of Sitagliptin can be decreased when used in combination with Methyclothiazide."
  ]
  edge [
    source 115
    target 189
    int "Aminosalicylic Acid may increase the hypoglycemic activities of Sitagliptin."
  ]
  edge [
    source 117
    target 167
    int "The metabolism of Albendazole can be decreased when combined with Sildenafil."
  ]
  edge [
    source 117
    target 138
    int "The metabolism of Albendazole can be decreased when combined with Theophylline."
  ]
  edge [
    source 117
    target 135
    int "The serum concentration of Everolimus can be increased when it is combined with Albendazole."
  ]
  edge [
    source 117
    target 141
    int "The serum concentration of Doxorubicin can be increased when it is combined with Albendazole."
  ]
  edge [
    source 117
    target 155
    int "The metabolism of Albendazole can be decreased when combined with Bortezomib."
  ]
  edge [
    source 117
    target 171
    int "The serum concentration of Albendazole can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 117
    target 196
    int "The metabolism of Albendazole can be decreased when combined with Dihydroergotamine."
  ]
  edge [
    source 117
    target 124
    int "The serum concentration of Pazopanib can be increased when it is combined with Albendazole."
  ]
  edge [
    source 117
    target 240
    int "The metabolism of Albendazole can be increased when combined with Primidone."
  ]
  edge [
    source 117
    target 244
    int "The serum concentration of Ranolazine can be increased when it is combined with Albendazole."
  ]
  edge [
    source 117
    target 246
    int "The serum concentration of Albendazole can be decreased when it is combined with Bosentan."
  ]
  edge [
    source 118
    target 123
    int "The risk or severity of adverse effects can be increased when Sunitinib is combined with Leflunomide."
  ]
  edge [
    source 118
    target 167
    int "The metabolism of Sunitinib can be decreased when combined with Sildenafil."
  ]
  edge [
    source 118
    target 137
    int "The metabolism of Sunitinib can be decreased when combined with Artemether."
  ]
  edge [
    source 118
    target 141
    int "The serum concentration of Doxorubicin can be increased when it is combined with Sunitinib."
  ]
  edge [
    source 118
    target 194
    int "Pargyline may increase the hypoglycemic activities of Sunitinib."
  ]
  edge [
    source 118
    target 196
    int "The metabolism of Sunitinib can be decreased when combined with Dihydroergotamine."
  ]
  edge [
    source 118
    target 198
    int "Miglitol may increase the hypoglycemic activities of Sunitinib."
  ]
  edge [
    source 118
    target 244
    int "The serum concentration of Ranolazine can be increased when it is combined with Sunitinib."
  ]
  edge [
    source 118
    target 247
    int "Mesalazine may increase the hypoglycemic activities of Sunitinib."
  ]
  edge [
    source 118
    target 174
    int "Sertraline may increase the hypoglycemic activities of Sunitinib."
  ]
  edge [
    source 118
    target 153
    int "Testosterone may increase the hypoglycemic activities of Sunitinib."
  ]
  edge [
    source 118
    target 155
    int "The metabolism of Sunitinib can be decreased when combined with Bortezomib."
  ]
  edge [
    source 118
    target 236
    int "Acetohexamide may increase the hypoglycemic activities of Sunitinib."
  ]
  edge [
    source 118
    target 237
    int "Rosiglitazone may increase the hypoglycemic activities of Sunitinib."
  ]
  edge [
    source 118
    target 240
    int "The serum concentration of Sunitinib can be decreased when it is combined with Primidone."
  ]
  edge [
    source 118
    target 243
    int "Miglustat may increase the hypoglycemic activities of Sunitinib."
  ]
  edge [
    source 118
    target 246
    int "The serum concentration of Sunitinib can be decreased when it is combined with Bosentan."
  ]
  edge [
    source 118
    target 125
    int "The metabolism of Sunitinib can be decreased when combined with Pentamidine."
  ]
  edge [
    source 118
    target 129
    int "Nateglinide may increase the hypoglycemic activities of Sunitinib."
  ]
  edge [
    source 118
    target 135
    int "The serum concentration of Everolimus can be increased when it is combined with Sunitinib."
  ]
  edge [
    source 118
    target 169
    int "Sunitinib may increase the QTc-prolonging activities of Asenapine."
  ]
  edge [
    source 118
    target 171
    int "The serum concentration of Sunitinib can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 118
    target 124
    int "The serum concentration of Pazopanib can be increased when it is combined with Sunitinib."
  ]
  edge [
    source 118
    target 170
    int "Metformin may increase the hypoglycemic activities of Sunitinib."
  ]
  edge [
    source 118
    target 189
    int "Aminosalicylic Acid may increase the hypoglycemic activities of Sunitinib."
  ]
  edge [
    source 119
    target 137
    int "The serum concentration of Triflupromazine can be increased when it is combined with Artemether."
  ]
  edge [
    source 119
    target 141
    int "The serum concentration of Doxorubicin can be increased when it is combined with Triflupromazine."
  ]
  edge [
    source 119
    target 142
    int "The risk or severity of adverse effects can be increased when Gabapentin is combined with Triflupromazine."
  ]
  edge [
    source 119
    target 148
    int "The risk or severity of adverse effects can be increased when Dantrolene is combined with Triflupromazine."
  ]
  edge [
    source 119
    target 149
    int "The serum concentration of Triflupromazine can be increased when it is combined with Halofantrine."
  ]
  edge [
    source 119
    target 150
    int "Lithium may increase the neurotoxic activities of Triflupromazine."
  ]
  edge [
    source 119
    target 195
    int "The risk or severity of adverse effects can be increased when Entacapone is combined with Triflupromazine."
  ]
  edge [
    source 119
    target 197
    int "The risk or severity of adverse effects can be increased when Buspirone is combined with Triflupromazine."
  ]
  edge [
    source 119
    target 196
    int "The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Triflupromazine."
  ]
  edge [
    source 119
    target 214
    int "The serum concentration of Triflupromazine can be increased when it is combined with Proguanil."
  ]
  edge [
    source 119
    target 222
    int "The risk or severity of adverse effects can be increased when Metaxalone is combined with Triflupromazine."
  ]
  edge [
    source 119
    target 224
    int "The risk or severity of adverse effects can be increased when Sumatriptan is combined with Triflupromazine."
  ]
  edge [
    source 119
    target 231
    int "The risk or severity of adverse effects can be increased when Carisoprodol is combined with Triflupromazine."
  ]
  edge [
    source 119
    target 174
    int "The risk or severity of adverse effects can be increased when Triflupromazine is combined with Sertraline."
  ]
  edge [
    source 119
    target 131
    int "The risk or severity of adverse effects can be increased when Rufinamide is combined with Triflupromazine."
  ]
  edge [
    source 119
    target 152
    int "The risk or severity of adverse effects can be increased when Efavirenz is combined with Triflupromazine."
  ]
  edge [
    source 119
    target 244
    int "The serum concentration of Ranolazine can be increased when it is combined with Triflupromazine."
  ]
  edge [
    source 119
    target 238
    int "Triflupromazine may increase the sedative activities of Pramipexole."
  ]
  edge [
    source 119
    target 240
    int "The risk or severity of adverse effects can be increased when Primidone is combined with Triflupromazine."
  ]
  edge [
    source 119
    target 234
    int "The risk or severity of adverse effects can be increased when Lamotrigine is combined with Triflupromazine."
  ]
  edge [
    source 119
    target 133
    int "The risk or severity of adverse effects can be increased when Risperidone is combined with Triflupromazine."
  ]
  edge [
    source 119
    target 135
    int "The serum concentration of Everolimus can be increased when it is combined with Triflupromazine."
  ]
  edge [
    source 119
    target 156
    int "The serum concentration of Triflupromazine can be increased when it is combined with Mefloquine."
  ]
  edge [
    source 119
    target 160
    int "The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Triflupromazine."
  ]
  edge [
    source 119
    target 169
    int "The risk or severity of adverse effects can be increased when Asenapine is combined with Triflupromazine."
  ]
  edge [
    source 119
    target 207
    int "The risk or severity of adverse effects can be increased when Zonisamide is combined with Triflupromazine."
  ]
  edge [
    source 119
    target 173
    int "The risk or severity of adverse effects can be increased when Tiagabine is combined with Triflupromazine."
  ]
  edge [
    source 119
    target 184
    int "The risk or severity of adverse effects can be increased when Triflupromazine is combined with Dexmedetomidine."
  ]
  edge [
    source 119
    target 206
    int "The risk or severity of adverse effects can be increased when Aripiprazole is combined with Triflupromazine."
  ]
  edge [
    source 119
    target 208
    int "The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Triflupromazine."
  ]
  edge [
    source 119
    target 124
    int "The serum concentration of Pazopanib can be increased when it is combined with Triflupromazine."
  ]
  edge [
    source 119
    target 168
    int "Triflupromazine may increase the hypotensive activities of Atenolol."
  ]
  edge [
    source 119
    target 191
    int "The risk or severity of adverse effects can be increased when Triflupromazine is combined with Trazodone."
  ]
  edge [
    source 119
    target 202
    int "The risk or severity of adverse effects can be increased when Maprotiline is combined with Triflupromazine."
  ]
  edge [
    source 121
    target 167
    int "The metabolism of Niclosamide can be decreased when combined with Sildenafil."
  ]
  edge [
    source 121
    target 152
    int "The metabolism of Niclosamide can be decreased when combined with Efavirenz."
  ]
  edge [
    source 121
    target 123
    int "The metabolism of Niclosamide can be decreased when combined with Leflunomide."
  ]
  edge [
    source 121
    target 232
    int "The metabolism of Niclosamide can be decreased when combined with Sorafenib."
  ]
  edge [
    source 121
    target 240
    int "The metabolism of Niclosamide can be increased when combined with Primidone."
  ]
  edge [
    source 122
    target 242
    int "Tranexamic Acid may increase the thrombogenic activities of Levonorgestrel."
  ]
  edge [
    source 122
    target 167
    int "The metabolism of Levonorgestrel can be decreased when combined with Sildenafil."
  ]
  edge [
    source 122
    target 136
    int "The therapeutic efficacy of Levonorgestrel can be decreased when used in combination with Ulipristal."
  ]
  edge [
    source 122
    target 129
    int "The therapeutic efficacy of Nateglinide can be decreased when used in combination with Levonorgestrel."
  ]
  edge [
    source 122
    target 137
    int "The serum concentration of Levonorgestrel can be decreased when it is combined with Artemether."
  ]
  edge [
    source 122
    target 152
    int "The serum concentration of Levonorgestrel can be decreased when it is combined with Efavirenz."
  ]
  edge [
    source 122
    target 155
    int "The metabolism of Levonorgestrel can be decreased when combined with Bortezomib."
  ]
  edge [
    source 122
    target 196
    int "The metabolism of Levonorgestrel can be decreased when combined with Dihydroergotamine."
  ]
  edge [
    source 122
    target 170
    int "The therapeutic efficacy of Metformin can be decreased when used in combination with Levonorgestrel."
  ]
  edge [
    source 122
    target 171
    int "The serum concentration of Levonorgestrel can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 122
    target 198
    int "The therapeutic efficacy of Miglitol can be decreased when used in combination with Levonorgestrel."
  ]
  edge [
    source 122
    target 243
    int "The therapeutic efficacy of Miglustat can be decreased when used in combination with Levonorgestrel."
  ]
  edge [
    source 122
    target 236
    int "The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Levonorgestrel."
  ]
  edge [
    source 122
    target 237
    int "The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Levonorgestrel."
  ]
  edge [
    source 122
    target 240
    int "The therapeutic efficacy of Levonorgestrel can be decreased when used in combination with Primidone."
  ]
  edge [
    source 122
    target 244
    int "The metabolism of Levonorgestrel can be decreased when combined with Ranolazine."
  ]
  edge [
    source 122
    target 246
    int "The serum concentration of Levonorgestrel can be decreased when it is combined with Bosentan."
  ]
  edge [
    source 122
    target 234
    int "Levonorgestrel may increase the excretion rate of Lamotrigine which could result in a lower serum level and potentially a reduction in efficacy."
  ]
  edge [
    source 123
    target 237
    int "The metabolism of Rosiglitazone can be decreased when combined with Leflunomide."
  ]
  edge [
    source 123
    target 167
    int "The metabolism of Leflunomide can be decreased when combined with Sildenafil."
  ]
  edge [
    source 123
    target 138
    int "The metabolism of Leflunomide can be decreased when combined with Theophylline."
  ]
  edge [
    source 123
    target 235
    int "The metabolism of Lansoprazole can be decreased when combined with Leflunomide."
  ]
  edge [
    source 123
    target 141
    int "The risk or severity of adverse effects can be increased when Doxorubicin is combined with Leflunomide."
  ]
  edge [
    source 123
    target 146
    int "The risk or severity of adverse effects can be increased when Leflunomide is combined with Chlorphenesin."
  ]
  edge [
    source 123
    target 150
    int "The serum concentration of Lithium can be increased when it is combined with Leflunomide."
  ]
  edge [
    source 123
    target 154
    int "The metabolism of Amprenavir can be decreased when combined with Leflunomide."
  ]
  edge [
    source 123
    target 213
    int "The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Leflunomide."
  ]
  edge [
    source 123
    target 182
    int "The metabolism of Mephenytoin can be decreased when combined with Leflunomide."
  ]
  edge [
    source 123
    target 214
    int "The metabolism of Proguanil can be decreased when combined with Leflunomide."
  ]
  edge [
    source 123
    target 217
    int "The risk or severity of adverse effects can be increased when Leflunomide is combined with Desoxycorticosterone Pivalate."
  ]
  edge [
    source 123
    target 220
    int "The metabolism of Sulfinpyrazone can be decreased when combined with Leflunomide."
  ]
  edge [
    source 123
    target 226
    int "The therapeutic efficacy of Bumetanide can be decreased when used in combination with Leflunomide."
  ]
  edge [
    source 123
    target 248
    int "The risk or severity of adverse effects can be increased when Azacitidine is combined with Leflunomide."
  ]
  edge [
    source 123
    target 232
    int "The risk or severity of adverse effects can be increased when Sorafenib is combined with Leflunomide."
  ]
  edge [
    source 123
    target 174
    int "The metabolism of Sertraline can be decreased when combined with Leflunomide."
  ]
  edge [
    source 123
    target 247
    int "The risk or severity of adverse effects can be increased when Leflunomide is combined with Mesalazine."
  ]
  edge [
    source 123
    target 147
    int "The metabolism of Metronidazole can be decreased when combined with Leflunomide."
  ]
  edge [
    source 123
    target 152
    int "The metabolism of Leflunomide can be decreased when combined with Efavirenz."
  ]
  edge [
    source 123
    target 153
    int "The metabolism of Testosterone can be decreased when combined with Leflunomide."
  ]
  edge [
    source 123
    target 155
    int "The metabolism of Leflunomide can be decreased when combined with Bortezomib."
  ]
  edge [
    source 123
    target 177
    int "The risk or severity of adverse effects can be increased when Mitoxantrone is combined with Leflunomide."
  ]
  edge [
    source 123
    target 181
    int "The metabolism of Dopamine can be decreased when combined with Leflunomide."
  ]
  edge [
    source 123
    target 168
    int "Leflunomide may decrease the antihypertensive activities of Atenolol."
  ]
  edge [
    source 123
    target 240
    int "The metabolism of Leflunomide can be increased when combined with Primidone."
  ]
  edge [
    source 123
    target 246
    int "The serum concentration of Bosentan can be increased when it is combined with Leflunomide."
  ]
  edge [
    source 123
    target 251
    int "The risk or severity of adverse effects can be increased when Pentostatin is combined with Leflunomide."
  ]
  edge [
    source 123
    target 203
    int "The risk or severity of adverse effects can be increased when Carboplatin is combined with Leflunomide."
  ]
  edge [
    source 123
    target 176
    int "The risk or severity of adverse effects can be increased when Cytarabine is combined with Leflunomide."
  ]
  edge [
    source 123
    target 162
    int "Leflunomide may decrease the antihypertensive activities of Spironolactone."
  ]
  edge [
    source 123
    target 169
    int "Leflunomide may decrease the antihypertensive activities of Asenapine."
  ]
  edge [
    source 123
    target 129
    int "The metabolism of Nateglinide can be decreased when combined with Leflunomide."
  ]
  edge [
    source 123
    target 135
    int "The risk or severity of adverse effects can be increased when Everolimus is combined with Leflunomide."
  ]
  edge [
    source 123
    target 204
    int "The risk or severity of adverse effects can be increased when Leflunomide is combined with Oxyphenbutazone."
  ]
  edge [
    source 123
    target 201
    int "Leflunomide may decrease the antihypertensive activities of Aliskiren."
  ]
  edge [
    source 123
    target 124
    int "The risk or severity of adverse effects can be increased when Pazopanib is combined with Leflunomide."
  ]
  edge [
    source 123
    target 229
    int "Leflunomide may decrease the excretion rate of Paromomycin which could result in a higher serum level."
  ]
  edge [
    source 123
    target 200
    int "The metabolism of Zalcitabine can be decreased when combined with Leflunomide."
  ]
  edge [
    source 123
    target 137
    int "The metabolism of Artemether can be decreased when combined with Leflunomide."
  ]
  edge [
    source 123
    target 128
    int "The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Leflunomide."
  ]
  edge [
    source 123
    target 218
    int "The risk or severity of adverse effects can be increased when Altretamine is combined with Leflunomide."
  ]
  edge [
    source 123
    target 199
    int "The risk or severity of adverse effects can be increased when Leflunomide is combined with Meclofenamic acid."
  ]
  edge [
    source 123
    target 221
    int "The risk or severity of adverse effects can be increased when Glatiramer Acetate is combined with Leflunomide."
  ]
  edge [
    source 123
    target 215
    int "The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Leflunomide."
  ]
  edge [
    source 123
    target 189
    int "The risk or severity of adverse effects can be increased when Leflunomide is combined with Aminosalicylic Acid."
  ]
  edge [
    source 123
    target 151
    int "The risk or severity of adverse effects can be increased when Temozolomide is combined with Leflunomide."
  ]
  edge [
    source 124
    target 249
    int "The serum concentration of Pazopanib can be increased when it is combined with Dipyridamole."
  ]
  edge [
    source 124
    target 167
    int "The metabolism of Pazopanib can be decreased when combined with Sildenafil."
  ]
  edge [
    source 124
    target 138
    int "The metabolism of Pazopanib can be decreased when combined with Theophylline."
  ]
  edge [
    source 124
    target 137
    int "Pazopanib may increase the QTc-prolonging activities of Artemether."
  ]
  edge [
    source 124
    target 141
    int "The serum concentration of Pazopanib can be increased when it is combined with Doxorubicin."
  ]
  edge [
    source 124
    target 150
    int "Lithium may increase the QTc-prolonging activities of Pazopanib."
  ]
  edge [
    source 124
    target 197
    int "The serum concentration of Pazopanib can be increased when it is combined with Buspirone."
  ]
  edge [
    source 124
    target 196
    int "The serum concentration of Pazopanib can be increased when it is combined with Dihydroergotamine."
  ]
  edge [
    source 124
    target 219
    int "The serum concentration of Pazopanib can be increased when it is combined with Nisoldipine."
  ]
  edge [
    source 124
    target 220
    int "The serum concentration of Pazopanib can be increased when it is combined with Sulfinpyrazone."
  ]
  edge [
    source 124
    target 224
    int "The serum concentration of Pazopanib can be increased when it is combined with Sumatriptan."
  ]
  edge [
    source 124
    target 232
    int "The serum concentration of Pazopanib can be increased when it is combined with Sorafenib."
  ]
  edge [
    source 124
    target 244
    int "The serum concentration of Pazopanib can be increased when it is combined with Ranolazine."
  ]
  edge [
    source 124
    target 208
    int "The serum concentration of Pazopanib can be increased when it is combined with Trifluoperazine."
  ]
  edge [
    source 124
    target 212
    int "The serum concentration of Pazopanib can be increased when it is combined with Loperamide."
  ]
  edge [
    source 124
    target 174
    int "The serum concentration of Pazopanib can be increased when it is combined with Sertraline."
  ]
  edge [
    source 124
    target 235
    int "The serum concentration of Pazopanib can be increased when it is combined with Lansoprazole."
  ]
  edge [
    source 124
    target 147
    int "Metronidazole may increase the QTc-prolonging activities of Pazopanib."
  ]
  edge [
    source 124
    target 152
    int "The metabolism of Pazopanib can be decreased when combined with Efavirenz."
  ]
  edge [
    source 124
    target 153
    int "The serum concentration of Pazopanib can be increased when it is combined with Testosterone."
  ]
  edge [
    source 124
    target 155
    int "The metabolism of Pazopanib can be decreased when combined with Bortezomib."
  ]
  edge [
    source 124
    target 177
    int "The serum concentration of Pazopanib can be increased when it is combined with Mitoxantrone."
  ]
  edge [
    source 124
    target 205
    int "Foscarnet may increase the QTc-prolonging activities of Pazopanib."
  ]
  edge [
    source 124
    target 237
    int "The metabolism of Pazopanib can be decreased when combined with Rosiglitazone."
  ]
  edge [
    source 124
    target 240
    int "The serum concentration of Pazopanib can be decreased when it is combined with Primidone."
  ]
  edge [
    source 124
    target 246
    int "The serum concentration of Pazopanib can be decreased when it is combined with Bosentan."
  ]
  edge [
    source 124
    target 154
    int "The serum concentration of Pazopanib can be increased when it is combined with Amprenavir."
  ]
  edge [
    source 124
    target 188
    int "Cerivastatin may increase the hepatotoxic activities of Pazopanib."
  ]
  edge [
    source 124
    target 125
    int "Pentamidine may increase the QTc-prolonging activities of Pazopanib."
  ]
  edge [
    source 124
    target 133
    int "Risperidone may increase the QTc-prolonging activities of Pazopanib."
  ]
  edge [
    source 124
    target 156
    int "The serum concentration of Pazopanib can be increased when it is combined with Mefloquine."
  ]
  edge [
    source 124
    target 164
    int "The serum concentration of Pazopanib can be increased when it is combined with Mebendazole."
  ]
  edge [
    source 124
    target 166
    int "The serum concentration of Pazopanib can be increased when it is combined with Tolvaptan."
  ]
  edge [
    source 124
    target 169
    int "Asenapine can cause a decrease in the absorption of Pazopanib resulting in a reduced serum concentration and potentially a decrease in efficacy."
  ]
  edge [
    source 124
    target 171
    int "The serum concentration of Pazopanib can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 124
    target 206
    int "Aripiprazole may increase the QTc-prolonging activities of Pazopanib."
  ]
  edge [
    source 124
    target 168
    int "The serum concentration of Pazopanib can be increased when it is combined with Atenolol."
  ]
  edge [
    source 124
    target 162
    int "The serum concentration of Pazopanib can be increased when it is combined with Spironolactone."
  ]
  edge [
    source 124
    target 191
    int "Trazodone may increase the QTc-prolonging activities of Pazopanib."
  ]
  edge [
    source 124
    target 202
    int "The serum concentration of Pazopanib can be increased when it is combined with Maprotiline."
  ]
  edge [
    source 125
    target 157
    int "The metabolism of Pentamidine can be decreased when combined with Armodafinil."
  ]
  edge [
    source 125
    target 167
    int "The metabolism of Pentamidine can be decreased when combined with Sildenafil."
  ]
  edge [
    source 125
    target 138
    int "The metabolism of Pentamidine can be decreased when combined with Theophylline."
  ]
  edge [
    source 125
    target 137
    int "Pentamidine may increase the QTc-prolonging activities of Artemether."
  ]
  edge [
    source 125
    target 142
    int "The therapeutic efficacy of Pentamidine can be increased when used in combination with Gabapentin."
  ]
  edge [
    source 125
    target 150
    int "Lithium may increase the QTc-prolonging activities of Pentamidine."
  ]
  edge [
    source 125
    target 194
    int "Pargyline may increase the hypoglycemic activities of Pentamidine."
  ]
  edge [
    source 125
    target 197
    int "The metabolism of Buspirone can be decreased when combined with Pentamidine."
  ]
  edge [
    source 125
    target 196
    int "The metabolism of Pentamidine can be decreased when combined with Dihydroergotamine."
  ]
  edge [
    source 125
    target 198
    int "The therapeutic efficacy of Miglitol can be decreased when used in combination with Pentamidine."
  ]
  edge [
    source 125
    target 219
    int "The therapeutic efficacy of Pentamidine can be increased when used in combination with Nisoldipine."
  ]
  edge [
    source 125
    target 232
    int "Sorafenib may increase the QTc-prolonging activities of Pentamidine."
  ]
  edge [
    source 125
    target 244
    int "The metabolism of Pentamidine can be decreased when combined with Ranolazine."
  ]
  edge [
    source 125
    target 247
    int "Mesalazine may increase the hypoglycemic activities of Pentamidine."
  ]
  edge [
    source 125
    target 174
    int "The metabolism of Pentamidine can be decreased when combined with Sertraline."
  ]
  edge [
    source 125
    target 212
    int "The therapeutic efficacy of Pentamidine can be increased when used in combination with Loperamide."
  ]
  edge [
    source 125
    target 147
    int "Metronidazole may increase the QTc-prolonging activities of Pentamidine."
  ]
  edge [
    source 125
    target 152
    int "The metabolism of Pentamidine can be decreased when combined with Efavirenz."
  ]
  edge [
    source 125
    target 153
    int "Testosterone may increase the hypoglycemic activities of Pentamidine."
  ]
  edge [
    source 125
    target 155
    int "The metabolism of Pentamidine can be decreased when combined with Bortezomib."
  ]
  edge [
    source 125
    target 205
    int "The risk or severity of adverse effects can be increased when Pentamidine is combined with Foscarnet."
  ]
  edge [
    source 125
    target 170
    int "The therapeutic efficacy of Metformin can be decreased when used in combination with Pentamidine."
  ]
  edge [
    source 125
    target 236
    int "The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Pentamidine."
  ]
  edge [
    source 125
    target 237
    int "The metabolism of Pentamidine can be decreased when combined with Rosiglitazone."
  ]
  edge [
    source 125
    target 240
    int "The metabolism of Pentamidine can be increased when combined with Primidone."
  ]
  edge [
    source 125
    target 243
    int "The therapeutic efficacy of Miglustat can be decreased when used in combination with Pentamidine."
  ]
  edge [
    source 125
    target 246
    int "The serum concentration of Pentamidine can be decreased when it is combined with Bosentan."
  ]
  edge [
    source 125
    target 234
    int "The therapeutic efficacy of Pentamidine can be increased when used in combination with Lamotrigine."
  ]
  edge [
    source 125
    target 129
    int "Nateglinide may increase the hypoglycemic activities of Pentamidine."
  ]
  edge [
    source 125
    target 133
    int "Risperidone may increase the QTc-prolonging activities of Pentamidine."
  ]
  edge [
    source 125
    target 156
    int "Mefloquine may increase the QTc-prolonging activities of Pentamidine."
  ]
  edge [
    source 125
    target 169
    int "Pentamidine may increase the QTc-prolonging activities of Asenapine."
  ]
  edge [
    source 125
    target 171
    int "The serum concentration of Pentamidine can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 125
    target 207
    int "The therapeutic efficacy of Pentamidine can be increased when used in combination with Zonisamide."
  ]
  edge [
    source 125
    target 206
    int "Aripiprazole may increase the QTc-prolonging activities of Pentamidine."
  ]
  edge [
    source 125
    target 191
    int "Trazodone may increase the QTc-prolonging activities of Pentamidine."
  ]
  edge [
    source 125
    target 202
    int "Maprotiline may increase the QTc-prolonging activities of Pentamidine."
  ]
  edge [
    source 125
    target 189
    int "Aminosalicylic Acid may increase the hypoglycemic activities of Pentamidine."
  ]
  edge [
    source 126
    target 213
    int "The serum concentration of Mercaptopurine can be increased when it is combined with Febuxostat."
  ]
  edge [
    source 126
    target 138
    int "The serum concentration of the active metabolites of Theophylline can be increased when Theophylline is used in combination with Febuxostat."
  ]
  edge [
    source 127
    target 154
    int "The serum concentration of Abacavir can be decreased when it is combined with Amprenavir."
  ]
  edge [
    source 127
    target 179
    int "The serum concentration of Abacavir can be decreased when it is combined with Cilastatin."
  ]
  edge [
    source 128
    target 204
    int "The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Oxyphenbutazone."
  ]
  edge [
    source 128
    target 199
    int "The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Meclofenamic acid."
  ]
  edge [
    source 128
    target 247
    int "The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Mesalazine."
  ]
  edge [
    source 129
    target 194
    int "Pargyline may increase the hypoglycemic activities of Nateglinide."
  ]
  edge [
    source 129
    target 198
    int "Miglitol may increase the hypoglycemic activities of Nateglinide."
  ]
  edge [
    source 129
    target 196
    int "The metabolism of Nateglinide can be decreased when combined with Dihydroergotamine."
  ]
  edge [
    source 129
    target 225
    int "The therapeutic efficacy of Nateglinide can be decreased when used in combination with Epinephrine."
  ]
  edge [
    source 129
    target 226
    int "The therapeutic efficacy of Nateglinide can be decreased when used in combination with Bumetanide."
  ]
  edge [
    source 129
    target 232
    int "The metabolism of Nateglinide can be decreased when combined with Sorafenib."
  ]
  edge [
    source 129
    target 244
    int "The metabolism of Nateglinide can be decreased when combined with Ranolazine."
  ]
  edge [
    source 129
    target 247
    int "Mesalazine may increase the hypoglycemic activities of Nateglinide."
  ]
  edge [
    source 129
    target 158
    int "The therapeutic efficacy of Nateglinide can be decreased when used in combination with Piperazine."
  ]
  edge [
    source 129
    target 174
    int "The metabolism of Nateglinide can be decreased when combined with Sertraline."
  ]
  edge [
    source 129
    target 137
    int "The metabolism of Nateglinide can be decreased when combined with Artemether."
  ]
  edge [
    source 129
    target 152
    int "The metabolism of Nateglinide can be decreased when combined with Efavirenz."
  ]
  edge [
    source 129
    target 153
    int "Testosterone may increase the hypoglycemic activities of Nateglinide."
  ]
  edge [
    source 129
    target 155
    int "The metabolism of Nateglinide can be decreased when combined with Bortezomib."
  ]
  edge [
    source 129
    target 167
    int "The metabolism of Nateglinide can be decreased when combined with Sildenafil."
  ]
  edge [
    source 129
    target 236
    int "Acetohexamide may increase the hypoglycemic activities of Nateglinide."
  ]
  edge [
    source 129
    target 237
    int "Rosiglitazone may increase the hypoglycemic activities of Nateglinide."
  ]
  edge [
    source 129
    target 240
    int "The metabolism of Nateglinide can be increased when combined with Primidone."
  ]
  edge [
    source 129
    target 243
    int "Miglustat may increase the hypoglycemic activities of Nateglinide."
  ]
  edge [
    source 129
    target 246
    int "The serum concentration of Nateglinide can be decreased when it is combined with Bosentan."
  ]
  edge [
    source 129
    target 133
    int "The therapeutic efficacy of Nateglinide can be decreased when used in combination with Risperidone."
  ]
  edge [
    source 129
    target 135
    int "The therapeutic efficacy of Nateglinide can be decreased when used in combination with Everolimus."
  ]
  edge [
    source 129
    target 169
    int "The therapeutic efficacy of Nateglinide can be decreased when used in combination with Asenapine."
  ]
  edge [
    source 129
    target 171
    int "The serum concentration of Nateglinide can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 129
    target 206
    int "The therapeutic efficacy of Nateglinide can be decreased when used in combination with Aripiprazole."
  ]
  edge [
    source 129
    target 170
    int "Metformin may increase the hypoglycemic activities of Nateglinide."
  ]
  edge [
    source 129
    target 215
    int "The therapeutic efficacy of Nateglinide can be decreased when used in combination with Methyclothiazide."
  ]
  edge [
    source 129
    target 189
    int "Aminosalicylic Acid may increase the hypoglycemic activities of Nateglinide."
  ]
  edge [
    source 130
    target 155
    int "The metabolism of Thiabendazole can be decreased when combined with Bortezomib."
  ]
  edge [
    source 130
    target 138
    int "The metabolism of Theophylline can be decreased when combined with Thiabendazole."
  ]
  edge [
    source 131
    target 142
    int "The risk or severity of adverse effects can be increased when Rufinamide is combined with Gabapentin."
  ]
  edge [
    source 131
    target 148
    int "The risk or severity of adverse effects can be increased when Rufinamide is combined with Dantrolene."
  ]
  edge [
    source 131
    target 150
    int "The risk or severity of adverse effects can be increased when Rufinamide is combined with Lithium."
  ]
  edge [
    source 131
    target 195
    int "The risk or severity of adverse effects can be increased when Rufinamide is combined with Entacapone."
  ]
  edge [
    source 131
    target 197
    int "The risk or severity of adverse effects can be increased when Rufinamide is combined with Buspirone."
  ]
  edge [
    source 131
    target 222
    int "The risk or severity of adverse effects can be increased when Rufinamide is combined with Metaxalone."
  ]
  edge [
    source 131
    target 231
    int "The risk or severity of adverse effects can be increased when Rufinamide is combined with Carisoprodol."
  ]
  edge [
    source 131
    target 152
    int "The risk or severity of adverse effects can be increased when Rufinamide is combined with Efavirenz."
  ]
  edge [
    source 131
    target 240
    int "The serum concentration of Rufinamide can be decreased when it is combined with Primidone."
  ]
  edge [
    source 131
    target 234
    int "The risk or severity of adverse effects can be increased when Rufinamide is combined with Lamotrigine."
  ]
  edge [
    source 131
    target 133
    int "The risk or severity of adverse effects can be increased when Rufinamide is combined with Risperidone."
  ]
  edge [
    source 131
    target 156
    int "The therapeutic efficacy of Rufinamide can be decreased when used in combination with Mefloquine."
  ]
  edge [
    source 131
    target 160
    int "The risk or severity of adverse effects can be increased when Rufinamide is combined with Chlorzoxazone."
  ]
  edge [
    source 131
    target 169
    int "The risk or severity of adverse effects can be increased when Rufinamide is combined with Asenapine."
  ]
  edge [
    source 131
    target 207
    int "The risk or severity of adverse effects can be increased when Rufinamide is combined with Zonisamide."
  ]
  edge [
    source 131
    target 173
    int "The risk or severity of adverse effects can be increased when Rufinamide is combined with Tiagabine."
  ]
  edge [
    source 131
    target 184
    int "The risk or severity of adverse effects can be increased when Rufinamide is combined with Dexmedetomidine."
  ]
  edge [
    source 131
    target 206
    int "The serum concentration of Aripiprazole can be decreased when it is combined with Rufinamide."
  ]
  edge [
    source 131
    target 208
    int "The risk or severity of adverse effects can be increased when Rufinamide is combined with Trifluoperazine."
  ]
  edge [
    source 131
    target 191
    int "The risk or severity of adverse effects can be increased when Rufinamide is combined with Trazodone."
  ]
  edge [
    source 131
    target 202
    int "The risk or severity of adverse effects can be increased when Rufinamide is combined with Maprotiline."
  ]
  edge [
    source 132
    target 249
    int "The therapeutic efficacy of Memantine can be decreased when used in combination with Dipyridamole."
  ]
  edge [
    source 132
    target 192
    int "The therapeutic efficacy of Mecamylamine can be decreased when used in combination with Memantine."
  ]
  edge [
    source 132
    target 168
    int "Memantine may increase the bradycardic activities of Atenolol."
  ]
  edge [
    source 132
    target 159
    int "The risk or severity of adverse effects can be increased when Memantine is combined with Cevimeline."
  ]
  edge [
    source 132
    target 239
    int "The risk or severity of adverse effects can be increased when Memantine is combined with Carbachol."
  ]
  edge [
    source 132
    target 216
    int "The therapeutic efficacy of Vecuronium can be decreased when used in combination with Memantine."
  ]
  edge [
    source 132
    target 217
    int "The risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Memantine."
  ]
  edge [
    source 132
    target 169
    int "Memantine may increase the bradycardic activities of Asenapine."
  ]
  edge [
    source 133
    target 167
    int "Sildenafil may increase the hypotensive activities of Risperidone."
  ]
  edge [
    source 133
    target 228
    int "Bretylium may increase the hypotensive activities of Risperidone."
  ]
  edge [
    source 133
    target 225
    int "Risperidone may increase the antihypertensive activities of Epinephrine."
  ]
  edge [
    source 133
    target 137
    int "Risperidone may increase the QTc-prolonging activities of Artemether."
  ]
  edge [
    source 133
    target 142
    int "The risk or severity of adverse effects can be increased when Risperidone is combined with Gabapentin."
  ]
  edge [
    source 133
    target 150
    int "Lithium may increase the neurotoxic activities of Risperidone."
  ]
  edge [
    source 133
    target 195
    int "The risk or severity of adverse effects can be increased when Risperidone is combined with Entacapone."
  ]
  edge [
    source 133
    target 197
    int "The risk or severity of adverse effects can be increased when Buspirone is combined with Risperidone."
  ]
  edge [
    source 133
    target 198
    int "The therapeutic efficacy of Miglitol can be decreased when used in combination with Risperidone."
  ]
  edge [
    source 133
    target 196
    int "The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Risperidone."
  ]
  edge [
    source 133
    target 219
    int "Nisoldipine may increase the hypotensive activities of Risperidone."
  ]
  edge [
    source 133
    target 222
    int "The risk or severity of adverse effects can be increased when Risperidone is combined with Metaxalone."
  ]
  edge [
    source 133
    target 224
    int "The risk or severity of adverse effects can be increased when Sumatriptan is combined with Risperidone."
  ]
  edge [
    source 133
    target 230
    int "Isosorbide Dinitrate may increase the hypotensive activities of Risperidone."
  ]
  edge [
    source 133
    target 231
    int "The risk or severity of adverse effects can be increased when Risperidone is combined with Carisoprodol."
  ]
  edge [
    source 133
    target 174
    int "The metabolism of Risperidone can be decreased when combined with Sertraline."
  ]
  edge [
    source 133
    target 226
    int "The risk or severity of adverse effects can be increased when Bumetanide is combined with Risperidone."
  ]
  edge [
    source 133
    target 152
    int "The risk or severity of adverse effects can be increased when Risperidone is combined with Efavirenz."
  ]
  edge [
    source 133
    target 249
    int "Dipyridamole may increase the hypotensive activities of Risperidone."
  ]
  edge [
    source 133
    target 155
    int "Bortezomib may increase the hypotensive activities of Risperidone."
  ]
  edge [
    source 133
    target 244
    int "The metabolism of Risperidone can be decreased when combined with Ranolazine."
  ]
  edge [
    source 133
    target 168
    int "Atenolol may increase the hypotensive activities of Risperidone."
  ]
  edge [
    source 133
    target 170
    int "The therapeutic efficacy of Metformin can be decreased when used in combination with Risperidone."
  ]
  edge [
    source 133
    target 236
    int "The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Risperidone."
  ]
  edge [
    source 133
    target 237
    int "The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Risperidone."
  ]
  edge [
    source 133
    target 238
    int "Risperidone may increase the sedative activities of Pramipexole."
  ]
  edge [
    source 133
    target 241
    int "Tolazoline may increase the hypotensive activities of Risperidone."
  ]
  edge [
    source 133
    target 243
    int "The therapeutic efficacy of Miglustat can be decreased when used in combination with Risperidone."
  ]
  edge [
    source 133
    target 246
    int "The serum concentration of Risperidone can be decreased when it is combined with Bosentan."
  ]
  edge [
    source 133
    target 234
    int "The risk or severity of adverse effects can be increased when Risperidone is combined with Lamotrigine."
  ]
  edge [
    source 133
    target 138
    int "Theophylline may increase the hypotensive activities of Risperidone."
  ]
  edge [
    source 133
    target 161
    int "Minoxidil may increase the hypotensive activities of Risperidone."
  ]
  edge [
    source 133
    target 162
    int "Spironolactone may increase the hypotensive activities of Risperidone."
  ]
  edge [
    source 133
    target 166
    int "The serum concentration of Tolvaptan can be increased when it is combined with Risperidone."
  ]
  edge [
    source 133
    target 169
    int "Risperidone may increase the antihypertensive activities of Asenapine."
  ]
  edge [
    source 133
    target 171
    int "The serum concentration of Risperidone can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 133
    target 207
    int "The risk or severity of adverse effects can be increased when Risperidone is combined with Zonisamide."
  ]
  edge [
    source 133
    target 173
    int "The risk or severity of adverse effects can be increased when Risperidone is combined with Tiagabine."
  ]
  edge [
    source 133
    target 184
    int "Dexmedetomidine may increase the hypotensive activities of Risperidone."
  ]
  edge [
    source 133
    target 201
    int "Aliskiren may increase the hypotensive activities of Risperidone."
  ]
  edge [
    source 133
    target 206
    int "Risperidone may increase the antihypertensive activities of Aripiprazole."
  ]
  edge [
    source 133
    target 208
    int "Risperidone may increase the antihypertensive activities of Trifluoperazine."
  ]
  edge [
    source 133
    target 212
    int "The risk or severity of hypotension can be increased when Risperidone is combined with Loperamide."
  ]
  edge [
    source 133
    target 160
    int "The risk or severity of adverse effects can be increased when Risperidone is combined with Chlorzoxazone."
  ]
  edge [
    source 133
    target 188
    int "The serum concentration of Cerivastatin can be increased when it is combined with Risperidone."
  ]
  edge [
    source 133
    target 148
    int "The risk or severity of adverse effects can be increased when Risperidone is combined with Dantrolene."
  ]
  edge [
    source 133
    target 240
    int "The metabolism of Risperidone can be increased when combined with Primidone."
  ]
  edge [
    source 133
    target 191
    int "Trazodone may increase the antihypertensive activities of Risperidone."
  ]
  edge [
    source 133
    target 192
    int "Mecamylamine may increase the hypotensive activities of Risperidone."
  ]
  edge [
    source 133
    target 202
    int "The risk or severity of adverse effects can be increased when Risperidone is combined with Maprotiline."
  ]
  edge [
    source 133
    target 215
    int "The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Risperidone."
  ]
  edge [
    source 135
    target 249
    int "The serum concentration of Everolimus can be increased when it is combined with Dipyridamole."
  ]
  edge [
    source 135
    target 167
    int "The serum concentration of Everolimus can be increased when it is combined with Sildenafil."
  ]
  edge [
    source 135
    target 141
    int "The serum concentration of Everolimus can be increased when it is combined with Doxorubicin."
  ]
  edge [
    source 135
    target 197
    int "The serum concentration of Everolimus can be increased when it is combined with Buspirone."
  ]
  edge [
    source 135
    target 198
    int "The therapeutic efficacy of Miglitol can be decreased when used in combination with Everolimus."
  ]
  edge [
    source 135
    target 219
    int "The serum concentration of Everolimus can be increased when it is combined with Nisoldipine."
  ]
  edge [
    source 135
    target 220
    int "The serum concentration of Everolimus can be increased when it is combined with Sulfinpyrazone."
  ]
  edge [
    source 135
    target 224
    int "The serum concentration of Everolimus can be increased when it is combined with Sumatriptan."
  ]
  edge [
    source 135
    target 232
    int "The serum concentration of Everolimus can be increased when it is combined with Sorafenib."
  ]
  edge [
    source 135
    target 244
    int "The serum concentration of Everolimus can be increased when it is combined with Ranolazine."
  ]
  edge [
    source 135
    target 174
    int "The serum concentration of Everolimus can be increased when it is combined with Sertraline."
  ]
  edge [
    source 135
    target 235
    int "The serum concentration of Everolimus can be increased when it is combined with Lansoprazole."
  ]
  edge [
    source 135
    target 152
    int "The serum concentration of Everolimus can be decreased when it is combined with Efavirenz."
  ]
  edge [
    source 135
    target 153
    int "The serum concentration of Everolimus can be increased when it is combined with Testosterone."
  ]
  edge [
    source 135
    target 155
    int "The serum concentration of Everolimus can be increased when it is combined with Bortezomib."
  ]
  edge [
    source 135
    target 177
    int "The serum concentration of Everolimus can be increased when it is combined with Mitoxantrone."
  ]
  edge [
    source 135
    target 170
    int "The therapeutic efficacy of Metformin can be decreased when used in combination with Everolimus."
  ]
  edge [
    source 135
    target 236
    int "The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Everolimus."
  ]
  edge [
    source 135
    target 237
    int "The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Everolimus."
  ]
  edge [
    source 135
    target 240
    int "The serum concentration of Everolimus can be decreased when it is combined with Primidone."
  ]
  edge [
    source 135
    target 243
    int "The therapeutic efficacy of Miglustat can be decreased when used in combination with Everolimus."
  ]
  edge [
    source 135
    target 246
    int "The serum concentration of Everolimus can be decreased when it is combined with Bosentan."
  ]
  edge [
    source 135
    target 154
    int "The serum concentration of Everolimus can be increased when it is combined with Amprenavir."
  ]
  edge [
    source 135
    target 156
    int "The serum concentration of Everolimus can be increased when it is combined with Mefloquine."
  ]
  edge [
    source 135
    target 196
    int "The serum concentration of Everolimus can be increased when it is combined with Dihydroergotamine."
  ]
  edge [
    source 135
    target 162
    int "The serum concentration of Everolimus can be increased when it is combined with Spironolactone."
  ]
  edge [
    source 135
    target 164
    int "The serum concentration of Everolimus can be increased when it is combined with Mebendazole."
  ]
  edge [
    source 135
    target 166
    int "The serum concentration of Everolimus can be increased when it is combined with Tolvaptan."
  ]
  edge [
    source 135
    target 171
    int "The serum concentration of Everolimus can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 135
    target 208
    int "The serum concentration of Everolimus can be increased when it is combined with Trifluoperazine."
  ]
  edge [
    source 135
    target 212
    int "The serum concentration of Everolimus can be increased when it is combined with Loperamide."
  ]
  edge [
    source 135
    target 188
    int "The risk or severity of rhabdomyolysis can be increased when Everolimus is combined with Cerivastatin."
  ]
  edge [
    source 135
    target 168
    int "The serum concentration of Everolimus can be increased when it is combined with Atenolol."
  ]
  edge [
    source 135
    target 202
    int "The serum concentration of Everolimus can be increased when it is combined with Maprotiline."
  ]
  edge [
    source 136
    target 242
    int "Tranexamic Acid may increase the thrombogenic activities of Ulipristal."
  ]
  edge [
    source 136
    target 167
    int "The serum concentration of Ulipristal can be increased when it is combined with Sildenafil."
  ]
  edge [
    source 136
    target 137
    int "The serum concentration of Ulipristal can be decreased when it is combined with Artemether."
  ]
  edge [
    source 136
    target 138
    int "The metabolism of Ulipristal can be decreased when combined with Theophylline."
  ]
  edge [
    source 136
    target 152
    int "The serum concentration of Ulipristal can be decreased when it is combined with Efavirenz."
  ]
  edge [
    source 136
    target 155
    int "The serum concentration of Ulipristal can be increased when it is combined with Bortezomib."
  ]
  edge [
    source 136
    target 196
    int "The serum concentration of Ulipristal can be increased when it is combined with Dihydroergotamine."
  ]
  edge [
    source 136
    target 171
    int "The serum concentration of Ulipristal can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 136
    target 240
    int "The serum concentration of Ulipristal can be decreased when it is combined with Primidone."
  ]
  edge [
    source 136
    target 244
    int "The serum concentration of Ulipristal can be increased when it is combined with Ranolazine."
  ]
  edge [
    source 136
    target 246
    int "The serum concentration of Ulipristal can be decreased when it is combined with Bosentan."
  ]
  edge [
    source 136
    target 234
    int "Ulipristal may increase the excretion rate of Lamotrigine which could result in a lower serum level and potentially a reduction in efficacy."
  ]
  edge [
    source 137
    target 157
    int "The metabolism of Artemether can be decreased when combined with Armodafinil."
  ]
  edge [
    source 137
    target 167
    int "The metabolism of Artemether can be decreased when combined with Sildenafil."
  ]
  edge [
    source 137
    target 141
    int "The metabolism of Doxorubicin can be decreased when combined with Artemether."
  ]
  edge [
    source 137
    target 142
    int "The therapeutic efficacy of Artemether can be increased when used in combination with Gabapentin."
  ]
  edge [
    source 137
    target 149
    int "The risk or severity of QTc prolongation can be increased when Halofantrine is combined with Artemether."
  ]
  edge [
    source 137
    target 150
    int "Lithium may increase the QTc-prolonging activities of Artemether."
  ]
  edge [
    source 137
    target 196
    int "The metabolism of Artemether can be decreased when combined with Dihydroergotamine."
  ]
  edge [
    source 137
    target 197
    int "The metabolism of Buspirone can be decreased when combined with Artemether."
  ]
  edge [
    source 137
    target 182
    int "The metabolism of Mephenytoin can be decreased when combined with Artemether."
  ]
  edge [
    source 137
    target 214
    int "The risk or severity of QTc prolongation can be increased when Proguanil is combined with Artemether."
  ]
  edge [
    source 137
    target 219
    int "The therapeutic efficacy of Artemether can be increased when used in combination with Nisoldipine."
  ]
  edge [
    source 137
    target 232
    int "Sorafenib may increase the QTc-prolonging activities of Artemether."
  ]
  edge [
    source 137
    target 212
    int "The metabolism of Loperamide can be decreased when combined with Artemether."
  ]
  edge [
    source 137
    target 158
    int "The metabolism of Piperazine can be decreased when combined with Artemether."
  ]
  edge [
    source 137
    target 174
    int "Sertraline may increase the QTc-prolonging activities of Artemether."
  ]
  edge [
    source 137
    target 147
    int "Metronidazole may increase the QTc-prolonging activities of Artemether."
  ]
  edge [
    source 137
    target 152
    int "The serum concentration of Artemether can be decreased when it is combined with Efavirenz."
  ]
  edge [
    source 137
    target 155
    int "Bortezomib may increase the QTc-prolonging activities of Artemether."
  ]
  edge [
    source 137
    target 159
    int "The metabolism of Cevimeline can be decreased when combined with Artemether."
  ]
  edge [
    source 137
    target 244
    int "Ranolazine may increase the QTc-prolonging activities of Artemether."
  ]
  edge [
    source 137
    target 205
    int "Foscarnet may increase the QTc-prolonging activities of Artemether."
  ]
  edge [
    source 137
    target 240
    int "The metabolism of Artemether can be increased when combined with Primidone."
  ]
  edge [
    source 137
    target 246
    int "The serum concentration of Artemether can be decreased when it is combined with Bosentan."
  ]
  edge [
    source 137
    target 234
    int "The therapeutic efficacy of Artemether can be increased when used in combination with Lamotrigine."
  ]
  edge [
    source 137
    target 154
    int "The metabolism of Amprenavir can be decreased when combined with Artemether."
  ]
  edge [
    source 137
    target 138
    int "The metabolism of Theophylline can be decreased when combined with Artemether."
  ]
  edge [
    source 137
    target 181
    int "The metabolism of Dopamine can be decreased when combined with Artemether."
  ]
  edge [
    source 137
    target 156
    int "The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Artemether."
  ]
  edge [
    source 137
    target 160
    int "The metabolism of Chlorzoxazone can be decreased when combined with Artemether."
  ]
  edge [
    source 137
    target 169
    int "The risk or severity of QTc prolongation can be increased when Asenapine is combined with Artemether."
  ]
  edge [
    source 137
    target 171
    int "The serum concentration of Artemether can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 137
    target 207
    int "The therapeutic efficacy of Artemether can be increased when used in combination with Zonisamide."
  ]
  edge [
    source 137
    target 206
    int "The serum concentration of Aripiprazole can be decreased when it is combined with Artemether."
  ]
  edge [
    source 137
    target 208
    int "The serum concentration of Trifluoperazine can be increased when it is combined with Artemether."
  ]
  edge [
    source 137
    target 200
    int "The metabolism of Zalcitabine can be decreased when combined with Artemether."
  ]
  edge [
    source 137
    target 191
    int "Trazodone may increase the QTc-prolonging activities of Artemether."
  ]
  edge [
    source 137
    target 202
    int "Maprotiline may increase the QTc-prolonging activities of Artemether."
  ]
  edge [
    source 138
    target 167
    int "The risk or severity of adverse effects can be increased when Sildenafil is combined with Theophylline."
  ]
  edge [
    source 138
    target 228
    int "Theophylline may increase the antihypertensive activities of Bretylium."
  ]
  edge [
    source 138
    target 150
    int "The serum concentration of Lithium can be decreased when it is combined with Theophylline."
  ]
  edge [
    source 138
    target 194
    int "Theophylline may increase the antihypertensive activities of Pargyline."
  ]
  edge [
    source 138
    target 154
    int "The serum concentration of Theophylline can be decreased when it is combined with Amprenavir."
  ]
  edge [
    source 138
    target 182
    int "The metabolism of Mephenytoin can be decreased when combined with Theophylline."
  ]
  edge [
    source 138
    target 193
    int "The metabolism of Flutamide can be decreased when combined with Theophylline."
  ]
  edge [
    source 138
    target 196
    int "The metabolism of Theophylline can be decreased when combined with Dihydroergotamine."
  ]
  edge [
    source 138
    target 219
    int "Theophylline may increase the antihypertensive activities of Nisoldipine."
  ]
  edge [
    source 138
    target 225
    int "Theophylline may increase the hypotensive activities of Epinephrine."
  ]
  edge [
    source 138
    target 232
    int "The metabolism of Theophylline can be decreased when combined with Sorafenib."
  ]
  edge [
    source 138
    target 214
    int "The metabolism of Proguanil can be decreased when combined with Theophylline."
  ]
  edge [
    source 138
    target 174
    int "The metabolism of Sertraline can be decreased when combined with Theophylline."
  ]
  edge [
    source 138
    target 230
    int "Theophylline may increase the vasodilatory activities of Isosorbide Dinitrate."
  ]
  edge [
    source 138
    target 152
    int "The metabolism of Theophylline can be decreased when combined with Efavirenz."
  ]
  edge [
    source 138
    target 249
    int "The risk or severity of adverse effects can be increased when Dipyridamole is combined with Theophylline."
  ]
  edge [
    source 138
    target 155
    int "The metabolism of Theophylline can be decreased when combined with Bortezomib."
  ]
  edge [
    source 138
    target 180
    int "The serum concentration of Theophylline can be increased when it is combined with Disulfiram."
  ]
  edge [
    source 138
    target 244
    int "The metabolism of Theophylline can be decreased when combined with Ranolazine."
  ]
  edge [
    source 138
    target 168
    int "Atenolol may decrease the bronchodilatory activities of Theophylline."
  ]
  edge [
    source 138
    target 237
    int "The metabolism of Theophylline can be decreased when combined with Rosiglitazone."
  ]
  edge [
    source 138
    target 240
    int "The metabolism of Theophylline can be increased when combined with Primidone."
  ]
  edge [
    source 138
    target 241
    int "Theophylline may increase the hypotensive activities of Tolazoline."
  ]
  edge [
    source 138
    target 246
    int "The serum concentration of Theophylline can be decreased when it is combined with Bosentan."
  ]
  edge [
    source 138
    target 179
    int "The serum concentration of Theophylline can be decreased when it is combined with Cilastatin."
  ]
  edge [
    source 138
    target 160
    int "The metabolism of Chlorzoxazone can be decreased when combined with Theophylline."
  ]
  edge [
    source 138
    target 161
    int "Theophylline may increase the antihypertensive activities of Minoxidil."
  ]
  edge [
    source 138
    target 169
    int "Theophylline may increase the hypotensive activities of Asenapine."
  ]
  edge [
    source 138
    target 171
    int "The serum concentration of Theophylline can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 138
    target 201
    int "Theophylline may increase the antihypertensive activities of Aliskiren."
  ]
  edge [
    source 138
    target 206
    int "Theophylline may increase the hypotensive activities of Aripiprazole."
  ]
  edge [
    source 138
    target 208
    int "Theophylline may increase the hypotensive activities of Trifluoperazine."
  ]
  edge [
    source 138
    target 165
    int "The metabolism of Pyrazinamide can be decreased when combined with Theophylline."
  ]
  edge [
    source 138
    target 190
    int "The serum concentration of Theophylline can be increased when it is combined with Allopurinol."
  ]
  edge [
    source 138
    target 191
    int "Theophylline may increase the hypotensive activities of Trazodone."
  ]
  edge [
    source 138
    target 192
    int "Theophylline may increase the antihypertensive activities of Mecamylamine."
  ]
  edge [
    source 138
    target 202
    int "The metabolism of Maprotiline can be decreased when combined with Theophylline."
  ]
  edge [
    source 138
    target 253
    int "The serum concentration of Theophylline can be increased when it is combined with Propylthiouracil."
  ]
  edge [
    source 140
    target 167
    int "The metabolism of Tinidazole can be decreased when combined with Sildenafil."
  ]
  edge [
    source 140
    target 155
    int "The metabolism of Tinidazole can be decreased when combined with Bortezomib."
  ]
  edge [
    source 140
    target 171
    int "The serum concentration of Tinidazole can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 140
    target 180
    int "The risk or severity of adverse effects can be increased when Tinidazole is combined with Disulfiram."
  ]
  edge [
    source 140
    target 196
    int "The metabolism of Tinidazole can be decreased when combined with Dihydroergotamine."
  ]
  edge [
    source 140
    target 240
    int "The metabolism of Tinidazole can be increased when combined with Primidone."
  ]
  edge [
    source 140
    target 244
    int "The metabolism of Tinidazole can be decreased when combined with Ranolazine."
  ]
  edge [
    source 140
    target 246
    int "The serum concentration of Tinidazole can be decreased when it is combined with Bosentan."
  ]
  edge [
    source 141
    target 249
    int "The serum concentration of Doxorubicin can be increased when it is combined with Dipyridamole."
  ]
  edge [
    source 141
    target 167
    int "The metabolism of Doxorubicin can be decreased when combined with Sildenafil."
  ]
  edge [
    source 141
    target 213
    int "Doxorubicin may increase the hepatotoxic activities of Mercaptopurine."
  ]
  edge [
    source 141
    target 197
    int "The serum concentration of Doxorubicin can be increased when it is combined with Buspirone."
  ]
  edge [
    source 141
    target 182
    int "The metabolism of Mephenytoin can be decreased when combined with Doxorubicin."
  ]
  edge [
    source 141
    target 196
    int "The serum concentration of Doxorubicin can be increased when it is combined with Dihydroergotamine."
  ]
  edge [
    source 141
    target 219
    int "The serum concentration of Doxorubicin can be increased when it is combined with Nisoldipine."
  ]
  edge [
    source 141
    target 220
    int "The serum concentration of Doxorubicin can be increased when it is combined with Sulfinpyrazone."
  ]
  edge [
    source 141
    target 224
    int "The serum concentration of Doxorubicin can be increased when it is combined with Sumatriptan."
  ]
  edge [
    source 141
    target 232
    int "The metabolism of Sorafenib can be decreased when combined with Doxorubicin."
  ]
  edge [
    source 141
    target 244
    int "The serum concentration of Doxorubicin can be increased when it is combined with Ranolazine."
  ]
  edge [
    source 141
    target 174
    int "The metabolism of Doxorubicin can be decreased when combined with Sertraline."
  ]
  edge [
    source 141
    target 235
    int "The serum concentration of Doxorubicin can be increased when it is combined with Lansoprazole."
  ]
  edge [
    source 141
    target 152
    int "The metabolism of Efavirenz can be decreased when combined with Doxorubicin."
  ]
  edge [
    source 141
    target 153
    int "The metabolism of Testosterone can be decreased when combined with Doxorubicin."
  ]
  edge [
    source 141
    target 155
    int "The metabolism of Doxorubicin can be decreased when combined with Bortezomib."
  ]
  edge [
    source 141
    target 177
    int "The serum concentration of Doxorubicin can be increased when it is combined with Mitoxantrone."
  ]
  edge [
    source 141
    target 240
    int "The metabolism of Doxorubicin can be increased when combined with Primidone."
  ]
  edge [
    source 141
    target 246
    int "The serum concentration of Doxorubicin can be decreased when it is combined with Bosentan."
  ]
  edge [
    source 141
    target 154
    int "The serum concentration of Doxorubicin can be increased when it is combined with Amprenavir."
  ]
  edge [
    source 141
    target 188
    int "The serum concentration of Cerivastatin can be increased when it is combined with Doxorubicin."
  ]
  edge [
    source 141
    target 156
    int "The serum concentration of Doxorubicin can be increased when it is combined with Mefloquine."
  ]
  edge [
    source 141
    target 164
    int "The serum concentration of Doxorubicin can be increased when it is combined with Mebendazole."
  ]
  edge [
    source 141
    target 166
    int "The serum concentration of Tolvaptan can be increased when it is combined with Doxorubicin."
  ]
  edge [
    source 141
    target 171
    int "The serum concentration of Doxorubicin can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 141
    target 208
    int "The serum concentration of Doxorubicin can be increased when it is combined with Trifluoperazine."
  ]
  edge [
    source 141
    target 212
    int "The metabolism of Loperamide can be decreased when combined with Doxorubicin."
  ]
  edge [
    source 141
    target 168
    int "The serum concentration of Doxorubicin can be increased when it is combined with Atenolol."
  ]
  edge [
    source 141
    target 162
    int "The serum concentration of Doxorubicin can be increased when it is combined with Spironolactone."
  ]
  edge [
    source 141
    target 191
    int "The serum concentration of Doxorubicin can be decreased when it is combined with Trazodone."
  ]
  edge [
    source 141
    target 202
    int "The serum concentration of Doxorubicin can be increased when it is combined with Maprotiline."
  ]
  edge [
    source 142
    target 195
    int "The risk or severity of adverse effects can be increased when Gabapentin is combined with Entacapone."
  ]
  edge [
    source 142
    target 148
    int "The risk or severity of adverse effects can be increased when Gabapentin is combined with Dantrolene."
  ]
  edge [
    source 142
    target 150
    int "The risk or severity of adverse effects can be increased when Gabapentin is combined with Lithium."
  ]
  edge [
    source 142
    target 197
    int "The risk or severity of adverse effects can be increased when Buspirone is combined with Gabapentin."
  ]
  edge [
    source 142
    target 222
    int "The risk or severity of adverse effects can be increased when Gabapentin is combined with Metaxalone."
  ]
  edge [
    source 142
    target 225
    int "The risk or severity of hypotension can be increased when Epinephrine is combined with Gabapentin."
  ]
  edge [
    source 142
    target 231
    int "The risk or severity of adverse effects can be increased when Gabapentin is combined with Carisoprodol."
  ]
  edge [
    source 142
    target 174
    int "The risk or severity of adverse effects can be increased when Gabapentin is combined with Sertraline."
  ]
  edge [
    source 142
    target 152
    int "The serum concentration of Gabapentin can be decreased when it is combined with Efavirenz."
  ]
  edge [
    source 142
    target 238
    int "Gabapentin may increase the sedative activities of Pramipexole."
  ]
  edge [
    source 142
    target 240
    int "The metabolism of Gabapentin can be increased when combined with Primidone."
  ]
  edge [
    source 142
    target 241
    int "The risk or severity of hypotension can be increased when Tolazoline is combined with Gabapentin."
  ]
  edge [
    source 142
    target 234
    int "The risk or severity of adverse effects can be increased when Gabapentin is combined with Lamotrigine."
  ]
  edge [
    source 142
    target 156
    int "The therapeutic efficacy of Gabapentin can be decreased when used in combination with Mefloquine."
  ]
  edge [
    source 142
    target 160
    int "The risk or severity of adverse effects can be increased when Gabapentin is combined with Chlorzoxazone."
  ]
  edge [
    source 142
    target 169
    int "The risk or severity of adverse effects can be increased when Gabapentin is combined with Asenapine."
  ]
  edge [
    source 142
    target 207
    int "The risk or severity of adverse effects can be increased when Gabapentin is combined with Zonisamide."
  ]
  edge [
    source 142
    target 173
    int "The risk or severity of adverse effects can be increased when Gabapentin is combined with Tiagabine."
  ]
  edge [
    source 142
    target 184
    int "The risk or severity of adverse effects can be increased when Gabapentin is combined with Dexmedetomidine."
  ]
  edge [
    source 142
    target 206
    int "The risk or severity of adverse effects can be increased when Gabapentin is combined with Aripiprazole."
  ]
  edge [
    source 142
    target 208
    int "The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Gabapentin."
  ]
  edge [
    source 142
    target 191
    int "The risk or severity of adverse effects can be increased when Gabapentin is combined with Trazodone."
  ]
  edge [
    source 142
    target 202
    int "The risk or severity of adverse effects can be increased when Gabapentin is combined with Maprotiline."
  ]
  edge [
    source 144
    target 166
    int "The serum concentration of Tolvaptan can be increased when it is combined with Anastrozole."
  ]
  edge [
    source 144
    target 196
    int "The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Anastrozole."
  ]
  edge [
    source 144
    target 188
    int "The serum concentration of Cerivastatin can be increased when it is combined with Anastrozole."
  ]
  edge [
    source 146
    target 174
    int "Sertraline may increase the antiplatelet activities of Chlorphenesin."
  ]
  edge [
    source 146
    target 204
    int "The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Chlorphenesin."
  ]
  edge [
    source 146
    target 199
    int "The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Chlorphenesin."
  ]
  edge [
    source 146
    target 206
    int "The serum concentration of Aripiprazole can be decreased when it is combined with Chlorphenesin."
  ]
  edge [
    source 146
    target 217
    int "The risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Chlorphenesin."
  ]
  edge [
    source 146
    target 247
    int "The risk or severity of adverse effects can be increased when Mesalazine is combined with Chlorphenesin."
  ]
  edge [
    source 147
    target 167
    int "The metabolism of Metronidazole can be decreased when combined with Sildenafil."
  ]
  edge [
    source 147
    target 232
    int "The metabolism of Metronidazole can be decreased when combined with Sorafenib."
  ]
  edge [
    source 147
    target 152
    int "The metabolism of Metronidazole can be decreased when combined with Efavirenz."
  ]
  edge [
    source 147
    target 155
    int "The metabolism of Metronidazole can be decreased when combined with Bortezomib."
  ]
  edge [
    source 147
    target 164
    int "The risk or severity of adverse effects can be increased when Mebendazole is combined with Metronidazole."
  ]
  edge [
    source 147
    target 196
    int "The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Metronidazole."
  ]
  edge [
    source 147
    target 171
    int "The serum concentration of Metronidazole can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 147
    target 180
    int "The risk or severity of adverse effects can be increased when Disulfiram is combined with Metronidazole."
  ]
  edge [
    source 147
    target 188
    int "The serum concentration of Cerivastatin can be increased when it is combined with Metronidazole."
  ]
  edge [
    source 147
    target 240
    int "The serum concentration of Metronidazole can be decreased when it is combined with Primidone."
  ]
  edge [
    source 147
    target 166
    int "The serum concentration of Tolvaptan can be increased when it is combined with Metronidazole."
  ]
  edge [
    source 147
    target 169
    int "Metronidazole may increase the QTc-prolonging activities of Asenapine."
  ]
  edge [
    source 147
    target 244
    int "The metabolism of Metronidazole can be decreased when combined with Ranolazine."
  ]
  edge [
    source 147
    target 246
    int "The serum concentration of Metronidazole can be decreased when it is combined with Bosentan."
  ]
  edge [
    source 148
    target 167
    int "The metabolism of Dantrolene can be decreased when combined with Sildenafil."
  ]
  edge [
    source 148
    target 150
    int "The risk or severity of adverse effects can be increased when Dantrolene is combined with Lithium."
  ]
  edge [
    source 148
    target 195
    int "The risk or severity of adverse effects can be increased when Entacapone is combined with Dantrolene."
  ]
  edge [
    source 148
    target 197
    int "The risk or severity of adverse effects can be increased when Buspirone is combined with Dantrolene."
  ]
  edge [
    source 148
    target 196
    int "The metabolism of Dantrolene can be decreased when combined with Dihydroergotamine."
  ]
  edge [
    source 148
    target 222
    int "The risk or severity of adverse effects can be increased when Metaxalone is combined with Dantrolene."
  ]
  edge [
    source 148
    target 231
    int "The risk or severity of adverse effects can be increased when Carisoprodol is combined with Dantrolene."
  ]
  edge [
    source 148
    target 244
    int "The metabolism of Dantrolene can be decreased when combined with Ranolazine."
  ]
  edge [
    source 148
    target 174
    int "The risk or severity of adverse effects can be increased when Dantrolene is combined with Sertraline."
  ]
  edge [
    source 148
    target 152
    int "The risk or severity of adverse effects can be increased when Efavirenz is combined with Dantrolene."
  ]
  edge [
    source 148
    target 155
    int "The metabolism of Dantrolene can be decreased when combined with Bortezomib."
  ]
  edge [
    source 148
    target 216
    int "Dantrolene may increase the neuromuscular blocking activities of Vecuronium."
  ]
  edge [
    source 148
    target 238
    int "Dantrolene may increase the sedative activities of Pramipexole."
  ]
  edge [
    source 148
    target 240
    int "The metabolism of Dantrolene can be increased when combined with Primidone."
  ]
  edge [
    source 148
    target 246
    int "The serum concentration of Dantrolene can be decreased when it is combined with Bosentan."
  ]
  edge [
    source 148
    target 234
    int "The risk or severity of adverse effects can be increased when Lamotrigine is combined with Dantrolene."
  ]
  edge [
    source 148
    target 160
    int "The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Dantrolene."
  ]
  edge [
    source 148
    target 169
    int "The risk or severity of adverse effects can be increased when Asenapine is combined with Dantrolene."
  ]
  edge [
    source 148
    target 171
    int "The serum concentration of Dantrolene can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 148
    target 207
    int "The risk or severity of adverse effects can be increased when Zonisamide is combined with Dantrolene."
  ]
  edge [
    source 148
    target 173
    int "The risk or severity of adverse effects can be increased when Tiagabine is combined with Dantrolene."
  ]
  edge [
    source 148
    target 184
    int "The risk or severity of adverse effects can be increased when Dantrolene is combined with Dexmedetomidine."
  ]
  edge [
    source 148
    target 206
    int "The risk or severity of adverse effects can be increased when Aripiprazole is combined with Dantrolene."
  ]
  edge [
    source 148
    target 208
    int "The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Dantrolene."
  ]
  edge [
    source 148
    target 191
    int "The risk or severity of adverse effects can be increased when Dantrolene is combined with Trazodone."
  ]
  edge [
    source 148
    target 202
    int "The risk or severity of adverse effects can be increased when Maprotiline is combined with Dantrolene."
  ]
  edge [
    source 149
    target 167
    int "The serum concentration of Halofantrine can be increased when it is combined with Sildenafil."
  ]
  edge [
    source 149
    target 174
    int "The metabolism of Halofantrine can be decreased when combined with Sertraline."
  ]
  edge [
    source 149
    target 152
    int "The metabolism of Halofantrine can be decreased when combined with Efavirenz."
  ]
  edge [
    source 149
    target 155
    int "The serum concentration of Halofantrine can be increased when it is combined with Bortezomib."
  ]
  edge [
    source 149
    target 156
    int "Mefloquine may increase the QTc-prolonging activities of Halofantrine."
  ]
  edge [
    source 149
    target 196
    int "The serum concentration of Halofantrine can be increased when it is combined with Dihydroergotamine."
  ]
  edge [
    source 149
    target 208
    int "The serum concentration of Trifluoperazine can be increased when it is combined with Halofantrine."
  ]
  edge [
    source 149
    target 171
    int "The serum concentration of Halofantrine can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 149
    target 237
    int "The metabolism of Halofantrine can be decreased when combined with Rosiglitazone."
  ]
  edge [
    source 149
    target 240
    int "The metabolism of Halofantrine can be increased when combined with Primidone."
  ]
  edge [
    source 149
    target 244
    int "The serum concentration of Halofantrine can be increased when it is combined with Ranolazine."
  ]
  edge [
    source 149
    target 246
    int "The serum concentration of Halofantrine can be decreased when it is combined with Bosentan."
  ]
  edge [
    source 150
    target 195
    int "The risk or severity of adverse effects can be increased when Entacapone is combined with Lithium."
  ]
  edge [
    source 150
    target 197
    int "The risk or severity of adverse effects can be increased when Buspirone is combined with Lithium."
  ]
  edge [
    source 150
    target 194
    int "The risk or severity of adverse effects can be increased when Pargyline is combined with Lithium."
  ]
  edge [
    source 150
    target 196
    int "The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Lithium."
  ]
  edge [
    source 150
    target 222
    int "The risk or severity of adverse effects can be increased when Metaxalone is combined with Lithium."
  ]
  edge [
    source 150
    target 247
    int "The serum concentration of Lithium can be increased when it is combined with Mesalazine."
  ]
  edge [
    source 150
    target 174
    int "Lithium may increase the serotonergic activities of Sertraline."
  ]
  edge [
    source 150
    target 224
    int "The risk or severity of adverse effects can be increased when Sumatriptan is combined with Lithium."
  ]
  edge [
    source 150
    target 226
    int "The serum concentration of Lithium can be decreased when it is combined with Bumetanide."
  ]
  edge [
    source 150
    target 231
    int "The risk or severity of adverse effects can be increased when Carisoprodol is combined with Lithium."
  ]
  edge [
    source 150
    target 152
    int "The risk or severity of adverse effects can be increased when Efavirenz is combined with Lithium."
  ]
  edge [
    source 150
    target 216
    int "Lithium may increase the neuromuscular blocking activities of Vecuronium."
  ]
  edge [
    source 150
    target 238
    int "Lithium may increase the sedative activities of Pramipexole."
  ]
  edge [
    source 150
    target 240
    int "The risk or severity of adverse effects can be increased when Primidone is combined with Lithium."
  ]
  edge [
    source 150
    target 234
    int "The risk or severity of adverse effects can be increased when Lithium is combined with Lamotrigine."
  ]
  edge [
    source 150
    target 160
    int "The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Lithium."
  ]
  edge [
    source 150
    target 169
    int "Lithium may increase the neurotoxic activities of Asenapine."
  ]
  edge [
    source 150
    target 207
    int "The risk or severity of adverse effects can be increased when Zonisamide is combined with Lithium."
  ]
  edge [
    source 150
    target 173
    int "The risk or severity of adverse effects can be increased when Tiagabine is combined with Lithium."
  ]
  edge [
    source 150
    target 184
    int "The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Lithium."
  ]
  edge [
    source 150
    target 204
    int "The serum concentration of Lithium can be increased when it is combined with Oxyphenbutazone."
  ]
  edge [
    source 150
    target 206
    int "Lithium may increase the neurotoxic activities of Aripiprazole."
  ]
  edge [
    source 150
    target 208
    int "Lithium may increase the neurotoxic activities of Trifluoperazine."
  ]
  edge [
    source 150
    target 191
    int "The risk or severity of adverse effects can be increased when Trazodone is combined with Lithium."
  ]
  edge [
    source 150
    target 199
    int "The serum concentration of Lithium can be increased when it is combined with Meclofenamic acid."
  ]
  edge [
    source 150
    target 202
    int "The risk or severity of adverse effects can be increased when Maprotiline is combined with Lithium."
  ]
  edge [
    source 150
    target 215
    int "Methyclothiazide may decrease the excretion rate of Lithium which could result in a higher serum level."
  ]
  edge [
    source 151
    target 206
    int "The serum concentration of Aripiprazole can be decreased when it is combined with Temozolomide."
  ]
  edge [
    source 152
    target 237
    int "The metabolism of Rosiglitazone can be decreased when combined with Efavirenz."
  ]
  edge [
    source 152
    target 167
    int "The metabolism of Efavirenz can be decreased when combined with Sildenafil."
  ]
  edge [
    source 152
    target 188
    int "The serum concentration of Cerivastatin can be decreased when it is combined with Efavirenz."
  ]
  edge [
    source 152
    target 195
    int "The risk or severity of adverse effects can be increased when Entacapone is combined with Efavirenz."
  ]
  edge [
    source 152
    target 197
    int "The risk or severity of adverse effects can be increased when Buspirone is combined with Efavirenz."
  ]
  edge [
    source 152
    target 182
    int "The metabolism of Mephenytoin can be decreased when combined with Efavirenz."
  ]
  edge [
    source 152
    target 193
    int "The metabolism of Flutamide can be decreased when combined with Efavirenz."
  ]
  edge [
    source 152
    target 196
    int "The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Efavirenz."
  ]
  edge [
    source 152
    target 214
    int "The serum concentration of Proguanil can be decreased when it is combined with Efavirenz."
  ]
  edge [
    source 152
    target 219
    int "The serum concentration of Nisoldipine can be decreased when it is combined with Efavirenz."
  ]
  edge [
    source 152
    target 220
    int "The metabolism of Sulfinpyrazone can be decreased when combined with Efavirenz."
  ]
  edge [
    source 152
    target 222
    int "The risk or severity of adverse effects can be increased when Efavirenz is combined with Metaxalone."
  ]
  edge [
    source 152
    target 231
    int "The metabolism of Carisoprodol can be decreased when combined with Efavirenz."
  ]
  edge [
    source 152
    target 232
    int "The metabolism of Efavirenz can be decreased when combined with Sorafenib."
  ]
  edge [
    source 152
    target 175
    int "The serum concentration of Maraviroc can be decreased when it is combined with Efavirenz."
  ]
  edge [
    source 152
    target 174
    int "The serum concentration of Sertraline can be decreased when it is combined with Efavirenz."
  ]
  edge [
    source 152
    target 235
    int "The metabolism of Lansoprazole can be decreased when combined with Efavirenz."
  ]
  edge [
    source 152
    target 153
    int "The metabolism of Testosterone can be decreased when combined with Efavirenz."
  ]
  edge [
    source 152
    target 155
    int "The metabolism of Efavirenz can be decreased when combined with Bortezomib."
  ]
  edge [
    source 152
    target 244
    int "The metabolism of Efavirenz can be decreased when combined with Ranolazine."
  ]
  edge [
    source 152
    target 200
    int "The metabolism of Zalcitabine can be decreased when combined with Efavirenz."
  ]
  edge [
    source 152
    target 238
    int "Efavirenz may increase the sedative activities of Pramipexole."
  ]
  edge [
    source 152
    target 240
    int "The metabolism of Efavirenz can be increased when combined with Primidone."
  ]
  edge [
    source 152
    target 246
    int "The serum concentration of Bosentan can be increased when it is combined with Efavirenz."
  ]
  edge [
    source 152
    target 234
    int "The serum concentration of Lamotrigine can be decreased when it is combined with Efavirenz."
  ]
  edge [
    source 152
    target 154
    int "The metabolism of Amprenavir can be decreased when combined with Efavirenz."
  ]
  edge [
    source 152
    target 181
    int "The metabolism of Dopamine can be decreased when combined with Efavirenz."
  ]
  edge [
    source 152
    target 160
    int "The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Efavirenz."
  ]
  edge [
    source 152
    target 166
    int "The serum concentration of Tolvaptan can be increased when it is combined with Efavirenz."
  ]
  edge [
    source 152
    target 169
    int "The risk or severity of adverse effects can be increased when Asenapine is combined with Efavirenz."
  ]
  edge [
    source 152
    target 171
    int "The serum concentration of Efavirenz can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 152
    target 207
    int "The serum concentration of Zonisamide can be decreased when it is combined with Efavirenz."
  ]
  edge [
    source 152
    target 173
    int "The risk or severity of adverse effects can be increased when Efavirenz is combined with Tiagabine."
  ]
  edge [
    source 152
    target 184
    int "The risk or severity of adverse effects can be increased when Efavirenz is combined with Dexmedetomidine."
  ]
  edge [
    source 152
    target 206
    int "The serum concentration of Aripiprazole can be decreased when it is combined with Efavirenz."
  ]
  edge [
    source 152
    target 208
    int "The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Efavirenz."
  ]
  edge [
    source 152
    target 212
    int "The serum concentration of Loperamide can be decreased when it is combined with Efavirenz."
  ]
  edge [
    source 152
    target 191
    int "The risk or severity of adverse effects can be increased when Efavirenz is combined with Trazodone."
  ]
  edge [
    source 152
    target 202
    int "The risk or severity of adverse effects can be increased when Efavirenz is combined with Maprotiline."
  ]
  edge [
    source 153
    target 157
    int "The metabolism of Testosterone can be decreased when combined with Armodafinil."
  ]
  edge [
    source 153
    target 171
    int "The serum concentration of Testosterone can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 153
    target 244
    int "The serum concentration of Ranolazine can be increased when it is combined with Testosterone."
  ]
  edge [
    source 153
    target 167
    int "The metabolism of Testosterone can be decreased when combined with Sildenafil."
  ]
  edge [
    source 153
    target 174
    int "The metabolism of Testosterone can be decreased when combined with Sertraline."
  ]
  edge [
    source 153
    target 188
    int "The serum concentration of Cerivastatin can be increased when it is combined with Testosterone."
  ]
  edge [
    source 153
    target 155
    int "The metabolism of Testosterone can be decreased when combined with Bortezomib."
  ]
  edge [
    source 153
    target 166
    int "The serum concentration of Tolvaptan can be increased when it is combined with Testosterone."
  ]
  edge [
    source 153
    target 170
    int "Testosterone may increase the hypoglycemic activities of Metformin."
  ]
  edge [
    source 153
    target 240
    int "The metabolism of Testosterone can be increased when combined with Primidone."
  ]
  edge [
    source 153
    target 196
    int "The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Testosterone."
  ]
  edge [
    source 153
    target 198
    int "Testosterone may increase the hypoglycemic activities of Miglitol."
  ]
  edge [
    source 153
    target 206
    int "The serum concentration of Aripiprazole can be decreased when it is combined with Testosterone."
  ]
  edge [
    source 153
    target 217
    int "Desoxycorticosterone Pivalate may increase the fluid retaining activities of Testosterone."
  ]
  edge [
    source 153
    target 232
    int "The metabolism of Testosterone can be decreased when combined with Sorafenib."
  ]
  edge [
    source 153
    target 237
    int "The metabolism of Testosterone can be decreased when combined with Rosiglitazone."
  ]
  edge [
    source 153
    target 246
    int "The serum concentration of Testosterone can be decreased when it is combined with Bosentan."
  ]
  edge [
    source 154
    target 167
    int "The serum concentration of Sildenafil can be increased when it is combined with Amprenavir."
  ]
  edge [
    source 154
    target 174
    int "The metabolism of Amprenavir can be decreased when combined with Sertraline."
  ]
  edge [
    source 154
    target 155
    int "The metabolism of Amprenavir can be decreased when combined with Bortezomib."
  ]
  edge [
    source 154
    target 166
    int "The serum concentration of Tolvaptan can be increased when it is combined with Amprenavir."
  ]
  edge [
    source 154
    target 171
    int "The serum concentration of Amprenavir can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 154
    target 188
    int "The serum concentration of Cerivastatin can be increased when it is combined with Amprenavir."
  ]
  edge [
    source 154
    target 196
    int "The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Amprenavir."
  ]
  edge [
    source 154
    target 244
    int "The serum concentration of Ranolazine can be increased when it is combined with Amprenavir."
  ]
  edge [
    source 154
    target 232
    int "The metabolism of Amprenavir can be decreased when combined with Sorafenib."
  ]
  edge [
    source 154
    target 237
    int "The metabolism of Amprenavir can be decreased when combined with Rosiglitazone."
  ]
  edge [
    source 154
    target 240
    int "The serum concentration of Primidone can be increased when it is combined with Amprenavir."
  ]
  edge [
    source 154
    target 246
    int "The serum concentration of Bosentan can be increased when it is combined with Amprenavir."
  ]
  edge [
    source 155
    target 157
    int "The metabolism of Bortezomib can be decreased when combined with Armodafinil."
  ]
  edge [
    source 155
    target 241
    int "The risk or severity of adverse effects can be increased when Bortezomib is combined with Tolazoline."
  ]
  edge [
    source 155
    target 167
    int "The metabolism of Sildenafil can be decreased when combined with Bortezomib."
  ]
  edge [
    source 155
    target 228
    int "The risk or severity of adverse effects can be increased when Bortezomib is combined with Bretylium."
  ]
  edge [
    source 155
    target 196
    int "The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Bortezomib."
  ]
  edge [
    source 155
    target 197
    int "The metabolism of Buspirone can be decreased when combined with Bortezomib."
  ]
  edge [
    source 155
    target 182
    int "The metabolism of Mephenytoin can be decreased when combined with Bortezomib."
  ]
  edge [
    source 155
    target 193
    int "The metabolism of Flutamide can be decreased when combined with Bortezomib."
  ]
  edge [
    source 155
    target 214
    int "The metabolism of Proguanil can be decreased when combined with Bortezomib."
  ]
  edge [
    source 155
    target 219
    int "The metabolism of Nisoldipine can be decreased when combined with Bortezomib."
  ]
  edge [
    source 155
    target 220
    int "The metabolism of Sulfinpyrazone can be decreased when combined with Bortezomib."
  ]
  edge [
    source 155
    target 226
    int "The risk or severity of adverse effects can be increased when Bortezomib is combined with Bumetanide."
  ]
  edge [
    source 155
    target 230
    int "The metabolism of Isosorbide Dinitrate can be decreased when combined with Bortezomib."
  ]
  edge [
    source 155
    target 231
    int "The metabolism of Carisoprodol can be decreased when combined with Bortezomib."
  ]
  edge [
    source 155
    target 232
    int "The metabolism of Sorafenib can be decreased when combined with Bortezomib."
  ]
  edge [
    source 155
    target 174
    int "The metabolism of Sertraline can be decreased when combined with Bortezomib."
  ]
  edge [
    source 155
    target 235
    int "The metabolism of Lansoprazole can be decreased when combined with Bortezomib."
  ]
  edge [
    source 155
    target 249
    int "The risk or severity of adverse effects can be increased when Bortezomib is combined with Dipyridamole."
  ]
  edge [
    source 155
    target 159
    int "The metabolism of Cevimeline can be decreased when combined with Bortezomib."
  ]
  edge [
    source 155
    target 175
    int "The metabolism of Maraviroc can be decreased when combined with Bortezomib."
  ]
  edge [
    source 155
    target 180
    int "The metabolism of Disulfiram can be decreased when combined with Bortezomib."
  ]
  edge [
    source 155
    target 181
    int "The metabolism of Dopamine can be decreased when combined with Bortezomib."
  ]
  edge [
    source 155
    target 244
    int "The serum concentration of Ranolazine can be increased when it is combined with Bortezomib."
  ]
  edge [
    source 155
    target 168
    int "The risk or severity of adverse effects can be increased when Bortezomib is combined with Atenolol."
  ]
  edge [
    source 155
    target 238
    int "The risk or severity of adverse effects can be increased when Bortezomib is combined with Pramipexole."
  ]
  edge [
    source 155
    target 240
    int "The serum concentration of Bortezomib can be decreased when it is combined with Primidone."
  ]
  edge [
    source 155
    target 246
    int "The serum concentration of Bosentan can be increased when it is combined with Bortezomib."
  ]
  edge [
    source 155
    target 176
    int "The metabolism of Cytarabine can be decreased when combined with Bortezomib."
  ]
  edge [
    source 155
    target 188
    int "The serum concentration of Cerivastatin can be increased when it is combined with Bortezomib."
  ]
  edge [
    source 155
    target 156
    int "The metabolism of Mefloquine can be decreased when combined with Bortezomib."
  ]
  edge [
    source 155
    target 160
    int "The metabolism of Chlorzoxazone can be decreased when combined with Bortezomib."
  ]
  edge [
    source 155
    target 161
    int "The risk or severity of adverse effects can be increased when Bortezomib is combined with Minoxidil."
  ]
  edge [
    source 155
    target 162
    int "The risk or severity of adverse effects can be increased when Bortezomib is combined with Spironolactone."
  ]
  edge [
    source 155
    target 164
    int "The metabolism of Mebendazole can be decreased when combined with Bortezomib."
  ]
  edge [
    source 155
    target 169
    int "Bortezomib may increase the QTc-prolonging activities of Asenapine."
  ]
  edge [
    source 155
    target 171
    int "The serum concentration of Bortezomib can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 155
    target 173
    int "The metabolism of Tiagabine can be decreased when combined with Bortezomib."
  ]
  edge [
    source 155
    target 184
    int "The risk or severity of adverse effects can be increased when Bortezomib is combined with Dexmedetomidine."
  ]
  edge [
    source 155
    target 187
    int "The metabolism of Clofibrate can be decreased when combined with Bortezomib."
  ]
  edge [
    source 155
    target 200
    int "The metabolism of Zalcitabine can be decreased when combined with Bortezomib."
  ]
  edge [
    source 155
    target 201
    int "The metabolism of Aliskiren can be decreased when combined with Bortezomib."
  ]
  edge [
    source 155
    target 206
    int "The serum concentration of Aripiprazole can be increased when it is combined with Bortezomib."
  ]
  edge [
    source 155
    target 208
    int "The metabolism of Trifluoperazine can be decreased when combined with Bortezomib."
  ]
  edge [
    source 155
    target 212
    int "The metabolism of Loperamide can be decreased when combined with Bortezomib."
  ]
  edge [
    source 155
    target 165
    int "The metabolism of Pyrazinamide can be decreased when combined with Bortezomib."
  ]
  edge [
    source 155
    target 186
    int "The metabolism of Dutasteride can be decreased when combined with Bortezomib."
  ]
  edge [
    source 155
    target 191
    int "The metabolism of Trazodone can be decreased when combined with Bortezomib."
  ]
  edge [
    source 155
    target 192
    int "The risk or severity of adverse effects can be increased when Bortezomib is combined with Mecamylamine."
  ]
  edge [
    source 155
    target 202
    int "The metabolism of Maprotiline can be decreased when combined with Bortezomib."
  ]
  edge [
    source 155
    target 166
    int "The serum concentration of Tolvaptan can be increased when it is combined with Bortezomib."
  ]
  edge [
    source 155
    target 215
    int "The risk or severity of adverse effects can be increased when Bortezomib is combined with Methyclothiazide."
  ]
  edge [
    source 155
    target 207
    int "The metabolism of Zonisamide can be decreased when combined with Bortezomib."
  ]
  edge [
    source 156
    target 249
    int "The therapeutic efficacy of Mefloquine can be decreased when used in combination with Dipyridamole."
  ]
  edge [
    source 156
    target 167
    int "The metabolism of Mefloquine can be decreased when combined with Sildenafil."
  ]
  edge [
    source 156
    target 196
    int "The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Mefloquine."
  ]
  edge [
    source 156
    target 182
    int "The therapeutic efficacy of Mephenytoin can be decreased when used in combination with Mefloquine."
  ]
  edge [
    source 156
    target 217
    int "The risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Mefloquine."
  ]
  edge [
    source 156
    target 244
    int "The serum concentration of Ranolazine can be increased when it is combined with Mefloquine."
  ]
  edge [
    source 156
    target 159
    int "The risk or severity of adverse effects can be increased when Mefloquine is combined with Cevimeline."
  ]
  edge [
    source 156
    target 216
    int "The therapeutic efficacy of Vecuronium can be decreased when used in combination with Mefloquine."
  ]
  edge [
    source 156
    target 240
    int "The therapeutic efficacy of Primidone can be decreased when used in combination with Mefloquine."
  ]
  edge [
    source 156
    target 246
    int "The serum concentration of Mefloquine can be decreased when it is combined with Bosentan."
  ]
  edge [
    source 156
    target 234
    int "The therapeutic efficacy of Lamotrigine can be decreased when used in combination with Mefloquine."
  ]
  edge [
    source 156
    target 163
    int "The therapeutic efficacy of Lacosamide can be decreased when used in combination with Mefloquine."
  ]
  edge [
    source 156
    target 166
    int "The serum concentration of Tolvaptan can be increased when it is combined with Mefloquine."
  ]
  edge [
    source 156
    target 169
    int "Mefloquine may increase the QTc-prolonging activities of Asenapine."
  ]
  edge [
    source 156
    target 171
    int "The serum concentration of Mefloquine can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 156
    target 207
    int "The therapeutic efficacy of Zonisamide can be decreased when used in combination with Mefloquine."
  ]
  edge [
    source 156
    target 173
    int "The therapeutic efficacy of Tiagabine can be decreased when used in combination with Mefloquine."
  ]
  edge [
    source 156
    target 208
    int "The serum concentration of Trifluoperazine can be increased when it is combined with Mefloquine."
  ]
  edge [
    source 156
    target 168
    int "Mefloquine may increase the bradycardic activities of Atenolol."
  ]
  edge [
    source 156
    target 239
    int "The risk or severity of adverse effects can be increased when Mefloquine is combined with Carbachol."
  ]
  edge [
    source 156
    target 188
    int "The serum concentration of Cerivastatin can be increased when it is combined with Mefloquine."
  ]
  edge [
    source 156
    target 192
    int "The therapeutic efficacy of Mecamylamine can be decreased when used in combination with Mefloquine."
  ]
  edge [
    source 157
    target 167
    int "The metabolism of Sildenafil can be decreased when combined with Armodafinil."
  ]
  edge [
    source 157
    target 174
    int "The metabolism of Sertraline can be decreased when combined with Armodafinil."
  ]
  edge [
    source 157
    target 235
    int "The metabolism of Lansoprazole can be decreased when combined with Armodafinil."
  ]
  edge [
    source 157
    target 181
    int "The metabolism of Dopamine can be decreased when combined with Armodafinil."
  ]
  edge [
    source 157
    target 182
    int "The metabolism of Mephenytoin can be decreased when combined with Armodafinil."
  ]
  edge [
    source 157
    target 193
    int "The metabolism of Flutamide can be decreased when combined with Armodafinil."
  ]
  edge [
    source 157
    target 206
    int "The serum concentration of Aripiprazole can be decreased when it is combined with Armodafinil."
  ]
  edge [
    source 157
    target 214
    int "The metabolism of Proguanil can be decreased when combined with Armodafinil."
  ]
  edge [
    source 157
    target 231
    int "The metabolism of Carisoprodol can be decreased when combined with Armodafinil."
  ]
  edge [
    source 157
    target 240
    int "The metabolism of Primidone can be decreased when combined with Armodafinil."
  ]
  edge [
    source 158
    target 174
    int "The metabolism of Piperazine can be decreased when combined with Sertraline."
  ]
  edge [
    source 158
    target 170
    int "The therapeutic efficacy of Metformin can be decreased when used in combination with Piperazine."
  ]
  edge [
    source 158
    target 198
    int "The therapeutic efficacy of Miglitol can be decreased when used in combination with Piperazine."
  ]
  edge [
    source 158
    target 236
    int "The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Piperazine."
  ]
  edge [
    source 158
    target 237
    int "The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Piperazine."
  ]
  edge [
    source 158
    target 243
    int "The therapeutic efficacy of Miglustat can be decreased when used in combination with Piperazine."
  ]
  edge [
    source 158
    target 244
    int "The metabolism of Piperazine can be decreased when combined with Ranolazine."
  ]
  edge [
    source 159
    target 167
    int "The metabolism of Cevimeline can be decreased when combined with Sildenafil."
  ]
  edge [
    source 159
    target 174
    int "The metabolism of Cevimeline can be decreased when combined with Sertraline."
  ]
  edge [
    source 159
    target 168
    int "The risk or severity of adverse effects can be increased when Atenolol is combined with Cevimeline."
  ]
  edge [
    source 159
    target 171
    int "The serum concentration of Cevimeline can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 159
    target 196
    int "The metabolism of Cevimeline can be decreased when combined with Dihydroergotamine."
  ]
  edge [
    source 159
    target 244
    int "The metabolism of Cevimeline can be decreased when combined with Ranolazine."
  ]
  edge [
    source 159
    target 169
    int "The risk or severity of adverse effects can be increased when Asenapine is combined with Cevimeline."
  ]
  edge [
    source 159
    target 240
    int "The metabolism of Cevimeline can be increased when combined with Primidone."
  ]
  edge [
    source 159
    target 246
    int "The serum concentration of Cevimeline can be decreased when it is combined with Bosentan."
  ]
  edge [
    source 160
    target 167
    int "The metabolism of Chlorzoxazone can be decreased when combined with Sildenafil."
  ]
  edge [
    source 160
    target 197
    int "The risk or severity of adverse effects can be increased when Buspirone is combined with Chlorzoxazone."
  ]
  edge [
    source 160
    target 195
    int "The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Entacapone."
  ]
  edge [
    source 160
    target 196
    int "The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Chlorzoxazone."
  ]
  edge [
    source 160
    target 222
    int "The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Metaxalone."
  ]
  edge [
    source 160
    target 231
    int "The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Carisoprodol."
  ]
  edge [
    source 160
    target 244
    int "The metabolism of Chlorzoxazone can be decreased when combined with Ranolazine."
  ]
  edge [
    source 160
    target 174
    int "The metabolism of Chlorzoxazone can be decreased when combined with Sertraline."
  ]
  edge [
    source 160
    target 180
    int "The metabolism of Chlorzoxazone can be decreased when combined with Disulfiram."
  ]
  edge [
    source 160
    target 238
    int "Chlorzoxazone may increase the sedative activities of Pramipexole."
  ]
  edge [
    source 160
    target 240
    int "The metabolism of Chlorzoxazone can be increased when combined with Primidone."
  ]
  edge [
    source 160
    target 246
    int "The serum concentration of Chlorzoxazone can be decreased when it is combined with Bosentan."
  ]
  edge [
    source 160
    target 234
    int "The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Lamotrigine."
  ]
  edge [
    source 160
    target 166
    int "The serum concentration of Tolvaptan can be increased when it is combined with Chlorzoxazone."
  ]
  edge [
    source 160
    target 169
    int "The risk or severity of adverse effects can be increased when Asenapine is combined with Chlorzoxazone."
  ]
  edge [
    source 160
    target 171
    int "The serum concentration of Chlorzoxazone can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 160
    target 207
    int "The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Zonisamide."
  ]
  edge [
    source 160
    target 173
    int "The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Tiagabine."
  ]
  edge [
    source 160
    target 184
    int "The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Dexmedetomidine."
  ]
  edge [
    source 160
    target 206
    int "The risk or severity of adverse effects can be increased when Aripiprazole is combined with Chlorzoxazone."
  ]
  edge [
    source 160
    target 208
    int "The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Chlorzoxazone."
  ]
  edge [
    source 160
    target 188
    int "The serum concentration of Cerivastatin can be increased when it is combined with Chlorzoxazone."
  ]
  edge [
    source 160
    target 191
    int "The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Trazodone."
  ]
  edge [
    source 160
    target 202
    int "The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Maprotiline."
  ]
  edge [
    source 161
    target 249
    int "The risk or severity of adverse effects can be increased when Minoxidil is combined with Dipyridamole."
  ]
  edge [
    source 161
    target 167
    int "Sildenafil may increase the antihypertensive activities of Minoxidil."
  ]
  edge [
    source 161
    target 228
    int "Minoxidil may increase the hypotensive activities of Bretylium."
  ]
  edge [
    source 161
    target 226
    int "The risk or severity of adverse effects can be increased when Minoxidil is combined with Bumetanide."
  ]
  edge [
    source 161
    target 192
    int "Minoxidil may increase the hypotensive activities of Mecamylamine."
  ]
  edge [
    source 161
    target 162
    int "The risk or severity of adverse effects can be increased when Minoxidil is combined with Spironolactone."
  ]
  edge [
    source 161
    target 168
    int "Minoxidil may increase the hypotensive activities of Atenolol."
  ]
  edge [
    source 161
    target 184
    int "The risk or severity of adverse effects can be increased when Minoxidil is combined with Dexmedetomidine."
  ]
  edge [
    source 161
    target 201
    int "Minoxidil may increase the hypotensive activities of Aliskiren."
  ]
  edge [
    source 161
    target 194
    int "Pargyline may increase the hypotensive activities of Minoxidil."
  ]
  edge [
    source 161
    target 206
    int "Aripiprazole may increase the hypotensive activities of Minoxidil."
  ]
  edge [
    source 161
    target 215
    int "The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Minoxidil."
  ]
  edge [
    source 161
    target 219
    int "Minoxidil may increase the hypotensive activities of Nisoldipine."
  ]
  edge [
    source 161
    target 230
    int "The risk or severity of adverse effects can be increased when Minoxidil is combined with Isosorbide Dinitrate."
  ]
  edge [
    source 161
    target 238
    int "The risk or severity of adverse effects can be increased when Pramipexole is combined with Minoxidil."
  ]
  edge [
    source 161
    target 240
    int "Primidone may increase the hypotensive activities of Minoxidil."
  ]
  edge [
    source 161
    target 241
    int "Minoxidil may increase the hypotensive activities of Tolazoline."
  ]
  edge [
    source 161
    target 246
    int "Minoxidil may increase the hypotensive activities of Bosentan."
  ]
  edge [
    source 162
    target 225
    int "Spironolactone may decrease the vasoconstricting activities of Epinephrine."
  ]
  edge [
    source 162
    target 196
    int "Spironolactone may decrease the vasoconstricting activities of Dihydroergotamine."
  ]
  edge [
    source 162
    target 219
    int "The risk or severity of adverse effects can be increased when Nisoldipine is combined with Spironolactone."
  ]
  edge [
    source 162
    target 226
    int "The risk or severity of adverse effects can be increased when Spironolactone is combined with Bumetanide."
  ]
  edge [
    source 162
    target 230
    int "The risk or severity of adverse effects can be increased when Spironolactone is combined with Isosorbide Dinitrate."
  ]
  edge [
    source 162
    target 244
    int "The serum concentration of Ranolazine can be increased when it is combined with Spironolactone."
  ]
  edge [
    source 162
    target 247
    int "Mesalazine may decrease the antihypertensive activities of Spironolactone."
  ]
  edge [
    source 162
    target 249
    int "The risk or severity of adverse effects can be increased when Spironolactone is combined with Dipyridamole."
  ]
  edge [
    source 162
    target 168
    int "The risk or severity of adverse effects can be increased when Atenolol is combined with Spironolactone."
  ]
  edge [
    source 162
    target 228
    int "The risk or severity of adverse effects can be increased when Spironolactone is combined with Bretylium."
  ]
  edge [
    source 162
    target 238
    int "The risk or severity of adverse effects can be increased when Pramipexole is combined with Spironolactone."
  ]
  edge [
    source 162
    target 240
    int "Primidone may increase the hypotensive activities of Spironolactone."
  ]
  edge [
    source 162
    target 241
    int "The risk or severity of adverse effects can be increased when Tolazoline is combined with Spironolactone."
  ]
  edge [
    source 162
    target 166
    int "Tolvaptan may increase the hyperkalemic activities of Spironolactone."
  ]
  edge [
    source 162
    target 171
    int "The therapeutic efficacy of Mitotane can be decreased when used in combination with Spironolactone."
  ]
  edge [
    source 162
    target 184
    int "Spironolactone may decrease the vasoconstricting activities of Dexmedetomidine."
  ]
  edge [
    source 162
    target 204
    int "Oxyphenbutazone may decrease the antihypertensive activities of Spironolactone."
  ]
  edge [
    source 162
    target 201
    int "The risk or severity of adverse effects can be increased when Spironolactone is combined with Aliskiren."
  ]
  edge [
    source 162
    target 206
    int "Aripiprazole may increase the hypotensive activities of Spironolactone."
  ]
  edge [
    source 162
    target 192
    int "The risk or severity of adverse effects can be increased when Spironolactone is combined with Mecamylamine."
  ]
  edge [
    source 162
    target 199
    int "Meclofenamic acid may decrease the antihypertensive activities of Spironolactone."
  ]
  edge [
    source 162
    target 215
    int "The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Spironolactone."
  ]
  edge [
    source 163
    target 168
    int "Atenolol may increase the atrioventricular blocking (AV block) activities of Lacosamide."
  ]
  edge [
    source 163
    target 184
    int "Dexmedetomidine may increase the atrioventricular blocking (AV block) activities of Lacosamide."
  ]
  edge [
    source 164
    target 167
    int "The metabolism of Mebendazole can be decreased when combined with Sildenafil."
  ]
  edge [
    source 164
    target 171
    int "The serum concentration of Mebendazole can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 164
    target 196
    int "The metabolism of Mebendazole can be decreased when combined with Dihydroergotamine."
  ]
  edge [
    source 164
    target 240
    int "The metabolism of Mebendazole can be increased when combined with Primidone."
  ]
  edge [
    source 164
    target 244
    int "The serum concentration of Ranolazine can be increased when it is combined with Mebendazole."
  ]
  edge [
    source 164
    target 246
    int "The serum concentration of Mebendazole can be decreased when it is combined with Bosentan."
  ]
  edge [
    source 165
    target 167
    int "The metabolism of Pyrazinamide can be decreased when combined with Sildenafil."
  ]
  edge [
    source 165
    target 171
    int "The serum concentration of Pyrazinamide can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 165
    target 196
    int "The metabolism of Pyrazinamide can be decreased when combined with Dihydroergotamine."
  ]
  edge [
    source 165
    target 240
    int "The metabolism of Pyrazinamide can be increased when combined with Primidone."
  ]
  edge [
    source 165
    target 244
    int "The metabolism of Pyrazinamide can be decreased when combined with Ranolazine."
  ]
  edge [
    source 165
    target 246
    int "The serum concentration of Pyrazinamide can be decreased when it is combined with Bosentan."
  ]
  edge [
    source 166
    target 167
    int "The serum concentration of Tolvaptan can be increased when it is combined with Sildenafil."
  ]
  edge [
    source 166
    target 196
    int "The serum concentration of Tolvaptan can be increased when it is combined with Dihydroergotamine."
  ]
  edge [
    source 166
    target 219
    int "The serum concentration of Tolvaptan can be increased when it is combined with Nisoldipine."
  ]
  edge [
    source 166
    target 220
    int "The serum concentration of Tolvaptan can be increased when it is combined with Sulfinpyrazone."
  ]
  edge [
    source 166
    target 225
    int "The serum concentration of Tolvaptan can be increased when it is combined with Epinephrine."
  ]
  edge [
    source 166
    target 232
    int "The serum concentration of Tolvaptan can be increased when it is combined with Sorafenib."
  ]
  edge [
    source 166
    target 244
    int "The serum concentration of Tolvaptan can be increased when it is combined with Ranolazine."
  ]
  edge [
    source 166
    target 235
    int "The serum concentration of Tolvaptan can be increased when it is combined with Lansoprazole."
  ]
  edge [
    source 166
    target 177
    int "The serum concentration of Tolvaptan can be increased when it is combined with Mitoxantrone."
  ]
  edge [
    source 166
    target 240
    int "The serum concentration of Tolvaptan can be decreased when it is combined with Primidone."
  ]
  edge [
    source 166
    target 246
    int "The serum concentration of Tolvaptan can be decreased when it is combined with Bosentan."
  ]
  edge [
    source 166
    target 171
    int "The serum concentration of Tolvaptan can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 166
    target 188
    int "The serum concentration of Tolvaptan can be increased when it is combined with Cerivastatin."
  ]
  edge [
    source 166
    target 174
    int "The serum concentration of Tolvaptan can be increased when it is combined with Sertraline."
  ]
  edge [
    source 167
    target 241
    int "Sildenafil may increase the hypotensive activities of Tolazoline."
  ]
  edge [
    source 167
    target 194
    int "Sildenafil may increase the antihypertensive activities of Pargyline."
  ]
  edge [
    source 167
    target 197
    int "The metabolism of Buspirone can be decreased when combined with Sildenafil."
  ]
  edge [
    source 167
    target 182
    int "The metabolism of Mephenytoin can be decreased when combined with Sildenafil."
  ]
  edge [
    source 167
    target 193
    int "The metabolism of Flutamide can be decreased when combined with Sildenafil."
  ]
  edge [
    source 167
    target 214
    int "The metabolism of Proguanil can be decreased when combined with Sildenafil."
  ]
  edge [
    source 167
    target 219
    int "Sildenafil may increase the antihypertensive activities of Nisoldipine."
  ]
  edge [
    source 167
    target 220
    int "The metabolism of Sulfinpyrazone can be decreased when combined with Sildenafil."
  ]
  edge [
    source 167
    target 225
    int "Sildenafil may increase the hypotensive activities of Epinephrine."
  ]
  edge [
    source 167
    target 232
    int "The metabolism of Sorafenib can be decreased when combined with Sildenafil."
  ]
  edge [
    source 167
    target 249
    int "The risk or severity of adverse effects can be increased when Sildenafil is combined with Dipyridamole."
  ]
  edge [
    source 167
    target 196
    int "The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Sildenafil."
  ]
  edge [
    source 167
    target 174
    int "The metabolism of Sertraline can be decreased when combined with Sildenafil."
  ]
  edge [
    source 167
    target 235
    int "The metabolism of Lansoprazole can be decreased when combined with Sildenafil."
  ]
  edge [
    source 167
    target 230
    int "Sildenafil may increase the vasodilatory activities of Isosorbide Dinitrate."
  ]
  edge [
    source 167
    target 175
    int "The metabolism of Maraviroc can be decreased when combined with Sildenafil."
  ]
  edge [
    source 167
    target 180
    int "The metabolism of Disulfiram can be decreased when combined with Sildenafil."
  ]
  edge [
    source 167
    target 181
    int "The metabolism of Dopamine can be decreased when combined with Sildenafil."
  ]
  edge [
    source 167
    target 244
    int "The serum concentration of Ranolazine can be increased when it is combined with Sildenafil."
  ]
  edge [
    source 167
    target 168
    int "Sildenafil may increase the antihypertensive activities of Atenolol."
  ]
  edge [
    source 167
    target 237
    int "The metabolism of Rosiglitazone can be decreased when combined with Sildenafil."
  ]
  edge [
    source 167
    target 240
    int "The metabolism of Sildenafil can be increased when combined with Primidone."
  ]
  edge [
    source 167
    target 246
    int "The serum concentration of Bosentan can be increased when it is combined with Sildenafil."
  ]
  edge [
    source 167
    target 176
    int "The metabolism of Cytarabine can be decreased when combined with Sildenafil."
  ]
  edge [
    source 167
    target 188
    int "The serum concentration of Cerivastatin can be increased when it is combined with Sildenafil."
  ]
  edge [
    source 167
    target 179
    int "The serum concentration of Sildenafil can be increased when it is combined with Cilastatin."
  ]
  edge [
    source 167
    target 169
    int "Sildenafil may increase the hypotensive activities of Asenapine."
  ]
  edge [
    source 167
    target 171
    int "The serum concentration of Sildenafil can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 167
    target 173
    int "The metabolism of Tiagabine can be decreased when combined with Sildenafil."
  ]
  edge [
    source 167
    target 187
    int "The metabolism of Clofibrate can be decreased when combined with Sildenafil."
  ]
  edge [
    source 167
    target 201
    int "Sildenafil may increase the antihypertensive activities of Aliskiren."
  ]
  edge [
    source 167
    target 200
    int "The metabolism of Zalcitabine can be decreased when combined with Sildenafil."
  ]
  edge [
    source 167
    target 206
    int "The serum concentration of Aripiprazole can be increased when it is combined with Sildenafil."
  ]
  edge [
    source 167
    target 208
    int "Sildenafil may increase the hypotensive activities of Trifluoperazine."
  ]
  edge [
    source 167
    target 212
    int "The metabolism of Loperamide can be decreased when combined with Sildenafil."
  ]
  edge [
    source 167
    target 228
    int "Sildenafil may increase the antihypertensive activities of Bretylium."
  ]
  edge [
    source 167
    target 186
    int "The metabolism of Dutasteride can be decreased when combined with Sildenafil."
  ]
  edge [
    source 167
    target 191
    int "Sildenafil may increase the hypotensive activities of Trazodone."
  ]
  edge [
    source 167
    target 192
    int "The risk or severity of adverse effects can be increased when Sildenafil is combined with Mecamylamine."
  ]
  edge [
    source 167
    target 207
    int "The metabolism of Zonisamide can be decreased when combined with Sildenafil."
  ]
  edge [
    source 168
    target 249
    int "Dipyridamole may increase the bradycardic activities of Atenolol."
  ]
  edge [
    source 168
    target 194
    int "Pargyline may increase the hypotensive activities of Atenolol."
  ]
  edge [
    source 168
    target 174
    int "The serum concentration of Atenolol can be increased when it is combined with Sertraline."
  ]
  edge [
    source 168
    target 219
    int "Atenolol may increase the hypotensive activities of Nisoldipine."
  ]
  edge [
    source 168
    target 225
    int "Epinephrine may increase the atrioventricular blocking (AV block) activities of Atenolol."
  ]
  edge [
    source 168
    target 226
    int "The risk or severity of adverse effects can be increased when Atenolol is combined with Bumetanide."
  ]
  edge [
    source 168
    target 230
    int "The risk or severity of adverse effects can be increased when Atenolol is combined with Isosorbide Dinitrate."
  ]
  edge [
    source 168
    target 244
    int "The serum concentration of Ranolazine can be increased when it is combined with Atenolol."
  ]
  edge [
    source 168
    target 247
    int "Mesalazine may decrease the antihypertensive activities of Atenolol."
  ]
  edge [
    source 168
    target 228
    int "Bretylium may increase the bradycardic activities of Atenolol."
  ]
  edge [
    source 168
    target 236
    int "Atenolol may increase the hypoglycemic activities of Acetohexamide."
  ]
  edge [
    source 168
    target 238
    int "The risk or severity of adverse effects can be increased when Pramipexole is combined with Atenolol."
  ]
  edge [
    source 168
    target 239
    int "The risk or severity of adverse effects can be increased when Atenolol is combined with Carbachol."
  ]
  edge [
    source 168
    target 240
    int "The serum concentration of Atenolol can be decreased when it is combined with Primidone."
  ]
  edge [
    source 168
    target 241
    int "Atenolol may increase the orthostatic hypotensive activities of Tolazoline."
  ]
  edge [
    source 168
    target 246
    int "Bosentan may increase the hypotensive activities of Atenolol."
  ]
  edge [
    source 168
    target 196
    int "Dihydroergotamine may increase the atrioventricular blocking (AV block) activities of Atenolol."
  ]
  edge [
    source 168
    target 169
    int "Atenolol may increase the orthostatic hypotensive activities of Asenapine."
  ]
  edge [
    source 168
    target 184
    int "Dexmedetomidine may increase the atrioventricular blocking (AV block) activities of Atenolol."
  ]
  edge [
    source 168
    target 204
    int "Oxyphenbutazone may decrease the antihypertensive activities of Atenolol."
  ]
  edge [
    source 168
    target 201
    int "Atenolol may increase the hypotensive activities of Aliskiren."
  ]
  edge [
    source 168
    target 206
    int "Aripiprazole may increase the hypotensive activities of Atenolol."
  ]
  edge [
    source 168
    target 208
    int "Atenolol may increase the orthostatic hypotensive activities of Trifluoperazine."
  ]
  edge [
    source 168
    target 191
    int "Atenolol may increase the orthostatic hypotensive activities of Trazodone."
  ]
  edge [
    source 168
    target 192
    int "Mecamylamine may increase the hypotensive activities of Atenolol."
  ]
  edge [
    source 168
    target 199
    int "Meclofenamic acid may decrease the antihypertensive activities of Atenolol."
  ]
  edge [
    source 168
    target 215
    int "The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Atenolol."
  ]
  edge [
    source 169
    target 173
    int "The risk or severity of adverse effects can be increased when Asenapine is combined with Tiagabine."
  ]
  edge [
    source 169
    target 224
    int "The risk or severity of adverse effects can be increased when Sumatriptan is combined with Asenapine."
  ]
  edge [
    source 169
    target 195
    int "The risk or severity of adverse effects can be increased when Asenapine is combined with Entacapone."
  ]
  edge [
    source 169
    target 196
    int "Dihydroergotamine may increase the atrioventricular blocking (AV block) activities of Asenapine."
  ]
  edge [
    source 169
    target 197
    int "The risk or severity of adverse effects can be increased when Buspirone is combined with Asenapine."
  ]
  edge [
    source 169
    target 198
    int "The therapeutic efficacy of Miglitol can be decreased when used in combination with Asenapine."
  ]
  edge [
    source 169
    target 219
    int "The risk or severity of hypotension can be increased when Asenapine is combined with Nisoldipine."
  ]
  edge [
    source 169
    target 232
    int "Sorafenib may increase the QTc-prolonging activities of Asenapine."
  ]
  edge [
    source 169
    target 225
    int "Asenapine may increase the antihypertensive activities of Epinephrine."
  ]
  edge [
    source 169
    target 222
    int "The risk or severity of adverse effects can be increased when Asenapine is combined with Metaxalone."
  ]
  edge [
    source 169
    target 174
    int "Sertraline may increase the QTc-prolonging activities of Asenapine."
  ]
  edge [
    source 169
    target 231
    int "The risk or severity of adverse effects can be increased when Asenapine is combined with Carisoprodol."
  ]
  edge [
    source 169
    target 244
    int "Ranolazine may increase the QTc-prolonging activities of Asenapine."
  ]
  edge [
    source 169
    target 205
    int "Foscarnet may increase the QTc-prolonging activities of Asenapine."
  ]
  edge [
    source 169
    target 170
    int "The therapeutic efficacy of Metformin can be decreased when used in combination with Asenapine."
  ]
  edge [
    source 169
    target 236
    int "The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Asenapine."
  ]
  edge [
    source 169
    target 237
    int "The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Asenapine."
  ]
  edge [
    source 169
    target 238
    int "Asenapine may increase the sedative activities of Pramipexole."
  ]
  edge [
    source 169
    target 239
    int "The risk or severity of adverse effects can be increased when Asenapine is combined with Carbachol."
  ]
  edge [
    source 169
    target 240
    int "The metabolism of Asenapine can be increased when combined with Primidone."
  ]
  edge [
    source 169
    target 241
    int "Tolazoline may increase the antihypertensive activities of Asenapine."
  ]
  edge [
    source 169
    target 243
    int "The therapeutic efficacy of Miglustat can be decreased when used in combination with Asenapine."
  ]
  edge [
    source 169
    target 246
    int "The serum concentration of Asenapine can be decreased when it is combined with Bosentan."
  ]
  edge [
    source 169
    target 234
    int "The risk or severity of adverse effects can be increased when Asenapine is combined with Lamotrigine."
  ]
  edge [
    source 169
    target 247
    int "The therapeutic efficacy of Mesalazine can be decreased when used in combination with Asenapine."
  ]
  edge [
    source 169
    target 171
    int "The serum concentration of Asenapine can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 169
    target 207
    int "The risk or severity of adverse effects can be increased when Asenapine is combined with Zonisamide."
  ]
  edge [
    source 169
    target 184
    int "Dexmedetomidine may increase the atrioventricular blocking (AV block) activities of Asenapine."
  ]
  edge [
    source 169
    target 204
    int "Oxyphenbutazone may decrease the antihypertensive activities of Asenapine."
  ]
  edge [
    source 169
    target 206
    int "Asenapine may increase the antihypertensive activities of Aripiprazole."
  ]
  edge [
    source 169
    target 208
    int "Trifluoperazine may increase the antihypertensive activities of Asenapine."
  ]
  edge [
    source 169
    target 212
    int "The risk or severity of hypotension can be increased when Asenapine is combined with Loperamide."
  ]
  edge [
    source 169
    target 191
    int "Trazodone may increase the antihypertensive activities of Asenapine."
  ]
  edge [
    source 169
    target 199
    int "Meclofenamic acid may decrease the antihypertensive activities of Asenapine."
  ]
  edge [
    source 169
    target 202
    int "Maprotiline may increase the QTc-prolonging activities of Asenapine."
  ]
  edge [
    source 170
    target 244
    int "The serum concentration of Metformin can be increased when it is combined with Ranolazine."
  ]
  edge [
    source 170
    target 225
    int "The therapeutic efficacy of Metformin can be decreased when used in combination with Epinephrine."
  ]
  edge [
    source 170
    target 234
    int "The serum concentration of Metformin can be increased when it is combined with Lamotrigine."
  ]
  edge [
    source 170
    target 174
    int "Sertraline may increase the hypoglycemic activities of Metformin."
  ]
  edge [
    source 170
    target 194
    int "Pargyline may increase the hypoglycemic activities of Metformin."
  ]
  edge [
    source 170
    target 206
    int "The therapeutic efficacy of Metformin can be decreased when used in combination with Aripiprazole."
  ]
  edge [
    source 170
    target 215
    int "The therapeutic efficacy of Metformin can be decreased when used in combination with Methyclothiazide."
  ]
  edge [
    source 170
    target 189
    int "Aminosalicylic Acid may increase the hypoglycemic activities of Metformin."
  ]
  edge [
    source 170
    target 226
    int "The therapeutic efficacy of Metformin can be decreased when used in combination with Bumetanide."
  ]
  edge [
    source 170
    target 247
    int "Mesalazine may increase the hypoglycemic activities of Metformin."
  ]
  edge [
    source 171
    target 197
    int "The serum concentration of Buspirone can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 171
    target 193
    int "The serum concentration of Flutamide can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 171
    target 196
    int "The serum concentration of Dihydroergotamine can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 171
    target 214
    int "The serum concentration of Proguanil can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 171
    target 217
    int "The serum concentration of Desoxycorticosterone Pivalate can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 171
    target 219
    int "The serum concentration of Nisoldipine can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 171
    target 220
    int "The serum concentration of Sulfinpyrazone can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 171
    target 230
    int "The serum concentration of Isosorbide Dinitrate can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 171
    target 232
    int "The serum concentration of Sorafenib can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 171
    target 244
    int "The serum concentration of Ranolazine can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 171
    target 174
    int "The serum concentration of Sertraline can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 171
    target 235
    int "The serum concentration of Lansoprazole can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 171
    target 175
    int "The serum concentration of Maraviroc can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 171
    target 176
    int "The serum concentration of Cytarabine can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 171
    target 180
    int "The serum concentration of Disulfiram can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 171
    target 246
    int "The serum concentration of Bosentan can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 171
    target 173
    int "The serum concentration of Tiagabine can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 171
    target 187
    int "The serum concentration of Clofibrate can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 171
    target 201
    int "The serum concentration of Aliskiren can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 171
    target 206
    int "The serum concentration of Aripiprazole can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 171
    target 212
    int "The serum concentration of Loperamide can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 171
    target 200
    int "The serum concentration of Zalcitabine can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 171
    target 186
    int "The serum concentration of Dutasteride can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 171
    target 188
    int "The serum concentration of Cerivastatin can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 171
    target 191
    int "The serum concentration of Trazodone can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 171
    target 207
    int "The serum concentration of Zonisamide can be decreased when it is combined with Mitotane."
  ]
  edge [
    source 173
    target 197
    int "The risk or severity of adverse effects can be increased when Buspirone is combined with Tiagabine."
  ]
  edge [
    source 173
    target 195
    int "The risk or severity of adverse effects can be increased when Entacapone is combined with Tiagabine."
  ]
  edge [
    source 173
    target 196
    int "The metabolism of Tiagabine can be decreased when combined with Dihydroergotamine."
  ]
  edge [
    source 173
    target 222
    int "The risk or severity of adverse effects can be increased when Metaxalone is combined with Tiagabine."
  ]
  edge [
    source 173
    target 231
    int "The risk or severity of adverse effects can be increased when Carisoprodol is combined with Tiagabine."
  ]
  edge [
    source 173
    target 244
    int "The metabolism of Tiagabine can be decreased when combined with Ranolazine."
  ]
  edge [
    source 173
    target 174
    int "The risk or severity of adverse effects can be increased when Tiagabine is combined with Sertraline."
  ]
  edge [
    source 173
    target 238
    int "Tiagabine may increase the sedative activities of Pramipexole."
  ]
  edge [
    source 173
    target 240
    int "The metabolism of Tiagabine can be increased when combined with Primidone."
  ]
  edge [
    source 173
    target 246
    int "The serum concentration of Tiagabine can be decreased when it is combined with Bosentan."
  ]
  edge [
    source 173
    target 234
    int "The risk or severity of adverse effects can be increased when Lamotrigine is combined with Tiagabine."
  ]
  edge [
    source 173
    target 207
    int "The risk or severity of adverse effects can be increased when Tiagabine is combined with Zonisamide."
  ]
  edge [
    source 173
    target 184
    int "The risk or severity of adverse effects can be increased when Tiagabine is combined with Dexmedetomidine."
  ]
  edge [
    source 173
    target 206
    int "The risk or severity of adverse effects can be increased when Aripiprazole is combined with Tiagabine."
  ]
  edge [
    source 173
    target 208
    int "The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Tiagabine."
  ]
  edge [
    source 173
    target 202
    int "The risk or severity of adverse effects can be increased when Tiagabine is combined with Maprotiline."
  ]
  edge [
    source 173
    target 191
    int "The risk or severity of adverse effects can be increased when Tiagabine is combined with Trazodone."
  ]
  edge [
    source 174
    target 222
    int "The risk or severity of adverse effects can be increased when Metaxalone is combined with Sertraline."
  ]
  edge [
    source 174
    target 194
    int "Pargyline may increase the serotonergic activities of Sertraline."
  ]
  edge [
    source 174
    target 195
    int "The risk or severity of adverse effects can be increased when Entacapone is combined with Sertraline."
  ]
  edge [
    source 174
    target 196
    int "The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Sertraline."
  ]
  edge [
    source 174
    target 197
    int "Buspirone may increase the serotonergic activities of Sertraline."
  ]
  edge [
    source 174
    target 198
    int "Sertraline may increase the hypoglycemic activities of Miglitol."
  ]
  edge [
    source 174
    target 182
    int "The metabolism of Mephenytoin can be decreased when combined with Sertraline."
  ]
  edge [
    source 174
    target 193
    int "The metabolism of Flutamide can be decreased when combined with Sertraline."
  ]
  edge [
    source 174
    target 214
    int "The metabolism of Proguanil can be decreased when combined with Sertraline."
  ]
  edge [
    source 174
    target 224
    int "The risk or severity of adverse effects can be increased when Sumatriptan is combined with Sertraline."
  ]
  edge [
    source 174
    target 231
    int "The metabolism of Carisoprodol can be decreased when combined with Sertraline."
  ]
  edge [
    source 174
    target 232
    int "The metabolism of Sertraline can be decreased when combined with Sorafenib."
  ]
  edge [
    source 174
    target 206
    int "The risk or severity of adverse effects can be increased when Sertraline is combined with Aripiprazole."
  ]
  edge [
    source 174
    target 244
    int "The serum concentration of Ranolazine can be increased when it is combined with Sertraline."
  ]
  edge [
    source 174
    target 247
    int "Sertraline may increase the antiplatelet activities of Mesalazine."
  ]
  edge [
    source 174
    target 235
    int "The metabolism of Lansoprazole can be decreased when combined with Sertraline."
  ]
  edge [
    source 174
    target 180
    int "The risk or severity of adverse effects can be increased when Disulfiram is combined with Sertraline."
  ]
  edge [
    source 174
    target 181
    int "The metabolism of Dopamine can be decreased when combined with Sertraline."
  ]
  edge [
    source 174
    target 237
    int "Sertraline may increase the hypoglycemic activities of Rosiglitazone."
  ]
  edge [
    source 174
    target 240
    int "The metabolism of Sertraline can be increased when combined with Primidone."
  ]
  edge [
    source 174
    target 246
    int "The serum concentration of Sertraline can be decreased when it is combined with Bosentan."
  ]
  edge [
    source 174
    target 234
    int "The risk or severity of adverse effects can be increased when Sertraline is combined with Lamotrigine."
  ]
  edge [
    source 174
    target 207
    int "The risk or severity of adverse effects can be increased when Zonisamide is combined with Sertraline."
  ]
  edge [
    source 174
    target 184
    int "The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Sertraline."
  ]
  edge [
    source 174
    target 208
    int "The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Sertraline."
  ]
  edge [
    source 174
    target 212
    int "The metabolism of Loperamide can be decreased when combined with Sertraline."
  ]
  edge [
    source 174
    target 215
    int "Sertraline may increase the hyponatremic activities of Methyclothiazide."
  ]
  edge [
    source 174
    target 200
    int "The metabolism of Zalcitabine can be decreased when combined with Sertraline."
  ]
  edge [
    source 174
    target 191
    int "Sertraline may increase the serotonergic activities of Trazodone."
  ]
  edge [
    source 174
    target 188
    int "The serum concentration of Cerivastatin can be increased when it is combined with Sertraline."
  ]
  edge [
    source 174
    target 199
    int "Sertraline may increase the antiplatelet activities of Meclofenamic acid."
  ]
  edge [
    source 174
    target 202
    int "The risk or severity of adverse effects can be increased when Maprotiline is combined with Sertraline."
  ]
  edge [
    source 174
    target 189
    int "Sertraline may increase the antiplatelet activities of Aminosalicylic Acid."
  ]
  edge [
    source 175
    target 196
    int "The metabolism of Maraviroc can be decreased when combined with Dihydroergotamine."
  ]
  edge [
    source 175
    target 240
    int "The serum concentration of Maraviroc can be decreased when it is combined with Primidone."
  ]
  edge [
    source 175
    target 244
    int "The metabolism of Maraviroc can be decreased when combined with Ranolazine."
  ]
  edge [
    source 175
    target 246
    int "The serum concentration of Maraviroc can be decreased when it is combined with Bosentan."
  ]
  edge [
    source 176
    target 240
    int "The metabolism of Cytarabine can be increased when combined with Primidone."
  ]
  edge [
    source 176
    target 196
    int "The metabolism of Cytarabine can be decreased when combined with Dihydroergotamine."
  ]
  edge [
    source 176
    target 244
    int "The metabolism of Cytarabine can be decreased when combined with Ranolazine."
  ]
  edge [
    source 176
    target 246
    int "The serum concentration of Cytarabine can be decreased when it is combined with Bosentan."
  ]
  edge [
    source 177
    target 188
    int "The serum concentration of Cerivastatin can be increased when it is combined with Mitoxantrone."
  ]
  edge [
    source 177
    target 196
    int "The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Mitoxantrone."
  ]
  edge [
    source 177
    target 244
    int "The serum concentration of Ranolazine can be increased when it is combined with Mitoxantrone."
  ]
  edge [
    source 179
    target 196
    int "The serum concentration of Dihydroergotamine can be increased when it is combined with Cilastatin."
  ]
  edge [
    source 180
    target 194
    int "The risk or severity of convulsion can be increased when Pargyline is combined with Disulfiram."
  ]
  edge [
    source 180
    target 196
    int "The metabolism of Disulfiram can be decreased when combined with Dihydroergotamine."
  ]
  edge [
    source 180
    target 240
    int "The metabolism of Disulfiram can be increased when combined with Primidone."
  ]
  edge [
    source 180
    target 244
    int "The metabolism of Disulfiram can be decreased when combined with Ranolazine."
  ]
  edge [
    source 180
    target 246
    int "The serum concentration of Disulfiram can be decreased when it is combined with Bosentan."
  ]
  edge [
    source 181
    target 244
    int "The metabolism of Dopamine can be decreased when combined with Ranolazine."
  ]
  edge [
    source 181
    target 225
    int "The risk or severity of adverse effects can be increased when Epinephrine is combined with Dopamine."
  ]
  edge [
    source 181
    target 195
    int "The metabolism of Dopamine can be decreased when combined with Entacapone."
  ]
  edge [
    source 181
    target 232
    int "The metabolism of Dopamine can be decreased when combined with Sorafenib."
  ]
  edge [
    source 181
    target 240
    int "The metabolism of Dopamine can be increased when combined with Primidone."
  ]
  edge [
    source 182
    target 232
    int "The metabolism of Mephenytoin can be decreased when combined with Sorafenib."
  ]
  edge [
    source 182
    target 237
    int "The metabolism of Mephenytoin can be decreased when combined with Rosiglitazone."
  ]
  edge [
    source 182
    target 240
    int "The metabolism of Mephenytoin can be increased when combined with Primidone."
  ]
  edge [
    source 182
    target 244
    int "The metabolism of Mephenytoin can be decreased when combined with Ranolazine."
  ]
  edge [
    source 183
    target 192
    int "The risk or severity of adverse effects can be increased when Sulfameter is combined with Mecamylamine."
  ]
  edge [
    source 184
    target 249
    int "The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Dipyridamole."
  ]
  edge [
    source 184
    target 195
    int "The risk or severity of adverse effects can be increased when Entacapone is combined with Dexmedetomidine."
  ]
  edge [
    source 184
    target 197
    int "The risk or severity of adverse effects can be increased when Buspirone is combined with Dexmedetomidine."
  ]
  edge [
    source 184
    target 196
    int "Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Dexmedetomidine."
  ]
  edge [
    source 184
    target 219
    int "The risk or severity of adverse effects can be increased when Nisoldipine is combined with Dexmedetomidine."
  ]
  edge [
    source 184
    target 225
    int "Epinephrine may decrease the vasoconstricting activities of Dexmedetomidine."
  ]
  edge [
    source 184
    target 230
    int "The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Isosorbide Dinitrate."
  ]
  edge [
    source 184
    target 231
    int "The risk or severity of adverse effects can be increased when Carisoprodol is combined with Dexmedetomidine."
  ]
  edge [
    source 184
    target 222
    int "The risk or severity of adverse effects can be increased when Metaxalone is combined with Dexmedetomidine."
  ]
  edge [
    source 184
    target 226
    int "The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Bumetanide."
  ]
  edge [
    source 184
    target 238
    int "Dexmedetomidine may increase the sedative activities of Pramipexole."
  ]
  edge [
    source 184
    target 240
    int "The risk or severity of adverse effects can be increased when Primidone is combined with Dexmedetomidine."
  ]
  edge [
    source 184
    target 241
    int "The risk or severity of adverse effects can be increased when Tolazoline is combined with Dexmedetomidine."
  ]
  edge [
    source 184
    target 234
    int "The risk or severity of adverse effects can be increased when Lamotrigine is combined with Dexmedetomidine."
  ]
  edge [
    source 184
    target 207
    int "The risk or severity of adverse effects can be increased when Zonisamide is combined with Dexmedetomidine."
  ]
  edge [
    source 184
    target 201
    int "The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Aliskiren."
  ]
  edge [
    source 184
    target 206
    int "Aripiprazole may increase the hypotensive activities of Dexmedetomidine."
  ]
  edge [
    source 184
    target 208
    int "The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Dexmedetomidine."
  ]
  edge [
    source 184
    target 228
    int "Bretylium may increase the bradycardic activities of Dexmedetomidine."
  ]
  edge [
    source 184
    target 191
    int "The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Trazodone."
  ]
  edge [
    source 184
    target 192
    int "The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Mecamylamine."
  ]
  edge [
    source 184
    target 202
    int "The risk or severity of adverse effects can be increased when Maprotiline is combined with Dexmedetomidine."
  ]
  edge [
    source 184
    target 215
    int "The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Dexmedetomidine."
  ]
  edge [
    source 186
    target 196
    int "The metabolism of Dutasteride can be decreased when combined with Dihydroergotamine."
  ]
  edge [
    source 186
    target 240
    int "The metabolism of Dutasteride can be increased when combined with Primidone."
  ]
  edge [
    source 186
    target 244
    int "The metabolism of Dutasteride can be decreased when combined with Ranolazine."
  ]
  edge [
    source 186
    target 246
    int "The serum concentration of Dutasteride can be decreased when it is combined with Bosentan."
  ]
  edge [
    source 187
    target 196
    int "The metabolism of Clofibrate can be decreased when combined with Dihydroergotamine."
  ]
  edge [
    source 187
    target 206
    int "The serum concentration of Aripiprazole can be decreased when it is combined with Clofibrate."
  ]
  edge [
    source 187
    target 236
    int "Clofibrate may increase the hypoglycemic activities of Acetohexamide."
  ]
  edge [
    source 187
    target 240
    int "The metabolism of Clofibrate can be increased when combined with Primidone."
  ]
  edge [
    source 187
    target 244
    int "The metabolism of Clofibrate can be decreased when combined with Ranolazine."
  ]
  edge [
    source 187
    target 246
    int "The serum concentration of Clofibrate can be decreased when it is combined with Bosentan."
  ]
  edge [
    source 188
    target 196
    int "The serum concentration of Cerivastatin can be increased when it is combined with Dihydroergotamine."
  ]
  edge [
    source 188
    target 219
    int "The serum concentration of Cerivastatin can be increased when it is combined with Nisoldipine."
  ]
  edge [
    source 188
    target 220
    int "The serum concentration of Cerivastatin can be increased when it is combined with Sulfinpyrazone."
  ]
  edge [
    source 188
    target 225
    int "The serum concentration of Cerivastatin can be increased when it is combined with Epinephrine."
  ]
  edge [
    source 188
    target 232
    int "The serum concentration of Cerivastatin can be increased when it is combined with Sorafenib."
  ]
  edge [
    source 188
    target 244
    int "The serum concentration of Cerivastatin can be increased when it is combined with Ranolazine."
  ]
  edge [
    source 188
    target 235
    int "The serum concentration of Cerivastatin can be increased when it is combined with Lansoprazole."
  ]
  edge [
    source 188
    target 237
    int "The metabolism of Cerivastatin can be decreased when combined with Rosiglitazone."
  ]
  edge [
    source 188
    target 240
    int "The metabolism of Cerivastatin can be increased when combined with Primidone."
  ]
  edge [
    source 188
    target 246
    int "The metabolism of Cerivastatin can be increased when combined with Bosentan."
  ]
  edge [
    source 188
    target 206
    int "The serum concentration of Aripiprazole can be decreased when it is combined with Cerivastatin."
  ]
  edge [
    source 189
    target 249
    int "The risk or severity of adverse effects can be increased when Dipyridamole is combined with Aminosalicylic Acid."
  ]
  edge [
    source 189
    target 198
    int "Aminosalicylic Acid may increase the hypoglycemic activities of Miglitol."
  ]
  edge [
    source 189
    target 217
    int "The risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Desoxycorticosterone Pivalate."
  ]
  edge [
    source 189
    target 226
    int "The therapeutic efficacy of Bumetanide can be decreased when used in combination with Aminosalicylic Acid."
  ]
  edge [
    source 189
    target 247
    int "The risk or severity of adverse effects can be increased when Mesalazine is combined with Aminosalicylic Acid."
  ]
  edge [
    source 189
    target 237
    int "The risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Rosiglitazone."
  ]
  edge [
    source 189
    target 204
    int "The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Aminosalicylic Acid."
  ]
  edge [
    source 189
    target 199
    int "The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Aminosalicylic Acid."
  ]
  edge [
    source 189
    target 215
    int "The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Aminosalicylic Acid."
  ]
  edge [
    source 190
    target 213
    int "The serum concentration of Mercaptopurine can be increased when it is combined with Allopurinol."
  ]
  edge [
    source 190
    target 215
    int "The risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Methyclothiazide."
  ]
  edge [
    source 190
    target 226
    int "The risk or severity of adverse effects can be increased when Bumetanide is combined with Allopurinol."
  ]
  edge [
    source 191
    target 194
    int "Pargyline may increase the serotonergic activities of Trazodone."
  ]
  edge [
    source 191
    target 195
    int "The risk or severity of adverse effects can be increased when Entacapone is combined with Trazodone."
  ]
  edge [
    source 191
    target 196
    int "The risk or severity of adverse effects can be increased when Trazodone is combined with Dihydroergotamine."
  ]
  edge [
    source 191
    target 197
    int "Buspirone may increase the serotonergic activities of Trazodone."
  ]
  edge [
    source 191
    target 219
    int "The risk or severity of hypotension can be increased when Trazodone is combined with Nisoldipine."
  ]
  edge [
    source 191
    target 222
    int "The risk or severity of adverse effects can be increased when Metaxalone is combined with Trazodone."
  ]
  edge [
    source 191
    target 224
    int "The risk or severity of adverse effects can be increased when Trazodone is combined with Sumatriptan."
  ]
  edge [
    source 191
    target 231
    int "The risk or severity of adverse effects can be increased when Carisoprodol is combined with Trazodone."
  ]
  edge [
    source 191
    target 244
    int "The metabolism of Trazodone can be decreased when combined with Ranolazine."
  ]
  edge [
    source 191
    target 225
    int "Trazodone may increase the antihypertensive activities of Epinephrine."
  ]
  edge [
    source 191
    target 249
    int "Dipyridamole may increase the hypotensive activities of Trazodone."
  ]
  edge [
    source 191
    target 238
    int "Trazodone may increase the sedative activities of Pramipexole."
  ]
  edge [
    source 191
    target 240
    int "The metabolism of Trazodone can be increased when combined with Primidone."
  ]
  edge [
    source 191
    target 241
    int "Tolazoline may increase the antihypertensive activities of Trazodone."
  ]
  edge [
    source 191
    target 246
    int "The serum concentration of Trazodone can be decreased when it is combined with Bosentan."
  ]
  edge [
    source 191
    target 234
    int "The risk or severity of adverse effects can be increased when Trazodone is combined with Lamotrigine."
  ]
  edge [
    source 191
    target 207
    int "The risk or severity of adverse effects can be increased when Zonisamide is combined with Trazodone."
  ]
  edge [
    source 191
    target 206
    int "Trazodone may increase the antihypertensive activities of Aripiprazole."
  ]
  edge [
    source 191
    target 208
    int "Trazodone may increase the antihypertensive activities of Trifluoperazine."
  ]
  edge [
    source 191
    target 212
    int "The risk or severity of hypotension can be increased when Trazodone is combined with Loperamide."
  ]
  edge [
    source 191
    target 202
    int "The risk or severity of adverse effects can be increased when Trazodone is combined with Maprotiline."
  ]
  edge [
    source 192
    target 194
    int "Pargyline may increase the hypotensive activities of Mecamylamine."
  ]
  edge [
    source 192
    target 219
    int "Mecamylamine may increase the hypotensive activities of Nisoldipine."
  ]
  edge [
    source 192
    target 224
    int "The risk or severity of adverse effects can be increased when Sumatriptan is combined with Mecamylamine."
  ]
  edge [
    source 192
    target 226
    int "The risk or severity of adverse effects can be increased when Bumetanide is combined with Mecamylamine."
  ]
  edge [
    source 192
    target 230
    int "The risk or severity of adverse effects can be increased when Mecamylamine is combined with Isosorbide Dinitrate."
  ]
  edge [
    source 192
    target 249
    int "The risk or severity of adverse effects can be increased when Mecamylamine is combined with Dipyridamole."
  ]
  edge [
    source 192
    target 216
    int "The risk or severity of adverse effects can be increased when Mecamylamine is combined with Vecuronium."
  ]
  edge [
    source 192
    target 228
    int "Mecamylamine may increase the hypotensive activities of Bretylium."
  ]
  edge [
    source 192
    target 240
    int "Primidone may increase the hypotensive activities of Mecamylamine."
  ]
  edge [
    source 192
    target 241
    int "Mecamylamine may increase the hypotensive activities of Tolazoline."
  ]
  edge [
    source 192
    target 246
    int "Bosentan may increase the hypotensive activities of Mecamylamine."
  ]
  edge [
    source 192
    target 201
    int "Mecamylamine may increase the hypotensive activities of Aliskiren."
  ]
  edge [
    source 192
    target 206
    int "Aripiprazole may increase the hypotensive activities of Mecamylamine."
  ]
  edge [
    source 192
    target 229
    int "Paromomycin may increase the neuromuscular blocking activities of Mecamylamine."
  ]
  edge [
    source 192
    target 238
    int "The risk or severity of adverse effects can be increased when Pramipexole is combined with Mecamylamine."
  ]
  edge [
    source 192
    target 215
    int "The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Mecamylamine."
  ]
  edge [
    source 193
    target 196
    int "The metabolism of Flutamide can be decreased when combined with Dihydroergotamine."
  ]
  edge [
    source 193
    target 240
    int "The metabolism of Flutamide can be increased when combined with Primidone."
  ]
  edge [
    source 193
    target 244
    int "The metabolism of Flutamide can be decreased when combined with Ranolazine."
  ]
  edge [
    source 193
    target 246
    int "The serum concentration of Flutamide can be decreased when it is combined with Bosentan."
  ]
  edge [
    source 194
    target 228
    int "Pargyline may increase the hypotensive activities of Bretylium."
  ]
  edge [
    source 194
    target 196
    int "The metabolism of Dihydroergotamine can be decreased when combined with Pargyline."
  ]
  edge [
    source 194
    target 197
    int "The risk or severity of adverse effects can be increased when Pargyline is combined with Buspirone."
  ]
  edge [
    source 194
    target 195
    int "The risk or severity of adverse effects can be increased when Entacapone is combined with Pargyline."
  ]
  edge [
    source 194
    target 198
    int "Pargyline may increase the hypoglycemic activities of Miglitol."
  ]
  edge [
    source 194
    target 219
    int "Pargyline may increase the hypotensive activities of Nisoldipine."
  ]
  edge [
    source 194
    target 224
    int "The metabolism of Sumatriptan can be decreased when combined with Pargyline."
  ]
  edge [
    source 194
    target 225
    int "Pargyline may increase the hypertensive activities of Epinephrine."
  ]
  edge [
    source 194
    target 249
    int "Dipyridamole may increase the antihypertensive activities of Pargyline."
  ]
  edge [
    source 194
    target 218
    int "Altretamine may increase the orthostatic hypotensive activities of Pargyline."
  ]
  edge [
    source 194
    target 237
    int "Pargyline may increase the hypoglycemic activities of Rosiglitazone."
  ]
  edge [
    source 194
    target 241
    int "Pargyline may increase the hypotensive activities of Tolazoline."
  ]
  edge [
    source 194
    target 246
    int "Pargyline may increase the hypotensive activities of Bosentan."
  ]
  edge [
    source 194
    target 201
    int "Pargyline may increase the hypotensive activities of Aliskiren."
  ]
  edge [
    source 194
    target 202
    int "The risk or severity of adverse effects can be increased when Pargyline is combined with Maprotiline."
  ]
  edge [
    source 195
    target 197
    int "The risk or severity of adverse effects can be increased when Buspirone is combined with Entacapone."
  ]
  edge [
    source 195
    target 222
    int "The risk or severity of adverse effects can be increased when Entacapone is combined with Metaxalone."
  ]
  edge [
    source 195
    target 231
    int "The risk or severity of adverse effects can be increased when Carisoprodol is combined with Entacapone."
  ]
  edge [
    source 195
    target 238
    int "Entacapone may increase the sedative activities of Pramipexole."
  ]
  edge [
    source 195
    target 240
    int "The risk or severity of adverse effects can be increased when Entacapone is combined with Primidone."
  ]
  edge [
    source 195
    target 234
    int "The risk or severity of adverse effects can be increased when Entacapone is combined with Lamotrigine."
  ]
  edge [
    source 195
    target 207
    int "The risk or severity of adverse effects can be increased when Entacapone is combined with Zonisamide."
  ]
  edge [
    source 195
    target 206
    int "The risk or severity of adverse effects can be increased when Aripiprazole is combined with Entacapone."
  ]
  edge [
    source 195
    target 208
    int "The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Entacapone."
  ]
  edge [
    source 195
    target 202
    int "The risk or severity of adverse effects can be increased when Entacapone is combined with Maprotiline."
  ]
  edge [
    source 196
    target 241
    int "Tolazoline may decrease the vasoconstricting activities of Dihydroergotamine."
  ]
  edge [
    source 196
    target 197
    int "The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Buspirone."
  ]
  edge [
    source 196
    target 214
    int "The metabolism of Proguanil can be decreased when combined with Dihydroergotamine."
  ]
  edge [
    source 196
    target 219
    int "The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Nisoldipine."
  ]
  edge [
    source 196
    target 220
    int "The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Sulfinpyrazone."
  ]
  edge [
    source 196
    target 224
    int "Dihydroergotamine may increase the vasoconstricting activities of Sumatriptan."
  ]
  edge [
    source 196
    target 232
    int "The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Sorafenib."
  ]
  edge [
    source 196
    target 235
    int "The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Lansoprazole."
  ]
  edge [
    source 196
    target 225
    int "The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Epinephrine."
  ]
  edge [
    source 196
    target 230
    int "The metabolism of Isosorbide Dinitrate can be decreased when combined with Dihydroergotamine."
  ]
  edge [
    source 196
    target 244
    int "The serum concentration of Ranolazine can be increased when it is combined with Dihydroergotamine."
  ]
  edge [
    source 196
    target 240
    int "The metabolism of Dihydroergotamine can be increased when combined with Primidone."
  ]
  edge [
    source 196
    target 246
    int "The serum concentration of Bosentan can be increased when it is combined with Dihydroergotamine."
  ]
  edge [
    source 196
    target 234
    int "The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Lamotrigine."
  ]
  edge [
    source 196
    target 201
    int "The metabolism of Aliskiren can be decreased when combined with Dihydroergotamine."
  ]
  edge [
    source 196
    target 206
    int "The serum concentration of Aripiprazole can be increased when it is combined with Dihydroergotamine."
  ]
  edge [
    source 196
    target 208
    int "The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Trifluoperazine."
  ]
  edge [
    source 196
    target 212
    int "The metabolism of Loperamide can be decreased when combined with Dihydroergotamine."
  ]
  edge [
    source 196
    target 200
    int "The metabolism of Zalcitabine can be decreased when combined with Dihydroergotamine."
  ]
  edge [
    source 196
    target 202
    int "The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Maprotiline."
  ]
  edge [
    source 196
    target 207
    int "The metabolism of Zonisamide can be decreased when combined with Dihydroergotamine."
  ]
  edge [
    source 197
    target 222
    int "The risk or severity of adverse effects can be increased when Buspirone is combined with Metaxalone."
  ]
  edge [
    source 197
    target 224
    int "The risk or severity of adverse effects can be increased when Buspirone is combined with Sumatriptan."
  ]
  edge [
    source 197
    target 231
    int "The risk or severity of adverse effects can be increased when Buspirone is combined with Carisoprodol."
  ]
  edge [
    source 197
    target 244
    int "The serum concentration of Ranolazine can be increased when it is combined with Buspirone."
  ]
  edge [
    source 197
    target 238
    int "Buspirone may increase the sedative activities of Pramipexole."
  ]
  edge [
    source 197
    target 240
    int "The metabolism of Buspirone can be increased when combined with Primidone."
  ]
  edge [
    source 197
    target 246
    int "The serum concentration of Buspirone can be decreased when it is combined with Bosentan."
  ]
  edge [
    source 197
    target 234
    int "The risk or severity of adverse effects can be increased when Buspirone is combined with Lamotrigine."
  ]
  edge [
    source 197
    target 207
    int "The risk or severity of adverse effects can be increased when Buspirone is combined with Zonisamide."
  ]
  edge [
    source 197
    target 206
    int "The risk or severity of adverse effects can be increased when Buspirone is combined with Aripiprazole."
  ]
  edge [
    source 197
    target 208
    int "The risk or severity of adverse effects can be increased when Buspirone is combined with Trifluoperazine."
  ]
  edge [
    source 197
    target 202
    int "The risk or severity of adverse effects can be increased when Buspirone is combined with Maprotiline."
  ]
  edge [
    source 198
    target 225
    int "The therapeutic efficacy of Miglitol can be decreased when used in combination with Epinephrine."
  ]
  edge [
    source 198
    target 206
    int "The therapeutic efficacy of Miglitol can be decreased when used in combination with Aripiprazole."
  ]
  edge [
    source 198
    target 215
    int "The therapeutic efficacy of Miglitol can be decreased when used in combination with Methyclothiazide."
  ]
  edge [
    source 198
    target 226
    int "The therapeutic efficacy of Miglitol can be decreased when used in combination with Bumetanide."
  ]
  edge [
    source 198
    target 247
    int "Mesalazine may increase the hypoglycemic activities of Miglitol."
  ]
  edge [
    source 199
    target 217
    int "The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Desoxycorticosterone Pivalate."
  ]
  edge [
    source 199
    target 226
    int "The therapeutic efficacy of Bumetanide can be decreased when used in combination with Meclofenamic acid."
  ]
  edge [
    source 199
    target 247
    int "The risk or severity of adverse effects can be increased when Mesalazine is combined with Meclofenamic acid."
  ]
  edge [
    source 199
    target 204
    int "The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Meclofenamic acid."
  ]
  edge [
    source 199
    target 201
    int "Meclofenamic acid may decrease the antihypertensive activities of Aliskiren."
  ]
  edge [
    source 199
    target 229
    int "Meclofenamic acid may decrease the excretion rate of Paromomycin which could result in a higher serum level."
  ]
  edge [
    source 199
    target 215
    int "The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Meclofenamic acid."
  ]
  edge [
    source 200
    target 244
    int "The metabolism of Zalcitabine can be decreased when combined with Ranolazine."
  ]
  edge [
    source 200
    target 232
    int "The metabolism of Zalcitabine can be decreased when combined with Sorafenib."
  ]
  edge [
    source 200
    target 240
    int "The metabolism of Zalcitabine can be increased when combined with Primidone."
  ]
  edge [
    source 200
    target 246
    int "The serum concentration of Zalcitabine can be decreased when it is combined with Bosentan."
  ]
  edge [
    source 201
    target 249
    int "The risk or severity of adverse effects can be increased when Dipyridamole is combined with Aliskiren."
  ]
  edge [
    source 201
    target 219
    int "Nisoldipine may increase the hypotensive activities of Aliskiren."
  ]
  edge [
    source 201
    target 226
    int "The risk or severity of adverse effects can be increased when Bumetanide is combined with Aliskiren."
  ]
  edge [
    source 201
    target 230
    int "The risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Aliskiren."
  ]
  edge [
    source 201
    target 244
    int "The metabolism of Aliskiren can be decreased when combined with Ranolazine."
  ]
  edge [
    source 201
    target 247
    int "Mesalazine may decrease the antihypertensive activities of Aliskiren."
  ]
  edge [
    source 201
    target 238
    int "The risk or severity of adverse effects can be increased when Pramipexole is combined with Aliskiren."
  ]
  edge [
    source 201
    target 240
    int "The metabolism of Aliskiren can be increased when combined with Primidone."
  ]
  edge [
    source 201
    target 241
    int "Tolazoline may increase the hypotensive activities of Aliskiren."
  ]
  edge [
    source 201
    target 246
    int "The serum concentration of Aliskiren can be decreased when it is combined with Bosentan."
  ]
  edge [
    source 201
    target 204
    int "Oxyphenbutazone may decrease the antihypertensive activities of Aliskiren."
  ]
  edge [
    source 201
    target 206
    int "Aripiprazole may increase the hypotensive activities of Aliskiren."
  ]
  edge [
    source 201
    target 228
    int "Bretylium may increase the hypotensive activities of Aliskiren."
  ]
  edge [
    source 201
    target 215
    int "The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Aliskiren."
  ]
  edge [
    source 202
    target 222
    int "The risk or severity of adverse effects can be increased when Metaxalone is combined with Maprotiline."
  ]
  edge [
    source 202
    target 224
    int "The risk or severity of adverse effects can be increased when Sumatriptan is combined with Maprotiline."
  ]
  edge [
    source 202
    target 231
    int "The risk or severity of adverse effects can be increased when Carisoprodol is combined with Maprotiline."
  ]
  edge [
    source 202
    target 244
    int "The serum concentration of Ranolazine can be increased when it is combined with Maprotiline."
  ]
  edge [
    source 202
    target 238
    int "Maprotiline may increase the sedative activities of Pramipexole."
  ]
  edge [
    source 202
    target 240
    int "The risk or severity of adverse effects can be increased when Primidone is combined with Maprotiline."
  ]
  edge [
    source 202
    target 234
    int "The risk or severity of adverse effects can be increased when Maprotiline is combined with Lamotrigine."
  ]
  edge [
    source 202
    target 207
    int "The risk or severity of adverse effects can be increased when Zonisamide is combined with Maprotiline."
  ]
  edge [
    source 202
    target 206
    int "The risk or severity of adverse effects can be increased when Aripiprazole is combined with Maprotiline."
  ]
  edge [
    source 202
    target 208
    int "The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Maprotiline."
  ]
  edge [
    source 203
    target 229
    int "Paromomycin may increase the ototoxic activities of Carboplatin."
  ]
  edge [
    source 203
    target 232
    int "The risk or severity of adverse effects can be increased when Sorafenib is combined with Carboplatin."
  ]
  edge [
    source 204
    target 217
    int "The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Desoxycorticosterone Pivalate."
  ]
  edge [
    source 204
    target 226
    int "The therapeutic efficacy of Bumetanide can be decreased when used in combination with Oxyphenbutazone."
  ]
  edge [
    source 204
    target 247
    int "The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Mesalazine."
  ]
  edge [
    source 204
    target 229
    int "Oxyphenbutazone may decrease the excretion rate of Paromomycin which could result in a higher serum level."
  ]
  edge [
    source 204
    target 215
    int "The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Oxyphenbutazone."
  ]
  edge [
    source 205
    target 215
    int "Methyclothiazide may decrease the excretion rate of Foscarnet which could result in a higher serum level."
  ]
  edge [
    source 205
    target 226
    int "Bumetanide may decrease the excretion rate of Foscarnet which could result in a higher serum level."
  ]
  edge [
    source 205
    target 229
    int "Foscarnet may increase the nephrotoxic activities of Paromomycin."
  ]
  edge [
    source 206
    target 228
    int "Aripiprazole may increase the hypotensive activities of Bretylium."
  ]
  edge [
    source 206
    target 219
    int "Aripiprazole may increase the hypotensive activities of Nisoldipine."
  ]
  edge [
    source 206
    target 220
    int "The serum concentration of Aripiprazole can be decreased when it is combined with Sulfinpyrazone."
  ]
  edge [
    source 206
    target 222
    int "The risk or severity of adverse effects can be increased when Aripiprazole is combined with Metaxalone."
  ]
  edge [
    source 206
    target 224
    int "The risk or severity of adverse effects can be increased when Sumatriptan is combined with Aripiprazole."
  ]
  edge [
    source 206
    target 230
    int "Aripiprazole may increase the hypotensive activities of Isosorbide Dinitrate."
  ]
  edge [
    source 206
    target 231
    int "The risk or severity of adverse effects can be increased when Aripiprazole is combined with Carisoprodol."
  ]
  edge [
    source 206
    target 249
    int "Aripiprazole may increase the hypotensive activities of Dipyridamole."
  ]
  edge [
    source 206
    target 250
    int "The serum concentration of Aripiprazole can be decreased when it is combined with Azatadine."
  ]
  edge [
    source 206
    target 235
    int "The serum concentration of Aripiprazole can be decreased when it is combined with Lansoprazole."
  ]
  edge [
    source 206
    target 225
    int "Aripiprazole may increase the antihypertensive activities of Epinephrine."
  ]
  edge [
    source 206
    target 226
    int "Aripiprazole may increase the hypotensive activities of Bumetanide."
  ]
  edge [
    source 206
    target 244
    int "The serum concentration of Aripiprazole can be increased when it is combined with Ranolazine."
  ]
  edge [
    source 206
    target 236
    int "The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Aripiprazole."
  ]
  edge [
    source 206
    target 237
    int "The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Aripiprazole."
  ]
  edge [
    source 206
    target 238
    int "Aripiprazole may increase the sedative activities of Pramipexole."
  ]
  edge [
    source 206
    target 240
    int "The serum concentration of Aripiprazole can be decreased when it is combined with Primidone."
  ]
  edge [
    source 206
    target 241
    int "Aripiprazole may increase the hypotensive activities of Tolazoline."
  ]
  edge [
    source 206
    target 243
    int "The therapeutic efficacy of Miglustat can be decreased when used in combination with Aripiprazole."
  ]
  edge [
    source 206
    target 246
    int "The serum concentration of Aripiprazole can be decreased when it is combined with Bosentan."
  ]
  edge [
    source 206
    target 234
    int "The risk or severity of adverse effects can be increased when Aripiprazole is combined with Lamotrigine."
  ]
  edge [
    source 206
    target 207
    int "The risk or severity of adverse effects can be increased when Aripiprazole is combined with Zonisamide."
  ]
  edge [
    source 206
    target 208
    int "Trifluoperazine may increase the antihypertensive activities of Aripiprazole."
  ]
  edge [
    source 206
    target 212
    int "The risk or severity of hypotension can be increased when Aripiprazole is combined with Loperamide."
  ]
  edge [
    source 206
    target 215
    int "Aripiprazole may increase the hypotensive activities of Methyclothiazide."
  ]
  edge [
    source 207
    target 222
    int "The risk or severity of adverse effects can be increased when Metaxalone is combined with Zonisamide."
  ]
  edge [
    source 207
    target 225
    int "The risk or severity of hypotension can be increased when Epinephrine is combined with Zonisamide."
  ]
  edge [
    source 207
    target 231
    int "The risk or severity of adverse effects can be increased when Carisoprodol is combined with Zonisamide."
  ]
  edge [
    source 207
    target 244
    int "The metabolism of Zonisamide can be decreased when combined with Ranolazine."
  ]
  edge [
    source 207
    target 238
    int "Zonisamide may increase the sedative activities of Pramipexole."
  ]
  edge [
    source 207
    target 240
    int "The metabolism of Zonisamide can be increased when combined with Primidone."
  ]
  edge [
    source 207
    target 241
    int "The risk or severity of hypotension can be increased when Tolazoline is combined with Zonisamide."
  ]
  edge [
    source 207
    target 246
    int "The serum concentration of Zonisamide can be decreased when it is combined with Bosentan."
  ]
  edge [
    source 207
    target 234
    int "The risk or severity of adverse effects can be increased when Lamotrigine is combined with Zonisamide."
  ]
  edge [
    source 207
    target 208
    int "The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Zonisamide."
  ]
  edge [
    source 208
    target 214
    int "The serum concentration of Trifluoperazine can be increased when it is combined with Proguanil."
  ]
  edge [
    source 208
    target 219
    int "The risk or severity of hypotension can be increased when Trifluoperazine is combined with Nisoldipine."
  ]
  edge [
    source 208
    target 222
    int "The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Metaxalone."
  ]
  edge [
    source 208
    target 224
    int "The risk or severity of adverse effects can be increased when Sumatriptan is combined with Trifluoperazine."
  ]
  edge [
    source 208
    target 231
    int "The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Carisoprodol."
  ]
  edge [
    source 208
    target 244
    int "The serum concentration of Ranolazine can be increased when it is combined with Trifluoperazine."
  ]
  edge [
    source 208
    target 212
    int "The risk or severity of hypotension can be increased when Trifluoperazine is combined with Loperamide."
  ]
  edge [
    source 208
    target 225
    int "Trifluoperazine may increase the antihypertensive activities of Epinephrine."
  ]
  edge [
    source 208
    target 249
    int "Dipyridamole may increase the hypotensive activities of Trifluoperazine."
  ]
  edge [
    source 208
    target 238
    int "Trifluoperazine may increase the sedative activities of Pramipexole."
  ]
  edge [
    source 208
    target 240
    int "The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Primidone."
  ]
  edge [
    source 208
    target 241
    int "Tolazoline may increase the antihypertensive activities of Trifluoperazine."
  ]
  edge [
    source 208
    target 234
    int "The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Lamotrigine."
  ]
  edge [
    source 212
    target 225
    int "The risk or severity of hypotension can be increased when Epinephrine is combined with Loperamide."
  ]
  edge [
    source 212
    target 232
    int "The metabolism of Loperamide can be decreased when combined with Sorafenib."
  ]
  edge [
    source 212
    target 237
    int "The metabolism of Loperamide can be decreased when combined with Rosiglitazone."
  ]
  edge [
    source 212
    target 240
    int "The metabolism of Loperamide can be increased when combined with Primidone."
  ]
  edge [
    source 212
    target 241
    int "The risk or severity of hypotension can be increased when Tolazoline is combined with Loperamide."
  ]
  edge [
    source 212
    target 244
    int "The serum concentration of Ranolazine can be increased when it is combined with Loperamide."
  ]
  edge [
    source 212
    target 246
    int "The serum concentration of Loperamide can be decreased when it is combined with Bosentan."
  ]
  edge [
    source 213
    target 247
    int "The metabolism of Mercaptopurine can be decreased when combined with Mesalazine."
  ]
  edge [
    source 214
    target 232
    int "The metabolism of Proguanil can be decreased when combined with Sorafenib."
  ]
  edge [
    source 214
    target 240
    int "The metabolism of Proguanil can be increased when combined with Primidone."
  ]
  edge [
    source 214
    target 244
    int "The metabolism of Proguanil can be decreased when combined with Ranolazine."
  ]
  edge [
    source 214
    target 246
    int "The serum concentration of Proguanil can be decreased when it is combined with Bosentan."
  ]
  edge [
    source 215
    target 249
    int "The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Dipyridamole."
  ]
  edge [
    source 215
    target 217
    int "Desoxycorticosterone Pivalate may increase the hypokalemic activities of Methyclothiazide."
  ]
  edge [
    source 215
    target 219
    int "The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Nisoldipine."
  ]
  edge [
    source 215
    target 225
    int "Epinephrine may increase the hypokalemic activities of Methyclothiazide."
  ]
  edge [
    source 215
    target 226
    int "The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Bumetanide."
  ]
  edge [
    source 215
    target 230
    int "The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Isosorbide Dinitrate."
  ]
  edge [
    source 215
    target 247
    int "The therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Mesalazine."
  ]
  edge [
    source 215
    target 216
    int "Methyclothiazide may decrease the neuromuscular blocking activities of Vecuronium."
  ]
  edge [
    source 215
    target 228
    int "The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Bretylium."
  ]
  edge [
    source 215
    target 236
    int "The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Methyclothiazide."
  ]
  edge [
    source 215
    target 240
    int "Primidone may increase the orthostatic hypotensive activities of Methyclothiazide."
  ]
  edge [
    source 215
    target 241
    int "The risk or severity of adverse effects can be increased when Tolazoline is combined with Methyclothiazide."
  ]
  edge [
    source 215
    target 243
    int "The therapeutic efficacy of Miglustat can be decreased when used in combination with Methyclothiazide."
  ]
  edge [
    source 215
    target 229
    int "The serum concentration of Paromomycin can be increased when it is combined with Methyclothiazide."
  ]
  edge [
    source 215
    target 237
    int "The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Methyclothiazide."
  ]
  edge [
    source 215
    target 238
    int "The risk or severity of adverse effects can be increased when Pramipexole is combined with Methyclothiazide."
  ]
  edge [
    source 216
    target 226
    int "Bumetanide may decrease the neuromuscular blocking activities of Vecuronium."
  ]
  edge [
    source 216
    target 229
    int "Paromomycin may increase the respiratory depressant activities of Vecuronium."
  ]
  edge [
    source 216
    target 244
    int "The serum concentration of Vecuronium can be increased when it is combined with Ranolazine."
  ]
  edge [
    source 217
    target 226
    int "Desoxycorticosterone Pivalate may increase the hypokalemic activities of Bumetanide."
  ]
  edge [
    source 217
    target 247
    int "The risk or severity of adverse effects can be increased when Mesalazine is combined with Desoxycorticosterone Pivalate."
  ]
  edge [
    source 217
    target 240
    int "The serum concentration of Desoxycorticosterone Pivalate can be decreased when it is combined with Primidone."
  ]
  edge [
    source 219
    target 249
    int "The risk or severity of adverse effects can be increased when Nisoldipine is combined with Dipyridamole."
  ]
  edge [
    source 219
    target 225
    int "The risk or severity of hypotension can be increased when Epinephrine is combined with Nisoldipine."
  ]
  edge [
    source 219
    target 226
    int "The risk or severity of adverse effects can be increased when Nisoldipine is combined with Bumetanide."
  ]
  edge [
    source 219
    target 230
    int "The risk or severity of adverse effects can be increased when Nisoldipine is combined with Isosorbide Dinitrate."
  ]
  edge [
    source 219
    target 244
    int "The serum concentration of Ranolazine can be increased when it is combined with Nisoldipine."
  ]
  edge [
    source 219
    target 238
    int "The risk or severity of adverse effects can be increased when Pramipexole is combined with Nisoldipine."
  ]
  edge [
    source 219
    target 240
    int "The metabolism of Nisoldipine can be increased when combined with Primidone."
  ]
  edge [
    source 219
    target 241
    int "Nisoldipine may increase the hypotensive activities of Tolazoline."
  ]
  edge [
    source 219
    target 246
    int "The serum concentration of Nisoldipine can be decreased when it is combined with Bosentan."
  ]
  edge [
    source 219
    target 228
    int "Nisoldipine may increase the hypotensive activities of Bretylium."
  ]
  edge [
    source 220
    target 232
    int "The metabolism of Sulfinpyrazone can be decreased when combined with Sorafenib."
  ]
  edge [
    source 220
    target 237
    int "The metabolism of Sulfinpyrazone can be decreased when combined with Rosiglitazone."
  ]
  edge [
    source 220
    target 240
    int "The metabolism of Sulfinpyrazone can be increased when combined with Primidone."
  ]
  edge [
    source 220
    target 244
    int "The serum concentration of Ranolazine can be increased when it is combined with Sulfinpyrazone."
  ]
  edge [
    source 220
    target 246
    int "The serum concentration of Sulfinpyrazone can be decreased when it is combined with Bosentan."
  ]
  edge [
    source 222
    target 231
    int "The risk or severity of adverse effects can be increased when Carisoprodol is combined with Metaxalone."
  ]
  edge [
    source 222
    target 238
    int "Metaxalone may increase the sedative activities of Pramipexole."
  ]
  edge [
    source 222
    target 240
    int "The risk or severity of adverse effects can be increased when Metaxalone is combined with Primidone."
  ]
  edge [
    source 222
    target 234
    int "The risk or severity of adverse effects can be increased when Lamotrigine is combined with Metaxalone."
  ]
  edge [
    source 224
    target 244
    int "The serum concentration of Ranolazine can be increased when it is combined with Sumatriptan."
  ]
  edge [
    source 224
    target 234
    int "The risk or severity of adverse effects can be increased when Sumatriptan is combined with Lamotrigine."
  ]
  edge [
    source 225
    target 226
    int "Epinephrine may increase the hypokalemic activities of Bumetanide."
  ]
  edge [
    source 225
    target 249
    int "Dipyridamole may increase the hypotensive activities of Epinephrine."
  ]
  edge [
    source 225
    target 236
    int "The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Epinephrine."
  ]
  edge [
    source 225
    target 237
    int "The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Epinephrine."
  ]
  edge [
    source 225
    target 241
    int "Tolazoline may increase the antihypertensive activities of Epinephrine."
  ]
  edge [
    source 225
    target 243
    int "The therapeutic efficacy of Miglustat can be decreased when used in combination with Epinephrine."
  ]
  edge [
    source 225
    target 234
    int "The risk or severity of hypotension can be increased when Epinephrine is combined with Lamotrigine."
  ]
  edge [
    source 226
    target 249
    int "The risk or severity of adverse effects can be increased when Bumetanide is combined with Dipyridamole."
  ]
  edge [
    source 226
    target 247
    int "The therapeutic efficacy of Bumetanide can be decreased when used in combination with Mesalazine."
  ]
  edge [
    source 226
    target 230
    int "The risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Bumetanide."
  ]
  edge [
    source 226
    target 236
    int "The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Bumetanide."
  ]
  edge [
    source 226
    target 240
    int "Primidone may increase the hypotensive activities of Bumetanide."
  ]
  edge [
    source 226
    target 241
    int "The risk or severity of adverse effects can be increased when Tolazoline is combined with Bumetanide."
  ]
  edge [
    source 226
    target 243
    int "The therapeutic efficacy of Miglustat can be decreased when used in combination with Bumetanide."
  ]
  edge [
    source 226
    target 229
    int "The serum concentration of Paromomycin can be increased when it is combined with Bumetanide."
  ]
  edge [
    source 226
    target 228
    int "The risk or severity of adverse effects can be increased when Bumetanide is combined with Bretylium."
  ]
  edge [
    source 226
    target 237
    int "The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Bumetanide."
  ]
  edge [
    source 226
    target 238
    int "The risk or severity of adverse effects can be increased when Pramipexole is combined with Bumetanide."
  ]
  edge [
    source 228
    target 238
    int "The risk or severity of adverse effects can be increased when Pramipexole is combined with Bretylium."
  ]
  edge [
    source 228
    target 230
    int "The risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Bretylium."
  ]
  edge [
    source 228
    target 240
    int "Primidone may increase the hypotensive activities of Bretylium."
  ]
  edge [
    source 228
    target 241
    int "Tolazoline may increase the hypotensive activities of Bretylium."
  ]
  edge [
    source 228
    target 246
    int "Bosentan may increase the hypotensive activities of Bretylium."
  ]
  edge [
    source 228
    target 249
    int "The risk or severity of adverse effects can be increased when Dipyridamole is combined with Bretylium."
  ]
  edge [
    source 229
    target 247
    int "Mesalazine may decrease the excretion rate of Paromomycin which could result in a higher serum level."
  ]
  edge [
    source 230
    target 249
    int "Dipyridamole may increase the vasodilatory activities of Isosorbide Dinitrate."
  ]
  edge [
    source 230
    target 237
    int "The risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Rosiglitazone."
  ]
  edge [
    source 230
    target 238
    int "The risk or severity of adverse effects can be increased when Pramipexole is combined with Isosorbide Dinitrate."
  ]
  edge [
    source 230
    target 240
    int "The metabolism of Isosorbide Dinitrate can be increased when combined with Primidone."
  ]
  edge [
    source 230
    target 241
    int "The risk or severity of adverse effects can be increased when Tolazoline is combined with Isosorbide Dinitrate."
  ]
  edge [
    source 230
    target 244
    int "The metabolism of Isosorbide Dinitrate can be decreased when combined with Ranolazine."
  ]
  edge [
    source 230
    target 246
    int "The serum concentration of Isosorbide Dinitrate can be decreased when it is combined with Bosentan."
  ]
  edge [
    source 231
    target 238
    int "Carisoprodol may increase the sedative activities of Pramipexole."
  ]
  edge [
    source 231
    target 240
    int "The risk or severity of adverse effects can be increased when Carisoprodol is combined with Primidone."
  ]
  edge [
    source 231
    target 234
    int "The risk or severity of adverse effects can be increased when Carisoprodol is combined with Lamotrigine."
  ]
  edge [
    source 232
    target 235
    int "The metabolism of Lansoprazole can be decreased when combined with Sorafenib."
  ]
  edge [
    source 232
    target 244
    int "The serum concentration of Ranolazine can be increased when it is combined with Sorafenib."
  ]
  edge [
    source 232
    target 237
    int "The metabolism of Rosiglitazone can be decreased when combined with Sorafenib."
  ]
  edge [
    source 232
    target 240
    int "The serum concentration of Sorafenib can be decreased when it is combined with Primidone."
  ]
  edge [
    source 232
    target 246
    int "The serum concentration of Bosentan can be increased when it is combined with Sorafenib."
  ]
  edge [
    source 234
    target 244
    int "The serum concentration of Lamotrigine can be increased when it is combined with Ranolazine."
  ]
  edge [
    source 234
    target 238
    int "Lamotrigine may increase the sedative activities of Pramipexole."
  ]
  edge [
    source 234
    target 240
    int "The serum concentration of Lamotrigine can be decreased when it is combined with Primidone."
  ]
  edge [
    source 234
    target 241
    int "The risk or severity of hypotension can be increased when Tolazoline is combined with Lamotrigine."
  ]
  edge [
    source 235
    target 244
    int "The serum concentration of Ranolazine can be increased when it is combined with Lansoprazole."
  ]
  edge [
    source 235
    target 237
    int "The metabolism of Lansoprazole can be decreased when combined with Rosiglitazone."
  ]
  edge [
    source 235
    target 240
    int "The metabolism of Lansoprazole can be increased when combined with Primidone."
  ]
  edge [
    source 235
    target 246
    int "The serum concentration of Lansoprazole can be decreased when it is combined with Bosentan."
  ]
  edge [
    source 235
    target 247
    int "The therapeutic efficacy of Mesalazine can be decreased when used in combination with Lansoprazole."
  ]
  edge [
    source 236
    target 237
    int "Rosiglitazone may increase the hypoglycemic activities of Acetohexamide."
  ]
  edge [
    source 237
    target 249
    int "Dipyridamole may increase the anticoagulant activities of Rosiglitazone."
  ]
  edge [
    source 237
    target 247
    int "The risk or severity of adverse effects can be increased when Mesalazine is combined with Rosiglitazone."
  ]
  edge [
    source 237
    target 240
    int "The metabolism of Rosiglitazone can be increased when combined with Primidone."
  ]
  edge [
    source 238
    target 249
    int "The risk or severity of adverse effects can be increased when Pramipexole is combined with Dipyridamole."
  ]
  edge [
    source 238
    target 240
    int "Primidone may increase the sedative activities of Pramipexole."
  ]
  edge [
    source 238
    target 241
    int "The risk or severity of adverse effects can be increased when Pramipexole is combined with Tolazoline."
  ]
  edge [
    source 240
    target 241
    int "Primidone may increase the hypotensive activities of Tolazoline."
  ]
  edge [
    source 240
    target 249
    int "Primidone may increase the hypotensive activities of Dipyridamole."
  ]
  edge [
    source 240
    target 244
    int "The metabolism of Ranolazine can be increased when combined with Primidone."
  ]
  edge [
    source 240
    target 246
    int "The metabolism of Bosentan can be increased when combined with Primidone."
  ]
  edge [
    source 241
    target 249
    int "Dipyridamole may increase the hypotensive activities of Tolazoline."
  ]
  edge [
    source 241
    target 246
    int "Bosentan may increase the hypotensive activities of Tolazoline."
  ]
  edge [
    source 244
    target 249
    int "The serum concentration of Ranolazine can be increased when it is combined with Dipyridamole."
  ]
  edge [
    source 244
    target 246
    int "The serum concentration of Bosentan can be increased when it is combined with Ranolazine."
  ]
  edge [
    source 246
    target 249
    int "The serum concentration of Dipyridamole can be decreased when it is combined with Bosentan."
  ]
  edge [
    source 247
    target 249
    int "The risk or severity of adverse effects can be increased when Dipyridamole is combined with Mesalazine."
  ]
]
